02212000000000445000450099100020000070000020000270600020000470100020000609100090
00081300026000171510015000430350010000584800069000680300016001379300004001531170
00600157085000300163935001000166031000300176032000200179036000600181042000200187
20000020018906500090019112200030020004800140020304800140021704800240023104900240
02550490031002790490028003100490043003380430065003810430064004460430064005105400
38800574540040200962540039601364541000601760#1#0#i#1#20110211#Acta Cirurgica Bra
sileira#Acta cir. bras#0102-8650#Sociedade Brasileira  para o Desenvolvimento da
 Pesquisa em Cirurgia#Acta Cir. Bras.#ACB#other#nd#1678-2674#26#1#20111#1#1#2011
0200#15#^les^hSumario#^lpt^hSumário#^len^hTable of Contents#^len^cACB710^tEditor
ial#^len^cACB720^tOriginal Article#^len^cACB820^tPoint of View#^lpt^cACB980^tCar
ta do Editor aos Leitores#^les^tActa Cir. Bras.^vvol.26^nno.1^cSão Paulo^menero/
feb.^a2011#^lpt^tActa Cir. Bras.^vvol.26^nno.1^cSão Paulo^mjan./fev.^a2011#^len^
tActa Cir. Bras.^vvol.26^nno.1^cSão Paulo^mJan./Feb.^a2011#^t<a rel="license" hr
ef="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Creative Commons L
icense" style="border-width:0" src="http://i.creativecommons.org/l/by-nc/3.0/80x
15.png" /></a> Todo el contenido de esta revista, excepto dónde está identificad
o, est&#225; bajo una <a rel="license" href="http://creativecommons.org/licenses
/by-nc/3.0/">Licencia Creative Commons</a>^les#^t<a rel="license" href="http://c
reativecommons.org/licenses/by-nc/3.0/"><img alt="Creative Commons License" styl
e="border-width:0" src="http://i.creativecommons.org/l/by-nc/3.0/80x15.png" /></
a> Todo o conteúdo deste periódico, exceto onde est&#225 identificado, est&#225;
 licenciado sob uma <a rel="license" href="http://creativecommons.org/licenses/b
y-nc/3.0/">Licen&#231;a Creative Commons</a>^lpt#^t<a rel="license" href="http:/
/creativecommons.org/licenses/by-nc/3.0/"><img alt="Creative Commons License" st
yle="border-width:0" src="http://i.creativecommons.org/l/by-nc/3.0/80x15.png" />
</a> All the contents of this journal, except where otherwise noted, is licensed
 under a <a rel="license" href="http://creativecommons.org/licenses/by-nc/3.0/">
Creative Commons Attribution License</a>^len#BY-NC##
00270000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660910009000680920007000770020013000847030
00300097#v26n1#V:\Scielo\serial\acb\v26n1\markup\a01v26n1.htm#S#o#1#1#text#1#201
10120#130119#a01v26n1.htm#32##
00616000000000361000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030001600102
03100030011803200020012106500090012301400070013203500100013912300020014901200450
0151010003500196070001000231002001300241#v26n1#V:\Scielo\serial\acb\v26n1\markup
\a01v26n1.htm#S#h#2#1#text#1#ed#pt#br1.1#1#4.0#ND#01#ACB710#nd#Acta Cir. Bras.#2
6#1#20110200#^f1^l1#0102-8650#1#Dia do pesquisador científico brasileiro^lpt#^rN
D^1A01^nAlcino Lázaro da^sSilva#UFMG^iA01#a01v26n1.htm##
00630000000000361000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030001600102
03100030011803200020012106500090012301400070013203500100013912300020014901200590
0151010003500210070001000245002001300255#v26n1#V:\Scielo\serial\acb\v26n1\markup
\a01v26n1.htm#S#f#3#1#text#1#ed#pt#br1.1#1#4.0#ND#01#ACB710#nd#Acta Cir. Bras.#2
6#1#20110200#^f1^l1#0102-8650#1#<b><b>Dia do pesquisador científico brasileiro</
b></b>^lpt#^rND^1A01^nAlcino Lázaro da^sSilva#UFMG^iA01#a01v26n1.htm##
00733000000000373000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660640018000680710003000860400003000890010
00600092042000200098120000400100121000300104049000700107158000300114030001500117
03100030013203200020013506500090013701400070014603500100015312300020016301200450
0165010003500210070001200245002001300257008008900270#v26n1#V:\Scielo\serial\acb\
v26n1\markup\a01v26n1.htm#S#l#4#1#text#1#^mjan./fev.^a2011#ed#pt#br1.1#1#4.0#01#
ACB710#nd#Acta cir. bras#26#1#20110200#^f1^l1#0102-8650#1#Dia do pesquisador cie
ntífico brasileiro^lpt#^rND^1A01^nAlcino Lázaro da^sSilva#^iA01^1UFMG#a01v26n1.h
tm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-865020
11000100001##
00320000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704009200069002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#5#1#text#28#<p align="right"><font fac
e="Verdana" size="2"><b>1 &#150; EDITORIAL</b></font></p>     ^cY#a01v26n1.htm##
00264000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704003600069002001300105#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#6#2#text#28#<p align="right">&nbsp;</p
>     ^cY#a01v26n1.htm##
00344000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704011600069002001300185#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#7#3#text#28#<p><font face="Verdana" si
ze="4"><B>Dia do pesquisador cient&iacute;fico brasileiro</B></font></p>    <B> 
      ^cY#a01v26n1.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#8#4#text#28#<p>&nbsp;</p>     ^cY#a01v
26n1.htm##
00316000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704008800069002001300157#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#9#5#text#28#<p><font face="Verdana" si
ze="2">Alcino L&aacute;zaro da Silva</font></p> </B>      ^cY#a01v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704010400070002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#10#6#text#28#<p><font face="Verdana" s
ize="2">Professor de Cirurgia e Em&eacute;rito da UFMG.    </font></p>     ^cY#a
01v26n1.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704002300070002001300093#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#11#7#text#28#<p>&nbsp; </p>     ^cY#a0
1v26n1.htm##
00468000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704023900070002001300309#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#12#8#text#28#<p><font face="Verdana" s
ize="2">&quot;Alea jact est&quot; (A sorte est&aacute;    lan&ccedil;ada). A dec
is&atilde;o, com base numa necessidade intelectual, foi    a de criar uma Revist
a para a Comunidade Experimental. </font></p>     ^cY#a01v26n1.htm##
00395000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704016600070002001300236#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#13#9#text#28#<p> <font face="Verdana" 
size="2">&quot;Ad astra per aspera ou Ad augusta per    augusta&quot; (Por camin
hos &aacute;speros se chega aos astros). </font></p>     ^cY#a01v26n1.htm##
00478000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704024800071002001300319#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#14#10#text#28#<p><font face="Verdana" 
size="2"> Foi esse o in&iacute;cio da Acta Cir&uacute;rgica    Brasileira que ti
ve a honra de receber, acompanhar e arquivar o seu primeiro    n&uacute;mero, el
aborado a partir de 17 de setembro de 1987. </font></p>     ^cY#a01v26n1.htm##
00498000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704026800071002001300339#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#15#11#text#28#<p><font face="Verdana" 
size="2"> Prof. Saul, sabiamente, saudavelmente e com    sapi&ecirc;ncia, congre
gou os seus mais &iacute;ntimos colaboradores e depois    os novos agregados na 
id&eacute;ia sadia de comunica&ccedil;&atilde;o em pesquisa.    </font></p>     
^cY#a01v26n1.htm##
00461000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704023100071002001300302#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#16#12#text#28#<p><font face="Verdana" 
size="2"> Agregar &eacute; qualidade de quem possui a    vontade de reunir para 
desdobrar-se. &quot;Facile est imperium in bonis&quot;    (E&#180; f&aacute;cil 
comandar homens valentes). </font></p>     ^cY#a01v26n1.htm##
00628000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704039800071002001300469#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#17#13#text#28#<p><font face="Verdana" 
size="2"> Todo o come&ccedil;o &eacute; cego, imprevis&iacute;vel    e incerto. 
Come&ccedil;ar &eacute; abrir as portas do desconhecido para se tornar    uma re
alidade, ainda que &aacute;rdua e duramente conquistada. &quot;Vulnera    qui pa
ssus fuit, est bonus ille chirurgus&quot; (N&atilde;o h&aacute; melhor    cirurg
i&atilde;o, que o bem acutilado). </font></p>     ^cY#a01v26n1.htm##
00616000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704038600071002001300457#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#18#14#text#28#<p><font face="Verdana" 
size="2"> Come&ccedil;ou. E da&iacute; ? H&aacute; que    mant&ecirc;-la. A manu
ten&ccedil;&atilde;o custa muito quando se trata de atividade    sem lucros e vo
ltada para o doce e sofrido mister de preparar seguidores. &quot;In    capite or
phani discit chirurgus&quot; (Na cabe&ccedil;a do &oacute;rf&atilde;o    aprende
 o cirurgi&atilde;o). </font></p>     ^cY#a01v26n1.htm##
00711000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704048100071002001300552#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#19#15#text#28#<p><font face="Verdana" 
size="2"> Manter &eacute; tolerar. Tolerar &eacute; &aacute;rduo    tamb&eacute;
m porque exige obstina&ccedil;&atilde;o e perseveran&ccedil;a. Nesta,    se incl
ui o ideal de que se investe, para a comunidade cient&iacute;fica obter    um re
torno afetivo, cultural, espiritual, ps&iacute;quico e at&eacute; material    em
 casos excepcionais. &quot;Obsequium amicos, veritas odium parit&quot; (O    fav
or faz amigos e a verdade inimigos). </font></p>     ^cY#a01v26n1.htm##
00663000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704043300071002001300504#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#20#16#text#28#<p><font face="Verdana" 
size="2"> A Acta passou pela aspereza do in&iacute;cio,    pela agrega&ccedil;&a
tilde;o dif&iacute;cil e pela dif&iacute;cil manuten&ccedil;&atilde;o    da id&e
acute;ia (ou do sonho). Navegou na perseveran&ccedil;a, balan&ccedil;ou-se    na
 preserva&ccedil;&atilde;o e hoje regozija-se da continuidade que possui,    usu
fruindo o privil&eacute;gio de uma indexa&ccedil;&atilde;o completa. </font></p>
     ^cY#a01v26n1.htm##
00962000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704073200071002001300803#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#21#17#text#28#<p><font face="Verdana" 
size="2"> Ela foi produto de qu&ecirc; ? De numerosos    fatores, entre identifi
cados ou n&atilde;o e entre importantes ou secund&aacute;rios.    Houve o profes
sor (es); houve a vontade de organizar cursos regulares de p&oacute;s-gradua&cce
dil;&atilde;o,    a exemplo de dezenas de pares brasileiros de mesma qualidade e
 objetivos; os    professores se dedicando &agrave; causa nobre de formarem home
ns universit&aacute;rios;    os alunos se sacrificando em favor de sua qualifica
&ccedil;&atilde;o e crescimento    e as universidades a abrirem espa&ccedil;os. 
No mais nobre entre tudo, est&aacute;    o pesquisador. &quot;Amor ordinem nesci
t&quot; (O amor n&atilde;o conhece a    ordem). </font></p>     ^cY#a01v26n1.htm
##
00529000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704029900071002001300370#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#22#18#text#28#<p><font face="Verdana" 
size="2"> Estamos vivendo, tamb&eacute;m, a cultura do    &quot;Dia&quot;. Todos
 os que colaboram com a manuten&ccedil;&atilde;o e o equil&iacute;brio    da hum
anidade recebem uma homenagem por meio da comemora&ccedil;&atilde;o do    seu &q
uot;Dia&quot;. </font></p>     ^cY#a01v26n1.htm##
00427000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704019700071002001300268#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#23#19#text#28#<p><font face="Verdana" 
size="2"> Se formos buscar no elenco das profiss&otilde;es    julgo, at&eacute; 
prova em contr&aacute;rio, que n&atilde;o havia o Dia do Pesquisador.    </font>
</p>     ^cY#a01v26n1.htm##
00514000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704028400071002001300355#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#24#20#text#28#<p><font face="Verdana" 
size="2"> O que nos cabe, ent&atilde;o, como conviventes    com esta classe que 
faz o mundo evoluir no crescimento t&eacute;cnico ou human&iacute;stico    ? &Ea
cute; obvio. Criar o &quot;Dia do Pesquisador&quot;, para celebr&aacute;-lo.    
</font></p>     ^cY#a01v26n1.htm##
01017000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704078700071002001300858#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#25#21#text#28#<p><font face="Verdana" 
size="2"> A iniciativa foi tomada pelo professor Saul.    Solicitou e motivou o 
deputado Adolfo Lobbe Neto a convencer os seus pares e    o fez com tanta efic&a
acute;cia que se criou o &quot;Dia do Pesquisador&quot;    no estado de S&atilde
;o Paulo. Apresentou o Projeto de Lei N&#186; 1.869/2003,    instituindo o Dia d
o Pesquisador Brasileiro a ser comemorado no dia 22 de agosto.    Al&eacute;m de
ste, ele relatou outro, 7.577/2006, com os mesmos objetivos a    ser comemorado 
no dia 8 de julho, no Senado Federal. Aprovado, foi para o Deputado    Eduardo C
unha que era o presidente da Comiss&atilde;o de Constitui&ccedil;&atilde;o    e 
Justi&ccedil;a e de Cidadania do Senado Federal. &quot;Amor vincit omnia&quot;  
  (O amor tudo vence). </font></p>     ^cY#a01v26n1.htm##
00537000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704030700071002001300378#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#26#22#text#28#<p><font face="Verdana" 
size="2"> A pergunta &oacute;bvia &eacute;: por que o    dia <B>17/09/1987 </B>?
 A resposta, sobre a legitimidade da data &eacute; que    no mesmo dia comemora-
se o nascimento da Sociedade Brasileira para o Desenvolvimento    da Pesquisa em
 Cirurgia (SOBRADPEC). </font></p>     ^cY#a01v26n1.htm##
00875000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704064500071002001300716#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#27#23#text#28#<p><font face="Verdana" 
size="2"> A proposta me foi repassada. Procurei o caminho    da governabilidade 
e por meio do deputado - m&eacute;dico Hely Tarqu&iacute;nio    fez-se a propost
a, aprovada pela Assembl&eacute;ia Legislativa de Minas Gerais    e confirmada p
ela assinatura do governador A&eacute;cio Neves, registrada no    Di&aacute;rio 
Oficial em 30/12/2008 (Lei N&#186; 1.789), criando-se o Dia Estadual    do Pesqu
isador Cient&iacute;fico em Minas Gerais, no dia 15 de fevereiro . Nesse    mesm
o dia a humanidade celebra o nascimento de Galilelo Galillei, um dos marcos    d
a pesquisa mundial. (Lei N&#186; 1.789). </font></p>     ^cY#a01v26n1.htm##
00719000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704048900071002001300560#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#28#24#text#28#<p><font face="Verdana" 
size="2"> N&atilde;o satisfeito, subi um pouco mais e    o Senador Eduardo Brand
&atilde;o Azeredo, criou a lei 11.807 de 13/11/2008,    sancionada pelo Vice Pre
sidente da Rep&uacute;blica, o mineiro Jos&eacute; de    Alencar, em exerc&iacut
e;cio no cargo da Presid&ecirc;ncia. Ficou criado o Dia    Nacional do Pesquisad
or em 8 de julho, homenageando a funda&ccedil;&atilde;o    da Sociedade Brasilei
ra para o Progresso da Ci&ecirc;ncia (SBPC). </font></p>     ^cY#a01v26n1.htm##
00369000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704013900071002001300210#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#29#25#text#28#<p> <font face="Verdana"
 size="2">&quot;In ardua virtus&quot; (O valor consiste    em se opor &agrave;s 
dificuldades). </font></p>     ^cY#a01v26n1.htm##
00506000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704027600071002001300347#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#30#26#text#28#<p><font face="Verdana" 
size="2"> Como resolver essa aparente diversifica&ccedil;&atilde;o    ao homenag
earmos o pesquisador brasileiro ? <B>Dia 17 de setembro em S&atilde;o    Paulo</
B>; dia 15 de fevereiro em Minas Gerais e no Brasil, dia 8 de julho.    </font><
/p>     ^cY#a01v26n1.htm##
01083000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704085300071002001300924#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#31#27#text#28#<p><font face="Verdana" 
size="2"> O que interessava era criar a data para comemorar.    Cada um julgou o
portuno escolher o marco motivado pela import&acirc;ncia do    patrono. O desejo
 se concretizou e h&aacute;, agora, o que discutir e caminhar-se    para um cons
enso. &quot;Alii sementem faciunt, alii metent&quot; (Uns plantam,    outros col
hem). O que vale, ent&atilde;o, &eacute; termos resolvido um fato    inexistente
, at&eacute; agora. H&aacute; o reconhecimento, h&aacute; o &quot;Dia&quot;    p
ara a comemora&ccedil;&atilde;o e falta-nos, pois, procurar equilibrar as    opi
ni&otilde;es dos pesquisadores e buscar a unidade de pensamento para que    as s
ementes s&oacute; gerem progresso, conc&oacute;rdia e paz. &quot;Sit salvus    s
ator, salva sint sata&quot; (Bendito seja o semeador, benditas sejam as sementei
ras).    </font></p>     ^cY#a01v26n1.htm##
00578000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704034800071002001300419#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a01v26n1.htm#S#p#32#28#text#28#<p><font face="Verdana" 
size="2"> Cabe agora ao Legislador ou &agrave;s Sociedades    de Pesquisa, se or
ganizarem, se entenderem e, em conjunto, formularem uma proposta    final, defin
itiva e nacional. As datas citadas ficam na hist&oacute;ria pois    a partir del
as &eacute; que se nacionalizou o Dia do Pesquisador Brasileiro.</font></p>     
^cY#a01v26n1.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v26n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#o#1#1#article#1#
20110120#130122#a02v26n1.htm#156##
04765000000000721000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400070014103500100014801201150
01580120125002730100039003980100033004370100036004700100044005060100038005500700
09800588070009800686070009100784070009800875083127600973085000802249085002902257
08500360228608500330232208500300235508500170238508313880240208500080379008500310
37980850037038290850030038660850030038960850018039261170006039440720003039501120
00903953111001403962116000903976115001903985114000904004113001704013002001304030
#v26n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#h#2#1#article#1#oa#en#br
1.1#1#4.0#ILUS#TAB#02#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f2^l6#0102-8650#E
valuation of optical density of bone defects filled with calcium phosphate cemen
t and bioactive glass in rats^len#Avaliação da densidade óptica de cavidades óss
eas preenchidas com cimento de fosfato de cálcio e vidro bioativo em ratos^lpt#^
rND^1A01^nLuiz Alberto^sBiancon Filho#^rND^1A02^nBruno Tochetto^sPrimo#^rND^1A02
^nHumberto Thomazi^sGassen#^rND^1A03^nVânia Regina Camargo^sFontanella#^rND^1A04
^nAurelício Novaes^sSilva Jr#ULBRA^iA01^1School of Dentistry^2Department of Oral
 and Maxillofacial Surgery^cCanoas^sRS^pBrazil#ULBRA^iA02^1School of Dentistry^2
Department of Oral and Maxillofacial Surgery^cCanoas^sRS^pBrazil#ULBRA^iA03^1Sch
ool of Dentistry^2Department of Maxillofacial Radiology^cCanoas^sRS^pBrazil#ULBR
A^iA04^1School of Dentistry^2Department of Oral and Maxillofacial Surgery^cCanoa
s^sRS^pBrazil#^len^aPurpose: To evaluate new bone formation, by the analysis of 
optical density, in rat femoral defects filled with calcium phosphate cement (CP
C) and bioactive glass (BG). Methods: Twenty-one rats were divided into three gr
oups, Group I (CPC), Group II (BG), and Group III (control), and assessed after 
7, 15, and 30 days. Three bone cavities were made in the left femur and filled w
ith CPC, BG, and no material (control). Digital images were obtained and the res
ults were subjected to statistical analysis of variance (ANOVA), complemented by
 the Friedman and Kruskal-Wallis nonparametric tests, with a significance level 
of 5%. Results: Regarding optical density, Group I showed statistical values sig
nificantly higher than Group III and also higher, although not statistically sig
nificant, than Group II, in all observation periods. When Groups II and III were
 compared, Group II showed higher optical density values, without statistically 
significant differences, in all periods. Conclusion: The biomaterials analyzed s
howed higher optical density in relation to the control group in all observation
 periods, calcium phosphate cement being the best option in the repair of bone d
efects, but without statistically significant differences in relation to bioacti
ve glass.#^dnd^i1#^tm^len^kBone Substitutes^i1#^tm^len^kBiocompatible Materials^
i1#^tm^len^kBone Transplantation^i1#^tm^len^kBone Regeneration^i1#^tm^len^kRats^
i1#^lpt^aObjetivo: Avaliar a neoformação óssea, por meio da análise de densidade
 óptica, em cavidades em ratos preenchidas com cimento de fosfato de cálcio (CFC
) e vidro bioativo (VB). Métodos: Utilizou-se 21 ratos distribuídos em três grup
os, sendo Grupo I (CFC), Grupo II (VB) e Grupo III (controle) avaliados em 07, 1
5 e 30 dias. Foram realizadas três cavidades, junto ao fêmur esquerdo e preenchi
das com CFC, VB e sem material (controle). Realizaram-se radiografias digitais e
 os resultados foram submetidos à análise estatística de variância (ANOVA), comp
lementada através dos testes não-paramétricos de Friedman e Kruskal-Wallis, com 
níveis de significância de 5%. Resultados: Comparando a densidade óptica o Grupo
 I apresentou valores estatísticos significativamente maiores que o Grupo III, e
 também apresenta valores maiores, sem diferença estatística significativa, em t
odos os períodos, quando comparado ao Grupo II. Quando comparamos o Grupo II com
 o Grupo III, o Grupo II apresenta valores maiores de densidade óptica, sem dife
rença estatística significativa, em todos os períodos. Conclusão: Observou-se ma
ior densidade óptica dos biomateriais em relação ao grupo controle em todos os p
eríodos avaliados, sendo o cimento de fosfato de cálcio a melhor opção para rest
auração de cavidades ósseas, porém sem diferenças estatisticamente significantes
 em relação ao vidro bioativo.#^dnd^i2#^tm^lpt^kSubstitutos Ósseos^i2#^tm^lpt^kM
ateriais Biocompatíveis^i2#^tm^lpt^kTransplante Ósseo^i2#^tm^lpt^kRegeneração Ós
sea^i2#^tm^lpt^kRatos^i2#other#15#20100714#July 14, 2010#20100920#September 20, 
2010#20101019#October 19, 2010#a02v26n1.htm##
04835000000000721000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400070014103500100014801201220
01580120132002800100039004120100033004510100036004840100044005200100038005640700
09800602070009800700070009100798070009800889083130400987085000802291085002902299
08500360232808500330236408500300239708500170242708314160244408500080386008500310
38680850037038990850030039360850030039660850018039961170006040140720003040201120
00904023111001404032116000904046115001904055114000904074113001704083002001304100
#v26n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#f#3#1#article#1#oa#en#br
1.1#1#4.0#ILUS#TAB#02#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f2^l6#0102-8650#<
b>Evaluation of optical density of bone defects filled with calcium phosphate ce
ment and bioactive glass in rats</b>^len#<b>Avaliação da densidade óptica de cav
idades ósseas preenchidas com cimento de fosfato de cálcio e vidro bioativo em r
atos</b>^lpt#^rND^1A01^nLuiz Alberto^sBiancon Filho#^rND^1A02^nBruno Tochetto^sP
rimo#^rND^1A02^nHumberto Thomazi^sGassen#^rND^1A03^nVânia Regina Camargo^sFontan
ella#^rND^1A04^nAurelício Novaes^sSilva Jr#ULBRA^iA01^1School of Dentistry^2Depa
rtment of Oral and Maxillofacial Surgery^cCanoas^sRS^pBrazil#ULBRA^iA02^1School 
of Dentistry^2Department of Oral and Maxillofacial Surgery^cCanoas^sRS^pBrazil#U
LBRA^iA03^1School of Dentistry^2Department of Maxillofacial Radiology^cCanoas^sR
S^pBrazil#ULBRA^iA04^1School of Dentistry^2Department of Oral and Maxillofacial 
Surgery^cCanoas^sRS^pBrazil#^len^a<b>Purpose</b>: To evaluate new bone formation
, by the analysis of optical density, in rat femoral defects filled with calcium
 phosphate cement (CPC) and bioactive glass (BG). <b>Methods</b>: Twenty-one rat
s were divided into three groups, Group I (CPC), Group II (BG), and Group III (c
ontrol), and assessed after 7, 15, and 30 days. Three bone cavities were made in
 the left femur and filled with CPC, BG, and no material (control). Digital imag
es were obtained and the results were subjected to statistical analysis of varia
nce (ANOVA), complemented by the Friedman and Kruskal-Wallis nonparametric tests
, with a significance level of 5%. <b>Results</b>: Regarding optical density, Gr
oup I showed statistical values significantly higher than Group III and also hig
her, although not statistically significant, than Group II, in all observation p
eriods. When Groups II and III were compared, Group II showed higher optical den
sity values, without statistically significant differences, in all periods. <b>C
onclusion</b>: The biomaterials analyzed showed higher optical density in relati
on to the control group in all observation periods, calcium phosphate cement bei
ng the best option in the repair of bone defects, but without statistically sign
ificant differences in relation to bioactive glass.#^dnd^i1#^tm^len^kBone Substi
tutes^i1#^tm^len^kBiocompatible Materials^i1#^tm^len^kBone Transplantation^i1#^t
m^len^kBone Regeneration^i1#^tm^len^kRats^i1#^lpt^a<b>Objetivo</b>: Avaliar a ne
oformação óssea, por meio da análise de densidade óptica, em cavidades em ratos 
preenchidas com cimento de fosfato de cálcio (CFC) e vidro bioativo (VB). <b>Mét
odos</b>: Utilizou-se 21 ratos distribuídos em três grupos, sendo Grupo I (CFC),
 Grupo II (VB) e Grupo III (controle) avaliados em 07, 15 e 30 dias. Foram reali
zadas três cavidades, junto ao fêmur esquerdo e preenchidas com CFC, VB e sem ma
terial (controle). Realizaram-se radiografias digitais e os resultados foram sub
metidos à análise estatística de variância (ANOVA), complementada através dos te
stes não-paramétricos de Friedman e Kruskal-Wallis, com níveis de significância 
de 5%. <b>Resultados</b>: Comparando a densidade óptica o Grupo I apresentou val
ores estatísticos significativamente maiores que o Grupo III, e também apresenta
 valores maiores, sem diferença estatística significativa, em todos os períodos,
 quando comparado ao Grupo II. Quando comparamos o Grupo II com o Grupo III, o G
rupo II apresenta valores maiores de densidade óptica, sem diferença estatística
 significativa, em todos os períodos. <b>Conclusão</b>: Observou-se maior densid
ade óptica dos biomateriais em relação ao grupo controle em todos os períodos av
aliados, sendo o cimento de fosfato de cálcio a melhor opção para restauração de
 cavidades ósseas, porém sem diferenças estatisticamente significantes em relaçã
o ao vidro bioativo.#^dnd^i2#^tm^lpt^kSubstitutos Ósseos^i2#^tm^lpt^kMateriais B
iocompatíveis^i2#^tm^lpt^kTransplante Ósseo^i2#^tm^lpt^kRegeneração Óssea^i2#^tm
^lpt^kRatos^i2#other#15#20100714#July 14, 2010#20100920#September 20, 2010#20101
019#October 19, 2010#a02v26n1.htm##
04923000000000745000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000150012903100030014403200020014706500090014901400070015803500100
01650120115001750120125002900100039004150100033004540100036004870100044005230100
04200567070010000609070010000709070009300809070010000902083128301002085000802285
08500290229308500360232208500330235808500300239108500170242108313970243808500080
38350850031038430850037038740850030039110850030039410850018039711170006039890720
00303995112000903998111001404007116000904021115001904030114000904049113001704058
002001304075008008904088#v26n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#
l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#02#ACB720#nd#Acta c
ir. bras#26#1#20110200#^f2^l6#0102-8650#Evaluation of optical density of bone de
fects filled with calcium phosphate cement and bioactive glass in rats^len#Avali
ação da densidade óptica de cavidades ósseas preenchidas com cimento de fosfato 
de cálcio e vidro bioativo em ratos^lpt#^rND^1A01^nLuiz Alberto^sBiancon Filho#^
rND^1A02^nBruno Tochetto^sPrimo#^rND^1A02^nHumberto Thomazi^sGassen#^rND^1A03^nV
ânia Regina Camargo^sFontanella#^rND^1A04^nAurelício Novaes^sSilva Júnior#^iA01^
1ULBRA^2School of Dentistry^3Department of Oral and Maxillofacial Surgery^cCanoa
s^sRS^pBrazil#^iA02^1ULBRA^2School of Dentistry^3Department of Oral and Maxillof
acial Surgery^cCanoas^sRS^pBrazil#^iA03^1ULBRA^2School of Dentistry^3Department 
of Maxillofacial Radiology^cCanoas^sRS^pBrazil#^iA04^1ULBRA^2School of Dentistry
^3Department of Oral and Maxillofacial Surgery^cCanoas^sRS^pBrazil#^len^aPurpose
: To evaluate new bone formation, by the analysis of optical density, in rat fem
oral defects filled with calcium phosphate cement (CPC) and bioactive glass (BG)
. Methods: Twenty-one rats were divided into three groups, Group I (CPC), Group 
II (BG), and Group III (control), and assessed after 7, 15, and 30 days. Three b
one cavities were made in the left femur and filled with CPC, BG, and no materia
l (control). Digital images were obtained and the results were subjected to stat
istical analysis of variance (ANOVA), complemented by the Friedman and Kruskal-W
allis nonparametric tests, with a significance level of 5 percent. Results: Rega
rding optical density, Group I showed statistical values significantly higher th
an Group III and also higher, although not statistically significant, than Group
 II, in all observation periods. When Groups II and III were compared, Group II 
showed higher optical density values, without statistically significant differen
ces, in all periods. Conclusion: The biomaterials analyzed showed higher optical
 density in relation to the control group in all observation periods, calcium ph
osphate cement being the best option in the repair of bone defects, but without 
statistically significant differences in relation to bioactive glass.#^dnd^i1#^t
m^len^kBone Substitutes^i1#^tm^len^kBiocompatible Materials^i1#^tm^len^kBone Tra
nsplantation^i1#^tm^len^kBone Regeneration^i1#^tm^len^kRats^i1#^lpt^aObjetivo: A
valiar a neoformação óssea, por meio da análise de densidade óptica, em cavidade
s em ratos preenchidas com cimento de fosfato de cálcio (CFC) e vidro bioativo (
VB). Métodos: Utilizou-se 21 ratos distribuídos em três grupos, sendo Grupo I (C
FC), Grupo II (VB) e Grupo III (controle) avaliados em 07, 15 e 30 dias. Foram r
ealizadas três cavidades, junto ao fêmur esquerdo e preenchidas com CFC, VB e se
m material (controle). Realizaram-se radiografias digitais e os resultados foram
 submetidos à análise estatística de variância (ANOVA), complementada através do
s testes não-paramétricos de Friedman e Kruskal-Wallis, com níveis de significân
cia de 5 por cento. Resultados: Comparando a densidade óptica o Grupo I apresent
ou valores estatísticos significativamente maiores que o Grupo III, e também apr
esenta valores maiores, sem diferença estatística significativa, em todos os per
íodos, quando comparado ao Grupo II. Quando comparamos o Grupo II com o Grupo II
I, o Grupo II apresenta valores maiores de densidade óptica, sem diferença estat
ística significativa, em todos os períodos. Conclusão: Observou-se maior densida
de óptica dos biomateriais em relação ao grupo controle em todos os períodos ava
liados, sendo o cimento de fosfato de cálcio a melhor opção para restauração de 
cavidades ósseas, porém sem diferenças estatisticamente significantes em relação
 ao vidro bioativo.#^dnd^i2#^tm^lpt^kSubstitutos Ósseos^i2#^tm^lpt^kMateriais Bi
ocompatíveis^i2#^tm^lpt^kTransplante Ósseo^i2#^tm^lpt^kRegeneração Óssea^i2#^tm^
lpt^kRatos^i2#other#15#20100714#July 14, 2010#20100920#September 20, 2010#201010
19#October 19, 2010#a02v26n1.htm#Internet^ihttp://www.scielo.br/scielo.php?scrip
t=sci_arttext&pid=S0102-86502011000100002##
00315000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704008300073002001300156#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#5#1#article#137#<p align="right"><font
 face="Verdana" size="2"><b>2 &#150; ORIGINAL ARTICLE    ^cY#a02v26n1.htm##
00280000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704004800073002001300121#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#6#2#article#137#<br>   MATERIALS TESTI
NG</b></font></p>     ^cY#a02v26n1.htm##
00273000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704004100073002001300114#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#7#3#article#137#<p align="right">&nbsp
;</p> <B>      ^cY#a02v26n1.htm##
00493000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704026100073002001300334#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#8#4#article#137#<p><font face="Verdana
" size="2"><a name="top"></a></font><font face="Verdana" size="4">Evaluation    
of optical density of bone defects filled with calcium phosphate cement and    b
ioactive glass in rats<a href="#end"><sup>1</sup></a></font></p> </B>      ^cY#a
02v26n1.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002100073002001300094#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#9#5#article#137#<p>&nbsp;</p>    ^cY#a
02v26n1.htm##
00458000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704022500074002001300299#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#10#6#article#137#<p><font face="Verdan
a" size="3"><b>Avalia&ccedil;&atilde;o da densidade &oacute;ptica    de cavidade
s &oacute;sseas preenchidas com cimento de fosfato de c&aacute;lcio    e vidro b
ioativo em ratos </b></font></p>        ^cY#a02v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#11#7#article#137#<p>&nbsp;</p>     ^cY
#a02v26n1.htm##
00515000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704028200074002001300356#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#12#8#article#137#<p><font face="Verdan
a" size="2"><B>Luiz Alberto Biancon Filho<sup>I</sup>, Bruno    Tochetto Primo<s
up>II</sup>, Humberto Thomazi Gassen<sup>II</sup>, V&acirc;nia    Regina Camargo
 Fontanella<sup>III</sup>, Aurel&iacute;cio Novaes Silva Jr<sup>IV</sup></B>    
</font></p>      ^cY#a02v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#13#9#article#137#<p>&nbsp;</p>     ^cY
#a02v26n1.htm##
00517000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028300075002001300358#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#14#10#article#137#<p><font face="Verda
na" size="2"><sup>I</sup> Fellow Master degree, Department    of Oral and Maxill
ofacial Surgery, School of Dentistry, ULBRA, Canoas-RS, Brazil.    <I>Main autho
r. Responsible for conception, design, intellectual and scientific    content of
 the study</I>.    ^cY#a02v26n1.htm##
00468000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704023400075002001300309#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#15#11#article#137#<br>   </font><font 
face="Verdana" size="2"><sup>II</sup> Fellow Master degree, Department    of Ora
l and Maxillofacial Surgery, School of Dentistry, ULBRA, Canoas-RS, Brazil.    <
I>Surgical procedures. Manuscript writing</I>.    ^cY#a02v26n1.htm##
00483000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024900075002001300324#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#16#12#article#137#<br>   </font><font 
face="Verdana" size="2"><sup>III</sup> PhD, Associate Professor,    Department o
f Maxillofacial Radiology, School of Dentistry, ULBRA, Canoas-RS,    Brazil. <I>
Acqusition and interpretation of data. Critical revision</I>.    ^cY#a02v26n1.ht
m##
00518000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028400075002001300359#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#17#13#article#137#<br>   </font><font 
face="Verdana" size="2"><sup>IV</sup> PhD, Associate Professor,    Department of
 Oral and Maxillofacial Surgery, School of Dentistry, ULBRA, Canoas-RS,    Brazi
l. <I>Tutor. Responsible for conception and critical revision of the study</I>. 
   </font></p>      ^cY#a02v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#18#14#article#137#<p><font face="Verda
na" size="2"><a href="#end">Correspondence</a></font></p>     ^cY#a02v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#19#15#article#137#<p>&nbsp;</p>     ^c
Y#a02v26n1.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#20#16#article#137#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a02v26n1.htm##
00304000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007000075002001300145#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#21#17#article#137#<p><font face="Verda
na" size="2"><B>ABSTRACT </B> </font></p>     ^cY#a02v26n1.htm##
01633000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704139900075002001301474#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#22#18#article#137#<p><font face="Verda
na" size="2"><B>Purpose</b>: To evaluate new bone formation,    by the analysis 
of optical density, in rat femoral defects filled with calcium    phosphate ceme
nt (CPC) and bioactive glass (BG). <B>Methods</B>: Twenty-one    rats were divid
ed into three groups, Group I (CPC), Group II (BG), and Group    III (control), 
and assessed after 7, 15, and 30 days. Three bone cavities were    made in the l
eft femur and filled with CPC, BG, and no material (control). Digital    images 
were obtained and the results were subjected to statistical analysis    of varia
nce (ANOVA), complemented by the Friedman and Kruskal-Wallis nonparametric    te
sts, with a significance level of 5%. <B>Results</B>: Regarding optical density,
    Group I showed statistical values significantly higher than Group III and al
so    higher, although not statistically significant, than Group II, in all obse
rvation    periods. When Groups II and III were compared, Group II showed higher
 optical    density values, without statistically significant differences, in al
l periods.    <B>Conclusion</B>: The biomaterials analyzed showed higher optical
 density in    relation to the control group in all observation periods, calcium
 phosphate    cement being the best option in the repair of bone defects, but wi
thout statistically    significant differences in relation to bioactive glass. <
/font></p>     ^cY#a02v26n1.htm##
00422000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704018800075002001300263#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#23#19#article#137#<p><font face="Verda
na" size="2"><B>Key words</B>: Bone Substitutes. Biocompatible    Materials. Bon
e Transplantation. Bone Regeneration. Rats. </font></p>   <hr size="1" noshade> 
    ^cY#a02v26n1.htm##
00301000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006700075002001300142#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#24#20#article#137#<p><font face="Verda
na" size="2"><B>RESUMO </B></font></p>     ^cY#a02v26n1.htm##
02070000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704183600075002001301911#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#25#21#article#137#<p><font face="Verda
na" size="2"><B>Objetivo</b>: Avaliar a neoforma&ccedil;&atilde;o    &oacute;sse
a, por meio da an&aacute;lise de densidade &oacute;ptica, em cavidades    em rat
os preenchidas com cimento de fosfato de c&aacute;lcio (CFC) e vidro bioativo   
 (VB). <B>M&eacute;todos</B>: Utilizou-se 21 ratos distribu&iacute;dos em tr&eci
rc;s    grupos, sendo Grupo I (CFC), Grupo II (VB) e Grupo III (controle) avalia
dos    em 07, 15 e 30 dias. Foram realizadas tr&ecirc;s cavidades, junto ao f&ec
irc;mur    esquerdo e preenchidas com CFC, VB e sem material (controle). Realiza
ram-se    radiografias digitais e os resultados foram submetidos &agrave; an&aac
ute;lise    estat&iacute;stica de vari&acirc;ncia (ANOVA), complementada atrav&e
acute;s    dos testes n&atilde;o-param&eacute;tricos de Friedman e Kruskal-Walli
s, com    n&iacute;veis de signific&acirc;ncia de 5%. <B>Resultados</B>: Compara
ndo a    densidade &oacute;ptica o Grupo I apresentou valores estat&iacute;stico
s significativamente    maiores que o Grupo III, e tamb&eacute;m apresenta valor
es maiores, sem diferen&ccedil;a    estat&iacute;stica significativa, em todos o
s per&iacute;odos, quando comparado    ao Grupo II. Quando comparamos o Grupo II
 com o Grupo III, o Grupo II apresenta    valores maiores de densidade &oacute;p
tica, sem diferen&ccedil;a estat&iacute;stica    significativa, em todos os per&
iacute;odos. <B>Conclus&atilde;o</B>: Observou-se    maior densidade &oacute;pti
ca dos biomateriais em rela&ccedil;&atilde;o ao grupo    controle em todos os pe
r&iacute;odos avaliados, sendo o cimento de fosfato de    c&aacute;lcio a melhor
 op&ccedil;&atilde;o para restaura&ccedil;&atilde;o de    cavidades &oacute;ssea
s, por&eacute;m sem diferen&ccedil;as estatisticamente    significantes em rela&
ccedil;&atilde;o ao vidro bioativo. </font></p>     ^cY#a02v26n1.htm##
00468000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704023400075002001300309#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#26#22#article#137#<p><font face="Verda
na" size="2"><B>Descritores</B>: Substitutos &Oacute;sseos.    Materiais Biocomp
at&iacute;veis. Transplante &Oacute;sseo. Regenera&ccedil;&atilde;o    &Oacute;s
sea. Ratos. </font></p> <hr size="1" noshade>     ^cY#a02v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#27#23#article#137#<p>&nbsp;</p>     ^c
Y#a02v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#28#24#article#137#<p>&nbsp;</p>     ^c
Y#a02v26n1.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007500075002001300150#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#29#25#article#137#<p> <font face="Verd
ana" size="3"><B>Introduction</B> </font></p>      ^cY#a02v26n1.htm##
01159000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704092500075002001301000#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#30#26#article#137#<p><font face="Verda
na" size="2"> The search for an ideal material that enables    tissue repair has
 become the predominant issue for researchers and surgeons    interested in the 
acceleration of fracture healing or reconstruction of bone    defects. The study
 and development of biomaterials have improved the characteristics    and proper
ties of synthetic bone graft substitutes. Of these, calcium phosphate    cement 
(CPC) lists the properties of biocompatibility, bioactivity1 and osteoconductivi
ty,    in addition to easy handling and molding that enable optimal adaptation t
o the    bone defect to be repaired. Bioactive glasses (BG) are silicon-based bo
ne graft    substitutes that, in addition to osteoinductive and osteoconductive 
properties,    have pro-angiogenic potential as a result of factors generated by
 products of    its dissolution2 and great ability to bond to bone and soft tiss
ue3. </font></p>     ^cY#a02v26n1.htm##
00533000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029900075002001300374#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#31#27#article#137#<p><font face="Verda
na" size="2"> Biomaterials that can substitute bone structures    are the curren
t choice in reconstruction, since they prevent patient complications    from a p
ossible autogenous donor site, such as inflammation, stiffness, pain,    and bac
terial infection4. </font></p>     ^cY#a02v26n1.htm##
00468000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704023400075002001300309#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#32#28#article#137#<p><font face="Verda
na" size="2"> Taking these data together, the objective of    this study was to 
evaluate new bone formation in rat femoral defects filled    with CPC and BG by 
the analysis of optical density. </font></p>      ^cY#a02v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#33#29#article#137#<p>&nbsp; </p>     ^
cY#a02v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#34#30#article#137#<p><font face="Verda
na" size="3"><B>Methods</B> </font></p>      ^cY#a02v26n1.htm##
00647000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704041300075002001300488#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#35#31#article#137#<p><font face="Verda
na" size="2"> The study protocol was analyzed and approved    by the Research Et
hics and Animal Care and Use Committees of Lutheran University    of Brazil (ULB
RA). The use of laboratory animals followed the ethical code for    animal exper
imentation of the Council for International Organization of Medical    Sciences 
and the Brazilian College on Animal Experimentation. </font></p>     ^cY#a02v26n
1.htm##
00490000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025600075002001300331#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#36#32#article#137#<p><font face="Verda
na" size="2"> Twenty-one clinically healthy, young adult,    male albino Wistar 
rats (<I>Norvegicus albinus</I>), at approximately 180 days    of age and mean w
eight of 300g at surgery, were selected for this study. </font></p>     ^cY#a02v
26n1.htm##
01162000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704092800075002001301003#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#37#33#article#137#<p><font face="Verda
na" size="2"> The CPC (Laboratory of Biomaterials, Federal    University of Rio 
Grande do Sul, Porto Alegre-RS, Brazil) used in the present    study was compose
d of 85% -tricalcium phosphate (-TCP) and 15% calcium sulfate,    mixed with an 
aqueous solution containing 2.5% Na<SUB>2</SUB>HPO<SUB>4</SUB>    (accelerator).
 This cement has a dual-setting hydraulic system. The initial    setting is obta
ined by the hydration reaction of calcium sulfate (CaSO<SUB>4</SUB>.&#189;H<SUB>
2</SUB>O    + H<SUB>2</SUB>O &#151;&gt; CaSO<SUB>4</SUB>.2H<SUB>2</SUB>O) and th
e final    setting is obtained by the hydration reaction of -TCP (Ca<SUB>3</SUB>
(PO<SUB>4</SUB>)<SUB>2</SUB>    + H<SUB>2</SUB>O &#151;&gt; Ca<SUB>9</SUB>(HPO<S
UB>4</SUB>)(PO<SUB>4</SUB>)5OH    ). The BG (3i Innovations, S&atilde;o Paulo, S
P, Brazil) used in this study    had granules of a narrow size range (300-355 &#
181;m). </font></p>     ^cY#a02v26n1.htm##
00947000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704071300075002001300788#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#38#34#article#137#<p><font face="Verda
na" size="2"> For experimental standardization, the animals    were divided into
 3 groups of 7 animals each. Three bone cavities were made    in the left femur 
of each rat, proximal to the coxofemoral joint: the first    cavity, located in 
the uppermost region of the femur, was filled with CPC; the    second cavity was
 filled with BG; and the third cavity, located in the lowest    region of the fe
mur, was the control bone defect (control group, CG) and received    no graft ma
terial. Each group was then randomly divided into three observation    time poin
ts: 7, 15, and 30 days after grafting. The groups were distributed    as follows
 (<a href="#tab01">Table 1</a>): </font></p>     ^cY#a02v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#39#35#article#137#<p align="center">&n
bsp;</p>     ^cY#a02v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#40#36#article#137#<p align="center">&n
bsp;</p>     ^cY#a02v26n1.htm##
00335000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010100075002001300176#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#41#37#article#137#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a01tab01.jpg"><a name="tab01"></a>  </p>     ^cY
#a02v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#42#38#article#137#<p>&nbsp;</p>     ^c
Y#a02v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#43#39#article#137#<p>&nbsp;</p>     ^c
Y#a02v26n1.htm##
00519000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028500075002001300360#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#44#40#article#137#<p><font face="Verda
na" size="2"> Initially, the animals were anesthetized with    20 mg/kg tiletami
ne-zolazepam combined (0.4 mL/kg) (Zoletil 50, Virbac, S&atilde;o    Paulo, Bras
il) intramuscularly, supplemented with half the dosage, if necessary    (0.2 mL/
kg). </font></p>     ^cY#a02v26n1.htm##
00735000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050100075002001300576#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#45#41#article#137#<p><font face="Verda
na" size="2"> Trichotomy was then performed in the coxofemoral    joint region, 
followed by antisepsis of the region with 2% alcohol-based iodophor.    Surgical
 access to the left femur was established by means of an incision of    approxim
ately 2.0 cm through the skin and subcutaneous tissue, with tissue tearing    ov
er the muscle and periosteum layers, in the upper left medial region, allowing  
  direct access to the exposed surface of the femoral shaft. </font></p>     ^cY
#a02v26n1.htm##
00866000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704063200075002001300707#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#46#42#article#137#<p><font face="Verda
na" size="2"> A titanium surgical guide was manufactured in    order to standard
ize the perforations, which were equally spaced. Bone perforations    were made 
using a 3.8-mm diameter trephine drill (Promm&#174;, Porto Alegre-RS,    Brazil)
, to create a &quot;critical size defect&quot; and prevent postoperative    femo
ral fractures, according to previous studies5 and an electric motor (Driller    
BLM600&#174;, Sao Paulo-SP, Brazil) coupled with a handpiece (KAVO&#174;, Bibera
ch,    Germany). The depth of the created defects was determined by the rupture 
of    the cortical bone marrow. </font></p>     ^cY#a02v26n1.htm##
00577000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034300075002001300418#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#47#43#article#137#<p><font face="Verda
na" size="2"> The first perforation was made in the lateral    surface of the le
ft femur, proximal to the coxofemoral joint. The second and    third perforation
s were made following the surgical guide and the same procedures    employed to 
produce the first bone defect (<a href="#img01">Figure 1</a>). </font></p>     ^
cY#a02v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#48#44#article#137#<p align="center">&n
bsp;</p>     ^cY#a02v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#49#45#article#137#<p align="center">&n
bsp;</p>     ^cY#a02v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#50#46#article#137#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a01img01.jpg"><a name="img01"></a></p>     ^cY#a
02v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#51#47#article#137#<p align="center">&n
bsp;</p>     ^cY#a02v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#52#48#article#137#<p align="center">&n
bsp;</p>     ^cY#a02v26n1.htm##
00407000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017300075002001300248#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#53#49#article#137#<p><font face="Verda
na" size="2"> Suture was performed in layers using absorbable    suture material
 (Vicryl 4.0 - Ethicon, Johnson &amp; Johnson, USA). </font></p>     ^cY#a02v26n
1.htm##
00803000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056900075002001300644#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#54#50#article#137#<p><font face="Verda
na" size="2"> After the surgical procedure, the animals received    40,000 IU/kg
 benzathine penicillin G (single dose) intramuscularly as </font><font face="Ver
dana" size="2">antibiotic    coverage. Topical Terramycin eye ointment (Pfizer, 
USA) and larvicide spray    (Lepecid, Dow Quimica Industrial Ltda, Sao Paulo, Br
azil) were applied on the    suture for 10 days as an antiseptic measure on the 
site of the surgical wound.    Each animal received oral analgesia (paracetamol 
drops), at a maximum daily    dose of 200 mg/kg. </font></p>     ^cY#a02v26n1.ht
m##
00785000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055100075002001300626#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#55#51#article#137#<p><font face="Verda
na" size="2"> For the acquisition of individual digital radiographs,    the anim
als, previously sedated, were secured in a standard position on a flat    acryli
c platform. A rod guided the position of the cone of the X-ray machine    to sta
ndardize the incidence of the central ray perpendicular to the horizontal    pla
ne, with 20-cm focal length. The place of the radiographic sensor was also    es
tablished on the platform so that this position remained the same for all    the
 necessary radiographic scans. </font></p>     ^cY#a02v26n1.htm##
00631000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039700075002001300472#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#56#52#article#137#<p><font face="Verda
na" size="2"> Digital radiographs were obtained using a direct    digital CCD sy
stem (Cygnus Ray MPS; Progeny, Buffalo Grove, IL, USA), a Gnatus    70X apparatu
s (Gnatus Equipamentos Medico-Odontologicos Ltda, Ribeirao Preto-SP,    Brazil) 
operating at 70 kVp and 10 mA, 20-cm focal length, and 0.25-second exposure    t
ime (<a href="#img02">Figure 2</a>). </font></p>     ^cY#a02v26n1.htm##
01588000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704135400075002001301429#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#57#53#article#137#<p><font face="Verda
na" size="2"> To obtain optical density values, the images    were imported into
 Adobe Photoshop v.6.0 (Adobe Systems, San Jose, CA, USA),    in which, using th
e histogram command, we obtained density mean values and standard    deviation o
f areas corresponding to graft materials and control defects, as    well as an u
nchanged area of normal bone tissue, which served as a parameter    for calculat
ing the difference in optical density. To obtain optical density    values from 
the exact site where femoral bone cavities were made, a digital    mask was desi
gned based on the scanned image of the surgical guide used in the    creation of
 bone defects during the surgical technique. The difference between    each area
 of unchanged bone tissue and each test area in the same femur was    then calcu
lated. Positive values represented gain and negative values expressed    loss of
 optical density in the radiographic images. The digital radiographs    revealed
 femoral fracture in 2 animals of the 30-day group and in 1 animal of    the 7-d
ay group. The results were stored in an Excel database for Windows (Microsoft   
 Corporation, Redmond, WA, USA) and then subjected to statistical analysis of   
 variance (ANOVA) using the Friedman and Kruskal-Wallis nonparametric tests,    
with a significance level of 5%. </font></p>      ^cY#a02v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#58#54#article#137#<p>&nbsp; </p>     ^
cY#a02v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#59#55#article#137#<p><font face="Verda
na" size="3"><B>Results</B> </font></p>      ^cY#a02v26n1.htm##
00342000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010800075002001300183#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#60#56#article#137#<p><font face="Verda
na" size="2"><I> Analysis of optical density between groups</I>    </font></p>  
    ^cY#a02v26n1.htm##
00468000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704023400075002001300309#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#61#57#article#137#<p><font face="Verda
na" size="2"> A comparative analysis of the biomaterials grafted    into the rat
 femurs (CPC and BG) and GC (without material) was performed between    groups 7
, 15, and 30 days after grafting. </font></p>     ^cY#a02v26n1.htm##
00876000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704064200075002001300717#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#62#58#article#137#<p><font face="Verda
na" size="2"> According to the Friedman nonparametric test,    complemented by i
ts multiple comparison test, at a significance level of 5%,    Group I (CPC) sho
wed significantly higher optical density values than Group    III (control) in a
ll observation periods. Group I also had higher optical density    values, altho
ugh not statistically significant, than Group II (BG), in all observation    per
iods. When Groups II and III were compared, Group II showed higher optical    de
nsity values, without statistically significant difference, in all observation  
  periods (<a href="#tab02">Table 2</a>). </font></p>     ^cY#a02v26n1.htm##
00272000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003800075002001300113#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#63#59#article#137#<p align="center">&n
bsp; </p>     ^cY#a02v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#64#60#article#137#<p align="center">&n
bsp;</p>     ^cY#a02v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#65#61#article#137#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a01img02.jpg"><a name="img02"></a></p>     ^cY#a
02v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#66#62#article#137#<p>&nbsp;</p>     ^c
Y#a02v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#67#63#article#137#<p>&nbsp;</p>     ^c
Y#a02v26n1.htm##
00335000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010100075002001300176#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#68#64#article#137#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a01tab02.jpg"><a name="tab02"></a>  </p>     ^cY
#a02v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#69#65#article#137#<p align="center">&n
bsp;</p>     ^cY#a02v26n1.htm##
00273000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003900075002001300114#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#70#66#article#137#<p align="center">&n
bsp; </p>      ^cY#a02v26n1.htm##
00456000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022200075002001300297#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#71#67#article#137#<p><font face="Verda
na" size="2"> AN analysis of the biomaterials grafted into    the rat femurs (CP
C and BG) and GC (without material) was performed within groups    7, 15, and 30
 days after grafting. </font></p>     ^cY#a02v26n1.htm##
00743000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050900075002001300584#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#72#68#article#137#<p><font face="Verda
na" size="2"> According to the Kruskal-Wallis nonparametric    test, complemente
d by its multiple comparison test, at a significance level    of 5%, differences
 in optical density for Groups I and II were significantly    lower at day 7 tha
n after 15 and 30 days. In Group III, the difference at day    7 did not differ 
significantly from that at day 15, and both were significantly    lower than tha
t observed 30 days after grafting (<a href="#tab03">Table 3</a>).    </font></p>
     ^cY#a02v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#73#69#article#137#<p>&nbsp; </p>     ^
cY#a02v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#74#70#article#137#<p>&nbsp;</p>     ^c
Y#a02v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#75#71#article#137#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a01tab03.jpg"><a name="tab03"></a></p>     ^cY#a
02v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#76#72#article#137#<p>&nbsp;</p>      ^
cY#a02v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#77#73#article#137#<p>&nbsp; </p>     ^
cY#a02v26n1.htm##
00306000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007200075002001300147#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#78#74#article#137#<p><font face="Verda
na" size="3"><B>Discussion</B> </font></p>      ^cY#a02v26n1.htm##
00540000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704030600075002001300381#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#79#75#article#137#<p><font face="Verda
na" size="2"> The results obtained reveal a consistently higher    optical densi
ty of biomaterials in relation to the control group in all observation    period
s, indicating CPC as the best option in the repair of bone defects when    compa
red to the control group. </font></p>     ^cY#a02v26n1.htm##
01089000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704085500075002001300930#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#80#76#article#137#<p><font face="Verda
na" size="2"> The values observed at day 7 suggest that the    mere presence of 
particles of these products filling the cavities already yields    higher densit
y values in relation to the natural process of bone regeneration,    as reported
 by V&auml;lim&auml;ki <I>et al.</I>6 and Sanzana <I>et al.</I>7    This phenome
non demonstrates the important role that the biomaterials studied    play as sca
ffolds for bone healing and new bone formation, since they are replaced    with 
bone tissue over time, through a phenomenon known as osteotransduction8.    At t
he same time, they promote faster bone regeneration due to their osteoconductive
    and osteoinductive properties3, through which the biomaterials seemed to ind
uce    the process of bone repair and new bone formation earlier than in the con
trol    group. </font></p>     ^cY#a02v26n1.htm##
01227000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704099300075002001301068#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#81#77#article#137#<p><font face="Verda
na" size="2"> CPC arises as one of the most promising biomaterials,    because i
t is well tolerated by the body and does not present chronic inflammatory    res
ponse, toxic reactions, or foreign body reactions; in addition, it establishes  
  a solid union with adjacent bone, with subsequent replacement with mature bone
3.    However, CPC requires a careful application technique, since, if the mater
ial    is not inserted appropriately into the bone defect or if contamination by
 fluids    occurs in the postoperative period, CPC may dissociate into small par
ticles    triggering an inflammatory reaction4. In the present study, the biomat
erials    showed uniform radiopacity in the cavities during the observation peri
ods, demonstrating    good handling, insertion, and stability of materials. Thus
, we believe that    the biomaterials met the characteristics required of an ide
al material which    include unlimited availability and filling ability. </font>
</p>     ^cY#a02v26n1.htm##
00716000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048200075002001300557#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#82#78#article#137#<p><font face="Verda
na" size="2"> Clinical applications of BG in dentistry have    become a common p
ractice, since BG belongs to a group of biomaterials that are    biocompatible a
nd osteopromotive, which favor osteoblast proliferation and differentiation6.   
 Moreover, BG has shown surface osteopromotive and osteoconductive ability, bioc
ompatibility    for bone migration, and a bioactive surface colonized by free os
teogenic cells    in the surgical wound9. </font></p>     ^cY#a02v26n1.htm##
01131000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704089700075002001300972#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#83#79#article#137#<p><font face="Verda
na" size="2"> When analyzing the results from the within-group    analysis, thro
ughout the observation periods, the control group showed increasing    values of
 optical density. After 30 days, optical density values were significantly    hi
gher than those observed at day 7 and 15, suggesting that a proper process    of
 new bone formation occurred inside these cavities. According to Schenk <I>et   
 al.</I>10, new bone formation within these defects begins in 2 days and, after 
   4 weeks, small or large defects (0.1 to 5.0 mm) are filled with compact bone.
    However, the process still depends on the defect size, and complete remodeli
ng    may persist for weeks or even some months. In the three observation period
s    analyzed, there was no significant difference between the two biomaterials,
    but CPC always showed higher optical density values. </font></p>     ^cY#a02
v26n1.htm##
01227000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704099300075002001301068#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#84#80#article#137#<p><font face="Verda
na" size="2"> The experimental model used is justified, since    there are no no
n-animal alternatives, in agreement with the current concepts    of bioethics, v
erifying this type of study in the literature. The choice of    rat femoral bone
 tissue as the defect site in the present study was based on    technical ration
ale, such as easy handling, compatible bone structure, and functional    resista
nce11. Both test and control defects were made in the rat left femur    to maint
ain as much as possible the same variables for all groups. Repair of    bone def
ects is a good model to study bone regeneration, being also very similar    to t
he direct or primary repair of fractures. During </font><font face="Verdana" siz
e="2">radiographic    assessment, femoral fracture was detected in some animals,
 reducing the sample    size. We believe that not filling the control defect may
 have acted as an adjuvant    factor in the etiology of these fractures. </font>
</p>     ^cY#a02v26n1.htm##
00860000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704062600075002001300701#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#85#81#article#137#<p><font face="Verda
na" size="2"> Although histological evaluation is considered    the gold standar
d for assessing bone growth inside bone cavities and defects,    this technique 
has some limitations. An important limitation is the fact that    the histologic
al section represents a specific area of the defect site, not    the entire defe
ct, thus excluding diversity in the sections and hindering comparison    of the 
results. Bone growth inside cavities may exhibit an irregular pattern,    and hi
stological analysis using sections from the center might not represent    bone g
rowth in other regions12. </font></p>     ^cY#a02v26n1.htm##
01061000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704082700075002001300902#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#86#82#article#137#<p><font face="Verda
na" size="2"> Digital imaging systems have been widely used    in Dental Radiolo
gy, which, in view of the few studies evaluating radiopacity    of these biomate
rials in the early stages of bone regeneration, motivated the    development of 
this research. Furthermore, these systems show similar patterns    when expressi
ng variation in relation to the thickness of the material evaluated13.    They c
an be used not only as a tool for assessing cases of fractures, but also    to e
valuate procedures that involve bone repair and regeneration14, meeting    the o
bjective proposed in the present study. The acquisition of digital radiographs  
  with animals secured on a radiographic platform, as described in the methods, 
   enabled us to obtain standardized, good quality radiographs15. </font></p>   
   ^cY#a02v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#87#83#article#137#<p>&nbsp; </p>     ^
cY#a02v26n1.htm##
00306000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007200075002001300147#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#88#84#article#137#<p><font face="Verda
na" size="3"><B>Conclusion</B> </font></p>      ^cY#a02v26n1.htm##
00547000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031300075002001300388#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#89#85#article#137#<p><font face="Verda
na" size="2"> Calcium phosphate cement was the best option    for restoration of
 bone defects when compared to the control group. In relation    to bioactive gl
ass, calcium phosphate cement showed better results, although    without statist
ically significant differences. </font></p>      ^cY#a02v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#90#86#article#137#<p>&nbsp; </p>     ^
cY#a02v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007400075002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#91#87#article#137#<p> <font face="Verd
ana" size="3"><B>References </B> </font></p>      ^cY#a02v26n1.htm##
00486000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704023800077002001300315#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#92#88#article#137#1#<p><fo
nt face="Verdana" size="2">1. Habraken WJEM, De Jonge LT, Wolke JGC, Yubao    L,
 Mikos AG, Jansen JA. Introduction of gelatin microspheres into an injectable   
 calcium phosphate cement. J Biomed Mater Res A. 2008;87:643-55.    ^cY#a02v26n1
.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#93#89#article#137# </font></p>     ^cY
#a02v26n1.htm##
00479000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704023100077002001300308#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#94#90#article#137#2#<p><fo
nt face="Verdana" size="2">2. Leu A, Stieger SM, Dayton P, Ferrara KW, Leach    
JK. Angiogenic response to bioactive glass promotes bone healing in an irradiate
d    calvarial defect. Tissue Eng Part A. 2009;15:877-85.    ^cY#a02v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#95#91#article#137# </font></p>     ^cY
#a02v26n1.htm##
00467000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704021900077002001300296#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#96#92#article#137#3#<p><fo
nt face="Verdana" size="2">3. Macedo NL, Matuda FS, Macedo LS, Gonzalez    MB, O
uchi SM, Carvalho YR. Bone defect regeneration with bioactive glass implantation
    in rats. J Appl Oral Sci. 2004;12:137-43.    ^cY#a02v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#97#93#article#137# </font></p>     ^cY
#a02v26n1.htm##
00491000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704024300077002001300320#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#98#94#article#137#4#<p><fo
nt face="Verdana" size="2">4. Moghadam HG, S&aacute;ndor GK, Holmes HH,    Cloki
e CM. Histomorphometric evaluation of bone regeneration using allogeneic    and 
alloplastic bone substitutes. J Oral Maxillofac Surg. 2004;62:202-13.    ^cY#a02
v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#99#95#article#137# </font></p>     ^cY
#a02v26n1.htm##
00521000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000200076704027200078002001300350#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#100#96#article#137#5#<p><f
ont face="Verdana" size="2">5. Le Guehennec L, Goyenvalle E, Aguado E, Houchmand
-Cuny    M, Enkel B, Pilet P, Daculsi G, Layrolle P. Small-animal models for tes
ting    macroporous ceramic bone substitutes. J Biomed Mater Res B Appl Biomater
. 2005;72(1):69-78.    ^cY#a02v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002400076002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#101#97#article#137#    </font></p>    
 ^cY#a02v26n1.htm##
00495000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000200076704024600078002001300324#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#102#98#article#137#6#<p><f
ont face="Verdana" size="2">6. V&auml;lim&auml;ki VV, Moritz N, Yrjans J,    Dal
astra M, Aro HT. Peripheral quantitative computed tomography in evaluation    of
 bioactive glass incorporation with bone. Biomaterials. 2005;26:6693-703.    ^cY
#a02v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002400076002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#103#99#article#137#    </font></p>    
 ^cY#a02v26n1.htm##
00481000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704023100079002001300310#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#104#100#article#137#7#<p><
font face="Verdana" size="2">7. Sanzana ES, Navarro M, Macule F, Suso S, Planell
    JA, Ginebra MP. Of the in vivo behavior of calcium phosphate cements and gla
sses    as bone substitutes. Acta Biomater. 2008;4:1924-33.    ^cY#a02v26n1.htm#
#
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#105#101#article#137# </font></p>     ^
cY#a02v26n1.htm##
00426000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704017600079002001300255#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#106#102#article#137#8#<p><
font face="Verdana" size="2">8. V&auml;limaki VV, Aro HT. Molecular basis    for
 action of bioactive glasses as bone graft substitute. Scand J Surg. 2006;95:95-
102.    ^cY#a02v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#107#103#article#137#    </font></p>   
  ^cY#a02v26n1.htm##
00449000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704019900079002001300278#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#108#104#article#137#9#<p><
font face="Verdana" size="2">9. Schepers E, de Clercq M, Ducheyne P, Kempeneers 
   R. Bioactive glass particulate material as a filler for bone lesions. J Oral 
   Rehabil. 1991;18:439-52.    ^cY#a02v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#109#105#article#137# </font></p>     ^
cY#a02v26n1.htm##
00501000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025000080002001300330#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#110#106#article#137#10#<p>
<font face="Verdana" size="2">10. Schenk RK, Buser D, Hardwick WR, Dahlin C.    
Healing pattern of bone regeneration in membrane-protected defects: a histologic
    study in the canine mandible. Int J Oral Maxillofac Implants. 1994;9:13-29. 
   ^cY#a02v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#111#107#article#137#    </font></p>   
  ^cY#a02v26n1.htm##
00444000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019300080002001300273#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#112#108#article#137#11#<p>
<font face="Verdana" size="2">11. Yuan H, Li Y, de Bruijn JD, de Groot K, Zhang 
   X. Tissue responses of calcium phosphate cement: a study in dogs. Biomaterial
s.    2000;21:1283-90.    ^cY#a02v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#113#109#article#137# </font></p>     ^
cY#a02v26n1.htm##
00482000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023100080002001300311#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#114#110#article#137#12#<p>
<font face="Verdana" size="2">12. Schortinghuis J, Ruben JL, Meijer HJA, Bronker
s    AJ, Raghoebar GM, Stegenga B. Microradiography to evaluate bone growth into
    a rat mandibular defect. Arch Oral Biol. 2003;48:155-60.    ^cY#a02v26n1.htm
##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#115#111#article#137# </font></p>     ^
cY#a02v26n1.htm##
00462000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021100080002001300291#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#116#112#article#137#13#<p>
<font face="Verdana" size="2">13. Farman AG, Farman TT. A comparison of 18    di
fferent x-ray detectors currently used in dentistry. Oral Surg Oral Med Oral    
Pathol Oral Radiol Endod. 2005;99:485-9.    ^cY#a02v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#117#113#article#137# </font></p>     ^
cY#a02v26n1.htm##
00478000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022700080002001300307#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#118#114#article#137#14#<p>
<font face="Verdana" size="2">14. Bozzo RO; Rocha RG; Haiter Neto F; Paganini   
 GA; Cavalcanti MGP. Linear density analysis of bone repair in rats using digita
l    direct radiograph. J Appl Oral Sci. 2004;12:317-21.    ^cY#a02v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#119#115#article#137# </font></p>     ^
cY#a02v26n1.htm##
00478000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022700080002001300307#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#p#120#116#article#137#15#<p>
<font face="Verdana" size="2">15. Mahl CRW, Fontanella V. Evaluation by digital 
   subtraction radiography of induced changes in the bone density of the female 
   rat mandible. Dentomaxillofac Radiol. 2008;37:438-44.    ^cY#a02v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#121#117#article#137# </font></p>      
^cY#a02v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#122#118#article#137#<p>&nbsp; </p>    
 ^cY#a02v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#123#119#article#137#<p>&nbsp;</p>     
^cY#a02v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#124#120#article#137#<p>&nbsp; </p>    
 ^cY#a02v26n1.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704015500077002001300232#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#125#121#article#137#<p><font face="Ver
dana" size="2"><B><a name="end"></a><a href="#top"><img src="/img/revistas/acb/v
26n1/seta.gif" border="0"></a>Correspondence</B>:    ^cY#a02v26n1.htm##
00298000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006200077002001300139#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#126#122#article#137#<br>   Dr. Aurel&i
acute;cio Novaes Silva J&uacute;nior    ^cY#a02v26n1.htm##
00282000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004600077002001300123#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#127#123#article#137#<br>   Universidad
e Luterana do Brasil    ^cY#a02v26n1.htm##
00319000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704008300077002001300160#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#128#124#article#137#<br>   Faculdade d
e Odontologia - Depto. P&oacute;s-Gradua&ccedil;&atilde;o    ^cY#a02v26n1.htm##
00289000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005300077002001300130#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#129#125#article#137#<br>   Rua Farroup
ilha, 8001/Pr&eacute;dio 59    ^cY#a02v26n1.htm##
00279000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004300077002001300120#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#130#126#article#137#<br>   92425-900 C
anoas _ RS Brasil    ^cY#a02v26n1.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004200077002001300119#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#131#127#article#137#<br>   Phone/Fax: 
(55 51)9229-8277    ^cY#a02v26n1.htm##
00339000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010300077002001300180#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#132#128#article#137#<br>   <a href="ma
ilto:aurelicio.junior@uol.com.br">aurelicio.junior@uol.com.br</a></font></p>    
 ^cY#a02v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#133#129#article#137#<p>&nbsp; </p>    
 ^cY#a02v26n1.htm##
00300000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006400077002001300141#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#134#130#article#137#<p><font face="Ver
dana" size="2">Received: July 14, 2010    ^cY#a02v26n1.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#135#131#article#137#<br>   </font><fon
t face="Verdana" size="2">Review: September 20, 2010    ^cY#a02v26n1.htm##
00327000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009100077002001300168#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#136#132#article#137#<br>   </font><fon
t face="Verdana" size="2">Accepted: October 19, 2010 </font></p>     ^cY#a02v26n
1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006700077002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#137#133#article#137#<p><font face="Ver
dana" size="2">Conflict of interest: none    ^cY#a02v26n1.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704008700077002001300164#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#138#134#article#137#<br>   </font><fon
t face="Verdana" size="2">Financial source: none </font></p>     ^cY#a02v26n1.ht
m##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#139#135#article#137#<p>&nbsp;</p>     
^cY#a02v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#140#136#article#137#<p>&nbsp;</p>     
^cY#a02v26n1.htm##
00716000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704048000077002001300557#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a02v26n1.htm#S#p#141#137#article#137#<p><font face="Ver
dana" size="2"><a name="end"></a><a href="#top">1</a> Research    performed at t
he Animal Experimentation Unit, Research Center, Department of    Veterinary Med
icine, School of Veterinary Medicine, Lutheran University of Brazil    (ULBRA), 
Canoas-RS, Brazil. <i>Part of the dissertation of the first author.    Tutor: Au
rel&iacute;cio Novaes Silva Jr, Postgraduate Program on Oral and Maxillofacial  
  Surgery, School of Dentistry, ULBRA</i>.</font></p>     ^cY#a02v26n1.htm##
00650000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100021000760100019000970100
01700116010001500133010001600148010001700164012008500181030002200266710000200288
065000900290064000500299031000300304014000700307865000900314002001300323#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#c#142#1#article#15#1#^rND^sHabra
ken^nWJEM#^rND^sDe Jonge^nLT#^rND^sWolke^nJGC#^rND^sYubao^nL#^rND^sMikos^nAG#^rN
D^sJansen^nJA#Introduction of gelatin microspheres into an injectable calcium ph
osphate cement^len#J Biomed Mater Res A.#2#20080000#2008#87#643-55#20110200#a02v
26n1.htm##
00625000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100013000760100018000890100
01600107010001800123010001600141012009900157030001900256710000200275065000900277
064000500286031000300291014000700294865000900301002001300310#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a02v26n1.htm#S#c#143#2#article#15#2#^rND^sLeu^nA#^rND^sStie
ger^nSM#^rND^sDayton^nP#^rND^sFerrara^nKW#^rND^sLeach^nJK#Angiogenic response to
 bioactive glass promotes bone healing in an irradiated calvarial defect^len#Tis
sue Eng Part A.#2#20090000#2009#15#877-85#20110200#a02v26n1.htm##
00631000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100017000930100
01700110010001900127010001600146010001900162012007100181030001700252710000200269
065000900271064000500280031000300285014000700288865000900295002001300304#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#c#144#3#article#15#3#^rND^sMaced
o^nNL#^rND^sMatuda^nFS#^rND^sMacedo^nLS#^rND^sGonzalez^nMB#^rND^sOuchi^nSM#^rND^
sCarvalho^nYR#Bone defect regeneration with bioactive glass implantation in rats
^len#J Appl Oral Sci.#2#20040000#2004#12#137-43#20110200#a02v26n1.htm##
00612000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100017000950100
01700112010001700129012010400146030002400250710000200274065000900276064000500285
031000300290014000700293865000900300002001300309#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a02v26n1.htm#S#c#145#4#article#15#4#^rND^sMoghadam^nHG#^rND^sSándor^nGK
#^rND^sHolmes^nHH#^rND^sClokie^nCM#Histomorphometric evaluation of bone regenera
tion using allogeneic and alloplastic bone substitutes^len#J Oral Maxillofac Sur
g.#2#20040000#2004#62#202-13#20110200#a02v26n1.htm##
00731000000000349000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100022000760100020000980100
01600118010002400134010001500158010001500173010001700188010001800205012007300223
03000360029671000020033206500090033406400050034303100030034803200020035101400060
0353865000900359002001300368#v26n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.ht
m#S#c#146#5#article#15#5#^rND^sLe Guehennec^nL#^rND^sGoyenvalle^nE#^rND^sAguado^
nE#^rND^sHouchmand-Cuny^nM#^rND^sEnkel^nB#^rND^sPilet^nP#^rND^sDaculsi^nG#^rND^s
Layrolle^nP#Small-animal models for testing macroporous ceramic bone substitutes
^len#J Biomed Mater Res B Appl Biomater.#2#20050000#2005#72#1#69-78#20110200#a02
v26n1.htm##
00630000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100016000950100
01600111010001800127010001400145012010500159030001400264710000200278065000900280
064000500289031000300294014000900297865000900306002001300315#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a02v26n1.htm#S#c#147#6#article#15#6#^rND^sVälimäki^nVV#^rND
^sMoritz^nN#^rND^sYrjans^nJ#^rND^sDalastra^nM#^rND^sAro^nHT#Peripheral quantitat
ive computed tomography in evaluation of bioactive glass incorporation with bone
^len#Biomaterials.#2#20050000#2005#26#6693-703#20110200#a02v26n1.htm##
00643000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100017000940100
01600111010001400127010001800141010001800159012008900177030001500266710000200281
065000900283064000500292031000200297014000800299865000900307002001300316#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#c#148#7#article#15#7#^rND^sSanza
na^nES#^rND^sNavarro^nM#^rND^sMacule^nF#^rND^sSuso^nS#^rND^sPlanell^nJA#^rND^sGi
nebra^nMP#Of the in vivo behavior of calcium phosphate cements and glasses as bo
ne substitutes^len#Acta Biomater.#2#20080000#2008#4#1924-33#20110200#a02v26n1.ht
m##
00514000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100014000950120
07700109030001400186710000200200065000900202064000500211031000300216014000700219
865000900226002001300235#v26n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#
c#149#8#article#15#8#^rND^sVälimaki^nVV#^rND^sAro^nHT#Molecular basis for action
 of bioactive glasses as bone graft substitute^len#Scand J Surg.#2#20060000#2006
#95#95-102#20110200#a02v26n1.htm##
00575000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100019000940100
01800113010002000131012007000151030001600221710000200237065000900239064000500248
031000300253014000700256865000900263002001300272#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a02v26n1.htm#S#c#150#9#article#15#9#^rND^sSchepers^nE#^rND^sde Clercq^n
M#^rND^sDucheyne^nP#^rND^sKempeneers^nR#Bioactive glass particulate material as 
a filler for bone lesions^len#J Oral Rehabil.#2#19910000#1991#18#439-52#20110200
#a02v26n1.htm##
00627000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100015000950100
01900110010001600129012011400145030003200259710000200291065000900293064000500302
031000200307014000600309865000900315002001300324#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a02v26n1.htm#S#c#151#10#article#15#10#^rND^sSchenk^nRK#^rND^sBuser^nD#^
rND^sHardwick^nWR#^rND^sDahlin^nC#Healing pattern of bone regeneration in membra
ne-protected defects: a histologic study in the canine mandible^len#Int J Oral M
axillofac Implants.#2#19940000#1994#9#13-29#20110200#a02v26n1.htm##
00588000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100012000920100
02000104010001800124010001500142012006600157030001400223710000200237065000900239
064000500248031000300253014000800256865000900264002001300273#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a02v26n1.htm#S#c#152#11#article#15#11#^rND^sYuan^nH#^rND^sL
i^nY#^rND^sde Bruijn^nJD#^rND^sde Groot^nK#^rND^sZhang^nX#Tissue responses of ca
lcium phosphate cement: a study in dogs^len#Biomaterials.#2#20000000#2000#21#128
3-90#20110200#a02v26n1.htm##
00644000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100023000780100016001010100
01800117010001900135010002000154010001800174012007400192030001600266710000200282
065000900284064000500293031000300298014000700301865000900308002001300317#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#c#153#12#article#15#12#^rND^sSch
ortinghuis^nJ#^rND^sRuben^nJL#^rND^sMeijer^nHJA#^rND^sBronkers^nAJ#^rND^sRaghoeb
ar^nGM#^rND^sStegenga^nB#Microradiography to evaluate bone growth into a rat man
dibular defect^len#Arch Oral Biol.#2#20030000#2003#48#155-60#20110200#a02v26n1.h
tm##
00552000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950120
07700112030005000189710000200239065000900241064000500250031000300255014000600258
865000900264002001300273#v26n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#
c#154#13#article#15#13#^rND^sFarman^nAG#^rND^sFarman^nTT#A comparison of 18 diff
erent x-ray detectors currently used in dentistry^len#Oral Surg Oral Med Oral Pa
thol Oral Radiol Endod.#2#20050000#2005#99#485-9#20110200#a02v26n1.htm##
00622000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100016000940100
02100110010001900131010002200150012008300172030001700255710000200272065000900274
064000500283031000300288014000700291865000900298002001300307#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a02v26n1.htm#S#c#155#14#article#15#14#^rND^sBozzo^nRO#^rND^
sRocha^nRG#^rND^sHaiter Neto^nF#^rND^sPaganini^nGA#^rND^sCavalcanti^nMGP#Linear 
density analysis of bone repair in rats using digital direct radiograph^len#J Ap
pl Oral Sci.#2#20040000#2004#12#317-21#20110200#a02v26n1.htm##
00568000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100020000940120
11600114030002400230710000200254065000900256064000500265031000300270014000700273
865000900280002001300289#v26n1#V:\Scielo\serial\acb\v26n1\markup\a02v26n1.htm#S#
c#156#15#article#15#15#^rND^sMahl^nCRW#^rND^sFontanella^nV#Evaluation by digital
 subtraction radiography of induced changes in the bone density of the female ra
t mandible^len#Dentomaxillofac Radiol.#2#20080000#2008#37#438-44#20110200#a02v26
n1.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v26n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#o#1#1#article#1#
20110120#130126#a03v26n1.htm#170##
04892000000000733000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400080014103500100014901200900
01590120113002490100038003620100033004000100042004330100038004750100030005130100
03200543070010400575070008200679070005800761070011500819070011500934070009601049
08312510114508500080239608500360240408500230244008500270246308500250249008314140
25150850008039290850037039370850027039740850026040010850032040271170006040590720
00304065112000904068111001404077116000904091115001904100114000904119113001704128
002001304145#v26n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#h#2#1#articl
e#1#oa#en#br1.1#1#4.0#ILUS#TAB#03#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f7^l1
1#0102-8650#Use of calcium phosphate cement scaffolds for bone tissue engineerin
g: in vitro study^len#A utilização do cimento de fosfato de cálcio como arcabouç
o para engenharia de tecido ósseo: estudo in vitro^lpt#^rND^1A01^nTaís Somacal N
ovaes^sSilva#^rND^1A02^nBruno Tochetto^sPrimo#^rND^1A03^nAurelício Novaes^sSilva
 Júnior#^rND^1A04^nDenise Cantarelli^sMachado#^rND^1A05^nChristian^sViezzer#^rND
^1A06^nLuis Alberto^sSantos#PUCRS^iA01^1School of Dentistry^2Department of Oral 
and Maxillofacial Surgery^cPorto Alegre^sRS^pBrazil#Lutheran University of Brazi
l^iA02^1School of Dentistry^2OMFS^cCanoas^sRS^pBrazil#ULBRA^iA03^1School of Dent
istry^2OMFS^cCanoas^sRS^pBrazil#PUCRS^iA04^1School of Dentistry^2Department of C
ellular Biology and Respiratory Diseases^cPorto Alegre^sRS^pBrazil#PUCRS^iA05^1S
chool of Dentistry^2Department of Cellular Biology and Respiratory Diseases^cPor
to Alegre^sRS^pBrazil#UFRGS^iA06^1School of Mechanical Engineering^2Department o
f Materials^cPorto Alegre^sRS^pBrazil#^len^aPurpose: To evaluate the ability of 
macroporous tricalcium phosphate cement (CPC) scaffolds to enable the adhesion, 
proliferation, and differentiation of mesenchymal stem cells derived from human 
bone marrow. Methods: Cells from the iliac crest of an adult human donor were pr
ocessed and cultured on macroporous CPC discs. Paraffin spheres sized between 10
0 and 250µm were used as porogens. Cells were cultured for 5, 10, and 15 days. N
ext, we assessed cells' behavior and morphology on the biomaterial by scanning e
lectron microscopy. The expression levels of the BGLA and SSP1 genes and the alk
aline phosphatase (ALP) activity were quantified by the quantitative real-time p
olymerase chain reaction technique (QT-PCR) using the fluorophore SYBR GREEN®. R
esults: QT-PCR detected the expression of the BGLA and SSP1 genes and the ALP ac
tivity in the periods of 10 and 15 days of culture. Thus, we found out that ther
e was cell proliferation and differentiation in osteogenic cells. Conclusion: Ma
croporous CPC, with pore sized between 100 and 250µm and developed using paraffi
n spheres, enables adhesion, proliferation, and differentiation of mesenchymal s
tem cells in osteogenic cells and can be used as a scaffold for bone tissue engi
neering.#^dnd^i1#^tm^len^kBiocompatible Materials^i1#^tm^len^kStem Cells^i1#^tm^
len^kBioengineering^i1#^tm^len^kBone Cements^i1#^lpt^aObjetivo: Avaliar a capaci
dade de suportes tridimensionais macroporosos de cimento de fosfato de cálcio (C
FC), de permitir a adesão, proliferação e diferenciação de células-tronco mesenq
uimais derivadas da medula óssea humana. Métodos: células obtidas da crista ilía
ca de um doador humano adulto foram processadas e cultivadas sobre suportes de C
FC, macroporosos, que tiveram como corpo gerador de poros, microesferas de paraf
ina, com tamanho entre 100 e 250µm. Os períodos de cultura estabelecidos foram d
e cinco, 10 e 15 dias. Após estes períodos, o comportamento e a morfologia das c
élulas junto ao biomaterial foram avaliados por meio de Microscopia Eletrônica d
e Varredura. Os níveis de expressão dos genes BGLA e SSP1 bem como a atividade d
a Fosfatase Alcalina (ALP) foram quantificados pela técnica de PCR em Tempo Real
 (QT-PCR) utilizando o fluoróforo SYBR Green®. Resultados: O QT-PCR detectou a e
xpressão dos genes BGLA e SSP1 e a atividade da fosfatase alcalina nos períodos 
de 10 e 15 dias de cultura. No período de cinco dias, não foi observada a expres
são de nenhum dos genes investigados. Conclusão: O CFC, macroporoso, com tamanho
 de poros entre 100 e 250µm, criados por meio da utilização de microesferas de p
arafina, permite a adesão, proliferação e diferenciação de células-tronco mesenq
uimais em células osteogênicas, podendo ser utilizado como arcabouço para engenh
aria de tecido ósseo.#^dnd^i2#^tm^lpt^kMateriais Biocompatíveis^i2#^tm^lpt^kCélu
las-Tronco^i2#^tm^lpt^kBioengenharia^i2#^tm^lpt^kCimentos para ossos^i2#other#14
#20100706#July 06, 2010#20100914#September 14, 2010#20101019#October 19, 2010#a0
3v26n1.htm##
05036000000000733000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400080014103500100014901201180
01590120134002770100038004110100033004490100042004820100038005240100030005620100
03200592070010400624070008200728070005800810070011500868070011500983070009601098
08312900119408500080248408500360249208500230252808500270255108500250257808314700
26030850008040730850037040810850027041180850026041450850032041711170006042030720
00304209112000904212111001404221116000904235115001904244114000904263113001704272
002001304289#v26n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#f#3#1#articl
e#1#oa#en#br1.1#1#4.0#ILUS#TAB#03#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f7^l1
1#0102-8650#<b>Use of calcium phosphate cement scaffolds for bone tissue enginee
ring</b>: <b><i>in vitro </i></b><b>study</b>^len#<b>A utilização do cimento de 
fosfato de cálcio como arcabouço para engenharia de tecido ósseo</b>: <b>estudo 
<i>in vitro</i></b>^lpt#^rND^1A01^nTaís Somacal Novaes^sSilva#^rND^1A02^nBruno T
ochetto^sPrimo#^rND^1A03^nAurelício Novaes^sSilva Júnior#^rND^1A04^nDenise Canta
relli^sMachado#^rND^1A05^nChristian^sViezzer#^rND^1A06^nLuis Alberto^sSantos#PUC
RS^iA01^1School of Dentistry^2Department of Oral and Maxillofacial Surgery^cPort
o Alegre^sRS^pBrazil#Lutheran University of Brazil^iA02^1School of Dentistry^2OM
FS^cCanoas^sRS^pBrazil#ULBRA^iA03^1School of Dentistry^2OMFS^cCanoas^sRS^pBrazil
#PUCRS^iA04^1School of Dentistry^2Department of Cellular Biology and Respiratory
 Diseases^cPorto Alegre^sRS^pBrazil#PUCRS^iA05^1School of Dentistry^2Department 
of Cellular Biology and Respiratory Diseases^cPorto Alegre^sRS^pBrazil#UFRGS^iA0
6^1School of Mechanical Engineering^2Department of Materials^cPorto Alegre^sRS^p
Brazil#^len^a<b>Purpose</b>: To evaluate the ability of macroporous tricalcium p
hosphate cement (CPC) scaffolds to enable the adhesion, proliferation, and diffe
rentiation of mesenchymal stem cells derived from human bone marrow. <b>Methods<
/b>: Cells from the iliac crest of an adult human donor were processed and cultu
red on macroporous CPC discs. Paraffin spheres sized between 100 and 250µm were 
used as porogens. Cells were cultured for 5, 10, and 15 days. Next, we assessed 
cells' behavior and morphology on the biomaterial by scanning electron microscop
y. The expression levels of the BGLA and SSP1 genes and the alkaline phosphatase
 (ALP) activity were quantified by the quantitative real-time polymerase chain r
eaction technique (QT-PCR) using the fluorophore SYBR GREEN<sup>®</sup>. <b>Resu
lts</b>: QT-PCR detected the expression of the BGLA and SSP1 genes and the ALP a
ctivity in the periods of 10 and 15 days of culture. Thus, we found out that the
re was cell proliferation and differentiation in osteogenic cells. <b>Conclusion
</b>: Macroporous CPC, with pore sized between 100 and 250µm and developed using
 paraffin spheres, enables adhesion, proliferation, and differentiation of mesen
chymal stem cells in osteogenic cells and can be used as a scaffold for bone tis
sue engineering.#^dnd^i1#^tm^len^kBiocompatible Materials^i1#^tm^len^kStem Cells
^i1#^tm^len^kBioengineering^i1#^tm^len^kBone Cements^i1#^lpt^a<b>Objetivo</b>: A
valiar a capacidade de suportes tridimensionais macroporosos de cimento de fosfa
to de cálcio (CFC), de permitir a adesão, proliferação e diferenciação de célula
s-tronco mesenquimais derivadas da medula óssea humana. <b>Métodos</b>: células 
obtidas da crista ilíaca de um doador humano adulto foram processadas e cultivad
as sobre suportes de CFC, macroporosos, que tiveram como corpo gerador de poros,
 microesferas de parafina, com tamanho entre 100 e 250µm. Os períodos de cultura
 estabelecidos foram de cinco, 10 e 15 dias. Após estes períodos, o comportament
o e a morfologia das células junto ao biomaterial foram avaliados por meio de Mi
croscopia Eletrônica de Varredura. Os níveis de expressão dos genes <i>BGLA </i>
e <i>SSP1 </i>bem como a atividade da Fosfatase Alcalina (ALP) foram quantificad
os pela técnica de PCR em Tempo Real (QT-PCR) utilizando o fluoróforo SYBR Green
®. <b>Resultados</b>: O QT-PCR detectou a expressão dos genes <i>BGLA </i>e <i>S
SP1 </i>e a atividade da fosfatase alcalina nos períodos de 10 e 15 dias de cult
ura. No período de cinco dias, não foi observada a expressão de nenhum dos genes
 investigados. <b>Conclusão</b>: O CFC, macroporoso, com tamanho de poros entre 
100 e 250µm, criados por meio da utilização de microesferas de parafina, permite
 a adesão, proliferação e diferenciação de células-tronco mesenquimais em célula
s osteogênicas, podendo ser utilizado como arcabouço para engenharia de tecido ó
sseo.#^dnd^i2#^tm^lpt^kMateriais Biocompatíveis^i2#^tm^lpt^kCélulas-Tronco^i2#^t
m^lpt^kBioengenharia^i2#^tm^lpt^kCimentos para ossos^i2#other#14#20100706#July 0
6, 2010#20100914#September 14, 2010#20101019#October 19, 2010#a03v26n1.htm##
05034000000000757000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000150012903100030014403200020014706500090014901400080015803500100
01660120090001760120113002660100038003790100033004170100042004500100038004920100
03000530010003200560070010600592070008400698070006000782070011700842070011700959
07000980107608312510117408500080242508500360243308500230246908500270249208500250
25190831414025440850008039580850037039660850027040030850026040300850032040561170
00604088072000304094112000904097111001404106116000904120115001904129114000904148
113001704157002001304174008008904187#v26n1#V:\Scielo\serial\acb\v26n1\markup\a03
v26n1.htm#S#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#03#ACB7
20#nd#Acta cir. bras#26#1#20110200#^f7^l11#0102-8650#Use of calcium phosphate ce
ment scaffolds for bone tissue engineering: in vitro study^len#A utilização do c
imento de fosfato de cálcio como arcabouço para engenharia de tecido ósseo: estu
do in vitro^lpt#^rND^1A01^nTaís Somacal Novaes^sSilva#^rND^1A02^nBruno Tochetto^
sPrimo#^rND^1A03^nAurelício Novaes^sSilva Júnior#^rND^1A04^nDenise Cantarelli^sM
achado#^rND^1A05^nChristian^sViezzer#^rND^1A06^nLuis Alberto^sSantos#^iA01^1PUCR
S^2School of Dentistry^3Department of Oral and Maxillofacial Surgery^cPorto Aleg
re^sRS^pBrazil#^iA02^1Lutheran University of Brazil^2School of Dentistry^3OMFS^c
Canoas^sRS^pBrazil#^iA03^1ULBRA^2School of Dentistry^3OMFS^cCanoas^sRS^pBrazil#^
iA04^1PUCRS^2School of Dentistry^3Department of Cellular Biology and Respiratory
 Diseases^cPorto Alegre^sRS^pBrazil#^iA05^1PUCRS^2School of Dentistry^3Departmen
t of Cellular Biology and Respiratory Diseases^cPorto Alegre^sRS^pBrazil#^iA06^1
UFRGS^2School of Mechanical Engineering^3Department of Materials^cPorto Alegre^s
RS^pBrazil#^len^aPurpose: To evaluate the ability of macroporous tricalcium phos
phate cement (CPC) scaffolds to enable the adhesion, proliferation, and differen
tiation of mesenchymal stem cells derived from human bone marrow. Methods: Cells
 from the iliac crest of an adult human donor were processed and cultured on mac
roporous CPC discs. Paraffin spheres sized between 100 and 250µm were used as po
rogens. Cells were cultured for 5, 10, and 15 days. Next, we assessed cells' beh
avior and morphology on the biomaterial by scanning electron microscopy. The exp
ression levels of the BGLA and SSP1 genes and the alkaline phosphatase (ALP) act
ivity were quantified by the quantitative real-time polymerase chain reaction te
chnique (QT-PCR) using the fluorophore SYBR GREEN®. Results: QT-PCR detected the
 expression of the BGLA and SSP1 genes and the ALP activity in the periods of 10
 and 15 days of culture. Thus, we found out that there was cell proliferation an
d differentiation in osteogenic cells. Conclusion: Macroporous CPC, with pore si
zed between 100 and 250µm and developed using paraffin spheres, enables adhesion
, proliferation, and differentiation of mesenchymal stem cells in osteogenic cel
ls and can be used as a scaffold for bone tissue engineering.#^dnd^i1#^tm^len^kB
iocompatible Materials^i1#^tm^len^kStem Cells^i1#^tm^len^kBioengineering^i1#^tm^
len^kBone Cements^i1#^lpt^aObjetivo: Avaliar a capacidade de suportes tridimensi
onais macroporosos de cimento de fosfato de cálcio (CFC), de permitir a adesão, 
proliferação e diferenciação de células-tronco mesenquimais derivadas da medula 
óssea humana. Métodos: células obtidas da crista ilíaca de um doador humano adul
to foram processadas e cultivadas sobre suportes de CFC, macroporosos, que tiver
am como corpo gerador de poros, microesferas de parafina, com tamanho entre 100 
e 250µm. Os períodos de cultura estabelecidos foram de cinco, 10 e 15 dias. Após
 estes períodos, o comportamento e a morfologia das células junto ao biomaterial
 foram avaliados por meio de Microscopia Eletrônica de Varredura. Os níveis de e
xpressão dos genes BGLA e SSP1 bem como a atividade da Fosfatase Alcalina (ALP) 
foram quantificados pela técnica de PCR em Tempo Real (QT-PCR) utilizando o fluo
róforo SYBR Green®. Resultados: O QT-PCR detectou a expressão dos genes BGLA e S
SP1 e a atividade da fosfatase alcalina nos períodos de 10 e 15 dias de cultura.
 No período de cinco dias, não foi observada a expressão de nenhum dos genes inv
estigados. Conclusão: O CFC, macroporoso, com tamanho de poros entre 100 e 250µm
, criados por meio da utilização de microesferas de parafina, permite a adesão, 
proliferação e diferenciação de células-tronco mesenquimais em células osteogêni
cas, podendo ser utilizado como arcabouço para engenharia de tecido ósseo.#^dnd^
i2#^tm^lpt^kMateriais Biocompatíveis^i2#^tm^lpt^kCélulas-Tronco^i2#^tm^lpt^kBioe
ngenharia^i2#^tm^lpt^kCimentos para ossos^i2#other#14#20100706#July 06, 2010#201
00914#September 14, 2010#20101019#October 19, 2010#a03v26n1.htm#Internet^ihttp:/
/www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502011000100003##
00314000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704008200073002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#5#1#article#152#<p align="right"><font
 face="Verdana" size="2"><b>3 - ORIGINAL ARTICLE</b>    ^cY#a03v26n1.htm##
00283000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704005100073002001300124#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#6#2#article#152#<br>   <b>MATERIALS TE
STING</b></font></p>     ^cY#a03v26n1.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704003800073002001300111#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#7#3#article#152#<p align="right">&nbsp
;</p>       ^cY#a03v26n1.htm##
00476000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704024400073002001300317#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#8#4#article#152#<p><font face="Verdana
" size="2"><a name="top"></a></font><font face="Verdana" size="4"><b>Use    of c
alcium phosphate cement scaffolds for bone tissue engineering: <I>in vitro    </
I>study<SUP><a href="#end">1</a></SUP></b></font></p>     ^cY#a03v26n1.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#9#5#article#152#<p>&nbsp;</p>     ^cY#
a03v26n1.htm##
00450000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704021700074002001300291#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#10#6#article#152#<p><b><font face="Ver
dana" size="3">A utiliza&ccedil;&atilde;o do cimento de fosfato    de c&aacute;l
cio como arcabou&ccedil;o para engenharia de tecido &oacute;sseo:    estudo <I>i
n vitro</I> </font></b></p>     ^cY#a03v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#11#7#article#152#<p>&nbsp;</p>     ^cY
#a03v26n1.htm##
00547000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704031400074002001300388#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#12#8#article#152#<p><font face="Verdan
a" size="2"><B>Ta&iacute;s Somacal Novaes Silva<SUP>I</SUP>,    Bruno Tochetto P
rimo<SUP>II</SUP>, Aurel&iacute;cio Novaes Silva J&uacute;nior<SUP>III</SUP>,   
 Denise Cantarelli Machado<SUP>IV</SUP>, Christian Viezzer<SUP>V</SUP>, Luis    
Alberto Santos<SUP>VI</SUP></B> </font></p>      ^cY#a03v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#13#9#article#152#<p>&nbsp;</p>     ^cY
#a03v26n1.htm##
00510000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027600075002001300351#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#14#10#article#152#<p><font face="Verda
na" size="2"><SUP>I</SUP>Fellow PhD degree, Department of    Oral and Maxillofac
ial Surgery (OMFS), School of Dentistry, PUCRS, Porto Alegre-RS,    Brazil. <I>M
ain author. Conception, design, intellectual and scientific content    of the st
udy</I>.    ^cY#a03v26n1.htm##
00418000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704018400075002001300259#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#15#11#article#152#<br>   <SUP>II</SUP>
Fellow Master degree, OMFS, School of Dentistry, Lutheran University    of Brazi
l (ULBRA), Canoas-RS, Brazil. <I>Acquisition and interpretation of data</I>.    
^cY#a03v26n1.htm##
00409000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017500075002001300250#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#16#12#article#152#<br>   <SUP>III</SUP
>PhD, Full Professor, OMFS, School of Dentistry, ULBRA, Canoas-RS,    Brazil. <I
>Responsible for conception of the study and critical revision</I>.    ^cY#a03v2
6n1.htm##
00471000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704023700075002001300312#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#17#13#article#152#<br>   <SUP>IV</SUP>
PhD, Full Professor, Department of Cellular Biology and Respiratory    Diseases,
 School of Dentistry, PUCRS, Porto Alegre-RS, Brazil. <I>Tutor. Supervised    al
l phases of the study and manuscript writing</I>.    ^cY#a03v26n1.htm##
00445000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021100075002001300286#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#18#14#article#152#<br>   <SUP>V</SUP>F
ellow Master degree, Department of Cellular Biology and Respiratory    Diseases,
 School of Dentistry, PUCRS, Porto Alegre-RS, Brazil. <I>Acquisition    and inte
rpretation of data</I>.    ^cY#a03v26n1.htm##
00416000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704018200075002001300257#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#19#15#article#152#<br>   <SUP>VI</SUP>
PhD, Full Professor, Department of Materials, School of Mechanical    Engineerin
g, UFRGS, Porto Alegre-RS, Brazil. <I>Critical revision</I>. </font></p>      ^c
Y#a03v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#20#16#article#152#<p><font face="Verda
na" size="2"><a href="#end">Correspondence</a></font></p>     ^cY#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#21#17#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#22#18#article#152#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a03v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#23#19#article#152#<p><font face="Verda
na" size="2"><B>ABSTRACT </B></font></p>     ^cY#a03v26n1.htm##
01634000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704140000075002001301475#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#24#20#article#152#<p><font face="Verda
na" size="2"><B>Purpose</b>: To evaluate the ability of macroporous    tricalciu
m phosphate cement (CPC) scaffolds to enable the adhesion, proliferation,    and
 differentiation of mesenchymal stem cells derived from human bone marrow.    <B
>Methods</B>: Cells from the iliac crest of an adult human donor were processed 
   and cultured on macroporous CPC discs. Paraffin spheres sized between 100 and
    250&#181;m were used as porogens. Cells were cultured for 5, 10, and 15 days
.    Next, we assessed cells' behavior and morphology on the biomaterial by scan
ning    electron microscopy. The expression levels of the BGLA and SSP1 genes an
d the    alkaline phosphatase (ALP) activity were quantified by the quantitative
 real-time    polymerase chain reaction technique (QT-PCR) using the fluorophore
 SYBR GREEN<SUP>&#174;</SUP>.    <B>Results</B>: QT-PCR detected the expression 
of the BGLA and SSP1 genes and    the ALP activity in the periods of 10 and 15 d
ays of culture. Thus, we found    out that there was cell proliferation and diff
erentiation in osteogenic cells.    <B>Conclusion</B>: Macroporous CPC, with por
e sized between 100 and 250&#181;m    and developed using paraffin spheres, enab
les adhesion, proliferation, and differentiation    of mesenchymal stem cells in
 osteogenic cells and can be used as a scaffold    for bone tissue engineering. 
</font></p>     ^cY#a03v26n1.htm##
00398000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704016400075002001300239#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#25#21#article#152#<p><font face="Verda
na" size="2"><B>Key words</B>: Biocompatible Materials. Stem    Cells. Bioengine
ering. Bone Cements. </font></p> <hr size="1" noshade>      ^cY#a03v26n1.htm##
00301000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006700075002001300142#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#26#22#article#152#<p><font face="Verda
na" size="2"><B>RESUMO </B></font></p>     ^cY#a03v26n1.htm##
02096000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704186200075002001301937#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#27#23#article#152#<p><font face="Verda
na" size="2"><B>Objetivo</b>: Avaliar a capacidade de suportes    tridimensionai
s macroporosos de cimento de fosfato de c&aacute;lcio (CFC), de    permitir a ad
es&atilde;o, prolifera&ccedil;&atilde;o e diferencia&ccedil;&atilde;o    de c&ea
cute;lulas-tronco mesenquimais derivadas da medula &oacute;ssea humana.    <B>M&
eacute;todos</B>: c&eacute;lulas obtidas da crista il&iacute;aca de um    doador
 humano adulto foram processadas e cultivadas sobre suportes de CFC, macroporoso
s,    que tiveram como corpo gerador de poros, microesferas de parafina, com tam
anho    entre 100 e 250&#181;m. Os per&iacute;odos de cultura estabelecidos fora
m de    cinco, 10 e 15 dias. Ap&oacute;s estes per&iacute;odos, o comportamento 
e a    morfologia das c&eacute;lulas junto ao biomaterial foram avaliados por me
io    de Microscopia Eletr&ocirc;nica de Varredura. Os n&iacute;veis de express&
atilde;o    dos genes <I>BGLA </I>e <I>SSP1 </I>bem como a atividade da Fosfatas
e Alcalina    (ALP) foram quantificados pela t&eacute;cnica de PCR em Tempo Real
 (QT-PCR)    utilizando o fluor&oacute;foro SYBR Green&#174;. <B>Resultados</B>:
 O QT-PCR    detectou a express&atilde;o dos genes <I>BGLA </I>e <I>SSP1 </I>e a
 atividade    da fosfatase alcalina nos per&iacute;odos de 10 e 15 dias de cultu
ra. No per&iacute;odo    de cinco dias, n&atilde;o foi observada a express&atild
e;o de nenhum dos genes    investigados. <B>Conclus&atilde;o</B>: O CFC, macropo
roso, com tamanho de poros    entre 100 e 250&#181;m, criados por meio da utiliz
a&ccedil;&atilde;o de microesferas    de parafina, permite a ades&atilde;o, prol
ifera&ccedil;&atilde;o e diferencia&ccedil;&atilde;o    de c&eacute;lulas-tronco
 mesenquimais em c&eacute;lulas osteog&ecirc;nicas,    podendo ser utilizado com
o arcabou&ccedil;o para engenharia de tecido &oacute;sseo.    </font></p>     ^c
Y#a03v26n1.htm##
00423000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704018900075002001300264#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#28#24#article#152#<p><font face="Verda
na" size="2"><B>Descritores</B>: Materiais Biocompat&iacute;veis.    C&eacute;lu
las-Tronco. Bioengenharia. Cimentos para ossos.</font></p> <hr size="1" noshade>
     ^cY#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#29#25#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#30#26#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007400075002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#31#27#article#152#<p><font face="Verda
na" size="3"><B>Introduction</B> </font></p>      ^cY#a03v26n1.htm##
00712000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704047800075002001300553#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#32#28#article#152#<p><font face="Verda
na" size="2"> The strategies commonly used to treat bone defects    in the maxil
lofacial region include autogenous bone grafts, allografts, metals    and cerami
cs. All these alternatives have specific limitations such as restricted    amoun
t of tissue obtained with autogenous grafts, difficulty of preparing grafts    w
ith the desired shape, and risk of transferring pathogens when using synthetic  
  implants and allograft<SUP>1</SUP>. </font></p>     ^cY#a03v26n1.htm##
00665000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704043100075002001300506#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#33#29#article#152#<p><font face="Verda
na" size="2"> The regenerative medicine that makes use of    stem cells is a fas
t developing field in the treatment of bone defects<SUP>2</SUP>.    Its basic pr
inciple involves the use of an appropriate type of cell and a biocompatible    a
nd bioabsorbable scaffold (matrix, carrier) to produce a biosystem that mimics  
  the function and structure of a specific type of tissue<SUP>3</SUP>. </font></
p>     ^cY#a03v26n1.htm##
00690000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045600075002001300531#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#34#30#article#152#<p><font face="Verda
na" size="2"> Recently, much attention has been paid to the    use of calcium ph
osphate cement (CPC) as a bone substitute. Such biomaterial    has a composition
 and structure very similar to the mineral portion of the bone    tissue and has
 been considered appropriate to develop scaffolds for bone tissue    engineering
<SUP>4</SUP>. In addition to these characteristics, CPCs are also    easily hand
led and molded. </font></p>     ^cY#a03v26n1.htm##
00609000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704037500075002001300450#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#35#31#article#152#<p><font face="Verda
na" size="2"> The main objective of this study was to assess    the viability of
 using a CPC made of Brazilian raw material, with porosity created    by paraffi
n spheres, as a scaffold for bone tissue engineering by analyzing    the behavio
r of mesenchymal    stem cells cultivated in osteogenic induction medium on this
 biomaterial. </font></p>      ^cY#a03v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#36#32#article#152#<p>&nbsp; </p>     ^
cY#a03v26n1.htm##
00304000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007000075002001300145#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#37#33#article#152#<p><font face="Verda
na" size="3"><B>Methods </B> </font></p>      ^cY#a03v26n1.htm##
00310000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007600075002001300151#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#38#34#article#152#<p><font face="Verda
na" size="2"><I> CPC scaffolds</I> </font></p>      ^cY#a03v26n1.htm##
01559000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704132500075002001301400#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#39#35#article#152#<p><font face="Verda
na" size="2"> We selected 15 tricalcium phosphate cement scaffolds    of 15mm in
 diameter (<a href="/img/revistas/acb/v26n1/a03img01.jpg">Figure 1A</a>)    and 
around 3 mm in height (<a href="/img/revistas/acb/v26n1/a03img01.jpg">Figure    
1B</a>). The paraffin spheres used as porogens were responsible for the macropor
ous    and interconnected structure of the scaffolds. Based on the fact that, ac
cording    to the literature<SUP>5,6</SUP>, optimal pore size for bone tissue gr
owth is    above 100&#181;m, we decided to use a size range between 100 and 250&
#181;m.    Alpha-tricalcium phosphate cement (&#945;-TPC) was synthesized in a l
aboratory according    to the method reported by Driessens<SUP>7</SUP>. Scaffold
s were produced by    the homogenization of paraffin spheres and &#945;-TPC, wit
h the later addition of the liquid phase. This phase was    always added in the 
proportion of 1 ml for each 1 g of -TPC. The resulting paste    was poured into 
silicon molds and the test specimens were removed from the mold    after 24 h, t
hen undergoing another heat treatment for paraffin removal. The    characteristi
cs of the specimens were obtained by scanning electron microscopy    (SEM), whic
h identified the morphology, distribution and size of the pores in    the scaffo
lds. </font></p>     ^cY#a03v26n1.htm##
00535000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704030100075002001300376#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#40#36#article#152#<p><font face="Verda
na" size="2"> After being autoclaved at 121&#176;C for 15    min<SUP>8</SUP>, sc
affolds were arranged on 24-well polystyrene plates (Nunclon<SUP>TM</SUP>    Del
ta Surface, Nunc Products; Denmark), with one plate for each culture period    o
f 5, 10 and 15 days. </font></p>     ^cY#a03v26n1.htm##
00681000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704044700075002001300522#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#41#37#article#152#<p><font face="Verda
na" size="2"> Each plate held five discs, with four of them    being used to car
ry out the quantitative real-time polymerase chain reaction    technique (QT-PCR
), with the purpose of measuring the expression of the genes    encoding osteopo
ntin (OP), osteocalcin (OC), and alkaline phosphatase (ALP),    and one gene to 
assess the behavior and morphology of the cells that adhered    to the CPC using
 SEM. </font></p>      ^cY#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#42#38#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00326000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009200075002001300167#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#43#39#article#152#<p><font face="Verda
na" size="2"><I>Human bone marrow cell culture</I> </font></p>      ^cY#a03v26n1
.htm##
01366000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704113200075002001301207#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#44#40#article#152#<p><font face="Verda
na" size="2"> Human bone marrow cells in good physiological    state were obtain
ed from a 44-year-old patient admitted to the Oral and    Maxillofacial Surgery 
Unit of Hospital Independ&ecirc;ncia, Lutheran University    of Brazil (ULBRA), 
for atresic maxilla reconstruction surgery using autogenous    iliac crest bone 
graft. Purified bone marrow cells were suspended in a Dulbecco's    modified Eag
le medium (DMEM), supplemented with 10% bovine fetal serum, 100    U/ml penicill
in, 100&#181;g/ml streptomycin, and 50&#181;g/ml gentamicin. After    being susp
ended the cells were counted. A new culture medium was then added    to adjust c
ell concentration. This medium was composed of 40&#181;g of bone    morphogenic 
protein 4 (BMP-4) per ml of DMEM. The suspension was added to the    previously 
prepared 24-well plates containing the CPC scaffolds in aliquots    of 500&#181;
l with a density of 0.5 x 10<SUP>5</SUP> cells per milliliter, being    counted 
in a hemocytometer. Finally, cultures were incubated and kept in a humidified   
 oven at 37&#186;C containing 5% of CO<SUB>2</SUB>. </font></p>     ^cY#a03v26n1
.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#45#41#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00374000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704014000075002001300215#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#46#42#article#152#<p><font face="Verda
na" size="2"><I>Analysis of the expression of the bgla, ssp1    and alkaline pho
sphatase genes</I> </font></p>      ^cY#a03v26n1.htm##
00931000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704069700075002001300772#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#47#43#article#152#<p><font face="Verda
na" size="2"> The expression levels of the BGLA and SSP1 genes,    which encode 
OC and OP, respectively, and the ALP activity were quantified by    the QT-PCR t
echnique using fluorophore SYBR GREEN<SUP>&#174;</SUP>. The QT-PCR    technique 
used in the present study was based on the amplification of the cDNA    with gen
e-specific primer oligonucleotides and detection using a laser beam    able to c
apture the fluorescence emitted by the fluorophore SYBR Green<SUP>&#174;</SUP>  
  at each synthesis cycle. This process made it possible to quantify the levels 
   of the sequences complementary to mRNA for those genes present in the specime
ns    analyzed. </font></p>      ^cY#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#48#44#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00324000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009000075002001300165#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#49#45#article#152#<p><font face="Verda
na" size="2"><I>Scanning electron microscopy</I> </font></p>      ^cY#a03v26n1.h
tm##
00600000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036600075002001300441#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#50#46#article#152#<p><font face="Verda
na" size="2"> After each culture period, the discs were assessed    by SEM to an
alyze the behavior of the cells in contact with the biomaterial    surface. The 
scanning electron microscope used in our study was a PHILIPS<SUP>&#174;</SUP>   
 device, model XL30. A thin layer of gold was sputtered on the specimens analyze
d.    </font></p>     ^cY#a03v26n1.htm##
00586000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704035200075002001300427#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#51#47#article#152#<p><font face="Verda
na" size="2"> This research project was approved by the Scientific    and Ethics
 Committee of the School of Dentistry of PUCRS and by the Research    Ethics Com
mittee of PUCRS. This study is in accordance with items III.3.i and    III.3.t o
f the Brazilian Guidelines and Norms for Research involving Humans.    </font></
p>      ^cY#a03v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#52#48#article#152#<p>&nbsp; </p>     ^
cY#a03v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#53#49#article#152#<p><font face="Verda
na" size="3"><B>Results</B> </font></p>      ^cY#a03v26n1.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009700075002001300172#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#54#50#article#152#<p><font face="Verda
na" size="2"><I> Characterization of the specimens </I> </font></p>      ^cY#a03
v26n1.htm##
00829000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704059500075002001300670#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#55#51#article#152#<p><font face="Verda
na" size="2"> The SEM images showed the spherical shape of    the pores and thei
r interconnectivity (<a href="#img02">Figure 2</a>). The amount    of spheres ad
ded is linked to the formation of a thin layer of cement between    the spheres,
 enabling them to have contact with one another and, thus, after    paraffin rem
oval, promoting the establishment of interconnections between the    pores gener
ated by the paraffin spheres. The size of the pores we found is the    same as t
he size of the paraffin spheres used, ranging from 100 and 250 &#181;m.    </fon
t></p>     ^cY#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#56#52#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#57#53#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#58#54#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a03img02.jpg"><a name="img02"></a></p>     ^cY#a
03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#59#55#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#60#56#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00324000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009000075002001300165#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#61#57#article#152#<p><font face="Verda
na" size="2"><I>Scanning electron microscopy</I> </font></p>      ^cY#a03v26n1.h
tm##
00409000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017500075002001300250#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#62#58#article#152#<p><font face="Verda
na" size="2"> On the fifth day of culture, we found a small    number of elongat
ed and fusiform cells (<a href="#img03">Figure 3</a>). </font></p>     ^cY#a03v2
6n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#63#59#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#64#60#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#65#61#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a03img03.jpg"><a name="img03"></a></p>     ^cY#a
03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#66#62#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#67#63#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00529000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029500075002001300370#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#68#64#article#152#<p><font face="Verda
na" size="2"> On the tenth day of the experiment, we could    observe the deposi
tion of the extracellular matrix on the biomaterial. There    were cell elongati
ons inside the pores (<a href="#img04">Figure 4</a>). Cells    began to have a c
uboidal shape. </font></p>     ^cY#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#69#65#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#70#66#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#71#67#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a03img04.jpg"><a name="img04"></a></p>     ^cY#a
03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#72#68#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#73#69#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00599000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036500075002001300440#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#74#70#article#152#<p><font face="Verda
na" size="2"> On the 15th day of culture, we could observe    cuboidal cells (<a
 href="#img05">Figure 5A</a>), compatible with the morphology    of osteogenic c
ells. There were connections between the cells (Figure 5B). We    also found tha
t the cells and their elongations had migrated to the inner portion    of the po
res. </font></p>     ^cY#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#75#71#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#76#72#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#77#73#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a03img05.jpg"><a name="img05"></a></p>     ^cY#a
03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#78#74#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#79#75#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00364000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013000075002001300205#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#80#76#article#152#<p><font face="Verda
na" size="2"><I>   Real-time PCR for expression of the genes encoding op, oc and
 alp</I> </font></p>      ^cY#a03v26n1.htm##
00446000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021200075002001300287#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#81#77#article#152#<p><font face="Verda
na" size="2"> The expression of the BGLA and SSP1 genes responsible    for encod
ing OC and OP, respectively, and the    ALP activity were detected by the QT-PCR
 technique. </font></p>     ^cY#a03v26n1.htm##
00544000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031000075002001300385#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#82#78#article#152#<p><font face="Verda
na" size="2"> The value of the threshold cycle (C<SUB>T</SUB>)    was determined
 by the thermal cycler to measure the expression. We calculated    the mean and 
standard deviation of the C<SUB>T</SUB> values based on duplicate    analysis (<
a href="#tab01">Table 1</a>). </font></p>     ^cY#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#83#79#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#84#80#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#85#81#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a03tab01.jpg"><a name="tab01"></a></p>     ^cY#a
03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#86#82#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#87#83#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00458000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022400075002001300299#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#88#84#article#152#<p><font face="Verda
na" size="2">C<sub>T</sub> values represent the cycle in which    the gene start
ed to be expressed. The lower the C<sub>T</sub> value, the earlier    the gene e
xpression was detected. </font></p>     ^cY#a03v26n1.htm##
00546000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031200075002001300387#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#89#85#article#152#<p><font face="Verda
na" size="2">The levels of the relative expression of each    gene were normaliz
ed with the expression of &szlig;-actin in the relation (C<sub>T(OP/OC/ALP</sub>
/C<sub>T(&szlig;-actin)</sub>    ), where we found the values described next (<a
 href="#tab02">Table 2</a>).    </font></p>     ^cY#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#90#86#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#91#87#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#92#88#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a03tab02.jpg"><a name="tab02"></a></p>     ^cY#a
03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#93#89#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#94#90#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00557000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704032300075002001300398#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#95#91#article#152#<p><font face="Verda
na" size="2">After normalization of the C<sub>T</sub> values,    we could compar
e the relative expression of the genes during the periods studied    and we foun
d, as shown in the previous table, that in the 15-day period there    was higher
 expression of all the genes investigated. </font></p>     ^cY#a03v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#96#92#article#152#<p>&nbsp;</p>     ^c
Y#a03v26n1.htm##
00306000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007200075002001300147#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#97#93#article#152#<p><font face="Verda
na" size="3"><B>Discussion</B> </font></p>      ^cY#a03v26n1.htm##
00735000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050100075002001300576#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#98#94#article#152#<p><font face="Verda
na" size="2"> Several materials have been investigated as    potential scaffolds
 for bone tissue engineering. Each one of them has advantages    and limitations
. In the present study, we decided to investigate CPC made of    Brazilian raw m
aterial based on its low cost in comparison with the imported    cements availab
le in the market and because the national material showed biocompatibility    an
d easiness of handling similar to those of imported cements. </font></p>     ^cY
#a03v26n1.htm##
00838000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704060400075002001300679#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#99#95#article#152#<p><font face="Verda
na" size="2"> One of the characteristics required by bone    tissue engineering 
for scaffolds is that they must have a porous and interconnected    structure, e
nabling the migration and distribution of cells<SUP>9</SUP>. With    the purpose
 of achieving this characteristic, we decided to use paraffin spheres    as poro
gens in the scaffolds. Paraffin was chosen because it is an organic material    
with a low melting point, which made it possible to control the distribution    
and size of the pores, thus producing a macroporous and interconnected scaffold.
    </font></p>     ^cY#a03v26n1.htm##
00964000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704072900076002001300805#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#100#96#article#152#<p><font face="Verd
ana" size="2"> On the 15th day of culture, we used QT-PCR to    detect the expre
ssion of the BGLA and SSP1 genes responsible for encoding OC    and OP, respecti
vely. We also detected ALP activity, and the results showed    an earlier detect
ion of the expression of these genes throughout the experiment    periods. Such 
data allow us to conclude that there was cell proliferation and    osteogenic di
fferentiation during these periods, since these proteins are considered    osteo
blast markers because they are exclusively expressed by preosteogenic cells    a
nd mature osteoblasts, except for OP, which is detectable in precursor cells    
at early stages of differentiation<SUP>8,13</SUP>.</font></p>     ^cY#a03v26n1.h
tm##
00900000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704066500076002001300741#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#101#97#article#152#<p><font face="Verd
ana" size="2"> Tissue engineering involves the association    of an osteoconduct
ive matrix (CPC in the present study), osteoprogenitor cells,    and osteoinduct
ive growth factors. Our choice for mesenchymal stem cells derived    from human 
bone marrow is based on their potential of expansion and differentiation    in s
pecific strains, as well as their autogenous origin, which make them good    can
didates for use in tissue engineering and regenerative therapies. As they    hav
e advantages in comparison with other types of cells, mesenchymal stem cells    
have been widely used in bone tissue engineering<sup>3,4,9</sup>. </font></p>   
  ^cY#a03v26n1.htm##
01146000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704091100076002001300987#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#102#98#article#152#<p><font face="Verd
ana" size="2"> No consensus has been reached in the literature    regarding the 
pore size that best promotes osteoconduction. It has been established    that bo
ne growth occurs when the pore is large enough to house the cells and    the blo
od flow system. A pore size larger than 100 &#181;m and smaller than    400&#181
;m is usually considered optimal for osteoconduction<sup>10</sup>; however,    t
here are conflicting scientific reports demonstrating that there can occur    bo
ne growth in pores smaller than 100&#181;m and larger than 500&#181;m<sup>11</su
p>.    In the present study, we decided to use the range 100-250&#181;m because 
such    porosity enables cell growth, but does not have a significant influence 
on the    mechanical resistance of the biomaterial, as there is a close relation
ship between    porosity and the amount and size of pores<sup>12</sup>. </font><
/p>     ^cY#a03v26n1.htm##
00814000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704057900076002001300655#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#103#99#article#152#<p><font face="Verd
ana" size="2"> Based on the SEM images obtained in the present    study, we coul
d confirm that there was cell proliferation on the CPC scaffold.    We were also
 able to detect differentiation of osteogenic cells. Such differentiation    was
 made evident by their cuboidal shape compatible with the shape of osteogenic   
 cells, which was acquired close to the 15th day of culture. The QT-PCR techniqu
e    corroborated these findings with the detection of the expression of the gen
es    investigated in the 10- and 15-day period of culture. </font></p>     ^cY#
a03v26n1.htm##
00964000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704072800077002001300805#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#104#100#article#152#<p><font face="Ver
dana" size="2">On the 15th day of culture, we used QT-PCR to    detect the expre
ssion of the BGLA and SSP1 genes responsible for encoding OC    and OP, respecti
vely. We also detected ALP activity, and the results showed    an earlier detect
ion of the expression of these genes throughout the experiment    periods. Such 
data allow us to conclude that there was cell proliferation and    osteogenic di
fferentiation during these periods, since these proteins are considered    osteo
blast markers because they are exclusively expressed by preosteogenic cells    a
nd mature osteoblasts, except for OP, which is detectable in precursor cells    
at early stages of differentiation<sup>8,13</sup>.</font></p>     ^cY#a03v26n1.h
tm##
00914000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704067800077002001300755#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#105#101#article#152#<p><font face="Ver
dana" size="2"> Several authors have drawn attention to the    need of good mech
anical properties in scaffolds intended to be used in bone    tissue engineering
<SUP>14</SUP>. However, we tend to agree with Logeart-Avramoglou<SUP>9,11</SUP> 
   when they state that such requirements are not necessary because the main fun
ction    of a scaffold is to support bone growth instead of supporting mechanica
l forces.    The scaffolds investigated in the present study were minimally resi
stant, which    was sufficient for them to be handled, as this resistance would 
increase with    the proliferation of osteoblasts while generating bone tissue. 
</font></p>     ^cY#a03v26n1.htm##
00520000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704028400077002001300361#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#106#102#article#152#<p><font face="Ver
dana" size="2"> CPC has a great potential for being used in    bone tissue engin
eering and its association with polymeric materials is a quite    promising fiel
d for further investigations aimed at combining the advantages    of both materi
als. </font></p>      ^cY#a03v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#107#103#article#152#<p>&nbsp; </p>    
 ^cY#a03v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007200077002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#108#104#article#152#<p><font face="Ver
dana" size="3"><B>Conclusion</B> </font></p>      ^cY#a03v26n1.htm##
00739000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704050300077002001300580#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#109#105#article#152#<p><font face="Ver
dana" size="2"> Based on the findings of the present study,    we conclude that 
CPC scaffolds with macroporosity generated by paraffin spheres    have interconn
ected pores and pore sizes compatible with the size of the spheres    used, whic
h was between 100 and 250&#181;m. These scaffolds enabled adhesion,    prolifera
tion, and differentiation of the mesenchymal stem cells in osteogenic    cells a
nd, therefore, can be used as scaffolds for tissue engineering. </font></p>     
 ^cY#a03v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#110#106#article#152#<p>&nbsp; </p>    
 ^cY#a03v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007200077002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#111#107#article#152#<p><font face="Ver
dana" size="3"><B>References</B> </font></p>      ^cY#a03v26n1.htm##
00569000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704031900079002001300398#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#p#112#108#article#152#1#<p><
font face="Verdana" size="2">1. Turhani D, Watzinger E, Weissenb&ouml;ck M,    C
vikl B, Thurnher D, Wittwer G, Yerit K, Ewers R. Analysis of cell-seeded 3-dimen
sional    bone constructs manufactured in vitro with hydroxyapatite granules obt
ained    from red algae. J Oral Maxillofac Surg. 2005;63(5):673-81.    ^cY#a03v2
6n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#113#109#article#152# </font></p>     ^
cY#a03v26n1.htm##
00601000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704035100079002001300430#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#p#114#110#article#152#2#<p><
font face="Verdana" size="2">2. Kasten P, Beyen I, Niemeyer P, Luginb&uuml;hl   
 R, Bohner M, Richter W. Porosity and pore size of &szlig;-tricalcium phosphate 
   scaffold can influence protein production and osteogenic differentiation of  
  human mesenchymal stem cells: an in vitro and in vivo study. Acta Biomater.   
 2008;4(6):1904-15.    ^cY#a03v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#115#111#article#152# </font></p>     ^
cY#a03v26n1.htm##
00488000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704023800079002001300317#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#p#116#112#article#152#3#<p><
font face="Verdana" size="2">3. Li WJ, Tuli R, Huang X, Laquerriere P, Tuan    R
S. Multilineage differentiation of human mesenchymal stem cells in a three-dimen
sional    nanofibrous scaffold. Biomaterials. 2005;26(25):5158-66.    ^cY#a03v26
n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#117#113#article#152# </font></p>     ^
cY#a03v26n1.htm##
00513000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704026300079002001300342#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#p#118#114#article#152#4#<p><
font face="Verdana" size="2">4. Guo H, Su J, Wei J, Kong H, Liu C. Biocompatibil
ity    and osteogenicity of degradable Ca-deficient hydroxyapatite scaffolds fro
m calcium    phosphate cement for bone tissue engineering. Acta Biomater. 2009;5
(1):268-78.    ^cY#a03v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#119#115#article#152#    </font></p>   
  ^cY#a03v26n1.htm##
00514000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704026400079002001300343#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#p#120#116#article#152#5#<p><
font face="Verdana" size="2">5. Gauthier O, Bouler JM, Aguado E, Pilet P,    Dac
ulsi G. Macroporous biphasic calcium phosphate ceramics: influence of macropore 
   diameter and macroporosity percentage on bone ingrowth. Biomaterials. 1998;19
(1-3):133-9.    ^cY#a03v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#121#117#article#152#    </font></p>   
  ^cY#a03v26n1.htm##
00471000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704022100079002001300300#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#p#122#118#article#152#6#<p><
font face="Verdana" size="2">6. Chang BS, Lee CK, Hong KS, Youn HJ, Ryu HS,    C
hung SS, Park KW. Osteoconduction at porous hydroxyapatite with various pore    
configurations. Biomaterials. 2000;21(12):1291-8.    ^cY#a03v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#123#119#article#152# </font></p>     ^
cY#a03v26n1.htm##
00562000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704031200079002001300391#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#p#124#120#article#152#7#<p><
font face="Verdana" size="2">7. Fern&aacute;ndez E, Gil FJ, Ginebra MP, Driessen
s    FC, Planell JA, Best SM. Production and characterization of new calcium pho
sphate    bone cements in the CaHPO4-alpha-Ca3(PO4)2 system: pH, workability and
 setting    times. J Mater Sci Mater Med. 1999;10(4):223-30.    ^cY#a03v26n1.htm
##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#125#121#article#152# </font></p>     ^
cY#a03v26n1.htm##
00466000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704021600079002001300295#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#p#126#122#article#152#8#<p><
font face="Verdana" size="2">8. Ozawa S, Kasugai S. Evaluation of implant    mat
erials (hydroxyapatite, glass-ceramics, titanium) in rat bone marrow stromal    
cell culture. Biomaterials. 1996;17(1):23-9.    ^cY#a03v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#127#123#article#152# </font></p>     ^
cY#a03v26n1.htm##
00429000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704017900079002001300258#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#p#128#124#article#152#9#<p><
font face="Verdana" size="2">9. Logeart-Avramoglou D, Anagnostou F, Bizios    R,
 Petite H. Engineering bone: challenges and obstacles. J Cell Mol Med. 2005;9(1)
:72-84.    ^cY#a03v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#129#125#article#152#    </font></p>   
  ^cY#a03v26n1.htm##
00452000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020100080002001300281#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#p#130#126#article#152#10#<p>
<font face="Verdana" size="2">10. Boyan BD, Hummert TW, Dean DD, Schwartz Z.    
Role of materials surfaces in regulating bone and cartilage cell response. Bioma
terials.    1996;17(2):137-46.    ^cY#a03v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#131#127#article#152# </font></p>     ^
cY#a03v26n1.htm##
00552000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704030100080002001300381#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#p#132#128#article#152#11#<p>
<font face="Verdana" size="2">11. Cyster LA, Grant DM, Howdle SM, Rose FR,    Ir
vine DJ, Freeman D, Scotchford CA, Shakesheff KM. The influence of dispersant   
 concentration on the pore morphology of hydroxyapatite ceramics for bone tissue
    engineering. Biomaterials. 2005;26(7):697-702.    ^cY#a03v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#133#129#article#152# </font></p>     ^
cY#a03v26n1.htm##
00564000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704031300080002001300393#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#p#134#130#article#152#12#<p>
<font face="Verdana" size="2">12. Chouteau J, Bignon A, Chavassieux P, Chevalier
    J, Melin M, Fantozzi G, Boivin G, Hartmann D, Carret JP. Cellular culture of
    osteoblasts and fibroblasts on macroporous calcium-phosphate bone substitute
s.    Rev Chir Orthop Reparatrice Appar Mot. 2003;89(1):44-52.    ^cY#a03v26n1.h
tm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#135#131#article#152# </font></p>     ^
cY#a03v26n1.htm##
00379000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704012800080002001300208#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#p#136#132#article#152#13#<p>
<font face="Verdana" size="2">13. Aubin JE. Advances in osteoblast lineage.    B
iochem Cell Biol. 1998;76(6):899-910.    ^cY#a03v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#137#133#article#152# </font></p>     ^
cY#a03v26n1.htm##
00509000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025800080002001300338#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#p#138#134#article#152#14#<p>
<font face="Verdana" size="2">14. Kim K, Yeatts A, Dean D, Fisher JP. Stereolith
ographic    bone scaffold design parameters: osteogenic differentiation and sign
al expression.    Tissue Eng Part B Rev. 2010 May 26. [Epub ahead of print]</fon
t></p>     ^cY#a03v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#139#135#article#152#<p>&nbsp;</p>     
^cY#a03v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#140#136#article#152#<p>&nbsp;</p>     
^cY#a03v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#141#137#article#152#<p>&nbsp;</p>     
^cY#a03v26n1.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704015500077002001300232#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#142#138#article#152#<p><font face="Ver
dana" size="2"><B><a name="end"></a><a href="#top"><img src="/img/revistas/acb/v
26n1/seta.gif" border="0"></a>Correspondence</B>:    ^cY#a03v26n1.htm##
00283000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004700077002001300124#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#143#139#article#152#<br>   Ta&iacute;s
 Somacal Novaes Silva    ^cY#a03v26n1.htm##
00282000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004600077002001300123#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#144#140#article#152#<br>   Av. Viscond
e do Herval, 915/604    ^cY#a03v26n1.htm##
00285000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004900077002001300126#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#145#141#article#152#<br>   91450-151 P
orto Alegre _ RS Brasil    ^cY#a03v26n1.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004200077002001300119#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#146#142#article#152#<br>   Phone/Fax: 
(55 51)3225-2521    ^cY#a03v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009700077002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#147#143#article#152#<br>   <a href="ma
ilto:tais.somacal@hotmail.com">tais.somacal@hotmail.com</a></font></p>     ^cY#a
03v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#148#144#article#152#<p>&nbsp;</p>     
^cY#a03v26n1.htm##
00300000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006400077002001300141#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#149#145#article#152#<p><font face="Ver
dana" size="2">Received: July 06, 2010    ^cY#a03v26n1.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#150#146#article#152#<br>   </font><fon
t face="Verdana" size="2">Review: September 14, 2010    ^cY#a03v26n1.htm##
00326000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009000077002001300167#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#151#147#article#152#<br>   </font><fon
t face="Verdana" size="2">Accepted: October 19, 2010</font></p>     ^cY#a03v26n1
.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006700077002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#152#148#article#152#<p><font face="Ver
dana" size="2">Conflict of interest: none    ^cY#a03v26n1.htm##
00324000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704008800077002001300165#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#153#149#article#152#<br>   </font><fon
t face="Verdana" size="2">Financial source: CAPES </font></p>     ^cY#a03v26n1.h
tm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#154#150#article#152#<p>&nbsp;</p>     
^cY#a03v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#155#151#article#152#<p>&nbsp;</p>     
^cY#a03v26n1.htm##
00556000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704032000077002001300397#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a03v26n1.htm#S#p#156#152#article#152#<p><font face="Ver
dana" size="2"><sup><a name="end"></a><a href="#top">1</a> </sup>Research    per
formed at the Institute of Biomedical Research, Sao Lucas Hospital, Pontifical  
  Catholic University of Rio Grande do Sul (PUCRS), Brazil. <i>Part of a thesis:
    Tutor, Denise Cantarelli Machado</i>. </font></p>     ^cY#a03v26n1.htm##
00770000000000349000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100019000930100
02100112010001500133010001800148010001700166010001500183010001500198012013300213
03000240034671000020037006500090037206400050038103100030038603200020038901400070
0391865000900398002001300407#v26n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.ht
m#S#c#157#1#article#14#1#^rND^sTurhani^nD#^rND^sWatzinger^nE#^rND^sWeissenböck^n
M#^rND^sCvikl^nB#^rND^sThurnher^nD#^rND^sWittwer^nG#^rND^sYerit^nK#^rND^sEwers^n
R#Analysis of cell-seeded 3-dimensional bone constructs manufactured in vitro wi
th hydroxyapatite granules obtained from red algae^len#J Oral Maxillofac Surg.#2
#20050000#2005#63#5#673-81#20110200#a03v26n1.htm##
00757000000000325000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100015000920100
01800107010001900125010001600144010001700160012018900177030001500366710000200381
06500090038306400050039203100020039703200020039901400080040186500090040900200130
0418#v26n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#c#158#2#article#14#2
#^rND^sKasten^nP#^rND^sBeyen^nI#^rND^sNiemeyer^nP#^rND^sLuginbühl^nR#^rND^sBohne
r^nM#^rND^sRichter^nW#Porosity and pore size of ß-tricalcium phosphate scaffold 
can influence protein production and osteogenic differentiation of human mesench
ymal stem cells: an in vitro and in vivo study^len#Acta Biomater.#2#20080000#200
8#4#6#1904-15#20110200#a03v26n1.htm##
00643000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100013000760100014000890100
01500103010002100118010001500139012010900154030001400263710000200277065000900279
064000500288031000300293032000300296014000800299865000900307002001300316#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#c#159#3#article#14#3#^rND^sLi^nW
J#^rND^sTuli^nR#^rND^sHuang^nX#^rND^sLaquerriere^nP#^rND^sTuan^nRS#Multilineage 
differentiation of human mesenchymal stem cells in a three-dimensional nanofibro
us scaffold^len#Biomaterials.#2#20050000#2005#26#25#5158-66#20110200#a03v26n1.ht
m##
00668000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100013000760100012000890100
01300101010001400114010001300128012014900141030001500290710000200305065000900307
064000500316031000200321032000200323014000700325865000900332002001300341#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#c#160#4#article#14#4#^rND^sGuo^n
H#^rND^sSu^nJ#^rND^sWei^nJ#^rND^sKong^nH#^rND^sLiu^nC#Biocompatibility and osteo
genicity of degradable Ca-deficient hydroxyapatite scaffolds from calcium phosph
ate cement for bone tissue engineering^len#Acta Biomater.#2#20090000#2009#5#1#26
8-78#20110200#a03v26n1.htm##
00669000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100017000940100
01600111010001500127010001700142012013100159030001400290710000200304065000900306
064000500315031000300320032000400323014000600327865000900333002001300342#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#c#161#5#article#14#5#^rND^sGauth
ier^nO#^rND^sBouler^nJM#^rND^sAguado^nE#^rND^sPilet^nP#^rND^sDaculsi^nG#Macropor
ous biphasic calcium phosphate ceramics: influence of macropore diameter and mac
roporosity percentage on bone ingrowth^len#Biomaterials.#2#19980000#1998#19#1-3#
133-9#20110200#a03v26n1.htm##
00662000000000337000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100014000920100
01500106010001500121010001400136010001600150010001500166012007800181030001400259
71000020027306500090027506400050028403100030028903200030029201400070029586500090
0302002001300311#v26n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#c#162#6#
article#14#6#^rND^sChang^nBS#^rND^sLee^nCK#^rND^sHong^nKS#^rND^sYoun^nHJ#^rND^sR
yu^nHS#^rND^sChung^nSS#^rND^sPark^nKW#Osteoconduction at porous hydroxyapatite w
ith various pore configurations^len#Biomaterials.#2#20000000#2000#21#12#1291-8#2
0110200#a03v26n1.htm##
00725000000000325000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100014000950100
01800109010002000127010001800147010001500165012014600180030002300326710000200349
06500090035106400050036003100030036503200020036801400070037086500090037700200130
0386#v26n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#c#163#7#article#14#7
#^rND^sFernández^nE#^rND^sGil^nFJ#^rND^sGinebra^nMP#^rND^sDriessens^nFC#^rND^sPl
anell^nJA#^rND^sBest^nSM#Production and characterization of new calcium phosphat
e bone cements in the CaHPO4-alpha-Ca3(PO4)2 system: pH, workability and setting
 times^len#J Mater Sci Mater Med.#2#19990000#1999#10#4#223-30#20110200#a03v26n1.
htm##
00567000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100017000910120
11900108030001400227710000200241065000900243064000500252031000300257032000200260
014000500262865000900267002001300276#v26n1#V:\Scielo\serial\acb\v26n1\markup\a03
v26n1.htm#S#c#164#8#article#14#8#^rND^sOzawa^nS#^rND^sKasugai^nS#Evaluation of i
mplant materials (hydroxyapatite, glass-ceramics, titanium) in rat bone marrow s
tromal cell culture^len#Biomaterials.#2#19960000#1996#17#1#23-9#20110200#a03v26n
1.htm##
00569000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100028000760100020001040100
01600124010001600140012004700156030001600203710000200219065000900221064000500230
031000200235032000200237014000600239865000900245002001300254#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a03v26n1.htm#S#c#165#9#article#14#9#^rND^sLogeart-Avramoglo
u^nD#^rND^sAnagnostou^nF#^rND^sBizios^nR#^rND^sPetite^nH#Engineering bone: chall
enges and obstacles^len#J Cell Mol Med.#2#20050000#2005#9#1#72-84#20110200#a03v2
6n1.htm##
00589000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01500112010001800127012007800145030001400223710000200237065000900239064000500248
031000300253032000200256014000700258865000900265002001300274#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a03v26n1.htm#S#c#166#10#article#14#10#^rND^sBoyan^nBD#^rND^
sHummert^nTW#^rND^sDean^nDD#^rND^sSchwartz^nZ#Role of materials surfaces in regu
lating bone and cartilage cell response^len#Biomaterials.#2#19960000#1996#17#2#1
37-46#20110200#a03v26n1.htm##
00758000000000349000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
01700111010001500128010001700143010001700160010002100177010002100198012012400219
03000140034371000020035706500090035906400050036803100030037303200020037601400080
0378865000900386002001300395#v26n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.ht
m#S#c#167#11#article#14#11#^rND^sCyster^nLA#^rND^sGrant^nDM#^rND^sHowdle^nSM#^rN
D^sRose^nFR#^rND^sIrvine^nDJ#^rND^sFreeman^nD#^rND^sScotchford^nCA#^rND^sShakesh
eff^nKM#The influence of dispersant concentration on the pore morphology of hydr
oxyapatite ceramics for bone tissue engineering^len#Biomaterials.#2#20050000#200
5#26#7#697-702#20110200#a03v26n1.htm##
00788000000000361000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960100
02100112010001900133010001500152010001800167010001600185010001800201010001700219
01201020023603000390033871000020037706500090037906400050038803100030039303200020
0396014000600398865000900404002001300413#v26n1#V:\Scielo\serial\acb\v26n1\markup
\a03v26n1.htm#S#c#168#12#article#14#12#^rND^sChouteau^nJ#^rND^sBignon^nA#^rND^sC
havassieux^nP#^rND^sChevalier^nJ#^rND^sMelin^nM#^rND^sFantozzi^nG#^rND^sBoivin^n
G#^rND^sHartmann^nD#^rND^sCarret^nJP#Cellular culture of osteoblasts and fibrobl
asts on macroporous calcium-phosphate bone substitutes^len#Rev Chir Orthop Repar
atrice Appar Mot.#2#20030000#2003#89#1#44-52#20110200#a03v26n1.htm##
00465000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780120035000940300
01900129710000200148065000900150064000500159031000300164032000200167014000800169
865000900177002001300186#v26n1#V:\Scielo\serial\acb\v26n1\markup\a03v26n1.htm#S#
c#169#13#article#14#13#^rND^sAubin^nJE#Advances in osteoblast lineage^len#Bioche
m Cell Biol.#2#19980000#1998#76#6#899-910#20110200#a03v26n1.htm##
00610000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100013000780100016000910100
01400107010001700121012010500138030002200243710000200265065000900267064001200276
061002200288865000900310002001300319#v26n1#V:\Scielo\serial\acb\v26n1\markup\a03
v26n1.htm#S#c#170#14#article#14#14#^rND^sKim^nK#^rND^sYeatts^nA#^rND^sDean^nD#^r
ND^sFisher^nJP#Stereolithographic bone scaffold design parameters: osteogenic di
fferentiation and signal expression^len#Tissue Eng Part B Rev#2#20100526#2010 Ma
y 26#[Epub ahead of print]#20110200#a03v26n1.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v26n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#o#1#1#article#1#
20110120#130129#a04v26n1.htm#169##
04593000000000709000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094038000400098121000300102049000700105
15800030011203000160011503100030013103200020013406500090013601400090014503500100
01540120113001640120141002770100042004180100044004600100034005040100040005380100
04300578010004500621070005900666070006200725070006200787070005500849070004500904
08312580094908500080220708500370221508500310225208500250228308313620230808500080
36700850049036780850032037270850025037591170006037840720003037901120009037931110
01403802116000903816115001903825114000903844113001703853002001303870#v26n1#V:\Sc
ielo\serial\acb\v26n1\markup\a04v26n1.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#IL
US#GRA#TAB#04#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f12^l18#0102-8650#Histolo
gical analysis of low-intensity laser therapy effects in peripheral nerve regene
ration in Wistar rats^len#Avaliação histológica dos efeitos da laserterapia de b
aixa potência sobre os processos de regeneração nervosa periférica em ratos Wist
ar^lpt#^rND^1A01^nCibele Nazaré da Silva^sCâmara#^rND^1A02^nMarcus Vinicius Henr
iques^sBrito#^rND^1A03^nEdvaldo Lima^sSilveira#^rND^1A04^nDiego Sá Guimarães da^
sSilva#^rND^1A05^nVivian Roberta Ferreira^sSimões#^rND^1A05^nRoberto Waldesmand 
Farias^sPontes#UNAMA^iA01^1Department of Physiotherapy^cBelem^sPA^pBrazil#UEPA^i
A02^1Department of Integrated Health^cBelem^sPA^pBrazil#UEPA^iA03^1Department of
 Integrated Health^cBelem^sPA^pBrazil#UEPA^iA04^1Department of Psychology^cBelem
^sPA^pBrazil#UEPA^iA05^1Medical School^cBelem^sPA^pBrazil#^len^aPurpose: Analyze
 the influence of low-intensity laser therapy in the sciatic nerve regeneration 
of rats submitted to controlled crush through histological analysis. Methods: We
re used 20 Wistar rats, to analyze the influence of low-intensity laser therapy 
in the sciatic nerve regeneration, where the injury of the type axonotmesis was 
induced by a haemostatic clamp Crile (2nd level of the rack). The animals were r
andomly distributed in 2 groups. Control group (CG n = 10) and Laser group (LG n
 = 10). These were subdivided in 2 subgroups each, according to the euthanasia p
eriod: (CG14 _ n = 5 and CG21 _ n = 5) and (LG14 _ n = 5 and LG21 _ n = 5). At t
he end of treatment, the samples were removed and prepared for histological anal
ysis, where were analyzed and quantified the following findings: Schwann cells, 
myelinic axons with large diameter and neurons. Results: In the groups submitted
 to low-intensity laser therapy, were observed an increase in the number of all 
analyzed aspects with significance level. Conclusion: The irradiation with low i
ntensity laser (904nm) influenced positively the regeneration of the sciatic ner
ve in Wistar rats after being injured by crush (axonotmesis), becoming the nerve
 recovery more rapid and efficient.#^dnd^i1#^tm^len^kLaser Therapy, Low-Level^i1
#^tm^len^kNerve Regeneration^i1#^tm^len^kRats, Wistar^i1#^lpt^aObjetivo: Verific
ar a influência da terapia com laser de baixa potência na regeneração histológic
a do nervo ciático de ratos submetidos à neuropraxia controlada. Métodos: Foi ut
ilizada a amostra de 20 ratos da linhagem Wistar, para verificar a influência da
 terapia com laser de baixa intensidade na regeneração nervosa periférica, onde 
a lesão do tipo axoniotmese foi induzida por meio de preensão com pinça hemostát
ica de Crile. Os animais foram distribuídos randomicamente dois grupos. Grupo co
ntrole (CG n = 10), e Grupo laser (LG n = 10). Cada um destes grupos foi subdivi
dido em dois subgrupos dependendo do período da eutanásia: (CG14 - n = 5 e CG21 
- n = 5) e (LG14 - n = 5 e LG21 - n = 5). Ao final do tratamento, amostras do ne
rvo foram retiradas e analisadas histologicamente, nas quais foi adotado na pesq
uisa a análise do número de neurônios, de células de Schwann (CS) e de axônios m
ielínicos de grande diâmetro. Resultados: Nos grupos submetidos à terapia com la
ser de baixa potencia foi observado aumento do número de todos os aspectos anali
sados com diferença estatisticamente significante. Conclusão: A irradiação com o
 laser de baixa intensidade (904nm) influenciou positivamente na regeneração do 
nervo ciático de ratos da linhagem Wistar pós neuropraxia controlada (axonotmese
), tornando a recuperação nervosa mais rápida e eficiente.#^dnd^i2#^tm^lpt^kTera
pia a Laser de Baixa Intensidade^i2#^tm^lpt^kRegeneração Nervosa^i2#^tm^lpt^kRat
os Wistar^i2#other#13#20100706#July 06, 2010#20100913#September 13, 2010#2010101
9#October 19, 2010#a04v26n1.htm##
04663000000000709000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094038000400098121000300102049000700105
15800030011203000160011503100030013103200020013406500090013601400090014503500100
01540120120001640120148002840100042004320100044004740100034005180100040005520100
04300592010004500635070005900680070006200739070006200801070005500863070004500918
08312860096308500080224908500370225708500310229408500250232508313900235008500080
37400850049037480850032037970850025038291170006038540720003038601120009038631110
01403872116000903886115001903895114000903914113001703923002001303940#v26n1#V:\Sc
ielo\serial\acb\v26n1\markup\a04v26n1.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#IL
US#GRA#TAB#04#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f12^l18#0102-8650#<b>Hist
ological analysis of low-intensity laser therapy effects in peripheral nerve reg
eneration in Wistar rats</b>^len#<b>Avaliação histológica dos efeitos da laserte
rapia de baixa potência sobre os processos de regeneração nervosa periférica em 
ratos Wistar</b>^lpt#^rND^1A01^nCibele Nazaré da Silva^sCâmara#^rND^1A02^nMarcus
 Vinicius Henriques^sBrito#^rND^1A03^nEdvaldo Lima^sSilveira#^rND^1A04^nDiego Sá
 Guimarães da^sSilva#^rND^1A05^nVivian Roberta Ferreira^sSimões#^rND^1A05^nRober
to Waldesmand Farias^sPontes#UNAMA^iA01^1Department of Physiotherapy^cBelem^sPA^
pBrazil#UEPA^iA02^1Department of Integrated Health^cBelem^sPA^pBrazil#UEPA^iA03^
1Department of Integrated Health^cBelem^sPA^pBrazil#UEPA^iA04^1Department of Psy
chology^cBelem^sPA^pBrazil#UEPA^iA05^1Medical School^cBelem^sPA^pBrazil#^len^a<b
>Purpose</b>: Analyze the influence of low-intensity laser therapy in the sciati
c nerve regeneration of rats submitted to controlled crush through histological 
analysis. <b>Methods</b>: Were used 20 Wistar rats, to analyze the influence of 
low-intensity laser therapy in the sciatic nerve regeneration, where the injury 
of the type axonotmesis was induced by a haemostatic clamp Crile (2nd level of t
he rack). The animals were randomly distributed in 2 groups. Control group (CG n
 = 10) and Laser group (LG n = 10). These were subdivided in 2 subgroups each, a
ccording to the euthanasia period: (CG14 _ n = 5 and CG21 _ n = 5) and (LG14 _ n
 = 5 and LG21 _ n = 5). At the end of treatment, the samples were removed and pr
epared for histological analysis, where were analyzed and quantified the followi
ng findings: Schwann cells, myelinic axons with large diameter and neurons. <b>R
esults</b>: In the groups submitted to low-intensity laser therapy, were observe
d an increase in the number of all analyzed aspects with significance level. <b>
Conclusion</b>: The irradiation with low intensity laser (904nm) influenced posi
tively the regeneration of the sciatic nerve in Wistar rats after being injured 
by crush (axonotmesis), becoming the nerve recovery more rapid and efficient.#^d
nd^i1#^tm^len^kLaser Therapy, Low-Level^i1#^tm^len^kNerve Regeneration^i1#^tm^le
n^kRats, Wistar^i1#^lpt^a<b>Objetivo</b>: Verificar a influência da terapia com 
laser de baixa potência na regeneração histológica do nervo ciático de ratos sub
metidos à neuropraxia controlada. <b>Métodos</b>: Foi utilizada a amostra de 20 
ratos da linhagem Wistar, para verificar a influência da terapia com laser de ba
ixa intensidade na regeneração nervosa periférica, onde a lesão do tipo axoniotm
ese foi induzida por meio de preensão com pinça hemostática de Crile. Os animais
 foram distribuídos randomicamente dois grupos. Grupo controle (CG n = 10), e Gr
upo laser (LG n = 10). Cada um destes grupos foi subdividido em dois subgrupos d
ependendo do período da eutanásia: (CG14 - n = 5 e CG21 - n = 5) e (LG14 - n = 5
 e LG21 - n = 5). Ao final do tratamento, amostras do nervo foram retiradas e an
alisadas histologicamente, nas quais foi adotado na pesquisa a análise do número
 de neurônios, de células de Schwann (CS) e de axônios mielínicos de grande diâm
etro. <b>Resultados</b>: Nos grupos submetidos à terapia com laser de baixa pote
ncia foi observado aumento do número de todos os aspectos analisados com diferen
ça estatisticamente significante. <b>Conclusão</b>: A irradiação com o laser de 
baixa intensidade (904nm) influenciou positivamente na regeneração do nervo ciát
ico de ratos da linhagem Wistar pós neuropraxia controlada (axonotmese), tornand
o a recuperação nervosa mais rápida e eficiente.#^dnd^i2#^tm^lpt^kTerapia a Lase
r de Baixa Intensidade^i2#^tm^lpt^kRegeneração Nervosa^i2#^tm^lpt^kRatos Wistar^
i2#other#13#20100706#July 06, 2010#20100913#September 13, 2010#20101019#October 
19, 2010#a04v26n1.htm##
04733000000000733000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112038000400116121000300120
04900070012315800030013003000150013303100030014803200020015106500090015301400090
01620350010001710120113001810120141002940100042004350100044004770100034005210100
04000555010004300595010004500638070006100683070006400744070006400808070005700872
07000470092908312580097608500080223408500370224208500310227908500250231008313620
23350850008036970850049037050850032037540850025037861170006038110720003038171120
00903820111001403829116000903843115001903852114000903871113001703880002001303897
008008903910#v26n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#l#4#1#articl
e#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#gra#tab#04#ACB720#nd#Acta cir. bras
#26#1#20110200#^f12^l18#0102-8650#Histological analysis of low-intensity laser t
herapy effects in peripheral nerve regeneration in Wistar rats^len#Avaliação his
tológica dos efeitos da laserterapia de baixa potência sobre os processos de reg
eneração nervosa periférica em ratos Wistar^lpt#^rND^1A01^nCibele Nazaré da Silv
a^sCâmara#^rND^1A02^nMarcus Vinicius Henriques^sBrito#^rND^1A03^nEdvaldo Lima^sS
ilveira#^rND^1A04^nDiego Sá Guimarães da^sSilva#^rND^1A05^nVivian Roberta Ferrei
ra^sSimões#^rND^1A05^nRoberto Waldesmand Farias^sPontes#^iA01^1UNAMA^2Department
 of Physiotherapy^cBelem^sPA^pBrazil#^iA02^1UEPA^2Department of Integrated Healt
h^cBelem^sPA^pBrazil#^iA03^1UEPA^2Department of Integrated Health^cBelem^sPA^pBr
azil#^iA04^1UEPA^2Department of Psychology^cBelem^sPA^pBrazil#^iA05^1UEPA^2Medic
al School^cBelem^sPA^pBrazil#^len^aPurpose: Analyze the influence of low-intensi
ty laser therapy in the sciatic nerve regeneration of rats submitted to controll
ed crush through histological analysis. Methods: Were used 20 Wistar rats, to an
alyze the influence of low-intensity laser therapy in the sciatic nerve regenera
tion, where the injury of the type axonotmesis was induced by a haemostatic clam
p Crile (2nd level of the rack). The animals were randomly distributed in 2 grou
ps. Control group (CG n = 10) and Laser group (LG n = 10). These were subdivided
 in 2 subgroups each, according to the euthanasia period: (CG14 _ n = 5 and CG21
 _ n = 5) and (LG14 _ n = 5 and LG21 _ n = 5). At the end of treatment, the samp
les were removed and prepared for histological analysis, where were analyzed and
 quantified the following findings: Schwann cells, myelinic axons with large dia
meter and neurons. Results: In the groups submitted to low-intensity laser thera
py, were observed an increase in the number of all analyzed aspects with signifi
cance level. Conclusion: The irradiation with low intensity laser (904nm) influe
nced positively the regeneration of the sciatic nerve in Wistar rats after being
 injured by crush (axonotmesis), becoming the nerve recovery more rapid and effi
cient.#^dnd^i1#^tm^len^kLaser Therapy, Low-Level^i1#^tm^len^kNerve Regeneration^
i1#^tm^len^kRats, Wistar^i1#^lpt^aObjetivo: Verificar a influência da terapia co
m laser de baixa potência na regeneração histológica do nervo ciático de ratos s
ubmetidos à neuropraxia controlada. Métodos: Foi utilizada a amostra de 20 ratos
 da linhagem Wistar, para verificar a influência da terapia com laser de baixa i
ntensidade na regeneração nervosa periférica, onde a lesão do tipo axoniotmese f
oi induzida por meio de preensão com pinça hemostática de Crile. Os animais fora
m distribuídos randomicamente dois grupos. Grupo controle (CG n = 10), e Grupo l
aser (LG n = 10). Cada um destes grupos foi subdividido em dois subgrupos depend
endo do período da eutanásia: (CG14 - n = 5 e CG21 - n = 5) e (LG14 - n = 5 e LG
21 - n = 5). Ao final do tratamento, amostras do nervo foram retiradas e analisa
das histologicamente, nas quais foi adotado na pesquisa a análise do número de n
eurônios, de células de Schwann (CS) e de axônios mielínicos de grande diâmetro.
 Resultados: Nos grupos submetidos à terapia com laser de baixa potencia foi obs
ervado aumento do número de todos os aspectos analisados com diferença estatisti
camente significante. Conclusão: A irradiação com o laser de baixa intensidade (
904nm) influenciou positivamente na regeneração do nervo ciático de ratos da lin
hagem Wistar pós neuropraxia controlada (axonotmese), tornando a recuperação ner
vosa mais rápida e eficiente.#^dnd^i2#^tm^lpt^kTerapia a Laser de Baixa Intensid
ade^i2#^tm^lpt^kRegeneração Nervosa^i2#^tm^lpt^kRatos Wistar^i2#other#13#2010070
6#July 06, 2010#20100913#September 13, 2010#20101019#October 19, 2010#a04v26n1.h
tm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-865020
11000100004##
00354000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704012200073002001300195#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#5#1#article#152#<p align="right"><font
 face="Verdana" size="2"><b>4 - ORIGINAL ARTICLE</b></font><b><font face="Verdan
a" size="2">    ^cY#a04v26n1.htm##
00276000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704004400073002001300117#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#6#2#article#152#<br>   WOUND HEALING</
font></b></p>     ^cY#a04v26n1.htm##
00268000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704003600073002001300109#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#7#3#article#152#<p align="right">&nbsp
;</p>     ^cY#a04v26n1.htm##
00492000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704026000073002001300333#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#8#4#article#152#<p><b><font face="Verd
ana" size="2"><a name="top"></a></font><font face="Verdana" size="4">Histologica
l    analysis of low-intensity laser therapy effects in peripheral nerve regener
ation    in Wistar rats<SUP><a href="#end">1</a></SUP></font></b></p>     ^cY#a0
4v26n1.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#9#5#article#152#<p>&nbsp;</p>     ^cY#
a04v26n1.htm##
00523000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704029000074002001300364#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#10#6#article#152#<p><b><font face="Ver
dana" size="3">Avalia&ccedil;&atilde;o histol&oacute;gica    dos efeitos da lase
rterapia de baixa pot&ecirc;ncia sobre os processos de regenera&ccedil;&atilde;o
    nervosa perif&eacute;rica em ratos Wistar </font></b><font face="Verdana" si
ze="2"></font></p>       ^cY#a04v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#11#7#article#152#<p>&nbsp;</p>     ^cY
#a04v26n1.htm##
00597000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704036400074002001300438#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#12#8#article#152#<p><font face="Verdan
a" size="2"><B>Cibele Nazar&eacute; da Silva C&acirc;mara<SUP>I</SUP>,    Marcus
 Vinicius Henriques Brito<SUP>II</SUP>, Edvaldo Lima Silveira<SUP>III</SUP>,    
Diego S&aacute; Guimar&atilde;es da Silva<SUP>IV</SUP>, Vivian Roberta Ferreira 
   Sim&otilde;es<SUP>V</SUP>, Roberto Waldesmand Farias Pontes<SUP>V</SUP></B>  
  </font></p>      ^cY#a04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002300074002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#13#9#article#152#<p>&nbsp;</p>      ^c
Y#a04v26n1.htm##
00517000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028300075002001300358#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#14#10#article#152#<p><font face="Verda
na" size="2"><SUP>I</SUP>Master, Associate Professor, Department    of Physiothe
rapy, UNAMA, Belem-PA, Brazil. <I>Conception, design and scientific    content o
f the study. Analysis and interpretation of data. Manuscript writing.    Critica
l revision</I>.    ^cY#a04v26n1.htm##
00525000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029100075002001300366#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#15#11#article#152#<br>   </font><font 
face="Verdana" size="2"><SUP>II</SUP>PhD, Associate Professor,    Department of 
Integrated Health, UEPA, Belem-PA, Brazil. <I>Provided guidelines    for the sur
gical interventions. Analysis and interpretation of data. Manuscript    writing.
 Critical revision</I>.    ^cY#a04v26n1.htm##
00463000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022900075002001300304#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#16#12#article#152#<br>   </font><font 
face="Verdana" size="2"><SUP>III</SUP>Master, Associate Professor,    Department
 of Integrated Health, UEPA, Belem-PA, Brazil. <I>Histophatological    analysis.
 Analysis and interpretation of data</I>.    ^cY#a04v26n1.htm##
00447000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021300075002001300288#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#17#13#article#152#<br>   </font><font 
face="Verdana" size="2"><SUP>IV</SUP>Fellow of Psychology, Department    of Psyc
hology, UFPA, Belem-PA, Brazil. <I>Technical procedures. Manuscript writing.    
Statistical analysis</I>.    ^cY#a04v26n1.htm##
00451000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021700075002001300292#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#18#14#article#152#<br>   </font><font 
face="Verdana" size="2"><SUP>V</SUP>Graduate student, Medical School,    UEPA, B
elem-PA, Brazil. <I>Helped with technical procedures and collection of    study 
informations</I>.</font></p>     ^cY#a04v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#19#15#article#152#<p><font face="Verda
na" size="2"><a href="#end">Correspondence</a></font></p>     ^cY#a04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#20#16#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#21#17#article#152#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a04v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#22#18#article#152#<p><font face="Verda
na" size="2"><B>ABSTRACT </B></font></p>     ^cY#a04v26n1.htm##
01615000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704138100075002001301456#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#23#19#article#152#<p><font face="Verda
na" size="2"><B>Purpose</b>: Analyze the influence of low-intensity    laser the
rapy in the sciatic nerve regeneration of rats submitted to controlled    crush 
through histological analysis. <B>Methods</B>: Were used 20 Wistar rats,    to a
nalyze the influence of low-intensity laser therapy in the sciatic nerve    rege
neration, where the injury of the type axonotmesis was induced by a haemostatic 
   clamp Crile (2nd level of the rack). The animals were randomly distributed in
    2 groups. Control group (CG n = 10) and Laser group (LG n = 10). These were 
   subdivided in 2 subgroups each, according to the euthanasia period: (CG14 _  
  n = 5 and CG21 _ n = 5) and (LG14 _ n = 5 and LG21 _ n = 5). At the end of tre
atment,    the samples were removed and prepared for histological analysis, wher
e were    analyzed and quantified the following findings: Schwann cells, myelini
c axons    with large diameter and neurons. <B>Results</B>: In the groups submit
ted to    low-intensity laser therapy, were observed an increase in the number o
f all    analyzed aspects with significance level. <B>Conclusion</B>: The irradi
ation    with low intensity laser (904nm) influenced positively the regeneration
 of the    sciatic nerve in Wistar rats after being injured by crush (axonotmesi
s), becoming    the nerve recovery more rapid and efficient. </font></p>     ^cY
#a04v26n1.htm##
00390000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015600075002001300231#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#24#20#article#152#<p><font face="Verda
na" size="2"><B>Key words</B>: Laser Therapy, Low-Level. Nerve    Regeneration. 
Rats, Wistar. </font></p> <hr size="1" noshade>     ^cY#a04v26n1.htm##
00301000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006700075002001300142#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#25#21#article#152#<p><font face="Verda
na" size="2"><B>RESUMO </B></font></p>     ^cY#a04v26n1.htm##
02001000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704176700075002001301842#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#26#22#article#152#<p><font face="Verda
na" size="2"><B>Objetivo</b>: Verificar a influ&ecirc;ncia    da terapia com las
er de baixa pot&ecirc;ncia na regenera&ccedil;&atilde;o histol&oacute;gica    do
 nervo ci&aacute;tico de ratos submetidos &agrave; neuropraxia controlada.    <B
>M&eacute;todos</B>: Foi utilizada a amostra de 20 ratos da linhagem Wistar,    
para verificar a influ&ecirc;ncia da terapia com laser de baixa intensidade    n
a regenera&ccedil;&atilde;o nervosa perif&eacute;rica, onde a les&atilde;o    do
 tipo axoniotmese foi induzida por meio de preens&atilde;o com pin&ccedil;a    h
emost&aacute;tica de Crile. Os animais foram distribu&iacute;dos randomicamente 
   dois grupos. Grupo controle (CG n = 10), e Grupo laser (LG n = 10). Cada um  
  destes grupos foi subdividido em dois subgrupos dependendo do per&iacute;odo  
  da eutan&aacute;sia: (CG14 - n = 5 e CG21 - n = 5) e (LG14 - n = 5 e LG21 -   
 n = 5). Ao final do tratamento, amostras do nervo foram retiradas e analisadas 
   histologicamente, nas quais foi adotado na pesquisa a an&aacute;lise do n&uac
ute;mero    de neur&ocirc;nios, de c&eacute;lulas de Schwann (CS) e de ax&ocirc;
nios miel&iacute;nicos    de grande di&acirc;metro. <B>Resultados</B>: Nos grupo
s submetidos &agrave;    terapia com laser de baixa potencia foi observado aumen
to do n&uacute;mero de    todos os aspectos analisados com diferen&ccedil;a esta
tisticamente significante.    <B>Conclus&atilde;o</B>: A irradia&ccedil;&atilde;
o com o laser de baixa intensidade    (904nm) influenciou positivamente na regen
era&ccedil;&atilde;o do nervo ci&aacute;tico    de ratos da linhagem Wistar p&oa
cute;s neuropraxia controlada (axonotmese),    tornando a recupera&ccedil;&atild
e;o nervosa mais r&aacute;pida e eficiente.    </font></p>     ^cY#a04v26n1.htm#
#
00418000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704018400075002001300259#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#27#23#article#152#<p><font face="Verda
na" size="2"><B>Descritores</B>: Terapia a Laser de Baixa    Intensidade. Regene
ra&ccedil;&atilde;o Nervosa. Ratos Wistar.</font></p> <hr size="1" noshade>     
^cY#a04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#28#24#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#29#25#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007400075002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#30#26#article#152#<p><font face="Verda
na" size="3"><B>Introduction</B> </font></p>      ^cY#a04v26n1.htm##
00596000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036200075002001300437#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#31#27#article#152#<p><font face="Verda
na" size="2"> Peripheral nerves are structures frequently    affected by traumat
ic lesions, as total or partial crush, compression, stretch,    avulsion and sec
tion that cause the interruption of the transmission of nerve    impulses, the r
eduction or lost of sensitivity and motility in the innerved    area<SUP>1</SUP>
. </font></p>     ^cY#a04v26n1.htm##
00576000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034200075002001300417#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#32#28#article#152#<p><font face="Verda
na" size="2"> According to Pachioni <I>et al.</I><SUP>2 </SUP>this    type of le
sion if not adequately treated may provoke a significant deficit,    with damage
s not only in the quality of life of patients, but also to the state    system i
n cases of premature retirement due to functional incapacity. </font></p>     ^c
Y#a04v26n1.htm##
00520000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028600075002001300361#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#33#29#article#152#<p><font face="Verda
na" size="2"> Therefore, numerous studies have searched for    the optimization 
of the regeneration of peripheral nerves utilizing different    techniques, alwa
ys aiming to abbreviate the period of recovery of the injured    nerve<SUP>3,4</
SUP>. </font></p>     ^cY#a04v26n1.htm##
00719000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048500075002001300560#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#34#30#article#152#<p><font face="Verda
na" size="2"> Thus, the model of crush lesion has been adopted    by several aut
hors that emphasize the fact that the crush preserves, at least    in part, the 
nerve structure, facilitating its regeneration, and for not demonstrating    the
 necessity of realizing a suture, what implicates in previous training in    mic
rosurgical techniques and the availability of adequate instrumental and material
,    in general, with high cost<SUP>1</SUP>. </font></p>     ^cY#a04v26n1.htm##
00480000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024600075002001300321#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#35#31#article#152#<p><font face="Verda
na" size="2"> Studies on molecular biology have sustained    that the laser ther
apy increases the rates of nerve regeneration, reinnervation    and neuronal sur
vival after the rupture of axons<SUP>5</SUP>. </font></p>     ^cY#a04v26n1.htm##
00693000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045900075002001300534#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#36#32#article#152#<p><font face="Verda
na" size="2"> The molecular base that would justify the effectiveness    of the 
laser therapy on the nerve regeneration has not been clear yet. However    studi
es suggest that low-intensity laser therapy improves function, accelerates    re
generative process, and decreases inflammatory response in the nerve. It can    
also promote a higher    metabolism in neurons and a better ability to produce m
yelin<SUP>6</SUP>. </font></p>     ^cY#a04v26n1.htm##
00575000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034100075002001300416#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#37#33#article#152#<p><font face="Verda
na" size="2"> Among several generators of laser therapy, we    may highlight Ars
enate-Gallium Laser (As-Ga), which is already known to accelerate    the recover
y of peripheral nerves<SUP>7</SUP>. The results can vary depending    on the pat
tern of the lesion induced and the lasers range<SUP>8</SUP>. </font></p>     ^cY
#a04v26n1.htm##
00486000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025200075002001300327#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#38#34#article#152#<p><font face="Verda
na" size="2"> The objective of this study was to analyze the    influence of Low
-intensity laser therapy in the sciatic nerve regeneration of    rats submitted 
to controlled crush through histological analysis. </font></p>      ^cY#a04v26n1
.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#39#35#article#152#<p>&nbsp; </p>     ^
cY#a04v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#40#36#article#152#<p><font face="Verda
na" size="3"><B>Methods</B> </font></p>      ^cY#a04v26n1.htm##
00662000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704042800075002001300503#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#41#37#article#152#<p><font face="Verda
na" size="2"> All animals of the present research were cared    according to the
 norms of the Brazilian School of Animal Experimentation (COBEA)    and the curr
ent national legislation for vivisection (Federal Law 11,794 on    October 9th, 
2008), being the research project approved by the Committee of    Ethics in Rese
arch with Animals - CEPAN at Evandro Chagas Institute, Belem-PA.    </font></p> 
    ^cY#a04v26n1.htm##
00584000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704035000075002001300425#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#42#38#article#152#<p><font face="Verda
na" size="2"> An experimental analytic study assay type clinical    and randomiz
ed controlled was realized (systematic randomization), and the capacity    of pe
ripheral nerve regeneration was evaluated with Wistar rats submitted to    axono
tmesis, after the application of Low-intensity laser therapy (Ga-As). </font></p
>     ^cY#a04v26n1.htm##
00636000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040200075002001300477#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#43#39#article#152#<p><font face="Verda
na" size="2"> Therefore, 20 male adult Wistar rats were utilized,    with body w
eight varying between 250 and 350 grams. The animals were maintained    in indiv
idual plastic cages in adequate sanitary conditions, and put in a temperature-co
ntrolled    environment (22&#186;C), provided with water and standardized food (
ration for    rodents) <I>ad libitum</I>. </font></p>     ^cY#a04v26n1.htm##
00385000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015100075002001300226#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#44#40#article#152#<p><font face="Verda
na" size="2"> The animals were randomly distributed according    to the treatmen
t and the euthanasia period:   </font></p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#45#41#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#46#42#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#47#43#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a04key01.jpg"></p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#48#44#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#49#45#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00786000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055200075002001300627#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#50#46#article#152#<p><font face="Verda
na" size="2"> The animals were anesthetized intraperitoneal    with solutions of
 ketamine chloridrate, (80mg/Kg), Xylazine hydrochloride 2%    (10mg/Kg) and atr
opine (0,05mg/Kg). They were maintained in ventral decubitus,    and the epilati
ng of the caudal region was realized, followed by local anti-sepsis    with poly
vinylpyrrolidone - iodine (PVPI) solution. The incision was performed    on the 
right side to be operated, and transversely, in the gluteus region, with    a sc
alpel cable # 3 and blade # 15. </font></p>     ^cY#a04v26n1.htm##
00632000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039800075002001300473#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#51#47#article#152#<p><font face="Verda
na" size="2"> The sciatic nerve was exposed by a longitudinal    posterior-later
al incision since the great trochanter until the region next    to the femur lat
eral condyles. Subsequently, a rhombic dissection between the    maximum gluteus
 and quadriceps muscles was carried out allowing the complete    vision of the n
erve (<a href="#img01">Figure 1</a>). </font></p>     ^cY#a04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#52#48#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#53#49#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#54#50#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a04img01.jpg"><a name="img01"></a></p>     ^cY#a
04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#55#51#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#56#52#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#57#53#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00702000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704046800075002001300543#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#58#54#article#152#<p><font face="Verda
na" size="2">A haemostatic clamp Crile, in which the second    level of the rack
 was utilized for maintaining the nerve crush, realized, then,    the crush. The
 same was maintained closed in order to crush the nerve during    30 seconds, co
nsidering that the same was approached in a standardized way around    0.5 cm di
stal at its emergence. Then, the surgical closure of the region was    realized 
with Mononylon 4-0 threads. </font></p>     ^cY#a04v26n1.htm##
00564000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704033000075002001300405#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#59#55#article#152#<p><font face="Verda
na" size="2"> To treat animals, was utilized Arsenate of Gallium    Laser (GaAs)
, brand KLD<sup>&#174;</sup>, model LASER I R (<a href="#img02">Figure    2</a>)
, with the extension of wave of 904nm, 26.3mW power, beam area of 0.63cm<sup>2</
sup>,    penetration of 1.5cm, in the pulsed form.</font></p>     ^cY#a04v26n1.h
tm##
00288000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704005400075002001300129#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#60#56#article#152#<p><font face="Verda
na" size="2"> </font></p>     ^cY#a04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#61#57#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#62#58#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a04img02.jpg"><a name="img02"></a></p>     ^cY#a
04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#63#59#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#64#60#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00728000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049400075002001300569#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#65#61#article#152#<p><font face="Verda
na" size="2"> The application form occurred through exact    transcutaneous meth
od and in contact (for reducing the reflection) with power    density of 4J/cm<s
up>2</sup>, potential density of 0.0413W/cm<sup>2</sup> and    the duration of t
ime of 32 seconds of application in each point, where the same    ones were mark
ed around the surgical incision, being three points of each side    of it, total
ing, then, six points (<a href="#img03">Figure 3</a>).</font></p>     ^cY#a04v26
n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#66#62#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#67#63#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#68#64#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a04img03.jpg"><a name="img03"></a></p>     ^cY#a
04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#69#65#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#70#66#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00505000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027100075002001300346#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#71#67#article#152#<p><font face="Verda
na" size="2"> The Laser therapy was initiated on the post-surgical    first day,
 where all the animals in the laser group were submitted to the same    procedur
e with applications once a day during 14 and 21 days, respectively.    </font></
p>     ^cY#a04v26n1.htm##
00671000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704043700075002001300512#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#72#68#article#152#<p><font face="Verda
na" size="2"> On the 14th day, the first 10 animals were submitted    to euthana
sia by an anesthetic overdoses, after that a sciatic nerve part was    removed f
rom the right hind leg of 5 animals from each subgroup (5 CG, 5 LG),    totaling
 10 samples. The same procedure was performed on the 21st day according    to th
e subgroups that were submitted to treatment during 21 days (5 CG, 5 LG).    </f
ont></p>     ^cY#a04v26n1.htm##
00844000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704061000075002001300685#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#73#69#article#152#<p><font face="Verda
na" size="2"> Immediately after the material collection, the    samples were pre
pared for histopathological analysis realized in the Central    Laboratory of Pa
thology of the Department of Pathological Anatomy at Jo&atilde;o    de Barros Ba
rreto University Hospital (HUJBB). The blades were examined and    analyzed thro
ugh the utilization of an optical microscope, with an objective    lens with 40X
; 15 microscopic fields from those were analyzed and quantified    the following
 histological findings: Schwann cells, myelinic axons with large    diameter and
 neurons. </font></p>     ^cY#a04v26n1.htm##
00884000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704065000075002001300725#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#74#70#article#152#<p><font face="Verda
na" size="2"> For the statistic evaluation, BioEstat version    5.0 software was
 utilized, and 95% as the level of significance, &#945; = 0.05 as level of decis
ion for the rejection hypothesis of nullity,    were previously established. Dat
a from the histological analysis were submitted    to statistic tests through va
riance analysis (ANOVA) with Tukey's post-test,    being the results with&#160;<
I>P</I>&#160;smaller than 0.05 considered significant.    The results were expre
ssed as average &#177; standard deviation among the control    and laser therapy
 groups on the post-surgical 14th and 21st day.   </font></p>     ^cY#a04v26n1.h
tm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#75#71#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00292000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704005800075002001300133#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#76#72#article#152#<p> <font face="Verd
ana" size="2">   </font></p>      ^cY#a04v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#77#73#article#152#<p>&nbsp;</p>     ^c
Y#a04v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#78#74#article#152#<p><font face="Verda
na" size="3"><B>Results </B> </font></p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#79#75#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#80#76#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#81#77#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a04tab01.jpg"></p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#82#78#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#83#79#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#84#80#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a04img04.jpg"></p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#85#81#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#86#82#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#87#83#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a04tab02.jpg"></p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#88#84#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#89#85#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#90#86#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a04img05.jpg"></p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#91#87#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#92#88#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#93#89#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a04tab03.jpg"></p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#94#90#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#95#91#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#96#92#article#152#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a04img06.jpg"></p>     ^cY#a04v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#97#93#article#152#<p align="center">&n
bsp;</p>     ^cY#a04v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#98#94#article#152#<p>&nbsp; </p>     ^
cY#a04v26n1.htm##
00306000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007200075002001300147#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#99#95#article#152#<p><font face="Verda
na" size="3"><B>Discussion</B> </font></p>      ^cY#a04v26n1.htm##
00551000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704031600076002001300392#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#100#96#article#152#<p><font face="Verd
ana" size="2"> Although little is known on the role of the    laser in the treat
ment of peripheral nerve lesions, the irradiation with laser    is very utilized
 for treating a variety of pathological conditions of the system    of skeletal-
muscle, including peripheral nerves. </font></p>     ^cY#a04v26n1.htm##
00782000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704054700076002001300623#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#101#97#article#152#<p><font face="Verd
ana" size="2"> The irradiation with laser interfere somehow    in the nerve func
tion, according to some demonstrations that evidence that there    is a reductio
n of latency time and an increase in the speed of the nerve conduction.    There
 are still some experimental evidences that a laser has a positive effect    in 
the regeneration of injured nerves<SUP>9</SUP>. The use of AlGaAs laser (660    
nm) provided significant changes to the morphometrically assessed area of the   
 myelin sheath<SUP>8</SUP>. </font></p>     ^cY#a04v26n1.htm##
01036000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704080100076002001300877#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#102#98#article#152#<p><font face="Verd
ana" size="2"> In the present research, we observed a significant    difference 
among the groups for the proliferation of neurons and Schwann cells    over 14 a
nd 21 days of treatment through laser therapy, making the treatment    efficienc
y through this resource, even in a short period of time, statistically    proved
. Immunohistochemical staining in the laser-treated group for 21 consecutive    
days showed an increased total number of axons and better quality of the regener
ation    process, due to an increased number of large-diameter axons, compared t
o the    non-irradiated control group. The study suggests that postoperative LPL
I enhances    the regenerative processes of peripheral nerves after complete tra
nsection and    anastomosis<SUP>10</SUP>. </font></p>     ^cY#a04v26n1.htm##
00600000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704036500076002001300441#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#103#99#article#152#<p><font face="Verd
ana" size="2"> This laser effect in the regeneration is probably    mediated by 
growth factors of local action, but the possibility that the laser    also stimu
lates the liberation of chemical mediators and chemiotaxics may not    be discar
ded, which accelerate the production of axoplasm in the cellular body<SUP>9</SUP
>.    </font></p>     ^cY#a04v26n1.htm##
00707000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704047100077002001300548#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#104#100#article#152#<p><font face="Ver
dana" size="2">There are evidences, in clinical and experimental    researches, 
that one of the laser effects is to increase the nerve function,    preventing t
he formation of wounds, elevating the metabolism of neurons and    increasing th
e capacity of myelin production. The fact that the laser therapy    is not invas
ive in the ability of irradiating injured nerves without surgical    interventio
ns has been useful<sup>11</sup>. </font></p>     ^cY#a04v26n1.htm##
01085000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704084900077002001300926#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#105#101#article#152#<p><font face="Ver
dana" size="2"> Studies by Mohammed <i>et al.</i><sup>6 </sup>have    demonstrat
ed the laser potential with low intensity, which by specimens collected    from 
animals in two experimental groups showed significant variation between    contr
ol and treated animals when examined histopathologically. The treated animals   
 showed better results regarding the two factors studied in the experiment: larg
er    diameter of nerve fibers and longer inter-nodal distance. These findings s
uggest    better nerve function, acceleration of the regenerative process, and l
ess inflamatory    response (less debris and macrophages accumelation) and less 
swelling of paranodal    areas after low-level laser therapy (LLLT). LLLT may pr
omoted higher metabolism    in neurons and a better ability to produce myelin<su
p>6</sup>. </font></p>     ^cY#a04v26n1.htm##
00841000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704060500077002001300682#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#106#102#article#152#<p><font face="Ver
dana" size="2"> Studies by Ehrlicher <i>et al.</i><sup>12 </sup>have    demonstr
ated the laser potential with low intensity, which by being applied    in neuron
s in culture, the same have proliferated and changed the dislocation    of the g
rowth cone of neurons that suffered total transaction. In addition to    these e
xplanations, there are some evidences demonstrating that the laser may    positi
vely interfere in the peripheral nerve regeneration, influencing the production 
   of trophic proteins as the basic fibroblastic growth factor (bFGF)<sup>13</su
p>.    </font></p>     ^cY#a04v26n1.htm##
00805000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704056900077002001300646#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#107#103#article#152#<p><font face="Ver
dana" size="2"> Therefore, the present study highlighted the    effectiveness of
 As-Ga laser for the treatment of peripheral nerve lesions,    utilizing the his
tological analysis for proving such effect, being necessary    in order to have 
a better understanding of nerve regeneration processes, and    new studies that 
may evaluate growth factors as the basic fibroblastic growth    factor, neuronal
 growth factor (NGF), GAP-43 (protein associated with the axonal    peripheral r
egeneration).</font><font face="Verdana" size="2"> </font></p>     ^cY#a04v26n1.
htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#108#104#article#152#<p>&nbsp;</p>     
^cY#a04v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007200077002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#109#105#article#152#<p><font face="Ver
dana" size="3"><B>Conclusion</B> </font></p>      ^cY#a04v26n1.htm##
00523000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704028700077002001300364#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#110#106#article#152#<p><font face="Ver
dana" size="2"> The irradiation with low intensity laser (904nm)    influenced p
ositively the regeneration of the sciatic nerve in Wistar rats after    being in
jured by crush (axonotmesis), becoming the nerve recovery more rapid    and effi
cient. </font></p>       ^cY#a04v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#111#107#article#152#<p>&nbsp; </p>    
 ^cY#a04v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007200077002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#112#108#article#152#<p><font face="Ver
dana" size="3"><B>References</B> </font></p>      ^cY#a04v26n1.htm##
00534000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704028400079002001300363#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#p#113#109#article#152#1#<p><
font face="Verdana" size="2">1. Monte-Raso VV, Barbieri CH, Mazzer N, Fazan    V
PS. Os efeitos do ultra-som terap&ecirc;utico nas les&otilde;es por esmagamento 
   do nervo ci&aacute;tico de ratos: an&aacute;lise funcional da marcha. Rev Bra
s    Fisioter. 2006;10(1):113-9.    ^cY#a04v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#114#110#article#152# </font></p>     ^
cY#a04v26n1.htm##
00530000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704028000079002001300359#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#p#115#111#article#152#2#<p><
font face="Verdana" size="2">2. Pachioni CAS, Mazzer N, Barbieri CH, Fazan    VP
S, Padovanis CR, Moro CA, Silva CAA. Les&atilde;o por esmagamento do nervo    is
qui&aacute;tico de ratos: estudo da vasculariza&ccedil;&atilde;o.&#160;Acta    O
rtop Bras. 2006;14(4):203-7.    ^cY#a04v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#116#112#article#152# </font></p>     ^
cY#a04v26n1.htm##
00543000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704029300079002001300372#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#p#117#113#article#152#3#<p><
font face="Verdana" size="2">3. Girard C, Liu S, Cadepond F, Adams D, Lacroix   
 C, Verleye M, Gillardin JM, Baulieu EE, Schumacher M, Schweizer-Groyer G. Etifo
xine    improves peripheral nerve regeneration and functional recovery. Proc Nat
l Acad    Sci USA. 2008;105(51):20505_10.    ^cY#a04v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#118#114#article#152# </font></p>     ^
cY#a04v26n1.htm##
00533000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704028300079002001300362#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#p#119#115#article#152#4#<p><
font face="Verdana" size="2">4. Mehanna A, Mishra B, Kurschat N, Schulze C,    B
ian S, Loers G, Irintchev A, Schachner M. Polysialic acid glycomimetics promote 
   myelination and functional recovery after peripheral nerve injury in mice. Br
ain.    2009;132(Pt 6):1449-62.    ^cY#a04v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#120#116#article#152# </font></p>     ^
cY#a04v26n1.htm##
00538000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704028800079002001300367#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#p#121#117#article#152#5#<p><
font face="Verdana" size="2">5. Snyder SK, Byrnes KR, Borke RC, Sanches A,    An
ders JJ. Quantitation of calcitonin gene-related peptide mRNA and Neuronal    ce
ll death in facial motor nuclei following axotomy and 633 nm low power laser.   
 Lasers Surg Med. 2002;31(3):216-22.    ^cY#a04v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#122#118#article#152# </font></p>     ^
cY#a04v26n1.htm##
00476000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704022600079002001300305#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#p#123#119#article#152#6#<p><
font face="Verdana" size="2">6. Mohammed IF, Al-Mustawfi N, Kaka LN. Promotion  
  of regenerative processes in injured peripheral nerve induced by low-level las
er    therapy. Photomed Laser Surg. 2007;25(2):107-11.    ^cY#a04v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#124#120#article#152# </font></p>     ^
cY#a04v26n1.htm##
00535000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704028500079002001300364#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#p#125#121#article#152#7#<p><
font face="Verdana" size="2">7. Camargo VM, Costa J, Andr&eacute; ES. Estudo    
comparativo entre dois tipos de raio laser de baixa pot&ecirc;ncia e seus respec
tivos    efeitos sobre a regenera&ccedil;&atilde;o nervosa perif&eacute;rica. Fi
sioter    Mov. 2006;19(2):127-34.    ^cY#a04v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#126#122#article#152# </font></p>     ^
cY#a04v26n1.htm##
00570000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704032000079002001300399#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#p#127#123#article#152#8#<p><
font face="Verdana" size="2">8. Dos Reis FA, Belchior AC, de Carvalho Pde    T, 
da Silva BA, Pereira DM, Silva IS, Nicolau RA. Effect of laser therapy (660    n
m) on recovery of the sciatic nerve in rats after injury through neurotmesis    
followed by epineural anastomosis. Lasers Med Sci. 2009;24(5):741-7.    ^cY#a04v
26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#128#124#article#152# </font></p>     ^
cY#a04v26n1.htm##
00485000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704023500079002001300314#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#p#129#125#article#152#9#<p><
font face="Verdana" size="2">9. Endo C, Barbieri CH, Mazzer N, Fasan, VS.    A l
aserterapia de baixa intensidade acelera a regenera&ccedil;&atilde;o de nervos  
  perif&eacute;ricos. Acta Ortop. Bras.&#160;2008;16(5):305-10.    ^cY#a04v26n1.
htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#130#126#article#152# </font></p>     ^
cY#a04v26n1.htm##
00537000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028600080002001300366#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#p#131#127#article#152#10#<p>
<font face="Verdana" size="2">10. Shamir MH, Rochkind S, Sandbank J, Alon M.    
Double-blind randomized study evaluating regeneration of the rat transected    s
ciatic nerve after suturing and postoperative low-power laser treatment. J    Re
constr Microsurg. 2001;17(2):133-7.    ^cY#a04v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#132#128#article#152# </font></p>     ^
cY#a04v26n1.htm##
00511000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026000080002001300340#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#p#133#129#article#152#11#<p>
<font face="Verdana" size="2">11. Carvalho PTC, Mazzer N, Dos Reis FA, Belchior 
   ACG, Silva IS. Analysis of the influence of low-power HeNe laser on the heali
ng    of skin wounds in diabetic and non-diabetic rats. Acta Cir Bras. 2006;21(3
):177-83.    ^cY#a04v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#134#130#article#152#    </font></p>   
  ^cY#a04v26n1.htm##
00452000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020100080002001300281#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#p#135#131#article#152#12#<p>
<font face="Verdana" size="2">12. Ehrlicher A, Betz T, Stuhrmann B, Koch D,    M
ilner V, Raizen MG, K&auml;s J. Guiding neuronal growth with light. Proc Nac    
Acad Sci. 2002;99(25):16024-8.    ^cY#a04v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#136#132#article#152# </font></p>     ^
cY#a04v26n1.htm##
00452000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020100080002001300281#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#p#137#133#article#152#13#<p>
<font face="Verdana" size="2">13. Shen N, Zhu J. Experimental study a direct    
current electrical field to promote peripheral nerve regeneration. J Reconstr   
 Microsurg. 1995;11(3):189-93.    ^cY#a04v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#138#134#article#152# </font></p>      
 ^cY#a04v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#139#135#article#152#<p>&nbsp;</p>     
^cY#a04v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#140#136#article#152#<p>&nbsp;</p>     
^cY#a04v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#141#137#article#152#<p>&nbsp;</p>     
^cY#a04v26n1.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704015500077002001300232#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#142#138#article#152#<p><font face="Ver
dana" size="2"><B><a name="end"></a><a href="#top"><img src="/img/revistas/acb/v
26n1/seta.gif" border="0"></a>Correspondence</B>:    ^cY#a04v26n1.htm##
00293000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005700077002001300134#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#143#139#article#152#<br>   Cibele Naza
r&eacute; da Silva C&acirc;mara    ^cY#a04v26n1.htm##
00287000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005100077002001300128#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#144#140#article#152#<br>   Rua Jer&oci
rc;nimo Pimentel, 426/402    ^cY#a04v26n1.htm##
00283000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004700077002001300124#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#145#141#article#152#<br>   66055-000 B
el&eacute;m-PA Brasil    ^cY#a04v26n1.htm##
00286000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005000077002001300127#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#146#142#article#152#<br>   Phone: (55 
91)3222-8292 / 8148-9060    ^cY#a04v26n1.htm##
00335000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009900077002001300176#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#147#143#article#152#<br>   <a href="ma
ilto:camaracibele@yahoo.com.br">camaracibele@yahoo.com.br</a></font></p>     ^cY
#a04v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#148#144#article#152#<p>&nbsp;</p>     
^cY#a04v26n1.htm##
00300000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006400077002001300141#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#149#145#article#152#<p><font face="Ver
dana" size="2">Received: July 06, 2010    ^cY#a04v26n1.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#150#146#article#152#<br>   </font><fon
t face="Verdana" size="2">Review: September 13, 2010    ^cY#a04v26n1.htm##
00326000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009000077002001300167#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#151#147#article#152#<br>   </font><fon
t face="Verdana" size="2">Accepted: October 19, 2010</font></p>     ^cY#a04v26n1
.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006700077002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#152#148#article#152#<p><font face="Ver
dana" size="2">Conflict of interest: none    ^cY#a04v26n1.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704008700077002001300164#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#153#149#article#152#<br>   </font><fon
t face="Verdana" size="2">Financial source: none </font></p>     ^cY#a04v26n1.ht
m##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#154#150#article#152#<p>&nbsp;</p>     
^cY#a04v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#155#151#article#152#<p>&nbsp;</p>     
^cY#a04v26n1.htm##
00448000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704021200077002001300289#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a04v26n1.htm#S#p#156#152#article#152#<p><font face="Ver
dana" size="2"><sup><a name="end"></a><a href="#top">1</a></sup>    Research per
formed at Experimental Surgery Laboratory, Para State University    (UEPA), Bele
m-PA, Brazil. </font></p>     ^cY#a04v26n1.htm##
00641000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100021000760100019000970100
01600116010001700132012012200149030001900271710000200290065000900292064000500301
031000300306032000200309014000600311865000900317002001300326#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a04v26n1.htm#S#c#157#1#article#13#1#^rND^sMonte-Raso^nVV#^r
ND^sBarbieri^nCH#^rND^sMazzer^nN#^rND^sFazan^nVPS#Os efeitos do ultra-som terapê
utico nas lesões por esmagamento do nervo ciático de ratos: análise funcional da
 marcha^lpt#Rev Bras Fisioter.#2#20060000#2006#10#1#113-9#20110200#a04v26n1.htm#
#
00684000000000337000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100020000760100016000960100
01900112010001700131010002000148010001500168010001700183012008100200030001600281
71000020029706500090029906400050030803100030031303200020031601400060031886500090
0324002001300333#v26n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#c#158#2#
article#13#2#^rND^sPachioni^nCAS#^rND^sMazzer^nN#^rND^sBarbieri^nCH#^rND^sFazan^
nVPS#^rND^sPadovanis^nCR#^rND^sMoro^nCA#^rND^sSilva^nCAA#Lesão por esmagamento d
o nervo isquiático de ratos: estudo da vascularização^lpt#Acta Ortop Bras#2#2006
0000#2006#14#4#203-7#20110200#a04v26n1.htm##
00785000000000373000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100013000920100
01800105010001500123010001700138010001700155010002000172010001800192010002000210
01000260023001200770025603000240033371000020035706500090035906400050036803100040
0373032000300377014000900380865000900389002001300398#v26n1#V:\Scielo\serial\acb\
v26n1\markup\a04v26n1.htm#S#c#159#3#article#13#3#^rND^sGirard^nC#^rND^sLiu^nS#^r
ND^sCadepond^nF#^rND^sAdams^nD#^rND^sLacroix^nC#^rND^sVerleye^nM#^rND^sGillardin
^nJM#^rND^sBaulieu^nEE#^rND^sSchumacher^nM#^rND^sSchweizer-Groyer^nG#Etifoxine i
mproves peripheral nerve regeneration and functional recovery^len#Proc Natl Acad
 Sci USA.#2#20080000#2008#105#51#20505_10#20110200#a04v26n1.htm##
00739000000000349000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100016000930100
01800109010001700127010001400144010001500158010001900173010001900192012011600211
03000070032771000020033406500090033606400050034503100040035003200050035401400080
0359865000900367002001300376#v26n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.ht
m#S#c#160#4#article#13#4#^rND^sMehanna^nA#^rND^sMishra^nB#^rND^sKurschat^nN#^rND
^sSchulze^nC#^rND^sBian^nS#^rND^sLoers^nG#^rND^sIrintchev^nA#^rND^sSchachner^nM#
Polysialic acid glycomimetics promote myelination and functional recovery after 
peripheral nerve injury in mice^len#Brain.#2#20090000#2009#132#Pt 6#1449-62#2011
0200#a04v26n1.htm##
00690000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100017000930100
01600110010001700126010001700143012014900160030001700309710000200326065000900328
064000500337031000300342032000200345014000700347865000900354002001300363#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#c#161#5#article#13#5#^rND^sSnyde
r^nSK#^rND^sByrnes^nKR#^rND^sBorke^nRC#^rND^sSanches^nA#^rND^sAnders^nJJ#Quantit
ation of calcitonin gene-related peptide mRNA and Neuronal cell death in facial 
motor nuclei following axotomy and 633 nm low power laser^len#Lasers Surg Med.#2
#20020000#2002#31#3#216-22#20110200#a04v26n1.htm##
00595000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100021000950100
01500116012010300131030002100234710000200255065000900257064000500266031000300271
032000200274014000700276865000900283002001300292#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a04v26n1.htm#S#c#162#6#article#13#6#^rND^sMohammed^nIF#^rND^sAl-Mustawf
i^nN#^rND^sKaka^nLN#Promotion of regenerative processes in injured peripheral ne
rve induced by low-level laser therapy^len#Photomed Laser Surg.#2#20070000#2007#
25#2#107-11#20110200#a04v26n1.htm##
00617000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100015000940100
01600109012013800125030001400263710000200277065000900279064000500288031000300293
032000200296014000700298865000900305002001300314#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a04v26n1.htm#S#c#163#7#article#13#7#^rND^sCamargo^nVM#^rND^sCosta^nJ#^r
ND^sAndré^nES#Estudo comparativo entre dois tipos de raio laser de baixa potênci
a e seus respectivos efeitos sobre a regeneração nervosa periférica^lpt#Fisioter
 Mov.#2#20060000#2006#19#2#127-34#20110200#a04v26n1.htm##
00758000000000337000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100019000950100
02500114010001900139010001800158010001600176010001800192012014500210030001600355
71000020037106500090037306400050038203100030038703200020039001400060039286500090
0398002001300407#v26n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#c#164#8#
article#13#8#^rND^sDos Reis^nFA#^rND^sBelchior^nAC#^rND^sde Carvalho^nPde T#^rND
^sda Silva^nBA#^rND^sPereira^nDM#^rND^sSilva^nIS#^rND^sNicolau^nRA#Effect of las
er therapy (660 nm) on recovery of the sciatic nerve in rats after injury throug
h neurotmesis followed by epineural anastomosis^len#Lasers Med Sci.#2#20090000#2
009#24#5#741-7#20110200#a04v26n1.htm##
00595000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100014000760100019000900100
01600109010001700125012008400142030001700226710000200243065000900245064000500254
031000300259032000200262014000700264865000900271002001300280#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a04v26n1.htm#S#c#165#9#article#13#9#^rND^sEndo^nC#^rND^sBar
bieri^nCH#^rND^sMazzer^nN#^rND^sFasan,^nVS#A laserterapia de baixa intensidade a
celera a regeneração de nervos periféricos^lpt#Acta Ortop. Bras#2#20080000#2008#
16#5#305-10#20110200#a04v26n1.htm##
00671000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950100
01800113010001400131012015300145030002200298710000200320065000900322064000500331
031000300336032000200339014000600341865000900347002001300356#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a04v26n1.htm#S#c#166#10#article#13#10#^rND^sShamir^nMH#^rND
^sRochkind^nS#^rND^sSandbank^nJ#^rND^sAlon^nM#Double-blind randomized study eval
uating regeneration of the rat transected sciatic nerve after suturing and posto
perative low-power laser treatment^len#J Reconstr Microsurg.#2#20010000#2001#17#
2#133-7#20110200#a04v26n1.htm##
00666000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100016000980100
01900114010002000133010001600153012011800169030001500287710000200302065000900304
064000500313031000300318032000200321014000700323865000900330002001300339#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#c#167#11#article#13#11#^rND^sCar
valho^nPTC#^rND^sMazzer^nN#^rND^sDos Reis^nFA#^rND^sBelchior^nACG#^rND^sSilva^nI
S#Analysis of the influence of low-power HeNe laser on the healing of skin wound
s in diabetic and non-diabetic rats^len#Acta Cir Bras.#2#20060000#2006#21#3#177-
83#20110200#a04v26n1.htm##
00638000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100014000970100
01900111010001400130010001600144010001700160010001300177012003900190030001900229
71000020024806500090025006400050025903100030026403200030026701400080027086500090
0278002001300287#v26n1#V:\Scielo\serial\acb\v26n1\markup\a04v26n1.htm#S#c#168#12
#article#13#12#^rND^sEhrlicher^nA#^rND^sBetz^nT#^rND^sStuhrmann^nB#^rND^sKoch^nD
#^rND^sMilner^nV#^rND^sRaizen^nMG#^rND^sKäs^nJ#Guiding neuronal growth with ligh
t^len#Proc Nac Acad Sci.#2#20020000#2002#99#25#16024-8#20110200#a04v26n1.htm##
00553000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100013000920120
09800105030002200203710000200225065000900227064000500236031000300241032000200244
014000700246865000900253002001300262#v26n1#V:\Scielo\serial\acb\v26n1\markup\a04
v26n1.htm#S#c#169#13#article#13#13#^rND^sShen^nN#^rND^sZhu^nJ#Experimental study
 a direct current electrical field to promote peripheral nerve regeneration^len#
J Reconstr Microsurg.#2#19950000#1995#11#3#189-93#20110200#a04v26n1.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v26n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#o#1#1#article#1#
20110120#130137#a06v26n1.htm#178##
03892000000000781000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400090014103500100015001200790
01600120088002390100030003270100029003570100040003860100029004260100036004550100
03100491010003400522070005900556070005900615070005900674070005900733070006400792
08309450085608500080180108500240180908500190183308500250185208500190187708500170
18960850037019130830898019500850008028480850025028560850021028810850024029020850
01902926085001702945085004902962117000603011072000303017112000903020111001403029
116000903043115001903052114000903071113001703080002001303097#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a06v26n1.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#0
6#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f25^l30#0102-8650#In vitro effect of 
470 nm LED (Light Emitting Diode) in keloid fibroblasts^len#Efeito in vitro do L
ED (Light Emitting Diode) de 470 nm em fibroblastos de quelóide^lpt#^rND^1A01^nS
ilvilena^sBonatti#^rND^1A02^nBernardo^sHochman#^rND^1A03^nVanina Monique^sTucci-
Viegas#^rND^1A03^nFabianne^sFurtado#^rND^1A04^nCarlos Eduardo^sPinfildi#^rND^1A0
5^nAna Carolina^sPedro#^rND^1A05^nLydia Masako^sFerreira#UNIFESP^iA01^1Departmen
t of Surgery^cSao Paulo^sSP^pBrazil#UNIFESP^iA02^1Department of Surgery^cSao Pau
lo^sSP^pBrazil#UNIFESP^iA03^1Department of Surgery^cSao Paulo^sSP^pBrazil#UNIFES
P^iA04^1Department of Surgery^cSao Paulo^sSP^pBrazil#UNIFESP^iA05^1Head Departme
nt of Surgery^cSao Paulo^sSP^pBrazil#^len^aPurpose: To quantify keloid fibroblas
ts after irradiation with 470nm blue LED, in vitro. Methods: Fibroblasts from ke
loid and adjacent skin have been obtained from 6 patients. Cells have been culti
vated and maintained in DMEM culture medium. In Petri dishes, they were irradiat
ed with energy doses of 6J, 12J and 18J. After 24 h, counting was done by the av
erage of the triplicates for each sample. Results: There were no significant dif
ferences in the number of irradiated keloid fibroblasts at the studied doses (p=
0.261). In adjacent skin fibroblasts, differences were observed (p=0.025) concer
ning the doses of 18 J and 6 J (p=0.03). Conclusions: There was a reduction in t
he number of adjacent skin fibroblasts irradiated with 470nm blue LED at the ene
rgy dose of 18 J compared to the ones irradiated at the energy dose of 6 J. Ther
e were no changes in keloid fibroblasts counting at any of the doses applied, 24
 h after irradiation.#^dnd^i1#^tm^len^kFibroblasts^i1#^tm^len^kKeloid^i1#^tm^len
^kPhototherapy^i1#^tm^len^kLasers^i1#^tm^len^kSkin^i1#^tm^len^kLaser Therapy, Lo
w-Level^i1#^lpt^aObjetivo: Quantificar fibroblastos de quelóide após irradiação 
com LED azul de 470nm, in vitro. Métodos: Foram obtidos fibroblastos de quelóide
 e pele adjacente, de seis pacientes. As células foram cultivadas e mantidas em 
meio de cultura DMEM. Em placas de Petri, receberam irradiação com doses de ener
gia de 6J, 12J e 18J. Após 24 horas a contagem foi feita pela média da triplicat
a para cada amostra. Resultados: Não houve diferença na quantidade de fibroblast
os de quelóide irradiados nas doses estudadas (p=0,261). Observou-se diferença n
os fibroblastos de pele adjacente (p=0,025), com relação às doses de 18 J e 6 J 
(p=0,03). Conclusões: Houve redução dos fibroblastos de pele adjacente irradiado
s com LED azul de 470 nm na dose de energia de 18 J em relação à dose de 6 J. Nã
o houve alteração na quantidade de fibroblastos de quelóide nas doses aplicadas 
após 24 horas da irradiação.#^dnd^i2#^tm^lpt^kFibroblastos^i2#^tm^lpt^kQuelóide^
i2#^tm^lpt^kFototerapia^i2#^tm^lpt^kLasers^i2#^tm^lpt^kPele^i2#^tm^lpt^kTerapia 
a Laser de Baixa Intensidade^i2#other#24#20100706#July 06, 2010#20100914#Septemb
er 14, 2010#20101019#October 19, 2010#a06v26n1.htm##
04019000000000781000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400090014103500100015001201050
01600120114002650100030003790100029004090100040004380100029004780100036005070100
03100543010003400574070005900608070005900667070005900726070005900785070006400844
08309850090808500080189308500240190108500190192508500250194408500190196908500170
19880850037020050830933020420850008029750850025029830850021030080850024030290850
01903053085001703072085004903089117000603138072000303144112000903147111001403156
116000903170115001903179114000903198113001703207002001303224#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a06v26n1.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#0
6#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f25^l30#0102-8650#<b><i>In vitro</i><
/b><b> effect of 470&nbsp;nm LED (Light Emitting Diode) in keloid fibroblasts</b
>^len#<b>Efeito <i>in vitro</i> do LED (<i>Light Emitting Diode</i>) de 470&nbsp
;nm em fibroblastos de quelóide</b>^lpt#^rND^1A01^nSilvilena^sBonatti#^rND^1A02^
nBernardo^sHochman#^rND^1A03^nVanina Monique^sTucci-Viegas#^rND^1A03^nFabianne^s
Furtado#^rND^1A04^nCarlos Eduardo^sPinfildi#^rND^1A05^nAna Carolina^sPedro#^rND^
1A05^nLydia Masako^sFerreira#UNIFESP^iA01^1Department of Surgery^cSao Paulo^sSP^
pBrazil#UNIFESP^iA02^1Department of Surgery^cSao Paulo^sSP^pBrazil#UNIFESP^iA03^
1Department of Surgery^cSao Paulo^sSP^pBrazil#UNIFESP^iA04^1Department of Surger
y^cSao Paulo^sSP^pBrazil#UNIFESP^iA05^1Head Department of Surgery^cSao Paulo^sSP
^pBrazil#^len^a<b>Purpose</b>: To quantify keloid fibroblasts after irradiation 
with 470nm blue LED, <i>in vitro</i>. <b>Methods</b>: Fibroblasts from keloid an
d adjacent skin have been obtained from 6 patients. Cells have been cultivated a
nd maintained in DMEM culture medium. In Petri dishes, they were irradiated with
 energy doses of 6J, 12J and 18J. After 24&nbsp;h, counting was done by the aver
age of the triplicates for each sample. <b>Results</b>: There were no significan
t differences in the number of irradiated keloid fibroblasts at the studied dose
s (p=0.261). In adjacent skin fibroblasts, differences were observed (p=0.025) c
oncerning the doses of 18 J and 6 J (p=0.03). <b>Conclusions</b>: There was a re
duction in the number of adjacent skin fibroblasts irradiated with 470nm blue LE
D at the energy dose of 18 J compared to the ones irradiated at the energy dose 
of 6 J. There were no changes in keloid fibroblasts counting at any of the doses
 applied, 24 h after irradiation.#^dnd^i1#^tm^len^kFibroblasts^i1#^tm^len^kKeloi
d^i1#^tm^len^kPhototherapy^i1#^tm^len^kLasers^i1#^tm^len^kSkin^i1#^tm^len^kLaser
 Therapy, Low-Level^i1#^lpt^a<b>Objetivo</b>: Quantificar fibroblastos de quelói
de após irradiação com LED azul de 470nm, <i>in vitro</i>. <b>Métodos</b>: Foram
 obtidos fibroblastos de quelóide e pele adjacente, de seis pacientes. As célula
s foram cultivadas e mantidas em meio de cultura DMEM. Em placas de Petri, receb
eram irradiação com doses de energia de 6J, 12J e 18J. Após 24 horas a contagem 
foi feita pela média da triplicata para cada amostra. <b>Resultados</b>: Não hou
ve diferença na quantidade de fibroblastos de quelóide irradiados nas doses estu
dadas (p=0,261). Observou-se diferença nos fibroblastos de pele adjacente (p=0,0
25), com relação às doses de 18 J e 6 J (p=0,03). <b>Conclusões</b>: Houve reduç
ão dos fibroblastos de pele adjacente irradiados com LED azul de 470 nm na dose 
de energia de 18 J em relação à dose de 6 J. Não houve alteração na quantidade d
e fibroblastos de quelóide nas doses aplicadas após 24 horas da irradiação.#^dnd
^i2#^tm^lpt^kFibroblastos^i2#^tm^lpt^kQuelóide^i2#^tm^lpt^kFototerapia^i2#^tm^lp
t^kLasers^i2#^tm^lpt^kPele^i2#^tm^lpt^kTerapia a Laser de Baixa Intensidade^i2#o
ther#24#20100706#July 06, 2010#20100914#September 14, 2010#20101019#October 19, 
2010#a06v26n1.htm##
04032000000000805000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000150012903100030014403200020014706500090014901400090015803500100
01670120079001770120088002560100030003440100029003740100040004030100029004430100
03600472010003100508010003400539070006100573070006100634070006100695070006100756
07000660081708309450088308500080182808500240183608500190186008500250187908500190
19040850017019230850037019400830898019770850008028750850025028830850021029080850
02402929085001902953085001702972085004902989117000603038072000303044112000903047
11100140305611600090307011500190307911400090309811300170310700200130312400800890
3137#v26n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#l#4#1#article#1#^mJa
n./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#06#ACB720#nd#Acta cir. bras#26#1#201102
00#^f25^l30#0102-8650#In vitro effect of 470 nm LED (Light Emitting Diode) in ke
loid fibroblasts^len#Efeito in vitro do LED (Light Emitting Diode) de 470 nm em 
fibroblastos de quelóide^lpt#^rND^1A01^nSilvilena^sBonatti#^rND^1A02^nBernardo^s
Hochman#^rND^1A03^nVanina Monique^sTucci-Viegas#^rND^1A03^nFabianne^sFurtado#^rN
D^1A04^nCarlos Eduardo^sPinfildi#^rND^1A05^nAna Carolina^sPedro#^rND^1A05^nLydia
 Masako^sFerreira#^iA01^1UNIFESP^2Department of Surgery^cSao Paulo^sSP^pBrazil#^
iA02^1UNIFESP^2Department of Surgery^cSao Paulo^sSP^pBrazil#^iA03^1UNIFESP^2Depa
rtment of Surgery^cSao Paulo^sSP^pBrazil#^iA04^1UNIFESP^2Department of Surgery^c
Sao Paulo^sSP^pBrazil#^iA05^1UNIFESP^2Head Department of Surgery^cSao Paulo^sSP^
pBrazil#^len^aPurpose: To quantify keloid fibroblasts after irradiation with 470
nm blue LED, in vitro. Methods: Fibroblasts from keloid and adjacent skin have b
een obtained from 6 patients. Cells have been cultivated and maintained in DMEM 
culture medium. In Petri dishes, they were irradiated with energy doses of 6J, 1
2J and 18J. After 24 h, counting was done by the average of the triplicates for 
each sample. Results: There were no significant differences in the number of irr
adiated keloid fibroblasts at the studied doses (p=0.261). In adjacent skin fibr
oblasts, differences were observed (p=0.025) concerning the doses of 18 J and 6 
J (p=0.03). Conclusions: There was a reduction in the number of adjacent skin fi
broblasts irradiated with 470nm blue LED at the energy dose of 18 J compared to 
the ones irradiated at the energy dose of 6 J. There were no changes in keloid f
ibroblasts counting at any of the doses applied, 24 h after irradiation.#^dnd^i1
#^tm^len^kFibroblasts^i1#^tm^len^kKeloid^i1#^tm^len^kPhototherapy^i1#^tm^len^kLa
sers^i1#^tm^len^kSkin^i1#^tm^len^kLaser Therapy, Low-Level^i1#^lpt^aObjetivo: Qu
antificar fibroblastos de quelóide após irradiação com LED azul de 470nm, in vit
ro. Métodos: Foram obtidos fibroblastos de quelóide e pele adjacente, de seis pa
cientes. As células foram cultivadas e mantidas em meio de cultura DMEM. Em plac
as de Petri, receberam irradiação com doses de energia de 6J, 12J e 18J. Após 24
 horas a contagem foi feita pela média da triplicata para cada amostra. Resultad
os: Não houve diferença na quantidade de fibroblastos de quelóide irradiados nas
 doses estudadas (p=0,261). Observou-se diferença nos fibroblastos de pele adjac
ente (p=0,025), com relação às doses de 18 J e 6 J (p=0,03). Conclusões: Houve r
edução dos fibroblastos de pele adjacente irradiados com LED azul de 470 nm na d
ose de energia de 18 J em relação à dose de 6 J. Não houve alteração na quantida
de de fibroblastos de quelóide nas doses aplicadas após 24 horas da irradiação.#
^dnd^i2#^tm^lpt^kFibroblastos^i2#^tm^lpt^kQuelóide^i2#^tm^lpt^kFototerapia^i2#^t
m^lpt^kLasers^i2#^tm^lpt^kPele^i2#^tm^lpt^kTerapia a Laser de Baixa Intensidade^
i2#other#24#20100706#July 06, 2010#20100914#September 14, 2010#20101019#October 
19, 2010#a06v26n1.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_artte
xt&pid=S0102-86502011000100006##
00310000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704007800073002001300151#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#5#1#article#150#<p align="right"><font
 face="Verdana" size="2"><b>6 - ORIGINAL ARTICLE    ^cY#a06v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704008800073002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#6#2#article#150#<br>   </b></font><b><
font face="Verdana" size="2">WOUND HEALING</font></b></p>     ^cY#a06v26n1.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704003700073002001300110#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#7#3#article#150#<p align="right">&nbsp
;</p>      ^cY#a06v26n1.htm##
00467000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704023500073002001300308#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#8#4#article#150#<p><b><font face="Verd
ana" size="2"><a name="top"></a></font><font face="Verdana" size="4"><I>In    vi
tro</I> effect of 470&#160;nm LED (Light Emitting Diode) in keloid fibroblasts<S
UP><a href="#end">1</a></SUP></font></b></p>     ^cY#a06v26n1.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#9#5#article#150#<p>&nbsp;</p>     ^cY#
a06v26n1.htm##
00405000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704017200074002001300246#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#10#6#article#150#<p><b><font face="Ver
dana" size="3">Efeito <I>in vitro</I> do LED (<I>Light Emitting    Diode</I>) de
 470&#160;nm em fibroblastos de quel&oacute;ide</font></b></p>     ^cY#a06v26n1.
htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002400074002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#11#7#article#150#<p>&nbsp;</p>       ^
cY#a06v26n1.htm##
00545000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704031200074002001300386#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#12#8#article#150#<p><font face="Verdan
a" size="2"><B>Silvilena Bonatti<SUP>I</SUP>, Bernardo Hochman<SUP>II</SUP>,    
Vanina Monique Tucci-Viegas<SUP>III</SUP>, Fabianne Furtado<SUP>III</SUP>, Carlo
s    Eduardo Pinfildi<SUP>IV</SUP>, Ana Carolina Pedro<SUP>V</SUP>, Lydia Masako
    Ferreira<SUP>VI</SUP></B> </font></p>      ^cY#a06v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002300074002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#13#9#article#150#<p>&nbsp;</p>      ^c
Y#a06v26n1.htm##
00534000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704030000075002001300375#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#14#10#article#150#<p><font face="Verda
na" size="2"><SUP>I</SUP>PT, Fellow Improvement Program, Plastic    Surgery Divi
sion, Department of Surgery, UNIFESP, Sao Paulo-SP, Brazil. <I>Acquisition    of
 data, helped with technical procedures, collection and processing of study    i
nformations, manuscript writing.    ^cY#a06v26n1.htm##
00498000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704026400075002001300339#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#15#11#article#150#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>II</SUP>Affiliate Professor, Plastic    Surgery
 Division, Department of Surgery, UNIFESP, Sao Paulo-SP, Brazil. <I>Mentor,    c
onception and design of the study, manuscript writing and critical revision.    
^cY#a06v26n1.htm##
00494000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704026000075002001300335#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#16#12#article#150#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>III</SUP>Fellow PhD degree, Plastic    Surgery 
Division, Department of Surgery, UNIFESP, Sao Paulo-SP, Brazil. <I>Helped    wit
h technical procedures, collection and processing of study informations.    ^cY#
a06v26n1.htm##
00626000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039200075002001300467#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#17#13#article#150#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>IV</SUP>Associate Professor, Plastic    Surgery
 Division, Department of Surgery, UNIFESP, Sao Paulo-SP, Brazil. <I>Collection  
  of study informations.</I></font><font face="Verdana" size="2"><SUP>V</SUP>Gra
duate    student, UNIFESP, Sao Paulo-SP, Brazil. <I>Processing of study informat
ions,    involved with technical procedures.    ^cY#a06v26n1.htm##
00551000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031700075002001300392#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#18#14#article#150#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>VI</SUP>Full Professor, Chairwoman    Plastic S
urgery Division, Head Department of Surgery, UNIFESP, Sao Paulo-SP,    Brazil. <
I>Scientific and intellectual content of the study, acquisition and    interpret
ation of data, critical revision.</I></font></p>     ^cY#a06v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#19#15#article#150#<p><font face="Verda
na" size="2"><a href="#end">Correspondence</a></font></p>     ^cY#a06v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#20#16#article#150#<p>&nbsp;</p>     ^c
Y#a06v26n1.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#21#17#article#150#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a06v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#22#18#article#150#<p><font face="Verda
na" size="2"><B>ABSTRACT </B></font></p>     ^cY#a06v26n1.htm##
01302000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704106800075002001301143#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#23#19#article#150#<p><font face="Verda
na" size="2"><B>Purpose</b>: To quantify keloid fibroblasts    after irradiation
 with 470nm blue LED, <I>in vitro</I>. <B>Methods</B>: Fibroblasts    from keloi
d and adjacent skin have been obtained from 6 patients. Cells have    been culti
vated and maintained in DMEM culture medium. In Petri dishes, they    were irrad
iated with energy doses of 6J, 12J and 18J. After 24&#160;h, counting    was don
e by the average of the triplicates for each sample. <B>Results</B>:    There we
re no significant differences in the number of irradiated keloid fibroblasts    
at the studied doses (p=0.261). In adjacent skin fibroblasts, differences were  
  observed (p=0.025) concerning the doses of 18 J and 6 J (p=0.03). <B>Conclusio
ns</B>:    There was a reduction in the number of adjacent skin fibroblasts irra
diated    with 470nm blue LED at the energy dose of 18 J compared to the ones ir
radiated    at the energy dose of 6 J. There were no changes in keloid fibroblas
ts counting    at any of the doses applied, 24 h after irradiation. </font></p> 
    ^cY#a06v26n1.htm##
00405000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017100075002001300246#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#24#20#article#150#<p><font face="Verda
na" size="2"><B>Key words</B>: Fibroblasts. Keloid. Phototherapy.    Lasers. Ski
n. Laser Therapy, Low-Level.</font></p> <hr size="1" noshade>      ^cY#a06v26n1.
htm##
00301000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006700075002001300142#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#25#21#article#150#<p><font face="Verda
na" size="2"><B>RESUMO </B></font></p>     ^cY#a06v26n1.htm##
01473000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704123900075002001301314#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#26#22#article#150#<p><font face="Verda
na" size="2"><B>Objetivo</b>: Quantificar fibroblastos de    quel&oacute;ide ap&
oacute;s irradia&ccedil;&atilde;o com LED azul de 470nm,    <I>in vitro</I>. <B>
M&eacute;todos</B>: Foram obtidos fibroblastos de quel&oacute;ide    e pele adja
cente, de seis pacientes. As c&eacute;lulas foram cultivadas e mantidas    em me
io de cultura DMEM. Em placas de Petri, receberam irradia&ccedil;&atilde;o    co
m doses de energia de 6J, 12J e 18J. Ap&oacute;s 24 horas a contagem foi feita  
  pela m&eacute;dia da triplicata para cada amostra. <B>Resultados</B>: N&atilde
;o    houve diferen&ccedil;a na quantidade de fibroblastos de quel&oacute;ide ir
radiados    nas doses estudadas (p=0,261). Observou-se diferen&ccedil;a nos fibr
oblastos    de pele adjacente (p=0,025), com rela&ccedil;&atilde;o &agrave;s dos
es de 18    J e 6 J (p=0,03). <B>Conclus&otilde;es</B>: Houve redu&ccedil;&atild
e;o dos    fibroblastos de pele adjacente irradiados com LED azul de 470 nm na d
ose de    energia de 18 J em rela&ccedil;&atilde;o &agrave; dose de 6 J. N&atild
e;o houve    altera&ccedil;&atilde;o na quantidade de fibroblastos de quel&oacut
e;ide nas    doses aplicadas ap&oacute;s 24 horas da irradia&ccedil;&atilde;o. <
/font></p>     ^cY#a06v26n1.htm##
00428000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704019400075002001300269#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#27#23#article#150#<p><font face="Verda
na" size="2"><B>Descritores</B>: Fibroblastos. Quel&oacute;ide.    Fototerapia. 
Lasers. Pele. Terapia a Laser de Baixa Intensidade. </font></p> <hr size="1" nos
hade>     ^cY#a06v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#28#24#article#150#<p>&nbsp;</p>     ^c
Y#a06v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#29#25#article#150#<p>&nbsp;</p>     ^c
Y#a06v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007400075002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#30#26#article#150#<p><font face="Verda
na" size="3"><B>Introduction</B> </font></p>      ^cY#a06v26n1.htm##
00842000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704060800075002001300683#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#31#27#article#150#<p><font face="Verda
na" size="2"> Keloid is a wound repair disorder resulting    from excessive coll
agen deposition, which occurs in susceptible individuals,    and its pathophysio
logy has not yet been fully elucidated<SUP>1-3</SUP>. The    literature presents
 many options of treatment, alone or in combination, nevertheless    they are no
t specific. Among the therapeutic modalities that have been most    used, stand 
out the administration of topical and intralesional    corticosteroids, the use 
of silicon plates, pressotherapy and exeresis followed    by betatherapy<SUP>4,5
</SUP>. </font></p>     ^cY#a06v26n1.htm##
00632000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039800075002001300473#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#32#28#article#150#<p><font face="Verda
na" size="2"> Recently, high potency LASER (Light Amplification    by Stimulated
 Emission of Radiation) and IPL (Intense Pulsed Light) were added    to that ars
enal. However, these resources of phototherapy have high cost and    relative su
ccess, besides the fact that the applications are painful and involve    risks o
f burns and hypochromia<SUP>6,7</SUP>.</font></p>     ^cY#a06v26n1.htm##
01239000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704100500075002001301080#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#33#29#article#150#<p><font face="Verda
na" size="2">   Low-level LASER therapy (LLLT) is a modality of treatment that i
s being used    for the improvement of impaired wound healing due to its biomodu
latory character,    with major action in mitochondrial metabolism<SUP>8</SUP>. 
In this sense, nowadays,    LED (Light Emitting Diode) appears as an alternative
 to LLLT and differentiates    itself by not showing collimated and coherent bea
m. However, both lasertherapy    and LED may have similar biological effects due
 to absorption of photons by    tissue chromophores. Such resources are already 
being used in many skin diseases    like acne<SUP>9</SUP>, in which blue light e
xerts anti-bacterial effect stimulating    bacterial membrane chromophores from 
<I>Propionum</I> acnes and releasing reactive    oxygen species. Phototherapy is
 also used in tissue repair treatments, acting    on fibroblasts proliferation<S
UP>10</SUP>, collagen synthesis<SUP>11</SUP> and    neovascularization<SUP>12</S
UP>. </font></p>     ^cY#a06v26n1.htm##
01082000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704084800075002001300923#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#34#30#article#150#<p> <font face="Verd
ana" size="2"><I>In vitro </I>studies with red<SUP>13</SUP>    and infrared LASE
R<SUP>14,15</SUP> showed that the highest doses investigated    inhibited fibrob
last proliferation. In hypertrophic scars and skin fibroblasts,    <I>in vitro</
I>, it was demonstrated that low intensity LASER with wavelength    680&#160;nm 
(red) and energy (E) 0.5&#160;J (31&#160;s) and 0.8&#160;J (52&#160;s)    had a 
stimulatory effect on both cell counts, with a more pronounced result    obtaine
d with the lowest dose used<SUP>13</SUP>. On the other hand, 880&#160;nm    infr
ared LASER at doses of 0.71&#160;J (44.5&#160;s) and 1.18&#160;J (74&#160;s)    
resulted in reduction of cell proliferation in both skin and hypertrophic scar  
  fibroblasts, noting that the second dose led to a greater inhibition<SUP>14</S
UP>.    </font></p>     ^cY#a06v26n1.htm##
01097000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704086300075002001300938#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#35#31#article#150#<p><font face="Verda
na" size="2"> Experimental studies with LED, in wavelengths    corresponding to 
green and blue, reported effects in fibroblasts. In chicken    embryos, it was o
bserved that irradiation with green spectrum (532&#160;nm)    at a dose of 0.90&
#160;J, for 1&#160;s caused an increase in the number of fibroblasts<SUP>16</SUP
>,    compared with the group of cells that was not irradiated. In blue spectrum
 of    470&#160;nm, irradiation with LED for 180&#160;s inhibited proliferation 
of    gingival fibroblasts<SUP>17</SUP>. However, no studies were found using LE
D    in blue spectrum, in keloid fibroblasts, which could be valuable as a preve
ntion    or treatment of this disorder. Therefore, the objective of this study w
as to    quantify keloid fibroblasts after irradiation with 470&#160;nm blue LED
, <I>in    vitro</I>. </font></p>      ^cY#a06v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#36#32#article#150#<p>&nbsp; </p>     ^
cY#a06v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#37#33#article#150#<p><font face="Verda
na" size="3"><B>Methods</B> </font></p>      ^cY#a06v26n1.htm##
00485000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025100075002001300326#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#38#34#article#150#<p><font face="Verda
na" size="2"> This study was approved by the Research Ethics    Committee of the
 Federal University of Sao Paulo and the discarded parts were    used after all 
patients signed a free and informed consent form. </font></p>      ^cY#a06v26n1.
htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#39#35#article#150#<p>&nbsp;</p>     ^c
Y#a06v26n1.htm##
00324000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009000075002001300165#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#40#36#article#150#<p><font face="Verda
na" size="2"><I>Collection of keloid samples</I> </font></p>      ^cY#a06v26n1.h
tm##
01183000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704094900075002001301024#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#41#37#article#150#<p><font face="Verda
na" size="2"> Keloid samples used were obtained from six female    patients aged
 18-50 years and with Fitzpatrick skin types II to VI. The scars    had at least
 1-year evolution, were in clinical activity, presenting hyperemia,    pruritus 
and/or pain, and also central involution (<I>i.e.</I> a lower relief    in the c
entral compared with the peripheral area) and with minimum dimensions    3&#160;
cm at the longitudinal axe and 2&#160;cm at the transversal axe. Keloid    locat
ion was delimited in the thoracic region, between a transverse plane at    the l
evel of the acromion and a transverse plane at the level    of xiphoid process<S
UP>3</SUP>. Were excluded keloids previously treated or    patients with chronic
 dermatopathies, metabolic, collagen or degenerative&#160;/&#160;auto-immune    
diseases, malignant neoplasms, or patients submitted to systemic or topic treatm
ent    with corticosteroids. </font></p>     ^cY#a06v26n1.htm##
00784000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055000075002001300625#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#42#38#article#150#<p><font face="Verda
na" size="2"> Keloids were excised in the subcutaneous plane,    under local ane
sthesia, with exceeding skin fragments represented by the &quot;dog    ears&quot
;. After exeresis of the keloid lesions, samples were obtained from    adjacent 
skin and peripheral keloid (between the excisional margin and the central    umb
ilication) of the surgical specimens using a circular punch of 3&#160;mm    diam
eter, from the epithelialized surface of tissue containing epithelium and    con
nective tissue<SUP>18</SUP>. </font></p>      ^cY#a06v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#43#39#article#150#<p>&nbsp;</p>     ^c
Y#a06v26n1.htm##
00336000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010200075002001300177#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#44#40#article#150#<p><font face="Verda
na" size="2"><I>Obtainment of the fibroblast cultures</I>    </font></p>      ^c
Y#a06v26n1.htm##
01445000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704121100075002001301286#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#45#41#article#150#<p><font face="Verda
na" size="2"> Primary keloid fibroblast culture was done by    explant<SUP>19,20
</SUP> by which the fractions corresponding to samples of adjacent    skin and k
eloid were obtained. Fractions were placed in 15&#160;ml conic tubes    and exha
ustively rinsed (six times) with 10&#160;ml PBS (Phosphate-Buffered    Saline, C
ultilab, Brazil) containing penicillin (100Ul/ml, Gibco<SUP>&#174;</SUP>)    and
 streptomycin (100&#181;/ml, Gibco<SUP>&#174;</SUP>) under vigorous agitation,  
  changing tubes and PBS at each repetition. Then, fractions were transferred   
 to 60&#160;mm&#178; diameter Petri dishes, in grid areas scratched with a scalp
el,    and plates were left semi-opened in the laminar flow for 30&#160;min, for
 the    fragments to adhere to its surface. Then, 6&#160;ml of DMEM (Dulbecco's 
Modified    Eagle's Medium, Cultilab, Brazil) supplemented with 15% FBS (Fetal B
ovine Serum,    Cultilab, Brazil), penicillin (100&#160;UI/ml, Gibco<SUP>&#174;<
/SUP>) and streptomycin    (100&#160;&#181;g/ml, Gibco<SUP>&#174;</SUP>) were ca
refully added to each plate.    Plates were kept in humidified incubator at 37&#
186;C, 95% O<SUB>2</SUB> and    5% CO<SUB>2</SUB>. </font></p>     ^cY#a06v26n1.
htm##
00707000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704047300075002001300548#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#46#42#article#150#<p><font face="Verda
na" size="2"> Culture medium was changed every two days and    a few days after 
establishing the primary culture, spindle-like cells were seen    proliferating 
from the edges of the explanted tissue, regarded as culturing    fibroblasts. Fi
broblast satisfactory proliferation was observed in approximately    7-14 days a
nd subculturing (passage) was performed when cellular confluence    reached appr
oximately 80% at the Petri dish. </font></p>     ^cY#a06v26n1.htm##
01559000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704132500075002001301400#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#47#43#article#150#<p><font face="Verda
na" size="2"> For subculturing, the culture medium was aspirated    and the kelo
id fragments, discarded with tweezers. The plate containing fibroblasts    was w
ashed with PBS, and then quickly rinsed with Versene&#153; (PBS with 0.05M    ED
TA, Ethylene Diamine Tetra Acetic, Sigma<SUP>&#174;</SUP>). Versene&#153;    was
 aspirated and 1&#160;ml of trypsin 0.25% with EDTA 0.02% was added to the    pl
ate. The plate was kept for 2&#160;min in the incubator and taken to the microsc
ope    to confirm fibroblast detachment from the dish surface. Trypsin was neutr
alized    with 3.0&#160;ml DMEM 10% FBS and the cellular suspension was centrifu
ged (100&#160;g,    6&#160;min). The pellet was resuspended in DMEM 10% FBS and 
antibiotics (penicillin    100&#160;UI/ml and streptomycin 100&#160;&#181;g/ml) 
and 100,000 cells were    seeded in each 75&#160;cm<SUP>2</SUP> culture flask. F
or the experiments, cells    were seeded in 30&#160;mm<SUP>2</SUP> diameter (10&
#160;mm height) Petri dishes,    in triplicates. In the first sample, 2x10<SUP>5
</SUP> cells were seeded per    plate and, for better confluence, in all other s
amples, 5x10<SUP>4</SUP> cells    were seeded per plate, always in triplicates. 
Before irradiation, cells were    kept for 48&#160;h in the incubator, at 37&#18
6;C. </font></p>     ^cY#a06v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#48#44#article#150#<p>&nbsp;</p>     ^c
Y#a06v26n1.htm##
00312000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007800075002001300153#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#49#45#article#150#<p><font face="Verda
na" size="2"><I>Cell irradiation</I> </font></p>      ^cY#a06v26n1.htm##
00600000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036600075002001300441#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#50#46#article#150#<p><font face="Verda
na" size="2"> The equipment Quasar Esthetique<SUP>&#174;</SUP>    was used for c
ell irradiation. The device has a handpiece with LEDs, covering    the blue spec
trum (470&#160;nm) with 100&#160;mW power, 125&#160;mW/cm<SUP>2</SUP>    power d
ensity, optical fiber diameter 1&#160;cm and beam area of 0.8&#160;cm<SUP>2</SUP
>.    </font></p>     ^cY#a06v26n1.htm##
00759000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052500075002001300600#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#51#47#article#150#<p><font face="Verda
na" size="2"> The samples of keloid and adjacent skin fibroblasts    were divide
d into groups according to the total energy supplied: Control Group,    received
 no irradiation; Group 1&#160;min, received 6&#160;J total energy (E)    and ene
rgy density (ED) 59.87&#160;J/cm<SUP>2</SUP>, Group 2&#160;min received    12&#1
60;J (E) and (ED) 122.3&#160;J/cm<SUP>2</SUP>, Group 3&#160;min, received    18&
#160;J (E), and (ED) 183.43&#160;J/cm<SUP>2</SUP> (<a href="#tab01">Table    1</
a>). </font></p>     ^cY#a06v26n1.htm##
00642000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040800075002001300483#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#52#48#article#150#<p><font face="Verda
na" size="2">The device tip was fixed at a distance of 2&#160;cm    in height fr
om the plate's bottom. The culture medium was aspirated for 3&#160;min    in all
 groups, for homogenization of the samples. Irradiation was performed    with th
e LED's collimator perpendicular to the Petri dish, which was placed    on top o
f a black base (<a href="#img01">Figure 1</a>). </font></p>     ^cY#a06v26n1.htm
##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#53#49#article#150#<p>&nbsp;</p>     ^c
Y#a06v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#54#50#article#150#<p>&nbsp;</p>     ^c
Y#a06v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#55#51#article#150#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a06tab01.jpg"><a name="tab01"></a></p>     ^cY#a
06v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#56#52#article#150#<p>&nbsp;</p>     ^c
Y#a06v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#57#53#article#150#<p>&nbsp;</p>     ^c
Y#a06v26n1.htm##
00671000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704043700075002001300512#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#58#54#article#150#<p><font face="Verda
na" size="2"> After irradiation, cells were put back in incubator    for another
 24&#160;h. After this period, cell cultures were prepared for counting    in Ne
ubauer chamber. Each sample (adjacent skin and keloid fibroblasts) was    counte
d three times, using a manual cell counter, and data were expressed as    the av
erage of the triplicates. Statistical significance was set at p&lt;0.05.    </fo
nt></p>      ^cY#a06v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#59#55#article#150#<p>&nbsp; </p>     ^
cY#a06v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#60#56#article#150#<p><font face="Verda
na" size="3"><B>Results</B> </font></p>      ^cY#a06v26n1.htm##
00527000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029300075002001300368#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#61#57#article#150#<p><font face="Verda
na" size="2"> The values obtained after cell counting are    shown in <a href="/
img/revistas/acb/v26n1/a06tab02.jpg">table 2</a>.    &#160;With the Kolmogorov-S
mirnov test, it was verified that the samples did    not show normal distributio
n (p=0.016). </font></p>     ^cY#a06v26n1.htm##
00288000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704005400075002001300129#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#62#58#article#150#<p><font face="Verda
na" size="2"> </font></p>     ^cY#a06v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#63#59#article#150#<p align="center">&n
bsp;</p>     ^cY#a06v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#64#60#article#150#<p align="center">&n
bsp;</p>     ^cY#a06v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#65#61#article#150#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a06img01.jpg"><a name="img01"></a></p>     ^cY#a
06v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#66#62#article#150#<p align="center">&n
bsp;</p>     ^cY#a06v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#67#63#article#150#<p align="center">&n
bsp;</p>     ^cY#a06v26n1.htm##
01124000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704089000075002001300965#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#68#64#article#150#<p><font face="Verda
na" size="2"> Friedman's test showed no differences on the    keloid fibroblasts
 amounts at the energy doses applied (p=0.261) compared to    the control group.
 However, the same test showed that there was a difference    in the amounts of 
skin fibroblasts irradiated with 18 J (3 min) according to    the energy doses s
upplied (p=0.025), compared to the control group. Wilcoxon's    test revealed th
at adjacent skin fibroblasts irradiated with 18 J (3 min) presented    a reducti
on of its total amount when compared to adjacent skin fibroblasts irradiated    
with 6 J (1 min) (p=0.03) although there wasn't, in the control group, any signi
ficant    difference on the number of irradiated cells between the groups irradi
ated with    18 J (p=0.5) and those irradiated with 6 J (p=0.09) (<a href="/img/
revistas/acb/v26n1/a06tab03.jpg">Table    3</a>). </font></p>     ^cY#a06v26n1.h
tm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#69#65#article#150#<p>&nbsp;</p>     ^c
Y#a06v26n1.htm##
00307000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007300075002001300148#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#70#66#article#150#<p> <font face="Verd
ana" size="3"><B>Discussion</B> </font></p>      ^cY#a06v26n1.htm##
00974000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704074000075002001300815#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#71#67#article#150#<p><font face="Verda
na" size="2"> Nowadays, some alternative therapies, such as    Pumped Dye Laser<
SUP>6</SUP> and IPL (Intense Pulsed Light)<SUP>7</SUP>, are    being used in kel
oid. Success has been relative concerning reduction of scar    height and scar l
ightening, yet it involves risks such as dyschromia, burns    and discomfort dur
ing application, as those are high potency equipments. However,    in the arsena
l of phototherapy there are LLLT, widely used in tissue repair    process<SUP>11
</SUP> and LED, recently investigated as a low cost, alternative    source of li
ght<SUP>12</SUP>. However, there are still no researches with LED    and fibropr
oliferative scars, a fact that motivated the present study. </font></p>     ^cY#
a06v26n1.htm##
01341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704110700075002001301182#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#72#68#article#150#<p><font face="Verda
na" size="2"> It is known that the mechanism of action of    low intensity photo
therapy depends on the wavelength used and on the total energy    supplied, whic
h directly affects mitochondrial metabolism, acting on the chromophores    of th
e respiratory chain<SUP>8</SUP>. Wavelengths above 500&#160;nm are widely    use
d to stimulate wound healing, specially red and infrared bands<SUP>11</SUP>.    
In the blue spectral region, flavoproteins such as NADHdehydrogenase and succina
te    dehydrogenase, and also porphyrins can work as photoacceptors<SUP>8,21</SU
P>.    This enzyme acts in the oxidation of ketone bodies and its suppression le
ads    to a pH decrease, which can lead to cell death (apoptosis)<SUP>21</SUP>. 
In    the researched literature, the studies found, concerning blue spectrum, re
ported    the inhibition of cell proliferation or no change in fibroblasts<SUP>1
7</SUP>.    In addition, this wavelength also exerts an inhibitory effect on acn
e<SUP>9</SUP>,    characterized by neurogenic inflammation, which is exacerbated
 in keloid<SUP>5</SUP>.    </font></p>     ^cY#a06v26n1.htm##
01420000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704118600075002001301261#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#73#69#article#150#<p> <font face="Verd
ana" size="2"><I>In vitro</I> studies with LASER or LED often    use well plates
, in which one well is next to the other, eventually dissipating    energy to ea
ch other. In this study, cells were irradiated in Petri dishes,    to ensure tha
t light scattering from one dish wouldn't interfere with the cells    in the oth
er ones. Besides that, a black base was used under the Petri dishes    to make s
ure that light wouldn't be reflected. The culture medium was also aspirated    p
rior to irradiation, to avoid the light to be refracted before reaching the    c
ell layer on the bottom of the Petri dish. These measures were adopted to ensure
    the best possible use of the energy supplied and    to keep each sample of c
ells completely isolated from the others. There is no    consensus concerning th
e distance from the light source to the cell layer. Therefore,    to avoid conta
ct of the LED's device tip with the cell layer, we standardized    in this study
 the distance of 2&#160;cm height from the plate's bottom, considering    that t
he plate's border is 1&#160;cm height and leaving the device tip 1&#160;cm    hi
gher, as a safety margin. </font></p>     ^cY#a06v26n1.htm##
02620000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704238600075002001302461#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#74#70#article#150#<p><font face="Verda
na" size="2"> Wataha <I>et al.</I><SUP>22</SUP>, irradiated    gingival fibrobla
sts, with LED between 400 and 500&#160;nm (blue), with ED 60&#160;J/cm<SUP>2</SU
P>    for 60&#160;s and verified, after 24&#160;h, suppression of the enzyme suc
cinate    dehydrogenase and as a consequence, inhibition of cell proliferation. 
One of    the exposure times used in the present study was 60&#160;s, with energ
y similar    (59.87 J/cm<SUP>2</SUP>) to that used by Wataha <I>et al.</I><SUP>2
2</SUP>;    nevertheless there was no significant changes in the number of keloi
d or skin    cells. On the other hand, Taoufik <I>et al.</I><SUP>17 </SUP>irradi
ated gingival    fibroblasts with a wavelength of 470&#160;nm for 180&#160;s, wh
ich was also    similar to our study, and they performed counting after 24&#160;
h and 1 week.    After 24&#160;h, they didn't detect any changes, corroborating 
with the present    study, when compared to keloid fibroblasts which also didn't
 show any changes    with the same irradiation times and counting. However, thos
e authors' data confront    the results obtained here in this study with adjacen
t skin fibroblasts, since    the cell counting performed 24 h after irradiation 
for 180&#160;s (18&#160;J)    showed a reduction in the number of cells compared
 to the group irradiated for    60&#160;s (6&#160;J). Taoufik <I>et al.</I><SUP>
17 </SUP>observed inhibition    of gingival fibroblasts irradiated for 180&#160;
s, after a week. Since Whataha    <I>et al.</I><SUP>22 </SUP>found cell alterati
ons as early as 24&#160;h after    light exposure, and Taoufik <I>et al.</I><SUP
>17</SUP>, after seven days, it    leaves opened the perspective to perform cell
 counting with different intervals    of time so that it could be checked the in
hibitory effect on cell growth, depending    not only on the dose applied, but a
lso on the interval of time. Both cited studies    did not provide sufficient da
ta to calculate the total energy supplied, which    would be ideal to compare wi
th our study. However, exposure times were similar:    60&#160;s<SUP>22</SUP> an
d 180&#160;s<SUP>17</SUP>. It is necessary a better    standardization of data p
rovided by phototherapy studies, such as time, energy    density, beam area and 
power for greater reliability when comparing, for example,    the energy doses u
sed in different studies. </font></p>     ^cY#a06v26n1.htm##
01261000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704102700075002001301102#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#75#71#article#150#<p><font face="Verda
na" size="2"> Webb and Dyson<SUP>13</SUP> irradiated hypertrophic    scars and s
kin fibroblasts, using LLLT at a wavelength of 660&#160;nm with energies    of 0
.52&#160;J (31&#160;s) and 0.8&#160;J (52&#160;s), and performed differential   
 counting during 5 consecutive days. They observed an increase of the cell numbe
rs    in all counting periods, comparing to the groups of non-irradiated cells. 
This    is an expected result when using red spectrum, which increases mitochond
rial    activity and ATP synthesis in respiratory chain<SUP>8</SUP>. Even though
, despite    the wavelength, Webb and Dyson<SUP>13</SUP> irradiated hypertrophic
 scar fibroblasts    using the same conditions of cultivation and preservation o
f cells and obtained    results after one day of irradiation, the present study 
was performed under    similar conditions of cultivation, irradiation and counti
ng, but there was no    change in the number of keloid or skin fibroblasts regar
dless of the dose used.    </font></p>     ^cY#a06v26n1.htm##
02082000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704184800075002001301923#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#76#72#article#150#<p><font face="Verda
na" size="2"> After that, Webb <I>et al.</I><SUP>14 </SUP>investigated    the ef
fect of 880&#160;nm infrared LASER in hypertrophic scar and skin fibroblasts    
at doses of 0.71&#160;J (44.5&#160;s) and 1.18&#160;J (74&#160;s). 24&#160;hours
    after irradiation, they didn't find any difference in cell counts compared w
ith    the controls. However, from the second day on, they reported a reduction 
in    the number of cells of both skin and hypertrophic scar. It can be confirme
d    at the literature that high doses used in <I>in vitro</I> experiments rangi
ng    from 1.19&#160;J<SUP>14</SUP> to 145.2&#160;J<SUP>15</SUP>, especially wit
h    infrared, cause inhibition of cell proliferation<SUP>15</SUP>. As a result,
    some authors suggest this wavelength as a possible alternative for the treat
ment    of hypertrophic scars<SUP>14</SUP>. In the present study, in addition to
 the    different wavelength, the doses used (6&#160;J, 12&#160;J and 18&#160;J)
 were    higher than those used by Webb <I>et al.</I><SUP>14 </SUP>and applied i
n keloid    cells. Nevertheless, it is worth noting that there is a consensus no
wadays in    literature<SUP>3,23</SUP> that keloid fibroblasts and hypertrophic 
scars fibroblasts    have the same pathophysiology,<I> i.e.</I>, they would be b
oth fibroproliferative    scars with different expressions. Webb <I>et al.</I><S
UP>14</SUP>, using infrared    laser observed, after 48&#160;h, a reduction on t
he cell number with a smaller    energy and time of exposure and thus, different
ly from this study, using blue    led, which observed no change in the keloid fi
broblast number, regardless of    the dose of energy supplied. On the other hand
, the skin fibroblasts response    goes towards those authors' findings, since t
he greater dose used caused cell    inhibition. </font></p>     ^cY#a06v26n1.htm
##
00958000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704072400075002001300799#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#77#73#article#150#<p><font face="Verda
na" size="2"> It becomes essential to have more studies comparing    the effects
 on keloid and hypertrophic scar fibroblasts, in the infrared and    blue spectr
a, since both are the most frequently reported, according to the    literature, 
as potential inhibitors of mithochondrial metabolism, especially    in high dose
s Another perspective with blue LED would be its application in    preoperative 
and postoperative groups in experimental studies, to verify its    action in the
 wound healing process, and more specifically in the neurogenic    inflammation 
phase, and thus be able to raise hypothesis of its use in clinical    trials in 
the prevention of fibroproliferative scars. </font></p>     ^cY#a06v26n1.htm##
00532000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029800075002001300373#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#78#74#article#150#<p><font face="Verda
na" size="2"> Even more, the fact that this study verified    a reduction in the
 skin fibroblasts counting, might open the possibility of    applying pre-operat
ive blue LED on the adjacent skin of patients undergoing    excision of fibropro
liferative scars. </font></p>     ^cY#a06v26n1.htm##
00784000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055000075002001300625#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#79#75#article#150#<p><font face="Verda
na" size="2"> Shi <I>et al.</I><SUP>24 </SUP>recently demonstrated    that the m
etabolic activity of keloid fibroblasts is increased when compared    to skin fi
broblasts, and that their rate of apoptosis is lower. This could explain    why 
keloid fibroblasts didn't show any changes after being irradiated with blue    L
ED at the doses used in this study. Perhaps, with doses above 18&#160;J, keloid 
   fibroblasts could have showed some inhibitory response, similar to those obse
rved    in skin fibroblasts. </font></p>      ^cY#a06v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002400075002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#80#76#article#150#<p>&nbsp; </p>      
^cY#a06v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007400075002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#81#77#article#150#<p> <font face="Verd
ana" size="3"><B>Conclusions</B> </font></p>      ^cY#a06v26n1.htm##
00631000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039700075002001300472#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#82#78#article#150#<p><font face="Verda
na" size="2"> This study demonstrated that a single <I>in    vitro</I> applicati
on of 470 nm blue LED caused, after 24 h, a decrease in the    total amount of a
djacent skin fibroblasts at a dose of 18&#160;J when compared    to a dose of 6&
#160;J. However, at the doses tested, there were no significant    differences i
n the amount of keloid fibroblasts. </font></p>      ^cY#a06v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#83#79#article#150#<p>&nbsp; </p>     ^
cY#a06v26n1.htm##
00307000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007300075002001300148#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#84#80#article#150#<p><font face="Verda
na" size="3"><B>References </B> </font></p>      ^cY#a06v26n1.htm##
00508000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704026000077002001300337#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#85#81#article#150#1#<p><fo
nt face="Verdana" size="2">1. Campaner AB, Ferreira LM, Gragnani A, Bruder    JM
, Cusick JL, Morgan JR. Upregulation of TGF-beta1 expression may be necessary   
 but is not sufficient for excessive scarring. J Invest Dermatol. 2006;126(5):11
68-76.    ^cY#a06v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002400075002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#86#82#article#150#    </font></p>     
^cY#a06v26n1.htm##
00427000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704017900077002001300256#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#87#83#article#150#2#<p><fo
nt face="Verdana" size="2">2. Ramos ML, Gragnani A, Ferreira LM. Is there    an 
ideal animal model to study hypertrophic scarring? J Burn Care Res. 2008;29(2):3
63-8.    ^cY#a06v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002400075002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#88#84#article#150#    </font></p>     
^cY#a06v26n1.htm##
00461000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704021300077002001300290#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#89#85#article#150#3#<p><fo
nt face="Verdana" size="2">3. Hochman B, Nahas FX, Sobral CS, Arias V, Locali   
 RF, Juliano Y, Ferreira LM. Nerve fibers: a possible role in keloid pathogenesi
s.    Br J Dermatol. 2008;158(3):651-2.    ^cY#a06v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#90#86#article#150# </font></p>     ^cY
#a06v26n1.htm##
00444000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704019600077002001300273#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#91#87#article#150#4#<p><fo
nt face="Verdana" size="2">4. Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal    
scars: a review with a critical look at therapeutic options. J Am Acad Dermatol.
    2002;46(2):S63-97.    ^cY#a06v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#92#88#article#150# </font></p>     ^cY
#a06v26n1.htm##
00466000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704021800077002001300295#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#93#89#article#150#5#<p><fo
nt face="Verdana" size="2">5. Hochman B, Locali RF, Matsuoka PK, Ferreira    LM.
 Intralesional triamcinolone acetonide for keloid treatment: a systematic    rev
iew. Aesthetic Plast Surg. 2008;32(4):705-9.    ^cY#a06v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#94#90#article#150# </font></p>     ^cY
#a06v26n1.htm##
00411000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704016300077002001300240#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#95#91#article#150#6#<p><fo
nt face="Verdana" size="2">6. Bouzari N, Davis SC, Nouri K. Laser treatment    o
f keloids and hypertrophic scars. Intern J Dermatol. 2007;46(1):80-8.    ^cY#a06
v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#96#92#article#150# </font></p>     ^cY
#a06v26n1.htm##
00464000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704021600077002001300293#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#97#93#article#150#7#<p><fo
nt face="Verdana" size="2">7. Erol OO, Gurlek A, Agaoglu G, Topcuoglu E,    Oz H
. Treatment of hypertrophic scars and keloids using intense pulsed light    (IPL
). Aesthetic Plast Surg. 2008;32(6):902-9.    ^cY#a06v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#98#94#article#150# </font></p>     ^cY
#a06v26n1.htm##
00426000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704017800077002001300255#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#99#95#article#150#8#<p><fo
nt face="Verdana" size="2">8. Karu TI, Kolyakov SF. Exact action spectra    for 
cellular responses relevant to phototherapy. Photomed Laser Surg. 2005;23(4):355
-61.    ^cY#a06v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002400076002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#100#96#article#150#    </font></p>    
 ^cY#a06v26n1.htm##
00384000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000200076704013500078002001300213#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#101#97#article#150#9#<p><f
ont face="Verdana" size="2">9. Toyoda M, Morohashi M. New aspects in acne    inf
lammation. Dermatology. 2003;206(1):17-23.    ^cY#a06v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#102#98#article#150# </font></p>     ^c
Y#a06v26n1.htm##
00454000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704020400079002001300283#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#103#99#article#150#10#<p><
font face="Verdana" size="2">10. Hawkins DH, Abrahamse H. Time-dependent respons
es    of wounded human skin fibroblasts following phototherapy. J Photochem Phot
obiol    B. 2007;88(2-3):147-55.    ^cY#a06v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#104#100#article#150# </font></p>     ^
cY#a06v26n1.htm##
00484000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023300080002001300313#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#105#101#article#150#11#<p>
<font face="Verdana" size="2">11. da Silva JP, da Silva MA, Almeida AP, Lombardi
    Junior I, Matos AP. Laser therapy in the tissue repair process: a literature
    review. Photomed Laser Surg. 2010;28(1):17-21 </font></p>     ^cY#a06v26n1.h
tm##
00477000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022600080002001300306#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#106#102#article#150#12#<p>
<font face="Verdana" size="2">12. Corazza AV, Jorge J, Kurachi C, Bagnato VS.   
 Photobiomodulation on the angiogenesis of skin wounds in rats using different  
  light sources. Photomed Laser Surg. 2007;25(2):102-6.    ^cY#a06v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#107#103#article#150# </font></p>     ^
cY#a06v26n1.htm##
00513000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026200080002001300342#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#108#104#article#150#13#<p>
<font face="Verdana" size="2">13. Webb C, Dyson M, Lewis WHP. Stimulatory effect
    of 660&#160;nm low level laser energy on hypertrophic scar-derived fibroblas
ts:    possible mechanisms for increase in cell counts. Laser Surg Med. 1998;22(
5):294-301.    ^cY#a06v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#109#105#article#150#    </font></p>   
  ^cY#a06v26n1.htm##
00496000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024500080002001300325#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#110#106#article#150#14#<p>
<font face="Verdana" size="2">14. Webb C, Dyson M. The effect of 880&#160;nm    
low level laser energy on human fibroblast cell numbers: a possible role in    h
ypertrophic wound healing. J Photochem Photobiol Biol B. 2003;70(1):39-44.    ^c
Y#a06v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#111#107#article#150#    </font></p>   
  ^cY#a06v26n1.htm##
00499000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024800080002001300328#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#112#108#article#150#15#<p>
<font face="Verdana" size="2">15. Houreld NN, Abrahamse H. Laser light influence
s    cellular viability and proliferation in diabetic-wounded fibroblast cells i
n    a dose and wavelength dependent manner. Lasers Med Sci. 2008;23(1):11-8.   
 ^cY#a06v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#113#109#article#150# </font></p>     ^
cY#a06v26n1.htm##
00489000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023800080002001300318#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#114#110#article#150#16#<p>
<font face="Verdana" size="2">   16. Vinck EM, Cagnie BJ, Cornelissen MJ, Decler
cq HA, Cambier DC. Increased    fibroblast proliferation induced emitting diode 
and low power laser irradiation.    Laser Med Sci. 2003;18(2):95-9.    ^cY#a06v2
6n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#115#111#article#150# </font></p>     ^
cY#a06v26n1.htm##
00482000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023100080002001300311#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#116#112#article#150#17#<p>
<font face="Verdana" size="2">17. Taoufik K, Mavrogonatou E, T Eliades, L Papagi
annoulis,    Eliades G, Kletsas D. Effect of blue light on the proferation of hu
man gingival    fibroblasts. Dent Mater. 2008;24(7):895-900.    ^cY#a06v26n1.htm
##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#117#113#article#150# </font></p>     ^
cY#a06v26n1.htm##
00536000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028500080002001300365#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#118#114#article#150#18#<p>
<font face="Verdana" size="2">18. Tucci-Viegas VM, Hochman B, Fran&ccedil;a    J
P, Ferreira LM. Keloid explant culture: a model for keloid fibroblasts isolation
    and cultivation based on the biological differences of its specific regions.
    Int Wound J. 2010;7(5):339-48.    ^cY#a06v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#119#115#article#150# </font></p>     ^
cY#a06v26n1.htm##
00442000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019100080002001300271#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#120#116#article#150#19#<p>
<font face="Verdana" size="2">19. Keira SM, Ferreira LM, Gragnani A, Duarte    I
S, Santos, IAN. Experimental model for fibroblast culture. Acta Cir Bras. 2004;1
9    (Suppl 1):11-6.    ^cY#a06v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#121#117#article#150# </font></p>     ^
cY#a06v26n1.htm##
00509000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025800080002001300338#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#122#118#article#150#20#<p>
<font face="Verdana" size="2">20. Gragnani A, Giannoccaro FB, Sobral CS, Moraes 
   AA, Fran&ccedil;a JP, Ferreira AT, Ferreira LM. Dimethylaminoethanol affects 
   the viability of human cultured fibroblasts. Aesthetic Plast Surg. 2007;31(6)
:711-8.    ^cY#a06v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#123#119#article#150#    </font></p>   
  ^cY#a06v26n1.htm##
00422000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704017100080002001300251#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#124#120#article#150#21#<p>
<font face="Verdana" size="2">21. Gorgidze LA, Oshemkova SA, Vorobjev IA. Blue  
  light inhibits mitosis in tissue culture cells. Biosci Rep. 1998;18(4):215-24.
    ^cY#a06v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#125#121#article#150#    </font></p>   
  ^cY#a06v26n1.htm##
00474000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022300080002001300303#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#126#122#article#150#22#<p>
<font face="Verdana" size="2">22. Wataha JC, Lewis JB, Lockwood PE, Hsu S,    Me
sserRL, Rueggeberg FA, Bouillaguet S. Blue light differentially modulates    cel
l survival and growth. J Dent Res. 2004;83(2):104-8.    ^cY#a06v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#127#123#article#150# </font></p>     ^
cY#a06v26n1.htm##
00541000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029000080002001300370#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#128#124#article#150#23#<p>
<font face="Verdana" size="2">23. Suetake T, Sasai S, Zhen YX, Ohi T, Tagami    
H. Functional analyses of the stratum corneum in scars. Sequential studies after
    injury and comparison among keloids, hypertrophic scars, and atrophic scars.
    Arch Dermatol. 1996;132(12):1453-8.    ^cY#a06v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#129#125#article#150# </font></p>     ^
cY#a06v26n1.htm##
00469000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021800080002001300298#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#p#130#126#article#150#24#<p>
<font face="Verdana" size="2">24. Shih B, Garside E, McGrouther DA, Bayat A.    
Molecular dissection of abnormal wound healing processes resulting in keloid    
disease. Wound Repair Regen. 2010;18(2):139-53.    ^cY#a06v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#131#127#article#150# </font></p>      
 ^cY#a06v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#132#128#article#150#<p>&nbsp; </p>    
  ^cY#a06v26n1.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007700077002001300154#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#133#129#article#150#<p> <font face="Ve
rdana" size="3"><B>Acknowledgment</B> </font></p>      ^cY#a06v26n1.htm##
00478000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704024200077002001300319#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#134#130#article#150#<p><font face="Ver
dana" size="2"> Special thanks to the company Modella Ltda.    (Sao Paulo/SP) fo
r their generous loan of the equipment <I>Quasar Esthetique</I><SUP>&#174;</SUP>
,    which made the present study possible. </font></p>     ^cY#a06v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#135#131#article#150#<p>&nbsp; </p>    
 ^cY#a06v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#136#132#article#150#<p>&nbsp;</p>     
^cY#a06v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#137#133#article#150#<p>&nbsp; </p>    
  ^cY#a06v26n1.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704015500077002001300232#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#138#134#article#150#<p><font face="Ver
dana" size="2"><B><a name="end"></a><a href="#top"><img src="/img/revistas/acb/v
26n1/seta.gif" border="0"></a>Correspondence</B>:    ^cY#a06v26n1.htm##
00267000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003100077002001300108#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#139#135#article#150#<br>   Bernardo Ho
chman    ^cY#a06v26n1.htm##
00299000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006300077002001300140#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#140#136#article#150#<br>   Disciplina 
de Cirurgia Pl&aacute;stica - UNIFESP    ^cY#a06v26n1.htm##
00299000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006300077002001300140#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#141#137#article#150#<br>   Rua Napole&
atilde;o de Barros, 715/4&#186; andar    ^cY#a06v26n1.htm##
00282000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004600077002001300123#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#142#138#article#150#<br>   04042-002 S
ao Paulo - SP Brazil    ^cY#a06v26n1.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003800077002001300115#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#143#139#article#150#<br>   Phone: (55 
11)5576-4118    ^cY#a06v26n1.htm##
00272000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003600077002001300113#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#144#140#article#150#<br>   Fax: (55 11
)5571-6579    ^cY#a06v26n1.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010100077002001300178#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#145#141#article#150#<br>   <a href="ma
ilto:bernardohochman@uol.com.br">bernardohochman@uol.com.br</a></font></p>     ^
cY#a06v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#146#142#article#150#<p>&nbsp; </p>    
 ^cY#a06v26n1.htm##
00300000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006400077002001300141#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#147#143#article#150#<p><font face="Ver
dana" size="2">Received: July 06, 2010    ^cY#a06v26n1.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#148#144#article#150#<br>   </font><fon
t face="Verdana" size="2">Review: September 14, 2010    ^cY#a06v26n1.htm##
00327000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009100077002001300168#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#149#145#article#150#<br>   </font><fon
t face="Verdana" size="2">Accepted: October 19, 2010 </font></p>     ^cY#a06v26n
1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006700077002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#150#146#article#150#<p><font face="Ver
dana" size="2">Conflict of interest: none    ^cY#a06v26n1.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704008700077002001300164#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#151#147#article#150#<br>   </font><fon
t face="Verdana" size="2">Financial source: none </font></p>     ^cY#a06v26n1.ht
m##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#152#148#article#150#<p>&nbsp;</p>     
^cY#a06v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#153#149#article#150#<p>&nbsp;</p>     
^cY#a06v26n1.htm##
00471000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704023500077002001300312#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a06v26n1.htm#S#p#154#150#article#150#<p><font face="Ver
dana" size="2"><sup><a name="end"></a><a href="#top">1</a></sup>    Research per
formed at the Plastic Surgery Division, Department of Surgery, Federal    Univer
sity of Sao Paulo (UNIFESP), Brazil. </font></p>     ^cY#a06v26n1.htm##
00683000000000325000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100019000950100
01800114010001700132010001700149010001700166012010300183030001900286710000200305
06500090030706400050031603100040032103200020032501400080032786500090033500200130
0344#v26n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#c#155#1#article#24#1
#^rND^sCampaner^nAB#^rND^sFerreira^nLM#^rND^sGragnani^nA#^rND^sBruder^nJM#^rND^s
Cusick^nJL#^rND^sMorgan^nJR#Upregulation of TGF-beta1 expression may be necessar
y but is not sufficient for excessive scarring^len#J Invest Dermatol.#2#20060000
#2006#126#5#1168-76#20110200#a06v26n1.htm##
00551000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100018000920100
01900110012006700129030001600196710000200212065000900214064000500223031000300228
032000200231014000600233865000900239002001300248#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a06v26n1.htm#S#c#156#2#article#24#2#^rND^sRamos^nML#^rND^sGragnani^nA#^
rND^sFerreira^nLM#Is there an ideal animal model to study hypertrophic scarring?
^len#J Burn Care Res#2#20080000#2008#29#2#363-8#20110200#a06v26n1.htm##
00654000000000337000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100016000930100
01700109010001500126010001700141010001700158010001900175012005700194030001500251
71000020026606500090026806400050027703100040028203200020028601400060028886500090
0294002001300303#v26n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#c#157#3#
article#24#3#^rND^sHochman^nB#^rND^sNahas^nFX#^rND^sSobral^nCS#^rND^sArias^nV#^r
ND^sLocali^nRF#^rND^sJuliano^nY#^rND^sFerreira^nLM#Nerve fibers: a possible role
 in keloid pathogenesis^len#Br J Dermatol.#2#20080000#2008#158#3#651-2#20110200#
a06v26n1.htm##
00565000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100017000940100
02100111012007300132030002000205710000200225065000900227064000500236031000300241
032000200244014000700246865000900253002001300262#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a06v26n1.htm#S#c#158#4#article#24#4#^rND^sShaffer^nJJ#^rND^sTaylor^nSC#
^rND^sCook-Bolden^nF#Keloidal scars: a review with a critical look at therapeuti
c options^len#J Am Acad Dermatol.#2#20020000#2002#46#2#S63-97#20110200#a06v26n1.
htm##
00605000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100017000930100
01900110010001900129012008400148030002200232710000200254065000900256064000500265
031000300270032000200273014000600275865000900281002001300290#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a06v26n1.htm#S#c#159#5#article#24#5#^rND^sHochman^nB#^rND^s
Locali^nRF#^rND^sMatsuoka^nPK#^rND^sFerreira^nLM#Intralesional triamcinolone ace
tonide for keloid treatment: a systematic review^len#Aesthetic Plast Surg.#2#200
80000#2008#32#4#705-9#20110200#a06v26n1.htm##
00535000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100016000930100
01500109012005400124030001900178710000200197065000900199064000500208031000300213
032000200216014000500218865000900223002001300232#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a06v26n1.htm#S#c#160#6#article#24#6#^rND^sBouzari^nN#^rND^sDavis^nSC#^r
ND^sNouri^nK#Laser treatment of keloids and hypertrophic scars^len#Intern J Derm
atol.#2#20070000#2007#46#1#80-8#20110200#a06v26n1.htm##
00621000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100016000910100
01700107010001900124010001200143012008100155030002200236710000200258065000900260
064000500269031000300274032000200277014000600279865000900285002001300294#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#c#161#7#article#24#7#^rND^sErol^
nOO#^rND^sGurlek^nA#^rND^sAgaoglu^nG#^rND^sTopcuoglu^nE#^rND^sOz^nH#Treatment of
 hypertrophic scars and keloids using intense pulsed light (IPL)^len#Aesthetic P
last Surg.#2#20080000#2008#32#6#902-9#20110200#a06v26n1.htm##
00532000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100019000910120
07300110030002100183710000200204065000900206064000500215031000300220032000200223
014000700225865000900232002001300241#v26n1#V:\Scielo\serial\acb\v26n1\markup\a06
v26n1.htm#S#c#162#8#article#24#8#^rND^sKaru^nTI#^rND^sKolyakov^nSF#Exact action 
spectra for cellular responses relevant to phototherapy^len#Photomed Laser Surg.
#2#20050000#2005#23#4#355-61#20110200#a06v26n1.htm##
00489000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100019000920120
03700111030001300148710000200161065000900163064000500172031000400177032000200181
014000600183865000900189002001300198#v26n1#V:\Scielo\serial\acb\v26n1\markup\a06
v26n1.htm#S#c#163#9#article#24#9#^rND^sToyoda^nM#^rND^sMorohashi^nM#New aspects 
in acne inflammation^len#Dermatology.#2#20030000#2003#206#1#17-23#20110200#a06v2
6n1.htm##
00556000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100019000960120
08600115030002500201710000200226065000900228064000500237031000300242032000400245
014000700249865000900256002001300265#v26n1#V:\Scielo\serial\acb\v26n1\markup\a06
v26n1.htm#S#c#164#10#article#24#10#^rND^sHawkins^nDH#^rND^sAbrahamse^nH#Time-dep
endent responses of wounded human skin fibroblasts following phototherapy^len#J 
Photochem Photobiol B.#2#20070000#2007#88#2-3#147-55#20110200#a06v26n1.htm##
00627000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100019000970100
01800116010002500134010001600159012006800175030002100243710000200264065000900266
064000500275031000300280032000200283014000600285865000900291002001300300#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#c#165#11#article#24#11#^rND^sda 
Silva^nJP#^rND^sda Silva^nMA#^rND^sAlmeida^nAP#^rND^sLombardi Junior^nI#^rND^sMa
tos^nAP#Laser therapy in the tissue repair process: a literature review^len#Phot
omed Laser Surg.#2#20100000#2010#28#1#17-21#20110200#a06v26n1.htm##
00614000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100015000960100
01700111010001800128012009600146030002100242710000200263065000900265064000500274
031000300279032000200282014000600284865000900290002001300299#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a06v26n1.htm#S#c#166#12#article#24#12#^rND^sCorazza^nAV#^rN
D^sJorge^nJ#^rND^sKurachi^nC#^rND^sBagnato^nVS#Photobiomodulation on the angioge
nesis of skin wounds in rats using different light sources^len#Photomed Laser Su
rg.#2#20070000#2007#25#2#102-6#20110200#a06v26n1.htm##
00627000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100015000920100
01700107012014600124030001600270710000200286065000900288064000500297031000300302
032000200305014000800307865000900315002001300324#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a06v26n1.htm#S#c#167#13#article#24#13#^rND^sWebb^nC#^rND^sDyson^nM#^rND
^sLewis^nWHP#Stimulatory effect of 660 nm low level laser energy on hypertrophic
 scar-derived fibroblasts: possible mechanisms for increase in cell counts^len#L
aser Surg Med.#2#19980000#1998#22#5#294-301#20110200#a06v26n1.htm##
00592000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100015000920120
12800107030003000235710000200265065000900267064000500276031000300281032000200284
014000600286865000900292002001300301#v26n1#V:\Scielo\serial\acb\v26n1\markup\a06
v26n1.htm#S#c#168#14#article#24#14#^rND^sWebb^nC#^rND^sDyson^nM#The effect of 88
0 nm low level laser energy on human fibroblast cell numbers: a possible role in
 hypertrophic wound healing^len#J Photochem Photobiol Biol B.#2#20030000#2003#70
#1#39-44#20110200#a06v26n1.htm##
00600000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100019000960120
14300115030001600258710000200274065000900276064000500285031000300290032000200293
014000500295865000900300002001300309#v26n1#V:\Scielo\serial\acb\v26n1\markup\a06
v26n1.htm#S#c#169#15#article#24#15#^rND^sHoureld^nNN#^rND^sAbrahamse^nH#Laser li
ght influences cellular viability and proliferation in diabetic-wounded fibrobla
st cells in a dose and wavelength dependent manner^len#Lasers Med Sci.#2#2008000
0#2008#23#1#11-8#20110200#a06v26n1.htm##
00641000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100017000940100
02200111010001900133010001800152012009400170030001500264710000200279065000900281
064000500290031000300295032000200298014000500300865000900305002001300314#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#c#170#16#article#24#16#^rND^sVin
ck^nEM#^rND^sCagnie^nBJ#^rND^sCornelissen^nMJ#^rND^sDeclercq^nHA#^rND^sCambier^n
DC#Increased fibroblast proliferation induced emitting diode and low power laser
 irradiation^len#Laser Med Sci.#2#20030000#2003#18#2#95-9#20110200#a06v26n1.htm#
#
00685000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100022000950100
01700117010002400134010001700158010001700175012007400192030001100266065000900277
06400050028603100030029103200020029401400080029686500090030400200130031303500100
0326801001100336#v26n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#c#171#17
#article#24#17#^rND^sTaoufik^nK#^rND^sMavrogonatou^nE#^rND^nT^sEliades#^rND^nL^s
Papagiannoulis#^rND^sEliades^nG#^rND^sKletsas^nD#Effect of blue light on the pro
feration of human gingival fibroblasts^len#Dent Mater#20080000#2008#24#7#895-900
#20110200#a06v26n1.htm#0109-5641#Dent Mater##
00663000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100023000780100017001010100
01700118010001900135012014500154030001300299710000200312065000900314064000500323
031000200328032000200330014000700332865000900339002001300348#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a06v26n1.htm#S#c#172#18#article#24#18#^rND^sTucci-Viegas^nV
M#^rND^sHochman^nB#^rND^sFrança^nJP#^rND^sFerreira^nLM#Keloid explant culture: a
 model for keloid fibroblasts isolation and cultivation based on the biological 
differences of its specific regions^len#Int Wound J.#2#20100000#2010#7#5#339-48#
20110200#a06v26n1.htm##
00598000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100019000940100
01800113010001700131010001900148012004600167030001500213710000200228065000900230
064000500239031000300244032001000247014000500257865000900262002001300271#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#c#173#19#article#24#19#^rND^sKei
ra^nSM#^rND^sFerreira^nLM#^rND^sGragnani^nA#^rND^sDuarte^nIS#^rND^sSantos,^nIAN#
Experimental model for fibroblast culture^len#Acta Cir Bras.#2#20040000#2004#19#
^sSuppl 1#11-6#20110200#a06v26n1.htm##
00693000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100022000960100
01700118010001700135010001700152010001900169010001900188012007700207030002200284
71000020030606500090030806400050031703100030032203200020032501400060032786500090
0333002001300342#v26n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#c#174#20
#article#24#20#^rND^sGragnani^nA#^rND^sGiannoccaro^nFB#^rND^sSobral^nCS#^rND^sMo
raes^nAA#^rND^sFrança^nJP#^rND^sFerreira^nAT#^rND^sFerreira^nLM#Dimethylaminoeth
anol affects the viability of human cultured fibroblasts^len#Aesthetic Plast Sur
g.#2#20070000#2007#31#6#711-8#20110200#a06v26n1.htm##
00544000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100020000970100
01900117012005600136030001200192710000200204065000900206064000500215031000300220
032000200223014000700225865000900232002001300241#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a06v26n1.htm#S#c#175#21#article#24#21#^rND^sGorgidze^nLA#^rND^sOshemkov
a^nSA#^rND^sVorobjev^nIA#Blue light inhibits mitosis in tissue culture cells^len
#Biosci Rep.#2#19980000#1998#18#4#215-24#20110200#a06v26n1.htm##
00666000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
01900111010001300130010001700143010002100160010002100181012006500202030001200267
71000020027906500090028106400050029003100030029503200020029801400060030086500090
0306002001300315#v26n1#V:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#c#176#22
#article#24#22#^rND^sWataha^nJC#^rND^sLewis^nJB#^rND^sLockwood^nPE#^rND^sHsu^nS#
^rND^sMesser^nRL#^rND^sRueggeberg^nFA#^rND^sBouillaguet^nS#Blue light differenti
ally modulates cell survival and growth^len#J Dent Res.#2#20040000#2004#83#2#104
-8#20110200#a06v26n1.htm##
00693000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100015000950100
01500110010001300125010001600138012005600154030011700210710000200327065000900329
064000500338031000400343032000300347014000700350865000900357002001300366#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a06v26n1.htm#S#c#177#23#article#24#23#^rND^sSue
take^nT#^rND^sSasai^nS#^rND^sZhen^nYX#^rND^sOhi^nT#^rND^sTagami^nH#Functional an
alyses of the stratum corneum in scars^len#Sequential studies after injury and c
omparison among keloids, hypertrophic scars, and atrophic scars. Arch Dermatol.#
2#19960000#1996#132#12#1453-8#20110200#a06v26n1.htm##
00606000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100017000920100
02100109010001500130012008900145030002000234710000200254065000900256064000500265
031000300270032000200273014000700275865000900282002001300291#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a06v26n1.htm#S#c#178#24#article#24#24#^rND^sShih^nB#^rND^sG
arside^nE#^rND^sMcGrouther^nDA#^rND^sBayat^nA#Molecular dissection of abnormal w
ound healing processes resulting in keloid disease^len#Wound Repair Regen.#2#201
00000#2010#18#2#139-53#20110200#a06v26n1.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v26n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#o#1#1#article#1#
20110120#130140#a07v26n1.htm#172##
04892000000000721000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400090014103500100015001200760
01600120076002360100035003120100036003470100040003830100041004230100043004640700
09000507070009100597070009000688070009000778070009100868083135400959085000802313
08500260232108500400234708500210238708500170240808315240242508500080394908500270
39570850040039840850022040240850018040461170006040640720003040700580007040731120
00904080111001404089116000904103115001904112114000904131113001704140002001304157
#v26n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#h#2#1#article#1#oa#en#br
1.1#1#4.0#ILUS#TAB#07#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f31^l37#0102-8650
#Miniplate 1.5 fixation for the repair of mandibular osteotomies in cats^len#Fix
ação interna de osteotomias mandibulares com miniplacas 1.5 em gatos^lpt#^rND^1A
01^nAdelina Maria da^sSilva#^rND^1A02^nWilson Machado de^sSouza#^rND^1A03^nPatrí
cia de Athayde^sBarnabé#^rND^1A04^nMarion Burkhardt de^sKoivisto#^rND^1A05^nNair
 Trevizan Machado de^sSouza#UNESP^iA01^1Department of Clinics, Surgery and Anima
l Reproduction^cAraçatuba^sSP^pBrazil#UNESP^iA02^1Department of Biosciences, Pro
duction and Animal Health^cAraçatuba^sSP^pBrazil#UNESP^iA03^1Department of Clini
cs, Surgery and Animal Reproduction^cAraçatuba^sSP^pBrazil#UNESP^iA04^1Departmen
t of Clinics, Surgery and Animal Reproduction^cAraçatuba^sSP^pBrazil#UNESP^iA05^
1Department of Biosciences, Production and Animal Health^cAraçatuba^sSP^pBrazil#
^len^aPurpose: To evaluate the application of the maxillofacial miniplate 1.5 in
 the repair of unilateral mandibular osteotomies in cats. Methods: Twelve adult 
cats were divided into two groups. In group 1 (n=6), the osteotomy was performed
 in the body of the mandible, behind the 1st molar. In group 2 (n=6), the osteot
omy was performed between the 4th premolar and 1st molar. The osteotomy was fixe
d with a titanium miniplate 1.5. Oral alimentation was reinitiated 24 hours afte
r surgery. Cats were euthanized at 12 weeks postoperative. Results: Radiographs 
taken 1 week after surgery showed a radiolucent line. The osteotomy line was not
 more visible on the radiographs taken at 12 weeks postoperative. Macroscopic ex
amination confirmed alignment and bone union of operated hemimandibles. Histolog
ical examination showed formation of woven bone within the osteotomy line. The p
ercentage of bone tissue at these areas was measured by the histometry. There wa
s no statistically significant difference between the values of group 1(75.07 ± 
5.99) and group 2 (74.76 ± 8.54) (Mann-Whitney's test p= 0.469). Conclusion: We 
concluded that the use of miniplate 1.5 for the fixation of mandibular osteotomy
 in cats provided the main goals in the treatment of mandibular fractures: bone 
union, normal dental occlusion and immediate return to oral alimentation.#^dnd^i
1#^tm^len^kSurgery, Oral^i1#^tm^len^kFracture Fixation, Internal^i1#^tm^len^kMan
dible^i1#^tm^len^kCats^i1#^lpt^aObjetivo: Avaliar a fixação de osteotomias mandi
bulares unilaterais com miniplacas 1.5 em gatos. Métodos: Foram utilizados 12 ga
tos adultos divididos em dois grupos de seis animais cada. No grupo 1, a osteoto
mia foi realizada caudalmente ao 1º molar e no grupo 2, entre o 4º pré-molar e 1
º molar. A osteotomia foi fixada com uma miniplaca 1.5 de titânio. A alimentação
 oral foi reiniciada 24 horas após a cirurgia. Os animais foram submetidos a eut
anásia 12 semanas após a cirurgia. Resultados: A osteotomia pode ser notada como
 uma linha de radiolucência nas radiografias realizadas uma semana após a cirurg
ia. Essa linha de radiolucência não foi mais vista nas radiografias realizadas 1
2 semanas após a cirurgia. No exame macroscópico a hemimandíbula operada apresen
tava conformação semelhante à hemimandíbula contralateral. A união óssea pode se
r confirmada por meio dos exames histológicos que demonstraram a presença de tec
ido ósseo esponjoso no local da osteotomia. Os exames histométricos demonstraram
 que não houve diferença estatisticamente significante nos valores observados de
 porcentagem de tecido ósseo na área de osteotomia das hemimandíbulas operadas d
os gatos do grupo 1 (75,07 ± 5.99) e grupo 2 (74,76 ±8,56) (Teste de Mann-Whitne
y p=0,469). Conclusão: Os resultados deste experimento permitiram concluir que a
 fixação de osteotomias com miniplacas 1.5 em gatos garante os principais objeti
vos no tratamento de fraturas da mandíbula: união óssea, oclusão dentária normal
 e alimentação oral imediata.#^dnd^i2#^tm^lpt^kCirurgia Bucal^i2#^tm^lpt^kFixaçã
o Interna de Fraturas^i2#^tm^lpt^kMandíbula^i2#^tm^lpt^kGatos^i2#other#13#FAPESP
#20100721#July 21, 2010#20100915#September 15, 2010#20101019#October 19, 2010#a0
7v26n1.htm##
04995000000000721000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400090014103500100015001200830
01600120083002430100035003260100036003610100040003970100041004370100043004780700
09000521070009100611070009000702070009000792070009100882083141500973085000802388
08500260239608500400242208500210246208500170248308315520250008500080405208500270
40600850040040870850022041270850018041491170006041670720003041730580007041761120
00904183111001404192116000904206115001904215114000904234113001704243002001304260
#v26n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#f#3#1#article#1#oa#en#br
1.1#1#4.0#ILUS#TAB#07#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f31^l37#0102-8650
#<b>Miniplate 1.5 fixation for the repair of mandibular osteotomies in cats</b>^
len#<b>Fixação interna de osteotomias mandibulares com miniplacas 1.5 em gatos</
b>^lpt#^rND^1A01^nAdelina Maria da^sSilva#^rND^1A02^nWilson Machado de^sSouza#^r
ND^1A03^nPatrícia de Athayde^sBarnabé#^rND^1A04^nMarion Burkhardt de^sKoivisto#^
rND^1A05^nNair Trevizan Machado de^sSouza#UNESP^iA01^1Department of Clinics, Sur
gery and Animal Reproduction^cAraçatuba^sSP^pBrazil#UNESP^iA02^1Department of Bi
osciences, Production and Animal Health^cAraçatuba^sSP^pBrazil#UNESP^iA03^1Depar
tment of Clinics, Surgery and Animal Reproduction^cAraçatuba^sSP^pBrazil#UNESP^i
A04^1Department of Clinics, Surgery and Animal Reproduction^cAraçatuba^sSP^pBraz
il#UNESP^iA05^1Department of Biosciences, Production and Animal Health^cAraçatub
a^sSP^pBrazil#^len^a<b>Purpose</b>: To evaluate the application of the maxillofa
cial miniplate 1.5 in the repair of unilateral mandibular osteotomies in cats. <
b>Methods</b>: Twelve adult cats were divided into two groups. In group 1 (n=6),
 the osteotomy was performed in the body of the mandible, behind the 1<sup>st</s
up> molar. In group 2 (n=6), the osteotomy was performed between the 4<sup>th</s
up> premolar and 1<sup>st </sup>molar. The osteotomy was fixed with a titanium m
iniplate 1.5. Oral alimentation was reinitiated 24 hours after surgery. Cats wer
e euthanized at 12 weeks postoperative. <b>Results</b>: Radiographs taken 1 week
 after surgery showed a radiolucent line. The osteotomy line was not more visibl
e on the radiographs taken at 12 weeks postoperative. Macroscopic examination co
nfirmed alignment and bone union of operated hemimandibles. Histological examina
tion showed formation of woven bone within the osteotomy line. The percentage of
 bone tissue at these areas was measured by the histometry. There was no statist
ically significant difference between the values of group 1(75.07 ± 5.99) and gr
oup 2 (74.76 ± 8.54) (Mann-Whitney's test p= 0.469). <b>Conclusion</b>: We concl
uded that the use of miniplate 1.5 for the fixation of mandibular osteotomy in c
ats provided the main goals in the treatment of mandibular fractures: bone union
, normal dental occlusion and immediate return to oral alimentation.#^dnd^i1#^tm
^len^kSurgery, Oral^i1#^tm^len^kFracture Fixation, Internal^i1#^tm^len^kMandible
^i1#^tm^len^kCats^i1#^lpt^a<b>Objetivo</b>: Avaliar a fixação de osteotomias man
dibulares unilaterais com miniplacas 1.5 em gatos. <b>Métodos</b>: Foram utiliza
dos 12 gatos adultos divididos em dois grupos de seis animais cada. No grupo 1, 
a osteotomia foi realizada caudalmente ao 1º molar e no grupo 2, entre o 4º pré-
molar e 1º molar. A osteotomia foi fixada com uma miniplaca 1.5 de titânio. A al
imentação oral foi reiniciada 24 horas após a cirurgia. Os animais foram submeti
dos a eutanásia 12 semanas após a cirurgia. <b>Resultados</b>: A osteotomia pode
 ser notada como uma linha de radiolucência nas radiografias realizadas uma sema
na após a cirurgia. Essa linha de radiolucência não foi mais vista nas radiograf
ias realizadas 12 semanas após a cirurgia. No exame macroscópico a hemimandíbula
 operada apresentava conformação semelhante à hemimandíbula contralateral. A uni
ão óssea pode ser confirmada por meio dos exames histológicos que demonstraram a
 presença de tecido ósseo esponjoso no local da osteotomia. Os exames histométri
cos demonstraram que não houve diferença estatisticamente significante nos valor
es observados de porcentagem de tecido ósseo na área de osteotomia das hemimandí
bulas operadas dos gatos do grupo 1 (75,07 ± 5.99) e grupo 2 (74,76 ±8,56) (Test
e de Mann-Whitney p=0,469). <b>Conclusão</b>: Os resultados deste experimento pe
rmitiram concluir que a fixação de osteotomias com miniplacas 1.5 em gatos garan
te os principais objetivos no tratamento de fraturas da mandíbula: união óssea, 
oclusão dentária normal e alimentação oral imediata.#^dnd^i2#^tm^lpt^kCirurgia B
ucal^i2#^tm^lpt^kFixação Interna de Fraturas^i2#^tm^lpt^kMandíbula^i2#^tm^lpt^kG
atos^i2#other#13#FAPESP#20100721#July 21, 2010#20100915#September 15, 2010#20101
019#October 19, 2010#a07v26n1.htm##
05032000000000745000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000150012903100030014403200020014706500090014901400090015803500100
01670120076001770120076002530100035003290100036003640100040004000100041004400100
04300481070009200524070009300616070009200709070009200801070009300893083135400986
08500080234008500260234808500400237408500210241408500170243508315240245208500080
39760850027039840850040040110850022040510850018040731170006040910720003040970580
00704100112000904107111001404116116000904130115001904139114000904158113001704167
002001304184008008904197#v26n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#
l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#07#ACB720#nd#Acta c
ir. bras#26#1#20110200#^f31^l37#0102-8650#Miniplate 1.5 fixation for the repair 
of mandibular osteotomies in cats^len#Fixação interna de osteotomias mandibulare
s com miniplacas 1.5 em gatos^lpt#^rND^1A01^nAdelina Maria da^sSilva#^rND^1A02^n
Wilson Machado de^sSouza#^rND^1A03^nPatrícia de Athayde^sBarnabé#^rND^1A04^nMari
on Burkhardt de^sKoivisto#^rND^1A05^nNair Trevizan Machado de^sSouza#^iA01^1UNES
P^2Department of Clinics, Surgery and Animal Reproduction^cAraçatuba^sSP^pBrazil
#^iA02^1UNESP^2Department of Biosciences, Production and Animal Health^cAraçatub
a^sSP^pBrazil#^iA03^1UNESP^2Department of Clinics, Surgery and Animal Reproducti
on^cAraçatuba^sSP^pBrazil#^iA04^1UNESP^2Department of Clinics, Surgery and Anima
l Reproduction^cAraçatuba^sSP^pBrazil#^iA05^1UNESP^2Department of Biosciences, P
roduction and Animal Health^cAraçatuba^sSP^pBrazil#^len^aPurpose: To evaluate th
e application of the maxillofacial miniplate 1.5 in the repair of unilateral man
dibular osteotomies in cats. Methods: Twelve adult cats were divided into two gr
oups. In group 1 (n=6), the osteotomy was performed in the body of the mandible,
 behind the 1st molar. In group 2 (n=6), the osteotomy was performed between the
 4th premolar and 1st molar. The osteotomy was fixed with a titanium miniplate 1
.5. Oral alimentation was reinitiated 24 hours after surgery. Cats were euthaniz
ed at 12 weeks postoperative. Results: Radiographs taken 1 week after surgery sh
owed a radiolucent line. The osteotomy line was not more visible on the radiogra
phs taken at 12 weeks postoperative. Macroscopic examination confirmed alignment
 and bone union of operated hemimandibles. Histological examination showed forma
tion of woven bone within the osteotomy line. The percentage of bone tissue at t
hese areas was measured by the histometry. There was no statistically significan
t difference between the values of group 1(75.07 ± 5.99) and group 2 (74.76 ± 8.
54) (Mann-Whitney's test p= 0.469). Conclusion: We concluded that the use of min
iplate 1.5 for the fixation of mandibular osteotomy in cats provided the main go
als in the treatment of mandibular fractures: bone union, normal dental occlusio
n and immediate return to oral alimentation.#^dnd^i1#^tm^len^kSurgery, Oral^i1#^
tm^len^kFracture Fixation, Internal^i1#^tm^len^kMandible^i1#^tm^len^kCats^i1#^lp
t^aObjetivo: Avaliar a fixação de osteotomias mandibulares unilaterais com minip
lacas 1.5 em gatos. Métodos: Foram utilizados 12 gatos adultos divididos em dois
 grupos de seis animais cada. No grupo 1, a osteotomia foi realizada caudalmente
 ao 1º molar e no grupo 2, entre o 4º pré-molar e 1º molar. A osteotomia foi fix
ada com uma miniplaca 1.5 de titânio. A alimentação oral foi reiniciada 24 horas
 após a cirurgia. Os animais foram submetidos a eutanásia 12 semanas após a ciru
rgia. Resultados: A osteotomia pode ser notada como uma linha de radiolucência n
as radiografias realizadas uma semana após a cirurgia. Essa linha de radiolucênc
ia não foi mais vista nas radiografias realizadas 12 semanas após a cirurgia. No
 exame macroscópico a hemimandíbula operada apresentava conformação semelhante à
 hemimandíbula contralateral. A união óssea pode ser confirmada por meio dos exa
mes histológicos que demonstraram a presença de tecido ósseo esponjoso no local 
da osteotomia. Os exames histométricos demonstraram que não houve diferença esta
tisticamente significante nos valores observados de porcentagem de tecido ósseo 
na área de osteotomia das hemimandíbulas operadas dos gatos do grupo 1 (75,07 ± 
5.99) e grupo 2 (74,76 ±8,56) (Teste de Mann-Whitney p=0,469). Conclusão: Os res
ultados deste experimento permitiram concluir que a fixação de osteotomias com m
iniplacas 1.5 em gatos garante os principais objetivos no tratamento de fraturas
 da mandíbula: união óssea, oclusão dentária normal e alimentação oral imediata.
#^dnd^i2#^tm^lpt^kCirurgia Bucal^i2#^tm^lpt^kFixação Interna de Fraturas^i2#^tm^
lpt^kMandíbula^i2#^tm^lpt^kGatos^i2#other#13#FAPESP#20100721#July 21, 2010#20100
915#September 15, 2010#20101019#October 19, 2010#a07v26n1.htm#Internet^ihttp://w
ww.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502011000100007##
00310000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704007800073002001300151#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#5#1#article#155#<p align="right"><font
 face="Verdana" size="2"><b>7 - ORIGINAL ARTICLE    ^cY#a07v26n1.htm##
00345000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704011300073002001300186#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#6#2#article#155#<br>   </b></font><b><
font face="Verdana" size="2">EXPERIMENTAL ORTHOPAEDIC SURGERY</font></b></p>  <B
>      ^cY#a07v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002800073002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#7#3#article#155#<p>&nbsp;</p> </B>    
  ^cY#a07v26n1.htm##
00452000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704022000073002001300293#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#8#4#article#155#<p><b><font face="Verd
ana" size="2"><a name="top"></a></font><font face="Verdana" size="4">Miniplate  
  1.5 fixation for the repair of mandibular osteotomies in cats<SUP><a href="#en
d">1</a></SUP></font></b></p>     ^cY#a07v26n1.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#9#5#article#155#<p>&nbsp;</p>     ^cY#
a07v26n1.htm##
00421000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704018800074002001300262#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#10#6#article#155#<p><b><font face="Ver
dana" size="3">Fixa&ccedil;&atilde;o interna de osteotomias    mandibulares com 
miniplacas 1.5 em gatos </font></b><font face="Verdana" size="2"></font></p>    
   ^cY#a07v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#11#7#article#155#<p>&nbsp;</p>     ^cY
#a07v26n1.htm##
00520000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704028700074002001300361#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#12#8#article#155#<p><font face="Verdan
a" size="2"><B>Adelina Maria da Silva<SUP>I</SUP>, Wilson    Machado de Souza<SU
P>II</SUP>, Patr&iacute;cia de Athayde Barnab&eacute;<SUP>III</SUP>,    Marion B
urkhardt de Koivisto<SUP>IV</SUP>, Nair Trevizan Machado de Souza<SUP>V</SUP></B
>    </font></p>      ^cY#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002300074002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#13#9#article#155#<p>&nbsp;</p>      ^c
Y#a07v26n1.htm##
00638000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040400075002001300479#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#14#10#article#155#<p><font face="Verda
na" size="2"><SUP>I</SUP>PhD, Assistant Professor, Department    of Clinics, Sur
gery and Animal Reproduction, UNESP, Ara&ccedil;atuba-SP, Brazil.    <I>Responsi
ble for conception, design, intellectual and scientific content of    the study.
 Acquisition and interpretation of data: surgical procedures and radiographic   
 examinations. Manuscript writing. Statistical analysis.    ^cY#a07v26n1.htm##
00530000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029600075002001300371#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#15#11#article#155#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>II</SUP>Full Professor, Department    of Biosci
ences, Production and Animal Health, UNESP, Ara&ccedil;atuba-SP, Brazil.    <I>A
cquisition and interpretation of data: macroscopic and histopathological    exam
inations. Critical revision.    ^cY#a07v26n1.htm##
00480000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024600075002001300321#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#16#12#article#155#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>III</SUP>PhD, DVM, Department    of Clinics, Su
rgery and Animal Reproduction, UNESP, Ara&ccedil;atuba-SP, Brazil.    <I>Acquisi
tion and interpretation of data. Histometric examinations.    ^cY#a07v26n1.htm##
00490000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025600075002001300331#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#17#13#article#155#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>IV</SUP>Associate Professor, Department    of C
linics, Surgery and Animal Reproduction, UNESP, Ara&ccedil;atuba-SP, Brazil.    
<I>Acquisition and interpretation of data. Histometric examinations.    ^cY#a07v
26n1.htm##
00528000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029400075002001300369#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#18#14#article#155#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>V</SUP>PhD, Zootechnist, Department    of Biosc
iences, Production and Animal Health, UNESP, Ara&ccedil;atuba-SP, Brazil.    <I>
Acquisition and interpretation of data. Macroscopic and histopathological    exa
minations.</I></font></p>     ^cY#a07v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#19#15#article#155#<p><font face="Verda
na" size="2"><a href="#end">Correspondence</a></font></p>     ^cY#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#20#16#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#21#17#article#155#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a07v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#22#18#article#155#<p><font face="Verda
na" size="2"><B>ABSTRACT </B></font></p>     ^cY#a07v26n1.htm##
01757000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704152300075002001301598#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#23#19#article#155#<p><font face="Verda
na" size="2"><B>Purpose</b>: To evaluate the application of    the maxillofacial
 miniplate 1.5 in the repair of unilateral mandibular osteotomies    in cats. <B
>Methods</B>: Twelve adult cats were divided into two groups. In    group 1 (n=6
), the osteotomy was performed in the body of the mandible, behind    the 1<SUP>
st</SUP> molar. In group 2 (n=6), the osteotomy was performed between    the 4<S
UP>th</SUP> premolar and 1<SUP>st </SUP>molar. The osteotomy was fixed    with a
 titanium miniplate 1.5. Oral alimentation was reinitiated 24 hours after    sur
gery. Cats were euthanized at 12 weeks postoperative. <B>Results</B>: Radiograph
s    taken 1 week after surgery showed a radiolucent line. The osteotomy line wa
s    not more visible on the radiographs taken at 12 weeks postoperative. Macros
copic    examination confirmed alignment and bone union of operated hemimandible
s. Histological    examination showed formation of woven bone within the osteoto
my line. The percentage    of bone tissue at these areas was measured by the his
tometry. There was no statistically    significant difference between the values
 of group 1(75.07 &#177; 5.99) and    group 2 (74.76 &#177; 8.54) (Mann-Whitney'
s test p= 0.469). <B>Conclusion</B>:    We concluded that the use of miniplate 1
.5 for the fixation of mandibular osteotomy    in cats provided the main goals i
n the treatment of mandibular fractures: bone    union, normal dental occlusion 
and immediate return to oral alimentation. </font></p>     ^cY#a07v26n1.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015700075002001300232#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#24#20#article#155#<p><font face="Verda
na" size="2"><B>Key words</B>: Surgery, Oral. Fracture Fixation,    Internal. Ma
ndible. Cats. </font></p> <hr size="1" noshade>      ^cY#a07v26n1.htm##
00301000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006700075002001300142#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#25#21#article#155#<p><font face="Verda
na" size="2"><B>RESUMO </B></font></p>     ^cY#a07v26n1.htm##
02218000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704198400075002001302059#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#26#22#article#155#<p><font face="Verda
na" size="2"><B>Objetivo</b>: Avaliar a fixa&ccedil;&atilde;o    de osteotomias 
mandibulares unilaterais com miniplacas 1.5 em gatos. <B>M&eacute;todos</B>:    
Foram utilizados 12 gatos adultos divididos em dois grupos de seis animais cada.
    No grupo 1, a osteotomia foi realizada caudalmente ao 1&#186; molar e no gru
po    2, entre o 4&#186; pr&eacute;-molar e 1&#186; molar. A osteotomia foi fixa
da    com uma miniplaca 1.5 de tit&acirc;nio. A alimenta&ccedil;&atilde;o oral f
oi    reiniciada 24 horas ap&oacute;s a cirurgia. Os animais foram submetidos a 
eutan&aacute;sia    12 semanas ap&oacute;s a cirurgia. <B>Resultados</B>: A oste
otomia pode ser    notada como uma linha de radioluc&ecirc;ncia nas radiografias
 realizadas uma    semana ap&oacute;s a cirurgia. Essa linha de radioluc&ecirc;n
cia n&atilde;o    foi mais vista nas radiografias realizadas 12 semanas ap&oacut
e;s a cirurgia.    No exame macrosc&oacute;pico a hemimand&iacute;bula operada a
presentava conforma&ccedil;&atilde;o    semelhante &agrave; hemimand&iacute;bula
 contralateral. A uni&atilde;o &oacute;ssea    pode ser confirmada por meio dos 
exames histol&oacute;gicos que demonstraram    a presen&ccedil;a de tecido &oacu
te;sseo esponjoso no local da osteotomia. Os    exames histom&eacute;tricos demo
nstraram que n&atilde;o houve diferen&ccedil;a    estatisticamente significante 
nos valores observados de porcentagem de tecido    &oacute;sseo na &aacute;rea d
e osteotomia das hemimand&iacute;bulas operadas    dos gatos do grupo 1 (75,07 &
#177; 5.99) e grupo 2 (74,76 &#177;8,56) (Teste    de Mann-Whitney p=0,469). <B>
Conclus&atilde;o</B>: Os resultados deste experimento    permitiram concluir que
 a fixa&ccedil;&atilde;o de osteotomias com miniplacas    1.5 em gatos garante o
s principais objetivos no tratamento de fraturas da mand&iacute;bula:    uni&ati
lde;o &oacute;ssea, oclus&atilde;o dent&aacute;ria normal e alimenta&ccedil;&ati
lde;o    oral imediata. </font></p>     ^cY#a07v26n1.htm##
00416000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704018200075002001300257#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#27#23#article#155#<p><font face="Verda
na" size="2"><B>Descritores</B>: Cirurgia Bucal. Fixa&ccedil;&atilde;o    Intern
a de Fraturas. Mand&iacute;bula. Gatos. </font></p> <hr size="1" noshade>     ^c
Y#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#28#24#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#29#25#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007400075002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#30#26#article#155#<p><font face="Verda
na" size="3"><B>Introduction</B> </font></p>      ^cY#a07v26n1.htm##
00750000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704051600075002001300591#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#31#27#article#155#<p><font face="Verda
na" size="2"> The use of miniplates has revolutionized the    treatment of mandi
bular and maxillofacial fractures in humans. Miniaturized    implants are desira
ble because of the limited surgical field observed in these    cases. Besides th
at, smaller plate systems minimize tissue trauma and facilitates    preservation
 of the periosteal blood supply<SUP>1-5</SUP>. The crescent clinical    applicat
ion of this method is also observed in small animal surgery<SUP>6</SUP>.    </fo
nt></p>     ^cY#a07v26n1.htm##
00578000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034400075002001300419#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#32#28#article#155#<p><font face="Verda
na" size="2"> The objective of this study was to evaluate    the use of maxillof
acial miniplate 1.5 in the repair of unilateral mandibular    osteotomies in cat
s. We hypothesized that these miniaturized implants could    represent a good al
ternative in the treatment of mandibular fractures in cats.    </font></p>      
^cY#a07v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#33#29#article#155#<p>&nbsp; </p>     ^
cY#a07v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#34#30#article#155#<p><font face="Verda
na" size="3"><B>Methods</B> </font></p>      ^cY#a07v26n1.htm##
00399000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704016500075002001300240#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#35#31#article#155#<p><font face="Verda
na" size="2"> This study was approved by the Ethics Committee    for Animal Rese
arch of UNESP, Ara&ccedil;atuba-SP, Brazil. </font></p>      ^cY#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#36#32#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00327000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009300075002001300168#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#37#33#article#155#<p><font face="Verda
na" size="2"><I>Animals and experimental design</I> </font></p>      ^cY#a07v26n
1.htm##
00921000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704068700075002001300762#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#38#34#article#155#<p><font face="Verda
na" size="2"> Twelve healthy young adult (aging between 12    and 36 months) mix
ed breed cats (weighing 3.1 &#177; 0.3kg) were utilized. Six    spayed females a
nd 6 neutered males were used and evenly distributed between    2 groups. In gro
up 1 (n=6, 3.2&#177;0.2 kg), the osteotomy was performed in    the body of the m
andible, behind the 1<SUP>st</SUP> molar. In group 2 (n=6,    3.0&#177;0.3 kg), 
the osteotomy was performed between the 4<SUP>th</SUP> premolar    and 1<SUP>st<
/SUP> molar. The unilateral osteotomy was performed at random in    either the r
ight or the left hemimandible. The cats were euthanized at 12 weeks    postopera
tive. </font></p>      ^cY#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#39#35#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008000075002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#40#36#article#155#<p><font face="Verda
na" size="2"><I>Surgical procedure</I> </font></p>      ^cY#a07v26n1.htm##
01039000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704080500075002001300880#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#41#37#article#155#<p><font face="Verda
na" size="2"> Food was withheld for 12 hours prior to anesthesia.    The cats we
re premedicated with atropine (0.05mg/kg SC), xylazine (2mg/kg SC)    and ketami
ne (15mg/kg, SC). Thiopental (5mg/kg IV) was administered to allow    endotrache
al intubation. Inhalation anesthesia was maintained with halothane    and oxygen
. Fentanyl (0.0125mg/kg IM) was administered after anesthesia induction.    Lact
ated Ringer's solution (10ml/kg IV) was administered throughout anesthesia.    L
ocal anesthesia of the inferior alveolar nerve was done with mepivacain (7mg/kg)
    and epinephrine. Ketoprofen (2mg/kg, SC) was administered preoperatively and
    for 3 days postoperatively. Enrofloxacin (5mg/kg, SC) was administered preop
eratively    and for 5 days postoperatively. </font></p>     ^cY#a07v26n1.htm##
01101000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704086700075002001300942#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#42#38#article#155#<p><font face="Verda
na" size="2"> The cats were positioned in dorsal recumbency.    The ventral cran
ial and cervical regions were clipped, prepared, and draped    under sterile tec
hnique. A ventral surgical approach to the mandible was performed.    The hemima
ndible was transected transversely. Initially a gap was performed    in the cort
ical bone of the lingual and buccal surfaces and the ventral border    with a bu
rr on a low-speed hand-piece under watering. Next, the osteotomy was    complete
d with an osteotome and mallet. The osteotomy was fixed with a 5-hole    titaniu
m miniplate 1.5. The miniplate was applied with 4 bicortical screw placement    
on the ventrobuccal aspect of the hemimandible. Subcutaneous layer was closed   
    with 4-0 polyglactin 910. Skin closure was with 4-0 nylon. Skin sutures were
    removed after 7 days. </font></p>      ^cY#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#43#39#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00341000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010700075002001300182#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#44#40#article#155#<p><font face="Verda
na" size="2"><I>Postoperative observations and radiographs</I>    </font></p>   
   ^cY#a07v26n1.htm##
00555000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704032100075002001300396#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#45#41#article#155#<p><font face="Verda
na" size="2"> Oral alimentation was reinitiated 24 hours after    surgery with c
anned food. This soft food was offered during 3 weeks. After this    period, the
 animals were feed with commercial dry feline diet. Cats were weighted    again 
at the end of the study (3.2&#177;0.3kg) </font></p>     ^cY#a07v26n1.htm##
00519000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028500075002001300360#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#46#42#article#155#<p><font face="Verda
na" size="2"> Radiographs were performed one week after surgery    and at the en
d of the study, i.e., after 12 weeks postoperative. The lateral    and ventrodor
sal views of the mandible were taken. Intraoral radiographs were    also perform
ed. </font></p>      ^cY#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#47#43#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00352000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011800075002001300193#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#48#44#article#155#<p><font face="Verda
na" size="2"><I>Macroscopic analysis, histolopathology and    histometry</I> </f
ont></p>      ^cY#a07v26n1.htm##
01151000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704091700075002001300992#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#49#45#article#155#<p><font face="Verda
na" size="2"> Cats were euthanized at 12 weeks postoperative    by intravenous t
hiopental overdosage. The operated and unoperated hemimandibles    of each cat o
btained at necropsy were fixed in 10% formaldehyde solution. Then,    each of th
ese hemimandibles was divided longitudinally into two segments. The    superior 
half was demineralised in an aqueous solution of 5.66 formalin 10%    to 1 of ni
tric acid (v/v). The demineralised specimens were dehydrated in ethanol,    clar
ified in xylol and embedded in paraffin. Thin sections were made and stained    
with hematoxilin-eosin for microscopic evaluation. The inferior half was process
ed    undecalcified. The undecalcified specimens were dehydrated in ethanol, cla
rified    in xylol and embedded in glycol methacrylate. The thin sections of the
se specimens    were stained with Masson-Goldner for microscopic evaluation. </f
ont></p>     ^cY#a07v26n1.htm##
00696000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704046200075002001300537#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#50#46#article#155#<p><font face="Verda
na" size="2"> For the histometric analysis, the images of    sections were acqui
red using a digital camera (Olympus DP71) coupled to a microscope    (Olympus BX
61). The percentage of newly formed bone in the osteotomy area was    measured u
sing the Image Pro Plus 6.1 software (<a href="#img01">Figures 1</a>    and <a h
ref="#img02">2</a>). The percentage of bone tissue of unoperated hemimandibles  
  were also measured. </font></p>     ^cY#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#51#47#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#52#48#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#53#49#article#155#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a07img01.jpg"><a name="img01"></a></p>     ^cY#a
07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#54#50#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#55#51#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#56#52#article#155#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a07img02.jpg"><a name="img02"></a></p>     ^cY#a
07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#57#53#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#58#54#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00317000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008300075002001300158#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#59#55#article#155#<p><font face="Verda
na" size="2"><I> Statistical analysis</I> </font></p>      ^cY#a07v26n1.htm##
00628000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039400075002001300469#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#60#56#article#155#<p><font face="Verda
na" size="2"> Non-parametric tests were utilized for the data    analysis, takin
g into consideration the nature of the variables. Mann-Whitney's    test was use
d to compare histometric data between the two groups. Wilcoxon'test    was used 
to compare histometric data between operated and unoperated hemimandibles.    Si
gnificance was set at p&lt;0.05. </font></p>      ^cY#a07v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#61#57#article#155#<p>&nbsp; </p>     ^
cY#a07v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#62#58#article#155#<p><font face="Verda
na" size="3"><B>Results</B> </font></p>      ^cY#a07v26n1.htm##
00555000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704032100075002001300396#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#63#59#article#155#<p><font face="Verda
na" size="2"> There were no clinical complications and the    operated hemimandi
bles healed uneventfully and with appropriate occlusion. During    the experimen
tal period the cats showed normal activity and mastication and    maintained the
ir initial weight or even gained weight. </font></p>     ^cY#a07v26n1.htm##
00898000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704066400075002001300739#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#64#60#article#155#<p><font face="Verda
na" size="2"> Postoperative radiography (intraoral, oblique    lateral and ventr
odorsal views) was useful in evaluating mandibular alignment    and bone healing
. Good reduction was obtained and maintained throughout the    observation perio
d of 12 weeks and no implant failure occurred. Radiographs    taken 1 week after
 surgery showed a radiolucent line (<a href="#img03">Figures    3</a>, <a href="
#img04">4</a>, <a href="#img05">5</a> and <a href="#img07">7</a>).    The osteot
omy line was not more visible on the radiographs taken at 12 weeks    postoperat
ive (<a href="#img06">Figures 6</a> and <a href="#img08">8</a>).</font></p>     
^cY#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#65#61#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#66#62#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#67#63#article#155#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a07img03.jpg"><a name="img03"></a></p>     ^cY#a
07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#68#64#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#69#65#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#70#66#article#155#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a07img04.jpg"><a name="img04"></a></p>     ^cY#a
07v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#71#67#article#155#<p align="center">&n
bsp;</p>     ^cY#a07v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#72#68#article#155#<p align="center">&n
bsp;</p>     ^cY#a07v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#73#69#article#155#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a07img05.jpg"><a name="img05"></a></p>     ^cY#a
07v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#74#70#article#155#<p align="center">&n
bsp;</p>     ^cY#a07v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#75#71#article#155#<p align="center">&n
bsp;</p>     ^cY#a07v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#76#72#article#155#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a07img06.jpg"><a name="img06"></a></p>     ^cY#a
07v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#77#73#article#155#<p align="center">&n
bsp;</p>     ^cY#a07v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#78#74#article#155#<p align="center">&n
bsp;</p>     ^cY#a07v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#79#75#article#155#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a07img07.jpg"><a name="img07"></a></p>     ^cY#a
07v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#80#76#article#155#<p align="center">&n
bsp;</p>     ^cY#a07v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#81#77#article#155#<p align="center">&n
bsp;</p>     ^cY#a07v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#82#78#article#155#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a07img08.jpg"><a name="img08"></a></p>     ^cY#a
07v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#83#79#article#155#<p align="center">&n
bsp;</p>     ^cY#a07v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#84#80#article#155#<p align="center">&n
bsp;</p>     ^cY#a07v26n1.htm##
00731000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049700075002001300572#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#85#81#article#155#<p><font face="Verda
na" size="2"> Macroscopic examination confirmed the alignment    and bone union 
of the operated hemimandibles. Normal dental occlusion was also    observed. His
tological examination showed that the bone edges created by the    osteotomy wer
e linked by woven bone, indicating bone union. The new bone formation    almost 
totally obliterated the mandibular canal adjacent to the osteotomy line    (<a h
ref="#img09">Figures 9</a> and <a href="#img10">10</a>). </font></p>     ^cY#a07
v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#86#82#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#87#83#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#88#84#article#155#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a07img09.jpg"><a name="img09"></a></p>     ^cY#a
07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#89#85#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#90#86#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#91#87#article#155#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a07img10.jpg"><a name="img10"></a></p>     ^cY#a
07v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#92#88#article#155#<p align="center">&n
bsp;</p>     ^cY#a07v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#93#89#article#155#<p align="center">&n
bsp;</p>     ^cY#a07v26n1.htm##
01016000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704078200075002001300857#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#94#90#article#155#<p><font face="Verda
na" size="2"> The percentage of bone tissue in the area of    the previous osteo
tomy was measured by the histometry. There was no statistically    significant d
ifference between the values of group 1 ((75.07 &#177; 5.99) and    group 2 (74.
76 &#177; 8.54) (Mann-Whitney's test p=0.469) (<a href="/img/revistas/acb/v26n1/
a07tab01.jpg">Table    1</a>). These values were smaller from those observed in 
unoperated hemimandibles    (Group 1: 95.80 &#177; 2.50%; Group 2: 96.18 &#177; 
3.09%). The differences    between operated and unoperated hemimandibles were st
atistically significant    (Wilcoxon'test p &lt; 0.05*) (<a href="/img/revistas/
acb/v26n1/a07tab02.jpg">Tables    2</a> and <a href="/img/revistas/acb/v26n1/a07
tab03.jpg">3</a>).    </font></p>     ^cY#a07v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#95#91#article#155#<p>&nbsp;</p>     ^c
Y#a07v26n1.htm##
00306000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007200075002001300147#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#96#92#article#155#<p><font face="Verda
na" size="3"><B>Discussion</B> </font></p>      ^cY#a07v26n1.htm##
00576000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034200075002001300417#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#97#93#article#155#<p><font face="Verda
na" size="2"> In the present study we used a single miniplate    1.5 applied on 
the ventrobuccal aspect of the mandible, without damaging the    teeth roots. Th
e same technique was adopted by Boudrieau and Kudisch<SUP>6</SUP>    on the repa
ir of mandibular angle fractures in cats with miniplates 2.0. </font></p>     ^c
Y#a07v26n1.htm##
00507000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027300075002001300348#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#98#94#article#155#<p><font face="Verda
na" size="2"> In human patients, mandibular angle fractures    can be fixed with
 a single miniplate, but the implant is applied on the alveolar    border, which
 is the ideal line of osteosynthesis in the mandible<SUP>1,2,4</SUP>.    </font>
</p>     ^cY#a07v26n1.htm##
00648000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704041400075002001300489#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#99#95#article#155#<p><font face="Verda
na" size="2"> Mandibular fractures can also be treated with    two miniplates<SU
P>3,7</SUP>. In experimental study with dogs, one miniplate    was applied on th
e ventral border of the mandible with bicortical screws placement    and a secon
d miniplate was applied on the alveolar border, with monocortical    screws plac
ement to avoid damage to the teeth roots<SUP>8</SUP>. </font></p>     ^cY#a07v26
n1.htm##
00699000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704046400076002001300540#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#100#96#article#155#<p><font face="Verd
ana" size="2"> A ventral surgical approach to the mandible    was used in the pr
esent study, as adopted by some experimental studies and clinical    reports in 
dogs and cats<SUP>6,8,9</SUP>. Contamination seems to be lower in    this surgic
al approach, thereafter a scar in the face doesn't represent an aesthetic    pre
judice for hairy animals. An intraoral incision is usually preferred in human   
 patients<SUP>1-4</SUP>. </font></p>     ^cY#a07v26n1.htm##
00632000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704039700076002001300473#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#101#97#article#155#<p><font face="Verd
ana" size="2"> Our results showed that the application of miniplate    provided 
a fixation stable enough to allow immediate oral alimentation. The    cats maint
ained their initial weight or even gained weight at the end of the    present st
udy. Body weight is an important data to be monitored in animals submitted    to
 maxillofacial surgeries<SUP>9</SUP>. </font></p>     ^cY#a07v26n1.htm##
00618000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704038300076002001300459#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#102#98#article#155#<p><font face="Verd
ana" size="2"> Postoperative radiography was useful in evaluating    hemimandibu
lar alignment and bone healing. Good osteotomy reduction was obtained    and mai
ntained throughout the observation period of 12 weeks and no implant    failure 
occurred. Similar results were reported on experimental studies and    clinical 
trials<SUP>5,6,8</SUP>. </font></p>     ^cY#a07v26n1.htm##
00753000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704051800076002001300594#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#103#99#article#155#<p><font face="Verd
ana" size="2"> The radiolucent line observed in the immediate    postoperative r
adiographs was not more visible in radiographs taken 12 weeks    after surgery, 
indicating bone healing. But the overlap of cranial bones in    oblique lateral 
and ventrodorsal radiographic views impaired a better visualization    of the os
teotomy line in some animals. Intraoral radiographs improved the accuracy    of 
the radiographic examination as reported by Kern <I>et al.</I><SUP>9</SUP>.    <
/font></p>     ^cY#a07v26n1.htm##
00798000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704056200077002001300639#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#104#100#article#155#<p><font face="Ver
dana" size="2"> The macroscopic examination confirmed the hemimandibular    alig
nment and bone union. Histological evaluation 12 weeks after surgery showed    w
oven bone within the osteotomy line in the presence of endosteal and periosteal 
   callus. Similar results were reported by Freitag and Landau<SUP>5</SUP> in th
eir    experimental study in dogs. These authors compared the treatment of mandi
bular    fractures with either a compression plate or a miniplate and observed b
one healing    at 6-8 weeks after fixation. </font></p>     ^cY#a07v26n1.htm##
00563000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704032700077002001300404#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#105#101#article#155#<p><font face="Ver
dana" size="2"> With regard to histological and histometric    analysis, the pre
sent findings are also in agreement with those observed by    Sverzut <I>et al.<
/I><SUP>8 </SUP>Their experimental study in dogs evaluated    the bone repair in
 mandibular osteotomy fixed with two miniplates. </font></p>     ^cY#a07v26n1.ht
m##
00839000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704060300077002001300680#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#106#102#article#155#<p><font face="Ver
dana" size="2"> Samples of demineralised bone allowed the preparation    of hist
ological sections of approximately 2 cm in length. Therefore, the area    of the
 osteotomy line bridged by woven bone could be clearly located. Furthermore,    
there was no significant disruption of the trabecular structure from sectioning 
   as bone trabeculae were thicker after an observation period of 12 weeks. For 
   these two reasons, the sections of demineralised bone embedded in paraffin an
d    stained with hematoxylin-eosin were chosen for the histometric examinations
.    </font></p>     ^cY#a07v26n1.htm##
00842000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704060600077002001300683#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#107#103#article#155#<p><font face="Ver
dana" size="2"> As recommended by several authors, it was only    possible to ob
tain histological sections from small samples (5mm diameter) of    undecalcified
 bone embedded in glycol methacrylate<SUP>10-13</SUP>. Another    factor that co
ntributed to the difficulty in seccioning was the greatest thickness    of bone 
trabeculae after 12 weeks postoperatively. Nevertheless, histological    section
s were made even from samples of normal hemimandibles formed primarily    of com
pact bone. However, most histological sections showed disruption of bone    trab
eculae. </font></p>     ^cY#a07v26n1.htm##
00653000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704041700077002001300494#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#108#104#article#155#<p><font face="Ver
dana" size="2"> Masson-Goldner staining demonstrated clear differentiation    be
tween mineralised bone matrix (green) and osteoid (orange), as described by    Y
ang <I>et al.</I><SUP>13</SUP>. The discrete presence of osteoid in histological
    sections of operated hemimandibles, was due to the 12 week observation perio
d,    corresponding to a bone union at an advanced stage. </font></p>      ^cY#a
07v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#109#105#article#155#<p>&nbsp; </p>    
 ^cY#a07v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007200077002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#110#106#article#155#<p><font face="Ver
dana" size="3"><B>Conclusion</B> </font></p>      ^cY#a07v26n1.htm##
00590000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704035400077002001300431#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#111#107#article#155#<p><font face="Ver
dana" size="2"> Based on the results obtained here, it was possible    to conclu
de that the use of miniplate 1.5 for the fixation of mandibular osteotomy    in 
cats provided the main goals in the treatment of mandibular fractures: bone    u
nion, normal dental occlusion and immediate return to oral alimentation. </font>
</p>        ^cY#a07v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#112#108#article#155#<p>&nbsp; </p>    
 ^cY#a07v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007200077002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#113#109#article#155#<p><font face="Ver
dana" size="3"><B>References</B> </font></p>      ^cY#a07v26n1.htm##
00447000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704019700079002001300276#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#p#114#110#article#155#1#<p><
font face="Verdana" size="2">1. Champy M, Lodd&eacute; JP, Schmitt R. Mandibular
    osteosynthesis by miniature screwed plates via a buccal approach. J Maxillof
ac    Surg. 1978;6:14-21.    ^cY#a07v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#115#111#article#155# </font></p>     ^
cY#a07v26n1.htm##
00560000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704031000079002001300389#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#p#116#112#article#155#2#<p><
font face="Verdana" size="2">2. Schmelzeisen R, Mciff T, Rahn B. Further develop
ment    of titanium miniplate fixation for mandibular fractures. Experience gain
ed and    questions raised from a prospective clinical pilot study with 2.0 mm f
ixation    plates. J Craniomaxillofac Surg. 1992;20:251-6.    ^cY#a07v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#117#113#article#155# </font></p>     ^
cY#a07v26n1.htm##
00439000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704018900079002001300268#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#p#118#114#article#155#3#<p><
font face="Verdana" size="2">3. Ellis III E, Walker L. Treatment of mandibular  
  angle fractures using two noncompression miniplates. J Oral Maxillofac Surg.  
  1994;52:1032-6.    ^cY#a07v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#119#115#article#155# </font></p>     ^
cY#a07v26n1.htm##
00438000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704018800079002001300267#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#p#120#116#article#155#4#<p><
font face="Verdana" size="2">4. Ellis III E, Walker L. Treatment of mandibular  
  angle fractures using one noncompression miniplate. J Oral Maxillofac Surg.   
 1996;54:864-71.    ^cY#a07v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#121#117#article#155# </font></p>     ^
cY#a07v26n1.htm##
00493000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704024300079002001300322#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#p#122#118#article#155#5#<p><
font face="Verdana" size="2">5. Freitag V, Landau H. Healing of dentate or    ed
entulous mandibular fractures treated with rigid or semirigid plate fixation    
_ an experimental study in dogs. J Craniomaxillofac Surg. 1996;24:83-7.    ^cY#a
07v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#123#119#article#155# </font></p>     ^
cY#a07v26n1.htm##
00441000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704019100079002001300270#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#p#124#120#article#155#6#<p><
font face="Verdana" size="2">6. Boudrieau RJ, Kudisch M. Miniplate fixation    f
or repair of mandibular and maxillary fractures in 15 dogs and 3 cats. Vet    Su
rg. 1996;25:277-91.    ^cY#a07v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#125#121#article#155# </font></p>     ^
cY#a07v26n1.htm##
00494000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704024400079002001300323#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#p#126#122#article#155#7#<p><
font face="Verdana" size="2">7. Feller KU, Richter G, Schneider M, Eckelt    U. 
Combination of microplate and miniplate for osteosynthesis of mandibular    frac
tures: an experimental study. Int J Oral Maxillofac Surg. 2002;31:78-83.    ^cY#
a07v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#127#123#article#155#    </font></p>   
  ^cY#a07v26n1.htm##
00546000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704029600079002001300375#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#p#128#124#article#155#8#<p><
font face="Verdana" size="2">8. Sverzut CE, Lucas MA, Sverzut AT, Vieira EH,    
Trivellato AE, Belti MM, Rosa AL, Oliveira, PT. Bone repair in mandibular body  
  osteotomy after using 2.0 miniplate system Histologic and histometric analysis
    in dogs. Int J Exp Pathol. 2008;89:91-7.    ^cY#a07v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#129#125#article#155# </font></p>     ^
cY#a07v26n1.htm##
00494000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704024400079002001300323#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#p#130#126#article#155#9#<p><
font face="Verdana" size="2">   9. Kern DA, Smith MM, Stevenson S, Moon M, Saund
ers GK, Irby MH, Dyer KR. Evaluation    of three fixation techniques for repair 
of mandibular fractures in dogs. J Am    Vet Med Assoc. 1995;12:1883-90.    ^cY#
a07v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#131#127#article#155# </font></p>     ^
cY#a07v26n1.htm##
00459000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020800080002001300288#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#p#132#128#article#155#10#<p>
<font face="Verdana" size="2">10. Islam A, Frisch B. Plastic embedding in routin
e    histology.I: preparation of semi-thin sections of undecalcified marrow core
s.    Histopathology. 1995;9:1263-74.    ^cY#a07v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#133#129#article#155# </font></p>     ^
cY#a07v26n1.htm##
00483000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023200080002001300312#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#p#134#130#article#155#11#<p>
<font face="Verdana" size="2">11. Islam A, Henderson S. Glycol methacrylate    e
mbedding for light microscopy I enzyme histochemistry on semithin sections    of
 undecalcified marrow cores. J Clin Pathol. 1987;40:1194-200.    ^cY#a07v26n1.ht
m##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#135#131#article#155# </font></p>     ^
cY#a07v26n1.htm##
00573000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704032200080002001300402#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#p#136#132#article#155#12#<p>
<font face="Verdana" size="2">12. Wolf E, R&ouml;ser K, Hahn M, Welkerling    H,
 Delling G. Enzyme and immunohistochemistry on undecalcified bone and bone    ma
rrow biopsies after embedding in plastic: a new embedding method for routine    
application. Virchows Archiv A Pathol Anat Histopathol. 1992;420:17-24.    ^cY#a
07v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#137#133#article#155# </font></p>     ^
cY#a07v26n1.htm##
00490000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023900080002001300319#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#p#138#134#article#155#13#<p>
<font face="Verdana" size="2">13. Yang R, Davies CM, Archer CW, Richards RG.    
Immunohistochemistry of matrix markers in technovit 9100 new<SUP>&#174;</SUP>   
 embedded undecalcified bone sections. Eur Cell Mater. 2003;6:57-71.    ^cY#a07v
26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#139#135#article#155# </font></p>      
^cY#a07v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#140#136#article#155#<p>&nbsp; </p>    
 ^cY#a07v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#141#137#article#155#<p>&nbsp;</p>     
^cY#a07v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#142#138#article#155#<p>&nbsp; </p>    
 ^cY#a07v26n1.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704015500077002001300232#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#143#139#article#155#<p><font face="Ver
dana" size="2"><B><a name="end"></a><a href="#top"><img src="/img/revistas/acb/v
26n1/seta.gif" border="0"></a>Correspondence</B>:    ^cY#a07v26n1.htm##
00273000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003700077002001300114#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#144#140#article#155#<br>   Adelina Mar
ia da Silva    ^cY#a07v26n1.htm##
00280000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004400077002001300121#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#145#141#article#155#<br>   Univ. Estad
ual Paulista-UNESP    ^cY#a07v26n1.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704008700077002001300164#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#146#142#article#155#<br>   Depto. Cl&i
acute;nica Cir&uacute;rgica e Reprodu&ccedil;&atilde;o Animal    ^cY#a07v26n1.ht
m##
00281000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004500077002001300122#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#147#143#article#155#<br>   Rua Cl&oacu
te;vis Pestana, 793    ^cY#a07v26n1.htm##
00289000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005300077002001300130#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#148#144#article#155#<br>   16050-680 A
ra&ccedil;atuba - SP Brasil    ^cY#a07v26n1.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003800077002001300115#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#149#145#article#155#<br>   Phone: (55 
18)3636-1404    ^cY#a07v26n1.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009500077002001300172#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#150#146#article#155#<br>   <a href="ma
ilto:adelinasilva@uol.com.br">adelinasilva@uol.com.br</a></font></p>     ^cY#a07
v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#151#147#article#155#<p>&nbsp; </p>    
 ^cY#a07v26n1.htm##
00300000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006400077002001300141#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#152#148#article#155#<p><font face="Ver
dana" size="2">Received: July 21, 2010    ^cY#a07v26n1.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#153#149#article#155#<br>   </font><fon
t face="Verdana" size="2">Review: September 15, 2010    ^cY#a07v26n1.htm##
00327000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009100077002001300168#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#154#150#article#155#<br>   </font><fon
t face="Verdana" size="2">Accepted: October 19, 2010 </font></p>     ^cY#a07v26n
1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006700077002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#155#151#article#155#<p><font face="Ver
dana" size="2">Conflict of interest: none    ^cY#a07v26n1.htm##
00342000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010600077002001300183#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#156#152#article#155#<br>   </font><fon
t face="Verdana" size="2">Financial source: FAPESP and FUNDUNESP    </font></p> 
    ^cY#a07v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#157#153#article#155#<p>&nbsp;</p>     
^cY#a07v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#158#154#article#155#<p>&nbsp;</p>     
^cY#a07v26n1.htm##
00533000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704029700077002001300374#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a07v26n1.htm#S#p#159#155#article#155#<p><font face="Ver
dana" size="2"><sup><a name="end"></a><a href="#top">1</a> </sup>Research    per
formed at Department of Clinics, Surgery and Animal Reproduction, Division    of
 Veterinary Surgical Technique, Sao Paulo State University (UNESP), Ara&ccedil;a
tuba-SP,    Brazil.</font></p>     ^cY#a07v26n1.htm##
00548000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100016000920100
01700108012008000125030001900205710000200224065000900226064000500235031000200240
014000600242865000900248002001300257#v26n1#V:\Scielo\serial\acb\v26n1\markup\a07
v26n1.htm#S#c#160#1#article#13#1#^rND^sChampy^nM#^rND^sLoddé^nJP#^rND^sSchmitt^n
R#Mandibular osteosynthesis by miniature screwed plates via a buccal approach^le
n#J Maxillofac Surg.#2#19780000#1978#6#14-21#20110200#a07v26n1.htm##
00665000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100022000760100015000980100
01400113012018800127030002500315710000200340065000900342064000500351031000300356
014000600359865000900365002001300374#v26n1#V:\Scielo\serial\acb\v26n1\markup\a07
v26n1.htm#S#c#161#2#article#13#2#^rND^sSchmelzeisen^nR#^rND^sMciff^nT#^rND^sRahn
^nB#Further development of titanium miniplate fixation for mandibular fractures:
 Experience gained and questions raised from a prospective clinical pilot study 
with 2.0 mm fixation plates^len#J Craniomaxillofac Surg.#2#19920000#1992#20#251-
6#20110200#a07v26n1.htm##
00529000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100016000950120
08000111030002400191710000200215065000900217064000500226031000300231014000700234
865000900241002001300250#v26n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#
c#162#3#article#13#3#^rND^sEllis III^nE#^rND^sWalker^nL#Treatment of mandibular 
angle fractures using two noncompression miniplates^len#J Oral Maxillofac Surg.#
2#19940000#1994#52#1032-6#20110200#a07v26n1.htm##
00528000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100016000950120
07900111030002400190710000200214065000900216064000500225031000300230014000700233
865000900240002001300249#v26n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#
c#163#4#article#13#4#^rND^sEllis III^nE#^rND^sWalker^nL#Treatment of mandibular 
angle fractures using one noncompression miniplate^len#J Oral Maxillofac Surg.#2
#19960000#1996#54#864-71#20110200#a07v26n1.htm##
00583000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100016000930120
13700109030002500246710000200271065000900273064000500282031000300287014000500290
865000900295002001300304#v26n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#
c#164#5#article#13#5#^rND^sFreitag^nV#^rND^sLandau^nH#Healing of dentate or eden
tulous mandibular fractures treated with rigid or semirigid plate fixation _ an 
experimental study in dogs^len#J Craniomaxillofac Surg.#2#19960000#1996#24#83-7#
20110200#a07v26n1.htm##
00531000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100020000760100017000960120
09400113030001000207710000200217065000900219064000500228031000300233014000700236
865000900243002001300252#v26n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#
c#165#6#article#13#6#^rND^sBoudrieau^nRJ#^rND^sKudisch^nM#Miniplate fixation for
 repair of mandibular and maxillary fractures in 15 dogs and 3 cats^len#Vet Surg
.#2#19960000#1996#25#277-91#20110200#a07v26n1.htm##
00620000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100017000930100
01900110010001600129012011000145030002800255710000200283065000900285064000500294
031000300299014000600302865000900308002001300317#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a07v26n1.htm#S#c#166#7#article#13#7#^rND^sFeller^nKU#^rND^sRichter^nG#^
rND^sSchneider^nM#^rND^sEckelt^nU#Combination of microplate and miniplate for os
teosynthesis of mandibular fractures: an experimental study^len#Int J Oral Maxil
lofac Surg.#2#20020000#2002#31#78-83#20110200#a07v26n1.htm##
00741000000000337000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100016000940100
01800110010001700128010002100145010001600166010001500182010002000197012012200217
03000180033971000020035706500090035906400050036803100030037301400050037686500090
0381002001300390#v26n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#c#167#8#
article#13#8#^rND^sSverzut^nCE#^rND^sLucas^nMA#^rND^sSverzut^nAT#^rND^sVieira^nE
H#^rND^sTrivellato^nAE#^rND^sBelti^nMM#^rND^sRosa^nAL#^rND^sOliveira,^nPT#Bone r
epair in mandibular body osteotomy after using 2.0 miniplate system Histologic a
nd histometric analysis in dogs^len#Int J Exp Pathol.#2#20080000#2008#89#91-7#20
110200#a07v26n1.htm##
00671000000000325000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100016000910100
01900107010001400126010001900140010001500159010001500174012008700189030002000276
71000020029606500090029806400050030703100030031201400080031586500090032300200130
0332#v26n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#c#168#9#article#13#9
#^rND^sKern^nDA#^rND^sSmith^nMM#^rND^sStevenson^nS#^rND^sMoon^nM#^rND^sSaunders^
nGK#^rND^sIrby^nMH#^rND^sDyer^nKR#Evaluation of three fixation techniques for re
pair of mandibular fractures in dogs^len#J Am Vet Med Assoc.#2#19950000#1995#12#
1883-90#20110200#a07v26n1.htm##
00549000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100016000930120
11000109030001600219710000200235065000900237064000500246031000200251014000800253
865000900261002001300270#v26n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#
c#169#10#article#13#10#^rND^sIslam^nA#^rND^sFrisch^nB#Plastic embedding in routi
ne histology.I: preparation of semi-thin sections of undecalcified marrow cores^
len#Histopathology.#2#19950000#1995#9#1263-74#20110200#a07v26n1.htm##
00573000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100019000930120
13000112030001500242710000200257065000900259064000500268031000300273014000900276
865000900285002001300294#v26n1#V:\Scielo\serial\acb\v26n1\markup\a07v26n1.htm#S#
c#170#11#article#13#11#^rND^sIslam^nA#^rND^sHenderson^nS#Glycol methacrylate emb
edding for light microscopy I enzyme histochemistry on semithin sections of unde
calcified marrow cores^len#J Clin Pathol.#2#19870000#1987#40#1194-200#20110200#a
07v26n1.htm##
00709000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100015000920100
01400107010002000121010001700141012015800158030004300316710000200359065000900361
064000500370031000400375014000600379865000900385002001300394#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a07v26n1.htm#S#c#171#12#article#13#12#^rND^sWolf^nE#^rND^sR
öser^nK#^rND^sHahn^nM#^rND^sWelkerling^nH#^rND^sDelling^nG#Enzyme and immunohist
ochemistry on undecalcified bone and bone marrow biopsies after embedding in pla
stic: a new embedding method for routine application^len#Virchows Archiv A Patho
l Anat Histopathol.#2#19920000#1992#420#17-24#20110200#a07v26n1.htm##
00600000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100017000920100
01700109010001900126012010300145030001600248710000200264065000900266064000500275
031000200280014000600282865000900288002001300297#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a07v26n1.htm#S#c#172#13#article#13#13#^rND^sYang^nR#^rND^sDavies^nCM#^r
ND^sArcher^nCW#^rND^sRichards^nRG#Immunohistochemistry of matrix markers in tech
novit 9100 new® embedded undecalcified bone sections^len#Eur Cell Mater.#2#20030
000#2003#6#57-71#20110200#a07v26n1.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v26n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#o#1#1#article#1#
20110120#130143#a08v26n1.htm#174##
04322000000000733000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000400089038000400093121000300097049000700100158000300107
03000160011003100030012603200020012906500090013101400090014003500100014901201410
01590120139003000100034004390100041004730100026005140100032005400700064005720700
08700636070009200723070013200815083111000947085000802057085002702065085002902092
08500250212108500170214608500170216308311700218008500080335008500280335808500300
33860850023034160850019034390850018034581170006034760720003034820580006034850580
00703491112000903498111001403507116000903521115001903530114000903549113001703558
002001303575#v26n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#h#2#1#articl
e#1#oa#en#br1.1#1#4.0#GRA#TAB#08#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f38^l4
3#0102-8650#Standardization of a method of prolonged thoracic surgery and mechan
ical ventilation in rats to evaluate local and systemic inflammation^len#Padroni
zação de um modelo de cirurgia torácica prolongada e ventilação mecânica em rato
s para avaliação inflamatória local e sistêmica^lpt#^rND^1A01^nCamila Ferreira^s
Leite#^rND^1A02^nIvan Felizardo Contrera^sToro#^rND^1A03^nEdson^sAntunes#^rND^1A
04^nRicardo Kalaf^sMussi#UNICAMP^iA01^1Faculty of Medical Sciences^cCampinas^sSP
^pBrazil#UNICAMP^iA02^1Faculty of Medical Sciences^2Department of Surgery^cCampi
nas^sSP^pBrazil#UNICAMP^iA03^1Faculty of Medical Sciences^2Department of Pharmac
ology^cCampinas^sSP^pBrazil#UNICAMP^iA04^1Faculty of Medical Sciences^2Postgradu
ate Program in Sciences of Surgery^3Department of Surgery^cCampinas^sSP^pBrazil#
^len^aPurpose: To evaluate the immediate pulmonary and systemic inflammatory res
ponse after a long-term operative period. Methods: Wistar rats in the experiment
al group were anaesthetized and submitted to tracheostomy, thoracotomy and remai
ned on mechanical ventilation during three hours. Control animals were not submi
tted to the operative protocol. The following parameters have been evaluated: pu
lmonary myeloperoxidase activity, pulmonary serum protein extravasation, lung we
t/dry weight ratio and measurement of levels of cytokines in serum. Results: Ope
rated animals exhibited significantly lower serum protein extravasation in lungs
 compared with control animals. The lung wet/dry weight ratio and myeloperoxidas
e activity did not differ between groups. Serum cytokines IL-1ß, TNF-, and IL-10
 levels were not detected in groups, whereas IL-6 was detected only in operated 
animals. Conclusion: The experimental mechanical ventilation in rats with a prol
onged surgical time did not produce significant local and systemic inflammatory 
changes and permit to evaluate others procedures in thoracic surgery.#^dnd^i1#^t
m^len^kModels, Animal^i1#^tm^len^kThoracic Surgery^i1#^tm^len^kInflammation^i1#^
tm^len^kLung^i1#^tm^len^kRats^i1#^lpt^aObjetivo: Investigar a resposta inflamató
ria pulmonar e sistêmica imediata após longo período operatório. Métodos: Ratos 
Wistar do grupo experimental foram anestesiados e submetidos à traqueostomia, to
racotomia e permaneceram em ventilação mecânica por três horas. O grupo controle
 não foi submetido ao protocolo operatório. Os seguintes parâmetros foram avalia
dos: atividade da mieloperoxidase pulmonar, níveis de extravasamento de proteína
s séricas pulmonares, relação peso pulmonar úmido/seco e medidas dos níveis séri
cos de citocinas. Resultados: Os animais operados apresentaram menor extravasame
nto de proteínas séricas nos pulmões comparados aos animais controle. A relação 
peso úmido/seco e a atividade de mieloperoxidase não diferiram entre os grupos. 
As citocinas séricas IL-1ß, TNF- e IL-10 não foram quantificáveis nos grupos, en
quanto que IL-6 só foi detectada no soro dos animais operados. Conclusão: O mode
lo experimental de ventilação mecânica em ratos com tempo cirúrgico prolongado n
ão apresentou alterações inflamatórias locais e sistêmicas significantes, permit
indo avaliar a resposta inflamatória em outros procedimentos da cirurgia torácic
a.#^dnd^i2#^tm^lpt^kModelos Animais^i2#^tm^lpt^kCirurgia Torácica^i2#^tm^lpt^kIn
flamação^i2#^tm^lpt^kPulmão^i2#^tm^lpt^kRatos^i2#other#20#CAPES#FAPESP#20100713#
July 13, 2010#20100914#September 14, 2010#20101020#October 20, 2010#a08v26n1.htm
##
04392000000000733000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000400089038000400093121000300097049000700100158000300107
03000160011003100030012603200020012906500090013101400090014003500100014901201480
01590120146003070100034004530100041004870100026005280100032005540700064005860700
08700650070009200737070013200829083113800961085000802099085002702107085002902134
08500250216308500170218808500170220508311980222208500080342008500280342808500300
34560850023034860850019035090850018035281170006035460720003035520580006035550580
00703561112000903568111001403577116000903591115001903600114000903619113001703628
002001303645#v26n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#f#3#1#articl
e#1#oa#en#br1.1#1#4.0#GRA#TAB#08#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f38^l4
3#0102-8650#<b>Standardization of a method of prolonged thoracic surgery and mec
hanical ventilation in rats to evaluate local and systemic inflammation</b>^len#
<b>Padronização de um modelo de cirurgia torácica prolongada e ventilação mecâni
ca em ratos para avaliação inflamatória local e sistêmica</b>^lpt#^rND^1A01^nCam
ila Ferreira^sLeite#^rND^1A02^nIvan Felizardo Contrera^sToro#^rND^1A03^nEdson^sA
ntunes#^rND^1A04^nRicardo Kalaf^sMussi#UNICAMP^iA01^1Faculty of Medical Sciences
^cCampinas^sSP^pBrazil#UNICAMP^iA02^1Faculty of Medical Sciences^2Department of 
Surgery^cCampinas^sSP^pBrazil#UNICAMP^iA03^1Faculty of Medical Sciences^2Departm
ent of Pharmacology^cCampinas^sSP^pBrazil#UNICAMP^iA04^1Faculty of Medical Scien
ces^2Postgraduate Program in Sciences of Surgery^3Department of Surgery^cCampina
s^sSP^pBrazil#^len^a<b>Purpose</b>: To evaluate the immediate pulmonary and syst
emic inflammatory response after a long-term operative period. <b>Methods</b>: W
istar rats in the experimental group were anaesthetized and submitted to tracheo
stomy, thoracotomy and remained on mechanical ventilation during three hours. Co
ntrol animals were not submitted to the operative protocol. The following parame
ters have been evaluated: pulmonary myeloperoxidase activity, pulmonary serum pr
otein extravasation, lung wet/dry weight ratio and measurement of levels of cyto
kines in serum. <b>Results</b>: Operated animals exhibited significantly lower s
erum protein extravasation in lungs compared with control animals. The lung wet/
dry weight ratio and myeloperoxidase activity did not differ between groups. Ser
um cytokines IL-1ß, TNF-, and IL-10 levels were not detected in groups, whereas 
IL-6 was detected only in operated animals. <b>Conclusion</b>: The experimental 
mechanical ventilation in rats with a prolonged surgical time did not produce si
gnificant local and systemic inflammatory changes and permit to evaluate others 
procedures in thoracic surgery.#^dnd^i1#^tm^len^kModels, Animal^i1#^tm^len^kThor
acic Surgery^i1#^tm^len^kInflammation^i1#^tm^len^kLung^i1#^tm^len^kRats^i1#^lpt^
a<b>Objetivo</b>: Investigar a resposta inflamatória pulmonar e sistêmica imedia
ta após longo período operatório. <b>Métodos</b>: Ratos Wistar do grupo experime
ntal foram anestesiados e submetidos à traqueostomia, toracotomia e permaneceram
 em ventilação mecânica por três horas. O grupo controle não foi submetido ao pr
otocolo operatório. Os seguintes parâmetros foram avaliados: atividade da mielop
eroxidase pulmonar, níveis de extravasamento de proteínas séricas pulmonares, re
lação peso pulmonar úmido/seco e medidas dos níveis séricos de citocinas. <b>Res
ultados</b>: Os animais operados apresentaram menor extravasamento de proteínas 
séricas nos pulmões comparados aos animais controle. A relação peso úmido/seco e
 a atividade de mieloperoxidase não diferiram entre os grupos. As citocinas séri
cas IL-1ß, TNF- e IL-10 não foram quantificáveis nos grupos, enquanto que IL-6 s
ó foi detectada no soro dos animais operados. <b>Conclusão</b>: O modelo experim
ental de ventilação mecânica em ratos com tempo cirúrgico prolongado não apresen
tou alterações inflamatórias locais e sistêmicas significantes, permitindo avali
ar a resposta inflamatória em outros procedimentos da cirurgia torácica.#^dnd^i2
#^tm^lpt^kModelos Animais^i2#^tm^lpt^kCirurgia Torácica^i2#^tm^lpt^kInflamação^i
2#^tm^lpt^kPulmão^i2#^tm^lpt^kRatos^i2#other#20#CAPES#FAPESP#20100713#July 13, 2
010#20100914#September 14, 2010#20101020#October 20, 2010#a08v26n1.htm##
04460000000000757000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000400107038000400111121000300115049000700118
15800030012503000150012803100030014303200020014606500090014801400090015703500100
01660120141001760120139003170100034004560100041004900100026005310100032005570700
06600589070008900655070009400744070013400838083111000972085000802082085002702090
08500290211708500250214608500170217108500170218808311700220508500080337508500280
33830850030034110850023034410850019034640850018034831170006035010720003035070580
00603510058000703516112000903523111001403532116000903546115001903555114000903574
113001703583002001303600008008903613#v26n1#V:\Scielo\serial\acb\v26n1\markup\a08
v26n1.htm#S#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#gra#tab#08#ACB72
0#nd#Acta cir. bras#26#1#20110200#^f38^l43#0102-8650#Standardization of a method
 of prolonged thoracic surgery and mechanical ventilation in rats to evaluate lo
cal and systemic inflammation^len#Padronização de um modelo de cirurgia torácica
 prolongada e ventilação mecânica em ratos para avaliação inflamatória local e s
istêmica^lpt#^rND^1A01^nCamila Ferreira^sLeite#^rND^1A02^nIvan Felizardo Contrer
a^sToro#^rND^1A03^nEdson^sAntunes#^rND^1A04^nRicardo Kalaf^sMussi#^iA01^1UNICAMP
^2Faculty of Medical Sciences^cCampinas^sSP^pBrazil#^iA02^1UNICAMP^2Faculty of M
edical Sciences^3Department of Surgery^cCampinas^sSP^pBrazil#^iA03^1UNICAMP^2Fac
ulty of Medical Sciences^3Department of Pharmacology^cCampinas^sSP^pBrazil#^iA04
^1UNICAMP^2Faculty of Medical Sciences^3Postgraduate Program in Sciences of Surg
ery. Department of Surgery^cCampinas^sSP^pBrazil#^len^aPurpose: To evaluate the 
immediate pulmonary and systemic inflammatory response after a long-term operati
ve period. Methods: Wistar rats in the experimental group were anaesthetized and
 submitted to tracheostomy, thoracotomy and remained on mechanical ventilation d
uring three hours. Control animals were not submitted to the operative protocol.
 The following parameters have been evaluated: pulmonary myeloperoxidase activit
y, pulmonary serum protein extravasation, lung wet/dry weight ratio and measurem
ent of levels of cytokines in serum. Results: Operated animals exhibited signifi
cantly lower serum protein extravasation in lungs compared with control animals.
 The lung wet/dry weight ratio and myeloperoxidase activity did not differ betwe
en groups. Serum cytokines IL-1ß, TNF-, and IL-10 levels were not detected in gr
oups, whereas IL-6 was detected only in operated animals. Conclusion: The experi
mental mechanical ventilation in rats with a prolonged surgical time did not pro
duce significant local and systemic inflammatory changes and permit to evaluate 
others procedures in thoracic surgery.#^dnd^i1#^tm^len^kModels, Animal^i1#^tm^le
n^kThoracic Surgery^i1#^tm^len^kInflammation^i1#^tm^len^kLung^i1#^tm^len^kRats^i
1#^lpt^aObjetivo: Investigar a resposta inflamatória pulmonar e sistêmica imedia
ta após longo período operatório. Métodos: Ratos Wistar do grupo experimental fo
ram anestesiados e submetidos à traqueostomia, toracotomia e permaneceram em ven
tilação mecânica por três horas. O grupo controle não foi submetido ao protocolo
 operatório. Os seguintes parâmetros foram avaliados: atividade da mieloperoxida
se pulmonar, níveis de extravasamento de proteínas séricas pulmonares, relação p
eso pulmonar úmido/seco e medidas dos níveis séricos de citocinas. Resultados: O
s animais operados apresentaram menor extravasamento de proteínas séricas nos pu
lmões comparados aos animais controle. A relação peso úmido/seco e a atividade d
e mieloperoxidase não diferiram entre os grupos. As citocinas séricas IL-1ß, TNF
- e IL-10 não foram quantificáveis nos grupos, enquanto que IL-6 só foi detectad
a no soro dos animais operados. Conclusão: O modelo experimental de ventilação m
ecânica em ratos com tempo cirúrgico prolongado não apresentou alterações inflam
atórias locais e sistêmicas significantes, permitindo avaliar a resposta inflama
tória em outros procedimentos da cirurgia torácica.#^dnd^i2#^tm^lpt^kModelos Ani
mais^i2#^tm^lpt^kCirurgia Torácica^i2#^tm^lpt^kInflamação^i2#^tm^lpt^kPulmão^i2#
^tm^lpt^kRatos^i2#other#20#CAPES#FAPESP#20100713#July 13, 2010#20100914#Septembe
r 14, 2010#20101020#October 20, 2010#a08v26n1.htm#Internet^ihttp://www.scielo.br
/scielo.php?script=sci_arttext&pid=S0102-86502011000100008##
00310000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704007800073002001300151#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#5#1#article#150#<p align="right"><font
 face="Verdana" size="2"><b>8 - ORIGINAL ARTICLE    ^cY#a08v26n1.htm##
00325000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704009300073002001300166#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#6#2#article#150#<br>   </b></font><b><
font face="Verdana" size="2">MODELS, BIOLOGICAL</font></b></p>     ^cY#a08v26n1.
htm##
00543000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704031100073002001300384#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#7#3#article#150#<p align="right">&nbsp
;</p>  <B> <font face="Verdana" size="2"><a name="top"></a></font><font face="Ve
rdana" size="4">Standardization  of a method of prolonged thoracic surgery and m
echanical ventilation in rats to  evaluate local and systemic inflammation<SUP><
a href="#end">1</a></SUP> </font>  </B>      ^cY#a08v26n1.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#8#4#article#150#<p>&nbsp;</p>     ^cY#
a08v26n1.htm##
00506000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704027400073002001300347#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#9#5#article#150#<p><b><font face="Verd
ana" size="3">Padroniza&ccedil;&atilde;o de um modelo de    cirurgia tor&aacute;
cica prolongada e ventila&ccedil;&atilde;o mec&acirc;nica    em ratos para avali
a&ccedil;&atilde;o inflamat&oacute;ria local e sist&ecirc;mica    </font></b></p
>       ^cY#a08v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#10#6#article#150#<p>&nbsp;</p>     ^cY
#a08v26n1.htm##
00440000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704020700074002001300281#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#11#7#article#150#<p><font face="Verdan
a" size="2"><B>Camila Ferreira Leite<SUP>I</SUP>, Ivan Felizardo    Contrera Tor
o<SUP>II</SUP>, Edson Antunes<SUP>III</SUP>, Ricardo Kalaf Mussi<SUP>IV</SUP></B
>    </font></p>      ^cY#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002300074002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#12#8#article#150#<p>&nbsp;</p>      ^c
Y#a08v26n1.htm##
00483000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704025000074002001300324#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#13#9#article#150#<p><font face="Verdan
a" size="2"><SUP>I</SUP>Fellow Master degree, Faculty of    Medical Sciences, UN
ICAMP, Campinas-SP, Brazil. <I>Carried out the experiments,    collect the data,
 performed the statistical analysis and wrote the manuscript.    ^cY#a08v26n1.ht
m##
00493000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025900075002001300334#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#14#10#article#150#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>II</SUP>PhD, Head of Division    of Thoracic Su
rgery, Faculty of Medical Sciences, Department of Surgery, UNICAMP,    Campinas-
SP, Brazil. <I>Protocol standardization and methodological adjustments.    ^cY#a
08v26n1.htm##
00492000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025800075002001300333#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#15#11#article#150#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>III</SUP>Full Professor, Faculty    of Medical 
Sciences, Department of Pharmacology, UNICAMP, Campinas-SP, Brazil.    <I>Partic
ipated in the design, coordination and helped to draft the manuscript.    ^cY#a0
8v26n1.htm##
00564000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704033000075002001300405#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#16#12#article#150#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>IV</SUP>MD, PhD, Affiliate Professor,    Postgr
aduate Program in Sciences of Surgery, Faculty of Medical Sciences, Department  
  of Surgery, UNICAMP, Campinas-SP, Brazil. <I>Participated in the design, coord
ination    and helped to draft the manuscript.</I></font></p>     ^cY#a08v26n1.h
tm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#17#13#article#150#<p><font face="Verda
na" size="2"><a href="#end">Correspondence</a></font></p>     ^cY#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#18#14#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#19#15#article#150#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a08v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#20#16#article#150#<p><font face="Verda
na" size="2"><B>ABSTRACT </B></font></p>     ^cY#a08v26n1.htm##
01467000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704123300075002001301308#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#21#17#article#150#<p><font face="Verda
na" size="2"><B>Purpose</b>: To evaluate the immediate pulmonary    and systemic
 inflammatory response after a long-term operative period. <B>Methods</B>:    Wi
star rats in the experimental group were anaesthetized and submitted to tracheos
tomy,    thoracotomy and remained on mechanical ventilation during three hours. 
Control    animals were not submitted to the operative protocol. The following p
arameters    have been evaluated: pulmonary myeloperoxidase activity, pulmonary 
serum protein    extravasation, lung wet/dry weight ratio and measurement of lev
els of cytokines    in serum. <B>Results</B>: Operated animals exhibited signifi
cantly lower serum    protein extravasation in lungs compared with control anima
ls. The lung wet/dry    weight ratio and myeloperoxidase activity did not differ
 between groups. Serum    cytokines IL-1&szlig;, TNF-, and IL-10 levels were not
 detected in groups, whereas    IL-6 was detected only in operated animals. <B>C
onclusion</B>: The experimental    mechanical ventilation in rats with a prolong
ed surgical time did not produce    significant local and systemic inflammatory 
changes and permit to evaluate others    procedures in thoracic surgery. </font>
</p>     ^cY#a08v26n1.htm##
00390000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015600075002001300231#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#22#18#article#150#<p><font face="Verda
na" size="2"><B>Key words</B>: Models, Animal. Thoracic Surgery.    Inflammation
. Lung. Rats.</font></p> <hr size="1" noshade>      ^cY#a08v26n1.htm##
00301000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006700075002001300142#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#23#19#article#150#<p><font face="Verda
na" size="2"><B>RESUMO </B></font></p>     ^cY#a08v26n1.htm##
01848000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704161400075002001301689#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#24#20#article#150#<p><font face="Verda
na" size="2"><B>Objetivo</b>: Investigar a resposta inflamat&oacute;ria    pulmo
nar e sist&ecirc;mica imediata ap&oacute;s longo per&iacute;odo operat&oacute;ri
o.    <B>M&eacute;todos</B>: Ratos Wistar do grupo experimental foram anestesiad
os    e submetidos &agrave; traqueostomia, toracotomia e permaneceram em ventila
&ccedil;&atilde;o    mec&acirc;nica por tr&ecirc;s horas. O grupo controle n&ati
lde;o foi submetido    ao protocolo operat&oacute;rio. Os seguintes par&acirc;me
tros foram avaliados:    atividade da mieloperoxidase pulmonar, n&iacute;veis de
 extravasamento de prote&iacute;nas    s&eacute;ricas pulmonares, rela&ccedil;&a
tilde;o peso pulmonar &uacute;mido/seco    e medidas dos n&iacute;veis s&eacute;
ricos de citocinas. <B>Resultados</B>:    Os animais operados apresentaram menor
 extravasamento de prote&iacute;nas s&eacute;ricas    nos pulm&otilde;es compara
dos aos animais controle. A rela&ccedil;&atilde;o    peso &uacute;mido/seco e a 
atividade de mieloperoxidase n&atilde;o diferiram    entre os grupos. As citocin
as s&eacute;ricas IL-1&szlig;, TNF- e IL-10 n&atilde;o    foram quantific&aacute
;veis nos grupos, enquanto que IL-6 s&oacute; foi detectada    no soro dos anima
is operados. <B>Conclus&atilde;o</B>: O modelo experimental    de ventila&ccedil
;&atilde;o mec&acirc;nica em ratos com tempo cir&uacute;rgico    prolongado n&at
ilde;o apresentou altera&ccedil;&otilde;es inflamat&oacute;rias    locais e sist
&ecirc;micas significantes, permitindo avaliar a resposta inflamat&oacute;ria   
 em outros procedimentos da cirurgia tor&aacute;cica. </font></p>     ^cY#a08v26
n1.htm##
00426000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704019200075002001300267#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#25#21#article#150#<p><font face="Verda
na" size="2"><B>Descritores</B>: Modelos Animais. Cirurgia    Tor&aacute;cica. I
nflama&ccedil;&atilde;o. Pulm&atilde;o. Ratos.    </font></p> <hr size="1" nosha
de>     ^cY#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#26#22#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#27#23#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007400075002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#28#24#article#150#<p><font face="Verda
na" size="3"><B>Introduction</B> </font></p>      ^cY#a08v26n1.htm##
00790000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055600075002001300631#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#29#25#article#150#<p><font face="Verda
na" size="2"> Human thoracic surgeries cause inflammatory    responses of great 
magnitude and difficult management, representing a post-operative    challenge t
o surgeons. Oxidative stress, changes in the pro and anti-inflammatory    cytoki
nes balance, ischemia-reperfusion injury, one-lung ventilation effects<SUP>1</SU
P>,    handling of large neoplastic lesions and the surgical procedure itself ar
e the    outstanding elements that lead to endothelial dysfunction, responsible 
for acute    inflammatory reaction. </font></p>     ^cY#a08v26n1.htm##
01908000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704167400075002001301749#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#30#26#article#150#<p><font face="Verda
na" size="2"> The magnitude of the inflammatory response has    a cumulative cha
racter and depends on many factors. The knowledge of each factor    and preventi
ve actions to reduce its intensity are important in clinical practice.    Howeve
r, ethical questions along with reproducible and comparable methods greatly    d
ifficult the human intervention studies. Therefore, the experimental surgery    
is an alternative to answer important questions daily observed in clinical pract
ice<SUP>2</SUP>.    To date, there is no alternative yet to replace the animal m
odel to yield information    about of pathophysiology of acute lung injury or to
 test therapeutic interventions    in complex biological systems<SUP>2</SUP>. Ce
rtainly, animal models for human    diseases cannot be more than an approximatio
n of the human conditions<SUP>3</SUP>,    and caution must be taken. However, kn
owing the specific characteristics of    the animal species used and correctly i
nterpreting the findings it is possible    to obtain key elements to elucidate l
ung injury in humans<SUP>2</SUP>. The literature    reports experimental models 
in small animals that are standard for surgical    procedures of short duration,
 but standardization procedures for prolonged operative    times has been poorly
 explored. Therefore, this study aimed to standardize a    method of long-term t
horacic surgery in rats in an attempt to approximate as    much as possible the 
human practices. We have measured the immediate post-operative    pulmonary and 
systemic inflammatory response in anaesthetized rats undergoing    thoracic surg
ery with mechanical ventilation. </font></p>      ^cY#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#31#27#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#32#28#article#150#<p><font face="Verda
na" size="3"><B>Methods</B> </font></p>      ^cY#a08v26n1.htm##
00747000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704051300075002001300588#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#33#29#article#150#<p><font face="Verda
na" size="2"> The present study was approved by the Animals    Ethics Committee 
of the University of Campinas (CEEA-IB-UNICAMP, protocol number:    1609-1), and
 followed the Guide for the Care and Use of Laboratory Animals published    by t
he US National Institutes of Health (NIH Publication No.85-23, revised 1996).   
 Twenty-five male Wistar rats, weighing between 305 and 455 g, were randomly    
divided into two groups: Experimental (EG, n=13) and Control (CG, n=12). </font>
</p>     ^cY#a08v26n1.htm##
00628000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039400075002001300469#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#34#30#article#150#<p><font face="Verda
na" size="2"> All the EG rats were induced to anesthesia with    isoflurane 5% t
hrough a calibrated vaporizer (Marcovap IS 707, manufactured    by Scientific In
struments Narcosul LTDA - Porto Alegre, Brazil). After achieving    an adequate 
anesthesia (verified by absence of palpebral, plantar and tail reflexes),    the
 surgical protocol was initiated. </font></p>     ^cY#a08v26n1.htm##
00829000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704059500075002001300670#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#35#31#article#150#<p><font face="Verda
na" size="2"> The animals were placed on a heated blanket.    Initially, animals
 were tracheotomized and immediately connected to the Inter3    mechanical venti
lator (Intermed<SUP>&#174;</SUP> Sao Paulo, Brazil). The choice    of this equip
ment considered the efficient adaptation    with the vaporizer calibrated for is
oflurane, and the possibility of working    with low-flow and high respiratory r
ate (RR). A humidifier was also used to    ensure the heating of administered ga
ses to the animal, preventing obstructive    tracheal secretion formation. </fon
t></p>     ^cY#a08v26n1.htm##
00621000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704038700075002001300462#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#36#32#article#150#<p><font face="Verda
na" size="2"> The ventilation standardized parameters used    throughout the sur
gical protocol were: inspiratory pressure (IP) of 20 cmH<SUB>2</SUB>O,    positi
ve end expiratory pressure (PEEP) of 2 cmH<SUB>2</SUB>O, ratio inspiration/expir
ation    (I:E) of 1:3, with inspired oxygen fraction (FiO<SUB>2</SUB>) of 60% an
d RR    of 80 breaths/min. </font></p>     ^cY#a08v26n1.htm##
00725000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049100075002001300566#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#37#33#article#150#<p><font face="Verda
na" size="2"> After connecting to the mechanical ventilator,    the isoflurane a
nesthetic concentration was decreased to 1.5%, remaining in    this concentratio
n throughout the protocol. Then, the left femoral vein was    dissected and used
 for neuromuscular blocker (pancuronium bromide) administration<I>    in bolus</
I> (1 mg/kg.h). The same vein was used to administer 0.9% saline solution    (1 
mL/h) for fluid replacement during the experiment. </font></p>     ^cY#a08v26n1.
htm##
00773000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053900075002001300614#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#38#34#article#150#<p><font face="Verda
na" size="2"> The left carotid artery was cannulated and maintained    with 0.9%
 heparinized saline (5 UI/mL) for monitoring mean arterial blood pressure    (MA
P) using the MacLab/400 and the Software PowerLab<SUP>&#174;</SUP> (ADInstrument
s,    NSW, Australia). Immediately after the artery cannulation, we collected a 
blood    sample for gasometric analysis. The following gasometric parameters wer
e evaluated:    pH, PaO<SUB>2</SUB>, PaCO<SUB>2</SUB>, HCO<SUB>3</SUB>-, BE and 
SO<SUB>2</SUB>.    </font></p>     ^cY#a08v26n1.htm##
00694000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704046000075002001300535#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#39#35#article#150#<p><font face="Verda
na" size="2"> Right paraesternal thoracotomy with anterolateral    ipsilateral e
xtension was performed, simulating a surgical exploration necessary    to detect
 the animal hemodynamics during the operative procedures in the thoracic    cavi
ty. Next, albumin labeled with radioactive iodine (<SUP>125</SUP>I) was    injec
ted through the femoral vein for subsequent evaluation of pulmonary serum    pro
tein extravasation. </font></p>     ^cY#a08v26n1.htm##
00737000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050300075002001300578#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#40#36#article#150#<p><font face="Verda
na" size="2"> With the chest opened, rats remained on mechanical    ventilation 
for 3 h, and every 15 min MAP and temperature (which remained between    37 &#17
7; 0.8&#186;C) for individual control were checked. During this time,    lungs w
ere kept moist with periodic applications of warm saline and the incision    was
 covered to minimize evaporative losses. In the final minute of ventilation,    
a new arterial blood collection to gas analysis was performed. </font></p>     ^
cY#a08v26n1.htm##
00513000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027900075002001300354#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#41#37#article#150#<p><font face="Verda
na" size="2"> At the end of the experiment, the rats received    a higher dose o
f isoflurane. Laparotomy was then performed, and the rat was    bled by the abdo
minal aorta. This blood was processed and used for serum cytokine    analysis. <
/font></p>     ^cY#a08v26n1.htm##
00647000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704041300075002001300488#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#42#38#article#150#<p><font face="Verda
na" size="2"> The protocol in control rats (CG) involved anesthesia    induction
 with isoflurane just for injection of <SUP>125</SUP>I albumin via    penile vei
n. After a brief recovery period of anesthesia, the animals were returned    to 
their cages. Three h thereafter, all rats were anesthetized with isoflurane    a
nd sacrificed by exanguination similarly to EG rats. </font></p>     ^cY#a08v26n
1.htm##
00617000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704038300075002001300458#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#43#39#article#150#<p><font face="Verda
na" size="2"> Before removing the heart-lung block from the    thoracic cavity, 
the lungs of all animals were perfused with 40 mL of 0.9% saline    solution fro
m a height of 20 cm through a small incision in the right ventricle,    and cann
ulation of the pulmonar artery, followed by opening the left atrium    for efflu
ent drainage was done. </font></p>     ^cY#a08v26n1.htm##
00462000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022800075002001300303#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#44#40#article#150#<p><font face="Verda
na" size="2"> After this procedure, lungs were excised and    separately to meas
urement of MPO activity, extravasation of pulmonary serum    protein leakage and
 lung wet/dry weight ratio. </font></p>     ^cY#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#45#41#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00336000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010200075002001300177#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#46#42#article#150#<p><font face="Verda
na" size="2"><i>Pulmonary serum protein extravasation</I>    </font></p>      ^c
Y#a08v26n1.htm##
00762000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052800075002001300603#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#47#43#article#150#<p><font face="Verda
na" size="2"> Pulmonary serum protein extravasation was measured    by means of 
intravenously injected <SUP>125</SUP>I serum albumin (2.5 &#181;Ci/kg)    accumu
lation<SUP>4</SUP>. The radioactivity present in blood samples and lung    tissu
e was quantified in a <IMG SRC="./Simbolo_.JPG" WIDTH="6" HEIGHT="10"  ALIGN="BO
TTOM">-counter. The serum extravasation was expressed as the volume (in    micro
litres) of serum accumulated in the lung derived from the total count in    1mL 
serum. </font></p>      ^cY#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#48#44#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00326000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009200075002001300167#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#49#45#article#150#<p><font face="Verda
na" size="2"><I>Lung myeloperoxidase activity </I> </font></p>      ^cY#a08v26n1
.htm##
01228000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704099400075002001301069#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#50#46#article#150#<p><font face="Verda
na" size="2"> The right lung was removed and placed in a test    tube in the pre
sence of 0.5% hexadecyltrimethylammonium bromide in 50 mM potassium    phosphate
 buffer (pH 6.0). The tissue sample was homogenized and centrifuged    for 2 min
 at 14,000 rpm, and the supernatant collected. Myeloperoxidase (MPO)    activity
 assay was performed using a microplate spectrophotometer (Spectra Max    34; Mo
lecular Devices, Sunnyvale, CA, USA). Briefly, the assay consisted of    mixing 
a 5 &#181;L sample with 200 mL of o-dianisidine solution (0.167 mg/mL    o-diani
sidine dihydrochoride; 0.0005% hydrogen peroxide) prior to reading the    plate.
 The changes in absorbance were measured at 460 nm recorded at intervals    of 1
5 sec during 10 min. MPO activity was expressed as units of enzyme activity    p
er milligram of tissue (UMPO)/mg. One unit of MPO was defined the enzyme amount 
   that degrades one micromole of peroxide/min at 25&#186;C<SUP>5</SUP>. </font>
</p>      ^cY#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#51#47#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00328000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009400075002001300169#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#52#48#article#150#<p><font face="Verda
na" size="2"><I>Determination of serum cytokines</I> </font></p>      ^cY#a08v26
n1.htm##
00488000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025400075002001300329#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#53#49#article#150#<p><font face="Verda
na" size="2"> Serum levels of TNF-&#945;, IL-1&szlig;, IL-6 and IL-10 were measu
red using commercially    available ELISA according to the manufacturer's instru
ctions (R &amp; D Systems,    Minneapolis, MN, USA). </font></p>      ^cY#a08v26
n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#54#50#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00316000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008200075002001300157#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#55#51#article#150#<p><font face="Verda
na" size="2"><I>Statistical analysis</I> </font></p>      ^cY#a08v26n1.htm##
00980000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704074600075002001300821#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#56#52#article#150#<p><font face="Verda
na" size="2"> Statistical analysis was performed using the    software Stata 9.2
. All variables were tested for normal distribution using    Shapiro-Wilks W-tes
t. When normally distributed (parametric data), data were    presented as mean &
#177; standard error of mean (SEM), applying the Student    t-test. Nonparametri
c data were analyzed using Mann-Whitney test, and are presented    as median and
 interquartile range (p 25-75). For intra-group comparison of nonparametric    v
ariables (MPO, extravasation of serum proteins, pH, PaCO<SUB>2</SUB>, PaO<SUB>2<
/SUB>,    BE and SO<SUB>2</SUB>) Wilcoxon test was used. Differences were consid
ered statistically    significant for all analysis if p&lt;0.05. </font></p>    
  ^cY#a08v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#57#53#article#150#<p>&nbsp; </p>     ^
cY#a08v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#58#54#article#150#<p><font face="Verda
na" size="3"><B>Results</B> </font></p>      ^cY#a08v26n1.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010300075002001300178#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#59#55#article#150#<p><font face="Verda
na" size="2"><I> Pulmonary serum protein extravasation</I>    </font></p>      ^
cY#a08v26n1.htm##
00595000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036100075002001300436#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#60#56#article#150#<p><font face="Verda
na" size="2"> <a href="#img01">Figure 1</a> shows that pulmonary    serum protei
n extravasation in EG did not significantly change between right    and left lun
gs (p=0.196). On the other hand, the protein extravasation was significantly    
lower in both right (p=0.014) and left lungs (p=0.039) when compared with CG.   
 </font></p>     ^cY#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#61#57#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#62#58#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#63#59#article#150#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a08img01.jpg"><a name="img01"></a></p>     ^cY#a
08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#64#60#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#65#61#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00411000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017700075002001300252#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#66#62#article#150#<p><font face="Verda
na" size="2"> In CG was observed increased leakage values    on the right side (
p=0.041), with analysis performed by Wilcoxon test.      </font></p>     ^cY#a08
v26n1.htm##
00434000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020000075002001300275#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#67#63#article#150#<p><font face="Verda
na" size="2">The lung wet/dry weight ratio revealed no significant    difference
s between groups (p=0.081 for the right lung and p=0.478 for the left    lung). 
</font></p>     ^cY#a08v26n1.htm##
00363000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012900075002001300204#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#68#64#article#150#<p><font face="Verda
na" size="2"><I> MPO activity as a marker for pulmonary neutrophil    sequestrat
ion</I> </font></p>      ^cY#a08v26n1.htm##
00510000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027600075002001300351#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#69#65#article#150#<p><font face="Verda
na" size="2"> The MPO activity did not significantly differ    between any studi
ed groups (<a href="#img02">Figure 2</a>). No significant differences    were al
so found when intra-group analysis (right and left lungs) were compared.    </fo
nt></p>     ^cY#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#70#66#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#71#67#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#72#68#article#150#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a08img02.jpg"><a name="img02"></a></p>     ^cY#a
08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#73#69#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#74#70#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009500075002001300170#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#75#71#article#150#<p><font face="Verda
na" size="2"><I> Markers of systemic inflammation</I> </font></p>      ^cY#a08v2
6n1.htm##
00446000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021200075002001300287#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#76#72#article#150#<p><font face="Verda
na" size="2"> The levels of IL-1&szlig;, TNF- and IL-10 in    serum in both grou
ps (CG and EG) were below the limit of detection, as evaluated    by ELISA kit (
62.5pg/mL). </font></p>     ^cY#a08v26n1.htm##
00376000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704014200075002001300217#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#77#73#article#150#<p><font face="Verda
na" size="2"> The cytokine IL-6 was detected only at EG, with    mean value of 1
.11 &#177; 0.5 ng/mL. </font></p>     ^cY#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#78#74#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009500075002001300170#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#79#75#article#150#<p><font face="Verda
na" size="2"><i>Gasometric and hemodynamic behavior</i></font></p>     ^cY#a08v2
6n1.htm##
00894000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704066000075002001300735#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#80#76#article#150#<p> <font face="Verd
ana" size="2">The initial and final blood gas measurements    did not differ sig
nificantly in any parameter (pH, PaO<SUB>2</SUB>, PaCO<SUB>2</SUB>,    HCO<SUB>3
</SUB>-, BE and SO<SUB>2</SUB>), as presented in <a href="/img/revistas/acb/v26n
1/a08tab01.jpg">Table    1</a>. With respect to the MAP, operated group animals 
showed 114 mmHg as average    value throughout the experiment, and the average v
ariation between the highest    and lowest MAP recorded values was 38.6 mmHg. No
 animal showed hemodynamic instability    throughout the surgical protocol, and 
all of them tolerated the established    ventilation time. </font></p>      ^cY#
a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#81#77#article#150#<p>&nbsp;</p>     ^c
Y#a08v26n1.htm##
00306000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007200075002001300147#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#82#78#article#150#<p><font face="Verda
na" size="3"><B>Discussion</B> </font></p>      ^cY#a08v26n1.htm##
00789000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055500075002001300630#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#83#79#article#150#<p><font face="Verda
na" size="2"> Animal models provide homogeneous, reproductive    and comparable 
samples, which are not always achieved in clinical trials<SUP>3</SUP>.    In rat
s specifically, animals are easily manipulated and allow procedures that    woul
d be difficult to perform in mice<SUP>6</SUP>. National literature reports    th
e use of small animals under prolonged ventilation times, but no study exists   
 evaluating the impact of prolonged ventilation and anesthetic times in animals 
   undergoing surgical procedures. </font></p>     ^cY#a08v26n1.htm##
00643000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040900075002001300484#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#84#80#article#150#<p><font face="Verda
na" size="2"> Our purpose was to standardize a rat model that    incorporate gen
eral anesthesia, invasive mechanical ventilation, thoracic manipulative    proce
dures and prolonged operative time that produces no pulmonary inflammation    it
self (evaluated by MPO activity measurement and serum protein extravasation)    
and minimal impact in hemodynamic and gasometry. </font></p>     ^cY#a08v26n1.ht
m##
00515000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028100075002001300356#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#85#81#article#150#<p><font face="Verda
na" size="2"> Our choice for pressure-controlled ventilation    took into consid
eration the reduction of barotrauma risk, and the best ventilation/perfusion    
ratio (V/Q) when compared with the volume-controlled ventilation<SUP>7</SUP>.   
 </font></p>     ^cY#a08v26n1.htm##
00994000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704076000075002001300835#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#86#82#article#150#<p><font face="Verda
na" size="2"> The anesthetic agent isoflurane to induce hyperdynamic<SUP>8</SUP>
    instead of depressing response, proved to be a good option for the surgical 
   procedures with long duration. The use of volatile anesthetics was initially 
   questioned, because of its potential    influences in the target-organ on the
 inflammatory parameters. The lung, which    is the absorption route of isoflura
ne, would be exposed to its action; however,    previous studies rather show a p
rotective effect of volatile anesthetics in    pulmonary lesions, such as those 
induced by ischemia-reperfusion<SUP>9</SUP>.    Besides not causing lung inflamm
ation itself in rats, isoflurane is currently    employed in clinical practice. 
</font></p>     ^cY#a08v26n1.htm##
01564000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704133000075002001301405#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#87#83#article#150#<p><font face="Verda
na" size="2"> It is well-known that blood pressure varies    during surgery that
 may be due to changes in the central nervous system, cardiac    or respiratory,
 with the anesthesia contributing to this disturbance<SUP>10</SUP>.    After ane
sthesia induction and intubation, there is an initial period with minimum    sti
mulation that is often associated with hypotension, followed by periods of    in
tense stimulation (as evidenced in the skin incision and sternotomy), which    m
ay lead to tachycardia and hypertension<SUP>11</SUP>. Anesthetic agents should  
  be used appropriately in anticipation of these events<SUP>11</SUP>. In our stu
dy,    a stable hemodynamic response was achieved, as characterized by the absen
ce    of hemodynamic fluctuations from beginning to end of the experiment. We th
us    achieved an appropriate anesthetic-surgical procedure that is not usually 
seen    with other agents such as urethane, thiopental and the mixture of ketami
ne and    xylasine. Our gasometric data confirms the good conditions of our expe
rimental    procedures, provided no alterations in pH and gas analysis, excludin
g changes       in acid-base status which disturbing many enzymatic functions in
 biological    systems<SUP>12</SUP> occurs under the experimental conditions we 
employed. </font></p>     ^cY#a08v26n1.htm##
02453000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704221900075002001302294#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#88#84#article#150#<p><font face="Verda
na" size="2"> We also decided to evaluate the pulmonary inflammatory    conditio
ns of rats since they were under the influence of thoracotomy and mechanical    
ventilation. Increased permeability in the inflamed area results in loss of    f
luid and plasma proteins into tissues<SUP>13</SUP>. Our data showed that pulmona
ry    serum extravasation was lower in animal undergoing mechanical ventilation 
with    positive pressure compared with control rats. We believe this phenomenon
 is    a consequence of the pulmonary physiology and ventilatory mechanics. The 
mechanical    ventilation with positive pressure alters the cardiac performance 
when compared    to spontaneous breathing<SUP>14</SUP>. Under physiological brea
thing, the negative    pressure phase during the inspiration favors venous retur
n, relieves pressure    on the pulmonary capillaries and stimulates the flow; in
 contrast, with the    positive pressure ventilation, intrathoracic pressure inc
reases during inspiration    causing a decrease in venous return, in right ventr
icular output and in pulmonary    blood flow<SUP>15</SUP>. At expiration, the ve
nous return increases; however,    if PEEP is employed, the continuous positive 
intrathoracic pressure inhibits    venous return also during expiration<SUP>15</
SUP>. This may explain the lower    serum protein leakage seen in rats undergoin
g positive pressure through the    ventilatory cycle. PEEP was likely to be resp
onsible for increasing the interstitial    pressure, reducing the pressure gradi
ent between the vascular and interstitial    space<SUP>16</SUP>. In clinical pra
ctice, the use of positive pressure is routinely    used since moderate degrees 
of PEEP may limit the pulmonary edema formation<SUP>16</SUP>.    Furthermore, ex
posure of thoracic cavity to atmospheric pressure after thoracotomy    influence
s the strength of extra-alveolar vessels representing one more influential    fa
ctor on the lung perfusion in the operated animals group. The protein extravasat
ion    response was not observed when using the wet/dry lung weight analysis. Th
e lower    specificity of the gravimetric evaluation (wet/dry weight) may explai
n this    finding. </font></p>     ^cY#a08v26n1.htm##
02152000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704191800075002001301993#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#89#85#article#150#<p><font face="Verda
na" size="2"> Neutrophils are prominent in inflammation, because    they migrate
 directed by chemotactic gradients into the injured site and release    the cont
ents of their granules, which play a central role in the early inflammatory    r
esponse<SUP>17</SUP>. The MPO present in azurophilic granules of neutrophils    
generates oxygen reactive species, enhances the cytotoxic state and contributes 
   to inflammatory response<SUP>18</SUP>. The MPO enzymatic activity can be used
    as a marker for neutrophils sequestration<SUP>19</SUP>. In this work, the MP
O    activity did not differ significantly between groups, reinforcing the low g
rade    of injury caused by surgical and ventilatory technique in the immediate 
postoperative    evaluation. Moreover, we did not detect significant amounts of 
TNF-&#945; and IL-1&szlig; (along with the absence of the IL-10) in serum    of 
rats undergoing thoracotomy and mechanical ventilation. TNF-&#945; and IL-1&szli
g; are well-recognized to cause endothelial cell    damage and hence increased p
ermeability, and induce neutrophil transmigration    through the vascular endoth
elial membrane<SUP>14</SUP>, whereas the anti-inflammatory    IL-10 is present u
nder inflammatory conditions, yielding clinical protection    and reduction of l
ung pathology<SUP>20</SUP>. We may not neglect that volatile    anesthetics act 
negatively modulating the inflammatory response (and TNF-&#945; release) as demo
nstrated in    experimental models of ischemia and reperfusion<SUP>9</SUP>. Furt
hermore, this    study detected IL-6 serum only in animals undergoing surgery. A
n important finding    to consider is that although systemically expressed, this
 cytokine did not promote    the neutrophils recruitment to lung tissue in GE an
imals as demonstrated through    the absence of significant difference in MPO ac
tivity between the studied groups.    </font></p>     ^cY#a08v26n1.htm##
00553000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031900075002001300394#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#90#86#article#150#<p><font face="Verda
na" size="2"> Lastly, zero mortality index was detected in    our study, which a
llows us to support that, after several preliminary studies,    we develop a bio
logically correct model for inflammation study in lung surgical    procedures wi
th long anesthetic-surgical duration. </font></p>      ^cY#a08v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#91#87#article#150#<p>&nbsp; </p>     ^
cY#a08v26n1.htm##
00306000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007200075002001300147#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#92#88#article#150#<p><font face="Verda
na" size="3"><B>Conclusion</B> </font></p>      ^cY#a08v26n1.htm##
00507000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027300075002001300348#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#93#89#article#150#<p><font face="Verda
na" size="2"> The experimental mechanical ventilation in rats    with a prolonge
d surgical time did not produce significant local and systemic    inflammatory c
hanges and permit to evaluate others procedures in thoracic surgery.    </font><
/p>      ^cY#a08v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#94#90#article#150#<p>&nbsp; </p>     ^
cY#a08v26n1.htm##
00306000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007200075002001300147#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#95#91#article#150#<p><font face="Verda
na" size="3"><B>References</B> </font></p>      ^cY#a08v26n1.htm##
00399000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704015100077002001300228#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#96#92#article#150#1#<p><fo
nt face="Verdana" size="2">1. Gothard J. Lung injury after thoracic and    one-l
ung ventilation. Curr Opin Anaesthesiol. 2006;19(1):5-10.    ^cY#a08v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#97#93#article#150# </font></p>     ^cY
#a08v26n1.htm##
00421000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704017300077002001300250#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#98#94#article#150#2#<p><fo
nt face="Verdana" size="2">2. Matute-Bello G, Frevert CW, Martin TR. Animal    m
odels of acute lung injury. Am J Physiol Cell Mol Physiol. 2008;295(3):L379-99. 
   ^cY#a08v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002400075002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#99#95#article#150#    </font></p>     
^cY#a08v26n1.htm##
00446000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000200076704019700078002001300275#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#100#96#article#150#3#<p><f
ont face="Verdana" size="2">3. Braeuninger S, Kleinschnitz C. Rodent models    o
f focal ischemia: procedural pitfalls and translational problems. Exp Transl    
Stroke Med. 2009;25:1-8.    ^cY#a08v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#101#97#article#150# </font></p>     ^c
Y#a08v26n1.htm##
00491000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000200076704024200078002001300320#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#102#98#article#150#4#<p><f
ont face="Verdana" size="2">4. Brain SD, Williams TJ. Inflammatory oedema    ind
uced by synergism between calcitonin gene-related peptide (CGRP) and mediators  
  of increased vascular permeability. Br J Pharmacol. 1985;86:855-60.    ^cY#a08
v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#103#99#article#150# </font></p>     ^c
Y#a08v26n1.htm##
00484000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704023400079002001300313#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#104#100#article#150#5#<p><
font face="Verdana" size="2">5. Bradley PP, Priebat DA, Christensen RD, Rothstei
n    G. Measurement of cutaneous inflammation: estimation of neutrophil content 
with    an enzyme marker. J Invest Dermatol. 1982;78(3):206-9.    ^cY#a08v26n1.h
tm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#105#101#article#150# </font></p>     ^
cY#a08v26n1.htm##
00495000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704024500079002001300324#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#106#102#article#150#6#<p><
font face="Verdana" size="2">6. Chang KP,&#160;Huang SH,&#160;Lin CL,&#160;Chang
    LL,&#160;Lin SD,&#160;Lai CS. An alternative model of composite tissue allot
ransplantation:    groin-thigh flap. Transpl Int.&#160;2008;21(6):564-71.    ^cY
#a08v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#107#103#article#150# </font></p>     ^
cY#a08v26n1.htm##
00473000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704022300079002001300302#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#108#104#article#150#7#<p><
font face="Verdana" size="2">7. Unzueta MC, Casas JI, Moral MV. Pressure-control
led    versus volume-controlled ventilation during one-lung ventilation for thor
acic    surgery. Anesth Analg. 2007;104(5):1029-33.    ^cY#a08v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#109#105#article#150# </font></p>     ^
cY#a08v26n1.htm##
00543000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704029300079002001300372#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#110#106#article#150#8#<p><
font face="Verdana" size="2">8. Tanaka S, Tsuchida H, Nakabayashi K, Seki    S, 
Namiki A. The effects of sevoflurane, isoflurane, halothane, and enflurane    on
 hemodynamic responses during an inhaled induction of anesthesia via a mask    i
n humans. Anesth Analg. 1996;82(4):821-6.    ^cY#a08v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#111#107#article#150# </font></p>     ^
cY#a08v26n1.htm##
00483000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704023300079002001300312#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#112#108#article#150#9#<p><
font face="Verdana" size="2">9. Liu R, Ishibe Y, Ueda M. Isoflurane-sevoflurane 
   administration before ischemia attenuates ischemia-reperfusion-induced injury
    in isolated rat lungs. Anesthesiology. 2000;92(3):833-40.    ^cY#a08v26n1.ht
m##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#113#109#article#150# </font></p>     ^
cY#a08v26n1.htm##
00627000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704037600080002001300456#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#114#110#article#150#10#<p>
<font face="Verdana" size="2">10. Lima RC, Escobar MAS, Diniz R, D&#180;Aconda  
  G, Bergsland J, Salermo T. Avalia&ccedil;&atilde;o hemodin&acirc;mica intra-op
erat&oacute;ria    na cirurgia de revasculariza&ccedil;&atilde;o do mioc&aacute;
rdio sem o aux&iacute;lio    de circula&ccedil;&atilde;o extracorp&oacute;rea. R
ev Bras Circ Cardiovasc.    2000;15(3)201-11.    ^cY#a08v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#115#111#article#150# </font></p>     ^
cY#a08v26n1.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024900080002001300329#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#116#112#article#150#11#<p>
<font face="Verdana" size="2">11. Basagan-Mogol E, Goren S, Korfali G, Turker   
 G, Kaya FN. Induction of anesthesia in coronary artery bypass graft surgery:   
 the hemodynamic and analgesic effects of ketamine. Clinics. 2010;65(2):133-8.  
  ^cY#a08v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#117#113#article#150#    </font></p>   
  ^cY#a08v26n1.htm##
00507000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025600080002001300336#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#118#114#article#150#12#<p>
<font face="Verdana" size="2">12. Fuentes JM, Hanly EJ, Bachman SL, Aurora    AR
, Marohn MR, Talamini MA. Videoendoscopic endotracheal intubation in the rat:   
 a comprehensive rodent model of laparoscopic surgery. J Surg Res. 2004;122(2):2
40-8.    ^cY#a08v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#119#115#article#150#    </font></p>   
  ^cY#a08v26n1.htm##
00458000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020700080002001300287#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#120#116#article#150#13#<p>
<font face="Verdana" size="2">13. Lawrence T, Wlloughby DA, Gilroy DW. Anti-infl
ammatory    lipid mediators and insights into the resolution of inflammation. Na
t Rev Immunol.    2002;2(10):787-95.    ^cY#a08v26n1.htm##
00402000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704015100080002001300231#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#121#117#article#150#14# 14
. Lewis CA, Martin GS. Understanding and managing fluid    balance in patients w
ith acute lung injury. Curr Opin Crit Care. 2004;10(1):13-7.    ^cY#a08v26n1.htm
##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#122#118#article#150#    </font></p>   
  ^cY#a08v26n1.htm##
00406000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704015500080002001300235#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#123#119#article#150#15#<p>
<font face="Verdana" size="2">15. Soni N, Willians P. Positive pressure ventilat
ion:    what is the real cost? Br J Anaesth. 2008;101(4):446-57.    ^cY#a08v26n1
.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#124#120#article#150# </font></p>     ^
cY#a08v26n1.htm##
00573000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704032200080002001300402#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#125#121#article#150#16#<p>
<font face="Verdana" size="2">16. Schumann S, Kirschbaum A, Schliessmann SJ,    
Wagner G, Goebel U, Priebe HJ, Guttmann J. Low pulmonary artery flush perfusion 
   pressure combined with high positive end-expiratory pressure reduces oedema  
  formation in isolated porcine lungs. Physiol Meas. 2010;31(2):261-72.    ^cY#a
08v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#126#122#article#150# </font></p>     ^
cY#a08v26n1.htm##
00440000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018900080002001300269#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#127#123#article#150#17#<p>
<font face="Verdana" size="2">17. Soehnlein O,&#160;Weber C,&#160;Lindbom L.    
Neutrophil granule proteins tune monocytic cell function. Trends Immunol.&#160;2
009;30(11):538-46.    ^cY#a08v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#128#124#article#150#    </font></p>   
  ^cY#a08v26n1.htm##
00560000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704030900080002001300389#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#129#125#article#150#18#<p>
<font face="Verdana" size="2">18. Grattendick K, Stuart R, Roberts E, Lincoln   
 J, Lefkowitz SS, Bollen A, Moguilevsky N, Friedman H, Lefkowitz DL. Alveolar   
 macrophage activation by mieloperoxidase. A model for exacerbation of lung infl
ammation.    Am J Respir Cell Mol Biol. 2002;26(6):716-22.    ^cY#a08v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#130#126#article#150# </font></p>     ^
cY#a08v26n1.htm##
00463000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021200080002001300292#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#131#127#article#150#19#<p>
<font face="Verdana" size="2">19. Ferreira ALA, Matsubara LS. Radicais livres:  
  conceitos, doen&ccedil;as relacionadas, sistema de defesa e estresse oxidativo
.    Rev Assoc Med Bras. 1997;43(1):61-8.    ^cY#a08v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#132#128#article#150# </font></p>     ^
cY#a08v26n1.htm##
00440000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018900080002001300269#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#p#133#129#article#150#20#<p>
<font face="Verdana" size="2">20. Morrison DF, Foss DL, Murtaugh MP. Interleukin
-10    gene therapy-mediated amelioration of bacterial pneumonia. Infect Immun. 
2000;68(8):4752-8.    ^cY#a08v26n1.htm##
00262000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002600077002001300103#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#134#130#article#150#    </font></p>   
    ^cY#a08v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#135#131#article#150#<p>&nbsp;</p>     
^cY#a08v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#136#132#article#150#<p>&nbsp;</p>     
^cY#a08v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#137#133#article#150#<p>&nbsp;</p>     
^cY#a08v26n1.htm##
00397000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704016100077002001300238#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#138#134#article#150#<p><font face="Ver
dana" size="2"><B><a name="end"></a><a href="#top"><img src="/img/revistas/acb/v
26n1/seta.gif" border="0"></a>Correspondence</B>:&#160;    ^cY#a08v26n1.htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003400077002001300111#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#139#135#article#150#<br>   Ricardo Kal
af Mussi    ^cY#a08v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704008400077002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#140#136#article#150#<br>   Departament
o de Cirurgia _ Faculdade de Ci&ecirc;ncias M&eacute;dicas    ^cY#a08v26n1.htm##
00284000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004800077002001300125#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#141#137#article#150#<br>   Universidad
e Estadual de Campinas    ^cY#a08v26n1.htm##
00293000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005700077002001300134#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#142#138#article#150#<br>   Rua Tess&aa
cute;lia Vieira de Camargo, 126    ^cY#a08v26n1.htm##
00281000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004500077002001300122#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#143#139#article#150#<br>   13083-887 C
ampinas - SP Brasil    ^cY#a08v26n1.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003800077002001300115#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#144#140#article#150#<br>   Phone: (55 
19)3521-9441    ^cY#a08v26n1.htm##
00272000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003600077002001300113#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#145#141#article#150#<br>   Fax: (55 19
)3521-8043    ^cY#a08v26n1.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007700077002001300154#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#146#142#article#150#<br>   <a href="ma
ilto:rkm@unicamp.br">rkm@unicamp.br</a></font></p>     ^cY#a08v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#147#143#article#150#<p>&nbsp;</p>     
^cY#a08v26n1.htm##
00300000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006400077002001300141#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#148#144#article#150#<p><font face="Ver
dana" size="2">Received: July 13, 2010    ^cY#a08v26n1.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#149#145#article#150#<br>   </font><fon
t face="Verdana" size="2">Review: September 14, 2010    ^cY#a08v26n1.htm##
00326000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009000077002001300167#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#150#146#article#150#<br>   </font><fon
t face="Verdana" size="2">Accepted: October 20, 2010</font></p>     ^cY#a08v26n1
.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006700077002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#151#147#article#150#<p><font face="Ver
dana" size="2">Conflict of interest: none    ^cY#a08v26n1.htm##
00335000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009900077002001300176#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#152#148#article#150#<br>   </font><fon
t face="Verdana" size="2">Financial source: CAPES and FAPESP </font></p>     ^cY
#a08v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#153#149#article#150#<p>&nbsp;</p>     
^cY#a08v26n1.htm##
00504000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704026800077002001300345#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a08v26n1.htm#S#p#154#150#article#150#<p><font face="Ver
dana" size="2"><sup><a name="end"></a><a href="#top">1</a> </sup>Research    per
formed at the Laboratory of Inflammation, Department of Pharmacology, Faculty   
 of Medical Sciences, State University of Campinas (UNICAMP), Brazil. </font></p
>     ^cY#a08v26n1.htm##
00487000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760120056000930300
02400149710000200173065000900175064000500184031000300189032000200192014000500194
865000900199002001300208#v26n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#
c#155#1#article#20#1#^rND^sGothard^nJ#Lung injury after thoracic and one-lung ve
ntilation^len#Curr Opin Anaesthesiol.#2#20060000#2006#19#1#5-10#20110200#a08v26n
1.htm##
00545000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100022000760100018000980100
01700116012003900133030003100172710000200203065000900205064000500214031000400219
032000200223014000800225865000900233002001300242#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a08v26n1.htm#S#c#156#2#article#20#2#^rND^sMatute-Bello^nG#^rND^sFrevert
^nCW#^rND^sMartin^nTR#Animal models of acute lung injury^len#Am J Physiol Cell M
ol Physiol.#2#20080000#2008#295#3#L379-99#20110200#a08v26n1.htm##
00537000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100021000760100022000970120
08400119030002300203710000200226065000900228064000500237031000300242014000400245
865000900249002001300258#v26n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#
c#157#3#article#20#3#^rND^sBraeuninger^nS#^rND^sKleinschnitz^nC#Rodent models of
 focal ischemia: procedural pitfalls and translational problems^len#Exp Transl S
troke Med.#2#20090000#2009#25#1-8#20110200#a08v26n1.htm##
00582000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100019000920120
14100111030001600252710000200268065000900270064000500279031000300284014000700287
865000900294002001300303#v26n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#
c#158#4#article#20#4#^rND^sBrain^nSD#^rND^sWilliams^nTJ#Inflammatory oedema indu
ced by synergism between calcitonin gene-related peptide (CGRP) and mediators of
 increased vascular permeability^len#Br J Pharmacol.#2#19850000#1985#86#855-60#2
0110200#a08v26n1.htm##
00621000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100018000940100
02200112010001900134012009800153030001900251710000200270065000900272064000500281
031000300286032000200289014000600291865000900297002001300306#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a08v26n1.htm#S#c#159#5#article#20#5#^rND^sBradley^nPP#^rND^
sPriebat^nDA#^rND^sChristensen^nRD#^rND^sRothstein^nG#Measurement of cutaneous i
nflammation: estimation of neutrophil content with an enzyme marker^len#J Invest
 Dermatol.#2#19820000#1982#78#3#206-9#20110200#a08v26n1.htm##
00669000000000337000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100016000920100
01400108010001600122010001400138010001400152012008300166030001200249065000900261
06400050027003100030027503200020027801400070028086500090028700200130029603500100
0309801001200319#v26n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#c#160#6#
article#20#6#^rND^sChang^nKP#^rND^sHuang^nSH#^rND^sLin^nCL#^rND^sChang^nLL#^rND^
sLin^nSD#^rND^sLai^nCS#An alternative model of composite tissue allotransplantat
ion: groin-thigh flap^len#Transpl Int#20080000#2008#21#6#564-71#20110200#a08v26n
1.htm#0934-0874#Transpl Int##
00592000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100016000940100
01600110012011000126030001400236710000200250065000900252064000500261031000400266
032000200270014000800272865000900280002001300289#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a08v26n1.htm#S#c#161#7#article#20#7#^rND^sUnzueta^nMC#^rND^sCasas^nJI#^
rND^sMoral^nMV#Pressure-controlled versus volume-controlled ventilation during o
ne-lung ventilation for thoracic surgery^len#Anesth Analg.#2#20070000#2007#104#5
#1029-33#20110200#a08v26n1.htm##
00695000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100018000920100
02100110010001400131010001600145012015700161030001400318710000200332065000900334
064000500343031000300348032000200351014000600353865000900359002001300368#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#c#162#8#article#20#8#^rND^sTanak
a^nS#^rND^sTsuchida^nH#^rND^sNakabayashi^nK#^rND^sSeki^nS#^rND^sNamiki^nA#The ef
fects of sevoflurane, isoflurane, halothane, and enflurane on hemodynamic respon
ses during an inhaled induction of anesthesia via a mask in humans^len#Anesth An
alg.#2#19960000#1996#82#4#821-6#20110200#a08v26n1.htm##
00602000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100013000760100016000890100
01400105012012700119030001600246710000200262065000900264064000500273031000300278
032000200281014000700283865000900290002001300299#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a08v26n1.htm#S#c#163#9#article#20#9#^rND^sLiu^nR#^rND^sIshibe^nY#^rND^s
Ueda^nM#Isoflurane-sevoflurane administration before ischemia attenuates ischemi
a-reperfusion-induced injury in isolated rat lungs^len#Anesthesiology.#2#2000000
0#2000#92#3#833-40#20110200#a08v26n1.htm##
00713000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100019000930100
01500112010001800127010001900145010001700164012013100181030002500312710000200337
06500090033906400050034803100030035303200020035601400070035886500090036500200130
0374#v26n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#c#164#10#article#20#
10#^rND^sLima^nRC#^rND^sEscobar^nMAS#^rND^sDiniz^nR#^rND^sD´Aconda^nG#^rND^sBerg
sland^nJ#^rND^sSalermo^nT#Avaliação hemodinâmica intra-operatória na cirurgia de
 revascularização do miocárdio sem o auxílio de circulação extracorpórea^lpt#Rev
 Bras Circ Cardiovasc#2#20000000#2000#15#3#201-11#20110200#a08v26n1.htm##
00655000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100023000780100015001010100
01700116010001600133010001500149012011900164030000900283710000200292065000900294
064000500303031000300308032000200311014000600313865000900319002001300328#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#c#165#11#article#20#11#^rND^sBas
agan-Mogol^nE#^rND^sGoren^nS#^rND^sKorfali^nG#^rND^sTurker^nG#^rND^sKaya^nFN#Ind
uction of anesthesia in coronary artery bypass graft surgery: the hemodynamic an
d analgesic effects of ketamine^len#Clinics.#2#20100000#2010#65#2#133-8#20110200
#a08v26n1.htm##
00680000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960100
01800112010001700130010001700147010001900164012010900183030001200292710000200304
06500090030606400050031503100040032003200020032401400060032686500090033200200130
0341#v26n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#c#166#12#article#20#
12#^rND^sFuentes^nJM#^rND^sHanly^nEJ#^rND^sBachman^nSL#^rND^sAurora^nAR#^rND^sMa
rohn^nMR#^rND^sTalamini^nMA#Videoendoscopic endotracheal intubation in the rat: 
a comprehensive rodent model of laparoscopic surgery^len#J Surg Res.#2#20040000#
2004#122#2#240-8#20110200#a08v26n1.htm##
00577000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100020000960100
01700116012008700133030001700220710000200237065000900239064000500248031000200253
032000300255014000700258865000900265002001300274#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a08v26n1.htm#S#c#167#13#article#20#13#^rND^sLawrence^nT#^rND^sWlloughby
^nDA#^rND^sGilroy^nDW#Anti-inflammatory lipid mediators and insights into the re
solution of inflammation^len#Nat Rev Immunol.#2#20020000#2002#2#10#787-95#201102
00#a08v26n1.htm##
00538000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100017000940120
08000111030002100191710000200212065000900214064000500223031000300228032000200231
014000500233865000900238002001300247#v26n1#V:\Scielo\serial\acb\v26n1\markup\a08
v26n1.htm#S#c#168#14#article#20#14#^rND^sLewis^nCA#^rND^sMartin^nGS#Understandin
g and managing fluid balance in patients with acute lung injury^len#Curr Opin Cr
it Care.#2#20040000#2004#10#1#13-7#20110200#a08v26n1.htm##
00543000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100018000920120
05800110030001300168065000900181064000500190031000400195032000200199014000700201
865000900208002001300217035001000230801001300240#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a08v26n1.htm#S#c#169#15#article#20#15#^rND^sSoni^nN#^rND^sWillians^nP#P
ositive pressure ventilation: what is the real cost?^len#Br J Anaesth#20080000#2
008#101#4#446-57#20110200#a08v26n1.htm#0007-0912#Br J Anaesth##
00761000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100020000960100
02300116010001600139010001600155010001700171010001800188012015300206030001400359
71000020037306500090037506400050038403100030038903200020039201400070039486500090
0401002001300410#v26n1#V:\Scielo\serial\acb\v26n1\markup\a08v26n1.htm#S#c#170#16
#article#20#16#^rND^sSchumann^nS#^rND^sKirschbaum^nA#^rND^sSchliessmann^nSJ#^rND
^sWagner^nG#^rND^sGoebel^nU#^rND^sPriebe^nHJ#^rND^sGuttmann^nJ#Low pulmonary art
ery flush perfusion pressure combined with high positive end-expiratory pressure
 reduces oedema formation in isolated porcine lungs^len#Physiol Meas.#2#20100000
#2010#31#2#261-72#20110200#a08v26n1.htm##
00546000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100015000970100
01700112012006100129030001500190710000200205065000900207064000500216031000300221
032000300224014000700227865000900234002001300243#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a08v26n1.htm#S#c#171#17#article#20#17#^rND^sSoehnlein^nO#^rND^sWeber^nC
#^rND^sLindbom^nL#Neutrophil granule proteins tune monocytic cell function^len#T
rends Immunol#2#20090000#2009#30#11#538-46#20110200#a08v26n1.htm##
00829000000000373000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100021000780100016000990100
01700115010001700132010002000149010001600169010002100185010001800206010002000224
01201010024403000260034506500090037106400050038003100030038503200020038801400070
0390865000900397002001300406035001000419801002600429#v26n1#V:\Scielo\serial\acb\
v26n1\markup\a08v26n1.htm#S#c#172#18#article#20#18#^rND^sGrattendick^nK#^rND^sSt
uart^nR#^rND^sRoberts^nE#^rND^sLincoln^nJ#^rND^sLefkowitz^nSS#^rND^sBollen^nA#^r
ND^sMoguilevsky^nN#^rND^sFriedman^nH#^rND^sLefkowitz^nDL#Alveolar macrophage act
ivation by mieloperoxidase. A model for exacerbation of lung inflammation^len#Am
 J Respir Cell Mol Biol#20020000#2002#26#6#716-22#20110200#a08v26n1.htm#1044-154
9#Am J Respir Cell Mol Biol##
00557000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100020000980120
09300118030002000211710000200231065000900233064000500242031000300247032000200250
014000500252865000900257002001300266#v26n1#V:\Scielo\serial\acb\v26n1\markup\a08
v26n1.htm#S#c#173#19#article#20#19#^rND^sFerreira^nALA#^rND^sMatsubara^nLS#Radic
ais livres: conceitos, doenças relacionadas, sistema de defesa e estresse oxidat
ivo^lpt#Rev Assoc Med Bras.#2#19970000#1997#43#1#61-8#20110200#a08v26n1.htm##
00562000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100015000970100
01900112012007700131030001400208710000200222065000900224064000500233031000300238
032000200241014000700243865000900250002001300259#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a08v26n1.htm#S#c#174#20#article#20#20#^rND^sMorrison^nDF#^rND^sFoss^nDL
#^rND^sMurtaugh^nMP#Interleukin-10 gene therapy-mediated amelioration of bacteri
al pneumonia^len#Infect Immun.#2#20000000#2000#68#8#4752-8#20110200#a08v26n1.htm
##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#o#1#1#article#1#
20110120#130148#a09v26n1.htm#243##
04075000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400090014103500100015001200850
01600120083002450100032003280100035003600100039003950700086004340700052005200700
03400572083124200606085000801848085001901856085002401875085002401899085001701923
08312800194008500080322008500170322808500260324508500250327108500180329611700060
33140720003033201120009033231110014033321160009033461150019033551140009033741130
01703383002001303400#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#h#2#
1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#09#ACB720#nd#Acta Cir. Bras.#26#1#2011020
0#^f44^l50#0102-8650#Subtotal laparoscopic splenectomy in rats with preservation
 of the inferior pole^len#Esplenectomia subtotal laparoscópica com preservação d
o polo inferior em ratos^lpt#^rND^1A01^nJosé Jorge da^sSilva#^rND^1A02^nAlcino L
ázaro da^sSilva#^rND^1A03^nDanilo Nagib Salomão^sPaulo#Minas Gerais Federal Univ
ersity^iA01^1Postgraduate Program in General Surgery^pBrazil#UFMG^iA02^1School o
f Medicine^cMinas Gerais^pBrazil#EMESCAM^iA03^cVitoria^sES^pBrazil#^len^aPurpose
: To evaluate the feasibility and safety of subtotal splenectomy by laparoscopy 
with inferior pole preservation and to determine the viability of the splenic re
mnant. Methods: Twenty male Wistar rats weighing between 365 g and 474 g (mean 4
17.92 ± 36.15g SD) were operated and randomly assigned to two groups : Group 1 r
ats were killed on postoperative day 10 (n = 10), and Group 2 on the postoperati
ve day 80 (n = 10). Both the inferior splenic pole and the superior part of the 
spleen, which was used as a control to measure inferior pole viability, were wei
ghed and morphologically examined. Results: The technique was feasible in all ca
ses. There were two postoperative deaths on immediate postoperative and one not 
well defined. The average weight percentage of the inferior pole, measured indir
ectly on the 10th day, was 53.67% ± 11.59% and on the 80th day was 62.69% ± 6.89
%. The inferior pole was necrotic, with abscess formation in one case (5.9%) and
 appeared normal in all other cases. Microscopy showed features that were compat
ible with normality. Conclusions: Subtotal splenectomy with preservation of the 
inferior pole by laparoscopy was feasible and safety. The lower splenic pole was
 viable in 94.1% of animals.#^dnd^i1#^tm^len^kSpleen^i1#^tm^len^kSplenectomy^i1#
^tm^len^kLaparoscopy^i1#^tm^len^kRats^i1#^lpt^aObjetivo: Avaliar a exequibilidad
e e a segurança da esplenectomia subtotal com preservação do polo inferior do ba
ço por videolaparoscopia, e a viabilidade do referido polo. Métodos: 20 ratos Wi
star, machos, pesando entre 365g e 474g (MA 417,92 ± 36,15g) foram operados e di
stribuídos em dois grupos de acordo com a época da retirada do polo inferior par
a estudo: grupo 1 do 10º dia, (n= 10), grupo 2, do 80º dia (n=10). A porção supe
rior do baço que serviu de controle da viabilidade do pólo inferior e esse reman
escente, retirados no término do experimento, foram medidos, pesados e enviados 
para exame morfológico. Resultados: A técnica foi exeqüível em todos os casos. O
 peso médio percentual do polo inferior avaliado de forma indireta no 10º dia fo
i 53,67% ± 11,59%, e no 80º dia 62,69% ± 6,89%. Houve dois óbitos após a cirurgi
a, provavelmente por mal condução da anestesia e/ou do pneumoperitônio, e um tar
diamente por causa desconhecida. O exame macro e microscópico do polo inferior n
os 17 animais sobreviventes e no que faleceu tardiamente mostrou necrose em um c
aso (5,9%). Conclusões: A esplenectomia subtotal com preservação do pólo inferio
r por videolaparoscopia em ratos foi exequível e segura. O polo inferior do baço
 mostrou-se viável em 94,1% dos animais.#^dnd^i2#^tm^lpt^kBaço^i2#^tm^lpt^kEsple
nectomia^i2#^tm^lpt^kLaparoscopia^i2#^tm^lpt^kRatos^i2#other#36#20100727#July 27
, 2010#20100921#September 21, 2010#20101026#October 26, 2010#a09v26n1.htm##
04145000000000661000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400090014103500100015001200920
01600120090002520100032003420100035003740100039004090700086004480700052005340700
03400586083127000620085000801890085001901898085002401917085002401941085001701965
08313080198208500080329008500170329808500260331508500250334108500180336611700060
33840720003033901120009033931110014034021160009034161150019034251140009034441130
01703453002001303470#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#f#3#
1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#09#ACB720#nd#Acta Cir. Bras.#26#1#2011020
0#^f44^l50#0102-8650#<b>Subtotal laparoscopic splenectomy in rats with preservat
ion of the inferior pole</b>^len#<b>Esplenectomia subtotal laparoscópica com pre
servação do polo inferior em ratos</b>^lpt#^rND^1A01^nJosé Jorge da^sSilva#^rND^
1A02^nAlcino Lázaro da^sSilva#^rND^1A03^nDanilo Nagib Salomão^sPaulo#Minas Gerai
s Federal University^iA01^1Postgraduate Program in General Surgery^pBrazil#UFMG^
iA02^1School of Medicine^cMinas Gerais^pBrazil#EMESCAM^iA03^cVitoria^sES^pBrazil
#^len^a<b>Purpose</b>: To evaluate the feasibility and safety of subtotal splene
ctomy by laparoscopy with inferior pole preservation and to determine the viabil
ity of the splenic remnant. <b>Methods</b>: Twenty male Wistar rats weighing bet
ween 365 g and 474 g (mean 417.92 ± 36.15g SD) were operated and randomly assign
ed to two groups : Group 1 rats were killed on postoperative day 10 (n = 10), an
d Group 2 on the postoperative day 80 (n = 10). Both the inferior splenic pole a
nd the superior part of the spleen, which was used as a control to measure infer
ior pole viability, were weighed and morphologically examined. <b>Results</b>: T
he technique was feasible in all cases. There were two postoperative deaths on i
mmediate postoperative and one not well defined. The average weight percentage o
f the inferior pole, measured indirectly on the 10th day, was 53.67% ± 11.59% an
d on the 80th day was 62.69% ± 6.89%. The inferior pole was necrotic, with absce
ss formation in one case (5.9%) and appeared normal in all other cases. Microsco
py showed features that were compatible with normality. <b>Conclusions</b>: Subt
otal splenectomy with preservation of the inferior pole by laparoscopy was feasi
ble and safety. The lower splenic pole was viable in 94.1% of animals.#^dnd^i1#^
tm^len^kSpleen^i1#^tm^len^kSplenectomy^i1#^tm^len^kLaparoscopy^i1#^tm^len^kRats^
i1#^lpt^a<b>Objetivo</b>: Avaliar a exequibilidade e a segurança da esplenectomi
a subtotal com preservação do polo inferior do baço por videolaparoscopia, e a v
iabilidade do referido polo. <b>Métodos</b>: 20 ratos Wistar, machos, pesando en
tre 365g e 474g (MA 417,92 ± 36,15g) foram operados e distribuídos em dois grupo
s de acordo com a época da retirada do polo inferior para estudo: grupo 1 do 10º
 dia, (n= 10), grupo 2, do 80º dia (n=10). A porção superior do baço que serviu 
de controle da viabilidade do pólo inferior e esse remanescente, retirados no té
rmino do experimento, foram medidos, pesados e enviados para exame morfológico. 
<b>Resultados</b>: A técnica foi exeqüível em todos os casos. O peso médio perce
ntual do polo inferior avaliado de forma indireta no 10º dia foi 53,67% ± 11,59%
, e no 80º dia 62,69% ± 6,89%. Houve dois óbitos após a cirurgia, provavelmente 
por mal condução da anestesia e/ou do pneumoperitônio, e um tardiamente por caus
a desconhecida. O exame macro e microscópico do polo inferior nos 17 animais sob
reviventes e no que faleceu tardiamente mostrou necrose em um caso (5,9%). <b>Co
nclusões</b>: A esplenectomia subtotal com preservação do pólo inferior por vide
olaparoscopia em ratos foi exequível e segura. O polo inferior do baço mostrou-s
e viável em 94,1% dos animais.#^dnd^i2#^tm^lpt^kBaço^i2#^tm^lpt^kEsplenectomia^i
2#^tm^lpt^kLaparoscopia^i2#^tm^lpt^kRatos^i2#other#36#20100727#July 27, 2010#201
00921#September 21, 2010#20101026#October 26, 2010#a09v26n1.htm##
04307000000000685000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000150012903100030014403200020014706500090014901400090015803500100
01670120085001770120083002620100032003450100035003770100039004120700088004510700
05400539070003600593083128400629085000801913085001901921085002401940085002401964
08500170198808313340200508500080333908500170334708500260336408500250339008500180
34151170006034330720003034391120009034421110014034511160009034651150019034741140
00903493113001703502002001303519008008903532#v26n1#V:\Scielo\serial\acb\v26n1\ma
rkup\a09v26n1.htm#S#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#tab
#09#ACB720#nd#Acta cir. bras#26#1#20110200#^f44^l50#0102-8650#Subtotal laparosco
pic splenectomy in rats with preservation of the inferior pole^len#Esplenectomia
 subtotal laparoscópica com preservação do polo inferior em ratos^lpt#^rND^1A01^
nJosé Jorge da^sSilva#^rND^1A02^nAlcino Lázaro da^sSilva#^rND^1A03^nDanilo Nagib
 Salomão^sPaulo#^iA01^1Minas Gerais Federal University^2Postgraduate Program in 
General Surgery^pBrazil#^iA02^1UFMG^2School of Medicine^cMinas Gerais^pBrazil#^i
A03^1EMESCAM^cVitoria^sES^pBrazil#^len^aPurpose: To evaluate the feasibility and
 safety of subtotal splenectomy by laparoscopy with inferior pole preservation a
nd to determine the viability of the splenic remnant. Methods: Twenty male Wista
r rats weighing between 365 g and 474 g (mean 417.92 ± 36.15g SD) were operated 
and randomly assigned to two groups : Group 1 rats were killed on postoperative 
day 10 (n = 10), and Group 2 on the postoperative day 80 (n = 10). Both the infe
rior splenic pole and the superior part of the spleen, which was used as a contr
ol to measure inferior pole viability, were weighed and morphologically examined
. Results: The technique was feasible in all cases. There were two postoperative
 deaths on immediate postoperative and one not well defined. The average weight 
percentage of the inferior pole, measured indirectly on the 10th day, was 53.67 
percent ± 11.59 percent and on the 80th day was 62.69 percent ± 6.89 percent. Th
e inferior pole was necrotic, with abscess formation in one case (5.9 percent) a
nd appeared normal in all other cases. Microscopy showed features that were comp
atible with normality. Conclusions: Subtotal splenectomy with preservation of th
e inferior pole by laparoscopy was feasible and safety. The lower splenic pole w
as viable in 94.1 percent of animals.#^dnd^i1#^tm^len^kSpleen^i1#^tm^len^kSplene
ctomy^i1#^tm^len^kLaparoscopy^i1#^tm^len^kRats^i1#^lpt^aObjetivo: Avaliar a exeq
uibilidade e a segurança da esplenectomia subtotal com preservação do polo infer
ior do baço por videolaparoscopia, e a viabilidade do referido polo. Métodos: 20
 ratos Wistar, machos, pesando entre 365g e 474g (MA 417,92 ± 36,15g) foram oper
ados e distribuídos em dois grupos de acordo com a época da retirada do polo inf
erior para estudo: grupo 1 do 10º dia, (n= 10), grupo 2, do 80º dia (n=10). A po
rção superior do baço que serviu de controle da viabilidade do pólo inferior e e
sse remanescente, retirados no término do experimento, foram medidos, pesados e 
enviados para exame morfológico. Resultados: A técnica foi exeqüível em todos os
 casos. O peso médio percentual do polo inferior avaliado de forma indireta no 1
0º dia foi 53,67 por cento ± 11,59 por cento, e no 80º dia 62,69 por cento ± 6,8
9 por cento. Houve dois óbitos após a cirurgia, provavelmente por mal condução d
a anestesia e/ou do pneumoperitônio, e um tardiamente por causa desconhecida. O 
exame macro e microscópico do polo inferior nos 17 animais sobreviventes e no qu
e faleceu tardiamente mostrou necrose em um caso (5,9 por cento). Conclusões: A 
esplenectomia subtotal com preservação do pólo inferior por videolaparoscopia em
 ratos foi exequível e segura. O polo inferior do baço mostrou-se viável em 94,1
 por cento dos animais.#^dnd^i2#^tm^lpt^kBaço^i2#^tm^lpt^kEsplenectomia^i2#^tm^l
pt^kLaparoscopia^i2#^tm^lpt^kRatos^i2#other#36#20100727#July 27, 2010#20100921#S
eptember 21, 2010#20101026#October 26, 2010#a09v26n1.htm#Internet^ihttp://www.sc
ielo.br/scielo.php?script=sci_arttext&pid=S0102-86502011000100009##
00310000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704007800073002001300151#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#5#1#article#203#<p align="right"><font
 face="Verdana" size="2"><b>9 - ORIGINAL ARTICLE    ^cY#a09v26n1.htm##
00325000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704009300073002001300166#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#6#2#article#203#<br>   </b></font><b><
font face="Verdana" size="2">MODELS, BIOLOGICAL</font></b></p>     ^cY#a09v26n1.
htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704003700073002001300110#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#7#3#article#203#<p align="right">&nbsp
;</p>      ^cY#a09v26n1.htm##
00461000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704022900073002001300302#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#8#4#article#203#<p><b><font face="Verd
ana" size="2"><a name="top"></a></font><font face="Verdana" size="4">Subtotal   
 laparoscopic splenectomy in rats with preservation of the inferior pole<SUP><a 
href="#end">1</a></SUP></font></b></p>     ^cY#a09v26n1.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#9#5#article#203#<p>&nbsp;</p>     ^cY#
a09v26n1.htm##
00438000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704020500074002001300279#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#10#6#article#203#<p><b><font face="Ver
dana" size="3">Esplenectomia subtotal laparosc&oacute;pica    com preserva&ccedi
l;&atilde;o do polo inferior em ratos</font></b><font face="Verdana" size="2">  
  </font></p>       ^cY#a09v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#11#7#article#203#<p>&nbsp;</p>     ^cY
#a09v26n1.htm##
00432000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704019900074002001300273#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#12#8#article#203#<p><font face="Verdan
a" size="2"><B>Jos&eacute; Jorge da Silva<SUP>I</SUP>, Alcino    L&aacute;zaro d
a Silva<SUP>II</SUP>, Danilo Nagib Salom&atilde;o Paulo<SUP>III</SUP></B>    </f
ont></p>      ^cY#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002300074002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#13#9#article#203#<p>&nbsp;</p>      ^c
Y#a09v26n1.htm##
00478000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024400075002001300319#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#14#10#article#203#<p><font face="Verda
na" size="2"><SUP>I</SUP>Fellow Master degree, Postgraduate    Program in Genera
l Surgery, Minas Gerais Federal University (UFMG), Brazil.    <I>Main author. In
volved with technical procedures and manuscript writing.    ^cY#a09v26n1.htm##
00406000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017200075002001300247#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#15#11#article#203#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>II</SUP>Professor Emeritus of    Surgery, Schoo
l of Medicine, UFMG, Minas Gerais, Brazil. <I>Critical revision.    ^cY#a09v26n1
.htm##
00478000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024400075002001300319#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#16#12#article#203#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>III</SUP>Full Professor of Surgery,    EMESCAM,
 Vitoria-ES, Brazil. <I>Tutor. Responsible for intelectual, scientific    conten
t and statistical analysis of the study.</I></font></p>     ^cY#a09v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#17#13#article#203#<p><font face="Verda
na" size="2"><a href="#end">Correspondence</a></font></p>     ^cY#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#18#14#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#19#15#article#203#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a09v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#20#16#article#203#<p><font face="Verda
na" size="2"><B>ABSTRACT </B></font></p>     ^cY#a09v26n1.htm##
01614000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704138000075002001301455#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#21#17#article#203#<p><font face="Verda
na" size="2"><B>Purpose</b>: To evaluate the feasibility and    safety of subtot
al splenectomy by laparoscopy with inferior pole preservation    and to determin
e the viability of the splenic remnant. <B>Methods</B>: Twenty    male Wistar ra
ts weighing between 365 g and 474 g (mean 417.92 &#177; 36.15g    SD) were opera
ted and randomly assigned to two groups : Group 1 rats were killed    on postope
rative day 10 (n = 10), and Group 2 on the postoperative day 80 (n    = 10). Bot
h the inferior splenic pole and the superior part of the spleen, which    was us
ed as a control to measure inferior pole viability, were weighed and morphologic
ally    examined. <B>Results</B>: The technique was feasible in all cases. There
 were    two postoperative deaths on immediate postoperative and one not well de
fined.    The average weight percentage of the inferior pole, measured indirectl
y on the    10th day, was 53.67% &#177; 11.59% and on the 80th day was 62.69% &#
177; 6.89%.    The inferior pole was necrotic, with abscess formation in one cas
e (5.9%) and    appeared normal in all other cases. Microscopy showed features t
hat were compatible    with normality. <B>Conclusions</B>: Subtotal splenectomy 
with preservation of    the inferior pole by laparoscopy was feasible and safety
. The lower splenic    pole was viable in 94.1% of animals. </font></p>     ^cY#
a09v26n1.htm##
00371000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013700075002001300212#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#22#18#article#203#<p><font face="Verda
na" size="2"><B>Key words</B>: Spleen. Splenectomy. Laparoscopy.    Rats. </font
></p>  <hr size="1" noshade>     ^cY#a09v26n1.htm##
00301000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006700075002001300142#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#23#19#article#203#<p><font face="Verda
na" size="2"><B>RESUMO </B></font></p>     ^cY#a09v26n1.htm##
01888000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704165400075002001301729#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#24#20#article#203#<p><font face="Verda
na" size="2"><B>Objetivo</b>: Avaliar a exequibilidade e a    seguran&ccedil;a d
a esplenectomia subtotal com preserva&ccedil;&atilde;o do    polo inferior do ba
&ccedil;o por videolaparoscopia, e a viabilidade do referido    polo. <B>M&eacut
e;todos</B>: 20 ratos Wistar, machos, pesando entre 365g e 474g    (MA 417,92 &#
177; 36,15g) foram operados e distribu&iacute;dos em dois grupos    de acordo co
m a &eacute;poca da retirada do polo inferior para estudo: grupo    1 do 10&#186
; dia, (n= 10), grupo 2, do 80&#186; dia (n=10). A por&ccedil;&atilde;o    super
ior do ba&ccedil;o que serviu de controle da viabilidade do p&oacute;lo    infer
ior e esse remanescente, retirados no t&eacute;rmino do experimento, foram    me
didos, pesados e enviados para exame morfol&oacute;gico. <B>Resultados</B>:    A
 t&eacute;cnica foi exeq&uuml;&iacute;vel em todos os casos. O peso m&eacute;dio
    percentual do polo inferior avaliado de forma indireta no 10&#186; dia foi 5
3,67%    &#177; 11,59%, e no 80&#186; dia 62,69% &#177; 6,89%. Houve dois &oacut
e;bitos    ap&oacute;s a cirurgia, provavelmente por mal condu&ccedil;&atilde;o 
da anestesia    e/ou do pneumoperit&ocirc;nio, e um tardiamente por causa descon
hecida. O exame    macro e microsc&oacute;pico do polo inferior nos 17 animais s
obreviventes e    no que faleceu tardiamente mostrou necrose em um caso (5,9%). 
<B>Conclus&otilde;es</B>:    A esplenectomia subtotal com preserva&ccedil;&atild
e;o do p&oacute;lo inferior    por videolaparoscopia em ratos foi exequ&iacute;v
el e segura. O polo inferior    do ba&ccedil;o mostrou-se vi&aacute;vel em 94,1%
 dos animais. </font></p>     ^cY#a09v26n1.htm##
00381000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704014700075002001300222#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#25#21#article#203#<p><font face="Verda
na" size="2"><B>Descritores</B>: Ba&ccedil;o. Esplenectomia.    Laparoscopia. Ra
tos. </font></p> <hr size="1" noshade>     ^cY#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#26#22#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#27#23#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007400075002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#28#24#article#203#<p><font face="Verda
na" size="3"><B>Introduction</B> </font></p>      ^cY#a09v26n1.htm##
01957000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704172300075002001301798#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#29#25#article#203#<p><font face="Verda
na" size="2"> Total splenectomy may cause complications<SUP>1</SUP>,    the most
 feared of which are infections<SUP>2</SUP>, as observed in experimental    anim
als<SUP>3</SUP>. Changes in lipid metabolism have also been described in    huma
ns<SUP>4</SUP> and in experimental animals<SUP>5</SUP>, where these can    lead 
to atherosclerosis<SUP>6</SUP>. Thus, non-operative treatment of splenic    trau
ma, as well as operations for total or partial splenic preservation, is    incre
asingly valued. The advent of laparoscopic surgery with M&uuml;he<SUP>7</SUP>   
 in 1985 in Germany and laparoscopy from Mouret<SUP>8</SUP> in 1987 in France   
 motivated surgeons to develop minimally invasive technical modalities to diagno
se    and treat acute and chronic diseases of the abdominal cavity. The spleen i
s    an abdominal organ that is easily accessible by laparoscopy. Surgery on thi
s    organ is facilitated by the great magnification of the objective lens of th
e    laparoscope (up to 20-fold). One can identify the splenic pedicle and its s
egmental    branches and perform a splenectomy. Laparoscopic spleen surgery bega
n in the    1990s. Initially, total and partial splenectomies<SUP>9</SUP> were p
erformed    on humans<SUP>10</SUP> and experimental animals<SUP>11,12</SUP>. Par
tial splenectomy    that preserved the inferior pole, a more recent alternative 
for spleen-conserving    surgery, was described in experimental animals via lapa
rotomy. The technique    was feasible, and the inferior pole was viable in 86.6%
 of the cases<SUP>13</SUP>.    Until recently, partial splenectomy by laparoscop
ic access and viability of    the remaining inferior pole have not been describe
d. </font></p>     ^cY#a09v26n1.htm##
00555000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704032100075002001300396#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#30#26#article#203#<p><font face="Verda
na" size="2"> The objective of this study was to evaluate    the feasibility and
 safety of partial splenectomy by laparoscopy that preserves    the inferior pol
e and to study, after two distinct time intervals, the viability    of the remai
nder of the spleen after the operation. </font></p>      ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#31#27#article#203#<p>&nbsp; </p>     ^
cY#a09v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#32#28#article#203#<p><font face="Verda
na" size="3"><B>Methods</B> </font></p>      ^cY#a09v26n1.htm##
00518000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028400075002001300359#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#33#29#article#203#<p><font face="Verda
na" size="2"> This work was performed at the Fundamentals    of Surgery Laborato
ry, College of Science of Santa Casa de Misericordia de Vitoria-Emescam,    foll
owing approval from the Ethics Committee of the Minas Gerais Federal University.
    </font></p>     ^cY#a09v26n1.htm##
00735000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050100075002001300576#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#34#30#article#203#<p><font face="Verda
na" size="2"> The animals were placed in collective cages,    each with a capaci
ty of five animals, and were fed with commercial pellets for    laboratory anima
ls (Mill Primor MP-77, Sao Paulo). The bottom of each cage was    lined with sha
vings, and the ceiling was covered with a metal grille. The rats    underwent cl
inical examinations to rule out underlying conditions, and were    subsequently 
returned to their cages for an adaptation period of 15 days. </font></p>     ^cY
#a09v26n1.htm##
00565000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704033100075002001300406#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#35#31#article#203#<p><font face="Verda
na" size="2"> Twenty Wistar rats were used in this experiment,    each weighing 
between 365 g and 474 g (mean 417.92 &#177; 36.15) and approximately    12 weeks
 old. The rats were obtained from the vivarium of the School of Sciences    of S
anta Casa de Misericordia de Vitoria-ES (Emescam). </font></p>     ^cY#a09v26n1.
htm##
00782000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704054800075002001300623#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#36#32#article#203#<p><font face="Verda
na" size="2"> The rats were distributed into two groups with    the aid of a ran
dom numbers table prepared by a statistician, according to the    period during 
which the inferior pole (IP) was removed for the study: in Group    1 (n = 10), 
the IP was taken out on the 10th day after surgery, whereas in Group    2 (n = 1
0), the IP was removed on the 80th day after surgery The rats were fasted    for
 eight hours and then subjected to the subtotal laparoscopic splenectomy    ( SS
L/IP) following procedures: </font></p>     ^cY#a09v26n1.htm##
00600000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036600075002001300441#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#37#33#article#203#<p><font face="Verda
na" size="2"> - Anesthesia with ketamine hydrochloride at    a dose of 50 mg/kg 
and xylazine hydrochloride at a dose of 2.5 mg/kg intraperitoneally,    weighing
 (electronic scale Filizola<SUP>&#174;</SUP>-sensitivity to 1 g) and    identifi
cation by a mark on the ear (with a linear cut for group 1 and V-cut    for grou
p 2); </font></p>     ^cY#a09v26n1.htm##
00360000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012600075002001300201#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#38#34#article#203#<p><font face="Verda
na" size="2"> - Removal of the fur on abdominal wall at the    trocar insertion 
area; </font></p>     ^cY#a09v26n1.htm##
00372000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013800075002001300213#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#39#35#article#203#<p><font face="Verda
na" size="2"> - Placement in the supine position on the operating    table (hand
led by the feet); </font></p>     ^cY#a09v26n1.htm##
00384000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015000075002001300225#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#40#36#article#203#<p><font face="Verda
na" size="2"> - Antisepsis of the abdominal skin with iodinated    alcohol and d
raping of the surgical field; </font></p>     ^cY#a09v26n1.htm##
00407000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017300075002001300248#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#41#37#article#203#<p><font face="Verda
na" size="2"> - Insertion of the primary 10-mm trocar into    the lower left qua
drant of the abdomen under direct visualization (A); </font></p>     ^cY#a09v26n
1.htm##
00441000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020700075002001300282#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#42#38#article#203#<p><font face="Verda
na" size="2"> - Introduction of the 2nd trocar (5-mm) in the    right hypochondr
ium, guided by laparoscopy, through which the Maryland (B) forceps    were intro
duced; </font></p>     ^cY#a09v26n1.htm##
00455000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022100075002001300296#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#43#39#article#203#<p><font face="Verda
na" size="2"> - Placement of the third 5-mm trocar (C) in    the lower right qua
drant, also directed by laparoscopy, through which the clipper    was introduced
 (<a href="#img01">Figure 1</a>).    ^cY#a09v26n1.htm##
00261000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002700075002001300102#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#44#40#article#203#<BR>   </font></p>  
   ^cY#a09v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#45#41#article#203#<p align="center">&n
bsp;</p>     ^cY#a09v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#46#42#article#203#<p align="center">&n
bsp;</p>     ^cY#a09v26n1.htm##
00335000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704010100075002001300176#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#47#43#article#203#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a09img01.jpg"><a name="img01"></a>  </p>     ^cY
#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#48#44#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#49#45#article#203#<p>&nbsp; </p>     ^
cY#a09v26n1.htm##
00459000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022500075002001300300#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#50#46#article#203#<p><font face="Verda
na" size="2"> - The locations of the spleen and gastrosplenic    ligaments were 
determined by the surgeon by applying traction with the Maryland    forceps to e
xpose the splenic hilum; </font></p>     ^cY#a09v26n1.htm##
00532000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029800075002001300373#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#51#47#article#203#<p><font face="Verda
na" size="2"> - Dissection and clamping of segmental vessels    leading from the
 superior splenic portion to the inferior pole, with preservation    of vessels 
in the gastrosplenic ligament that supplied the inferior pole (<a href="#img02">
Figure    2</a>); </font></p>     ^cY#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#52#48#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#53#49#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#54#50#article#203#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a09img02.jpg"><a name="img02"></a></p>     ^cY#a
09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#55#51#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#56#52#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00393000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015900075002001300234#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#57#53#article#203#<p><font face="Verda
na" size="2"> - Use of the L200 Ethicon<SUP>&#174;</SUP>staples,    Endoview<SUP
>&#174;</SUP>clipper, and 5-mm trocar; </font></p>     ^cY#a09v26n1.htm##
00466000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704023200075002001300307#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#58#54#article#203#<p><font face="Verda
na" size="2"> - Sectioning the spleen and removing the superior    portion with 
preservation of inferior pole vessels supplied by the gastrosplenic    ligament 
(<a href="#img03">Figure 3</a>);</font></p>     ^cY#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#59#55#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#60#56#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#61#57#article#203#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a09img03.jpg"><a name="img03"></a></p>     ^cY#a
09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#62#58#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#63#59#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00344000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011000075002001300185#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#64#60#article#203#<p><font face="Verda
na" size="2"> - Hemostasis at the incision with local compression;    </font></p
>     ^cY#a09v26n1.htm##
00453000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021900075002001300294#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#65#61#article#203#<p><font face="Verda
na" size="2"> - Preservation of a thin peritoneal fold that    connects the grea
ter antral curvature to the anterior part of the inferior pole    (<a href="#img
03">Figure 3</a>); </font></p>     ^cY#a09v26n1.htm##
00351000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011700075002001300192#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#66#62#article#203#<p><font face="Verda
na" size="2"> - Deflation of pneumoperitoneum and removal    of the trocars; </f
ont></p>     ^cY#a09v26n1.htm##
00382000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704014800075002001300223#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#67#63#article#203#<p><font face="Verda
na" size="2"> - Suturing the abdominal skin wound and the    underlying muscles 
with 4-0 mononylon sutures; </font></p>     ^cY#a09v26n1.htm##
00354000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012000075002001300195#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#68#64#article#203#<p><font face="Verda
na" size="2"> - Application of topical povidone iodine on    the sutured wound. 
</font></p>     ^cY#a09v26n1.htm##
00501000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704026700075002001300342#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#69#65#article#203#<p><font face="Verda
na" size="2"> The superior portion that was removed was fixed    in 10% formalin
 for future microscopic study. This fragment served as a control    for analysis
 of the viability of the inferior pole.</font><font face="Verdana" size="2"><I> 
   ^cY#a09v26n1.htm##
00265000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003100075002001300106#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#70#66#article#203#<BR>   </I></font></
p>     ^cY#a09v26n1.htm##
00478000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024400075002001300319#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#71#67#article#203#<p><font face="Verda
na" size="2"> Student's t-test was used for related samples    to compare the we
ight of the rats at the beginning of the experiment with weight    at the end of
 the experiment within the same group. </font></p>          ^cY#a09v26n1.htm##
01393000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704115900075002001301234#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#72#68#article#203#<p><font face="Verda
na" size="2">At the end of surgery, the animals were returned    to their cages.
 In the immediate postoperative period, the rats received paracetamol    orally 
at a dose of 200 mg/kg, dissolved in drinking water, as well as diet    and wate
r <i>ad libitum</i>.The animals that died were autopsied, and those    that surv
ived were killed on postoperative day 10 (Group 1) or 80 (Group 2)    with a let
hal intraperitoneal dose of sodium pentobarbital. At the time of sacrifice,    t
he rat was weighed, and an incision was made in the form of an inverted U on    
the abdominal wall in order to study the cavity and remove the splenic remnant. 
   After macroscopic analysis, the inferior pole was weighed and sent for histol
ogical    examination after fixation in 10% formalin. The superior portion (remo
ved during    SSL/IP) and the inferior pole were embedded in paraffin, and secti
ons were stained    with hematoxylin-eosin. Analysis of the tissue was performed
 by a pathologist    with a binocular microscope. The sections were analyzed for
 morphological alterations.    The focus of our analysis was splenic viability.<
/font></p>     ^cY#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#73#69#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00315000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008100075002001300156#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#74#70#article#203#<p><font face="Verda
na" size="2"><i>Statistical analysis</i> </font></p>     ^cY#a09v26n1.htm##
00491000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025700075002001300332#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#75#71#article#203#<p><font face="Verda
na" size="2"> Descriptive statistics were used to calculate    the arithmetic me
an and standard deviation of the weights of the two rat groups    and the weight
 of the superior and inferior poles of the SSL/IP group. </font></p>     ^cY#a09
v26n1.htm##
00795000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056100075002001300636#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#76#72#article#203#<p><font face="Verda
na" size="2"> Linear regression analysis was used to calculate    the mass perce
ntage of the remaining inferior pole at the 10th and 80th postoperative    days.
 This was accomplished by dividing the weight of this splenic pole by the    ide
al weight for each animal in each group. The ideal splenic weight was calculated
    using the following formula: splenic weight (= (1.80 x body weight) + 230.49
.    The average percentage of the remaining splenic mass with its respective st
andard    deviation was then calculated. </font></p>     ^cY#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#77#73#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#78#74#article#203#<p><font face="Verda
na" size="3"><B>Results</B> </font></p>      ^cY#a09v26n1.htm##
00369000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013500075002001300210#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#79#75#article#203#<p><font face="Verda
na" size="2"> Performance of SSL/IP was feasible in all cases    and was efficac
ious and safe. </font></p>     ^cY#a09v26n1.htm##
00834000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704060000075002001300675#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#80#76#article#203#<p><font face="Verda
na" size="2"> Three rats died postoperatively in the 80-day    group. Two deaths
 occurred soon after surgery, and one death occurred in the    late postoperativ
e period. Autopsy of these animals did not identify a specific    cause. At the 
time of autopsy, the inferior pole was macroscopically preserved    in the anima
ls that died in the late postoperative period. For the two animals    that died 
during the immediate postoperative period, analysis was inconclusive    because 
it could not predict the likely evolution of the apparently normal remnants.    
</font></p>     ^cY#a09v26n1.htm##
00356000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012200075002001300197#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#81#77#article#203#<p><font face="Verda
na" size="2"> No complications were observed at the sites    of trocar insertion
. </font></p>     ^cY#a09v26n1.htm##
00456000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022200075002001300297#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#82#78#article#203#<p><font face="Verda
na" size="2"> The weight of animals subjected to SSL/IP in    the 10-day and 80-
day groups at the beginning and end of the experiment can    be seen in <a href=
"#tab01">Table 1</a>. </font></p>     ^cY#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#83#79#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#84#80#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#85#81#article#203#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a09tab01.jpg"><a name="tab01"></a></p>     ^cY#a
09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#86#82#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#87#83#article#203#<p>&nbsp; </p>     ^
cY#a09v26n1.htm##
00508000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027400075002001300349#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#88#84#article#203#<p><font face="Verda
na" size="2"> </font></p>     <font face="Verdana" size="2">The abdominal cavity
 displayed mild adhesions in  both groups (day 10 and day 80). These adhesions w
ere observed between the inferior  pole and the stomach and greater omentum. </f
ont>      ^cY#a09v26n1.htm##
00579000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704034500075002001300420#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#89#85#article#203#<p><font face="Verda
na" size="2"> In our analysis of 17 of the 20 rats operated    on, there was onl
y one case of necrosis, with an abscess in the inferior pole    (5.9%); this occ
urred in one animal in Group 2. The other poles were grossly    normal (94.1%) (
<a href="/img/revistas/acb/v26n1/a09img04.jpg">Figure    4</a>). </font></p>    
 ^cY#a09v26n1.htm##
00505000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027100075002001300346#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#90#86#article#203#<p><font face="Verda
na" size="2"> The average weight percentage of the inferior    pole, calculated 
with the aid of linear regression analysis, was 53.67 &#177;    11.59% on the 10
th and 62.69 &#177; 6.89% on the 80th postoperative day (p =    0.10). </font></
p>     ^cY#a09v26n1.htm##
00716000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048200075002001300557#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#91#87#article#203#<p><font face="Verda
na" size="2"> In Group 1 (10 days), the superior and inferior    pole exhibited 
structural preservation. In the white pulp, mild lymphoid hyperplasia    was obs
erved. The red pulp displayed sinusoidal dilatation with endothelial    hyperpla
sia and mild to moderate congestion. Macrophages with hemosiderin were also seen
 (<a href="#img05">Figure    5</a>). There were no significant differences betwe
en the superior and the inferior    pole. </font></p>     ^cY#a09v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#92#88#article#203#<p align="center">&n
bsp;</p>     ^cY#a09v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#93#89#article#203#<p align="center">&n
bsp;</p>     ^cY#a09v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#94#90#article#203#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a09img05.jpg"><a name="img05"></a></p>     ^cY#a
09v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#95#91#article#203#<p align="center">&n
bsp;</p>     ^cY#a09v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#96#92#article#203#<p align="center">&n
bsp;</p>     ^cY#a09v26n1.htm##
00956000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704072200075002001300797#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#97#93#article#203#<p><font face="Verda
na" size="2"> In Group 2 (80th day), the white pulp had moderate    lymphoid hyp
erplasia. The red pulp sinusoids appeared to be collapsed, with    slight endoth
elial hyperplasia. A slight increase in the amount of lymphocyte    traffic and 
the presence of macrophages containing hemosiderin were observed.    In the samp
les from inferior poles, there was a greater concentration of macrophages    wit
h hemosiderin compared to samples from the superior portion (<a href="#img06">Fi
gure    6</a>). Sinusoidal dilatation was present in samples from the inferior p
ole.    Stromal sclerosis was also seen in samples from the superior portion but
 not    in samples from the inferior pole.</font></p>     ^cY#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#98#94#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#99#95#article#203#<p>&nbsp;</p>     ^c
Y#a09v26n1.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704009900076002001300175#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#100#96#article#203#<p align="center"><
img src="/img/revistas/acb/v26n1/a09img06.jpg"><a name="img06"></a></p>     ^cY#
a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002200076002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#101#97#article#203#<p>&nbsp;</p>     ^
cY#a09v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002300076002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#102#98#article#203#<p>&nbsp;</p>      
^cY#a09v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704007300076002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#103#99#article#203#<p> <font face="Ver
dana" size="3"><B>Discussion</B> </font></p>      ^cY#a09v26n1.htm##
01715000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704147900077002001301556#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#104#100#article#203#<p><font face="Ver
dana" size="2"> Because of its important functions, the spleen    should be part
ially or fully preserved. This resolve should only be strengthened    by the rea
lization that this organ has functions that are still unknown. In    cases of sp
lenic trauma, medical (non-operative) therapy can be attempted in    children<SU
P>14 </SUP>and adults<SUP>15</SUP>. In these circumstances, of course,    the pa
tient should be hospitalized and closely monitored. When surgery becomes    nece
ssary, spleen-conserving operations such as splenorrhaphy<sup>16</sup>,    vascu
lar occlusion<sup>17-22</sup> and partial splenectomy<sup>23-26</sup> should    
be attempted. If the organ has been completely destroyed, autoimplantation shoul
d    be attempted<sup>27</sup>. Given that operations on the spleen often requir
e    extensive, painful, unsightly incisions that can result in loss of function
,    abdominal laparoscopy has been used to perform splenic operations in the la
st    several years<sup>28-30</sup>. Partial splenectomy with preservation of th
e    superior pole has been described on experimental animals<sup>12</sup>, as h
as    splenic tissue implantation by laparoscopy<sup>30</sup> and an experimenta
l    model of laparoscopic splenectomy<sup>31</sup>. This study describes spleen
-conserving    surgery via laparoscopy, this time with preservation of the infer
ior pole, a    technique already described by conventional access<sup>19</sup>. 
</font> </p>     ^cY#a09v26n1.htm##
03167000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704293100077002001303008#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#105#101#article#203#<p><font face="Ver
dana" size="2">At the beginning of this study, a pilot study    was necessary to
 devise several technical improvements. We initially had difficulty    achieving
 ideal pneumoperitoneum. The rats underwent general anesthesia without    intuba
tion or paralysis, and they displayed no relaxation of the abdominal wall    and
 breathed spontaneously. This complicated the pneumoperitoneum technique.    Ide
al pneumoperitoneum was finally achieved in our study under 4 mmHg pressure.    
The trocar position was optimized to yield the largest possible angle (0-90&#176
;)    between the working clamps, the best position for a surgeon to work in, as
 it    is otherwise difficult to handle the instruments during operations. These
 improvements    in technique showed that the best trocar positions were a) 1st 
trocar (10-mm)    in the left lower quadrant (optical port to 30 degrees), b) 2n
d trocar (5-mm)    in the right subcostal region on a line that intersects the j
unction of the    distal third of the clavicle, and c) 3rd trocar (5-mm) in the 
right lower quadrant.    In the pilot study, we developed an efficient way of fi
xing the trocars in the    abdominal wall with rings cut-off from 3.0 mononylon 
silicone hose. The 3-0    mononylon wire was used so that the trocar would not f
all out of the abdominal    cavity. Silicone rings (5 mm in diameter), made by c
utting silicone tubing similar    to that used in conventional vacuum apparatus,
 were placed around the trocar    ends, allowing only a short length to penetrat
e the abdominal cavity, thus preventing    the trocars from entering the abdomen
 too deeply. These procedures allowed wide    access to the abdominal cavity, ma
king the intended operation possible. Subtotal    laparoscopic splenectomy was p
erformed using conventional access techniques    to the spleen<sup>25</sup>. In 
addition to these precautions, two others were    taken during the operation tha
t followed the author's clinical SSL/IP technique<sup>13</sup>:    a) The first 
was to not position the inferior pole against the greater stomach    curvature, 
in order to avoid twisting the remainder of the spleen. This twist    is made po
ssible by the long inferior pole pedicle (about 1 cm). Experience    with the SS
L/IP technique on rats previously showed that positioning the inferior    pole a
gainst the stomach resulted in a high incidence of necrosis of the remaining    
spleen (data not shown). The inferior pole should be placed in the abdominal    
cavity with its cut surface facing anteriorly. After this maneuver, the greater 
   omentum falls naturally over the pole, which can be beneficial. b) The second
    precaution was to preserve the thin peritoneal membrane that connects the gr
eater    antral curvature to the inferior splenic pole, in order to maintain the
se organs    in their anatomical position, i.e., with the IP's cut surface facin
g anteriorly.</font></p>     ^cY#a09v26n1.htm##
00839000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704060300077002001300680#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#106#102#article#203#<p><font face="Ver
dana" size="2">   In Group 2, two animals died in the immediate postoperative pe
riod, and one    died in the late postoperative period. Autopsy was unable to de
termine the cause    of death of the animals that died in the late postoperative
 period. For animals    that died during the immediate postoperative period, it 
is possible that the    cause of death was an overdose of anesthesia and/or the 
technic of the pneumoperitoneum,    since the animals did not wake up after surg
ery. In the late postoperative period,    it was not possible to pinpoint the ca
use. </font></p>     ^cY#a09v26n1.htm##
01875000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704163900077002001301716#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#107#103#article#203#<p><font face="Ver
dana" size="2"> The technique was feasible in all animals after    initial diffi
culties were overcome in the pilot study. No accidents occurred    during surger
y that could have jeopardized the outcome of surgery. The animals    had excelle
nt postoperative courses and even gained weight. The average inferior    pole pe
rcentage was greater on postoperative day 80 than on day 10. This suggests    th
at the splenic remnant grew over time, as described by Paulo <I>et al.</I><SUP>3
2    </SUP>In another partial splenectomy model, growth was also seen in the inf
erior    pole<SUP>33</SUP>. This is a promising observation, as it suggests that
 splenic    function can improve, and was demonstrated in previous work<SUP>5</S
UP>. Bradshaw    and Thomas<SUP>34</SUP> reported that the greater the splenic r
emnant, the greater    the protection against sepsis, and calculated that 25% re
sidual splenic tissue    constituted the critical mass for retaining normal phag
ocytic function. This    report has been accepted by most authors who previously
 argued that the minimum    critical mass required to maintain splenic function 
is more than 25% of the    total splenic mass<SUP>35</SUP>. In an experimental s
tudy in rats, Van Wick    <I>et al.</I><SUP>36 </SUP>considered it necessary to 
maintain 1/3 of the total    spleen tissue in order to restore splenic function.
 In our study, the mass percentages    on the 10th and 80th days were 53.67 &#17
7; 11.59% and 62.69% &#177; 6.89%,    respectively. Based on these results, we e
xpect that the IP will eventually    be able to carry out all splenic functions.
 </font></p>     ^cY#a09v26n1.htm##
01611000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704137500077002001301452#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#108#104#article#203#<p><font face="Ver
dana" size="2"> In our macroscopic analysis of the inferior    pole, we noted th
at 17 splenic remnants from the 20 animals remaining appeared    to be macroscop
ically normal. However, two of the 20 animals died during the    immediate posto
perative period, and their inferior poles were analyzed within    the same timef
rame. This examination was inherently limited by the impossibility    of knowing
 how these poles would have evolved by the 80th day. Thus, our mass    percentag
e calculations were based on 17 animals, among which only one pole    displayed 
necrosis. However, our calculation of the percent feasibility of SSL/IP    was b
ased on results from all 20 animals. From these calculations, we found    that t
he percentage of viable poles was 94.1% and that the percent feasibility    100%
. Necrosis with abscess occurred in one case and may have been caused by    tors
ion of the pedicle or a pedicle that was not long enough to reach the pole.    I
t is important to remember that some technical conditions must also be met    in
 splenectomy in order to preserve the inferior pole. Other precautions, such    
as avoiding division of the thin peritoneal fold between the greater curvature  
  of the antrum and the inferior pole and preventing fixation of the inferior   
 pole in any one location have been described elsewhere. </font></p>     ^cY#a09
v26n1.htm##
00807000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704057100077002001300648#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#109#105#article#203#<p><font face="Ver
dana" size="2"> Microscopic analysis of the inferior pole on    the 10th day fou
nd no differences compared to microscopic analysis of the superior    portion du
ring the same period. However, on day 80, lymphoid hyperplasia of    the inferio
r pole was increased (slight at    day 10, moderate at day 80), and concentratio
ns of hemosiderin-containing macrophages    were higher in samples from the infe
rior pole compared to those from the superior    portion. Taken together, these 
observations suggest growth of the inferior pole.    </font></p>     ^cY#a09v26n
1.htm##
00808000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704057200077002001300649#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#110#106#article#203#<p><font face="Ver
dana" size="2"> Further work by surgical specialists is needed    to demonstrate
 the feasibility, efficacy and safety of SSL/IP using this technique.    The SSL
/IP can be used in other conservative splenic operations to treat traumatic    a
nd non-traumatic disorders of the spleen<SUP>13</SUP>. Because it retains all   
 the benefits of laparoscopy, including faster postoperative recovery, decreased
    endocrine response to trauma, lower risk of infection, better cosmetic and f
unctional    outcomes, and early hospital discharge. </font></p>      ^cY#a09v26
n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#111#107#article#203#<p>&nbsp; </p>    
 ^cY#a09v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007200077002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#112#108#article#203#<p><font face="Ver
dana" size="3"><B>Conclusion</B> </font></p>      ^cY#a09v26n1.htm##
00454000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704021800077002001300295#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#113#109#article#203#<p><font face="Ver
dana" size="2"> Subtotal splenectomy with preservation of the    inferior pole b
y laparoscopy was feasible and safety. The lower splenic pole    was viable in 9
4.1% of animals. </font></p>        ^cY#a09v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#114#110#article#203#<p>&nbsp; </p>    
 ^cY#a09v26n1.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007300077002001300150#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#115#111#article#203#<p> <font face="Ve
rdana" size="3"><B>References</B> </font></p>      ^cY#a09v26n1.htm##
00376000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704012600079002001300205#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#116#112#article#203#1#<p><
font face="Verdana" size="2">1. Cadili A, de Gara C. Complications of splenectom
y.    Am J Med. 2008;121(5):371-5.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#117#113#article#203# </font></p>     ^
cY#a09v26n1.htm##
00416000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704016600079002001300245#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#118#114#article#203#2#<p><
font face="Verdana" size="2">2. Sumaraju V, Smith LG, Smith SM. Infectious    co
mplications in asplenic hosts. Infect Dis Clin North Am. 2001;5(2):551-65.    ^c
Y#a09v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#119#115#article#203#    </font></p>   
  ^cY#a09v26n1.htm##
00455000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704020500079002001300284#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#120#116#article#203#3#<p><
font face="Verdana" size="2">3. Andersson R, Alwmark A, Bengmark S. Outcome    o
f pneumococcal challenge in rats after splenic artery ligation or splenectomy.  
  Acta Chir Scand. 1986;152:15-7.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#121#117#article#203# </font></p>     ^
cY#a09v26n1.htm##
00523000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704027300079002001300352#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#122#118#article#203#4#<p><
font face="Verdana" size="2">4. Aviram M, Brook JG, Tatarsky, Levy Y, Carter    
A. Increased low-density lipoprotein levels after splenectomy: a role for the   
 spleen in cholesterol metabolism in myeloproliferative disorders. Am J Med Sci.
    1986;291(1):25-8.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#123#119#article#203# </font></p>     ^
cY#a09v26n1.htm##
00463000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704021300079002001300292#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#124#120#article#203#5#<p><
font face="Verdana" size="2">5. Paulo DNS, L&aacute;zaro da Silva A. Lip&iacute;
dios    plasm&aacute;ticos ap&oacute;s esplenectomia total e parcial em c&atilde
;es.    Rev Col Bras Cir. 2001;28:264-70.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#125#121#article#203# </font></p>     ^
cY#a09v26n1.htm##
00450000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704020000079002001300279#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#126#122#article#203#6#<p><
font face="Verdana" size="2">6. Asai K, Kuzuya M, Naito M, Funaki C, Kuzuya    F
. Effects of splenectomy on serum lipids and experimental atherosclerosis.    An
giology. 1988;39(6):497-504.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#127#123#article#203# </font></p>     ^
cY#a09v26n1.htm##
00394000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704014400079002001300223#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#128#124#article#203#7#<p><
font face="Verdana" size="2">7. M&uuml;he E. Long-term follow-up after laparosco
pic    cholecystectomy. Endoscopy. 1992;24(9):754-8.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#129#125#article#203# </font></p>     ^
cY#a09v26n1.htm##
00384000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704013400079002001300213#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#130#126#article#203#8#<p><
font face="Verdana" size="2">8. Mouret P. Celioscopic surgery. Evolution or    r
evolution? Chirurgie. 1990;116(10):829-32.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#131#127#article#203# </font></p>     ^
cY#a09v26n1.htm##
00411000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704016100079002001300240#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#132#128#article#203#9#<p><
font face="Verdana" size="2">9. Delaitre B, Maignien B. Splenectomy by the    la
paroscopic approach. Report of a case. Presse Med. 1991;20(44): 2263.    ^cY#a09
v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#133#129#article#203# </font></p>     ^
cY#a09v26n1.htm##
00432000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018100080002001300261#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#134#130#article#203#10#<p>
<font face="Verdana" size="2">10. Poulin EC, Thibault C, DesC&ocirc;teaux JG,   
 Cote G. Partial laparoscopic splenectomy for trauma. Surg Laparosc Endosc. 1995
;5:306-10.    ^cY#a09v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#135#131#article#203#    </font></p>   
  ^cY#a09v26n1.htm##
00474000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022300080002001300303#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#136#132#article#203#11#<p>
<font face="Verdana" size="2">11. Espert JJ, Targarona EM, Bombuy E, Setoain    
J, Visa J, Trias M. Evaluation of risk of splenosis during laparoscopic splenect
omy    in rat model. World J Surg. 2001;25(7):882-5.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#137#133#article#203# </font></p>     ^
cY#a09v26n1.htm##
00436000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018500080002001300265#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#138#134#article#203#12#<p>
<font face="Verdana" size="2">12. Petroianu A, Berindoague Neto R. Esplenectomia
    subtotal por via laparosc&oacute;pica em c&atilde;es. Rev Col Bras Cir. 2006
;33(5):305-10.    ^cY#a09v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#139#135#article#203#    </font></p>   
  ^cY#a09v26n1.htm##
00567000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704031600080002001300396#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#140#136#article#203#13#<p>
<font face="Verdana" size="2">13. Paulo DNS, L&aacute;zaro da Silva A, Cintra   
 LC, Bof AM, Santiago DC, Ribeiro GB. Esplenectomia subtotal, em c&atilde;es,   
 com preserva&ccedil;&atilde;o do p&oacute;lo inferior suprido por vasos do liga
mento    gastroespl&ecirc;nico. Rev Col Bras Cir. 1999;26:147-52.    ^cY#a09v26n
1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#141#137#article#203# </font></p>     ^
cY#a09v26n1.htm##
00408000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704015700080002001300237#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#142#138#article#203#14#<p>
<font face="Verdana" size="2">14. Kakkasseril JS, Stewart D, Cox JA. Changing   
 treatment of pediatric splenic trauma. Arch Surg. 1982;117:758-9.    ^cY#a09v26
n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#143#139#article#203# </font></p>     ^
cY#a09v26n1.htm##
00423000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704017200080002001300252#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#144#140#article#203#15#<p>
<font face="Verdana" size="2">15. Brasel KJ, DeLisle CM, Olson CJ, Borgstrom    
DC. Splenic injury: trends in evaluation and management. J Trauma. 1998;44:283-6
.    ^cY#a09v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#145#141#article#203#    </font></p>   
  ^cY#a09v26n1.htm##
00444000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019300080002001300273#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#146#142#article#203#16#<p>
<font face="Verdana" size="2">16. Abrantes WL, Lucena MM, Schlobach MC. Cirurgia
    conservadora do trauma espl&ecirc;nico na crian&ccedil;a. Rev Assoc Med Bras
.    1994;40(2):113-7.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#147#143#article#203# </font></p>     ^
cY#a09v26n1.htm##
00444000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019300080002001300273#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#148#144#article#203#17#<p>
<font face="Verdana" size="2">   17. Haan JM, Bochicchio GV, Kramer N, Scalea TM
. Nonoperative management of    blunt splenic injury: a 5-year experience. J Tra
uma. 2005;58(3):492-8.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#149#145#article#203# </font></p>     ^
cY#a09v26n1.htm##
00617000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704036600080002001300446#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#150#146#article#203#18#<p>
<font face="Verdana" size="2">18. Iwase K, Higaki J, Mikata S, Tanaka Y, Yoshika
wa    M, Hori S, Osuga K, Kosugi S, Tamaki T, Kamiike W. Laparoscopically assist
ed    splenectomy following preoperative splenic artery embolization using conto
ur    emboli for myelofibrosis with massive splenomegaly. Surg Laparosc Endosc P
ercutan    Tech. 1999;9(3):197-202.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#151#147#article#203# </font></p>     ^
cY#a09v26n1.htm##
00454000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020300080002001300283#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#152#148#article#203#19#<p>
<font face="Verdana" size="2">19. Campbell R, Marik PE. Severe autoimmune hemoly
tic    anemia treated by paralysis, induced hypothermia, and splenic embolizatio
n.    Chest. 2005;127(2):678-81.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#153#149#article#203# </font></p>     ^
cY#a09v26n1.htm##
00452000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020100080002001300281#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#154#150#article#203#20#<p>
<font face="Verdana" size="2">20. Ortyl W, Turowska B, Ciazynski M, Zarborski   
 G, Turowski G. Anti-N antibodies after ligation of splenic artery in rabbits.  
  Mater Med Pol. 1989;21:35-7.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#155#151#article#203# </font></p>     ^
cY#a09v26n1.htm##
00393000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704014200080002001300222#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#156#152#article#203#21#<p>
<font face="Verdana" size="2">21. Warshaw A L. Conservation of the spleen with  
  distal pancreatectomy. Arch Surg. 1988;123:550-3.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#157#153#article#203# </font></p>     ^
cY#a09v26n1.htm##
00491000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024000080002001300320#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#158#154#article#203#22#<p>
<font face="Verdana" size="2">22. Ueno T, Okam, Nishihara K, Yamamoto K, Nakamur
a    M, Yahara N, Adachi T. Laparoscopic distal pancreatectomy with preservation
    of the spleen. Surg Laparosc Endosc Percut Tech. 1999;9(4):290-3.    ^cY#a09
v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#159#155#article#203# </font></p>     ^
cY#a09v26n1.htm##
00379000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704012800080002001300208#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#160#156#article#203#23#<p>
<font face="Verdana" size="2">23. Campos-Christo M. Esplenectomias parciais    r
egradas. O Hospital. 1959;56(4):93-8.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#161#157#article#203# </font></p>     ^
cY#a09v26n1.htm##
00453000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020200080002001300282#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#162#158#article#203#24#<p>
<font face="Verdana" size="2">24. Petroianu A. Esplenectomia subtotal e anastomo
se    esplenorrenal proximal para o tratamento da hipertens&atilde;o portal. Rev
 Bras    Cir. 1983;73(2):101-4.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#163#159#article#203# </font></p>     ^
cY#a09v26n1.htm##
00516000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026500080002001300345#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#164#160#article#203#25#<p>
<font face="Verdana" size="2">25. Paulo DNS,Paulo ICA, Kalil M, Vargas PM,    Si
lva AL, Baptista JF, Guerra AJ. Subtotal splenectomy preserving the lower    pol
e in rats: technical, morphological and functional aspects. Acta Cir Bras.    20
06;21(5):1-10.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#165#161#article#203# </font></p>     ^
cY#a09v26n1.htm##
00506000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025500080002001300335#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#166#162#article#203#26#<p>
<font face="Verdana" size="2">26. Paulo ICA, Paulo DNS, Cintra LC, Santos MCS,  
  Rodrigues H, Ferrari TA, Azevedo TCV, L&aacute;zaro da Silva A. Preservative  
  spleen surgery and hyperbaric oxygen therapy. Acta Cir Bras. 2007;22 Suppl 1:2
1-8.    ^cY#a09v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#167#163#article#203#    </font></p>   
  ^cY#a09v26n1.htm##
00458000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020700080002001300287#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#168#164#article#203#27#<p>
<font face="Verdana" size="2">27. Malago R, Reis NS, Ara&uacute;jo MR, Andreollo
    NA. Late histological aspects of spleen autologous transplantation in rats. 
   Acta Cir Bras. 2008;23(3):274-81.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#169#165#article#203# </font></p>     ^
cY#a09v26n1.htm##
00481000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023000080002001300310#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#170#166#article#203#28#<p>
<font face="Verdana" size="2">28. Vasilescu C, Stanciulea O, Colita A. Stoia    
R, Moicean A, Arion C. Splenectomia subtotala laparosc&oacute;pica in tratamentu
l    microsferocitozei ereditare. Chirurgia. 2003;98:571-6.    ^cY#a09v26n1.htm#
#
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#171#167#article#203# </font></p>     ^
cY#a09v26n1.htm##
00434000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018300080002001300263#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#172#168#article#203#29#<p>
<font face="Verdana" size="2">29. Mayberry JC, Sheppard BC, Mullins RJ. Laparosc
opic    management of an enlarging subcapsular splenic hematoma. J Trauma. 1998;
44(3):565-7.    ^cY#a09v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#173#169#article#203#    </font></p>   
  ^cY#a09v26n1.htm##
00440000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704018900080002001300269#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#174#170#article#203#30#<p>
<font face="Verdana" size="2">30. Petroianu A, Cabezas-Andrade MA, Neto RB.    L
aparoscopic splenic autotransplantation. Surg Laparosc Endosc Percutan Tech.    
2006;16(4):259-62.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#175#171#article#203# </font></p>     ^
cY#a09v26n1.htm##
00465000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021400080002001300294#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#176#172#article#203#31#<p>
<font face="Verdana" size="2">31. Costa VA, Oliveira FM, Oliveira Jr LC, Carreir
o    MC, Guimar&atilde;es P. An experimental model of laparoscopic splenectomy i
n    rats. Acta Cir Bras. 2003;18(6):553-6.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#177#173#article#203# </font></p>     ^
cY#a09v26n1.htm##
00445000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019400080002001300274#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#178#174#article#203#32#<p>
<font face="Verdana" size="2">32. Paulo DNS, Ramos BF, Zanetti FR. Growth of    
the lower spleen pole remaining after subtotal splenectomy in rats. Acta Cir    
Bras. 2008;23(2):125-9.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#179#175#article#203# </font></p>     ^
cY#a09v26n1.htm##
00505000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025400080002001300334#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#180#176#article#203#33#<p>
<font face="Verdana" size="2">33. Torres OJM, Macedo EL, Picciani ERG, Nunes    
PMS, Costa JVG, Carvalho AB, Lobato Jr PS. Histological study of splenic regener
ation    in rats underwent to subtotal splenectomy. Acta Cir Bras. 2000;15(2):1-
12.    ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#181#177#article#203# </font></p>     ^
cY#a09v26n1.htm##
00421000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704017000080002001300250#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#182#178#article#203#34#<p>
<font face="Verdana" size="2">34. Bradshaw PH, Thomas CG. Regeneration of spleni
c    remnants after partial splenectomy in rats. J Surg Res. 1982;32(2):176-81. 
   ^cY#a09v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#183#179#article#203# </font></p>     ^
cY#a09v26n1.htm##
00404000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704015300080002001300233#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#184#180#article#203#35#<p>
<font face="Verdana" size="2">35. Pisters PWT, Pachter HL. Autologus splenic    
transplantation for splenic trauma. Ann Surg. 1994;219:225-35.    ^cY#a09v26n1.h
tm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#185#181#article#203# </font></p>     ^
cY#a09v26n1.htm##
00426000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704017500080002001300255#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#p#186#182#article#203#36#<p>
<font face="Verdana" size="2">36. Van Wick DB, White MH, White CL. Critical    s
plenic mass for survival from experimental pneumococcemia. J Surg Res. 1980;28:1
4-7.    ^cY#a09v26n1.htm##
00261000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002500077002001300102#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#187#183#article#203#    </font></p>   
   ^cY#a09v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#188#184#article#203#<p>&nbsp; </p>    
 ^cY#a09v26n1.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007700077002001300154#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#189#185#article#203#<p><font face="Ver
dana" size="3"><B>Acknowledgments</B> </font></p>      ^cY#a09v26n1.htm##
00547000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704031100077002001300388#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#190#186#article#203#<p><font face="Ver
dana" size="2"> Rafael Melo Silva, Graduate Student, Emescam;    Bernardo Faria 
Ramos, Resident of Otorhinolaryngology, Clinical Hospital, University    of Sao 
Paulo and Fernando Roberte Zanetti, Resident of Ophthalmology from UNICAMP,    h
elped with technical procedure. </font></p>      ^cY#a09v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#191#187#article#203#<p>&nbsp;</p>     
^cY#a09v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#192#188#article#203#<p>&nbsp;</p>     
^cY#a09v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#193#189#article#203#<p>&nbsp;</p>     
^cY#a09v26n1.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704015500077002001300232#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#194#190#article#203#<p><font face="Ver
dana" size="2"><B><a name="end"></a><a href="#top"><img src="/img/revistas/acb/v
26n1/seta.gif" border="0"></a>Correspondence</B>:    ^cY#a09v26n1.htm##
00277000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004100077002001300118#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#195#191#article#203#<br>   Jos&eacute;
 Jorge da Silva    ^cY#a09v26n1.htm##
00293000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005700077002001300134#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#196#192#article#203#<br>   Rua Desemba
rgador Augusto Botelho, 108/904    ^cY#a09v26n1.htm##
00281000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004500077002001300122#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#197#193#article#203#<br>   29101-110 V
ila Velha-ES Brasil    ^cY#a09v26n1.htm##
00321000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704008500077002001300162#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#198#194#article#203#<br>   <a href="ma
ilto:drjjorge@gmail.com">drjjorge@gmail.com</a></font></p>     ^cY#a09v26n1.htm#
#
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#199#195#article#203#<p>&nbsp;</p>     
^cY#a09v26n1.htm##
00300000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006400077002001300141#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#200#196#article#203#<p><font face="Ver
dana" size="2">Received: July 27, 2010    ^cY#a09v26n1.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#201#197#article#203#<br>   </font><fon
t face="Verdana" size="2">Review: September 21, 2010    ^cY#a09v26n1.htm##
00326000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009000077002001300167#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#202#198#article#203#<br>   </font><fon
t face="Verdana" size="2">Accepted: October 26, 2010</font></p>     ^cY#a09v26n1
.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006700077002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#203#199#article#203#<p><font face="Ver
dana" size="2">Conflict of interest: none    ^cY#a09v26n1.htm##
00337000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010100077002001300178#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#204#200#article#203#<br>   </font><fon
t face="Verdana" size="2">Financial source: Solidary Institute </font></p>     ^
cY#a09v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#205#201#article#203#<p>&nbsp;</p>     
^cY#a09v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#206#202#article#203#<p>&nbsp;</p>     
^cY#a09v26n1.htm##
00504000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704026800077002001300345#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a09v26n1.htm#S#p#207#203#article#203#<p><font face="Ver
dana" size="2"><sup><a name="end"></a><a href="#top">1</a> </sup>Research    per
formed at the Laboratory of Inflammation, Department of Pharmacology, Faculty   
 of Medical Sciences, State University of Campinas (UNICAMP), Brazil. </font></p
>     ^cY#a09v26n1.htm##
00480000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100017000920120
03300109030001000142710000200152065000900154064000500163031000400168032000200172
014000600174865000900180002001300189#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09
v26n1.htm#S#c#208#1#article#36#1#^rND^sCadili^nA#^rND^sde Gara^nC#Complications 
of splenectomy^len#Am J Med.#2#20080000#2008#121#5#371-5#20110200#a09v26n1.htm##
00538000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100016000940100
01600110012004700126030002600173710000200199065000900201064000500210031000200215
032000200217014000700219865000900226002001300235#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a09v26n1.htm#S#c#209#2#article#36#2#^rND^sSumaraju^nV#^rND^sSmith^nLG#^
rND^sSmith^nSM#Infectious complications in asplenic hosts^len#Infect Dis Clin No
rth Am.#2#20010000#2001#5#2#551-65#20110200#a09v26n1.htm##
00563000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100017000950100
01800112012009100130030001700221710000200238065000900240064000500249031000400254
014000500258865000900263002001300272#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09
v26n1.htm#S#c#210#3#article#36#3#^rND^sAndersson^nR#^rND^sAlwmark^nA#^rND^sBengm
ark^nS#Outcome of pneumococcal challenge in rats after splenic artery ligation o
r splenectomy^len#Acta Chir Scand.#2#19860000#1986#152#15-7#20110200#a09v26n1.ht
m##
00656000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100016000920100
02300108010001600131012014400147030001400291710000200305065000900307064000500316
031000400321032000200325014000500327865000900332002001300341#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a09v26n1.htm#S#c#211#4#article#36#4#^rND^sAviram^nM#^rND^sB
rook^nJG#^rND^sTatarsky^nLevy Y#^rND^sCarter^nA#Increased low-density lipoprotei
n levels after splenectomy: a role for the spleen in cholesterol metabolism in m
yeloproliferative disorders^len#Am J Med Sci.#2#19860000#1986#291#1#25-8#2011020
0#a09v26n1.htm##
00518000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100025000930120
06800118030001800186710000200204065000900206064000500215031000300220014000700223
865000900230002001300239#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#
c#212#5#article#36#5#^rND^sPaulo^nDNS#^rND^sLázaro da Silva^nA#Lipídios plasmáti
cos após esplenectomia total e parcial em cães^lpt#Rev Col Bras Cir.#2#20010000#
2001#28#264-70#20110200#a09v26n1.htm##
00605000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100014000760100016000900100
01500106010001600121010001600137012007600153030001100229710000200240065000900242
064000500251031000300256032000200259014000800261865000900269002001300278#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#c#213#6#article#36#6#^rND^sAsai^
nK#^rND^sKuzuya^nM#^rND^sNaito^nM#^rND^sFunaki^nC#^rND^sKuzuya^nF#Effects of spl
enectomy on serum lipids and experimental atherosclerosis^len#Angiology.#2#19880
000#1988#39#6#497-504#20110200#a09v26n1.htm##
00475000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100014000760120059000900300
01100149710000200160065000900162064000500171031000300176032000200179014000600181
865000900187002001300196#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#
c#214#7#article#36#7#^rND^sMühe^nE#Long-term follow-up after laparoscopic cholec
ystectomy^len#Endoscopy.#2#19920000#1992#24#9#754-8#20110200#a09v26n1.htm##
00471000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760120050000920300
01100142710000200153065000900155064000500164031000400169032000300173014000700176
865000900183002001300192#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#
c#215#8#article#36#8#^rND^sMouret^nP#Celioscopic surgery. Evolution or revolutio
n?^len#Chirurgie.#2#19900000#1990#116#10#829-32#20110200#a09v26n1.htm##
00514000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100018000940120
04500112030003000157710000200187065000900189064000500198031000300203032000300206
014000500209865000900214002001300223#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09
v26n1.htm#S#c#216#9#article#36#9#^rND^sDelaitre^nB#^rND^sMaignien^nB#Splenectomy
 by the laparoscopic approach^len#Report of a case. Presse Med.#2#19910000#1991#
20#44#2263#20110200#a09v26n1.htm##
00555000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950100
02100113010001400134012004800148030002200196710000200218065000900220064000500229
031000200234014000700236865000900243002001300252#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a09v26n1.htm#S#c#217#10#article#36#10#^rND^sPoulin^nEC#^rND^sThibault^n
C#^rND^sDesCôteaux^nJG#^rND^sCote^nG#Partial laparoscopic splenectomy for trauma
^len#Surg Laparosc Endosc.#2#19950000#1995#5#306-10#20110200#a09v26n1.htm##
00647000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100020000950100
01600115010001700131010001400148010001500162012008100177030001400258710000200272
06500090027406400050028303100030028803200020029101400060029386500090029900200130
0308#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#c#218#11#article#36#
11#^rND^sEspert^nJJ#^rND^sTargarona^nEM#^rND^sBombuy^nE#^rND^sSetoain^nJ#^rND^sV
isa^nJ#^rND^sTrias^nM#Evaluation of risk of splenosis during laparoscopic splene
ctomy in rat model^len#World J Surg.#2#20010000#2001#25#7#882-5#20110200#a09v26n
1.htm##
00526000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100026000970120
05700123030001800180710000200198065000900200064000500209031000300214032000200217
014000700219865000900226002001300235#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09
v26n1.htm#S#c#219#12#article#36#12#^rND^sPetroianu^nA#^rND^sBerindoague Neto^nR#
Esplenectomia subtotal por via laparoscópica em cães^lpt#Rev Col Bras Cir.#2#200
60000#2006#33#5#305-10#20110200#a09v26n1.htm##
00685000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100025000950100
01700120010001400137010001900151010001800170012011700188030001800305710000200323
065000900325064000500334031000300339014000700342865000900349002001300358#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#c#220#13#article#36#13#^rND^sPau
lo^nDNS#^rND^sLázaro da Silva^nA#^rND^sCintra^nLC#^rND^sBof^nAM#^rND^sSantiago^n
DC#^rND^sRibeiro^nGB#Esplenectomia subtotal, em cães, com preservação do pólo in
ferior suprido por vasos do ligamento gastroesplênico^lpt#Rev Col Bras Cir.#2#19
990000#1999#26#147-52#20110200#a09v26n1.htm##
00519000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100022000780100017001000100
01400117012005100131030001100182710000200193065000900195064000500204031000400209
014000600213865000900219002001300228#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09
v26n1.htm#S#c#221#14#article#36#14#^rND^sKakkasseril^nJS#^rND^sStewart^nD#^rND^s
Cox^nJA#Changing treatment of pediatric splenic trauma^len#Arch Surg.#2#19820000
#1982#117#758-9#20110200#a09v26n1.htm##
00552000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950100
01600113010002000129012005600149030001000205710000200215065000900217064000500226
031000300231014000600234865000900240002001300249#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a09v26n1.htm#S#c#222#15#article#36#15#^rND^sBrasel^nKJ#^rND^sDeLisle^nC
M#^rND^sOlson^nCJ#^rND^sBorgstrom^nDC#Splenic injury: trends in evaluation and m
anagement^len#J Trauma.#2#19980000#1998#44#283-6#20110200#a09v26n1.htm##
00550000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100017000970100
02000114012005700134030002000191710000200211065000900213064000500222031000300227
032000200230014000600232865000900238002001300247#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a09v26n1.htm#S#c#223#16#article#36#16#^rND^sAbrantes^nWL#^rND^sLucena^n
MM#^rND^sSchlobach^nMC#Cirurgia conservadora do trauma esplênico na criança^lpt#
Rev Assoc Med Bras.#2#19940000#1994#40#2#113-7#20110200#a09v26n1.htm##
00581000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100021000930100
01600114010001700130012007300147030001000220710000200230065000900232064000500241
031000300246032000200249014000600251865000900257002001300266#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a09v26n1.htm#S#c#224#17#article#36#17#^rND^sHaan^nJM#^rND^s
Bochicchio^nGV#^rND^sKramer^nN#^rND^sScalea^nTM#Nonoperative management of blunt
 splenic injury: a 5-year experience^len#J Trauma.#2#20050000#2005#58#3#492-8#20
110200#a09v26n1.htm##
00856000000000373000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100016000930100
01600109010001600125010001900141010001400160010001500174010001600189010001600205
01000170022101201580023803000360039671000020043206500090043406400050044303100020
0448032000200450014000800452865000900460002001300469#v26n1#V:\Scielo\serial\acb\
v26n1\markup\a09v26n1.htm#S#c#225#18#article#36#18#^rND^sIwase^nK#^rND^sHigaki^n
J#^rND^sMikata^nS#^rND^sTanaka^nY#^rND^sYoshikawa^nM#^rND^sHori^nS#^rND^sOsuga^n
K#^rND^sKosugi^nS#^rND^sTamaki^nT#^rND^sKamiike^nW#Laparoscopically assisted spl
enectomy following preoperative splenic artery embolization using contour emboli
 for myelofibrosis with massive splenomegaly^len#Surg Laparosc Endosc Percutan T
ech.#2#19990000#1999#9#3#197-202#20110200#a09v26n1.htm##
00555000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960120
10700112030000700219710000200226065000900228064000500237031000400242032000200246
014000700248865000900255002001300264#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09
v26n1.htm#S#c#226#19#article#36#19#^rND^sCampbell^nR#^rND^sMarik^nPE#Severe auto
immune hemolytic anemia treated by paralysis, induced hypothermia, and splenic e
mbolization^len#Chest.#2#20050000#2005#127#2#678-81#20110200#a09v26n1.htm##
00596000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100018000930100
01900111010001900130010001800149012006600167030001500233710000200248065000900250
064000500259031000300264014000500267865000900272002001300281#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a09v26n1.htm#S#c#227#20#article#36#20#^rND^sOrtyl^nW#^rND^s
Turowska^nB#^rND^sCiazynski^nM#^rND^sZarborski^nG#^rND^sTurowski^nG#Anti-N antib
odies after ligation of splenic artery in rabbits^len#Mater Med Pol.#2#19890000#
1989#21#35-7#20110200#a09v26n1.htm##
00468000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780120058000970300
01100155710000200166065000900168064000500177031000400182014000600186865000900192
002001300201#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#c#228#21#art
icle#36#21#^rND^sWarshaw^nA L#Conservation of the spleen with distal pancreatect
omy^len#Arch Surg.#2#19880000#1988#123#550-3#20110200#a09v26n1.htm##
00663000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100024000920100
01800116010001800134010001600152010001600168012007100184030003400255710000200289
06500090029106400050030003100020030503200020030701400060030986500090031500200130
0324#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#c#229#22#article#36#
22#^rND^sUeno^nT#^rND^sOkam^nNishihara K#^rND^sYamamoto^nK#^rND^sNakamura^nM#^rN
D^sYahara^nN#^rND^sAdachi^nT#Laparoscopic distal pancreatectomy with preservatio
n of the spleen^len#Surg Laparosc Endosc Percut Tech.#2#19990000#1999#9#4#290-3#
20110200#a09v26n1.htm##
00465000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100024000780120037001020300
01200139710000200151065000900153064000500162031000300167032000200170014000500172
865000900177002001300186#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#
c#230#23#article#36#23#^rND^sCampos-Christo^nM#Esplenectomias parciais regradas^
len#O Hospital.#2#19590000#1959#56#4#93-8#20110200#a09v26n1.htm##
00529000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780120103000970300
01400200710000200214065000900216064000500225031000300230032000200233014000600235
865000900241002001300250#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#
c#231#24#article#36#24#^rND^sPetroianu^nA#Esplenectomia subtotal e anastomose es
plenorrenal proximal para o tratamento da hipertensão portal^lpt#Rev Bras Cir.#2
#19830000#1983#73#2#101-4#20110200#a09v26n1.htm##
00705000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01500112010001700127010001600144010001900160010001700179012010800196030001500304
71000020031906500090032106400050033003100030033503200020033801400050034086500090
0345002001300354#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#c#232#25
#article#36#25#^rND^sPaulo^nDNS#^rND^sPaulo^nICA#^rND^sKalil^nM#^rND^sVargas^nPM
#^rND^sSilva^nAL#^rND^sBaptista^nJF#^rND^sGuerra^nAJ#Subtotal splenectomy preser
ving the lower pole in rats: technical, morphological and functional aspects^len
#Acta Cir Bras.#2#20060000#2006#21#5#1-10#20110200#a09v26n1.htm##
00711000000000349000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01700112010001800129010001900147010001800166010001900184010002500203012006200228
03000150029071000020030506500090030706400050031603100030032103200100032401400050
0334865000900339002001300348#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.ht
m#S#c#233#26#article#36#26#^rND^sPaulo^nICA#^rND^sPaulo^nDNS#^rND^sCintra^nLC#^r
ND^sSantos^nMCS#^rND^sRodrigues^nH#^rND^sFerrari^nTA#^rND^sAzevedo^nTCV#^rND^sLá
zaro da Silva^nA#Preservative spleen surgery and hyperbaric oxygen therapy^len#A
cta Cir Bras.#2#20070000#2007#22#^sSuppl 1#21-8#20110200#a09v26n1.htm##
00588000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100015000940100
01700109010002000126012007500146030001500221710000200236065000900238064000500247
031000300252032000200255014000700257865000900264002001300273#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a09v26n1.htm#S#c#234#27#article#36#27#^rND^sMalago^nR#^rND^
sReis^nNS#^rND^sAraújo^nMR#^rND^sAndreollo^nNA#Late histological aspects of sple
en autologous transplantation in rats^len#Acta Cir Bras.#2#20080000#2008#23#3#27
4-81#20110200#a09v26n1.htm##
00636000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100020000970100
01600117010001500133010001700148010001500165012008400180030001100264710000200275
065000900277064000500286031000300291014000600294865000900300002001300309#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#c#235#28#article#36#28#^rND^sVas
ilescu^nC#^rND^sStanciulea^nO#^rND^sColita^nA#^rND^sStoia^nR#^rND^sMoicean^nA#^r
ND^sArion^nC#Splenectomia subtotala laparoscópica in tratamentul microsferocitoz
ei ereditare^lro#Chirurgia.#2#20030000#2003#98#571-6#20110200#a09v26n1.htm##
00556000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100019000970100
01800116012007300134030001000207710000200217065000900219064000500228031000300233
032000200236014000600238865000900244002001300253#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a09v26n1.htm#S#c#236#29#article#36#29#^rND^sMayberry^nJC#^rND^sSheppard
^nBC#^rND^sMullins^nRJ#Laparoscopic management of an enlarging subcapsular splen
ic hematoma^len#J Trauma.#2#19980000#1998#44#3#565-7#20110200#a09v26n1.htm##
00559000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100026000970100
01500123012004500138030003600183710000200219065000900221064000500230031000300235
032000200238014000700240865000900247002001300256#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a09v26n1.htm#S#c#237#30#article#36#30#^rND^sPetroianu^nA#^rND^sCabezas-
Andrade^nMA#^rND^sNeto^nRB#Laparoscopic splenic autotransplantation^len#Surg Lap
arosc Endosc Percutan Tech.#2#20060000#2006#16#4#259-62#20110200#a09v26n1.htm##
00613000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100019000940100
02200113010001900135010001900154012006200173030001500235710000200250065000900252
064000500261031000300266032000200269014000600271865000900277002001300286#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#c#238#31#article#36#31#^rND^sCos
ta^nVA#^rND^sOliveira^nFM#^rND^sOliveira Jr^nLC#^rND^sCarreiro^nMC#^rND^sGuimarã
es^nP#An experimental model of laparoscopic splenectomy in rats^len#Acta Cir Bra
s.#2#20030000#2003#18#6#553-6#20110200#a09v26n1.htm##
00564000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
01800111012008100129030001500210710000200225065000900227064000500236031000300241
032000200244014000600246865000900252002001300261#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a09v26n1.htm#S#c#239#32#article#36#32#^rND^sPaulo^nDNS#^rND^sRamos^nBF#
^rND^sZanetti^nFR#Growth of the lower spleen pole remaining after subtotal splen
ectomy in rats^len#Acta Cir Bras.#2#20080000#2008#23#2#125-9#20110200#a09v26n1.h
tm##
00696000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100017000960100
02000113010001700133010001700150010001900167010002000186012008900206030001500295
71000020031006500090031206400050032103100030032603200020032901400050033186500090
0336002001300345#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#c#240#33
#article#36#33#^rND^sTorres^nOJM#^rND^sMacedo^nEL#^rND^sPicciani^nERG#^rND^sNune
s^nPMS#^rND^sCosta^nJVG#^rND^sCarvalho^nAB#^rND^sLobato Jr^nPS#Histological stud
y of splenic regeneration in rats underwent to subtotal splenectomy^len#Acta Cir
 Bras.#2#20000000#2000#15#2#1-12#20110200#a09v26n1.htm##
00525000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100017000970120
07100114030001200185710000200197065000900199064000500208031000300213032000200216
014000700218865000900225002001300234#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09
v26n1.htm#S#c#241#34#article#36#34#^rND^sBradshaw^nPH#^rND^sThomas^nCG#Regenerat
ion of splenic remnants after partial splenectomy in rats^len#J Surg Res.#2#1982
0000#1982#32#2#176-81#20110200#a09v26n1.htm##
00497000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100018000970120
05700115030001000172710000200182065000900184064000500193031000400198014000700202
865000900209002001300218#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09v26n1.htm#S#
c#242#35#article#36#35#^rND^sPisters^nPWT#^rND^sPachter^nHL#Autologus splenic tr
ansplantation for splenic trauma^len#Ann Surg.#2#19940000#1994#219#225-35#201102
00#a09v26n1.htm##
00537000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100016000970100
01600113012007200129030001200201710000200213065000900215064000500224031000300229
014000500232865000900237002001300246#v26n1#V:\Scielo\serial\acb\v26n1\markup\a09
v26n1.htm#S#c#243#36#article#36#36#^rND^sVan Wick^nDB#^rND^sWhite^nMH#^rND^sWhit
e^nCL#Critical splenic mass for survival from experimental pneumococcemia^len#J 
Surg Res.#2#19800000#1980#28#14-7#20110200#a09v26n1.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#o#1#1#article#1#
20110120#130153#a10v26n1.htm#193##
04801000000000709000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400090014103500100015001201820
01600120164003420100025005060100028005310100025005590100024005840700111006080700
09600719070009200815070009700907083137401004085000802378085002202386085002702408
08500290243508500190246408500170248308313630250008500080386308500230387108500290
38940850033039230850018039560850018039741170006039920720003039981120009040011110
01404010116000904024115001904033114000904052113001704061002001304078#v26n1#V:\Sc
ielo\serial\acb\v26n1\markup\a10v26n1.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#IL
US#TAB#10#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f51^l57#0102-8650#The compari
son of methylene blue and vitamin E in prevention of abdominal postoperative adh
esion formation in rat uterine horn models: Biochemical and histopathologic eval
uation^len#Comparação do azul de metileno e vitamina E na prevenção de aderência
 abdominal pós-operatória em corno uterino de ratos: avalição bioquímica e histo
patológica^lpt#^rND^1A01^nHamit^sYildiz#^rND^1A02^nAli Said^sDurmus#^rND^1A03^nH
alil^sSimsek#^rND^1A04^nIhsan^sYaman#Firat University^iA01^1Faculty of Veterinar
y Medicine^2Department of Obstetrics and Gynecology^cElazig^pTurkey#University o
f Firat^iA02^1Faculty of Veterinary Medicine^2Department of Surgery^cElazig^pTur
key#University of Bingöl^iA03^1School of Higher Education^2Sanitary Services Voc
ational^pTurkey#University of Firat^iA04^1Faculty of Veterinary Medicine^2Depart
ment of Patology^cElazig^pTurkey#^len^aPurpose: To compare the effects of vitami
n E and 1% methylen blue solutions on prevention of experimentally induced adhes
ions in rats. Methods: Thirty seven female Spraque Dawley rats were randomized i
nto four groups. First group was kept as sham operated group. An adhesion model 
was constituted on the left uterine horn of the other groups. The lesion areas o
f rats from the second, the third and the fourth groups were coated with 2 ml 0.
9 % saline solution (C group), 10 mg vitamin E (VE group) and 1% methylen blue s
olutions (MB group), respectively. Results: Histopathologically, adhesion scores
, mononuclear cell infiltration, oedema and fibrosis were more prominent in the 
MB group compared with C and VE groups. There were no significant differences be
tween the groups in tissue glutathione peroxidase (GPx), catalase (CAT) activiti
es and glutation (GSH) level, these parameters were slightly increased in group 
with VE supplementation though. The administration of VE and MB significantly de
creased NO (P<0.01) levels when compared to the C group. The level of malondiald
ehyde (MDA) in the VE group was significantly lower (P<0.05) than those of the S
h and C groups. Conclusion: Intraperitoneal methylen blue solutions treatments w
ere more effective according to vitamin E in preventing the formation of intra-a
bdominal adhesion in a rat uterine horn model.#^dnd^i1#^tm^len^kVitamin E^i1#^tm
^len^kMethylene Blue^i1#^tm^len^kTissue Adhesions^i1#^tm^len^kUterus^i1#^tm^len^
kRats^i1#^lpt^aObjetivo: Comparar os efeitos da vitamina E e 1% da solução de az
ul de metileno na prevenção de aderências induzidas em ratos. Métodos: Trinta e 
sete ratos fêmeas Spraque Dawley foram distribuídos em quatro grupos. O primeiro
 grupo foi mantido como grupo sham. O modelo de aderência foi realizado no corno
 uterino esquerdo nos outros grupos. As áreas da lesão dos ratos do segundo, ter
ceiro e quarto grupos foram revestidas com 2 ml de solução salina 0,9% (Grupo C)
, 10 mg de vitamina E (Grupo VE) e solução de azul de metileno 1% (Grupo MB), re
spectivamente. Resultados: Histopatologicamente, o escore das aderências, infilt
ração celular mononuclear, edema e fibrose foram mais proeminentes no grupo MB e
m comparação aos grupos C e VE. Não houve diferença significante entre os grupos
 na peroxidase da glutatione do tecido (GPx), atividade da catalase (CAT) e o ní
vel de glutation (GSH). Estes parâmetros foram ligeiramente aumentados no grupo 
com suplemento da VE. A administração da VE e do MB diminuiu significantemente o
s níveis quando quando comparada ao Grupo C. O nível de malondialdeído no grupo 
VE foi significantemente mais baixo do que nos grupos sham e C. Conclusão: A adm
inistração intraperitoneal da solução de azul de metileno foi mais eficaz de aco
rdo com a vitamina E na prevenção de aderências intra-abdominais no corno uterin
o de ratos.#^dnd^i2#^tm^lpt^kVitamina E^i2#^tm^lpt^kAzul de Metileno^i2#^tm^lpt^
kAderências Teciduais^i2#^tm^lpt^kÚtero^i2#^tm^lpt^kRatos^i2#other#33#20100714#J
uly 14, 2010#20100921#September 21, 2010#20101020#October 20, 2010#a10v26n1.htm#
#
04898000000000709000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400090014103500100015001201960
01600120171003560100025005270100028005520100025005800100024006050700111006290700
09600740070009200836070009700928083140801025085000802433085002202441085002702463
08500290249008500190251908500170253808314050255508500080396008500230396808500290
39910850033040200850018040530850018040711170006040890720003040951120009040981110
01404107116000904121115001904130114000904149113001704158002001304175#v26n1#V:\Sc
ielo\serial\acb\v26n1\markup\a10v26n1.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#IL
US#TAB#10#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f51^l57#0102-8650#<b>The comp
arison of methylene blue and vitamin E in prevention of abdominal postoperative 
adhesion formation in rat uterine horn models</b>: <b>Biochemical and histopatho
logic evaluation</b>^len#<b>Comparação do azul de metileno e vitamina E na preve
nção de aderência abdominal pós-operatória em corno uterino de ratos</b>: avaliç
ão bioquímica e histopatológica^lpt#^rND^1A01^nHamit^sYildiz#^rND^1A02^nAli Said
^sDurmus#^rND^1A03^nHalil^sSimsek#^rND^1A04^nIhsan^sYaman#Firat University^iA01^
1Faculty of Veterinary Medicine^2Department of Obstetrics and Gynecology^cElazig
^pTurkey#University of Firat^iA02^1Faculty of Veterinary Medicine^2Department of
 Surgery^cElazig^pTurkey#University of Bingöl^iA03^1School of Higher Education^2
Sanitary Services Vocational^pTurkey#University of Firat^iA04^1Faculty of Veteri
nary Medicine^2Department of Patology^cElazig^pTurkey#^len^a<b>Purpose</b>: To c
ompare the effects of vitamin E and 1% methylen blue solutions on prevention of 
experimentally induced adhesions in rats. <b>Methods</b>: Thirty seven female Sp
raque Dawley rats were randomized into four groups. First group was kept as sham
 operated group. An adhesion model was constituted on the left uterine horn of t
he other groups. The lesion areas of rats from the second, the third and the fou
rth groups were coated with 2 ml 0.9 % saline solution (C group), 10 mg vitamin 
E (VE group) and 1% methylen blue solutions (MB group), respectively. <b>Results
</b>: Histopathologically, adhesion scores, mononuclear cell infiltration, oedem
a and fibrosis were more prominent in the MB group compared with C and VE groups
. There were no significant differences between the groups in tissue glutathione
 peroxidase (GPx), catalase (CAT) activities and glutation (GSH) level, these pa
rameters were slightly increased in group with VE supplementation though. The ad
ministration of VE and MB significantly decreased NO (P&lt;0.01) levels when com
pared to the C group. The level of malondialdehyde (MDA) in the VE group was sig
nificantly lower (P&lt;0.05) than those of the Sh and C groups. <b>Conclusion</b
>: Intraperitoneal methylen blue solutions treatments were more effective accord
ing to vitamin E in preventing the formation of intra-abdominal adhesion in a ra
t uterine horn model.#^dnd^i1#^tm^len^kVitamin E^i1#^tm^len^kMethylene Blue^i1#^
tm^len^kTissue Adhesions^i1#^tm^len^kUterus^i1#^tm^len^kRats^i1#^lpt^a<b>Objetiv
o</b>: Comparar os efeitos da vitamina E e 1% da solução de azul de metileno na 
prevenção de aderências induzidas em ratos. <b>Métodos</b>: Trinta e sete ratos 
fêmeas Spraque Dawley foram distribuídos em quatro grupos. O primeiro grupo foi 
mantido como grupo <i>sham</i>. O modelo de aderência foi realizado no corno ute
rino esquerdo nos outros grupos. As áreas da lesão dos ratos do segundo, terceir
o e quarto grupos foram revestidas com 2 ml de solução salina 0,9% (Grupo C), 10
 mg de vitamina E (Grupo VE) e solução de azul de metileno 1% (Grupo MB), respec
tivamente. <b>Resultados</b>: Histopatologicamente, o escore das aderências, inf
iltração celular mononuclear, edema e fibrose foram mais proeminentes no grupo M
B em comparação aos grupos C e VE. Não houve diferença significante entre os gru
pos na peroxidase da glutatione do tecido (GPx), atividade da catalase (CAT) e o
 nível de glutation (GSH). Estes parâmetros foram ligeiramente aumentados no gru
po com suplemento da VE. A administração da VE e do MB diminuiu significantement
e os níveis quando quando comparada ao Grupo C. O nível de malondialdeído no gru
po VE foi significantemente mais baixo do que nos grupos <i>sham </i>e C. <b>Con
clusão</b>: A administração intraperitoneal da solução de azul de metileno foi m
ais eficaz de acordo com a vitamina E na prevenção de aderências intra-abdominai
s no corno uterino de ratos.#^dnd^i2#^tm^lpt^kVitamina E^i2#^tm^lpt^kAzul de Met
ileno^i2#^tm^lpt^kAderências Teciduais^i2#^tm^lpt^kÚtero^i2#^tm^lpt^kRatos^i2#ot
her#33#20100714#July 14, 2010#20100921#September 21, 2010#20101020#October 20, 2
010#a10v26n1.htm##
04987000000000733000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000150012903100030014403200020014706500090014901400090015803500100
01670120182001770120164003590100025005230100028005480100025005760100024006010700
11300625070009800738070009400836070009900930083139501029085000802424085002202432
08500270245408500290248108500190251008500170252908313900254608500080393608500230
39440850029039670850033039960850018040290850018040471170006040650720003040711120
00904074111001404083116000904097115001904106114000904125113001704134002001304151
008008904164#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#l#4#1#articl
e#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#10#ACB720#nd#Acta cir. bras#26#
1#20110200#^f51^l57#0102-8650#The comparison of methylene blue and vitamin E in 
prevention of abdominal postoperative adhesion formation in rat uterine horn mod
els: Biochemical and histopathologic evaluation^len#Comparação do azul de metile
no e vitamina E na prevenção de aderência abdominal pós-operatória em corno uter
ino de ratos: avalição bioquímica e histopatológica^lpt#^rND^1A01^nHamit^sYildiz
#^rND^1A02^nAli Said^sDurmus#^rND^1A03^nHalil^sSimsek#^rND^1A04^nIhsan^sYaman#^i
A01^1Firat University^2Faculty of Veterinary Medicine^3Department of Obstetrics 
and Gynecology^cElazig^pTurkey#^iA02^1University of Firat^2Faculty of Veterinary
 Medicine^3Department of Surgery^cElazig^pTurkey#^iA03^1University of Bingöl^2Sc
hool of Higher Education^3Sanitary Services Vocational^pTurkey#^iA04^1University
 of Firat^2Faculty of Veterinary Medicine^3Department of Patology^cElazig^pTurke
y#^len^aPurpose: To compare the effects of vitamin E and 1 percent methylen blue
 solutions on prevention of experimentally induced adhesions in rats. Methods: T
hirty seven female Spraque Dawley rats were randomized into four groups. First g
roup was kept as sham operated group. An adhesion model was constituted on the l
eft uterine horn of the other groups. The lesion areas of rats from the second, 
the third and the fourth groups were coated with 2 ml 0.9  percent saline soluti
on (C group), 10 mg vitamin E (VE group) and 1 percent methylen blue solutions (
MB group), respectively. Results: Histopathologically, adhesion scores, mononucl
ear cell infiltration, oedema and fibrosis were more prominent in the MB group c
ompared with C and VE groups. There were no significant differences between the 
groups in tissue glutathione peroxidase (GPx), catalase (CAT) activities and glu
tation (GSH) level, these parameters were slightly increased in group with VE su
pplementation though. The administration of VE and MB significantly decreased NO
 (P<0.01) levels when compared to the C group. The level of malondialdehyde (MDA
) in the VE group was significantly lower (P<0.05) than those of the Sh and C gr
oups. Conclusion: Intraperitoneal methylen blue solutions treatments were more e
ffective according to vitamin E in preventing the formation of intra-abdominal a
dhesion in a rat uterine horn model.#^dnd^i1#^tm^len^kVitamin E^i1#^tm^len^kMeth
ylene Blue^i1#^tm^len^kTissue Adhesions^i1#^tm^len^kUterus^i1#^tm^len^kRats^i1#^
lpt^aObjetivo: Comparar os efeitos da vitamina E e 1 por cento da solução de azu
l de metileno na prevenção de aderências induzidas em ratos. Métodos: Trinta e s
ete ratos fêmeas Spraque Dawley foram distribuídos em quatro grupos. O primeiro 
grupo foi mantido como grupo sham. O modelo de aderência foi realizado no corno 
uterino esquerdo nos outros grupos. As áreas da lesão dos ratos do segundo, terc
eiro e quarto grupos foram revestidas com 2 ml de solução salina 0,9 por cento (
Grupo C), 10 mg de vitamina E (Grupo VE) e solução de azul de metileno 1 por cen
to (Grupo MB), respectivamente. Resultados: Histopatologicamente, o escore das a
derências, infiltração celular mononuclear, edema e fibrose foram mais proeminen
tes no grupo MB em comparação aos grupos C e VE. Não houve diferença significant
e entre os grupos na peroxidase da glutatione do tecido (GPx), atividade da cata
lase (CAT) e o nível de glutation (GSH). Estes parâmetros foram ligeiramente aum
entados no grupo com suplemento da VE. A administração da VE e do MB diminuiu si
gnificantemente os níveis quando quando comparada ao Grupo C. O nível de malondi
aldeído no grupo VE foi significantemente mais baixo do que nos grupos sham e C.
 Conclusão: A administração intraperitoneal da solução de azul de metileno foi m
ais eficaz de acordo com a vitamina E na prevenção de aderências intra-abdominai
s no corno uterino de ratos.#^dnd^i2#^tm^lpt^kVitamina E^i2#^tm^lpt^kAzul de Met
ileno^i2#^tm^lpt^kAderências Teciduais^i2#^tm^lpt^kÚtero^i2#^tm^lpt^kRatos^i2#ot
her#33#20100714#July 14, 2010#20100921#September 21, 2010#20101020#October 20, 2
010#a10v26n1.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pi
d=S0102-86502011000100010##
00311000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704007900073002001300152#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#5#1#article#156#<p align="right"><font
 face="Verdana" size="2"><b>10 - ORIGINAL ARTICLE    ^cY#a10v26n1.htm##
00325000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704009300073002001300166#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#6#2#article#156#<br>   </b></font><b><
font face="Verdana" size="2">MODELS, BIOLOGICAL</font></b></p>     ^cY#a10v26n1.
htm##
00270000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704003800073002001300111#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#7#3#article#156#<p align="right">&nbsp
;</p>       ^cY#a10v26n1.htm##
00564000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704033200073002001300405#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#8#4#article#156#<p><b><font face="Verd
ana" size="2"><a name="top"></a></font><font face="Verdana" size="4">The    comp
arison of methylene blue and vitamin E in prevention of abdominal postoperative 
   adhesion formation in rat uterine horn models. Biochemical and histopathologi
c    evaluation<SUP><a href="#end">1</a></SUP></font></b></p>     ^cY#a10v26n1.h
tm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#9#5#article#156#<p>&nbsp;</p>     ^cY#
a10v26n1.htm##
00579000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704034600074002001300420#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#10#6#article#156#<p><b><font face="Ver
dana" size="3">Compara&ccedil;&atilde;o do azul de metileno    e vitamina E na p
reven&ccedil;&atilde;o de ader&ecirc;ncia abdominal p&oacute;s-operat&oacute;ria
    em corno uterino de ratos. Avali&ccedil;&atilde;o bioqu&iacute;mica e histop
atol&oacute;gica    </font></b><font face="Verdana" size="2"></font></p>        
 ^cY#a10v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#11#7#article#156#<p>&nbsp;</p>     ^cY
#a10v26n1.htm##
00407000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704017400074002001300248#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#12#8#article#156#<p><font face="Verdan
a" size="2"><B>Hamit Yildiz<SUP>I</SUP>, Ali Said Durmus<SUP>II</SUP>,    Halil 
Simsek<SUP>III</SUP>, Ihsan Yaman<SUP>IV</SUP></B> </font></p>       ^cY#a10v26n
1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#13#9#article#156#<p>&nbsp;</p>     ^cY
#a10v26n1.htm##
00553000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031900075002001300394#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#14#10#article#156#<p><font face="Verda
na" size="2"><SUP>I</SUP>Associate Professor, Department of    Obstetrics and Gy
necology, Faculty of Veterinary Medicine, F?rat University,    Elazig, Turkey. <
I>Carried out the study, compiled the results, drafted the    manuscript, design
ing the study and statistical analysis of the data.    ^cY#a10v26n1.htm##
00476000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024200075002001300317#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#15#11#article#156#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>II</SUP>Associate Professor, Department    of S
urgery, Faculty of Veterinary Medicine, University of Firat, Elazig-Turkey.    <
I>Data collection and coordinated laboratory analysis.    ^cY#a10v26n1.htm##
00457000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022300075002001300298#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#16#12#article#156#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>III</SUP>Assistant Professor,    Sanitary Servi
ces Vocational School of Higher Education, University of Bing&ouml;l,    Turkey.
 <I>Performed biochemical analysis.    ^cY#a10v26n1.htm##
00482000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024800075002001300323#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#17#13#article#156#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>IV</SUP>Associate Professor, Department    of P
atology, Faculty of Veterinary Medicine, University of Firat, Elazig, Turkey.   
 <I>Performed histopathological examination.</I></font></p>     ^cY#a10v26n1.htm
##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#18#14#article#156#<p><font face="Verda
na" size="2"><a href="#end">Correspondence</a></font></p>     ^cY#a10v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#19#15#article#156#<p>&nbsp;</p>     ^c
Y#a10v26n1.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#20#16#article#156#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a10v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#21#17#article#156#<p><font face="Verda
na" size="2"><B>ABSTRACT </B></font></p>     ^cY#a10v26n1.htm##
01740000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704150600075002001301581#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#22#18#article#156#<p><font face="Verda
na" size="2"><B>Purpose</b>: To compare the effects of vitamin    E and 1% methy
len blue solutions on prevention of experimentally induced adhesions    in rats.
 <B>Methods</B>: Thirty seven female Spraque Dawley rats were randomized    into
 four groups. First group was kept as sham operated group. An adhesion model    
was constituted on the left uterine horn of the other groups. The lesion areas  
  of rats from the second, the third and the fourth groups were coated with 2   
 ml 0.9 % saline solution (C group), 10 mg vitamin E (VE group) and 1% methylen 
   blue solutions (MB group), respectively. <B>Results</B>: Histopathologically,
    adhesion scores, mononuclear cell infiltration, oedema and fibrosis were mor
e    prominent in the MB group compared with C and VE groups. There were no sign
ificant    differences between the groups in tissue glutathione peroxidase (GPx)
, catalase    (CAT) activities and glutation (GSH) level, these parameters were 
slightly increased    in group with VE supplementation though. The administratio
n of VE and MB significantly    decreased NO (P&lt;0.01) levels when compared to
 the C group. The level of malondialdehyde    (MDA) in the VE group was signific
antly lower (P&lt;0.05) than those of the    Sh and C groups. <B>Conclusion</B>:
 Intraperitoneal methylen blue solutions    treatments were more effective accor
ding to vitamin E in preventing the formation    of intra-abdominal adhesion in 
a rat uterine horn model. </font></p>     ^cY#a10v26n1.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015700075002001300232#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#23#19#article#156#<p><font face="Verda
na" size="2"><B>Key words</B>: Vitamin E. Methylene Blue.    Tissue Adhesions. U
terus. Rats. </font></p>   <hr size="1" noshade>     ^cY#a10v26n1.htm##
00301000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006700075002001300142#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#24#20#article#156#<p><font face="Verda
na" size="2"><B>RESUMO </B></font></p>     ^cY#a10v26n1.htm##
01999000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704176500075002001301840#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#25#21#article#156#<p><font face="Verda
na" size="2"><B>Objetivo</b>: Comparar os efeitos da vitamina    E e 1% da solu&
ccedil;&atilde;o de azul de metileno na preven&ccedil;&atilde;o    de ader&ecirc
;ncias induzidas em ratos. <B>M&eacute;todos</B>: Trinta e sete    ratos f&ecirc
;meas Spraque Dawley foram distribu&iacute;dos em quatro grupos.    O primeiro g
rupo foi mantido como grupo <I>sham</I>. O modelo de ader&ecirc;ncia    foi real
izado no corno uterino esquerdo nos outros grupos. As &aacute;reas da    les&ati
lde;o dos ratos do segundo, terceiro e quarto grupos foram revestidas    com 2 m
l de solu&ccedil;&atilde;o salina 0,9% (Grupo C), 10 mg de vitamina E    (Grupo 
VE) e solu&ccedil;&atilde;o de azul de metileno 1% (Grupo MB), respectivamente. 
   <B>Resultados</B>: Histopatologicamente, o escore das ader&ecirc;ncias, infil
tra&ccedil;&atilde;o    celular mononuclear, edema e fibrose foram mais proemine
ntes no grupo MB em    compara&ccedil;&atilde;o aos grupos C e VE. N&atilde;o ho
uve diferen&ccedil;a    significante entre os grupos na peroxidase da glutatione
 do tecido (GPx), atividade    da catalase (CAT) e o n&iacute;vel de glutation (
GSH). Estes par&acirc;metros    foram ligeiramente aumentados no grupo com suple
mento da VE. A administra&ccedil;&atilde;o    da VE e do MB diminuiu significant
emente os n&iacute;veis quando quando comparada    ao Grupo C. O n&iacute;vel de
 malondialde&iacute;do no grupo VE foi significantemente    mais baixo do que no
s grupos <I>sham </I>e C. <B>Conclus&atilde;o</B>: A administra&ccedil;&atilde;o
    intraperitoneal da solu&ccedil;&atilde;o de azul de metileno foi mais eficaz
    de acordo com a vitamina E na preven&ccedil;&atilde;o de ader&ecirc;ncias in
tra-abdominais    no corno uterino de ratos. </font></p>     ^cY#a10v26n1.htm##
00410000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017600075002001300251#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#26#22#article#156#<p><font face="Verda
na" size="2"><B>Descritores</B>: Vitamina E. Azul de Metileno.    Ader&ecirc;nci
as Teciduais. &Uacute;tero. Ratos.</font></p> <hr size="1" noshade>     ^cY#a10v
26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#27#23#article#156#<p>&nbsp;</p>     ^c
Y#a10v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#28#24#article#156#<p>&nbsp;</p>     ^c
Y#a10v26n1.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007500075002001300150#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#29#25#article#156#<p><font face="Verda
na" size="3"><B>Introduction</B> </font></p>       ^cY#a10v26n1.htm##
01015000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704078100075002001300856#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#30#26#article#156#<p><font face="Verda
na" size="2"> In intrabdominal surgery, development of peritoneal    adhesions i
s a serious postoperative complication. Postsurgical adhesions are    a conseque
nce of incision, cauterization, suturing or other means of trauma.    They lead 
to small-bowel obstruction, chronic abdominal and pelvic pain, and    female inf
ertility<SUP>1</SUP>. Several medications, such as non-steroidal anti-inflammato
ry    drugs (NSAIDs), glucocorticoids, progesterone, anticoagulants, fibrinolyti
cs,    antibiotics, vitamin E, methylen blue, pentoxifylline, carboxymethylcellu
lose,    dextran 70, promethazine, antihistaminics and prostaglandin synthetase 
inhibitors    are used in order to prevent the development of postoperatif adhes
ions<SUP>2</SUP>.    </font></p>     ^cY#a10v26n1.htm##
00612000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704037800075002001300453#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#31#27#article#156#<p><font face="Verda
na" size="2"> Vitamin E presents interesting biological properties    and activi
ties for preventing intraperitoneal adhesions. <I>In vitro</I> studies    have r
eported that it has antioxidant, anti-inflammatory, anticoagulant and    antifib
roblastic effects, and playing a role in diminishing the production of    collag
en<SUP>3-5</SUP>. </font></p>     ^cY#a10v26n1.htm##
01512000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704127800075002001301353#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#32#28#article#156#<p><font face="Verda
na" size="2"> In recent studies, it has been suggested that    intraperitoneal a
pplication of MB can be used as an effective agent in the prevention    of posto
perative adhesions<SUP>6</SUP>. MB is known to inhibit the formation    of super
oxide by competing with oxygen for the transfer of electrons from flavo-enzymes,
    primarily xanthine oxidase, and thus inhibitis the generation of oxygen radi
cals.    Several mediators of inflamation have been implicated in adhesion forma
tion.    These are locally generated free radicals such as superoxides, peroxide
s and    hydroxyl radicals, and therefore could induce adhesions by damaging cel
lular    membranes. MB is used in patients having refractory septic shock or som
e neurological    diseases<SUP>7</SUP>. In several studies, use of MB and VE hav
e been reported    for prevent of formation adhesion<SUP>3,4,6</SUP>. However, t
o date, there has    been no report on biochemical or histopathological changes 
in adhesion tissue    treated with MB and VE. Therefore, in the present study, w
e aimed to investigate    the comparative effects of MB and VE on healing and ad
hesion formation models,    and discussed the mechanisms underlying the effects 
of MB and VE on these processes.    </font></p>       ^cY#a10v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#33#29#article#156#<p>&nbsp; </p>     ^
cY#a10v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#34#30#article#156#<p><font face="Verda
na" size="3"><B>Methods</B></font></p>       ^cY#a10v26n1.htm##
00817000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058300075002001300658#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#35#31#article#156#<p><font face="Verda
na" size="2"> The guidelines for the care and use of the animals    approved by 
the local institution were followed. The local ethics committee    aproved this 
study. A total of 37 Sprague-Dawley (4-5 month-old female and weighing    betwee
n 200 and 220g) rats were housed in a climate-controlled (relative humidity    o
f 40-60% and temperature of 21 to 24&#176;C) animal care facility, with a 12    
hour light/dark cycle. Before and after surgical procedures, the animals were   
 provided with standard rat chow and water, <I>ad libitum</I>. </font></p>     ^
cY#a10v26n1.htm##
00656000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704042200075002001300497#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#36#32#article#156#<p><font face="Verda
na" size="2"> The rats were anaesthetized with IM ketamine    (Ketalar; Eczaciba
si, Istanbul, Turkey) at 85 mg/kg body weight and xylazine    (Rompun Vet; Bayer
 AG, Istanbul, Turkey) at 6 mg/kg body weight. Following anaesthesia,    abdomin
al skin was shaved and antisepsis was obtained by 10% povidone iodine    solutio
n. The laparotomy was performed with a 3 cm midline incision. </font></p>     ^c
Y#a10v26n1.htm##
01823000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704158900075002001301664#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#37#33#article#156#<p><font face="Verda
na" size="2"> The rats were divided into 4 groups and animals    each treated as
 follows: First group was kept as sham group (Sh, n=7),     on which only laparo
tomy was performed and they received 2 ml of 0.9 % saline    solution intraperit
oneally. In the remaining rats (n=30), the small bowel was    retracted and the 
uterus was exposed. Punctate serosal hemorrhages were generated    by scraping w
ith a No. 15 scalpel blade until petechial bleeding emerged at    the abdominal 
sidewall and antimesenteric surface of the left uterine horn to    create adhesi
ons. Prior to closure of the abdominal incision, 2 ml saline (0.9    % isotonic 
solution) to the animals in the control group were given intraperitoneally    (n
=10). 2 ml of 1 % methylene blue solution was administered to the rats in    met
hylen blue (MB, Sigma, St. Louis, Mo., USA) group (n=10) and 2 ml of Vitamin    
E (Evigen ampul, Aksu Farma, 300 mg/2ml, al-alpha-tocopheral acetate), which    
was dissolved in 58 ml of olive oil, and sterilized in an autoclave and cultured
    before use, was administered to the rats in vitamin E group (VE) group (n=10
).    The abdominal incision was subsequently closed, by suturing periton and mu
scular    layers with absorbe materials and then skin was closed with 4/0 silk s
utures.    Abdominal wall integrity and wound healing were checked during the fi
rst 2 days    after surgery. The animals were allowed to resume their diet until
 the 14th    postoperative day. Rats in all groups were reanaesthetized and rela
paratomy    was performed. </font></p>       ^cY#a10v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#38#34#article#156#<p>&nbsp;</p>     ^c
Y#a10v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#39#35#article#156#<p><font face="Verda
na" size="2"><I>Microscopic evaluations</I> </font></p>       ^cY#a10v26n1.htm##
00754000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052000075002001300595#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#40#36#article#156#<p><font face="Verda
na" size="2"> The intraabdominal cavity was inspected through    a U shaped inci
sion of the anterior abdominal wall, which was retracted caudal,    providing ma
ximal exposure. The peritoneal and left uterine horn tissue including    the tis
sue of adhesion were surgically removed and rats were killed. A half    of the e
ach adhesion tissue was preserved in 10 % neural buffered formalin for    histop
athological examination. The other parts were kept for biochemical analysis.    
</font></p>     ^cY#a10v26n1.htm##
00815000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058100075002001300656#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#41#37#article#156#<p><font face="Verda
na" size="2"> This tissue samples for histopathological examinations    were fix
ed in 10 % neutral buffered formalin, embedded in paraffin wax, and    were cut 
into 5 &#181;m sections and stained with hematoxylin and eosin. The    histologi
cal sections were examined for the presence of adhesion score, oedema,    fibros
is and mononuclear cell infiltration with a light microscope (Nikon optiphot,   
 Kanagawa, Japan) and photographed. The microscopic scoring was graded as follow
s:    on a scale of mild (1), moderate (2) and severe (3). </font></p>       ^cY
#a10v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#42#38#article#156#<p>&nbsp;</p>     ^c
Y#a10v26n1.htm##
00319000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008500075002001300160#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#43#39#article#156#<p><font face="Verda
na" size="2"><I>Homogenate preparation</I> </font></p>       ^cY#a10v26n1.htm##
00949000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704071500075002001300790#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#44#40#article#156#<p><font face="Verda
na" size="2"> Tissues were washed twice with cold saline solution,    placed in 
glass bottles, labeled and stored in a deep freeze (-30&#176;C) until    process
ing (maximum 10 hr). After weighing, the tissue (1 gr) were placed on    ice, cu
t into small pieces with scissors, and homogenized (2 min. at 3000 x    g) in fi
ve volumes (1:5, w/v) of ice-cold Tris-HCl buffer (50 mM, pH 7.4), using    a gl
ass-Teflon homogenizer (Caliskan Cam Teknik, Ankara, Turkey). All preparation   
 procedures were performed at 4&#176;C. After addition of butylhydroxytoluol    
(4&#181;l per ml), the tissue homogenate samples were used for immediate NO,    
MDA, GPx, CAT and GSH measurement. </font></p>     ^cY#a10v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#45#41#article#156#<p>&nbsp;</p>     ^c
Y#a10v26n1.htm##
00315000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008100075002001300156#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#46#42#article#156#<p><font face="Verda
na" size="2"><I>Biochemical assays</I> </font></p>       ^cY#a10v26n1.htm##
01600000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704136600075002001301441#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#47#43#article#156#<p><font face="Verda
na" size="2"> Lipid peroxidation levels in tissue homogenate    were measured wi
th the thiobarbituric-acid reaction by the method of Placer    <I>et al.</I><SUP
>8 </SUP>The values of MDA were expressed as &#181;mol per    g protein. The GSH
 content of the tissue homogenate was measured at 412 nm using    the method of 
Sedlak and Lindsay<SUP>9</SUP>. The solution was kept at room    temperature for
 5 min, and then read at 412 nm on the spectrophotometer. Results    were expres
sed as &#181;mol per gr protein. GSH-Px activities of the tissue    were spectro
photometrically measured at 37&#176;C and 412 nm according to the    Lawrence an
d Burk<SUP>10</SUP>. Results were expressed as &#181;mol per gr protein.    The 
protein content in the tissue was measured by method of Lowry <I>et al.</I><SUP>
11    </SUP>with bovine serum albumin as the standard. CAT activity was assayed 
in    tissue homogenate by the Aebi method<SUP>12</SUP>. The principle of the as
say    is based on the determination of the rate constant (s_1,k) for H<SUB>2</S
UB>O<SUB>2</SUB>    decomposition at 240 nm by the spectrophotometer. Results we
re expressed as    unit per gr tissue. The nitric oxide content of the tissue wa
s determined according    to method of Cortas and Wakid<SUP>13</SUP>. Results we
re expressed as &#181;mol    per gr tissue. </font></p>       ^cY#a10v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#48#44#article#156#<p>&nbsp;</p>     ^c
Y#a10v26n1.htm##
00317000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008300075002001300158#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#49#45#article#156#<p><font face="Verda
na" size="2"><I>Statistical analysis</I> </font></p>       ^cY#a10v26n1.htm##
00713000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704047900075002001300554#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#50#46#article#156#<p><font face="Verda
na" size="2"> Adhesion score, fibrosis, oedema and mononuclear    cell infiltrat
ion data were analyzed using Kruskal-Wallis test, whereas biochemical    data we
re analyzed using one-way Analysis of Varience (ANOVA). The Duncan test    was p
erformed for multiple comparisons using the SPSS 11.0 for Windows. The    data w
ere expressed as means&#177;standard errors (SEM). Results were considered    st
atistically significantat p&lt;0.05. </font></p>       ^cY#a10v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#51#47#article#156#<p>&nbsp; </p>     ^
cY#a10v26n1.htm##
00304000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007000075002001300145#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#52#48#article#156#<p><font face="Verda
na" size="3"><B>Results</B> </font></p>       ^cY#a10v26n1.htm##
01108000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704087400075002001300949#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#53#49#article#156#<p><font face="Verda
na" size="2"> All animals recovered from anaesthesia with    no evidence of comp
lications. In these rats, adhesions were also found between    the depersonalize
d antimesenteric surface of the left uterine horn and adjacent    abdominal wall
s. The histopathological findings including adhesion scores, oedema,    mononucl
ear cell infiltration and fibrosis scores in all groups are shown in    <a href=
"#tab01">Table 1</a>. There were significant differences beween groups    with r
espect to histopathological scores of adhesions. The histologic findings    of a
dhesions in the C group differed significantly those of MB groups with respect  
  to adhesion scores (P&lt;0.01), fibrosis (P&lt;0.01), mononuclear cell infiltr
ation    (P&lt;0.01) and oedema (P&lt;0.01). There were no significant differenc
e between    the C and VE groups. </font></p>     ^cY#a10v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#54#50#article#156#<p>&nbsp;</p>     ^c
Y#a10v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#55#51#article#156#<p>&nbsp;</p>     ^c
Y#a10v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#56#52#article#156#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a10tab01.jpg"><a name="tab01"></a></p>     ^cY#a
10v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#57#53#article#156#<p>&nbsp;</p>     ^c
Y#a10v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#58#54#article#156#<p>&nbsp;</p>     ^c
Y#a10v26n1.htm##
01572000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704133800075002001301413#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#59#55#article#156#<p><font face="Verda
na" size="2"> In microscopical examination of uterus of the    Sh group, no path
ological semptoms were found (<a href="/img/revistas/acb/v26n1/a10img01.jpg">Fig
ure    1A</a>). Whereas, in microscopical examination of the uterus sections of 
the    C group, the abdominal cavity of uterus was found to be attached to abdom
inal    wall and neighboring organs. When the sections of the adhesions are exam
ined,    oedema, thickness and occasionally capillary vascular proliferation wer
e noted    in the uterus seroza. There were also microabsce focus, fibrosis and 
intensive    mononuclear cell infiltration in the muscular layers of the uterus 
(<a href="/img/revistas/acb/v26n1/a10img01.jpg">Figure    1B</a>). Similar adhes
ions to thouse of C group were found in the uterus of    rats from VE groups, bu
t the severity of the adhesions were less. The degrees    of fibrosis, mononucle
ar cell infiltration, oedema and capillary vascular proliferation    were less i
n the uterus seroza when compared with those of the C group (<a href="/img/revis
tas/acb/v26n1/a10img01.jpg">Figure    1C</a>). In the rats treated with MB, oede
ma and mild mononuclear cell infiltration    were observed in the uterus seroza,
 there were no adhesion though (<a href="/img/revistas/acb/v26n1/a10img01.jpg">F
igure    1D</a>). </font></p>     ^cY#a10v26n1.htm##
00956000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704072200075002001300797#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#60#56#article#156#<p><font face="Verda
na" size="2"> The results of tisue GSH, MDA and NO values    and CAT and GPx enz
yme activities in all groups are shown in <a href="/img/revistas/acb/v26n1/a10ta
b02.jpg">Table    2</a>. The highest CAT, GSH and GPx values and the lowest MDA 
levels were determined    in tissue homogenates in VE group, the difference were
 not significant between    the groups though. Tissue MDA values were significan
tly reduced (P&lt;0.05)    in group with VE supplementation compared to Sh and C
 group. Levels of NO in    the C group was significantly higher than those in Sh
, VE and MB groups (P&lt;0.01).    The levels of NO in MB treated rats were sign
ificantly lower than in Sh and    C rats. </font></p>     ^cY#a10v26n1.htm##
00686000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045200075002001300527#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#61#57#article#156#<p><font face="Verda
na" size="2"> Adhesion scores were significantly correlated    with oedema, fibr
osis and mononuclear cell infiltration grades with p values    0.01, 0.01 and 0.
05, respectively. Also, the significance of the correlations    between fibrosis
 and mononuclear cell infiltration, oedema and fibrosis, and    mononuclear cell
 infiltration and oedema grades were determined to be 0.01,    0.01 and 0.01, re
spectively. </font></p>     ^cY#a10v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#62#58#article#156#<p>&nbsp;</p>     ^c
Y#a10v26n1.htm##
00307000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007300075002001300148#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#63#59#article#156#<p><font face="Verda
na" size="3"><B>Discussion</B> </font></p>       ^cY#a10v26n1.htm##
01780000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704154600075002001301621#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#64#60#article#156#<p><font face="Verda
na" size="2"> The histologic findings on adhesions showed    that the C group ha
d the highest adhesion, fibrosis, oedema and mononuclear    cell infiltration sc
ores (Figure 1B). We did not find these results surprising    because similar re
sults have been reported previously by authors<SUP>14</SUP>.    As shown in Tabl
e 1, histopathological score in MB treated group was markedly    diminished in c
omparison to the C group, whereas no significant difference was    found between
 MB and Sh groups. These findings were in agreement with the results    of previ
ous studies, in which similar doses and concentrations of MB were administred   
 for prevention of adhesion formation<SUP>6,15</SUP>. The results on histopathol
ogical    changes demonstrate that intraperitoneal treatment of MB decreases the
 incidence    of intra-abdominal adhesion in the experimental model employed for
t he current    study. Some authors<SUP>6,15</SUP> reported that MB prevented th
e formation    of intraperitoneal adhesion, possibly by reducing the initial inf
lammatory response    and the subsequent exudation in a rat uterine horn model. 
Heydrick <I>et al.</I><SUP>16    </SUP>showed that MB inhibits adhesion formatio
n via a mechanism that might    involve blocking an oxidative stress-dependent d
ecrease in peritoneal fibrinolytic    activity. This effect could be accounted f
or by the inhibition of inflammatory    cells accumulation and in particular sca
venging reactive oxygen radicals by    MB in the adhesion tissue. </font></p>   
  ^cY#a10v26n1.htm##
01830000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704159600075002001301671#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#65#61#article#156#<p><font face="Verda
na" size="2"> The recent studies<SUP>3,4,17</SUP> using intraperitonal    VE adm
inistration showed a significant reduction in postoperative peritoneal    adhesi
ons in rats. Our results are in agreement with previous studies reporting    on 
antioxidant agents<SUP>17</SUP>. Although adhesion, oedema, fibrosis and    mono
nuclear cell infiltration scores have been found to be lower in the VE group    
than C group, the differences were not statistically significant (Table 1).    W
e think that, morphological changes in uterus were because of adhesion formation
,    but these changes tended to be considerably mild in intraperitoneal VE trea
tment.    We found that the correlations between fibrosis_adhesion, mononuclear 
cell infiltration_adhesion    and oedema_adhesion were significant, which is als
o supported by the relationship    between adhesion scores and histopathological
 findings. Similarly, Sanfilippo    <I>et al.</I><SUP>17 </SUP>reported that alt
hough there was a trend of less    fibrosis with VE treatment, there was no stat
istically significant difference.    In addition, Yetkin <I>et al.</I><SUP>4 </S
UP>found that neovascularization,    inflammation and fibrosis scores regarding 
histological examination of adhesions    in the groups which underwent intraperi
toneal VE administration were lower compared    to the control groups. These fin
dings obtained in our study suggest that in    addition to its properties as an 
antioxidant, the VE prevents adhesions by inhibition    of fibrosis and mononucl
ear cell infiltration<SUP>17</SUP>. </font></p>     ^cY#a10v26n1.htm##
02391000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704215700075002001302232#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#66#62#article#156#<p><font face="Verda
na" size="2"> Vitamin E is a fat-soluble vitamin and one of    a number of nutri
ents called antioxidants. It is particularly important in protecting    cells ag
ainst oxidative damage by induced reactive oxygen species (ROS)<SUP>18</SUP>.   
 Levels of MDA in the VE treated rats were significantly lower (P&lt;0.05) than 
   those in the Sh and C groups. These results shows that MDA may play an import
ant    role     in the adhesion formation. In the rats treated with VE, tissue G
SH content and    CAT and GPx activities were slightly higher compared to the ot
her groups. However,    there were no significant differences between the any of
 the groups. In the    literature, there is no report on the effects of VE and M
B treatments for the    preventation of adhesion formation on tisssue MDA, NO, G
SH levels and CAT and    GPx activities in rats. Masugi and Nakamura<SUP>19</SUP
> concluded that VE decreased    the level of lipid peroxidation but did not cha
nge activity of the enzymatic    antioxidant system such as SOD, GPx and CAT. On
 the other hand, administration    of intraperitoneal of VE in rats with diabete
s<SUP>20</SUP> and nehprotoxicity<SUP>21</SUP>    caused a decrease in levels of
 lipid peroxidation in the liver and kidney, although    SOD, CAT and GPx activi
ties increased. In addition, when the rats were fed with    a VE-deficient diet,
 concentrations of MDA in the liver and lung tissues were    increased, but CAT 
and GPx activity were significantly decreased<SUP>22</SUP>.    Our results are i
n accordance with previous reports<SUP>19-21</SUP>. Vitamin    E probably reduce
s the afflicting effects of oxidative stress in living cell,    cleaning the fre
e radicals created locally as other antioxidants<SUP>3</SUP>.    The results of 
this study shows that VE action is due to its antioxidative effects    as shown 
by the decrease in tissue MDA concentration, and the slight increase    in CAT a
nd GPx activities and GSH level. However, we observed that VE has stronge    ant
ioxidative effects as well as antiinflammatoir and anticoagulant properties    f
or prevention of adhesion formation. </font></p>     ^cY#a10v26n1.htm##
01904000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704167000075002001301745#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#67#63#article#156#<p><font face="Verda
na" size="2"> NO is produced from L-arginine by the catalytic    action of nitri
c oxide synthases (NOS). In physiological levels, NO participates    in a variet
y of physiological processes consisting of neurotransmission and    regulation o
f the blood vessel wall. But increased NO, especially associated    with oxidati
ve stress, is a harmful condition for tissue<SUP>23</SUP>. In the    present stu
dy, the level of tissue NO increased (p&lt;0.01) significantly in    C group whe
n compared with Sh group. This indicates that adhesion formation    may lead to 
the induction of inducible nitric oxide synthase, resulting in an    increased p
roduction of nitric oxide<SUP>24,25</SUP>. Also, NO level decreased    significa
ntly in VE groups when compared with C groups in the present study.    This resu
lt suggests that VE blocks the occurrence of NO and therefore it has    a suppor
tive effect on the antioxidant system. It was reported that intraperitoneal    a
dministration of melatonin<SUP>24</SUP> and resveratrol<SUP>25</SUP> decreases  
  the incidence and extent of peritoneal adhesions and causes a decrease in NO  
  values. Gurel <I>et al.</I><SUP>26 </SUP>reported that administration of VE   
 decreased NO concentrations in both ipsilateral and contralateral renal tissues
    compared to ischemia-reperfusion group. In addition, VE administration cause
d    a significant decrease in NO metabolite levels after cerebral ischemia-repe
rfusion    injury<SUP>27</SUP>. Results were in agreement with other reports<SUP
>26,27</SUP>.    The lowering effect of VE on NO level presumably resulted from 
its antioxidative    effects. </font></p>     ^cY#a10v26n1.htm##
01307000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704107300075002001301148#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#68#64#article#156#<p><font face="Verda
na" size="2"> The effect of MB on oxidative stress controversial.    Liver and k
idney CAT activity and GSH level did not change after administration    of 1 mM 
MB to rats for 30 days<SUP>28</SUP>. In addition, MB when administrated    eithe
r to intact or to diabetic rats did not significantly change oxidative    stress
 parameters (MDA and SOD)<SUP>29</SUP>.         Moreover, it is reported that MB
 exposure for 5 hours on either ipsilateral    or contralateral testes did not a
meliorated biochemical or histological parameters    in unilateral spermatic cor
d torsion model<SUP>30</SUP>. On the contrary, systemic    administration of MB 
has been shown to reduce oxidative stress in kidney of    ciclosporine treated r
ats<SUP>31</SUP>. Aksu <I>et al.</I><SUP>32 </SUP>reported    that administratio
n of MB (2 mg/kg i.p.) to rats with bile-duct ligation for    14 days led to sig
nificant increases in SOD activity and decrease in MDA and    NO levels, indicat
ing that MB can attenuate hepatic damage by reducing oxidative    stres. </font>
</p>     ^cY#a10v26n1.htm##
01604000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704137000075002001301445#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#69#65#article#156#<p><font face="Verda
na" size="2"> In the present study, there were no significant    difference in t
he activities of tissue CAT and GPx, and levels of tissues MDA    and GSH in MB 
treated rats between Sh, C and VE groups. The results obtained    in the present
 study are similar to those reported by some researchers<SUP>28-30</SUP>    but 
differ from those reported by Rezzani<I> et al.</I><SUP>31 </SUP>and Aksu    <I>
et al.</I><SUP>32</SUP>. The differences may be due to the difference in    orga
n systems used, the dose and mode of application of the MB used in these    stud
ies. MB had no effect on tissue CAT and GPx activities and GSH and MDA levels.  
  The explanation of this study results is thus rather difficult. It is possible
    that the effect of MB might be transient and/or that it might have a partial
    inhibitory influence on the development of adhesion formation. <I>In vivo</I
>    effects of MB in the current study could be influenced by the interaction o
f    other redox systems. Another possibility is that the antioxidant effect of 
MB    is dose-dependent. The dose administrated in our study could be inappropri
ate    for inducing the antioxidant effect. Detailed studies are needed to clari
fy    the effects of MB at different doses, as well as frequency and duration of
 administration    on adhesion formation in rats. </font></p>     ^cY#a10v26n1.h
tm##
01130000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704089600075002001300971#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#70#66#article#156#<p><font face="Verda
na" size="2"> In the present study, the levels of NO in MB    treated rats were 
significantly lower than in Sh and C rats. Dinc <I>et al.</I><SUP>15    </SUP>re
ported a marked elevation in NO levels in the rats with adhesion formation,    b
ut significant reduction after intraperitoneal MB application. On the basis    o
f our results and earlier literature<SUP>15,32</SUP>, it is fair to state that  
  MB inhibitis adhesion formation by inhibiting NOS activity and decreasing NO  
  levels in tissue. Several mechanisms may contribute to reduced levels of NO   
 in MB treated rats. For instance, the main effect of MB is inhibition of solubl
e    guanylate cyclase and inducible NO synthase<SUP>33</SUP>. It competes with 
molecular    oxygen for the transfer of electrons from flavoenzymes and so inhib
its the generation    of oxygen radicals<SUP>7</SUP>. </font></p>       ^cY#a10v
26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#71#67#article#156#<p>&nbsp; </p>     ^
cY#a10v26n1.htm##
00307000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007300075002001300148#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#72#68#article#156#<p><font face="Verda
na" size="3"><B>Conclusion</B> </font></p>       ^cY#a10v26n1.htm##
00792000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055800075002001300633#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#73#69#article#156#<p><font face="Verda
na" size="2"> Our results showed that MB had a protective    effect on the devel
opment of adhesion damage according to the histopathological    evaluation, bioc
hemical findings did not support its ameliorating effects though.    The interes
ting finding in the current study is that VE-treatment resulted in    significan
t improvement of biochemical and mild histopathological recovery at    the adhes
ion tissue. Treatment of MB have more advantage according to VE in    terms of p
revention of postoperative adhesions. </font></p>     ^cY#a10v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#74#70#article#156#<p>&nbsp; </p>     ^
cY#a10v26n1.htm##
00307000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007300075002001300148#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#75#71#article#156#<p><font face="Verda
na" size="3"><B>References</B> </font></p>       ^cY#a10v26n1.htm##
00461000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704021300077002001300290#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#76#72#article#156#1#<p><fo
nt face="Verdana" size="2">1. Monk BJ, Berman ML, Montz FJ. Adhesions after    e
xtensive gynecologic surgery: clinical significance, etiology and prevention.   
 Am J Obstet Gynecol. 1994;170:1396-03.    ^cY#a10v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#77#73#article#156# </font></p>     ^cY
#a10v26n1.htm##
00385000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704013700077002001300214#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#78#74#article#156#2#<p><fo
nt face="Verdana" size="2">2. Ergul E, Korukluoglu B. Peritoneal adhesions:    f
acing the enemy. Int J Surg. 2007;6:253-60.    ^cY#a10v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#79#75#article#156# </font></p>     ^cY
#a10v26n1.htm##
00512000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704026400077002001300341#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#80#76#article#156#3#<p><fo
nt face="Verdana" size="2">3. De la Portilla F, Ynfante I, Bejarano D, Conde    
J, Fernandez A, Ortega JM. Prevention of peritoneal adhesions by intraperitoneal
    administration of vitamin E: an experimental study. Dis Colon Rectum. 2004;4
7:2157-61.    ^cY#a10v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002400075002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#81#77#article#156#    </font></p>     
^cY#a10v26n1.htm##
00499000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704025100077002001300328#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#82#78#article#156#4#<p><fo
nt face="Verdana" size="2">4. Yetkin G, Uludag M, Citgez B, Karakoc S, Polat    
N, Kabukcuoglu F. Prevention of peritoneal adhesions by intraperitoneal administ
ration    of vitamin E and human amniotic membrane. Int J Surg. 2009;7:561-5.   
 ^cY#a10v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#83#79#article#156# </font></p>     ^cY
#a10v26n1.htm##
00497000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704024900077002001300326#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#84#80#article#156#5#<p><fo
nt face="Verdana" size="2">5. Corrales F, Corrales M, Schirmer CC. Preventing   
 intraperitoneal adhesions with vitamin E and sodium hyaluronate/carboxymethylce
llulose.    A comparative study in rats. Acta Cir Bras.&#160;2008;23:36-41.    ^
cY#a10v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#85#81#article#156# </font></p>     ^cY
#a10v26n1.htm##
00448000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704020000077002001300277#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#86#82#article#156#6#<p><fo
nt face="Verdana" size="2">6. Galili Y, Ben-Abraham R, Rabau M, Klausner    J, K
luger Y. Reduction of surgery-induced peritoneal adhesions by methylene    blue.
 Am J Surg. 1998;175:30-2.    ^cY#a10v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#87#83#article#156# </font></p>     ^cY
#a10v26n1.htm##
00520000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704027200077002001300349#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#88#84#article#156#7#<p><fo
nt face="Verdana" size="2">7. Salaris SC, Babbs CF, Voorhees WD. Methylene    bl
ue as an inhibitor of superoxide generation by xanthine oxidase. A potential    
new drug for the attenuation of ischemia/reperfusion injury. Biochem Pharmacol. 
   1991;42:499-06.    ^cY#a10v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#89#85#article#156# </font></p>     ^cY
#a10v26n1.htm##
00449000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704020100077002001300278#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#90#86#article#156#8#<p><fo
nt face="Verdana" size="2">8. Placer ZA, Cushman L, Johnson BC. Estimation    of
 products of lipid peroxidation (malonyl dialdehyde) in biological fluids.    An
al Biochem. 1966;16:359_64.    ^cY#a10v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#91#87#article#156# </font></p>     ^cY
#a10v26n1.htm##
00453000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704020500077002001300282#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#92#88#article#156#9#<p><fo
nt face="Verdana" size="2">9. Sedlak J, Lindsay RHC. Estimation of total,    pro
tein bound and non-protein sulfhydryl groups in tissue with Ellmann's reagent.  
  Anal Biochem. 1968;25:192_05.    ^cY#a10v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#93#89#article#156# </font></p>     ^cY
#a10v26n1.htm##
00426000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704017700078002001300255#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#94#90#article#156#10#<p><f
ont face="Verdana" size="2">10. Lawrence RA, Burk RF. Glutathione peroxidase    
activity in selenium-deficient rat liver. Biochem Biophys Res Commun. 1976;71:95
2_8.    ^cY#a10v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002400075002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#95#91#article#156#    </font></p>     
^cY#a10v26n1.htm##
00423000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704017400078002001300252#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#96#92#article#156#11#<p><f
ont face="Verdana" size="2">11. Lowry OH, Rosebrough NJ, Farr AL, Randall    RJ.
 Protein measurement with the Folin-Phenol reagent. J Biol Chem. 1951;193:265_75
.    ^cY#a10v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002400075002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#97#93#article#156#    </font></p>     
^cY#a10v26n1.htm##
00356000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704010700078002001300185#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#98#94#article#156#12#<p><f
ont face="Verdana" size="2">12. Aebi H. Catalase in vitro. Methods Enzymol.    1
984;105:121-6.    ^cY#a10v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#99#95#article#156# </font></p>     ^cY
#a10v26n1.htm##
00449000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704019900079002001300278#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#100#96#article#156#13#<p><
font face="Verdana" size="2">13. Cortas NK, Wakid NW. Determination of inorganic
    nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem.
    1990;36(8 Pt 1):1440_3.    ^cY#a10v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#101#97#article#156# </font></p>     ^c
Y#a10v26n1.htm##
00459000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704020900079002001300288#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#102#98#article#156#14#<p><
font face="Verdana" size="2">14. Irkorucu O, Ferahk&ouml;se Z, Memis L, Ekinci  
  &Ouml;, Akin M. Reduction of postsurgical adhesions in a rat model: a comparat
ive    study. Clinics. 2009;64:143-8.    ^cY#a10v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#103#99#article#156# </font></p>     ^c
Y#a10v26n1.htm##
00521000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027000080002001300350#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#104#100#article#156#15#<p>
<font face="Verdana" size="2">15. Dinc S, Ozaslan C, Kuru B, Karaca S, Ustun    
H, Alagol H, Renda N, Oz M. Methylene blue prevents surgery-induced peritoneal  
  adhesions but impairs the early phase of anastomotic wound healing. Can J Surg
.    2006;49:321-8.    ^cY#a10v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#105#101#article#156# </font></p>     ^
cY#a10v26n1.htm##
00569000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704031800080002001300398#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#106#102#article#156#16#<p>
<font face="Verdana" size="2">16. Heydrick SJ, Reed KL, Cohen PA, Aarons CB,    
Gower AC, Becker JM, Stucchi AF. Intraperitoneal administration of methylene    
blue attenuates oxidative stress, increases peritoneal fibrinolysis, and inhibit
s    intraabdominal adhesion formation. J Surg Res. 2007;143:311_9.    ^cY#a10v2
6n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#107#103#article#156# </font></p>     ^
cY#a10v26n1.htm##
00406000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704015500080002001300235#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#108#104#article#156#17#<p>
<font face="Verdana" size="2">17. Sanfilippo JS, Booth RJ, Burns CD. Effect    o
f vitamin E on adhesion formation. J Reprod Med. 1995;40:278-82.    ^cY#a10v26n1
.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#109#105#article#156# </font></p>     ^
cY#a10v26n1.htm##
00510000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025900080002001300339#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#110#106#article#156#18#<p>
<font face="Verdana" size="2">18. Kosther GM, Ottl K, Jauhiainen M, Enholm    C,
 Esterbauer H. Human plasma phospholipids transfer protein accelerates exchange/
transfer    of a-toco-pherol between lipoproteins and cells. Biochem J. 1995;305
:659-67.    ^cY#a10v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#111#107#article#156#    </font></p>   
  ^cY#a10v26n1.htm##
00497000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024600080002001300326#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#112#108#article#156#19#<p>
<font face="Verdana" size="2">19. Masugi F, Nakamura T. Effect of vitamin E    d
eficiency on the level of superoxide dismutase, glutathione peroxidase, catalase
    and lipid peroxides in rat liver. Int J Vitam Nutr Res. 1976;46:187-91.    ^
cY#a10v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#113#109#article#156# </font></p>     ^
cY#a10v26n1.htm##
00479000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022800080002001300308#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#114#110#article#156#20#<p>
<font face="Verdana" size="2">20. Kinalski M, Sledziewski A, Telejko B, Zarzycki
    W, Kinalska I. Lipid peroxidation and scavenging enzyme activity in streptoz
otocin-induced    diabete. Acta Diabetol. 2000;37:179-83.    ^cY#a10v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#115#111#article#156# </font></p>     ^
cY#a10v26n1.htm##
00612000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704036100080002001300441#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#116#112#article#156#21#<p>
<font face="Verdana" size="2">    21. Armagan A, Kutluhan S, Yilmaz M, Yilmaz N,
 B&uuml;lb&uuml;l M, Vural H,    Soyupek S, Naziroglu M. Topiramate and vitamin 
e modulate antioxidant enzyme    activities, nitric oxide and lipid peroxidation
 levels in pentylenetetrazol-induced    nephrotoxicity in rats. Basic Clin Pharm
acol Toxicol. 2008;103:166-70.    ^cY#a10v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#117#113#article#156# </font></p>     ^
cY#a10v26n1.htm##
00465000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021400080002001300294#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#118#114#article#156#22#<p>
<font face="Verdana" size="2">22. Yoshioka T, Motoyama H, Yamasaki F, Ando    M,
 Takehara Y, Yamasaki M. Lipid peroxidation and vitamin E levels during pregnanc
y    in rats. Biol Neonate. 1987;52:223-31.    ^cY#a10v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#119#115#article#156# </font></p>     ^
cY#a10v26n1.htm##
00455000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020400080002001300284#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#120#116#article#156#23#<p>
<font face="Verdana" size="2">23. Alpay Z, Saed GM, Diamond MP. Female infertili
ty    and free radicals: potential role in adhesions and endonetriosis. J Soc Gy
necol    Investig. 2006;13:390-8.    ^cY#a10v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#121#117#article#156# </font></p>     ^
cY#a10v26n1.htm##
00531000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704028000080002001300360#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#122#118#article#156#24#<p>
<font face="Verdana" size="2">24. Ara CT, Kirimlioglu H, Karabulut AB, Coban    
S, Hascalik S, Celik O, Yilmaz S, Kirimlioglu V. Effect of melatonin against    
oxidative stress on adhesion formation in the rat cecum and uterine horn model. 
   Life Sci. 2005;77:1341-50.    ^cY#a10v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#123#119#article#156# </font></p>     ^
cY#a10v26n1.htm##
00500000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024900080002001300329#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#124#120#article#156#25#<p>
<font face="Verdana" size="2">25. Sogutlu G, Karabulut AB, Ara C, Cinpolat    O,
 Isik B, Piskin T, Celik O. The effect of resveratrol on surgery-induced periton
eal    adhesions in an experimental model. Cell Biochem Funct. 2007;25:217-20.  
  ^cY#a10v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#125#121#article#156# </font></p>     ^
cY#a10v26n1.htm##
00565000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704031400080002001300394#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#126#122#article#156#26#<p>
<font face="Verdana" size="2">26. Gurel A, Armutcu F, Sahin S, Sogut S, Ozyurt  
  H, Gulec M, Kutlu NO, Akyol O. Protective role of alpha-tocopherol and caffeic
    acid phenethyl ester on ischemia-reperfusion injury via nitric oxide and mye
loperoxidase    in rat kidneys. Clin Chim Acta. 2004;339:33-41.    ^cY#a10v26n1.
htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#127#123#article#156# </font></p>     ^
cY#a10v26n1.htm##
00619000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704036800080002001300448#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#128#124#article#156#27#<p>
<font face="Verdana" size="2">27. G&uuml;m&uuml;stas K, G&uuml;zeyli FM, At&uuml
;keren    P, Sanus GZ, Kemerdere R, Tanriverdi T, Kaynar MY. The effects of vita
min E    on lipid     peroxidation, nitric oxide production and superoxide dismu
tase expression in    hyperglycemic rats with cerebral ischemia-reperfusion inju
ry. Turk Neurosurg.    2007;17:78-82.    ^cY#a10v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#129#125#article#156# </font></p>     ^
cY#a10v26n1.htm##
00476000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022500080002001300305#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#130#126#article#156#28#<p>
<font face="Verdana" size="2">28. Jena S, Chainy GBN. Effect of Methylene blue  
  on oxidative stres and antioxidant defence parameters of rat hepatic and renal
    tissue. Indian J Physiol Pharmacol. 2008;52:293-6.    ^cY#a10v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#131#127#article#156# </font></p>     ^
cY#a10v26n1.htm##
00504000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025300080002001300333#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#132#128#article#156#29#<p>
<font face="Verdana" size="2">29. Haluz&iacute;k M, Nedvidkova J, Skrha J.    Th
e influence of NO synthase inhibitor and free oxygen radicals scavenger methylen
e    blue on streptozotocin-induced diabetes in rats. Physiol Res. 1998;47:337-4
1.    ^cY#a10v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#133#129#article#156#    </font></p>   
  ^cY#a10v26n1.htm##
00520000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026900080002001300349#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#134#130#article#156#30#<p>
<font face="Verdana" size="2">30. Inan M, Basaran UN, Dokmeci D, Yalcin O,    Ay
dogdu N, Turan N. Methylene blue increases contralateral testicular ischaemia-re
perfusion    injury after unilateral testicular torsion. Clin Exp Pharmacol Phys
iol. 2008;35:50-4.    ^cY#a10v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#135#131#article#156#    </font></p>   
  ^cY#a10v26n1.htm##
00466000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021500080002001300295#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#136#132#article#156#31#<p>
<font face="Verdana" size="2">31. Rezzani R, Rodella L, Corsetti G, Bianchi    R
. Does methylene blue protect the kidney tissues from damage induced by ciclospo
rin    A treatment? Nephron. 2001;89:329-36.    ^cY#a10v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#137#133#article#156# </font></p>     ^
cY#a10v26n1.htm##
00519000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026800080002001300348#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#138#134#article#156#32#<p>
<font face="Verdana" size="2">32. Aksu B, Umit H, Kanter M, Guzel A, Aktas    C,
 Civelek S, Uzun H. Effects of methylene blue in reducing cholestatic oxidative 
   stres and hepatic damage after bile-duct ligation in rats. Acta Histochem. 20
10;112(3):259-69.    ^cY#a10v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#139#135#article#156#    </font></p>   
  ^cY#a10v26n1.htm##
00561000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704031000080002001300390#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#p#140#136#article#156#33#<p>
<font face="Verdana" size="2">33. Lomniczi A, Cebral E, Canteros G, McCann    SM
, Rettori V. Methylene blue inhibits the increase of inducible nitric oxide    s
ynthase activity induced by stress and lipopolysaccharide in the medial basal   
 hypothalamus of rats. Neuroimmunomodulation. 2000;8:122_7.    ^cY#a10v26n1.htm#
#
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#141#137#article#156# </font></p>     ^
cY#a10v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#142#138#article#156#<p>&nbsp;</p>     
^cY#a10v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006700077002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#143#139#article#156#<p><font face="Ver
dana" size="2">Conflict of interest: none    ^cY#a10v26n1.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704008700077002001300164#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#144#140#article#156#<br>   </font><fon
t face="Verdana" size="2">Financial source: none </font></p>     ^cY#a10v26n1.ht
m##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#145#141#article#156#<p>&nbsp;</p>     
^cY#a10v26n1.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704015500077002001300232#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#146#142#article#156#<p><font face="Ver
dana" size="2"><B><a name="end"></a><a href="#top"><img src="/img/revistas/acb/v
26n1/seta.gif" border="0"></a>Correspondence</B>:    ^cY#a10v26n1.htm##
00263000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002700077002001300104#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#147#143#article#156#<br>   Hamit Yildi
z    ^cY#a10v26n1.htm##
00290000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005400077002001300131#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#148#144#article#156#<br>   Department 
of Obstetrics and Gynecology    ^cY#a10v26n1.htm##
00299000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006300077002001300140#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#149#145#article#156#<br>   Faculty of 
Veterinary Medicine, Firat University    ^cY#a10v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003500077002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#150#146#article#156#<br>   23119 Elazi
g, Turkey    ^cY#a10v26n1.htm##
00284000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004800077002001300125#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#151#147#article#156#<br>   Phone: 00 9
0 424 237 00 00 / 3854    ^cY#a10v26n1.htm##
00275000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003900077002001300116#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#152#148#article#156#<br>   Fax: 00 90 
424 238 81 73    ^cY#a10v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009700077002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#153#149#article#156#<br>   <a href="ma
ilto:hamityildiz@firat.edu.tr">hamityildiz@firat.edu.tr</a></font></p>     ^cY#a
10v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#154#150#article#156#<p>&nbsp;</p>     
^cY#a10v26n1.htm##
00300000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006400077002001300141#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#155#151#article#156#<p><font face="Ver
dana" size="2">Received: July 14, 2010    ^cY#a10v26n1.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#156#152#article#156#<br>   </font><fon
t face="Verdana" size="2">Review: September 21, 2010    ^cY#a10v26n1.htm##
00327000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009100077002001300168#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#157#153#article#156#<br>   </font><fon
t face="Verdana" size="2">Accepted: October 20, 2010 </font></p>     ^cY#a10v26n
1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#158#154#article#156#<p>&nbsp;</p>     
^cY#a10v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#159#155#article#156#<p>&nbsp;</p>     
^cY#a10v26n1.htm##
00474000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704023800077002001300315#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a10v26n1.htm#S#p#160#156#article#156#<p><font face="Ver
dana" size="2"><sup><a name="end"></a><a href="#top">1</a> </sup>Research    per
formed at Faculty of Veterinary Medicine, Department of Obstetrics and Gynecolog
y,    Firat University, Elazig, Turkey. </font></p>     ^cY#a10v26n1.htm##
00571000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100017000910100
01600108012009800124030002100222710000200243065000900245064000500254031000400259
014000800263865000900271002001300280#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10
v26n1.htm#S#c#161#1#article#33#1#^rND^sMonk^nBJ#^rND^sBerman^nML#^rND^sMontz^nFJ
#Adhesions after extensive gynecologic surgery: clinical significance, etiology 
and prevention^len#Am J Obstet Gynecol.#2#19940000#1994#170#1396-03#20110200#a10
v26n1.htm##
00480000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760100021000910120
04300112030001200155710000200167065000900169064000500178031000200183014000700185
865000900192002001300201#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#
c#162#2#article#33#2#^rND^sErgul^nE#^rND^sKorukluoglu^nB#Peritoneal adhesions: f
acing the enemy^len#Int J Surg.#2#20070000#2007#6#253-60#20110200#a10v26n1.htm##
00676000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100024000760100017001000100
01800117010001500135010001900150010001700169012010900186030001800295710000200313
065000900315064000500324031000300329014000800332865000900340002001300349#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#c#163#3#article#33#3#^rND^sDe la
 Portilla^nF#^rND^sYnfante^nI#^rND^sBejarano^nD#^rND^sConde^nJ#^rND^sFernandez^n
A#^rND^sOrtega^nJM#Prevention of peritoneal adhesions by intraperitoneal adminis
tration of vitamin E: an experimental study^len#Dis Colon Rectum.#2#20040000#200
4#47#2157-61#20110200#a10v26n1.htm##
00663000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100016000920100
01600108010001700124010001500141010002100156012011400177030001200291710000200303
065000900305064000500314031000200319014000600321865000900327002001300336#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#c#164#4#article#33#4#^rND^sYetki
n^nG#^rND^sUludag^nM#^rND^sCitgez^nB#^rND^sKarakoc^nS#^rND^sPolat^nN#^rND^sKabuk
cuoglu^nF#Prevention of peritoneal adhesions by intraperitoneal administration o
f vitamin E and human amniotic membrane^len#Int J Surg.#2#20090000#2009#7#561-5#
20110200#a10v26n1.htm##
00601000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100018000940100
01900112012013100131030001400262710000200276065000900278064000500287031000300292
014000600295865000900301002001300310#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10
v26n1.htm#S#c#165#5#article#33#5#^rND^sCorrales^nF#^rND^sCorrales^nM#^rND^sSchir
mer^nCC#Preventing intraperitoneal adhesions with vitamin E and sodium hyalurona
te/carboxymethylcellulose. A comparative study in rats^len#Acta Cir Bras#2#20080
000#2008#23#36-41#20110200#a10v26n1.htm##
00594000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100021000920100
01500113010001800128010001600146012007200162030001100234710000200245065000900247
064000500256031000400261014000500265865000900270002001300279#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a10v26n1.htm#S#c#166#6#article#33#6#^rND^sGalili^nY#^rND^sB
en-Abraham^nR#^rND^sRabau^nM#^rND^sKlausner^nJ#^rND^sKluger^nY#Reduction of surg
ery-induced peritoneal adhesions by methylene blue^len#Am J Surg.#2#19980000#199
8#175#30-2#20110200#a10v26n1.htm##
00627000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100016000940100
01900110012015300129030001900282710000200301065000900303064000500312031000300317
014000700320865000900327002001300336#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10
v26n1.htm#S#c#167#7#article#33#7#^rND^sSalaris^nSC#^rND^sBabbs^nCF#^rND^sVoorhee
s^nWD#Methylene blue as an inhibitor of superoxide generation by xanthine oxidas
e. A potential new drug for the attenuation of ischemia/reperfusion injury^len#B
iochem Pharmacol.#2#19910000#1991#42#499-06#20110200#a10v26n1.htm##
00559000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100017000930100
01800110012009100128030001400219710000200233065000900235064000500244031000300249
014000700252865000900259002001300268#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10
v26n1.htm#S#c#168#8#article#33#8#^rND^sPlacer^nZA#^rND^sCushman^nL#^rND^sJohnson
^nBC#Estimation of products of lipid peroxidation (malonyl dialdehyde) in biolog
ical fluids^len#Anal Biochem.#2#19660000#1966#16#359_64#20110200#a10v26n1.htm##
00545000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100019000920120
10600111030001400217710000200231065000900233064000500242031000300247014000700250
865000900257002001300266#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#
c#169#9#article#33#9#^rND^sSedlak^nJ#^rND^sLindsay^nRHC#Estimation of total, pro
tein bound and non-protein sulfhydryl groups in tissue with Ellmann's reagent^le
n#Anal Biochem.#2#19680000#1968#25#192_05#20110200#a10v26n1.htm##
00521000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100015000970120
06800112030002800180710000200208065000900210064000500219031000300224014000600227
865000900233002001300242#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#
c#170#10#article#33#10#^rND^sLawrence^nRA#^rND^sBurk^nRF#Glutathione peroxidase 
activity in selenium-deficient rat liver^len#Biochem Biophys Res Commun.#2#19760
000#1976#71#952_8#20110200#a10v26n1.htm##
00554000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100021000940100
01500115010001800130012005400148030001300202710000200215065000900217064000500226
031000400231014000700235865000900242002001300251#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a10v26n1.htm#S#c#171#11#article#33#11#^rND^sLowry^nOH#^rND^sRosebrough^
nNJ#^rND^sFarr^nAL#^rND^sRandall^nRJ#Protein measurement with the Folin-Phenol r
eagent^len#J Biol Chem.#2#19510000#1951#193#265_75#20110200#a10v26n1.htm##
00470000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780120022000920300
01700114065000900131064000500140031000400145014000600149865000900155002001300164
035001000177801001700187#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#
c#172#12#article#33#12#^rND^sAebi^nH#Catalase in vitro^len#Methods Enzymol.#1984
0000#1984#105#121-6#20110200#a10v26n1.htm#0076-6879#Methods Enzymol.##
00551000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950120
09600111030001100207710000200218065000900220064000500229031000300234032000700237
014000700244865000900251002001300260#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10
v26n1.htm#S#c#173#13#article#33#13#^rND^sCortas^nNK#^rND^sWakid^nNW#Determinatio
n of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method^
len#Clin Chem.#2#19900000#1990#36#8 Pt 1#1440_3#20110200#a10v26n1.htm##
00594000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100019000960100
01500115010001600130010001400146012007600160030000900236710000200245065000900247
064000500256031000300261014000600264865000900270002001300279#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a10v26n1.htm#S#c#174#14#article#33#14#^rND^sIrkorucu^nO#^rN
D^sFerahköse^nZ#^rND^sMemis^nL#^rND^sEkinci^nÖ#^rND^sAkin^nM#Reduction of postsu
rgical adhesions in a rat model: a comparative study^len#Clinics.#2#20090000#200
9#64#143-8#20110200#a10v26n1.htm##
00716000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100017000920100
01400109010001600123010001500139010001600154010001500170010001200185012012200197
03000120031971000020033106500090033306400050034203100030034701400060035086500090
0356002001300365#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#c#175#15
#article#33#15#^rND^sDinc^nS#^rND^sOzaslan^nC#^rND^sKuru^nB#^rND^sKaraca^nS#^rND
^sUstun^nH#^rND^sAlagol^nH#^rND^sRenda^nN#^rND^sOz^nM#Methylene blue prevents su
rgery-induced peritoneal adhesions but impairs the early phase of anastomotic wo
und healing^len#Can J Surg.#2#20060000#2006#49#321-8#20110200#a10v26n1.htm##
00746000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100015000970100
01600112010001700128010001600145010001700161010001800178012016400196030001200360
71000020037206500090037406400050038303100040038801400060039286500090039800200130
0407#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#c#176#16#article#33#
16#^rND^sHeydrick^nSJ#^rND^sReed^nKL#^rND^sCohen^nPA#^rND^sAarons^nCB#^rND^sGowe
r^nAC#^rND^sBecker^nJM#^rND^sStucchi^nAF#Intraperitoneal administration of methy
lene blue attenuates oxidative stress, increases peritoneal fibrinolysis, and in
hibits intraabdominal adhesion formation^len#J Surg Res.#2#20070000#2007#143#311
_9#20110200#a10v26n1.htm##
00517000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100021000780100016000990100
01600115012004600131030001400177710000200191065000900193064000500202031000300207
014000700210865000900217002001300226#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10
v26n1.htm#S#c#177#17#article#33#17#^rND^sSanfilippo^nJS#^rND^sBooth^nRJ#^rND^sBu
rns^nCD#Effect of vitamin E on adhesion formation^len#J Reprod Med.#2#19950000#1
995#40#278-82#20110200#a10v26n1.htm##
00654000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100014000960100
02000110010001600130010002000146012012600166030001100292710000200303065000900305
064000500314031000400319014000700323865000900330002001300339#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a10v26n1.htm#S#c#178#18#article#33#18#^rND^sKosther^nGM#^rN
D^sOttl^nK#^rND^sJauhiainen^nM#^rND^sEnholm^nC#^rND^sEsterbauer^nH#Human plasma 
phospholipids transfer protein accelerates exchange/transfer of a-toco-pherol be
tween lipoproteins and cells^len#Biochem J.#2#19950000#1995#305#659-67#20110200#
a10v26n1.htm##
00587000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940120
13900112030002200251710000200273065000900275064000500284031000300289014000700292
865000900299002001300308#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#
c#179#19#article#33#19#^rND^sMasugi^nF#^rND^sNakamura^nT#Effect of vitamin E def
iciency on the level of superoxide dismutase, glutathione peroxidase, catalase a
nd lipid peroxides in rat liver^len#Int J Vitam Nutr Res.#2#19760000#1976#46#187
-91#20110200#a10v26n1.htm##
00623000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100021000960100
01700117010001800134010001800152012008800170030001500258710000200273065000900275
064000500284031000300289014000700292865000900299002001300308#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a10v26n1.htm#S#c#180#20#article#33#20#^rND^sKinalski^nM#^rN
D^sSledziewski^nA#^rND^sTelejko^nB#^rND^sZarzycki^nW#^rND^sKinalska^nI#Lipid per
oxidation and scavenging enzyme activity in streptozotocin-induced diabete^len#A
cta Diabetol.#2#20000000#2000#37#179-83#20110200#a10v26n1.htm##
00793000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100018000950100
01600113010001600129010001600145010001500161010001700176010001900193012016400212
03000300037671000020040606500090040806400050041703100040042201400070042686500090
0433002001300442#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#c#181#21
#article#33#21#^rND^sArmagan^nA#^rND^sKutluhan^nS#^rND^sYilmaz^nM#^rND^sYilmaz^n
N#^rND^sBülbül^nM#^rND^sVural^nH#^rND^sSoyupek^nS#^rND^sNaziroglu^nM#Topiramate 
and vitamin e modulate antioxidant enzyme activities, nitric oxide and lipid per
oxidation levels in pentylenetetrazol-induced nephrotoxicity in rats^len#Basic C
lin Pharmacol Toxicol.#2#20080000#2008#103#166-70#20110200#a10v26n1.htm##
00627000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01800114010001400132010001800146010001800164012006900182030001400251710000200265
065000900267064000500276031000300281014000700284865000900291002001300300#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#c#182#22#article#33#22#^rND^sYos
hioka^nT#^rND^sMotoyama^nH#^rND^sYamasaki^nF#^rND^sAndo^nM#^rND^sTakehara^nY#^rN
D^sYamasaki^nM#Lipid peroxidation and vitamin E levels during pregnancy in rats^
len#Biol Neonate.#2#19870000#1987#52#223-31#20110200#a10v26n1.htm##
00563000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100015000930100
01800108012008800126030002400214710000200238065000900240064000500249031000300254
014000600257865000900263002001300272#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10
v26n1.htm#S#c#183#23#article#33#23#^rND^sAlpay^nZ#^rND^sSaed^nGM#^rND^sDiamond^n
MP#Female infertility and free radicals: potential role in adhesions and endonet
riosis^len#J Soc Gynecol Investig.#2#20060000#2006#13#390-8#20110200#a10v26n1.ht
m##
00726000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100021000920100
02000113010001500133010001800148010001500166010001600181010002100197012011100218
03000100032971000020033906500090034106400050035003100030035501400080035886500090
0366002001300375#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#c#184#24
#article#33#24#^rND^sAra^nCT#^rND^sKirimlioglu^nH#^rND^sKarabulut^nAB#^rND^sCoba
n^nS#^rND^sHascalik^nS#^rND^sCelik^nO#^rND^sYilmaz^nS#^rND^sKirimlioglu^nV#Effec
t of melatonin against oxidative stress on adhesion formation in the rat cecum a
nd uterine horn model^len#Life Sci.#2#20050000#2005#77#1341-50#20110200#a10v26n1
.htm##
00680000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100020000950100
01300115010001800128010001400146010001600160010001500176012009500191030002000286
71000020030606500090030806400050031703100030032201400070032586500090033200200130
0341#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#c#185#25#article#33#
25#^rND^sSogutlu^nG#^rND^sKarabulut^nAB#^rND^sAra^nC#^rND^sCinpolat^nO#^rND^sIsi
k^nB#^rND^sPiskin^nT#^rND^sCelik^nO#The effect of resveratrol on surgery-induced
 peritoneal adhesions in an experimental model^len#Cell Biochem Funct.#2#2007000
0#2007#25#217-20#20110200#a10v26n1.htm##
00760000000000337000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100017000930100
01500110010001500125010001600140010001500156010001600171010001500187012015600202
03000160035871000020037406500090037606400050038503100040039001400060039486500090
0400002001300409#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#c#186#26
#article#33#26#^rND^sGurel^nA#^rND^sArmutcu^nF#^rND^sSahin^nS#^rND^sSogut^nS#^rN
D^sOzyurt^nH#^rND^sGulec^nM#^rND^sKutlu^nNO#^rND^sAkyol^nO#Protective role of al
pha-tocopherol and caffeic acid phenethyl ester on ischemia-reperfusion injury v
ia nitric oxide and myeloperoxidase in rat kidneys^len#Clin Chim Acta.#2#2004000
0#2004#339#33-41#20110200#a10v26n1.htm##
00769000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960100
01800114010001600132010001900148010002000167010001700187012017600204030001600380
71000020039606500090039806400050040703100030041201400060041586500090042100200130
0430#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#c#187#27#article#33#
27#^rND^sGümüstas^nK#^rND^sGüzeyli^nFM#^rND^sAtükeren^nP#^rND^sSanus^nGZ#^rND^sK
emerdere^nR#^rND^sTanriverdi^nT#^rND^sKaynar^nMY#The effects of vitamin E on lip
id peroxidation, nitric oxide production and superoxide dismutase expression in 
hyperglycemic rats with cerebral ischemia-reperfusion injury^len#Turk Neurosurg.
#2#20070000#2007#17#78-82#20110200#a10v26n1.htm##
00566000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100018000920120
11500110030002800225710000200253065000900255064000500264031000300269014000600272
865000900278002001300287#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#
c#188#28#article#33#28#^rND^sJena^nS#^rND^sChainy^nGBN#Effect of Methylene blue 
on oxidative stres and antioxidant defence parameters of rat hepatic and renal t
issue^len#Indian J Physiol Pharmacol.#2#20080000#2008#52#293-6#20110200#a10v26n1
.htm##
00605000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100020000950100
01500115012013600130030001300266710000200279065000900281064000500290031000300295
014000700298865000900305002001300314#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10
v26n1.htm#S#c#189#29#article#33#29#^rND^sHaluzík^nM#^rND^sNedvidkova^nJ#^rND^sSk
rha^nJ#The influence of NO synthase inhibitor and free oxygen radicals scavenger
 methylene blue on streptozotocin-induced diabetes in rats^len#Physiol Res.#2#19
980000#1998#47#337-41#20110200#a10v26n1.htm##
00682000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100018000920100
01700110010001600127010001700143010001500160012011900175030002800294710000200322
065000900324064000500333031000300338014000500341865000900346002001300355#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a10v26n1.htm#S#c#190#30#article#33#30#^rND^sIna
n^nM#^rND^sBasaran^nUN#^rND^sDokmeci^nD#^rND^sYalcin^nO#^rND^sAydogdu^nN#^rND^sT
uran^nN#Methylene blue increases contralateral testicular ischaemia-reperfusion 
injury after unilateral testicular torsion^len#Clin Exp Pharmacol Physiol.#2#200
80000#2008#35#50-4#20110200#a10v26n1.htm##
00620000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01800112010001700130012009900147030000800246065000900254064000500263031000300268
014000700271865000900278002001300287035001000300801000800310#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a10v26n1.htm#S#c#191#31#article#33#31#^rND^sRezzani^nR#^rND
^sRodella^nL#^rND^sCorsetti^nG#^rND^sBianchi^nR#Does methylene blue protect the 
kidney tissues from damage induced by ciclosporin A treatment?^len#Nephron#20010
000#2001#89#329-36#20110200#a10v26n1.htm#0028-2766#Nephron##
00746000000000349000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100014000920100
01600106010001500122010001500137010001700152010001400169012012200183030001600305
06500090032106400050033003100040033503200020033901400070034186500090034800200130
0357035001000370801001600380#v26n1#V:\Scielo\serial\acb\v26n1\markup\a10v26n1.ht
m#S#c#192#32#article#33#32#^rND^sAksu^nB#^rND^sUmit^nH#^rND^sKanter^nM#^rND^sGuz
el^nA#^rND^sAktas^nC#^rND^sCivelek^nS#^rND^sUzun^nH#Effects of methylene blue in
 reducing cholestatic oxidative stres and hepatic damage after bile-duct ligatio
n in rats^len#Acta Histochem.#20100000#2010#112#3#259-69#20110200#a10v26n1.htm#0
065-1281#Acta Histochem.##
00702000000000301000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100016000960100
01800112010001700130010001700147012016700164030002300331710000200354065000900356
064000500365031000200370014000600372865000900378002001300387#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a10v26n1.htm#S#c#193#33#article#33#33#^rND^sLomniczi^nA#^rN
D^sCebral^nE#^rND^sCanteros^nG#^rND^sMcCann^nSM#^rND^sRettori^nV#Methylene blue 
inhibits the increase of inducible nitric oxide synthase activity induced by str
ess and lipopolysaccharide in the medial basal hypothalamus of rats^len#Neuroimm
unomodulation.#2#20000000#2000#8#122_7#20110200#a10v26n1.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v26n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#o#1#1#article#1#
20110120#130159#a11v26n1.htm#192##
04796000000000769000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094038000400098121000300102049000700105
15800030011203000160011503100030013103200020013406500090013601400090014503500100
01540120078001640120074002420100037003160100028003530100040003810100044004210100
02600465070012400491070008200615070006000697070006000757070008000817083126900897
08500080216608500230217408500290219708500330222608500210225908500220228008500170
23020831457023190850008037760850021037840850033038050850026038380850021038640850
02403885085001803909117000603927072000303933112000903936111001403945116000903959
115001903968114000903987113001703996002001304013#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a11v26n1.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#GRA#TAB#11#ACB720
#nd#Acta Cir. Bras.#26#1#20110200#^f58^l63#0102-8650#Neovascularization after is
chemic injury: evaluation with 99mTc-HYNIC-RGD^len#Neovascularização após lesão 
isquêmica: avaliação com 99mTc-HYNIC-RGD^lpt#^rND^1A01^nBluma Linkowski^sFaintuc
h#^rND^1A02^nRodrigo^sTeodoro#^rND^1A03^nErica Aparecida de^sOliveira#^rND^1A04^
nEutimio Gustavo Fernández^sNuñez#^rND^1A05^nJoel^sFaintuch#University of Sao Pa
ulo^iA01^1IPEN^2Radiopharmacy Center^3Postgraduate Program in Nuclear Technology
^cSao Paulo^sSP^pBrazil#USP^iA02^1IPEN^2Radiopharmacy Center^3Postgraduate Progr
am^cSao Paulo^sSP^pBrazil#USP^iA03^1IPEN^2Postgraduate Program^cSao Paulo^sSP^pB
razil#USP^iA04^1IPEN^2Postgraduate Program^cSao Paulo^sSP^pBrazil#USP^iA05^1Medi
cal School^2Department of Gastroenterology^cSao Paulo^sSP^pBrazil#^len^aPurpose:
 Angiogenesis involves many mediators including integrins, and the tripeptide RG
D is a target amino acid recognition sequence for many of them. Hindlimb ischemi
a is a simple and convenient animal model however standardization of the injecti
on procedures in the devascularized and control limb is lacking, thus rendering 
difficult the interpretation of results. The aim of this investigations was to e
valuate neovascularization in a hindlimb murine model by means of 99mTc-HYNIC-ß-
Ala-RGD. Methods: 99mTc-HYNIC-RGD analog was prepared using coligands. Ischemia 
was induced in Wistar rats by double- ligation of the common femoral artery. Rad
iolabeled RGD was injected after 2h, as well as 1, 3, 5, 7, 10 and 14 days. Upta
ke was evaluated by planar imaging and biodistribution studies. Results: The hig
hest ratio between ischemia and control was achieved at the 7th day (2.62 ± 0.95
), with substantial decrease by the 14th day. For pertechnetate the 7th day rati
o was 0.87 ± 0.23. Scintigraphic image confirmed different uptakes. Conclusion: 
99mTc-HYNIC-RGD analog concentrated in ischemic tissue by the time of widespread
 angiogenesis and pertechnetate confirmed reduction in blood flow. In this sense
, the protocol can be recommended for ischemic models.#^dnd^i1#^tm^len^kTechneti
um^i1#^tm^len^kIsotope Labeling^i1#^tm^len^kRadionuclide Imaging^i1#^tm^len^kIsc
hemia^i1#^tm^len^kDiagnosis^i1#^tm^len^kRats^i1#^lpt^aObjetivo: A angiogênese em
 resposta a fenômenos isquêmicos envolve vários mediadores como as integrinas, s
endo que o tripeptídeo RGD possui uma seqüência de aminoácidos com reconheciment
o para este alvo. O modelo animal de isquemia de pata traseira é simples e conve
niente, porém não há uma padronização do procedimento de injeção e controle radi
oisotópico em membro desvascularizado, dificultando, portanto a interpretação de
 resultados. O objetivo deste estudo foi avaliar a neovascularização em modelo m
urino de isquemia de pata traseira através do radiotraçador 99mTc-HYNIC-ß-Ala-RG
D. Métodos: O análogo 99mTc-HYNIC-RGD foi preparado usando coligantes. A isquemi
a foi induzida em ratos Wistar por dupla-ligação da artéria femoral comum na pre
ga inguinal. Peptídeo RGD radiomarcado foi injetado após 2h, assim como 1, 3, 5,
 7, 10 e 14 dias. A captação foi avaliada por imagem planar e estudos de biodist
ribuição. Resultados: A maior diferença de captação entre isquemia e pata contro
le foi obtida no 7º dia (2,62 ± 0,95), com decréscimo acentuado no 14º dia. Para
 o pertecnetato a razão no 7º dia foi 0,87 ± 0,23. A imagem cintilográfica confi
rmou as diferentes captações. Conclusões: O análogo 99mTc-HYNIC-RGD concentrou-s
e no tecido isquêmico na etapa em que a angiogênese é mais acentuada, e o estudo
 do pertecnetato confirmou a redução no fluxo sanguíneo. Desta maneira, este pro
tocolo diagnóstico pode ser recomendado para modelos isquêmicos.#^dnd^i2#^tm^lpt
^kTecnécio^i2#^tm^lpt^kMarcação por Isótopo^i2#^tm^lpt^kCintilografia^i2#^tm^lpt
^kIsquemia^i2#^tm^lpt^kDiagnóstico^i2#^tm^lpt^kRatos^i2#other#15#20100706#July 0
6, 2010#20100914#September 14, 2010#20101019#October 19, 2010#a11v26n1.htm##
04994000000000769000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094038000400098121000300102049000700105
15800030011203000160011503100030013103200020013406500090013601400090014503500100
01540120096001640120092002600100037003520100028003890100040004170100044004570100
02600501070012400527070008200651070006000733070006000793070008000853083133700933
08500080227008500230227808500290230108500330233008500210236308500220238408500170
24060831551024230850008039740850021039820850033040030850026040360850021040620850
02404083085001804107117000604125072000304131112000904134111001404143116000904157
115001904166114000904185113001704194002001304211#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a11v26n1.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#GRA#TAB#11#ACB720
#nd#Acta Cir. Bras.#26#1#20110200#^f58^l63#0102-8650#<b>Neovascularization after
 ischemic injury</b>: evaluation with <sup>99m</sup>Tc-HYNIC-RGD^len#<b>Neovascu
larização após lesão isquêmica</b>: avaliação com <sup>99m</sup>Tc-HYNIC-RGD^lpt
#^rND^1A01^nBluma Linkowski^sFaintuch#^rND^1A02^nRodrigo^sTeodoro#^rND^1A03^nEri
ca Aparecida de^sOliveira#^rND^1A04^nEutimio Gustavo Fernández^sNuñez#^rND^1A05^
nJoel^sFaintuch#University of Sao Paulo^iA01^1IPEN^2Radiopharmacy Center^3Postgr
aduate Program in Nuclear Technology^cSao Paulo^sSP^pBrazil#USP^iA02^1IPEN^2Radi
opharmacy Center^3Postgraduate Program^cSao Paulo^sSP^pBrazil#USP^iA03^1IPEN^2Po
stgraduate Program^cSao Paulo^sSP^pBrazil#USP^iA04^1IPEN^2Postgraduate Program^c
Sao Paulo^sSP^pBrazil#USP^iA05^1Medical School^2Department of Gastroenterology^c
Sao Paulo^sSP^pBrazil#^len^a<b>Purpose</b>: Angiogenesis involves many mediators
 including integrins, and the tripeptide RGD is a target amino acid recognition 
sequence for many of them. Hindlimb ischemia is a simple and convenient animal m
odel however standardization of the injection procedures in the devascularized a
nd control limb is lacking, thus rendering difficult the interpretation of resul
ts. The aim of this investigations was to evaluate neovascularization in a hindl
imb murine model by means of <sup>99m</sup>Tc-HYNIC-ß-Ala-RGD. <b>Methods</b>: <
sup>99m</sup>Tc-HYNIC-RGD analog was prepared using coligands. Ischemia was indu
ced in <i>Wistar </i>rats by double- ligation of the common femoral artery. Radi
olabeled RGD was injected after 2h, as well as 1, 3, 5, 7, 10 and 14 days. Uptak
e was evaluated by planar imaging and biodistribution studies. <b>Results</b>: T
he highest ratio between ischemia and control was achieved at the 7th day (2.62 
± 0.95), with substantial decrease by the 14th day. For pertechnetate the 7th da
y ratio was 0.87 ± 0.23. Scintigraphic image confirmed different uptakes. <b>Con
clusion</b>: <sup>99m</sup>Tc-HYNIC-RGD analog concentrated in ischemic tissue b
y the time of widespread angiogenesis and pertechnetate confirmed reduction in b
lood flow. In this sense, the protocol can be recommended for ischemic models.#^
dnd^i1#^tm^len^kTechnetium^i1#^tm^len^kIsotope Labeling^i1#^tm^len^kRadionuclide
 Imaging^i1#^tm^len^kIschemia^i1#^tm^len^kDiagnosis^i1#^tm^len^kRats^i1#^lpt^a<b
>Objetivo</b>: A angiogênese em resposta a fenômenos isquêmicos envolve vários m
ediadores como as integrinas, sendo que o tripeptídeo RGD possui uma seqüência d
e aminoácidos com reconhecimento para este alvo. O modelo animal de isquemia de 
pata traseira é simples e conveniente, porém não há uma padronização do procedim
ento de injeção e controle radioisotópico em membro desvascularizado, dificultan
do, portanto a interpretação de resultados. O objetivo deste estudo foi avaliar 
a neovascularização em modelo murino de isquemia de pata traseira através do rad
iotraçador <sup>99m</sup>Tc-HYNIC-ß-Ala-RGD. <b>Métodos</b>: O análogo <sup>99m<
/sup>Tc-HYNIC-RGD foi preparado usando coligantes. A isquemia foi induzida em ra
tos Wistar por dupla-ligação da artéria femoral comum na prega inguinal. Peptíde
o RGD radiomarcado foi injetado após 2h, assim como 1, 3, 5, 7, 10 e 14 dias. A 
captação foi avaliada por imagem planar e estudos de biodistribuição. <b>Resulta
dos</b>: A maior diferença de captação entre isquemia e pata controle foi obtida
 no 7<sup>o</sup> dia (2,62 ± 0,95), com decréscimo acentuado no 14<sup>o</sup> 
dia. Para o pertecnetato a razão no 7<sup>o</sup> dia foi 0,87 ± 0,23. A imagem 
cintilográfica confirmou as diferentes captações. <b>Conclusões</b>: O análogo <
sup>99m</sup>Tc-HYNIC-RGD concentrou-se no tecido isquêmico na etapa em que a an
giogênese é mais acentuada, e o estudo do pertecnetato confirmou a redução no fl
uxo sanguíneo. Desta maneira, este protocolo diagnóstico pode ser recomendado pa
ra modelos isquêmicos.#^dnd^i2#^tm^lpt^kTecnécio^i2#^tm^lpt^kMarcação por Isótop
o^i2#^tm^lpt^kCintilografia^i2#^tm^lpt^kIsquemia^i2#^tm^lpt^kDiagnóstico^i2#^tm^
lpt^kRatos^i2#other#15#20100706#July 06, 2010#20100914#September 14, 2010#201010
19#October 19, 2010#a11v26n1.htm##
04936000000000793000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112038000400116121000300120
04900070012315800030013003000150013303100030014803200020015106500090015301400090
01620350010001710120078001810120074002590100037003330100028003700100040003980100
04400438010002600482070012600508070008400634070006200718070006200780070008200842
08312690092408500080219308500230220108500290222408500330225308500210228608500220
23070850017023290831457023460850008038030850021038110850033038320850026038650850
02103891085002403912085001803936117000603954072000303960112000903963111001403972
116000903986115001903995114000904014113001704023002001304040008008904053#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#l#4#1#article#1#^mJan./Feb.^a201
1#oa#en#br1.1#1#4.0#ilus#gra#tab#11#ACB720#nd#Acta cir. bras#26#1#20110200#^f58^
l63#0102-8650#Neovascularization after ischemic injury: evaluation with 99mTc-HY
NIC-RGD^len#Neovascularização após lesão isquêmica: avaliação com 99mTc-HYNIC-RG
D^lpt#^rND^1A01^nBluma Linkowski^sFaintuch#^rND^1A02^nRodrigo^sTeodoro#^rND^1A03
^nErica Aparecida de^sOliveira#^rND^1A04^nEutimio Gustavo Fernández^sNuñez#^rND^
1A05^nJoel^sFaintuch#^iA01^1University of Sao Paulo^2IPEN^3Radiopharmacy Center.
 Postgraduate Program in Nuclear Technology^cSao Paulo^sSP^pBrazil#^iA02^1USP^2I
PEN^3Radiopharmacy Center. Postgraduate Program^cSao Paulo^sSP^pBrazil#^iA03^1US
P^2IPEN^3Postgraduate Program^cSao Paulo^sSP^pBrazil#^iA04^1USP^2IPEN^3Postgradu
ate Program^cSao Paulo^sSP^pBrazil#^iA05^1USP^2Medical School^3Department of Gas
troenterology^cSao Paulo^sSP^pBrazil#^len^aPurpose: Angiogenesis involves many m
ediators including integrins, and the tripeptide RGD is a target amino acid reco
gnition sequence for many of them. Hindlimb ischemia is a simple and convenient 
animal model however standardization of the injection procedures in the devascul
arized and control limb is lacking, thus rendering difficult the interpretation 
of results. The aim of this investigations was to evaluate neovascularization in
 a hindlimb murine model by means of 99mTc-HYNIC-ß-Ala-RGD. Methods: 99mTc-HYNIC
-RGD analog was prepared using coligands. Ischemia was induced in Wistar rats by
 double- ligation of the common femoral artery. Radiolabeled RGD was injected af
ter 2h, as well as 1, 3, 5, 7, 10 and 14 days. Uptake was evaluated by planar im
aging and biodistribution studies. Results: The highest ratio between ischemia a
nd control was achieved at the 7th day (2.62 ± 0.95), with substantial decrease 
by the 14th day. For pertechnetate the 7th day ratio was 0.87 ± 0.23. Scintigrap
hic image confirmed different uptakes. Conclusion: 99mTc-HYNIC-RGD analog concen
trated in ischemic tissue by the time of widespread angiogenesis and pertechneta
te confirmed reduction in blood flow. In this sense, the protocol can be recomme
nded for ischemic models.#^dnd^i1#^tm^len^kTechnetium^i1#^tm^len^kIsotope Labeli
ng^i1#^tm^len^kRadionuclide Imaging^i1#^tm^len^kIschemia^i1#^tm^len^kDiagnosis^i
1#^tm^len^kRats^i1#^lpt^aObjetivo: A angiogênese em resposta a fenômenos isquêmi
cos envolve vários mediadores como as integrinas, sendo que o tripeptídeo RGD po
ssui uma seqüência de aminoácidos com reconhecimento para este alvo. O modelo an
imal de isquemia de pata traseira é simples e conveniente, porém não há uma padr
onização do procedimento de injeção e controle radioisotópico em membro desvascu
larizado, dificultando, portanto a interpretação de resultados. O objetivo deste
 estudo foi avaliar a neovascularização em modelo murino de isquemia de pata tra
seira através do radiotraçador 99mTc-HYNIC-ß-Ala-RGD. Métodos: O análogo 99mTc-H
YNIC-RGD foi preparado usando coligantes. A isquemia foi induzida em ratos Wista
r por dupla-ligação da artéria femoral comum na prega inguinal. Peptídeo RGD rad
iomarcado foi injetado após 2h, assim como 1, 3, 5, 7, 10 e 14 dias. A captação 
foi avaliada por imagem planar e estudos de biodistribuição. Resultados: A maior
 diferença de captação entre isquemia e pata controle foi obtida no 7º dia (2,62
 ± 0,95), com decréscimo acentuado no 14º dia. Para o pertecnetato a razão no 7º
 dia foi 0,87 ± 0,23. A imagem cintilográfica confirmou as diferentes captações.
 Conclusões: O análogo 99mTc-HYNIC-RGD concentrou-se no tecido isquêmico na etap
a em que a angiogênese é mais acentuada, e o estudo do pertecnetato confirmou a 
redução no fluxo sanguíneo. Desta maneira, este protocolo diagnóstico pode ser r
ecomendado para modelos isquêmicos.#^dnd^i2#^tm^lpt^kTecnécio^i2#^tm^lpt^kMarcaç
ão por Isótopo^i2#^tm^lpt^kCintilografia^i2#^tm^lpt^kIsquemia^i2#^tm^lpt^kDiagnó
stico^i2#^tm^lpt^kRatos^i2#other#15#20100706#July 06, 2010#20100914#September 14
, 2010#20101019#October 19, 2010#a11v26n1.htm#Internet^ihttp://www.scielo.br/sci
elo.php?script=sci_arttext&pid=S0102-86502011000100011##
00311000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704007900073002001300152#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#5#1#article#173#<p align="right"><font
 face="Verdana" size="2"><b>11 - ORIGINAL ARTICLE    ^cY#a11v26n1.htm##
00327000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704009500073002001300168#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#6#2#article#173#<br>   </b></font><b><
font face="Verdana" size="2">ISCHEMIA-REPERFUSION</font></b></p>     ^cY#a11v26n
1.htm##
00269000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704003700073002001300110#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#7#3#article#173#<p align="right">&nbsp
;</p>      ^cY#a11v26n1.htm##
00465000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704023300073002001300306#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#8#4#article#173#<p><b><font face="Verd
ana" size="2"><a name="top"></a></font><font face="Verdana" size="4">Neovascular
ization    after ischemic injury. Evaluation with <SUP>99m</SUP>Tc-HYNIC-RGD<SUP
><a href="#end">1</a></SUP></font></b></p>     ^cY#a11v26n1.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#9#5#article#173#<p>&nbsp;</p>     ^cY#
a11v26n1.htm##
00428000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704019500074002001300269#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#10#6#article#173#<p><b><font face="Ver
dana" size="3">Neovasculariza&ccedil;&atilde;o ap&oacute;s    les&atilde;o isqu&
ecirc;mica. Avalia&ccedil;&atilde;o com <SUP>99m</SUP>Tc-HYNIC-RGD    </font></b
></p>     ^cY#a11v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002400074002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#11#7#article#173#<p>&nbsp;</p>       ^
cY#a11v26n1.htm##
00497000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704026400074002001300338#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#12#8#article#173#<p><font face="Verdan
a" size="2"><B>Bluma Linkowski Faintuch<SUP>I</SUP>, Rodrigo    Teodoro<SUP>II</
SUP>, Erica Aparecida de Oliveira<SUP>III</SUP>, Eutimio Gustavo    Fern&aacute;
ndez Nu&ntilde;ez<SUP>IV</SUP>, Joel Faintuch<SUP>V</SUP></B> </font></p>      ^
cY#a11v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002300074002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#13#9#article#173#<p>&nbsp;</p>      ^c
Y#a11v26n1.htm##
00600000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036600075002001300441#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#14#10#article#173#<p><font face="Verda
na" size="2"><SUP>I</SUP>PhD, Professor of Postgraduate Program    in Nuclear Te
chnology of the University of Sao Paulo (USP), Radiopharmacy Center,    IPEN/USP
, Sao Paulo-SP, Brazil. <I>Designed the protocol was involved with technical    
procedures, supervised all phases of the study, and was responsible for manuscri
pt    preparation.    ^cY#a11v26n1.htm##
00485000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025100075002001300326#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#15#11#article#173#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>II</SUP>PhD, Radiopharmacy Center,    Postgradu
ate Program, USP, IPEN/USP, Sao Paulo-SP, Brazil. <I>Helped with technical    pr
ocedures,&#160;collection and processing of study informations.    ^cY#a11v26n1.
htm##
00448000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021400075002001300289#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#16#12#article#173#<br>   </I></font><f
ont face="Verdana" size="2"><SUB>III</SUB>Fellow Master degree,    Postgraduate 
Program, USP, IPEN/USP, Sao Paulo-SP, Brazil. <I>Helped with collection    and p
rocessing of informations.    ^cY#a11v26n1.htm##
00444000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021000075002001300285#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#17#13#article#173#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>IV</SUP>Fellow PhD degree, Postgraduate    Prog
ram, USP, IPEN/USP, Sao Paulo-SP, Brazil. <I>Helped with collection and    proce
ssing of informations.    ^cY#a11v26n1.htm##
00485000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025100075002001300326#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#18#14#article#173#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>V</SUP>Associate Professor of    Surgery, Depar
tment of Gastroenterology, Medical School, USP, Sao Paulo-SP,    Brazil. <I>Prov
ided guidelines for the surgical interventions.</I></font></p>     ^cY#a11v26n1.
htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#19#15#article#173#<p><font face="Verda
na" size="2"><a href="#end">Correspondence</a></font></p>     ^cY#a11v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#20#16#article#173#<p>&nbsp;</p>     ^c
Y#a11v26n1.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#21#17#article#173#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a11v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#22#18#article#173#<p><font face="Verda
na" size="2"><B>ABSTRACT </B></font></p>     ^cY#a11v26n1.htm##
01685000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704145100075002001301526#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#23#19#article#173#<p><font face="Verda
na" size="2"><B>Purpose</b>: Angiogenesis involves many mediators    including i
ntegrins, and the tripeptide RGD is a target amino acid recognition    sequence 
for many of them. Hindlimb ischemia is a simple and convenient animal    model h
owever standardization of the injection procedures in the devascularized    and 
control limb is lacking, thus rendering difficult the interpretation of    resul
ts. The aim of this investigations was to evaluate neovascularization in    a hi
ndlimb murine model by means of <SUP>99m</SUP>Tc-HYNIC-&szlig;-Ala-RGD.    <B>Me
thods</B>: <SUP>99m</SUP>Tc-HYNIC-RGD analog was prepared using coligands.    Is
chemia was induced in <I>Wistar </I>rats by double- ligation of the common    fe
moral artery. Radiolabeled RGD was injected after 2h, as well as 1, 3, 5,    7, 
10 and 14 days. Uptake was evaluated by planar imaging and biodistribution    st
udies. <B>Results</B>: The highest ratio between ischemia and control was    ach
ieved at the 7th day (2.62 &#177; 0.95), with substantial decrease by the    14t
h day. For pertechnetate the 7th day ratio was 0.87 &#177; 0.23. Scintigraphic  
  image confirmed different uptakes. <B>Conclusion</B>: <SUP>99m</SUP>Tc-HYNIC-R
GD    analog concentrated in ischemic tissue by the time of widespread angiogene
sis    and pertechnetate confirmed reduction in blood flow. In this sense, the p
rotocol    can be recommended for ischemic models. </font></p>     ^cY#a11v26n1.
htm##
00409000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017500075002001300250#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#24#20#article#173#<p><font face="Verda
na" size="2"><B>Key words</B>: Technetium. Isotope Labeling.    Radionuclide Ima
ging. Ischemia. Diagnosis. Rats. </font></p> <hr size="1" noshade>     ^cY#a11v2
6n1.htm##
00301000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006700075002001300142#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#25#21#article#173#<p><font face="Verda
na" size="2"><B>RESUMO </B></font></p>     ^cY#a11v26n1.htm##
02272000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704203800075002001302113#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#26#22#article#173#<p><font face="Verda
na" size="2"><B>Objetivo</b>: A angiog&ecirc;nese em resposta    a fen&ocirc;men
os isqu&ecirc;micos envolve v&aacute;rios mediadores como as    integrinas, send
o que o tripept&iacute;deo RGD possui uma seq&uuml;&ecirc;ncia    de amino&aacut
e;cidos com reconhecimento para este alvo. O modelo animal de    isquemia de pat
a traseira &eacute; simples e conveniente, por&eacute;m n&atilde;o    h&aacute; 
uma padroniza&ccedil;&atilde;o do procedimento de inje&ccedil;&atilde;o    e con
trole radioisot&oacute;pico em membro desvascularizado, dificultando, portanto  
  a interpreta&ccedil;&atilde;o de resultados. O objetivo deste estudo foi avali
ar    a neovasculariza&ccedil;&atilde;o em modelo murino de isquemia de pata tra
seira    atrav&eacute;s do radiotra&ccedil;ador <SUP>99m</SUP>Tc-HYNIC-&szlig;-A
la-RGD.    <B>M&eacute;todos</B>: O an&aacute;logo <SUP>99m</SUP>Tc-HYNIC-RGD fo
i preparado    usando coligantes. A isquemia foi induzida em ratos Wistar por du
pla-liga&ccedil;&atilde;o    da art&eacute;ria femoral comum na prega inguinal. 
Pept&iacute;deo RGD radiomarcado    foi injetado ap&oacute;s 2h, assim como 1, 3
, 5, 7, 10 e 14 dias. A capta&ccedil;&atilde;o    foi avaliada por imagem planar
 e estudos de biodistribui&ccedil;&atilde;o. <B>Resultados</B>:    A maior difer
en&ccedil;a de capta&ccedil;&atilde;o entre isquemia e pata controle    foi obti
da no 7<SUP>o</SUP> dia (2,62 &#177; 0,95), com decr&eacute;scimo acentuado    n
o 14<SUP>o</SUP> dia. Para o pertecnetato a raz&atilde;o no 7<SUP>o</SUP> dia   
 foi 0,87 &#177; 0,23. A imagem cintilogr&aacute;fica confirmou as diferentes   
 capta&ccedil;&otilde;es. <B>Conclus&otilde;es</B>: O an&aacute;logo <SUP>99m</S
UP>Tc-HYNIC-RGD    concentrou-se no tecido isqu&ecirc;mico na etapa em que a ang
iog&ecirc;nese    &eacute; mais acentuada, e o estudo do pertecnetato confirmou 
a redu&ccedil;&atilde;o    no fluxo sangu&iacute;neo. Desta maneira, este protoc
olo diagn&oacute;stico    pode ser recomendado para modelos isqu&ecirc;micos. </
font></p>     ^cY#a11v26n1.htm##
00457000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022300075002001300298#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#27#23#article#173#<p><font face="Verda
na" size="2"><B>Descritores</B>: Tecn&eacute;cio. Marca&ccedil;&atilde;o    por 
Is&oacute;topo. Cintilografia. Isquemia. Diagn&oacute;stico. Ratos. <I>   </I>  
 </font></p> <hr size="1" noshade>     ^cY#a11v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#28#24#article#173#<p>&nbsp;</p>     ^c
Y#a11v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#29#25#article#173#<p>&nbsp;</p>     ^c
Y#a11v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007400075002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#30#26#article#173#<p><font face="Verda
na" size="3"><B>Introduction</B> </font></p>      ^cY#a11v26n1.htm##
00513000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027900075002001300354#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#31#27#article#173#<p><font face="Verda
na" size="2"> Several partially overlapping definitions apply    to the developm
ent of blood vessels. Neovascularization is the broad physiological    response 
to ischemia and corresponds to blood flow recovery detected <I>in vivo</I>.    <
/font></p>     ^cY#a11v26n1.htm##
00514000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028000075002001300355#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#32#28#article#173#<p><font face="Verda
na" size="2"> Angiogenesis is not only involved in cancer    progression but als
o plays an important role in the improvement and healing    of ischemic lesions<
SUP>1</SUP>. It is a complex process involving many components    as integrins. 
</font></p>     ^cY#a11v26n1.htm##
00483000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024900075002001300324#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#33#29#article#173#<p><font face="Verda
na" size="2"> Integrins are a notable class of receptor proteins,    from the la
rge family of cell adhesion receptors which are involved in cell-extracellular  
  matrix and cell-cell interactions<SUP>2</SUP>. </font></p>     ^cY#a11v26n1.ht
m##
00673000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704043900075002001300514#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#34#30#article#173#<p><font face="Verda
na" size="2"> They consist of two transmembrane glycoproteins    represented by 
non-covalently associated and &szlig;-units, which are essential    for the heal
ing of ischemic lesions. Accordingly, elevated <IMG SRC="./art_11_B.JPG" WIDTH="
22" HEIGHT="12"  ALIGN="BOTTOM"> integrin expression has been observed in ischem
ic tissue of the    brain, ophthalmological diseases, and muscles<SUP>3</SUP>. <
/font></p>     ^cY#a11v26n1.htm##
00472000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704023800075002001300313#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#35#31#article#173#<p><font face="Verda
na" size="2"> A majority of integrins, including the &#945;<sub>v</sub>&#946;<su
b>3</sub>    unit, recognize a conserved amino acid sequence, arginine-glycine-a
spartic acid    (Arg-Gly-Asp or RGD). </font></p>     ^cY#a11v26n1.htm##
00779000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704054500075002001300620#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#36#32#article#173#<p><font face="Verda
na" size="2"> Many of the first generation of RGD peptides    were low-binding &
#945;<sub>v</sub>&#946;<sub>3 </sub>integrins, because the    molecule was linea
r and highly susceptible to chemical degradation. That occured    due to reactio
n of the aspartic acid residue with the peptide backbone. Cyclization    of the 
molecule conferred rigidity to the structure improving binding properties,    an
d may serve as a vehicle to carry radionuclides to the integrin &#945;<sub>v</su
b>&#946;<sub>3</sub>.    </font></p>     ^cY#a11v26n1.htm##
00618000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704038400075002001300459#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#37#33#article#173#<p><font face="Verda
na" size="2"> RGD analogs have been radiolabeled with different    radioisotopes
, including, iodine-123 copper-64, indium-111, fluorine-18, technetium-99m,    y
ttrium-90, bromine-76, with the scope of achieving a radiopharmaceutical targete
d    for angiogenesis    processes in both tumors and regenerative neovasculariz
ation<SUP>4,5</SUP>.    </font></p>     ^cY#a11v26n1.htm##
00755000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052100075002001300596#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#38#34#article#173#<p><font face="Verda
na" size="2"> Technetium-99m (<SUP>99m</SUP>Tc) has the advantage    of optimal 
nuclear properties (6h half-life and monochromatic 140 keV photons),    along wi
th favorable logistics, being transportable and easily available from    <SUP>99
</SUP>Mo/<SUP>99m</SUP>Tc generators at low cost. The labeling was performed    
using the precursors <SUP>99m</SUP>Tc-nitrido and <SUP>99m</SUP>Tc- tricarbonyl<
SUP>6</SUP>    as well as BFCA 2-hydrazino-nicotinic acid (HYNIC)<SUP>4,7</SUP>.
 </font></p>     ^cY#a11v26n1.htm##
00689000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045500075002001300530#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#39#35#article#173#<p><font face="Verda
na" size="2"> The most common approach for designing a target-specific    <SUP>9
9m</SUP>Tc agent has been to attach a chelating group to a bioactive molecule,  
  resulting in a combined ligand that can form a complex with <SUP>99m</SUP>Tc  
  in a reduced oxidation state. This procedure is commonly known as a bifunction
al    approach, and the specific ligands employed as bifunctional chelating agen
ts    (BFCAs). </font></p>     ^cY#a11v26n1.htm##
00435000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020100075002001300276#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#40#36#article#173#<p><font face="Verda
na" size="2"> HYNIC has been reported as a BFCA of great interest    due to its 
high efficiency, fast radiolabeling and high radiolabeling yield<SUP>7</SUP>.   
 </font></p>     ^cY#a11v26n1.htm##
00787000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704055300075002001300628#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#41#37#article#173#<p><font face="Verda
na" size="2"> The molecule used in the current study is the    integrin &#945;<s
ub>v</sub>&#946;<sub>3</sub>-targeted radiotracer composed    of a targeting bio
molecule, cyclic RGD peptide (RGDyK), and a radiometal chelate.    The lysine re
sidue (K) serves as an ideal building block for further chemical    conjugation 
reactions<SUP>8</SUP>. For the molecule containing radiotracer,    a BFCA (HYNIC
) was used to attach the metallic radionuclide (<a href="/img/revistas/acb/v26n1
/a11img01.jpg">Figure    1</a>). </font></p>     ^cY#a11v26n1.htm##
00550000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031600075002001300391#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#42#38#article#173#<p><font face="Verda
na" size="2"> The animal ischemic hindlimb technique has been    often employed 
in neovascularization<SUP>9</SUP>, and other vascular investigations,    even th
ough results are occasionally questioned on account of inadequate standardizatio
n    of the procedure<SUP>10</SUP>. </font></p>     ^cY#a11v26n1.htm##
00530000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029600075002001300371#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#43#39#article#173#<p><font face="Verda
na" size="2"> The aim of this investigations was the use <SUP>99m</SUP>Tc-HYNIC-
&szlig;-Ala-RGD    as a diagnostic radiotracer to evaluate neovascularization in
 the extended period    of 14 days, in a hindlimb murine model with double arter
ial ligation.   </font></p>     ^cY#a11v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#44#40#article#173#<p>&nbsp;</p>      ^
cY#a11v26n1.htm##
00304000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007000075002001300145#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#45#41#article#173#<p> <font face="Verd
ana" size="3"><B>Methods</B> </font></p>      ^cY#a11v26n1.htm##
00446000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021200075002001300287#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#46#42#article#173#<p><font face="Verda
na" size="2"> Conventional reagents were purchased from Merck,    Brazil and Sig
ma-Aldrich, Brazil, unless otherwise stated, and were used without    further pu
rification. </font></p>     ^cY#a11v26n1.htm##
00362000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012800075002001300203#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#47#43#article#173#<p><font face="Verda
na" size="2"> - HYNIC-RGD derivative was synthesized by Biosynthan,    Berlin, G
ermany. </font></p>     ^cY#a11v26n1.htm##
00470000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704023600075002001300311#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#48#44#article#173#<p><font face="Verda
na" size="2"> - <SUP>99</SUP>Mo/<SUP>99m</SUP>Tc generator:    it is routinely m
anufactured and made available by the Institute of Energetic    and Nuclear Rese
arch (IPEN-CNEN/Sao Paulo, Brazil). </font></p>     ^cY#a11v26n1.htm##
00432000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704019800075002001300273#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#49#45#article#173#<p><font face="Verda
na" size="2"> - Animals for imaging and biodistribution studies:    <I>Wistar </
I>rats were supplied by the animal facility of IPEN-CNEN/Sao Paulo,    Brazil </
font></p>     ^cY#a11v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#50#46#article#173#<p>&nbsp;</p>     ^c
Y#a11v26n1.htm##
00357000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012300075002001300198#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#51#47#article#173#<p><font face="Verda
na" size="2"><I>Labeling procedure using EDDA/tricine as exchange    products</I
> </font></p>      ^cY#a11v26n1.htm##
00934000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704070000075002001300775#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#52#48#article#173#<p><font face="Verda
na" size="2"> HYNIC-Peptide labeling procedure was reported    before<SUP>7</SUP
>. Briefly, to a sealed reaction vial containing 20 mg Tricine    and 5 mg of ED
DA it was added 0.5 mL of 0.1M phosphate buffer solution, previously    nitrogen
ated, for the dissolution of the salts. Then 10 &#181;l of a solution    1.32 mM
 of [c[Arg-Gly-Asp-D-Tyr-(HYNIC)-Lys] plus 5 &#181;L of 8.9 mM SnCl<SUB>2</SUB>.
H<SUB>2</SUB>O    solution in 0.1N HCl (nitrogen-purged) and 500 &#181;L of Na<S
UP>99m</SUP>TcO<SUB>4</SUB>    was added. The mixture was heated for 15 minutes 
in water bath at 100<SUP>o</SUP>C    and cooled to room temperature; the pH of t
he reaction was 7. </font></p>      ^cY#a11v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#53#49#article#173#<p>&nbsp;</p>     ^c
Y#a11v26n1.htm##
00317000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008300075002001300158#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#54#50#article#173#<p><font face="Verda
na" size="2"><I>Radiochemical control</I> </font></p>      ^cY#a11v26n1.htm##
00637000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040300075002001300478#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#55#51#article#173#<p><font face="Verda
na" size="2"> Radiochemical analysis of <SUP>99m</SUP>Tc-HYNIC-RGDyK    was perf
ormed by thin-layer chromatography (TLC) on silica gel strips (ITLC-SG,    Gelma
n Sciences, Ann Arbor, MI) using a two solvent system, namely methylethylketone 
   (MEK) for detection of <SUP>99m</SUP>TcO<SUB>4</SUB>- and 50% Acetonitrile (A
CN)    for <SUP>99m</SUP>TcO<SUB>2</SUB>. </font></p>      ^cY#a11v26n1.htm##
01081000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704084700075002001300922#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#56#52#article#173#<p><font face="Verda
na" size="2"> Radiolabeled conjugate was also characterized    by Reverse Phase-
High Performance Liquid Chromatography (RP-HPLC). This analysis    was performed
 on a Waters 600E system equipped with a Waters 486 tunable absorbance    detect
or, an in-line Packard 150TR flow scintillation analyzer, and a Waters    746 da
ta module. HPLC solvents consisted of H<SUB>2</SUB>O containing 0.1% trifluoroac
etic    acid (Solvent A) and acetonitrile containing 0.1% trifluoracetic acid (S
olvent    B). A Symmetry C-18 column (5.0 &#181;m, 100 &Aring;, 4.6 x 250 mm, Wa
ters,    Milford, MA) was used with a flow rate of 0.5 ml/min. The HPLC gradient
 system    began with a solvent composition of 95% A and 5% B and followed a lin
ear gradient    of 30%A:70%B from 0-25 min, and 30%A:70%B to 5%A:95%B from 25-30
 min. </font></p>      ^cY#a11v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#57#53#article#173#<p>&nbsp;</p>     ^c
Y#a11v26n1.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008000075002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#58#54#article#173#<p><font face="Verda
na" size="2"><I>Biological studies</I> </font></p>      ^cY#a11v26n1.htm##
00685000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704045100075002001300526#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#59#55#article#173#<p><font face="Verda
na" size="2"> The study was approved by the institutional    Animal Welfare Comm
ittee, and all procedures were conducted in agreement with    the principles of 
the Brazilian College of Animal Experimentation. The <I>in    vivo</I> studies w
ere performed in male <I>Wistar </I>rats submitted to common    femoral artery d
ouble occlusion. The study was performed in groups of 6 animals    for each time
 studied. </font></p>      ^cY#a11v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#60#56#article#173#<p>&nbsp;</p>     ^c
Y#a11v26n1.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008000075002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#61#57#article#173#<p><font face="Verda
na" size="2"><I>Surgical technique</I> </font></p>      ^cY#a11v26n1.htm##
00967000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704073300075002001300808#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#62#58#article#173#<p><font face="Verda
na" size="2"> The animals were anesthetized (1 mL/Kg IP ketamine    and 0.5 ml/K
g IP xylazine) and shaved for surgical intervention. The right femoral    vessel
s were exposed through an inguinal skin incision, and the common femoral    arte
ry was carefully separated and double-ligated (<a href="#img02">Figure 2</a>).  
  The first ligation was done at the common artery proximal to the bifurcation  
  of the deep femoral artery and a second ligation followed on the superficial  
  artery below the bifurcation (<a href="#img03">Figure 3</a>). After the incisi
on    was sutured rats were allowed to recover. By 2h and after 1, 3, 5, 7, 10 a
nd    14 days the radiolabeled peptide was injected. </font></p>     ^cY#a11v26n
1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#63#59#article#173#<p align="center">&n
bsp;</p>     ^cY#a11v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#64#60#article#173#<p align="center">&n
bsp;</p>     ^cY#a11v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#65#61#article#173#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a11img02.jpg"><a name="img02"></a></p>     ^cY#a
11v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#66#62#article#173#<p align="center">&n
bsp;</p>     ^cY#a11v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#67#63#article#173#<p align="center">&n
bsp;</p>     ^cY#a11v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#68#64#article#173#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a11img03.jpg"><a name="img03"></a></p>     ^cY#a
11v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#69#65#article#173#<p align="center">&n
bsp;</p>     ^cY#a11v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#70#66#article#173#<p align="center">&n
bsp;</p>     ^cY#a11v26n1.htm##
00344000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011000075002001300185#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#71#67#article#173#<p><font face="Verda
na" size="2"><I> Biodistribution study and imaging evaluation</I>    </font></p>
      ^cY#a11v26n1.htm##
00711000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704047700075002001300552#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#72#68#article#173#<p><font face="Verda
na" size="2"> Each animal was injected with 0.1 mL of <SUP>99m</SUP>Tc-HYNIC-RGD
    analog via the tail vein. The animals were sacrificed 2 hours post-injection
.    Evaluation of the uptake by the ischemic limb and normal contralateral limb
    was done on each occasion. Hindlimb pertechnetate, which has no affinity for
    regenerating tissue and in the circumstances indicates just blood flow, was 
   also registered for confirmation. </font></p>     ^cY#a11v26n1.htm##
00683000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704044900075002001300524#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#73#69#article#173#<p><font face="Verda
na" size="2"> Complete biodistribution assessment was done    7 days after the s
urgical procedure. The animals were sacrificed by cervical    dislocation, and t
issues and organs were excised, weighted and radioactivity    measured in a gamm
a counter (Cobra 5002, Packard, USA), using the injected dose    as standard for
 calculation. Results were expressed in percentage of injected    dose per gram 
(%ID/g). </font></p>     ^cY#a11v26n1.htm##
00620000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704038600075002001300461#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#74#70#article#173#<p><font face="Verda
na" size="2"> For acquisition of images the rats were anesthetized    and horizo
ntally placed under the collimator of a Mediso Imaging System, Budapest,    Hung
ria, employing a LEHR collimator. Images were acquired at 2h post injection    u
sing a 256 x 256 x 16 matrix size with a 20% energy window set at 140 keV for   
 a period of 180 seconds. </font></p>     ^cY#a11v26n1.htm##
00422000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704018800075002001300263#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#75#71#article#173#<p><font face="Verda
na" size="2"><I>   </I>   Ratio between homologous images of the same animal was
 calculated by means of    the Region of Interest (ROI) technique. </font></p>  
    ^cY#a11v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#76#72#article#173#<p>&nbsp;</p>     ^c
Y#a11v26n1.htm##
00316000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008200075002001300157#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#77#73#article#173#<p><font face="Verda
na" size="2"><I>Statistical analysis</I> </font></p>      ^cY#a11v26n1.htm##
00661000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704042700075002001300502#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#78#74#article#173#<p><font face="Verda
na" size="2"> Discrepancies among the uptakes ratios between    of <SUP>99m</SUP
>Tc-HYNIC-RGD in ischemic hindlimbs and control side at different    times were 
analyzed by Statgraphics Plus 5.0 (Statistical Graphics Corp., Fairfax,    Va., 
U.S.A.). One-way analysis of variance (ANOVA) followed by post-hoc Tukey    test
 were performed. The adopted significance level () was P&lt;0.05. </font></p>   
   ^cY#a11v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#79#75#article#173#<p>&nbsp; </p>     ^
cY#a11v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#80#76#article#173#<p><font face="Verda
na" size="3"><B>Results</B> </font></p>      ^cY#a11v26n1.htm##
00358000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704012400075002001300199#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#81#77#article#173#<p><font face="Verda
na" size="2"><I> Labeling procedure using EDDA/tricine as    exchange products</
I> </font></p>      ^cY#a11v26n1.htm##
00395000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704016100075002001300236#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#82#78#article#173#<p><font face="Verda
na" size="2"> The conjugate HYNIC-RGDyK was radiolabeled using    the exchange l
abeling technology via tricine and EDDA. </font></p>     ^cY#a11v26n1.htm##
00650000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704041600075002001300491#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#83#79#article#173#<p><font face="Verda
na" size="2"> Radiochemical purity of <SUP>99m</SUP>Tc-HYNIC-RGD    was 99.45 &#
177; 0.12%. TLC findings were confirmed by HPLC (<a href="#img04">Figure    4</a
>) with a retention time for the product of 12.86 minutes. Only traces (&lt;    
0.6 %) of <SUP>99m</SUP>TcO<SUB>4</SUB>- could be detected, with a retention    
time of 5.33 min. Specific activity was 142.3 MBq/nmol. </font></p>     ^cY#a11v
26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#84#80#article#173#<p align="center">&n
bsp;</p>     ^cY#a11v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#85#81#article#173#<p align="center">&n
bsp;</p>     ^cY#a11v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#86#82#article#173#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a11img04.jpg"><a name="img04"></a></p>     ^cY#a
11v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#87#83#article#173#<p>&nbsp;</p>     ^c
Y#a11v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#88#84#article#173#<p align="center"><f
ont face="Verdana" size="2"> </font></p>     ^cY#a11v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#89#85#article#173#<p><font face="Verda
na" size="2"><I> Biodistribution studies</I> </font></p>      ^cY#a11v26n1.htm##
00626000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039200075002001300467#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#90#86#article#173#<p><font face="Verda
na" size="2"> Biodistribution of <SUP>99m</SUP>Tc-HYNIC-RGD    analog was expres
sed in %ID/g (<a href="#img05">Figure 5</a>). Uptake was ordinarily    below 1.0
 %ID/g. The best values corresponded to kidneys (2.30 &#177; 0.26 %ID/g),    liv
er, intestine and spleen. Blood uptake (0.07 &#177; 0.01% ID/mL) showed a    goo
d clearance of the radiotracer. </font></p>     ^cY#a11v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#91#87#article#173#<p align="center">&n
bsp;</p>     ^cY#a11v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#92#88#article#173#<p align="center">&n
bsp;</p>     ^cY#a11v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#93#89#article#173#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a11img05.jpg"><a name="img05"></a></p>     ^cY#a
11v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#94#90#article#173#<p align="center">&n
bsp;</p>     ^cY#a11v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#95#91#article#173#<p align="center">&n
bsp;</p>     ^cY#a11v26n1.htm##
00698000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704046400075002001300539#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#96#92#article#173#<p><font face="Verda
na" size="2"> Hindlimb uptake of <SUP>99m</SUP>Tc-HYNIC-RGD    can be observed i
n <a href="/img/revistas/acb/v26n1/a11tab01.jpg">Table    1</a>. The highest rat
io between ischemic hindlimb and control side was achieved    at the 7th day (2.
62 &#177; 0.33), with substantial decrease by the 14th day    (0.30 &#177; 0.02)
. This result was statistically confirmed by one way ANOVA    (p=6.24 x 10-24&lt
; 0.05) and Tukey test. </font></p>     ^cY#a11v26n1.htm##
00447000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021300075002001300288#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#97#93#article#173#<p><font face="Verda
na" size="2"> Pertchnetate uptake in both hindlimbs (control    and devasculariz
ed), was also documented as a control and the ratio for the    7th day was 0.87 
&#177; 0.23. </font></p>     ^cY#a11v26n1.htm##
00796000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056200075002001300637#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#98#94#article#173#<p><font face="Verda
na" size="2"> The images of pertechnetate (A) and <SUP>99m</SUP>Tc-HYNIC-RGD    
(B) in hindlimbs can be observed in <a href="/img/revistas/acb/v26n1/a11img06.jp
g">Figure    6</a>. Pertechnetate as a nonspecific marker for new vascularizatio
n, didn't    show differences between hindlimbs. Ratio of ischemic to normally-p
erfused hindlimb    in the images (B) (2.51), estimated by drawing regions of in
terest, did not    yield much additional information. General values were of the
 same range as    shown by gamma-counter. </font></p>     ^cY#a11v26n1.htm##
00444000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021000075002001300285#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#99#95#article#173#<p><font face="Verda
na" size="2"> Biodistribution in tissues and organs showed    the highest uptake
 by the kidneys reflecting a renal excretion, followed by    liver, intestine an
d spleen. </font></p>     ^cY#a11v26n1.htm##
00510000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704027500076002001300351#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#100#96#article#173#<p><font face="Verd
ana" size="2"> Major murine organs, such as liver, spleen and    colon showed sp
ecific uptake suggesting &#945;<sub>v</sub>&#946;<sub>3</sub>    expression in t
hese tissues as announced before by Dijkgraaf <I>et al.</I><SUP>2</SUP>.    </fo
nt></p>     ^cY#a11v26n1.htm##
00507000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704027200076002001300348#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#101#97#article#173#<p><font face="Verd
ana" size="2"> The highest uptake ratio of <SUP>99m</SUP>Tc-HYNIC-RGD    between
 ischemic hindlimb and control side was achieved at the 7th day, decreasing    i
n later days probably due to attenuation of the angiogenesis phenomenon. </font>
</p>     ^cY#a11v26n1.htm##
00463000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704022800076002001300304#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#102#98#article#173#<p><font face="Verd
ana" size="2"> Lee <I>et al.</I><SUP>11 </SUP>labeled HYNIC-c(RGDyK)    with <SU
P>18</SUP>F reported that the vascular endothelial growth factor protein    expr
ession was maximum on day 7. </font></p>     ^cY#a11v26n1.htm##
00797000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704056200076002001300638#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#103#99#article#173#<p><font face="Verd
ana" size="2"> Also Hua <I>et al.</I><SUP>12 </SUP>achieved    results compatibl
e with ours using <SUP>99m</SUP>Tc-NC100692. Their studies    were conducted in 
mice with NC100692, a product from &quot;Amersham&quot; in    which the sequence
 of amino acids RGD is held in a cycle by a disulphide and    a thioether bridge
, with a short polyethylene glycol unit. Edwards <I>et al.</I><SUP>13    </SUP>u
sed the same radiotracer, <SUP>99m</SUP>Tc-NC100692, to document the    dissocia
tion constant [Kd] for integrin receptors. </font></p>     ^cY#a11v26n1.htm##
00640000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704040400077002001300481#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#104#100#article#173#<p><font face="Ver
dana" size="2"> For pertechnetate a low ratio was registered    because as a pas
sive marker, it does not bind to new blood vessels, confirming    just blood flo
w. The importance of such procedure has not been emphasized in    other protocol
s. The ratio obtained for the 7th day was 0.87 &#177; 0.23, consistent    with r
educed perfusion following arterial ligation. </font></p>     ^cY#a11v26n1.htm##
00775000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704053900077002001300616#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#105#101#article#173#<p><font face="Ver
dana" size="2"> Experimental methods to create hindlimb ischemia    are not stan
dardized. Goto <I>et al.</I><SUP>10 </SUP>described a number of    methods to cr
eate stable hindlimb ischemia in the mouse by occluding the artery,    varying f
rom simple ligation, to cutting, or to excision of the artery. The    targeted v
essel could be the iliac artery, the femoral artery, or the femoral    and saphe
nous trunks. We opted to execute the ligation of the femoral artery    in two si
tes, encompassing    </font></p>     ^cY#a11v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#106#102#article#173#<p>&nbsp;</p>     
^cY#a11v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007200077002001300149#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#107#103#article#173#<p><font face="Ver
dana" size="3"><B>Discussion</B> </font></p>      ^cY#a11v26n1.htm##
00639000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704040300077002001300480#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#108#104#article#173#<p><font face="Ver
dana" size="2"> The major triggers of angiogenesis process can    be simplified 
into three broad categories: mechanical, chemical, and molecular    factors<SUP>
8</SUP>. Molecular mediators are not necessarily abundant or present    in all p
hases of the process, but they are specific and can be monitored by    radiotrac
ers using imaging or non-imaging techniques. </font></p>     ^cY#a11v26n1.htm##
00509000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704027300077002001300350#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#109#105#article#173#<p><font face="Ver
dana" size="2"> There are several advantages in using radiolabeled    small RGD 
peptides as radiotracers. They can tolerate harsh conditons for radiolabeling   
 and chemical modification due their small size and rapid blood clearance. </fon
t></p>     ^cY#a11v26n1.htm##
00525000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704028900077002001300366#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#110#106#article#173#<p><font face="Ver
dana" size="2"> The molecule containing the cyclic sequence    RGD usually is de
signed with more amino acids as fK, fV or yK<SUP>4</SUP>, besides    those molec
ules that compose the multimeric structure to allow the labeling    with the rad
ionuclide. </font></p>     ^cY#a11v26n1.htm##
00611000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704037500077002001300452#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#111#107#article#173#<p><font face="Ver
dana" size="2"> To the sequence RGD it was here added two amino    acids, D-Tyro
sine and Lysine. Non-natural peptide modifications such as the    introduction o
f D-amino acids, as well as replacement with peptidomimetic structures,    tend 
to grant RGD peptide ligands increased specificity and nanomolar or at    least 
higher affinity. </font></p>     ^cY#a11v26n1.htm##
00529000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704029300077002001300370#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#112#108#article#173#<p><font face="Ver
dana" size="2"> The radiolabeling of RGD analog using HYNIC    as BFCA was easy 
and quick to perform. Most importantly, it was associated with    a high yield a
nd no purification step was needed, so that the radiocompound    could be inject
ed right away. </font></p>     ^cY#a11v26n1.htm##
00610000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704037400077002001300451#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#113#109#article#173#<p><font face="Ver
dana" size="2"> Technetium-99m binds to the hydrazine-moiety    forming a <SUP>9
9m</SUP>Tc-N bond. As HYNIC alone cannot satisfy the coordination    requirement
s of Tc(V) because it occupies one or two coordination sites on the    radionucl
ide, coligands are necessary to complete the coordination sphere of    the techn
etium (V) core. </font></p>     ^cY#a11v26n1.htm##
00460000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704022400077002001300301#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#114#110#article#173#<p><font face="Ver
dana" size="2"> We had reported before<SUP>7</SUP> that conjugates    prepared b
y tricine/EDDA exchange labeling exhibit high specific activity and    excellent
 radiochemical stability. </font></p>     ^cY#a11v26n1.htm##
00399000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704016300077002001300240#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#115#111#article#173#<p><font face="Ver
dana" size="2">   both the common and superficial artery. This modality was easy
, convenient and    moderately reproducible. </font></p>     ^cY#a11v26n1.htm##
00579000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704034300077002001300420#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#116#112#article#173#<p><font face="Ver
dana" size="2"> Skjeldal <I>et al.</I><SUP>14 </SUP>reported    that, small anim
als as like mice are endowed with a well-developed innate collateral    system, 
and thus display remarkably high resistance to ischemia. Simple ligation    of t
he femoral artery is known to produce no severe ischemic change. </font></p>    
 ^cY#a11v26n1.htm##
00490000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704025400077002001300331#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#117#113#article#173#<p><font face="Ver
dana" size="2"> Within in this context, the animal used in the    study (Wistar 
rats) was not ideal due the well-developed collateral circulation    in hindlimb
. We achieved only 70% of reproducibility of the model. </font></p>     ^cY#a11v
26n1.htm##
00519000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704028300077002001300360#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#118#114#article#173#<p><font face="Ver
dana" size="2"> The weak image contrast between ischemic and    contralateral hi
ndlimb with <SUP>99m</SUP>Tc-HYNIC-RGD is partly due to residual    muscle uptak
e. It does not coincidence with biodistribution results and needs    to be impro
ved. </font></p>     ^cY#a11v26n1.htm##
00675000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704043900077002001300516#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#119#115#article#173#<p><font face="Ver
dana" size="2"> In synthesis, radiotracer assessment demonstrated    somewhat le
ss angiogenesis than anticipated. Lee <I>et al.</I><SUP>15</SUP>,    employing l
aser Doppler flowmetry on days 3 and 8 of ischemia, with <SUP>125</SUP>I-c(RGD(I
)yV)    and then RGD analog labeled with <SUP>123</SUP>I for scintigraphy, were 
also    disappointed by relatively modest image contrast between the hindlimbs. 
</font></p>      ^cY#a11v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#120#116#article#173#<p>&nbsp; </p>    
 ^cY#a11v26n1.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007300077002001300150#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#121#117#article#173#<p><font face="Ver
dana" size="3"><B>Conclusions</B> </font></p>      ^cY#a11v26n1.htm##
00710000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704047400077002001300551#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#122#118#article#173#<p> <font face="Ve
rdana" size="2"><SUP>99m</SUP>Tc-HYNIC-RGD analog corresponded    to expectation
s, displaying elevated uptake in ischemic tissue by the time of    widespread an
giogenesis. The animal model showed only 70% of reproducibility.    Utilization 
in other ischemic models can be recommended. The modest image obtained    with <
SUP>99m</SUP>Tc-HYNIC-RGD does not correspond to a previous result in    biodist
ribution and needs to be improved. </font></p>      ^cY#a11v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#123#119#article#173#<p>&nbsp; </p>    
 ^cY#a11v26n1.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007300077002001300150#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#124#120#article#173#<p><font face="Ver
dana" size="3"><B>References </B> </font></p>      ^cY#a11v26n1.htm##
00518000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704026800079002001300347#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#125#121#article#173#1#<p><
font face="Verdana" size="2">1. Baumgartner I, Pieczek A, Manor O. Constitutive 
   expression of VEGF 165 following intramuscular gene transfer promotes collate
ral    vessel development in patients with critical limb ischemia. Circulation. 
1998;97:1114-23.    ^cY#a11v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#126#122#article#173#    </font></p>   
  ^cY#a11v26n1.htm##
00531000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704028100079002001300360#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#127#123#article#173#2#<p><
font face="Verdana" size="2">2. Dijkgraaf I, Kruijtzer JA, Frielink C, Soede    
AC, Hilbers HW, Oyen WJ, Corstens FHM, Liskamp RMJ, Boerman OC. Synthesis and   
 biological evaluation of potent alphavbeta3-integrin receptor antagonists. Nucl
    Med Biol. 2006;33:953-61.    ^cY#a11v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#128#124#article#173# </font></p>     ^
cY#a11v26n1.htm##
00744000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704049400079002001300573#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#129#125#article#173#3#<p><
span lang=EN-US style='font-size:10.0pt;font-family:Verdana'>3. Muether PS,    D
ell S, Kociok N, Zahn G, Stragies R, Vossmeyer D, Joussen AM. The role of integr
in    </span><span style='font-size:10.0pt;font-family:Verdana'>&#945;</span><su
b><span lang=EN-US style='font-size:10.0pt;font-family: Verdana'>5</span></sub><
span lang=EN-US style='font-size:10.0pt;font-family: Verdana'>&szlig;<sub>1</sub
> in the regulation of corneal neovascularization.    Exp Eye Res. 2007;85:356-6
5.    ^cY#a11v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#130#126#article#173# </span></p>     ^
cY#a11v26n1.htm##
00705000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704045500079002001300534#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#131#127#article#173#4#<p><
span lang=EN-US style='font-size:10.0pt;font-family:Verdana'>4. Decristoforo    
D, Faintuch BL, Rey A, von Guggenberg E, Rupprich M, Hernandez-Gonzales I, Rodri
go    T, Haubner R. <sup>99m</sup>Tc&#093;HYNIC-RGD for imaging integrin </span>
<span style='font-size:10.0pt;font-family:Verdana'>&#945;<sub>v</sub>&szlig;<sub
>3</sub></span><span lang=EN-US style='font-size:10.0pt;font-family:Verdana'> ex
pression. Nucl Med    Biol. 2006;33:945-52.    ^cY#a11v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#132#128#article#173#</span></p>      ^
cY#a11v26n1.htm##
00466000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704021600079002001300295#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#133#129#article#173#5#<p><
font face="Verdana" size="2">5. Liu S. Radiolabeled multimeric cyclic RGD    pep
tides as integrin &#945;<sub>v</sub>&#946;<sub>3</sub> targeted radiotracers    
for tumor imaging. Mol Pharm. 2006;3:472-87.    ^cY#a11v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#134#130#article#173# </font></p>     ^
cY#a11v26n1.htm##
00607000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704035700079002001300436#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#135#131#article#173#6#<p><
font face="Verdana" size="2">6. Psimadas D, Fani M, Zikos C, Xanthopoulos    S, 
Archimandritis SC, Varvarigou AD. Study of the labeling of two novel RGD-peptidi
c    derivatives with the precursor [<SUP>99m</SUP>Tc(H<SUB>2</SUB>O)(CO)<SUB>3<
/SUB>]+    and evaluation for early angiogenesis detection in cancer. Appl Radia
t Isot.    2006;64:151-9.    ^cY#a11v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#136#132#article#173# </font></p>     ^
cY#a11v26n1.htm##
00581000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704033100079002001300410#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#137#133#article#173#7#<p><
font face="Verdana" size="2">7. Faintuch BL, Santos RLSR, Souza ALFM, Hoffman   
 TJ, Greeley M, Smith CJ. <SUP>99m</SUP>Tc-HYNIC-bombesin (7-14)NH2: Radiochemic
al    evaluation with co-ligands EDDA (EDDA=ethylenediamine-N,N'-diacetic acid),
 tricine,    and nicotinic acid. Synth React Inorg Met Org Chem. 2005;35:43-51. 
   ^cY#a11v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#138#134#article#173# </font></p>     ^
cY#a11v26n1.htm##
00485000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704023500079002001300314#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#139#135#article#173#8#<p><
font face="Verdana" size="2">8. Temming K, Schiffelers RM, Molema G, Kok RJ.    
RGD-based strategies for selective delivery of therapeutics and imaging agents  
  to the tumour vasculature. Drug Resist Updat. 2005;8:381-402.    ^cY#a11v26n1.
htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#140#136#article#173# </font></p>     ^
cY#a11v26n1.htm##
00657000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704040700079002001300486#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#141#137#article#173#9#<p><
font face="Verdana" size="2">9. Yamahara K, Sone M, Itoh H, Yamashita JK,    Yur
ugi-Kobayashi T, Homma K, Chao TH, Miyashita K, Park K, Oyamada N, Sawada    N, 
Taura D, Fukunaga Y, Tamura N, Nakao K. Augmentation of neovascularization    [c
orrected] in hindlimb ischemia by combined transplantation of human embryonic   
 stem cells-derived endothelial and mural cells. PLoS One. 2008;3(2):e1666.    ^
cY#a11v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#142#138#article#173# </font></p>     ^
cY#a11v26n1.htm##
00524000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027300080002001300353#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#143#139#article#173#10#<p>
<font face="Verdana" size="2">10. Goto T, Fukuyama N, Aki A, Kanabuchi K, Kimura
    K, Taira H, Tanaka E, Wakana N, Mori H, Inoue H. Search for appropriate expe
rimental    methods to create stable hindlimb ischemia in mouse. Tokai J Exp Cli
n Med. 2006;31:128-32.    ^cY#a11v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#144#140#article#173#    </font></p>   
  ^cY#a11v26n1.htm##
00564000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704031300080002001300393#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#145#141#article#173#11#<p>
<font face="Verdana" size="2">11. Lee YS, Jeong JM, Kim HW, Chang YS, Kim YJ,   
 Hong MK, Rai GB, Chi DY, Kang WJ, Kang JH, Lee DS, Chung JK, Lee MC, Suh YG    
. An improved method of <SUP>18</SUP>F peptide labeling: hidrazone formation    
with HYNIC-conjugated c(RGDyK). Nucl Med Biol. 2006;33:677-83.    ^cY#a11v26n1.h
tm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#146#142#article#173# </font></p>     ^
cY#a11v26n1.htm##
00663000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704041200080002001300492#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#147#143#article#173#12#<p>
<font face="Verdana" size="2">12. Hua J, Dobrucki LW, Sadeghi MM, Jiasheng    Z,
 Bourke BN, Cavaliere P, Song J, Chow C, Jahanshad N, van Royen N, Buschmann    
I, Madri JA, Mendizabal M, Sinusas AJ. Noninvasive imaging of angiogenesis with 
   a <SUP>99m</SUP>Tc-labeled peptide targeted at &#945;<sub>v</sub>&#946;<sub>3
</sub> integrin after murine hindlimb    ischemia. Circulation. 2005;111:3255-60
.    ^cY#a11v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#148#144#article#173# </font></p>     ^
cY#a11v26n1.htm##
00568000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704031700080002001300397#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#149#145#article#173#13#<p>
<font face="Verdana" size="2">13. Edwards D, Jones P, Haramis H, Battle M,    Le
ar R, Barnett DJ, Edwards C, Crawford H, Black A, Godden V. <SUP>99m</SUP>Tc-NC1
00692    - a tracer for imaging vitronectin receptors associated with angiogenes
is: a    preclinical investigation. Nucl Med Biol. 2008;35:365-75.    ^cY#a11v26
n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#150#146#article#173# </font></p>     ^
cY#a11v26n1.htm##
00491000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024000080002001300320#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#151#147#article#173#14#<p>
<font face="Verdana" size="2">14. Skjeldal S, Grogard B, Reikeras O, Muller    C
, Torvik A, Svindland A. Model for skeletal muscle ischemia in rat hindlimb:    
evaluation of reperfusion and necrosis. Eur Surg Res. 1999;23:355-65.    ^cY#a11
v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#152#148#article#173# </font></p>     ^
cY#a11v26n1.htm##
00765000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704051400080002001300594#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#p#153#149#article#173#15#<p>
<span lang=EN-US style='font-size:10.0pt;font-family:Verdana'>15. Lee KH, Jung  
  KH, Song SH, Kim DH, Lee BC, Sung HJ, Ham YM, Choe YS, Chi DY, Kim BT. Radiola
beled    RGD uptake and </span><span style='font-size:10.0pt;font-family:Verdana
'>&#945;</span><sub><span lang=EN-US style='font-size:10.0pt;font-family: Verdan
a'><sub>v</sub></span></sub><span lang=EN-US style='font-size:10.0pt;font-family
: Verdana'> integrin expression is enhanced in ischemic murine hindlimbs. J Nucl
    Med. 2005;46:472-8.    ^cY#a11v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#154#150#article#173#</span></p>      ^
cY#a11v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#155#151#article#173#<p>&nbsp; </p>    
 ^cY#a11v26n1.htm##
00312000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007600077002001300153#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#156#152#article#173#<p><font face="Ver
dana" size="3"><B>Acknowledgment</B> </font></p>      ^cY#a11v26n1.htm##
00355000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704011900077002001300196#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#157#153#article#173#<p><font face="Ver
dana" size="2"> We thank Natanael Gomes da Silva for image technical    support.
 </font></p>     ^cY#a11v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#158#154#article#173#<p>&nbsp;</p>     
^cY#a11v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#159#155#article#173#<p>&nbsp;</p>     
^cY#a11v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#160#156#article#173#<p>&nbsp;</p>     
^cY#a11v26n1.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704015500077002001300232#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#161#157#article#173#<p><font face="Ver
dana" size="2"><B><a name="end"></a><a href="#top"><img src="/img/revistas/acb/v
26n1/seta.gif" border="0"></a>Correspondence</B>:    ^cY#a11v26n1.htm##
00280000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004400077002001300121#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#162#158#article#173#<br>   Dra. Bluma 
Linkowski Faintuch    ^cY#a11v26n1.htm##
00299000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006300077002001300140#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#163#159#article#173#<br>   Centro de R
adiofarm&aacute;cia &#8211; IPEN/CNEN    ^cY#a11v26n1.htm##
00280000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004400077002001300121#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#164#160#article#173#<br>   Av. Prof. L
ineu Prestes, 2242    ^cY#a11v26n1.htm##
00290000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005400077002001300131#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#165#161#article#173#<br>   05508- 000 
S&atilde;o Paulo - SP Brasil    ^cY#a11v26n1.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003800077002001300115#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#166#162#article#173#<br>   Phone: (55 
11)3133-9531    ^cY#a11v26n1.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009300077002001300170#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#167#163#article#173#<br>   <a href="ma
ilto:blfaintuch@hotmail.com">blfaintuch@hotmail.com</a></font></p>     ^cY#a11v2
6n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#168#164#article#173#<p>&nbsp;</p>     
^cY#a11v26n1.htm##
00300000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006400077002001300141#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#169#165#article#173#<p><font face="Ver
dana" size="2">Received: July 06, 2010    ^cY#a11v26n1.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#170#166#article#173#<br>   </font><fon
t face="Verdana" size="2">Review: September 14, 2010    ^cY#a11v26n1.htm##
00327000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009100077002001300168#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#171#167#article#173#<br>   </font><fon
t face="Verdana" size="2">Accepted: October 19, 2010 </font></p>     ^cY#a11v26n
1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#172#168#article#173#<p>&nbsp;</p>     
^cY#a11v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006700077002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#173#169#article#173#<p><font face="Ver
dana" size="2">Conflict of interest: none    ^cY#a11v26n1.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704008700077002001300164#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#174#170#article#173#<br>   </font><fon
t face="Verdana" size="2">Financial source: none </font></p>     ^cY#a11v26n1.ht
m##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#175#171#article#173#<p>&nbsp;</p>     
^cY#a11v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#176#172#article#173#<p>&nbsp;</p>     
^cY#a11v26n1.htm##
00456000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704022000077002001300297#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a11v26n1.htm#S#p#177#173#article#173#<p><font face="Ver
dana" size="2"><sup><a name="end"></a><a href="#top">1</a> </sup>Research    per
formed at Radiopharmacy Center, Institute of Energetic and Nuclear Research,    
Sao Paulo-SP, Brazil. </font></p>     ^cY#a11v26n1.htm##
00626000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100021000760100017000970100
01500114012015700129030001300286710000200299065000900301064000500310031000300315
014000800318865000900326002001300335#v26n1#V:\Scielo\serial\acb\v26n1\markup\a11
v26n1.htm#S#c#178#1#article#15#1#^rND^sBaumgartner^nI#^rND^sPieczek^nA#^rND^sMan
or^nO#Constitutive expression of VEGF 165 following intramuscular gene transfer 
promotes collateral vessel development in patients with critical limb ischemia^l
en#Circulation.#2#19980000#1998#97#1114-23#20110200#a11v26n1.htm##
00744000000000349000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100020000950100
01800115010001600133010001800149010001500167010002000182010001900202010001800221
01200920023903000150033171000020034606500090034806400050035703100030036201400070
0365865000900372002001300381#v26n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.ht
m#S#c#179#2#article#15#2#^rND^sDijkgraaf^nI#^rND^sKruijtzer^nJA#^rND^sFrielink^n
C#^rND^sSoede^nAC#^rND^sHilbers^nHW#^rND^sOyen^nWJ#^rND^sCorstens^nFHM#^rND^sLis
kamp^nRMJ#^rND^sBoerman^nOC#Synthesis and biological evaluation of potent alphav
beta3-integrin receptor antagonists^len#Nucl Med Biol.#2#20060000#2006#33#953-61
#20110200#a11v26n1.htm##
00663000000000325000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100014000940100
01600108010001400124010001800138010001900156010001800175012008300193030001300276
71000020028906500090029106400050030003100030030501400070030886500090031500200130
0324#v26n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#c#180#3#article#15#3
#^rND^sMuether^nPS#^rND^sDell^nS#^rND^sKociok^nN#^rND^sZahn^nG#^rND^sStragies^nR
#^rND^sVossmeyer^nD#^rND^sJoussen^nAM#The role of integrin &#945;5ß1 in the regu
lation of corneal neovascularization^len#Exp Eye Res.#2#20070000#2007#85#356-65#
20110200#a11v26n1.htm##
00697000000000337000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100022000760100019000980100
01300117010002400130010001800154010002800172010001700200010001700217012006200234
03000150029671000020031106500090031306400050032203100030032701400070033086500090
0337002001300346#v26n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#c#181#4#
article#15#4#^rND^sDecristoforo^nD#^rND^sFaintuch^nBL#^rND^sRey^nA#^rND^svon Gug
genberg^nE#^rND^sRupprich^nM#^rND^sHernandez-Gonzales^nI#^rND^sRodrigo^nT#^rND^s
Haubner^nR#99mTc]HYNIC-RGD for imaging integrin &#945;vß3 expression^len#Nucl Me
d Biol.#2#20060000#2006#33#945-52#20110200#a11v26n1.htm##
00516000000000253000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100013000760120115000890300
01100204710000200215065000900217064000500226031000200231014000700233865000900240
002001300249#v26n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#c#182#5#arti
cle#15#5#^rND^sLiu^nS#Radiolabeled multimeric cyclic RGD peptides as integrin &#
945;v&#946;3 targeted radiotracers for tumor imaging^len#Mol Pharm.#2#20060000#2
006#3#472-87#20110200#a11v26n1.htm##
00730000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100014000940100
01500108010002200123010002500145010002100170012016000191030001800351710000200369
065000900371064000500380031000300385014000600388865000900394002001300403#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#c#183#6#article#15#6#^rND^sPsima
das^nD#^rND^sFani^nM#^rND^sZikos^nC#^rND^sXanthopoulos^nS#^rND^sArchimandritis^n
SC#^rND^sVarvarigou^nAD#Study of the labeling of two novel RGD-peptidic derivati
ves with the precursor [99mTc(H2O)(CO)3]+ and evaluation for early angiogenesis 
detection in cancer^len#Appl Radiat Isot.#2#20060000#2006#64#151-9#20110200#a11v
26n1.htm##
00729000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100019000950100
01800114010001800132010001700150010001600167012015300183030003200336710000200368
065000900370064000500379031000300384014000600387865000900393002001300402#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#c#184#7#article#15#7#^rND^sFaint
uch^nBL#^rND^sSantos^nRLSR#^rND^sSouza^nALFM#^rND^sHoffman^nTJ#^rND^sGreeley^nM#
^rND^sSmith^nCJ#99mTc-HYNIC-bombesin (7-14)NH2: Radiochemical evaluation with co
-ligands EDDA (EDDA=ethylenediamine-N,N'-diacetic acid), tricine, and nicotinic 
acid^len#Synth React Inorg Met Org Chem.#2#20050000#2005#35#43-51#20110200#a11v2
6n1.htm##
00611000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100022000930100
01600115010001400131012010900145030001900254710000200273065000900275064000500284
031000200289014000800291865000900299002001300308#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a11v26n1.htm#S#c#185#8#article#15#8#^rND^sTemming^nK#^rND^sSchiffelers^
nRM#^rND^sMolema^nG#^rND^sKok^nRJ#RGD-based strategies for selective delivery of
 therapeutics and imaging agents to the tumour vasculature^len#Drug Resist Updat
.#2#20050000#2005#8#381-402#20110200#a11v26n1.htm##
00975000000000421000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100014000940100
01400108010002000122010002600142010001500168010001500183010001900198010001400217
01000170023101000160024801000150026401000180027901000160029701000150031301201660
03280300010004947100002005040650009005060640005005150310005005200140006005258650
00900531002001300540#v26n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#c#18
6#9#article#15#9#^rND^sYamahara^nK#^rND^sSone^nM#^rND^sItoh^nH#^rND^sYamashita^n
JK#^rND^sYurugi-Kobayashi^nT#^rND^sHomma^nK#^rND^sChao^nTH#^rND^sMiyashita^nK#^r
ND^sPark^nK#^rND^sOyamada^nN#^rND^sSawada^nN#^rND^sTaura^nD#^rND^sFukunaga^nY#^r
ND^sTamura^nN#^rND^sNakao^nK#Augmentation of neovascularization [corrected] in h
indlimb ischemia by combined transplantation of human embryonic stem cells-deriv
ed endothelial and mural cells^len#PLoS One.#2#20080000#2008#3(2)#e1666#20110200
#a11v26n1.htm##
00758000000000361000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100018000920100
01300110010001900123010001600142010001500158010001600173010001600189010001400205
01000150021901200920023403000220032671000020034806500090035006400050035903100030
0364014000700367865000900374002001300383#v26n1#V:\Scielo\serial\acb\v26n1\markup
\a11v26n1.htm#S#c#187#10#article#15#10#^rND^sGoto^nT#^rND^sFukuyama^nN#^rND^sAki
^nA#^rND^sKanabuchi^nK#^rND^sKimura^nK#^rND^sTaira^nH#^rND^sTanaka^nE#^rND^sWaka
na^nN#^rND^sMori^nH#^rND^sInoue^nH#Search for appropriate experimental methods t
o create stable hindlimb ischemia in mouse^len#Tokai J Exp Clin Med.#2#20060000#
2006#31#128-32#20110200#a11v26n1.htm##
00855000000000409000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100016000920100
01400108010001600122010001400138010001500152010001400167010001400181010001500195
01000150021001000140022501000160023901000140025501000140026901200990028303000150
03827100002003970650009003990640005004080310003004130140007004168650009004230020
01300432#v26n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#c#188#11#article
#15#11#^rND^sLee^nYS#^rND^sJeong^nJM#^rND^sKim^nHW#^rND^sChang^nYS#^rND^sKim^nYJ
#^rND^sHong^nMK#^rND^sRai^nGB#^rND^sChi^nDY#^rND^sKang^nWJ#^rND^sKang^nJH#^rND^s
Lee^nDS#^rND^sChung^nJK#^rND^sLee^nMC#^rND^sSuh^nYG#An improved method of 18F pe
ptide labeling: hidrazone formation with HYNIC-conjugated c(RGDyK)^len#Nucl Med 
Biol.#2#20060000#2006#33#677-83#20110200#a11v26n1.htm##
00930000000000409000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100013000780100019000910100
01800110010001800128010001700146010001900163010001400182010001400196010001900210
01000190022901000190024801000160026701000200028301000180030301201360032103000130
04577100002004700650009004720640005004810310004004860140008004908650009004980020
01300507#v26n1#V:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#c#189#12#article
#15#12#^rND^sHua^nJ#^rND^sDobrucki^nLW#^rND^sSadeghi^nMM#^rND^sJiasheng^nZ#^rND^
sBourke^nBN#^rND^sCavaliere^nP#^rND^sSong^nJ#^rND^sChow^nC#^rND^sJahanshad^nN#^r
ND^svan Royen^nN#^rND^sBuschmann^nI#^rND^sMadri^nJA#^rND^sMendizabal^nM#^rND^sSi
nusas^nAJ#Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targe
ted at &#945;v&#946;3 integrin after murine hindlimb ischemia^len#Circulation.#2
#20050000#2005#111#3255-60#20110200#a11v26n1.htm##
00788000000000361000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100015000950100
01700110010001600127010001400143010001800157010001700175010001800192010001500210
01000160022501201220024103000150036371000020037806500090038006400050038903100030
0394014000700397865000900404002001300413#v26n1#V:\Scielo\serial\acb\v26n1\markup
\a11v26n1.htm#S#c#190#13#article#15#13#^rND^sEdwards^nD#^rND^sJones^nP#^rND^sHar
amis^nH#^rND^sBattle^nM#^rND^sLear^nR#^rND^sBarnett^nDJ#^rND^sEdwards^nC#^rND^sC
rawford^nH#^rND^sBlack^nA#^rND^sGodden^nV#99mTc-NC100692 - a tracer for imaging 
vitronectin receptors associated with angiogenesis: a preclinical investigation^
len#Nucl Med Biol.#2#20080000#2008#35#365-75#20110200#a11v26n1.htm##
00653000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100017000960100
01800113010001600131010001600147010001900163012009500182030001400277710000200291
065000900293064000500302031000300307014000700310865000900317002001300326#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a11v26n1.htm#S#c#191#14#article#15#14#^rND^sSkj
eldal^nS#^rND^sGrogard^nB#^rND^sReikeras^nO#^rND^sMuller^nC#^rND^sTorvik^nA#^rND
^sSvindland^nA#Model for skeletal muscle ischemia in rat hindlimb: evaluation of
 reperfusion and necrosis^len#Eur Surg Res.#2#19990000#1999#23#355-65#20110200#a
11v26n1.htm##
00744000000000361000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100015000920100
01500107010001400122010001400136010001500150010001400165010001500179010001400194
01000140020801201010022203000120032371000020033506500090033706400050034603100030
0351014000600354865000900360002001300369#v26n1#V:\Scielo\serial\acb\v26n1\markup
\a11v26n1.htm#S#c#192#15#article#15#15#^rND^sLee^nKH#^rND^sJung^nKH#^rND^sSong^n
SH#^rND^sKim^nDH#^rND^sLee^nBC#^rND^sSung^nHJ#^rND^sHam^nYM#^rND^sChoe^nYS#^rND^
sChi^nDY#^rND^sKim^nBT#Radiolabeled RGD uptake and &#945;v integrin expression i
s enhanced in ischemic murine hindlimbs^len#J Nucl Med.#2#20050000#2005#46#472-8
#20110200#a11v26n1.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#o#1#1#article#1#
20110120#130203#a12v26n1.htm#188##
06847000000000829000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400090014103500100015001201240
01600120137002840100047004210100039004680100042005070100040005490100037005890100
06000626010003400686010003200720010004500752070007800797070005600875070004600931
07000290097707000820100607000720108807000780116007000300123807000660126807000960
13340700030014300832103014600850008035630850023035710850027035940850025036210850
01603646083215203662085000805814085002305822085003105845085002605876085001605902
11700060591807200030592411200090592711100140593611600090595011500190595911400090
5978113001705987002001306004#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.ht
m#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#12#ACB720#nd#Acta Cir. Bras.#26#1
#20110200#^f64^l71#0102-8650#Anal cancer precursor lesions in HIV-positive and H
IV-negative patients seen at a tertiary health institution in Brazil^len#Lesões 
precursoras do câncer anal em pacientes HIV-positivos e HIV-negativos atendidos 
numa instituição de saúde terciária no Brasil^lpt#^rND^1A01 A02^nIvan Tramujas d
a Costa e^sSilva#^rND^1A03 A04^nJosé de Ribamar^sAraújo#^rND^1A03 A04^nRosilene 
Viana de^sAndrade#^rND^1A05^nCelso Rômulo Barbosa^sCabral#^rND^1A06^nFelicidad S
antos^sGimenez#^rND^1A07 A08^nAdriana Gonçalves Daumas Pinheiro^sGuimarães#^rND^
1A09^nTiciane Costa^sMartins#^rND^1A09^nLucília Rocha^sLopes#^rND^1A10 A11^nLuiz
 Carlos de Lima^sFerreira#UEA^iA01^1Post-Graduation Program of Tropical Medicine
 Foundation of Amazonas#Federal University of Amazonas^iA02^cManaus^sAM^pBrazil#
Tropical Medicine Foundation of Amazonas^iA03#UEA^iA04^cManaus^sAM^pBrazil#UFAM^
iA05^1Exact Sciences Institute^2Department of Statistics^cManaus^sAM^pBrazil#UFA
M^iA06^1Volunteer Faculty^2Department of Surgery^cManaus^sAM^pBrazil#UEA^iA07^1P
ost-Graduation Program of Tropical Medicine Foundation of Amazonas#UFAM^iA08^cMa
naus^sAM^pBrazil#UFAM^iA09^1Getúlio Vargas University Hospital^cManaus^sAM^pBraz
il#Tropical Medicine Foundation of Amazonas^iA10^1Department of Research and Div
ision of Pathology#UFAM^iA11^cManaus^sAM^pBrazil#^len^aPurpose: To investigate t
he prevalence of anal squamous intraepithelial lesions (ASIL) or anal cancer in 
patients attended at the Tropical Medicine Foundation of Amazonas. Methods: 344 
patients consecutively attended at the institution, in 2007/2008, were distribut
ed in the following strata according to presence/abscense of at risk conditions 
for anal cancer: Group 1 _ HIV-positive men-who-have-sex-with-men (101); Group 2
 _ HIV-positive females (49); Group 3 _ patients without any at risk condition f
or anal cancer (53); Group 4 _ HIV-positive heterosexual men (38); Group 5 _ HIV
-negative patients, without anoreceptive sexual habits, but with other at risk c
onditions for anal cancer (45); Group 6 _ HIV-negative men-who-have-sex-with-men
 (26); and Group 7 _ HIV-negative anoreceptive females (32). The histopathologic
al results of biopsies guided by high-resolution anoscopy were analyzed by frequ
entist and bayesian statistics in order to calculate the point-prevalence of ASI
L/cancer and observe any eventual preponderance of one group over the other. Res
ults: The point-prevalence of ASIL for all the patients studied was 93/344 (27%)
, the difference between HIV-positive and negative patients being statistically 
significant (38.3% versus 13.5%; p < 0.0001). The prevalence of ASIL for each on
e of the groups studied was: Group 1 = 49.5%, Group 2 = 28.6%, Group 3 = 3.8%, G
roup 4 = 21.1%, Group 5 = 11.1%, Group 6 = 30.8% and Group 7 = 18.8%. Standard r
esidual analysis demonstrated that ASIL was significantly prevalent in patients 
of Group 1 and high-grade ASIL in patients of Group 2. The odds for ASIL of Grou
p 1 was significantly higher in comparison to Groups 2, 3, 4, 5 and 7 (p < 0.03)
. The odds for ASIL of Groups 2, 4 and 6 were significantly higher in comparison
 to Group 3 (p < 0.03). Conclusions: In the patients studied, ASIL (low and/or h
igh-grade) tended to be significantly more prevalent in HIV-positive patients. N
onetheless, HIV-negative anoreceptive patients also presented great probability 
to have anal cancer precursor lesions, mainly those of the male gender.#^dnd^i1#
^tm^len^kAnal Canal^i1#^tm^len^kAnus Neoplasms^i1#^tm^len^kEpidemiology^i1#^tm^l
en^kHIV^i1#^lpt^aObjetivo: Investigar a prevalência de lesões intraepiteliais es
camosas anais (ASIL) ou câncer anal em pacientes atendidos na Fundação de Medici
na Tropical do Amazonas. Métodos: 344 pacientes consecutivamente atendidos na in
stituição, em 2007/2008, foram distribuídos nos seguintes estratos conforme a pr
esença/ausência de fatores de risco para o câncer anal: Grupo 1 _ homens-que-faz
em-sexo-com-homens HIV-positivos (101); Grupo 2 _ mulheres HIV-positivas (49); G
rupo 3 _ pacientes sem condição de risco para o câncer anal (53); Grupo 4 _ home
ns heterossexuais HIV-positivos (38); Grupo 5 _ pacientes HIV-negativos, sem háb
itos sexuais anorreceptivos, mas com outras condições de risco para o câncer ana
l (45); Grupo 6 _ homens-que-fazem-sexo-com-homens HIV-negativos (26); e Grupo 7
 _ mulheres HIV-negativas, com hábitos sexuais anorreceptivos (32). Os resultado
s histopatológicos das biópsias anais dirigidas pela colposcopia anal foram anal
isados por meio de estatística frequentista e bayesiana para a determinação da p
revalência-ponto de ASIL/câncer e verificar eventual preponderância estatística 
de um grupo sobre o outro. Resultados: A prevalência-ponto de ASIL para todos os
 pacientes estudados foi de 93/344 (27%), sendo significativa a diferença entre 
HIV-positivos e negativos (38,3% versus 13,5%; p < 0,0001). A prevalência de ASI
L para cada um dos grupos estudados foi: Grupo 1 = 49,5%, Grupo 2 = 28,6%, Grupo
 3 = 3,8%, Grupo 4 = 21,1%, Grupo 5 = 11,1%, Grupo 6 = 30,8% e Grupo 7 = 18,8%. 
A análise de resíduos demonstrou prevalência significante de ASIL para o Grupo 1
 e de ASIL de alto-grau para o Grupo 2. A razão-de-chances do Grupo 1 para ASIL 
foi significantemente maior em comparação com os Grupos 2, 3, 4, 5 e 7 (p < 0,03
). A razão-de-chances para ASIL dos Grupos 2, 4 e 6 foi significantemente maior 
em comparação com o Grupo 3 (p < 0.03). Conclusões: Nos pacientes estudados, ASI
L (baixo e/ou alto-grau) foi significantemente mais prevalente em pacientes HIV-
positivos. Entretanto, pacientes HIV-negativos anorreceptivos também apresentara
m grande probabilidade de possuir as lesões, especialmente os do gênero masculin
o.#^dnd^i2#^tm^lpt^kCanal Anal^i2#^tm^lpt^kNeoplasias do Ânus^i2#^tm^lpt^kEpidem
iologia^i2#^tm^lpt^kHIV^i2#other#19#20100706#July 06, 2010#20100914#September 14
, 2010#20101019#October 19, 2010#a12v26n1.htm##
06991000000000829000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400090014103500100015001201310
01600120144002910100047004350100039004820100042005210100040005630100037006030100
06000640010003400700010003200734010004500766070007800811070005600889070004600945
07000290099107000820102007000720110207000780117407000300125207000660128207000960
13480700030014440832168014740850008036420850023036500850027036730850025037000850
01603725083221703741085000805958085002305966085003105989085002606020085001606046
11700060606207200030606811200090607111100140608011600090609411500190610311400090
6122113001706131002001306148#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.ht
m#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#12#ACB720#nd#Acta Cir. Bras.#26#1
#20110200#^f64^l71#0102-8650#<b>Anal cancer precursor lesions in HIV-positive an
d HIV-negative patients seen at a tertiary health institution in Brazil</b>^len#
<b>Lesões precursoras do câncer anal em pacientes HIV-positivos e HIV-negativos 
atendidos numa instituição de saúde terciária no Brasil</b>^lpt#^rND^1A01 A02^nI
van Tramujas da Costa e^sSilva#^rND^1A03 A04^nJosé de Ribamar^sAraújo#^rND^1A03 
A04^nRosilene Viana de^sAndrade#^rND^1A05^nCelso Rômulo Barbosa^sCabral#^rND^1A0
6^nFelicidad Santos^sGimenez#^rND^1A07 A08^nAdriana Gonçalves Daumas Pinheiro^sG
uimarães#^rND^1A09^nTiciane Costa^sMartins#^rND^1A09^nLucília Rocha^sLopes#^rND^
1A10 A11^nLuiz Carlos de Lima^sFerreira#UEA^iA01^1Post-Graduation Program of Tro
pical Medicine Foundation of Amazonas#Federal University of Amazonas^iA02^cManau
s^sAM^pBrazil#Tropical Medicine Foundation of Amazonas^iA03#UEA^iA04^cManaus^sAM
^pBrazil#UFAM^iA05^1Exact Sciences Institute^2Department of Statistics^cManaus^s
AM^pBrazil#UFAM^iA06^1Volunteer Faculty^2Department of Surgery^cManaus^sAM^pBraz
il#UEA^iA07^1Post-Graduation Program of Tropical Medicine Foundation of Amazonas
#UFAM^iA08^cManaus^sAM^pBrazil#UFAM^iA09^1Getúlio Vargas University Hospital^cMa
naus^sAM^pBrazil#Tropical Medicine Foundation of Amazonas^iA10^1Department of Re
search and Division of Pathology#UFAM^iA11^cManaus^sAM^pBrazil#^len^a<b>Purpose<
/b>: To investigate the prevalence of anal squamous intraepithelial lesions (ASI
L) or anal cancer in patients attended at the Tropical Medicine Foundation of Am
azonas. <b>Methods</b>: 344 patients consecutively attended at the institution, 
in 2007/2008, were distributed in the following strata according to presence/abs
cense of at risk conditions for anal cancer: Group 1 _ HIV-positive men-who-have
-sex-with-men (101); Group 2 _ HIV-positive females (49); Group 3 _ patients wit
hout any at risk condition for anal cancer (53); Group 4 _ HIV-positive heterose
xual men (38); Group 5 _ HIV-negative patients, without anoreceptive sexual habi
ts, but with other at risk conditions for anal cancer (45); Group 6 _ HIV-negati
ve men-who-have-sex-with-men (26); and Group 7 _ HIV-negative anoreceptive femal
es (32). The histopathological results of biopsies guided by high-resolution ano
scopy were analyzed by frequentist and bayesian statistics in order to calculate
 the point-prevalence of ASIL/cancer and observe any eventual preponderance of o
ne group over the other. <b>Results</b>: The point-prevalence of ASIL for all th
e patients studied was 93/344 (27%), the difference between HIV-positive and neg
ative patients being statistically significant (38.3% <i>versus </i>13.5%; <i>p 
</i>&lt; 0.0001). The prevalence of ASIL for each one of the groups studied was:
 Group 1 = 49.5%, Group 2 = 28.6%, Group 3 = 3.8%, Group 4 = 21.1%, Group 5 = 11
.1%, Group 6 = 30.8% and Group 7 = 18.8%. Standard residual analysis demonstrate
d that ASIL was significantly prevalent in patients of Group 1 and high-grade AS
IL in patients of Group 2. The odds for ASIL of Group 1 was significantly higher
 in comparison to Groups 2, 3, 4, 5 and 7 (<i>p </i>&lt; 0.03). The odds for ASI
L of Groups 2, 4 and 6 were significantly higher in comparison to Group 3 (<i>p<
/i> &lt; 0.03). <b>Conclusions</b>: In the patients studied, ASIL (low and/or hi
gh-grade) tended to be significantly more prevalent in HIV-positive patients. No
netheless, HIV-negative anoreceptive patients also presented great probability t
o have anal cancer precursor lesions, mainly those of the male gender.#^dnd^i1#^
tm^len^kAnal Canal^i1#^tm^len^kAnus Neoplasms^i1#^tm^len^kEpidemiology^i1#^tm^le
n^kHIV^i1#^lpt^a<b>Objetivo</b>: Investigar a prevalência de lesões intraepiteli
ais escamosas anais (ASIL) ou câncer anal em pacientes atendidos na Fundação de 
Medicina Tropical do Amazonas. <b>Métodos</b>: 344 pacientes consecutivamente at
endidos na instituição, em 2007/2008, foram distribuídos nos seguintes estratos 
conforme a presença/ausência de fatores de risco para o câncer anal: Grupo 1 _ h
omens-que-fazem-sexo-com-homens HIV-positivos (101); Grupo 2 _ mulheres HIV-posi
tivas (49); Grupo 3 _ pacientes sem condição de risco para o câncer anal (53); G
rupo 4 _ homens heterossexuais HIV-positivos (38); Grupo 5 _ pacientes HIV-negat
ivos, sem hábitos sexuais anorreceptivos, mas com outras condições de risco para
 o câncer anal (45); Grupo 6 _ homens-que-fazem-sexo-com-homens HIV-negativos (2
6); e Grupo 7 _ mulheres HIV-negativas, com hábitos sexuais anorreceptivos (32).
 Os resultados histopatológicos das biópsias anais dirigidas pela colposcopia an
al foram analisados por meio de estatística frequentista e bayesiana para a dete
rminação da prevalência-ponto de ASIL/câncer e verificar eventual preponderância
 estatística de um grupo sobre o outro. <b>Resultados</b>: A prevalência-ponto d
e ASIL para todos os pacientes estudados foi de 93/344 (27%), sendo significativ
a a diferença entre HIV-positivos e negativos (38,3% <i>versus </i>13,5%; <i>p <
/i>&lt; 0,0001). A prevalência de ASIL para cada um dos grupos estudados foi: Gr
upo 1 = 49,5%, Grupo 2 = 28,6%, Grupo 3 = 3,8%, Grupo 4 = 21,1%, Grupo 5 = 11,1%
, Grupo 6 = 30,8% e Grupo 7 = 18,8%. A análise de resíduos demonstrou prevalênci
a significante de ASIL para o Grupo 1 e de ASIL de alto-grau para o Grupo 2. A r
azão-de-chances do Grupo 1 para ASIL foi significantemente maior em comparação c
om os Grupos 2, 3, 4, 5 e 7 (<i>p </i>&lt; 0,03). A razão-de-chances para ASIL d
os Grupos 2, 4 e 6 foi significantemente maior em comparação com o Grupo 3 (<i>p
 </i>&lt; 0.03). <b>Conclusões</b>: Nos pacientes estudados, ASIL (baixo e/ou al
to-grau) foi significantemente mais prevalente em pacientes HIV-positivos. Entre
tanto, pacientes HIV-negativos anorreceptivos também apresentaram grande probabi
lidade de possuir as lesões, especialmente os do gênero masculino.#^dnd^i2#^tm^l
pt^kCanal Anal^i2#^tm^lpt^kNeoplasias do Ânus^i2#^tm^lpt^kEpidemiologia^i2#^tm^l
pt^kHIV^i2#other#19#20100706#July 06, 2010#20100914#September 14, 2010#20101019#
October 19, 2010#a12v26n1.htm##
07199000000000853000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000150012903100030014403200020014706500090014901400090015803500100
01670120124001770120137003010100047004380100039004850100042005240100040005660100
03700606010006000643010003400703010003200737010004500769070010000814070005800914
07000480097207000310102007000840105107000740113507001000120907000320130907000680
13410700098014090700032015070832173015390850008037120850023037200850027037430850
02503770085001603795083224203811085000806053085002306061085003106084085002606115
08500160614111700060615707200030616311200090616611100140617511600090618911500190
6198114000906217113001706226002001306243008008906256#v26n1#V:\Scielo\serial\acb\
v26n1\markup\a12v26n1.htm#S#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#
ilus#tab#12#ACB720#nd#Acta cir. bras#26#1#20110200#^f64^l71#0102-8650#Anal cance
r precursor lesions in HIV-positive and HIV-negative patients seen at a tertiary
 health institution in Brazil^len#Lesões precursoras do câncer anal em pacientes
 HIV-positivos e HIV-negativos atendidos numa instituição de saúde terciária no 
Brasil^lpt#^rND^1A01 A02^nIvan Tramujas da Costa e^sSilva#^rND^1A03 A04^nJosé de
 Ribamar^sAraújo#^rND^1A03 A04^nRosilene Viana de^sAndrade#^rND^1A05^nCelso Rômu
lo Barbosa^sCabral#^rND^1A06^nFelicidad Santos^sGimenez#^rND^1A07 A08^nAdriana G
onçalves Daumas Pinheiro^sGuimarães#^rND^1A09^nTiciane Costa^sMartins#^rND^1A09^
nLucília Rocha^sLopes#^rND^1A10 A11^nLuiz Carlos de Lima^sFerreira#^iA01^1UEA^2P
ost-Graduation Program of Tropical Medicine Foundation of Amazonas^cManaus^sAM^p
Brazil#^iA02^1Federal University of Amazonas^cManaus^sAM^pBrazil#^iA03^1Tropical
 Medicine Foundation of Amazonas#^iA04^1UEA^cManaus^sAM^pBrazil#^iA05^1UFAM^2Exa
ct Sciences Institute^3Department of Statistics^cManaus^sAM^pBrazil#^iA06^1UFAM^
2Volunteer Faculty^3Department of Surgery^cManaus^sAM^pBrazil#^iA07^1UEA^2Post-G
raduation Program of Tropical Medicine Foundation of Amazonas^cManaus^sAM^pBrazi
l#^iA08^1UFAM^cManaus^sAM^pBrazil#^iA09^1UFAM^2Getúlio Vargas University Hospita
l^cManaus^sAM^pBrazil#^iA10^1Tropical Medicine Foundation of Amazonas^2Departmen
t of Research and Division of Pathology#^iA11^1UFAM^cManaus^sAM^pBrazil#^len^aPu
rpose: To investigate the prevalence of anal squamous intraepithelial lesions (A
SIL) or anal cancer in patients attended at the Tropical Medicine Foundation of 
Amazonas. Methods: 344 patients consecutively attended at the institution, in 20
07/2008, were distributed in the following strata according to presence/abscense
 of at risk conditions for anal cancer: Group 1 _ HIV-positive men-who-have-sex-
with-men (101); Group 2 _ HIV-positive females (49); Group 3 _ patients without 
any at risk condition for anal cancer (53); Group 4 _ HIV-positive heterosexual 
men (38); Group 5 _ HIV-negative patients, without anoreceptive sexual habits, b
ut with other at risk conditions for anal cancer (45); Group 6 _ HIV-negative me
n-who-have-sex-with-men (26); and Group 7 _ HIV-negative anoreceptive females (3
2). The histopathological results of biopsies guided by high-resolution anoscopy
 were analyzed by frequentist and bayesian statistics in order to calculate the 
point-prevalence of ASIL/cancer and observe any eventual preponderance of one gr
oup over the other. Results: The point-prevalence of ASIL for all the patients s
tudied was 93/344 (27 percent), the difference between HIV-positive and negative
 patients being statistically significant (38.3 percent versus 13.5 percent; p <
 0.0001). The prevalence of ASIL for each one of the groups studied was: Group 1
 = 49.5 percent, Group 2 = 28.6 percent, Group 3 = 3.8 percent, Group 4 = 21.1 p
ercent, Group 5 = 11.1 percent, Group 6 = 30.8 percent and Group 7 = 18.8 percen
t. Standard residual analysis demonstrated that ASIL was significantly prevalent
 in patients of Group 1 and high-grade ASIL in patients of Group 2. The odds for
 ASIL of Group 1 was significantly higher in comparison to Groups 2, 3, 4, 5 and
 7 (p < 0.03). The odds for ASIL of Groups 2, 4 and 6 were significantly higher 
in comparison to Group 3 (p < 0.03). Conclusions: In the patients studied, ASIL 
(low and/or high-grade) tended to be significantly more prevalent in HIV-positiv
e patients. Nonetheless, HIV-negative anoreceptive patients also presented great
 probability to have anal cancer precursor lesions, mainly those of the male gen
der.#^dnd^i1#^tm^len^kAnal Canal^i1#^tm^len^kAnus Neoplasms^i1#^tm^len^kEpidemio
logy^i1#^tm^len^kHIV^i1#^lpt^aObjetivo: Investigar a prevalência de lesões intra
epiteliais escamosas anais (ASIL) ou câncer anal em pacientes atendidos na Funda
ção de Medicina Tropical do Amazonas. Métodos: 344 pacientes consecutivamente at
endidos na instituição, em 2007/2008, foram distribuídos nos seguintes estratos 
conforme a presença/ausência de fatores de risco para o câncer anal: Grupo 1 _ h
omens-que-fazem-sexo-com-homens HIV-positivos (101); Grupo 2 _ mulheres HIV-posi
tivas (49); Grupo 3 _ pacientes sem condição de risco para o câncer anal (53); G
rupo 4 _ homens heterossexuais HIV-positivos (38); Grupo 5 _ pacientes HIV-negat
ivos, sem hábitos sexuais anorreceptivos, mas com outras condições de risco para
 o câncer anal (45); Grupo 6 _ homens-que-fazem-sexo-com-homens HIV-negativos (2
6); e Grupo 7 _ mulheres HIV-negativas, com hábitos sexuais anorreceptivos (32).
 Os resultados histopatológicos das biópsias anais dirigidas pela colposcopia an
al foram analisados por meio de estatística frequentista e bayesiana para a dete
rminação da prevalência-ponto de ASIL/câncer e verificar eventual preponderância
 estatística de um grupo sobre o outro. Resultados: A prevalência-ponto de ASIL 
para todos os pacientes estudados foi de 93/344 (27 por cento), sendo significat
iva a diferença entre HIV-positivos e negativos (38,3 por cento versus 13,5 por 
cento; p < 0,0001). A prevalência de ASIL para cada um dos grupos estudados foi:
 Grupo 1 = 49,5 por cento, Grupo 2 = 28,6 por cento, Grupo 3 = 3,8 por cento, Gr
upo 4 = 21,1 por cento, Grupo 5 = 11,1 por cento, Grupo 6 = 30,8 por cento e Gru
po 7 = 18,8 por cento. A análise de resíduos demonstrou prevalência significante
 de ASIL para o Grupo 1 e de ASIL de alto-grau para o Grupo 2. A razão-de-chance
s do Grupo 1 para ASIL foi significantemente maior em comparação com os Grupos 2
, 3, 4, 5 e 7 (p < 0,03). A razão-de-chances para ASIL dos Grupos 2, 4 e 6 foi s
ignificantemente maior em comparação com o Grupo 3 (p < 0.03). Conclusões: Nos p
acientes estudados, ASIL (baixo e/ou alto-grau) foi significantemente mais preva
lente em pacientes HIV-positivos. Entretanto, pacientes HIV-negativos anorrecept
ivos também apresentaram grande probabilidade de possuir as lesões, especialment
e os do gênero masculino.#^dnd^i2#^tm^lpt^kCanal Anal^i2#^tm^lpt^kNeoplasias do 
Ânus^i2#^tm^lpt^kEpidemiologia^i2#^tm^lpt^kHIV^i2#other#19#20100706#July 06, 201
0#20100914#September 14, 2010#20101019#October 19, 2010#a12v26n1.htm#Internet^ih
ttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502011000100012##
00263000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704003100073002001300104#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#5#1#article#165#<div align="right">   
     ^cY#a12v26n1.htm##
00298000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704006600073002001300139#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#6#2#article#165#<p><font face="Verdana
" size="2"><b>12 - ORIGINAL ARTICLE     ^cY#a12v26n1.htm##
00293000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704006100073002001300134#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#7#3#article#165#<br>     INVESTIGATIVE
 SURGERY</b></font></p> </div>     ^cY#a12v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002600073002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#8#4#article#165#<p>&nbsp;</p>         
^cY#a12v26n1.htm##
00467000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704023500073002001300308#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#9#5#article#165#<p><font face="Verdana
" size="4"><b><a name="top"></a>Anal cancer precursor lesions    in HIV-positive
 and HIV-negative patients seen at a tertiary health institution    in Brazil<SU
P><a href="#end">1</a></SUP> </b></font></p>     ^cY#a12v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#10#6#article#165#<p>&nbsp;</p>     ^cY
#a12v26n1.htm##
00473000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704024000074002001300314#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#11#7#article#165#<p><b><font face="Ver
dana" size="3">Les&otilde;es precursoras do c&acirc;ncer    anal em pacientes HI
V-positivos e HIV-negativos atendidos numa institui&ccedil;&atilde;o    de sa&ua
cute;de terci&aacute;ria no Brasil </font></b></p>     ^cY#a12v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002600074002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#12#8#article#165#<p>&nbsp;</p>        
 ^cY#a12v26n1.htm##
00724000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704049100074002001300565#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#13#9#article#165#<p><font face="Verdan
a" size="2"><B>Ivan Tramujas da Costa e Silva<SUP>I</SUP>,    Jos&eacute; de Rib
amar Ara&uacute;jo<SUP>II</SUP>, Rosilene Viana de Andrade<SUP>II</SUP>,    Cels
o R&ocirc;mulo Barbosa Cabral<SUP>III</SUP>, Felicidad Santos Gimenez<SUP>IV,</S
UP>    Adriana Gon&ccedil;alves Daumas Pinheiro Guimar&atilde;es<SUP>V</SUP>, Ti
ciane    Costa Martins<SUP>VI</SUP>, Luc&iacute;lia Rocha Lopes<SUP>VI</SUP>, Lu
iz Carlos    de Lima Ferreira<SUP>VII</SUP></B> </font></p>       ^cY#a12v26n1.h
tm##
00258000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002400075002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#14#10#article#165#<p>&nbsp;</p>       
^cY#a12v26n1.htm##
00816000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704058200075002001300657#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#15#11#article#165#<p><font face="Verda
na" size="2"><SUP>I</SUP>MD, Fellow PhD degree, Post-Graduation    Program of Tr
opical Medicine Foundation of Amazonas, UEA. Assistant Professor    of Surgery, 
Federal University of Amazonas (UFAM), Manaus-AM, Brazil. <I>Contribution:    ma
in author; study concept and design; acquisition of data; analysis and interpret
ation    of data; drafting of the manuscript; critical revision of the manuscrip
t for    important intellectual content; obtained funding; study supervision; te
chnical    support; composition of the manuscript in the English language.    ^c
Y#a12v26n1.htm##
00606000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704037200075002001300447#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#16#12#article#165#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>II</SUP>MD, Master, Division of    Pathology, T
ropical Medicine Foundation of Amazonas. Assistant Professor of    Pathology, UE
A, Manaus-AM, Brazil. <I>Participated in study concept and design;    acquisitio
n of data; critical revision of the manuscript for important intellectual    con
tent; technical support.    ^cY#a12v26n1.htm##
00594000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036000075002001300435#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#17#13#article#165#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>III</SUP>PhD, Associate Professor,    Departmen
t of Statistics, Exact Sciences Institute, UFAM, Manaus-AM, Brazil.    <I>Partic
ipated in study concept and design; analysis and interpretation of    data; stat
istical analysis; critical revision of the manuscript for important    intellect
ual content.    ^cY#a12v26n1.htm##
00547000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031300075002001300388#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#18#14#article#165#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>IV</SUP>MD, Master, Volunteer    Faculty, Depar
tment of Surgery, UFAM, Manaus-AM, Brazil. <I>Participated in    study concept a
nd design; acquisition of data; critical revision of the manuscript    for impor
tant intellectual content; technical support.    ^cY#a12v26n1.htm##
00624000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039000075002001300465#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#19#15#article#165#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>V</SUP>MD, Fellow PhD degree,    Post-Graduatio
n Program of Tropical Medicine Foundation of Amazonas, UEA. Assistant    Profess
or of Surgery, UFAM, Manaus-AM, Brazil. <I>Participated in study concept    and 
design; acquisition of data; critical revision of the manuscript for important  
  intellectual content; technical support.    ^cY#a12v26n1.htm##
00508000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027400075002001300349#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#20#16#article#165#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>VI</SUP>MD, Resident, Get&uacute;lio    Vargas 
University Hospital, UFAM, Manaus-AM, Brazil. <I>Acquisition of data;    critica
l revision of the manuscript for important intellectual content; technical    su
pport.    ^cY#a12v26n1.htm##
00655000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704042100075002001300496#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#21#17#article#165#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>VII</SUP>MD, PhD, Department of    Research and
 Division of Pathology, Tropical Medicine Foundation of Amazonas.    Associate P
rofessor of Pathology, UFAM, Manaus-AM, Brazil. <I>Tutor. Study concept    and d
esign; critical revision of the manuscript for important intellectual content;  
  obtained funding; study supervision; technical support.</I></font></p>     ^cY
#a12v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#22#18#article#165#<p><font face="Verda
na" size="2"><a href="#end">Correspondence</a></font></p>     ^cY#a12v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#23#19#article#165#<p>&nbsp;</p>     ^c
Y#a12v26n1.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#24#20#article#165#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a12v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#25#21#article#165#<p><font face="Verda
na" size="2"><B>ABSTRACT </B></font></p>     ^cY#a12v26n1.htm##
02530000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704229600075002001302371#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#26#22#article#165#<p><font face="Verda
na" size="2"><B>Purpose</b>: To investigate the prevalence    of anal squamous i
ntraepithelial lesions (ASIL) or anal cancer in patients attended    at the Trop
ical Medicine Foundation of Amazonas. <B>Methods</B>: 344 patients    consecutiv
ely attended at the institution, in 2007/2008, were distributed in    the follow
ing strata according to presence/abscense of at risk conditions for    anal canc
er: Group 1 _ HIV-positive men-who-have-sex-with-men (101); Group 2    _ HIV-pos
itive females (49); Group 3 _ patients without any at risk condition    for anal
 cancer (53); Group 4 _ HIV-positive heterosexual men (38); Group 5    _ HIV-neg
ative patients, without anoreceptive sexual habits, but with other    at risk co
nditions for anal cancer (45); Group 6 _ HIV-negative men-who-have-sex-with-men 
   (26); and Group 7 _ HIV-negative anoreceptive females (32). The histopatholog
ical    results of biopsies guided by high-resolution anoscopy were analyzed by 
frequentist    and bayesian statistics in order to calculate the point-prevalenc
e of ASIL/cancer    and observe any eventual preponderance of one group over the
 other. <B>Results</B>:    The point-prevalence of ASIL for all the patients stu
died was 93/344 (27%),    the difference between HIV-positive and negative patie
nts being statistically    significant (38.3% <I>versus </I>13.5%; <I>p </I>&lt;
 0.0001). The prevalence    of ASIL for each one of the groups studied was: Grou
p 1 = 49.5%, Group 2 = 28.6%,    Group 3 = 3.8%, Group 4 = 21.1%, Group 5 = 11.1
%, Group 6 = 30.8% and Group    7 = 18.8%. Standard residual analysis demonstrat
ed that ASIL was significantly    prevalent in patients of Group 1 and high-grad
e ASIL in patients of Group 2.    The odds for ASIL of Group 1 was significantly
 higher in comparison to Groups    2, 3, 4, 5 and 7 (<I>p </I>&lt; 0.03). The od
ds for ASIL of Groups 2, 4 and    6 were significantly higher in comparison to G
roup 3 (<I>p</I> &lt; 0.03). <B>Conclusions</B>:    In the patients studied, ASI
L (low and/or high-grade) tended to be significantly    more prevalent in HIV-po
sitive patients. Nonetheless, HIV-negative anoreceptive    patients also present
ed great probability to have anal cancer precursor lesions,    mainly those of t
he male gender. </font></p>     ^cY#a12v26n1.htm##
00376000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704014200075002001300217#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#27#23#article#165#<p><font face="Verda
na" size="2"><B>Key words</B>: Anal Canal. Anus Neoplasms.    Epidemiology. HIV.
</font></p> <hr size="1" noshade>     ^cY#a12v26n1.htm##
00301000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006700075002001300142#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#28#24#article#165#<p><font face="Verda
na" size="2"><B>RESUMO </B></font></p>     ^cY#a12v26n1.htm##
02893000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704265900075002001302734#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#29#25#article#165#<p><font face="Verda
na" size="2"><B>Objetivo</b>: Investigar a preval&ecirc;ncia    de les&otilde;es
 intraepiteliais escamosas anais (ASIL) ou c&acirc;ncer anal    em pacientes ate
ndidos na Funda&ccedil;&atilde;o de Medicina Tropical do Amazonas.    <B>M&eacut
e;todos</B>: 344 pacientes consecutivamente atendidos na institui&ccedil;&atilde
;o,    em 2007/2008, foram distribu&iacute;dos nos seguintes estratos conforme a
 presen&ccedil;a/aus&ecirc;ncia    de fatores de risco para o c&acirc;ncer anal:
 Grupo 1 _ homens-que-fazem-sexo-com-homens    HIV-positivos (101); Grupo 2 _ mu
lheres HIV-positivas (49); Grupo 3 _ pacientes    sem condi&ccedil;&atilde;o de 
risco para o c&acirc;ncer anal (53); Grupo 4 _    homens heterossexuais HIV-posi
tivos (38); Grupo 5 _ pacientes HIV-negativos,    sem h&aacute;bitos sexuais ano
rreceptivos, mas com outras condi&ccedil;&otilde;es    de risco para o c&acirc;n
cer anal (45); Grupo 6 _ homens-que-fazem-sexo-com-homens    HIV-negativos (26);
 e Grupo 7 _ mulheres HIV-negativas, com h&aacute;bitos sexuais    anorreceptivo
s (32). Os resultados histopatol&oacute;gicos das bi&oacute;psias    anais dirig
idas pela colposcopia anal foram analisados por meio de estat&iacute;stica    fr
equentista e bayesiana para a determina&ccedil;&atilde;o da preval&ecirc;ncia-po
nto    de ASIL/c&acirc;ncer e verificar eventual preponder&acirc;ncia estat&iacu
te;stica    de um grupo sobre o outro. <B>Resultados</B>: A preval&ecirc;ncia-po
nto de ASIL    para todos os pacientes estudados foi de 93/344 (27%), sendo sign
ificativa a    diferen&ccedil;a entre HIV-positivos e negativos (38,3% <I>versus
 </I>13,5%;    <I>p </I>&lt; 0,0001). A preval&ecirc;ncia de ASIL para cada um d
os grupos estudados    foi: Grupo 1 = 49,5%, Grupo 2 = 28,6%, Grupo 3 = 3,8%, Gr
upo 4 = 21,1%, Grupo    5 = 11,1%, Grupo 6 = 30,8% e Grupo 7 = 18,8%. A an&aacut
e;lise de res&iacute;duos    demonstrou preval&ecirc;ncia significante de ASIL p
ara o Grupo 1 e de ASIL de    alto-grau para o Grupo 2. A raz&atilde;o-de-chance
s do Grupo 1 para ASIL foi    significantemente maior em compara&ccedil;&atilde;
o com os Grupos 2, 3, 4, 5    e 7 (<I>p </I>&lt; 0,03). A raz&atilde;o-de-chance
s para ASIL dos Grupos 2,    4 e 6 foi significantemente maior em compara&ccedil
;&atilde;o com o Grupo 3    (<I>p </I>&lt; 0.03). <B>Conclus&otilde;es</B>: Nos 
pacientes estudados, ASIL    (baixo e/ou alto-grau) foi significantemente mais p
revalente em pacientes HIV-positivos.    Entretanto, pacientes HIV-negativos ano
rreceptivos tamb&eacute;m apresentaram    grande probabilidade de possuir as les
&otilde;es, especialmente os do g&ecirc;nero    masculino. </font></p>     ^cY#a
12v26n1.htm##
00390000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704015600075002001300231#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#30#26#article#165#<p><font face="Verda
na" size="2"><B>Descritores</B>: Canal Anal. Neoplasias do    &Acirc;nus. Epidem
iologia. HIV. </font></p> <hr size="1" noshade>     ^cY#a12v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#31#27#article#165#<p>&nbsp;</p>     ^c
Y#a12v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#32#28#article#165#<p>&nbsp;</p>     ^c
Y#a12v26n1.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007500075002001300150#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#33#29#article#165#<p><font face="Verda
na" size="3"><B>Introduction</B> </font></p>       ^cY#a12v26n1.htm##
00496000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704026200075002001300337#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#34#30#article#165#<p><font face="Verda
na" size="2"> Anal cancer, although rare in the general population,    has shown
 an increase in incidence in recent decades in some sections of the    populatio
n considered at greater risk of developing the disease&#185;. </font></p>     ^c
Y#a12v26n1.htm##
00794000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704056000075002001300635#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#35#31#article#165#<p><font face="Verda
na" size="2"> The disease is associated with continued anal    human papillomavi
rus (HPV) infection. About 75% of the sexually active population    will develop
 HPV anogenital infection throughout life, although most of the    affected indi
viduals will not present clinical signs of the illness&#178;. When    present, t
hese signs (mainly anal intraepithelial neoplasia, or AIN) are similar    to tho
se found in association with cervical cancer, a malignancy with which    anal ca
ncer shares many characteristics&#179;. </font></p>     ^cY#a12v26n1.htm##
00888000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704065400075002001300729#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#36#32#article#165#<p><font face="Verda
na" size="2"> Following the classification of cervical intraepithelial    neopla
sia, anal cancer precursor lesions, alike, have been conventionally defined    a
s AIN 1, AIN 2 and AIN 3. In accordance with what is experienced with cervical  
  intraepithelial neoplasia, to minimize considerable inter and intra-observer  
  interpretative variability, the 2001 Bethesda Classification System of cellula
r    atypia is used so that AIN 1 is defined as LSIL (low-grade squamous intraep
ithelial    lesion) and AIN 2 and 3 are unified in a sole category, HSIL (high-g
rade squamous    intraepithelial lesion)<SUP>4</SUP>. </font></p>     ^cY#a12v26
n1.htm##
00977000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704074300075002001300818#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#37#33#article#165#<p><font face="Verda
na" size="2"> Patients with HSIL lesions are at an increased    risk to develop 
anal cancer<SUP>5</SUP>. Nevertheless, depending on the genotype    of the infec
ting HPV, in the presence of infection with multiple HPV types and    under immu
nodepressive conditions, lesions considered to be LSIL at admittance    can evol
ve to HSIL. This is the case for individuals infected with acquired    immunodef
iciency virus (HIV-positive) and especially for HIV-positive men-who-    have-se
x-with-men (MSM)<SUP>6</SUP>. However, even among women, the incidence    of ana
l cancer is 7 times greater in HIV-positive individuals in contrast to    HIV-ne
gative with other at risk conditions for the malignancy&#178;. </font></p>     ^
cY#a12v26n1.htm##
00760000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052600075002001300601#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#38#34#article#165#<p><font face="Verda
na" size="2"> Strict follow-up policies directed at patients    considered to be
 at risk to develop anal cancer have been implemented in some    institutions ba
sed on data that indicate a historical increase in the incidence    of the malig
nancy in these population groups<SUP>7</SUP>. Therapeutic management    of lesio
ns at a higher risk to evolve to malignant degeneration is the objective    of t
hese policies in an attempt to reduce the incidence of anal neoplasia<SUP>8</SUP
>.    </font></p>     ^cY#a12v26n1.htm##
00947000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704071300075002001300788#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#39#35#article#165#<p><font face="Verda
na" size="2"> The Tropical Medicine Foundation of Amazonas    (FMT-AM) is a publ
ic health service of the state of Amazonas, Brazil, specialized    in the treatm
ent of infectious diseases. The majority of HIV infected individuals    of the s
tate are referred to FMT-AM for diagnosis, follow up and treatment.    From Janu
ary 2007, HIV-positive patients followed up in the institution, as    well as ot
her HIV-negative patients presenting colorectal complaints, were referred    to 
its Coloproctology Outpatient Clinic. Until then, there was no consolidated    d
ata on the magnitude of the frequency of anal cancer precursor lesions among    
patients managed only at FMT-AM. </font></p>     ^cY#a12v26n1.htm##
00641000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040700075002001300482#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#40#36#article#165#<p><font face="Verda
na" size="2"> This work was, therefore, designed to evaluate    the frequency of
 anal squamous intraepithelial lesions (ASIL) and anal cancer    in patients who
 were examined at the institution in order to gather evidence    to corroborate 
the need to implement a follow-up and treatment routine program    directed at p
atients at risk of developing anal malignancy. </font></p>     ^cY#a12v26n1.htm#
#
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#41#37#article#165#<p>&nbsp;</p>     ^c
Y#a12v26n1.htm##
00304000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007000075002001300145#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#42#38#article#165#<p><font face="Verda
na" size="3"><B>Methods</B> </font></p>       ^cY#a12v26n1.htm##
00317000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008300075002001300158#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#43#39#article#165#<p><font face="Verda
na" size="2"><I> Ethics and patients</I> </font></p>       ^cY#a12v26n1.htm##
00665000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704043100075002001300506#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#44#40#article#165#<p><font face="Verda
na" size="2"> This cross-sectional observational study was    approved by the Et
hics in Research Committee of FMT-AM (CEP/FMT-AM n&#186; 1768/2006).    The data
 relative to the patients herein included were collected from those    seeking m
edical evaluation at FMT-AM and referred to the institution's Coloproctology    
Outpatient Clinic for consultation from January 2007 to December 2008. </font></
p>     ^cY#a12v26n1.htm##
00571000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704033700075002001300412#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#45#41#article#165#<p><font face="Verda
na" size="2"> The population studied included consecutively    attended HIV-posi
tive and HIV-negative individuals, from both genders, with    and without risk f
actors for the development of anal cancer who had never before    been submitted
 to coloproctological examination or sampling at FMT-AM. </font></p>     ^cY#a12
v26n1.htm##
00613000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704037900075002001300454#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#46#42#article#165#<p><font face="Verda
na" size="2"> All the individuals presenting one the following    criteria were 
excluded: age below 18 years, developmental disabilities, native    Brazilian In
dians, those who did not complete any stage of specimen collection,    those wit
h missing or unsatisfactory specimens, and those missing crucial data    for sta
tistical analysis. </font></p>     ^cY#a12v26n1.htm##
00482000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024800075002001300323#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#47#43#article#165#<p><font face="Verda
na" size="2"> All the patients who signed the Informed Consent    forms were int
erviewed and responded to a questionnaire directed at their epidemiological    c
haracteristics and anal cancer risk conditions. </font></p>     ^cY#a12v26n1.htm
##
01332000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704109800075002001301173#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#48#44#article#165#<p><font face="Verda
na" size="2"> Out of the 399 patients examined in the study    period, after app
lying inclusion and exclusion criteria, 344 were screened for    analysis. These
 patients were further stratified in the following groups according    to the pr
esence or absence of anal cancer risk conditions: Group 1 = HIV-positive    MSM 
(101 patients); Group 2 = HIV-positive females (49 patients); Group 3 =    indiv
iduals of both genders without anal cancer risk factors or behaviors (53    pati
ents); Group 4 = HIV-positive heterosexual males (38 patients); Group 5    = HIV
-negative individuals of both genders without anoreceptive sexual habits,    but
 that reported at least one among the other inquired anal cancer risk factors   
 or behaviors (current tobacco smoking, injection drug addiction, sexually trans
mitted    diseases, solid organ transplantation, and history of anogenital cance
r or its    precursor lesions) (45 patients); Group 6 = HIV-negative MSM (26 pat
ients);    and Group 7 = HIV-negative females with anoreceptive sexual habits (3
2 patients).    </font></p>       ^cY#a12v26n1.htm##
00316000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008200075002001300157#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#49#45#article#165#<p><font face="Verda
na" size="2"><I> Biopsy proceedings</I> </font></p>       ^cY#a12v26n1.htm##
00977000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704074300075002001300818#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#50#46#article#165#<p><font face="Verda
na" size="2"> All the patients were submitted to high-resolution    anoscopy wit
h biopsies after topical application of a 3% acetic acid solution    for 2 minut
es as described elsewhere<SUP>9</SUP>, but with the following modifications:    
at least two biopsies were made in the anal canal of each subject. Patients    w
ithout acetowhitening at high-resolution anoscopy were submitted to biopsies    
within the anal transitional zone at standard positions (4 and 7 o'clock, consid
ering    the anterior anal commissure as 12 o'clock). Patients with anal canal a
cetowhitened    lesions had all of them biopsied and an additional biopsy was pe
rformed in a    non-acetowhitened anal transitional zone area. </font></p>     ^
cY#a12v26n1.htm##
00943000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704070900075002001300784#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#51#47#article#165#<p><font face="Verda
na" size="2"> The formalin-fixed biopsy specimens were delivered    to the Depar
tment of Pathology of FMT-AM for processing and evaluation. Hematoxilin-eosin-st
ained    slides prepared from 4 &#181;m-thick sections of the paraffin blocks co
ntaining    the anal specimens were diagnosed by three pathologists. Only consen
sual results    were considered. The projected possible histopathological result
s were: negative-for-ASIL    (LSIL or HSIL) or cancer, including benign inflamma
tory alterations, condyloma    acuminatum, LSIL, HSIL, epidermoid carcinoma <I>i
n situ</I>, adenocarcinoma    <I>in situ</I>, invasive epidermoid carcinoma, and
 invasive adenocarcinoma.    </font></p>     ^cY#a12v26n1.htm##
00407000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017300075002001300248#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#52#48#article#165#<p><font face="Verda
na" size="2"> Anal condyloma, LSIL and HSIL were diagnosed    according to well 
established morphological parameters<SUP>10</SUP>. </font></p>       ^cY#a12v26n
1.htm##
00318000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008400075002001300159#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#53#49#article#165#<p><font face="Verda
na" size="2"><I> Statistical analysis</I> </font></p>       ^cY#a12v26n1.htm##
00643000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704040900075002001300484#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#54#50#article#165#<p><font face="Verda
na" size="2"> Statistical analyses of the observed data were    performed with R
 statistical software<SUP>11</SUP> for the entire population    sample, consider
ing ethnic and educational differences, for HIV-positive and    HIV-negative pat
ients, and for the population sample strata that considered    the presence or a
bsence of anal cancer risk factors or behaviors. </font></p>     ^cY#a12v26n1.ht
m##
00697000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704046300075002001300538#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#55#51#article#165#<p><font face="Verda
na" size="2"> Descriptive summaries of epidemiological characteristics    were e
valuated. The population sample characteristics were tested against the    obser
ved histopathological results using frequentist and Bayesian - via R package    
LearnBayes<SUP>12</SUP> - statistical methods for analysis of contingency tables
,    the Monte Carlo test<SUP>13</SUP>, analysis of Standard Residuals and Corre
spondence    Analysis. </font></p>     ^cY#a12v26n1.htm##
00651000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704041700075002001300492#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#56#52#article#165#<p><font face="Verda
na" size="2"> The odds for association with ASIL were calculated    for each com
bination of two strata of patients. Statistical significance was    inferred whe
never the <I>p</I>-value of conventional statistical tests was found    below 5%
, when Bayesian posterior probabilities favored some given hypothesis    and whe
n absolute values of standard residuals were above 1.96. </font></p>     ^cY#a12
v26n1.htm##
00628000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704039400075002001300469#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#57#53#article#165#<p><font face="Verda
na" size="2"> For the statistical analysis, LSIL results encompassed    anal con
dyloma, and only one result was attributed per patient: that with the    highest
 grade of severity in the Negative-for-ASIL <IMG SRC="./flecha.JPG" WIDTH="16" H
EIGHT="8"  ALIGN="BOTTOM"> ASIL <IMG SRC="./flecha.JPG" WIDTH="16" HEIGHT="8"  A
LIGN="BOTTOM"> Cancer sequence. </font></p>       ^cY#a12v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#58#54#article#165#<p>&nbsp; </p>     ^
cY#a12v26n1.htm##
00304000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007000075002001300145#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#59#55#article#165#<p><font face="Verda
na" size="3"><B>Results</B> </font></p>       ^cY#a12v26n1.htm##
00416000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704018200075002001300257#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#60#56#article#165#<p><font face="Verda
na" size="2"> Due to missing data in respect to some non-crucial    study variab
les, the sample size of some epidemiological analyses varied. </font></p>     ^c
Y#a12v26n1.htm##
01113000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704087900075002001300954#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#61#57#article#165#<p><font face="Verda
na" size="2"> Regarding the ethnic breakdown, the larger number    of brown skin
ned patients reflects the regional ethnic composition of the Amazonian    popula
tion. In terms of educational level, patients with less than a higher    educati
onal level were significantly more numerous (<I>p </I>&lt; 0.0001). The    distr
ibution of ASIL-positive and ASIL-negative histopathological results in    relat
ion to the ethnic groups and to the educational level showed no differences    e
ither by frequentist or by Bayesian statistical analyses (Bayes factor = 0.00196
3119    for ethnic characteristics and 0.01647418 for educational level). The pr
evalence    of ASIL in all the patients analyzed showed a significant difference
 between    HIV-positive and HIV-negative individuals (<a href="/img/revistas/ac
b/v26n1/a12tab01.jpg">Table    1</a>). </font></p>     ^cY#a12v26n1.htm##
00509000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027500075002001300350#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#62#58#article#165#<p><font face="Verda
na" size="2"> The mean age of all the screened patients was    39 years. MSM ten
ded to be younger than females (33 years <I>versus </I>40 years)    and patients
 without risks for anal cancer older than all others groups (46    years). </fon
t></p>     ^cY#a12v26n1.htm##
00521000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028700075002001300362#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#63#59#article#165#<p><font face="Verda
na" size="2"> <a href="/img/revistas/acb/v26n1/a12tab02.jpg">Table    2</a> show
s the distribution of frequencies of histopathological results of    the anal ca
nal biopsies performed in all the patients studied relative to their    sample s
trata. </font></p>     ^cY#a12v26n1.htm##
01068000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704083400075002001300909#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#64#60#article#165#<p><font face="Verda
na" size="2"> As some of the cells of <a href="/img/revistas/acb/v26n1/a12tab02.
jpg">Table    2</a> contain less than 5 subjects, a feature that could compromis
e the validity    of the conventional statistical analysis of the data disposed 
in the table,    which pointed to a <I>p</I>-value below 0.0001, a Monte Carlo t
est was initially    applied to the same data. The approximated <I>p</I>-value o
btained was 0.0004998,    indicating that the null hypothesis of independence sh
ould indeed be rejected,    a reflex of statistical significance. A Bayesian ana
lysis of the data was also    undertaken for the same purpose and the value of t
he Bayes factor was 480,615.50,    indicating a very strong evidence against the
 existence of independence, again    indicating statistical significance. </font
></p>     ^cY#a12v26n1.htm##
00508000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027400075002001300349#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#65#61#article#165#<p><font face="Verda
na" size="2"> As all the statistical methods employed led    to the same results
, it could be stated that the strata of the population sample    studied showed 
very different histopathological findings when compared to each    other. </font
></p>     ^cY#a12v26n1.htm##
00769000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053500075002001300610#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#66#62#article#165#<p><font face="Verda
na" size="2"> The mosaic plot of <a href="#img01">Figure 1</a>    is a pictorial
 representation of the proportions of frequencies showed in Table    2 relative 
to each Group of patients. The width of each bar is representative    of the siz
e of the respective Group, while the height of each one of the three    segments
 that form a bar represents the proportional distribution of frequencies    of h
istopathological results (LSIL, HSIL and NEG) regarding every individual    Grou
p of patients. </font></p>     ^cY#a12v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#67#63#article#165#<p align="center">&n
bsp;</p>     ^cY#a12v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#68#64#article#165#<p align="center">&n
bsp;</p>     ^cY#a12v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#69#65#article#165#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a12img01.jpg"><a name="img01"></a></p>     ^cY#a
12v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#70#66#article#165#<p align="center">&n
bsp;</p>     ^cY#a12v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#71#67#article#165#<p align="center">&n
bsp;</p>     ^cY#a12v26n1.htm##
00769000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704053500075002001300610#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#72#68#article#165#<p><font face="Verda
na" size="2"> It can be visually perceived in <a href="#img01">Figure    1</a> t
hat patients of Groups 1 and 6 showed evident association with positive    resul
ts for ASIL (LSIL and HSIL), that patients of Group 2 showed evident association
    with HSIL, and that patients of Group 7 showed evident association with LSIL
.    As to results NEG, the most evident association is that presented by patien
ts    of Group 3. Despite being friendly, though, this is an entirely intuitive 
assessment.    </font></p>     ^cY#a12v26n1.htm##
00507000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027300075002001300348#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#73#69#article#165#<p><font face="Verda
na" size="2"> An evaluation of the behavior of the dependence    between histopa
thological results <I>versus </I>nature of sample strata was    then undertaken 
by the analysis of standard residuals (<a href="#tab03">Table    3</a>). </font>
</p>     ^cY#a12v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#74#70#article#165#<p align="center">&n
bsp;</p>     ^cY#a12v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#75#71#article#165#<p align="center">&n
bsp;</p>     ^cY#a12v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#76#72#article#165#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a12tab03.jpg"><a name="tab03"></a></p>     ^cY#a
12v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#77#73#article#165#<p align="center">&n
bsp;</p>     ^cY#a12v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#78#74#article#165#<p align="center">&n
bsp;</p>     ^cY#a12v26n1.htm##
00569000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704033500075002001300410#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#79#75#article#165#<p><font face="Verda
na" size="2"> The highest positive residuals were given by    the combinations: 
Group 1 + ASIL (either LSIL or HSIL), Group 2 + HSIL and Group    3 + Negative-f
or-ASIL. The most pronounced negative residuals were observed    with: Group 3 +
 ASIL, Group 1 + Negative-for-ASIL and Group 7 + HSIL. </font></p>     ^cY#a12v2
6n1.htm##
00714000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048000075002001300555#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#80#76#article#165#<p><font face="Verda
na" size="2"> Finally, concentrating the values of rows LSIL    and HSIL, from <
a href="/img/revistas/acb/v26n1/a12tab02.jpg">Table    2</a>, in a single row ca
lled ASIL, the odds ratios for ASIL of Group 1 were    estimated against the his
topathological results of each one of the other groups.    The associated confid
ence intervals were also obtained as well as a test for    the hypothesis of equ
al odds (<a href="#tab04">Table 4</a>). </font></p>     ^cY#a12v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#81#77#article#165#<p>&nbsp;</p>     ^c
Y#a12v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#82#78#article#165#<p>&nbsp;</p>     ^c
Y#a12v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#83#79#article#165#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a12tab04.jpg"><a name="tab04"></a></p>     ^cY#a
12v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#84#80#article#165#<p>&nbsp;</p>     ^c
Y#a12v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#85#81#article#165#<p>&nbsp;</p>     ^c
Y#a12v26n1.htm##
00288000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704005400075002001300129#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#86#82#article#165#<p><font face="Verda
na" size="2"> </font></p>     ^cY#a12v26n1.htm##
01024000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704079000075002001300865#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#87#83#article#165#<p><font face="Verda
na" size="2">The greatest Odds ratio was observed between    Groups 1 and 3. The
 hypothesis of equality between the odds for ASIL of Groups    1 and 6 could not
 be rejected, considering the observed 95% Confidence Interval    and the corres
ponding <I>p</I>-value (<I>p </I>= 0.0918). Inequality was observed    in all ot
her comparisons. The odds ratios formed between the remaining combinations    of
 two groups were also tested. All of them were non-significant, except for    th
ose obtained between Groups 2 and 3 (10.20; 95% Confidence Interval = 2.18    - 
47.71; <I>p </I>= 0.0031), 6 and 3 (11.33; 95% Confidence Interval = 2.20    - 5
8.43; <I>p </I>= 0.0037), and 4 and 3 (6.80; 95% Confidence Interval = 1.35    -
 34.15; <I>p </I>= 0.0199). </font></p>       ^cY#a12v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#88#84#article#165#<p>&nbsp; </p>     ^
cY#a12v26n1.htm##
00307000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007300075002001300148#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#89#85#article#165#<p><font face="Verda
na" size="3"><B>Discussion</B> </font></p>       ^cY#a12v26n1.htm##
01213000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704097900075002001301054#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#90#86#article#165#<p><font face="Verda
na" size="2"> This work is based on an analysis of frequencies    of histopathol
ogical diagnoses observed in anal canal biopsies performed in    HIV-positive an
d HIV-negative patients by attending Coloproctologists at FMT-AM.    All patient
s underwent biopsy proceedings, including those who had no obvious    acetowhite
 lesions during high-resolution anoscopy. This is a differential aspect    of th
is study, considering that if only individuals with positive anal cytology    an
d anoscopy were included, patients in whom these diagnostic tests were false-neg
ative    would have been excluded. Two biopsies were performed in each acetowhit
e negative    patient in order to minimize the chance of false negative anoscopy
 interpretations.    On the other hand, there were cases of diffuse anal transit
ional zone acetowhitening    either due to wart rings or to nonspecific staining
. Multiple biopsies were    performed for all these cases. </font></p>     ^cY#a
12v26n1.htm##
00610000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704037600075002001300451#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#91#87#article#165#<p><font face="Verda
na" size="2"> Statistical analysis of data gathered for this    study is distinc
tive in the aspect that it was conducted contrasting conventional    tests (freq
uentist, such as Chi-square and G tests) with non-conventional (mainly    Bayesi
an analysis and analysis of standard residuals), in order to validate    the fin
al conclusions. </font></p>     ^cY#a12v26n1.htm##
00742000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050800075002001300583#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#92#88#article#165#<p><font face="Verda
na" size="2"> The Bayesian method is based on the computation    of the Bayes fa
ctor, which is the ratio of probabilities observed after data    collection of t
wo considered hypotheses (presence of independence <i>versus    </i>lack of inde
pendence). It measures the evidence against the existence of    independence. A 
result greater than 1.00 favors lack of independence (statistical    significanc
e). Otherwise, the hypothesis of independence is to be accepted.    </font></p> 
    ^cY#a12v26n1.htm##
00830000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704059600075002001300671#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#93#89#article#165#<p><font face="Verda
na" size="2"> The analysis of standard residuals is a mensuration    of the degr
ee of deviation of the measurements away from the hypothesis of independence.   
 Each residual is calculated as <i>(observed - expected)/expected</i>&#178;,    
in which <i>observed </i>represents the cell value and expected is the expected 
   value of the cell considering the null hypothesis was true. Roughly, it is as
sumed    that residuals with absolute values above 1.96 represent cells with mor
e individuals    than expected for independence (statistical significance). </fo
nt></p>     ^cY#a12v26n1.htm##
00425000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704019100075002001300266#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#94#90#article#165#<p><font face="Verda
na" size="2"> The non-conventional statistics employed in    this study corrobor
ated and reinforced the results obtained by frequentist statistics.    </font></
p>     ^cY#a12v26n1.htm##
00914000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704068000075002001300755#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#95#91#article#165#<p><font face="Verda
na" size="2"> Abramowitz <i>et al.</i><sup>14 </sup>reported    108 HPV-related 
lesions in 473 HIV-positive patients of both genders with or    without anorecep
tive sexual habits (22.8%). The prevalence of ASIL (condyloma    included) was 3
6.5% in HIV-positive MSM, 14.6% in HIV-positive heterosexual    males and 11.3% 
in HIV-positive females, but only 47.2% of these lesions were    located solely 
in the anal canal. Comparatively, in FMT-AM's survey of exclusively    intra-ana
l HPV-induced lesions, the prevalence of ASIL among HIV-positive patients    was
 38.30% (49.50% in MSM, 28.57% in females and 21.05% in heterosexual males).    
</font></p>     ^cY#a12v26n1.htm##
00729000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049500075002001300570#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#96#92#article#165#<p><font face="Verda
na" size="2"> The initially managed group of HIV-positive    individuals at FMT-
AM showed a prevalence of ASIL above 60%, but most of them    had AIDS or HIV in
fection for many years. Durable HIV infection seems to be    accompanied by a hi
gher risk for ASIL because the frequency of precursor lesions    of anal cancer 
in HIV-positive patients has shown a tendency to increase since    the advent of
 highly active antiretroviral therapy<sup>2,5,6</sup>. </font></p>     ^cY#a12v2
6n1.htm##
00877000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704064300075002001300718#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#97#93#article#165#<p><font face="Verda
na" size="2"> As the coloproctological examination consolidated    as a routine 
for the initial evaluation of HIV-positive individuals at FMT-AM,    the frequen
cy of those with a less-than-a-year-diagnosed retrovirus increased,    so that i
t ultimately comprised 54.6% of all HIV-positive patients herein included.    Al
though patients with prolonged HIV infection may be at greater risk to present  
  ASIL<sup>8</sup>, it remains to be shown, in studies analyzing the prevalence 
   of ASIL in HIV-positive patients, that it is important to consider the length
    of time of HIV infection<sup>14</sup>. </font></p>     ^cY#a12v26n1.htm##
01116000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704088200075002001300957#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#98#94#article#165#<p><font face="Verda
na" size="2"> HIV-positive MSM are known to be the population    group most like
ly to develop anal cancer, and are followed by HIV-negative MSM    and by HIV-po
sitive females<sup>2,15</sup>. In HIV-positive MSM, the prevalence    of ASIL is
 also high, and was reported to be 81% in 357 patients studied at    the Univers
ity of California at San Francisco<sup>16</sup>. In fact, anoreceptive    habits
 increase the likelihood that male patients present ASIL compared with    anorec
eptive females since MSM tend to have anoreceptive sexual activity more    frequ
ently than women and also are prone to have more anal-introducer sexual    partn
ers, which makes them more likely to have anal HPV infection<sup>17</sup>.    Fu
rthermore, HIV infection confers MSM a relative risk 5.7 times greater to    hav
e ASIL than HIV-negative MSM<sup>15</sup>.</font></p>     ^cY#a12v26n1.htm##
00941000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704070700075002001300782#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#99#95#article#165#<p><font face="Verda
na" size="2">Prevalence of ASIL in men investigated at FMT-AM    was significant
ly higher among HIV-positive than in HIV-negative (<I>p </I>=    0.0003) irrespe
ctive of the presence of other risk factors for anal cancer.    Among HIV-positi
ve men, it was higher in MSM than in heterosexual (<I>p </I>=    0.0045). Nevert
heless, ASIL was not statistically more prevalent in HIV-positive    men (MSM or
 heterosexual) compared to HIV-negative MSM (<I>p </I>= 0.1363 and    <I>p </I>=
 0.3094, respectively), meaning that, in men, &quot;HIV-infection&quot;    and &
quot;receptive anal intercourse&quot; factors appeared both to be influential   
 in association with ASIL. </font></p>     ^cY#a12v26n1.htm##
00867000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704063200076002001300708#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#100#96#article#165#<p><font face="Verd
ana" size="2"> Prevalence of cytological or histological ASIL    in HIV-positive
 females was estimated to be 14.5% in a multicentric study recently    conducted
 at five academic centers in the U.S<SUP>18</SUP>. Although comparatively    sma
ller than the one reported for HIV-negative MSM in the EXPLORE study (20%),    w
hich was based on cytological results<SUP>19</SUP>, both prevalences are conside
rably    higher than that described by Holly <I>et al.</I><SUP>17 </SUP>(8%) in 
HIV-negative    females with other risk factors for anal cancer in a study also 
based on cytological    results. </font></p>     ^cY#a12v26n1.htm##
01385000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704115000076002001301226#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#101#97#article#165#<p><font face="Verd
ana" size="2"> In this study, HIV-positive females showed a    frequency of HSIL
 significantly higher than anoreceptive HIV-negative females    (<I>p </I>= 0.00
64), while the latter had a frequency of LSIL higher than the    former, but wit
hout statistical significance (<I>p </I>= 0.1139). Even considering    that 75% 
of the HIV-positive females studied practiced anoreceptive sex and    that the o
ther risk factors for anal cancer were unevenly distributed between    the two g
roups, it could be reasoned that, in the females studied, the condition    of be
ing HIV-positive was linked to the elevated association with HSIL and that    th
e practice of anoreceptive sex predisposed HIV-negative females to LSIL associat
ion.    Indeed, in Hessol<I> et al.</I><SUP>18 </SUP>study of a cohort of HIV-po
sitive    and HIV-negative US women, all at risk for anal cancer development, th
ose who    reported anal intercourse were 3.8 times more likely to have anal LSI
L than    women with no history of anoreceptive sex, while HIV-positive women we
re 3.1    times more likely to have anal HSIL than HIV-negative women. </font></
p>     ^cY#a12v26n1.htm##
01299000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704106400076002001301140#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#102#98#article#165#<p><font face="Verd
ana" size="2"> Despite that it was not possible to rigorously    and independent
ly indicate the exact factors mostly associated with the presence    of ASIL in 
each population strata, since some confounding factors could not    be dissociat
ed in the strata (e.g.: HIV-positive MSM, HIV-positive females,    HIV-positive 
heterosexual males, HIV-negative MSM and HIV-negative anoreceptive    females co
uld or could not have other risk factors for anal cancer, such as    current tob
acco smoking) it may be inferred from the comparative analysis of    the proport
ions of the frequencies of the histopathological diagnoses observed    among the
 groups, that conditions &quot;anal intercourse&quot; and &quot;HIV    infection
&quot; were those associated with more positive results for LSIL and/or    HSIL.
 The absence of risk factors for anal cancer (presented by Group 3 of patients) 
   was, conversely, the feature most significantly associated with negative resu
lts    (and also with lower rates of positive results) for ASIL. </font></p>    
 ^cY#a12v26n1.htm##
00582000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704034700076002001300423#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#103#99#article#165#<p><font face="Verd
ana" size="2"> One can argue that groups 3 and 5 should not    be compared to th
e remaining groups since they were composed of patients from    both genders, wh
ile the others were not. Nevertheless, there was no statistical    difference be
tween genders in the distribution of ASIL within groups 3 and 5.    </font></p> 
    ^cY#a12v26n1.htm##
00967000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704073100077002001300808#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#104#100#article#165#<p><font face="Ver
dana" size="2"> Although the population sample strata observed    in this study 
were unevenly sized, including some with few individuals, the    combined evalua
tion of the data done by frequentist and alternative statistical    methods sugg
ests, with a high degree of confidence, that HIV-positive MSM were    significan
tly more associated with ASIL results than all other groups, except    for HIV-n
egative MSM; that HIV-positive females were significantly more associated    wit
h HSIL results than all other groups, except for HIV-positive MSM; and that    p
atients from Group 3 were significantly more associated with Negative-for-ASIL  
  results than all other groups, except for Group 5. </font></p>     ^cY#a12v26n
1.htm##
00585000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704034900077002001300426#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#105#101#article#165#<p><font face="Ver
dana" size="2"> One can argue that groups 3 and 5 should not    be compared to t
he remaining groups since they were composed of patients from    both genders, w
hile the others were not. Nevertheless, there was no statistical    difference b
etween genders in the distribution of ASIL within groups 3 and 5.    </font></p>
       ^cY#a12v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#106#102#article#165#<p>&nbsp; </p>    
 ^cY#a12v26n1.htm##
00310000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007400077002001300151#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#107#103#article#165#<p><font face="Ver
dana" size="3"><B>Conclusions</B> </font></p>       ^cY#a12v26n1.htm##
00612000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704037600077002001300453#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#108#104#article#165#<p><font face="Ver
dana" size="2"> In the patients studied, anal squamous intraepithelial    lesion
s (low and/or high-grade) tended to be significantly more prevalent in    HIV-po
sitive patients. Nonetheless, HIV-negative anoreceptive patients also    present
ed great probability to have anal cancer precursor lesions, mainly those    of t
he male gender. </font></p>       ^cY#a12v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#109#105#article#165#<p>&nbsp;</p>     
^cY#a12v26n1.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007300077002001300150#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#110#106#article#165#<p><font face="Ver
dana" size="3"><B>References</B> </font></p>       ^cY#a12v26n1.htm##
00516000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704026600079002001300345#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#111#107#article#165#1#<p><
font face="Verdana" size="2">1. Daling JR, Weiss NS, Hislop TG, Maden C, Coates 
   RJ, Sherman KJ, Ashley RL, Beagrie M, Ryan JA, Corey L. Sexual practices, sex
ually    transmitted diseases, and the incidence of anal cancer. N Engl J Med. 1
987;317:973-7.    ^cY#a12v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#112#108#article#165#    </font></p>   
  ^cY#a12v26n1.htm##
00620000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704037000079002001300449#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#113#109#article#165#2#<p><
font face="Verdana" size="2">2. Bratcher J, Palefsky J. Anogenital human papillo
mavirus    infection and associated neoplasia in HIV-positive men and women. The
 PRN Notebook.    2008;13:1-8. Available from: &lt;<a href="http://www.prn.org/i
mages/pdfs/502_bratcher_palefsky.pdf" target="_blank">http://www.prn.org/images/
pdfs/502_bratcher_palefsky.pdf</a>&gt;    ^cY#a12v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#114#110#article#165#    </font></p>   
  ^cY#a12v26n1.htm##
00404000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704015400079002001300233#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#115#111#article#165#3#<p><
font face="Verdana" size="2">3. Melbye M, Sprogel P. Aetiological parallel    be
tween anal cancer and cervical cancer. Lancet. 1991;338:657-9.    ^cY#a12v26n1.h
tm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#116#112#article#165# </font></p>     ^
cY#a12v26n1.htm##
00488000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704023800079002001300317#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#117#113#article#165#4#<p><
font face="Verdana" size="2">4. Biggar RJ, Melbye M. Marital status in relation 
   to Kaposi's sarcoma, non-Hodgkin's lymphoma, and anal cancer in the pre-AIDS 
   era. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:178-82.    ^cY#a12v26
n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#118#114#article#165# </font></p>     ^
cY#a12v26n1.htm##
00498000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704024800079002001300327#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#119#115#article#165#5#<p><
font face="Verdana" size="2">5. Chin-Hong PV, Palefsky JM. Natural history    an
d clinical management of anal human papillomavirus disease in men and women    i
nfected with human immunodeficiency virus. Clin Infect Dis. 2002;35:1127-34.    
^cY#a12v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#120#116#article#165#    </font></p>   
  ^cY#a12v26n1.htm##
00395000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704014500079002001300224#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#121#117#article#165#6#<p><
font face="Verdana" size="2">6. Palefsky JM. Anal cancer prevention in HIV-posit
ive    men and women. Curr Opin Oncol. 2009;21:433-8.    ^cY#a12v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#122#118#article#165# </font></p>     ^
cY#a12v26n1.htm##
00548000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704029800079002001300377#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#123#119#article#165#7#<p><
font face="Verdana" size="2">7. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg    
KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness   
 of screening for anal squamous intraepithelial lesions in homosexual and bisexu
al    HIV-positive men. JAMA. 1999;281:1822-9.    ^cY#a12v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#124#120#article#165# </font></p>     ^
cY#a12v26n1.htm##
00650000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704040000079002001300479#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#125#121#article#165#8#<p><
font face="Verdana" size="2">8. Palefsky JM, Cranston RD. Anal intraepithelial  
  neoplasia: Diagnosis, screening and treatment. In: Dezube BJ and Ross ME (Ed).
    UpToDate, Waltham, MA, 2009. Available from: &lt;<a href="http://www.uptodat
e.com/online/content/topic.do?topicKey=tumorhiv/2317" target="_blank">http://www
.uptodate.com/online/content/topic.do?topicKey=tumorhiv/2317</a>&gt;    ^cY#a12v
26n1.htm##
00261000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002500077002001300102#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#126#122#article#165#.    </font></p>  
   ^cY#a12v26n1.htm##
00542000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704029200079002001300371#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#127#123#article#165#9#<p><
font face="Verdana" size="2">9. Costa e Silva IT, Ferreira LCD, Gimenez FS,    G
uimaraes RAG, Fujimoto LB, Cabral CRB, Mozzer RV, Atala LDS. High-resolution    
anoscopy in the diagnosis of anal cancer precursor lesions in renal graft recipi
ents.    Ann Surg Oncol. 2008;15:1470-5.    ^cY#a12v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#128#124#article#165# </font></p>     ^
cY#a12v26n1.htm##
00403000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704015200080002001300232#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#129#125#article#165#10#<p>
<font face="Verdana" size="2">10. Longacre TA, Kong CS, Welton ML. Diagnostic   
 problems in anal pathology. Adv Anat Pathol. 2008;15:263-78.    ^cY#a12v26n1.ht
m##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#130#126#article#165# </font></p>     ^
cY#a12v26n1.htm##
00542000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029100080002001300371#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#131#127#article#165#11#<p>
<font face="Verdana" size="2"> 11. R DEVELOPMENT CORE TEAM. R: A language and   
 environment for statistical computing. Vienna: R Foundation for Statistical    
Computing, 2008. Available from: &lt;<a href="http://www.R-project.org" target="
_blank">http://www.R-project.org</a>&gt;    ^cY#a12v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#132#128#article#165#    </font></p>   
  ^cY#a12v26n1.htm##
00604000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704035300080002001300433#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#133#129#article#165#12#<p>
<font face="Verdana" size="2">12. Albert J. LearnBayes: Functions for Learning  
  Bayesian Inference. Vienna: R Foundation for Statistical Computing, 2008. Avai
lable    from: &lt;<a href="http://cran.r-project.org/web/packages/LearnBayes/Le
arnBayes.pdf" target="_blank">http://cran.r-project.org/web/packages/LearnBayes/
LearnBayes.pdf</a>&gt;    ^cY#a12v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#134#130#article#165#    </font></p>   
  ^cY#a12v26n1.htm##
00399000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704014800080002001300228#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#135#131#article#165#13#<p>
<font face="Verdana" size="2">13. Hope ACA. A simplified Monte Carlo significanc
e    test procedure. J Roy Statist Soc B. 1968;30:582-98.    ^cY#a12v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#136#132#article#165# </font></p>     ^
cY#a12v26n1.htm##
00585000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704033400080002001300414#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#137#133#article#165#14#<p>
<font face="Verdana" size="2">14. Abramowitz L, Benabderrahmane D, Ravaud P,    
Walker F, Rioux C, Jestin C, Bouvet E, Soule JC, Leport C, Duval X. Anal squamou
s    intraepithelial lesions and condyloma in HIV-infected heterosexual men, hom
osexual    men and women: prevalence and associated factors. AIDS. 2007;21:1457-
65.    ^cY#a12v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#138#134#article#165# </font></p>     ^
cY#a12v26n1.htm##
00588000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704033700080002001300417#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#139#135#article#165#15#<p>
<font face="Verdana" size="2">15. Palefsky JM, Holly EA, Ralston ML, Arthur    S
P, Jay N, Berry JM, DaCosta MM, Botts R, Darragh TM. Anal squamous intraepitheli
al    lesions in HIV-positive and HIV-negative homosexual and bisexual men: prev
alence    and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:
320-6.    ^cY#a12v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#140#136#article#165#    </font></p>   
  ^cY#a12v26n1.htm##
00527000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704027600080002001300356#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#141#137#article#165#16#<p>
<font face="Verdana" size="2">16. Palefsky JM, Holly EA, Efirdc JT, Da Costa    
M, Jay N, Berry JM, Darragh TM. Anal intraepithelial neoplasia in the highly    
active antiretroviral therapy era among HIV-positive men who have sex with men. 
   AIDS. 2005;19:1407-14.    ^cY#a12v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#142#138#article#165# </font></p>     ^
cY#a12v26n1.htm##
00485000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023400080002001300314#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#143#139#article#165#17#<p>
<font face="Verdana" size="2">17. Holly EA, Ralston ML, Darragh TM, Greenblatt  
  RM, Jay N, Palefsky JM. Prevalence and risk factors for anal squamous intraepi
thelial    lesions in women. J Natl Cancer Inst. 2001;93:843-9.    ^cY#a12v26n1.
htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#144#140#article#165# </font></p>     ^
cY#a12v26n1.htm##
00548000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704029700080002001300377#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#145#141#article#165#18#<p>
<font face="Verdana" size="2">18. Hessol NA, Holly EA, Efird JT, Minkoff H,    S
chowalter K, Darragh TM, Burk RD, Strickler HD, Greenblatt RM, Palefsky JM.    A
nal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk
    HIV-uninfected women. AIDS. 2009;23:59-70.    ^cY#a12v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#146#142#article#165# </font></p>     ^
cY#a12v26n1.htm##
00575000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704032400080002001300404#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#p#147#143#article#165#19#<p>
<font face="Verdana" size="2">19. Chin-Hong PV, Vittinghoff E, Cranston RD,    B
rowne L, Buchbinder S, Colfax G, Da CM, Darragh T, Benet DJ, Judson F, Koblin   
 B, Mayer KH, Palefsky JM. Age-related prevalence of anal cancer precursors in  
  homosexual men: the EXPLORE study. J Natl Cancer Inst. 2005;97:896-905.    ^cY
#a12v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#148#144#article#165# </font></p>     ^
cY#a12v26n1.htm##
00264000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002800077002001300105#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#149#145#article#165#<p>&nbsp;</p>     
      ^cY#a12v26n1.htm##
00315000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007900077002001300156#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#150#146#article#165#<p> <font face="Ve
rdana" size="3"><B>Acknowledgments</B> </font></p>       ^cY#a12v26n1.htm##
00483000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704024700077002001300324#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#151#147#article#165#<p><font face="Ver
dana" size="2"> The authors are grateful to Pathology Laboratory    Technicians 
Sandra Caranhas, Andreza Fernandes and to Administrative Technician    Agustinho
 Monteiro for their expert technical assistance. </font></p>     ^cY#a12v26n1.ht
m##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#152#148#article#165#<p>&nbsp;</p>     
  ^cY#a12v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#153#149#article#165#<p>&nbsp;</p>     
^cY#a12v26n1.htm##
00262000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002600077002001300103#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#154#150#article#165#<p>&nbsp;</p>     
    ^cY#a12v26n1.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704015500077002001300232#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#155#151#article#165#<p><font face="Ver
dana" size="2"><B><a name="end"></a><a href="#top"><img src="/img/revistas/acb/v
26n1/seta.gif" border="0"></a>Correspondence</B>:    ^cY#a12v26n1.htm##
00281000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004500077002001300122#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#156#152#article#165#<br>   Ivan Tramuj
as da Costa e Silva    ^cY#a12v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003500077002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#157#153#article#165#<br>   R. Afonso P
ena, 1053    ^cY#a12v26n1.htm##
00279000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004300077002001300120#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#158#154#article#165#<br>   69020-160 M
anaus - AM Brasil    ^cY#a12v26n1.htm##
00327000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009100077002001300168#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#159#155#article#165#<br>   <a href="ma
ilto:itramujas@ufam.edu.br">itramujas@ufam.edu.br</a></font></p>     ^cY#a12v26n
1.htm##
00264000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002800077002001300105#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#160#156#article#165#<p>&nbsp;</p>     
      ^cY#a12v26n1.htm##
00338000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704010200077002001300179#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#161#157#article#165#<p><font face="Ver
dana" size="2">Received: July 06, 2010 </font><font face="Verdana" size="2">    
^cY#a12v26n1.htm##
00315000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007900077002001300156#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#162#158#article#165#<br>   Review: Sep
tember 14, 2010 </font><font face="Verdana" size="2">    ^cY#a12v26n1.htm##
00290000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005400077002001300131#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#163#159#article#165#<br>   Accepted: O
ctober 19, 2010 </font></p>     ^cY#a12v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006700077002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#164#160#article#165#<p><font face="Ver
dana" size="2">Conflict of interest: none    ^cY#a12v26n1.htm##
00335000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009900077002001300176#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#165#161#article#165#<br>   </font><fon
t face="Verdana" size="2">Financial source: National Program of DST-AIDS,    ^cY
#a12v26n1.htm##
00360000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704012400077002001300201#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#166#162#article#165#<br>   </font><fon
t face="Verdana" size="2">Ministry of Health of Brazil - UNESCO (grant    914BRA
1101) </font></p>     ^cY#a12v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#167#163#article#165#<p>&nbsp;</p>     
^cY#a12v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#168#164#article#165#<p>&nbsp;</p>     
^cY#a12v26n1.htm##
00733000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704049700077002001300574#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a12v26n1.htm#S#p#169#165#article#165#<p><font face="Ver
dana" size="2"><sup><a name="end"></a><a href="#top">1</a></sup>    Research per
formed at the Outpatient Clinic of Coloproctology and the Division    of Patholo
gy of the Tropical Medicine Foundation of Amazonas, Manaus-AM, Brazil.    Part o
f a PhD thesis in Tropical and Infectious Diseases of the Post-Graduation    Pro
gram of the Tropical Medicine Foundation of Amazonas, University of the State   
 of Amazonas (UEA). Tutor: Luiz Carlos de Lima Ferreira. </font></p>       ^cY#a
12v26n1.htm##
00750000000000361000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100016000930100
01700109010001500126010001700141010001800158010001700176010001700193010001500210
01000150022501200860024003000140032671000020034006500090034206400050035103100040
0356014000600360865000900366002001300375#v26n1#V:\Scielo\serial\acb\v26n1\markup
\a12v26n1.htm#S#c#170#1#article#19#1#^rND^sDaling^nJR#^rND^sWeiss^nNS#^rND^sHisl
op^nTG#^rND^sMaden^nC#^rND^sCoates^nRJ#^rND^sSherman^nKJ#^rND^sAshley^nRL#^rND^s
Beagrie^nM#^rND^sRyan^nJA#^rND^sCorey^nL#Sexual practices, sexually transmitted 
diseases, and the incidence of anal cancer^len#N Engl J Med.#2#19870000#1987#317
#973-7#20110200#a12v26n1.htm##
00610000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100018000940120
10100112030001700213710000200230065000900232064000500241031000300246014000400249
037005700253865000900310002001300319#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12
v26n1.htm#S#c#171#2#article#19#2#^rND^sBratcher^nJ#^rND^sPalefsky^nJ#Anogenital 
human papillomavirus infection and associated neoplasia in HIV-positive men and 
women^len#The PRN Notebook#2#20080000#2008#13#1-8#http://www.prn.org/images/pdfs
/502_bratcher_palefsky.pdf#20110200#a12v26n1.htm##
00497000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100017000920120
06600109030000800175710000200183065000900185064000500194031000400199014000600203
865000900209002001300218#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#
c#172#3#article#19#3#^rND^sMelbye^nM#^rND^sSprogel^nP#Aetiological parallel betw
een anal cancer and cervical cancer^len#Lancet.#2#19910000#1991#338#657-9#201102
00#a12v26n1.htm##
00641000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100016000930120
11200109030004300221065000900264064000500273031000300278014000700281865000900288
002001300297035001000310801004300320#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12
v26n1.htm#S#c#173#4#article#19#4#^rND^sBiggar^nRJ#^rND^sMelbye^nM#Marital status
 in relation to Kaposi's sarcoma, non-Hodgkin's lymphoma, and anal cancer in the
 pre-AIDS era^len#J Acquir Immune Defic Syndr Hum Retrovirol#19960000#1996#11#17
8-82#20110200#a12v26n1.htm#1077-9450#J Acquir Immune Defic Syndr Hum Retrovirol#
#
00588000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100020000760100019000960120
14100115030001700256710000200273065000900275064000500284031000300289014000800292
865000900300002001300309#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#
c#174#5#article#19#5#^rND^sChin-Hong^nPV#^rND^sPalefsky^nJM#Natural history and 
clinical management of anal human papillomavirus disease in men and women infect
ed with human immunodeficiency virus^len#Clin Infect Dis.#2#20020000#2002#35#112
7-34#20110200#a12v26n1.htm##
00470000000000253000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760120057000950300
01700152710000200169065000900171064000500180031000300185014000600188865000900194
002001300203#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#c#175#6#arti
cle#19#6#^rND^sPalefsky^nJM#Anal cancer prevention in HIV-positive men and women
^len#Curr Opin Oncol.#2#20090000#2009#21#433-8#20110200#a12v26n1.htm##
00707000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100016000930100
02000109010002000129010001700149010001900166012015300185030000600338710000200344
065000900346064000500355031000400360014000700364865000900371002001300380#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#c#176#7#article#19#7#^rND^sGoldi
e^nSJ#^rND^sKuntz^nKM#^rND^sWeinstein^nMC#^rND^sFreedberg^nKA#^rND^sWelton^nML#^
rND^sPalefsky^nJM#The clinical effectiveness and cost-effectiveness of screening
 for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positi
ve men^len#JAMA.#2#19990000#1999#281#1822-9#20110200#a12v26n1.htm##
00627000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100019000950120
07100114016001700185016001500202018001300217066001200230065000900242064000500251
037007100256865000900327002001300336#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12
v26n1.htm#S#c#177#8#article#19#8#^rND^sPalefsky^nJM#^rND^sCranston^nRD#Anal intr
aepithelial neoplasia: Diagnosis, screening and treatment^len#^rED^sDezube^nBJ#^
rED^sRoss^nME#UpToDate^len#Waltham^eMA#20090000#2009#http://www.uptodate.com/onl
ine/content/topic.do?topicKey=tumorhiv/2317#20110200#a12v26n1.htm##
00737000000000337000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100024000760100020001000100
01800120010002100138010001900159010001800178010001700196010001700213012010500230
03000160033571000020035106500090035306400050036203100030036701400070037086500090
0377002001300386#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#c#178#9#
article#19#9#^rND^sCosta e Silva^nIT#^rND^sFerreira^nLCD#^rND^sGimenez^nFS#^rND^
sGuimaraes^nRAG#^rND^sFujimoto^nLB#^rND^sCabral^nCRB#^rND^sMozzer^nRV#^rND^sAtal
a^nLDS#High-resolution anoscopy in the diagnosis of anal cancer precursor lesion
s in renal graft recipients^len#Ann Surg Oncol.#2#20080000#2008#15#1470-5#201102
00#a12v26n1.htm##
00514000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100015000970100
01700112012004200129030001700171710000200188065000900190064000500199031000300204
014000700207865000900214002001300223#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12
v26n1.htm#S#c#179#10#article#19#10#^rND^sLongacre^nTA#^rND^sKong^nCS#^rND^sWelto
n^nML#Diagnostic problems in anal pathology^len#Adv Anat Pathol.#2#20080000#2008
#15#263-78#20110200#a12v26n1.htm##
00511000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750170024000780180060001020660
00700162062003900169065000900208064000500217037002500222865000900247002001300256
#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#c#180#11#article#19#11#R
 DEVELOPMENT CORE TEAM#R: A language and environment for statistical computing^l
en#Vienna#R Foundation for Statistical Computing#20080000#2008#http://www.R-proj
ect.org#20110200#a12v26n1.htm##
00541000000000241000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750160016000780180058000940660
00700152062003900159065000900198064000500207037006500212865000900277002001300286
#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#c#181#12#article#19#12#^
rND^sAlbert^nJ#LearnBayes: Functions for Learning Bayesian Inference^len#Vienna#
R Foundation for Statistical Computing#20080000#2008#http://cran.r-project.org/w
eb/packages/LearnBayes/LearnBayes.pdf#20110200#a12v26n1.htm##
00474000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780120057000940300
02100151710000200172065000900174064000500183031000300188014000700191865000900198
002001300207#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#c#182#13#art
icle#19#13#^rND^sHope^nACA#A simplified Monte Carlo significance test procedure^
len#J Roy Statist Soc B.#2#19680000#1968#30#582-98#20110200#a12v26n1.htm##
00816000000000361000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100025000980100
01600123010001600139010001500155010001600170010001600186010001600202010001600218
01000150023401201500024903000060039971000020040506500090040706400050041603100030
0421014000800424865000900432002001300441#v26n1#V:\Scielo\serial\acb\v26n1\markup
\a12v26n1.htm#S#c#183#14#article#19#14#^rND^sAbramowitz^nL#^rND^sBenabderrahmane
^nD#^rND^sRavaud^nP#^rND^sWalker^nF#^rND^sRioux^nC#^rND^sJestin^nC#^rND^sBouvet^
nE#^rND^sSoule^nJC#^rND^sLeport^nC#^rND^sDuval^nX#Anal squamous intraepithelial 
lesions and condyloma in HIV-infected heterosexual men, homosexual men and women
: prevalence and associated factors^len#AIDS.#2#20070000#2007#21#1457-65#2011020
0#a12v26n1.htm##
00801000000000349000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100016000970100
01800113010001700131010001300148010001600161010001800177010001500195010001800210
01201320022803000440036071000020040406500090040606400050041503100030042001400060
0423865000900429002001300438#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.ht
m#S#c#184#15#article#19#15#^rND^sPalefsky^nJM#^rND^sHolly^nEA#^rND^sRalston^nML#
^rND^sArthur^nSP#^rND^sJay^nN#^rND^sBerry^nJM#^rND^sDaCosta^nMM#^rND^sBotts^nR#^
rND^sDarragh^nTM#Anal squamous intraepithelial lesions in HIV-positive and HIV-n
egative homosexual and bisexual men: prevalence and risk factors^len#J Acquir Im
mune Defic Syndr Hum Retrovirol.#2#19980000#1998#17#320-6#20110200#a12v26n1.htm#
#
00704000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780100016000970100
01700113010001800130010001300148010001600161010001800177012012800195030000600323
71000020032906500090033106400050034003100030034501400080034886500090035600200130
0365#v26n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#c#185#16#article#19#
16#^rND^sPalefsky^nJM#^rND^sHolly^nEA#^rND^sEfirdc^nJT#^rND^sDa Costa^nM#^rND^sJ
ay^nN#^rND^sBerry^nJM#^rND^sDarragh^nTM#Anal intraepithelial neoplasia in the hi
ghly active antiretroviral therapy era among HIV-positive men who have sex with 
men^len#AIDS.#2#20050000#2005#19#1407-14#20110200#a12v26n1.htm##
00647000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100018000940100
01800112010002100130010001300151010001900164012008300183030002000266710000200286
065000900288064000500297031000300302014000600305865000900311002001300320#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#c#186#17#article#19#17#^rND^sHol
ly^nEA#^rND^sRalston^nML#^rND^sDarragh^nTM#^rND^sGreenblatt^nRM#^rND^sJay^nN#^rN
D^sPalefsky^nJM#Prevalence and risk factors for anal squamous intraepithelial le
sions in women^len#J Natl Cancer Inst.#2#20010000#2001#93#843-9#20110200#a12v26n
1.htm##
00779000000000361000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100016000950100
01600111010001700127010002000144010001800164010001500182010002000197010002100217
01000190023801201070025703000060036471000020037006500090037206400050038103100030
0386014000600389865000900395002001300404#v26n1#V:\Scielo\serial\acb\v26n1\markup
\a12v26n1.htm#S#c#187#18#article#19#18#^rND^sHessol^nNA#^rND^sHolly^nEA#^rND^sEf
ird^nJT#^rND^sMinkoff^nH#^rND^sSchowalter^nK#^rND^sDarragh^nTM#^rND^sBurk^nRD#^r
ND^sStrickler^nHD#^rND^sGreenblatt^nRM#^rND^sPalefsky^nJM#Anal intraepithelial n
eoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women
^len#AIDS.#2#20090000#2009#23#59-70#20110200#a12v26n1.htm##
00860000000000397000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100020000780100021000980100
01900119010001600138010002000154010001600174010001300190010001700203010001600220
01000160023601000160025201000160026801000190028401200900030303000200039371000020
0413065000900415064000500424031000300429014000800432865000900440002001300449#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a12v26n1.htm#S#c#188#19#article#19#19#^rND^
sChin-Hong^nPV#^rND^sVittinghoff^nE#^rND^sCranston^nRD#^rND^sBrowne^nL#^rND^sBuc
hbinder^nS#^rND^sColfax^nG#^rND^sDa^nCM#^rND^sDarragh^nT#^rND^sBenet^nDJ#^rND^sJ
udson^nF#^rND^sKoblin^nB#^rND^sMayer^nKH#^rND^sPalefsky^nJM#Age-related prevalen
ce of anal cancer precursors in homosexual men: the EXPLORE study^len#J Natl Can
cer Inst.#2#20050000#2005#97#896-905#20110200#a12v26n1.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#o#1#1#article#1#
20110120#130207#a13v26n1.htm#161##
04867000000000733000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400090014103500100015001201310
01600120135002910100031004260100032004570100025004890100038005140100037005520700
09500589070004300684070007800727070009500805070004300900070006000943070004301003
08314580104608500080250408500340251208500250254608500270257108500270259808312880
26250850008039130850034039210850025039550850028039800850026040081170006040340720
00304040112000904043111001404052116000904066115001904075114000904094113001704103
002001304120#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#h#2#1#articl
e#1#oa#en#br1.1#1#4.0#ILUS#TAB#13#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f72^l
76#0102-8650#Latero-lateral femoro-femoral arteriovenous fistula: a new surgical
 approach for hemodialysis patients with no vascular access^len#Fístula artériov
enosa fêmoro-femoral látero-lateral: uma nova abordagem para hemodiálise de paci
entes sem opção de acesso vascular^lpt#^rND^1A01 A02^nJesualdo^sCerri#^rND^1A03^
nEduardo^sRamacciotti#^rND^1A03^nMarise^sGomes#^rND^1A04 A05^nWagner^sTedeschi F
ilho#^rND^1A06 A07^nCarlos Eli^sPiccinato#University Hospital^iA01^1Ribeirao Pre
to School of Medicine^2Department of Surgery and Anatomy#USP^iA02^1FMRP^cRibeira
o Preto^sSP^pBrazil#University of Michigan^iA03^1Research Laboratories, Vascular
 Surgery^sMI^pUSA#University Hospital^iA04^1Ribeirao Preto School of Medicine^2D
epartment of Surgery and Anatomy#USP^iA05^1FMRP^cRibeirao Preto^sSP^pBrazil#Univ
ersity Hospital^iA06^1Department of Surgery and Anatomy#USP^iA07^1FMRP^cRibeirao
 Preto^sSP^pBrazil#^len^aPurpose: A new surgical approach for vascular access fo
r hemodialysis using a latero-lateral arteriovenous fistula (AVF) in the thigh b
etween the femoral artery (FA) and superficial femoral vein (SFV) transposed to 
the subcutaneous layer in patients with no other access options is described. Me
thods: Ten patients (mean age: 37,9 years) for whom all possible sites for execu
tion of any other procedure had been exhausted, underwent latero-lateral AVF clo
se to the adductor channel between the FA and the SFV. The FSV was released and 
sectioned 2 cm from its confluence with the deep femoral vein and transposed in 
the subcutaneous tissue with extensions using saphenous vein or prosthetic mater
ial (PTFE) when needed. Follow -up included patency, flow evaluation and complic
ations. Results: Postoperative follow-up ranged from 3 to 96 months, with a mean
 of 38 months. The AVFs presented a flow of more than 350 ml/min and the AVFs re
mained patent for a mean period of 38 months. There were three failures of the p
rocedures at 3, 5 and 7 months during postoperative follow-up due to graft infec
tion and thrombosis (a case), anaphylactic shock and thrombosis (a case) and cal
f pain during dialysis (a case). Two patients developed slight inferior limb ede
ma. Conclusion: The new surgical approach for access for hemodialysis represents
 a feasible procedure, with acceptable patency rates in exceptional cases where 
no other access option is available.#^dnd^i1#^tm^len^kArteriovenous Fistula^i1#^
tm^len^kFemoral Vein^i1#^tm^len^kFemoral Artery^i1#^tm^len^kRenal Dialysis^i1#^l
pt^aObjetivo: Nova abordagem para acesso vascular para hemodiálise usando fistul
a artério-venosa (FAV) látero-lateral na coxa entre a artéria femoral (AF) e a v
eia femoral superficial (VFS) transposta no subcutâneo em pacientes sem opção de
 acesso. Métodos: Dez pacientes (idade média 37,9 anos), cuja possibilidade de a
cesso havia sido exaurido, foram submetidos a FAV látero-lateral na coxa entre a
 AF e a VFS.Esta veia foi liberada e seccionada 2 cm de sua confluência com a ve
ia femoral profunda e transposta no plano superficial com extensão usando a veia
 safena ou material protético (PTFE) quando necessário.O seguimento incluíu a pe
rviedade , fluxo e complicações. Resultados: O seguimento pós-operatório foi de 
3 a 96 meses (média 38). A FAV apresentou fluxo mínimo de 350 ml/min e permanece
u pérvia no período médio de 38 meses. Houve 3 falências aos 3, 5, e 7 meses pós
-operatórios por infecção de prótese e trombose da FAV (um caso), choque anafilá
tico e trombose (um caso) e dor na panturrilha na hemodiálise (um caso). Dois pa
cientes desenvolveram discreto edema de membro inferior. Conclusão: A nova abord
agem para acesso vascular para hemodiálise representa um procedimento factível, 
com aceitável perviedade em casos excepcionais onde nenhum outro acesso é dispon
ível.#^dnd^i2#^tm^lpt^kFístula Arteriovenosa^i2#^tm^lpt^kVeia Femoral^i2#^tm^lpt
^kArtéria Femoral^i2#^tm^lpt^kDiálise Renal^i2#other#20#20100714#July 14, 2010#2
0100916#September 16, 2010#20101019#October 19, 2010#a13v26n1.htm##
04937000000000733000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400090014103500100015001201380
01600120142002980100031004400100032004710100025005030100038005280100037005660700
09500603070004300698070007800741070009500819070004300914070006000957070004301017
08314860106008500080254608500340255408500250258808500270261308500270264008313160
26670850008039830850034039910850025040250850028040500850026040781170006041040720
00304110112000904113111001404122116000904136115001904145114000904164113001704173
002001304190#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#f#3#1#articl
e#1#oa#en#br1.1#1#4.0#ILUS#TAB#13#ACB720#nd#Acta Cir. Bras.#26#1#20110200#^f72^l
76#0102-8650#<b>Latero-lateral femoro-femoral arteriovenous fistula</b>: a new s
urgical approach for hemodialysis patients with no vascular access^len#<b>Fístul
a artériovenosa fêmoro-femoral látero-lateral</b>: uma nova abordagem para hemod
iálise de pacientes sem opção de acesso vascular^lpt#^rND^1A01 A02^nJesualdo^sCe
rri#^rND^1A03^nEduardo^sRamacciotti#^rND^1A03^nMarise^sGomes#^rND^1A04 A05^nWagn
er^sTedeschi Filho#^rND^1A06 A07^nCarlos Eli^sPiccinato#University Hospital^iA01
^1Ribeirao Preto School of Medicine^2Department of Surgery and Anatomy#USP^iA02^
1FMRP^cRibeirao Preto^sSP^pBrazil#University of Michigan^iA03^1Research Laborato
ries, Vascular Surgery^sMI^pUSA#University Hospital^iA04^1Ribeirao Preto School 
of Medicine^2Department of Surgery and Anatomy#USP^iA05^1FMRP^cRibeirao Preto^sS
P^pBrazil#University Hospital^iA06^1Department of Surgery and Anatomy#USP^iA07^1
FMRP^cRibeirao Preto^sSP^pBrazil#^len^a<b>Purpose</b>: A new surgical approach f
or vascular access for hemodialysis using a latero-lateral arteriovenous fistula
 (AVF) in the thigh between the femoral artery (FA) and superficial femoral vein
 (SFV) transposed to the subcutaneous layer in patients with no other access opt
ions is described. <b>Methods</b>: Ten patients (mean age: 37,9 years) for whom 
all possible sites for execution of any other procedure had been exhausted, unde
rwent latero-lateral AVF close to the adductor channel between the FA and the SF
V. The FSV was released and sectioned 2 cm from its confluence with the deep fem
oral vein and transposed in the subcutaneous tissue with extensions using saphen
ous vein or prosthetic material (PTFE) when needed. Follow -up included patency,
 flow evaluation and complications. <b>Results</b>: Postoperative follow-up rang
ed from 3 to 96 months, with a mean of 38 months. The AVFs presented a flow of m
ore than 350 ml/min and the AVFs remained patent for a mean period of 38 months.
 There were three failures of the procedures at 3, 5 and 7 months during postope
rative follow-up due to graft infection and thrombosis (a case), anaphylactic sh
ock and thrombosis (a case) and calf pain during dialysis (a case). Two patients
 developed slight inferior limb edema. <b>Conclusion</b>: The new surgical appro
ach for access for hemodialysis represents a feasible procedure, with acceptable
 patency rates in exceptional cases where no other access option is available.#^
dnd^i1#^tm^len^kArteriovenous Fistula^i1#^tm^len^kFemoral Vein^i1#^tm^len^kFemor
al Artery^i1#^tm^len^kRenal Dialysis^i1#^lpt^a<b>Objetivo</b>: Nova abordagem pa
ra acesso vascular para hemodiálise usando fistula artério-venosa (FAV) látero-l
ateral na coxa entre a artéria femoral (AF) e a veia femoral superficial (VFS) t
ransposta no subcutâneo em pacientes sem opção de acesso. <b>Métodos</b>: Dez pa
cientes (idade média 37,9 anos), cuja possibilidade de acesso havia sido exaurid
o, foram submetidos a FAV látero-lateral na coxa entre a AF e a VFS.Esta veia fo
i liberada e seccionada 2 cm de sua confluência com a veia femoral profunda e tr
ansposta no plano superficial com extensão usando a veia safena ou material prot
ético (PTFE) quando necessário.O seguimento incluíu a perviedade , fluxo e compl
icações. <b>Resultados</b>: O seguimento pós-operatório foi de 3 a 96 meses (méd
ia 38). A FAV apresentou fluxo mínimo de 350 ml/min e permaneceu pérvia no perío
do médio de 38 meses. Houve 3 falências aos 3, 5, e 7 meses pós-operatórios por 
infecção de prótese e trombose da FAV (um caso), choque anafilático e trombose (
um caso) e dor na panturrilha na hemodiálise (um caso). Dois pacientes desenvolv
eram discreto edema de membro inferior. <b>Conclusão</b>: A nova abordagem para 
acesso vascular para hemodiálise representa um procedimento factível, com aceitá
vel perviedade em casos excepcionais onde nenhum outro acesso é disponível.#^dnd
^i2#^tm^lpt^kFístula Arteriovenosa^i2#^tm^lpt^kVeia Femoral^i2#^tm^lpt^kArtéria 
Femoral^i2#^tm^lpt^kDiálise Renal^i2#other#20#20100714#July 14, 2010#20100916#Se
ptember 16, 2010#20101019#October 19, 2010#a13v26n1.htm##
05011000000000757000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000150012903100030014403200020014706500090014901400090015803500100
01670120131001770120135003080100031004430100032004740100025005060100038005310100
03700569070009700606070004500703070008000748070009700828070004500925070006200970
07000450103208314580107708500080253508500340254308500250257708500270260208500270
26290831288026560850008039440850034039520850025039860850028040110850026040391170
00604065072000304071112000904074111001404083116000904097115001904106114000904125
113001704134002001304151008008904164#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13
v26n1.htm#S#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#ilus#tab#13#ACB7
20#nd#Acta cir. bras#26#1#20110200#^f72^l76#0102-8650#Latero-lateral femoro-femo
ral arteriovenous fistula: a new surgical approach for hemodialysis patients wit
h no vascular access^len#Fístula artériovenosa fêmoro-femoral látero-lateral: um
a nova abordagem para hemodiálise de pacientes sem opção de acesso vascular^lpt#
^rND^1A01 A02^nJesualdo^sCerri#^rND^1A03^nEduardo^sRamacciotti#^rND^1A03^nMarise
^sGomes#^rND^1A04 A05^nWagner^sTedeschi Filho#^rND^1A06 A07^nCarlos Eli^sPiccina
to#^iA01^1University Hospital^2Ribeirao Preto School of Medicine^3Department of 
Surgery and Anatomy#^iA02^1USP^2FMRP^cRibeirao Preto^sSP^pBrazil#^iA03^1Universi
ty of Michigan^2Research Laboratories, Vascular Surgery^sMI^pUSA#^iA04^1Universi
ty Hospital^2Ribeirao Preto School of Medicine^3Department of Surgery and Anatom
y#^iA05^1USP^2FMRP^cRibeirao Preto^sSP^pBrazil#^iA06^1University Hospital^2Depar
tment of Surgery and Anatomy#^iA07^1USP^2FMRP^cRibeirao Preto^sSP^pBrazil#^len^a
Purpose: A new surgical approach for vascular access for hemodialysis using a la
tero-lateral arteriovenous fistula (AVF) in the thigh between the femoral artery
 (FA) and superficial femoral vein (SFV) transposed to the subcutaneous layer in
 patients with no other access options is described. Methods: Ten patients (mean
 age: 37,9 years) for whom all possible sites for execution of any other procedu
re had been exhausted, underwent latero-lateral AVF close to the adductor channe
l between the FA and the SFV. The FSV was released and sectioned 2 cm from its c
onfluence with the deep femoral vein and transposed in the subcutaneous tissue w
ith extensions using saphenous vein or prosthetic material (PTFE) when needed. F
ollow -up included patency, flow evaluation and complications. Results: Postoper
ative follow-up ranged from 3 to 96 months, with a mean of 38 months. The AVFs p
resented a flow of more than 350 ml/min and the AVFs remained patent for a mean 
period of 38 months. There were three failures of the procedures at 3, 5 and 7 m
onths during postoperative follow-up due to graft infection and thrombosis (a ca
se), anaphylactic shock and thrombosis (a case) and calf pain during dialysis (a
 case). Two patients developed slight inferior limb edema. Conclusion: The new s
urgical approach for access for hemodialysis represents a feasible procedure, wi
th acceptable patency rates in exceptional cases where no other access option is
 available.#^dnd^i1#^tm^len^kArteriovenous Fistula^i1#^tm^len^kFemoral Vein^i1#^
tm^len^kFemoral Artery^i1#^tm^len^kRenal Dialysis^i1#^lpt^aObjetivo: Nova aborda
gem para acesso vascular para hemodiálise usando fistula artério-venosa (FAV) lá
tero-lateral na coxa entre a artéria femoral (AF) e a veia femoral superficial (
VFS) transposta no subcutâneo em pacientes sem opção de acesso. Métodos: Dez pac
ientes (idade média 37,9 anos), cuja possibilidade de acesso havia sido exaurido
, foram submetidos a FAV látero-lateral na coxa entre a AF e a VFS.Esta veia foi
 liberada e seccionada 2 cm de sua confluência com a veia femoral profunda e tra
nsposta no plano superficial com extensão usando a veia safena ou material proté
tico (PTFE) quando necessário.O seguimento incluíu a perviedade , fluxo e compli
cações. Resultados: O seguimento pós-operatório foi de 3 a 96 meses (média 38). 
A FAV apresentou fluxo mínimo de 350 ml/min e permaneceu pérvia no período médio
 de 38 meses. Houve 3 falências aos 3, 5, e 7 meses pós-operatórios por infecção
 de prótese e trombose da FAV (um caso), choque anafilático e trombose (um caso)
 e dor na panturrilha na hemodiálise (um caso). Dois pacientes desenvolveram dis
creto edema de membro inferior. Conclusão: A nova abordagem para acesso vascular
 para hemodiálise representa um procedimento factível, com aceitável perviedade 
em casos excepcionais onde nenhum outro acesso é disponível.#^dnd^i2#^tm^lpt^kFí
stula Arteriovenosa^i2#^tm^lpt^kVeia Femoral^i2#^tm^lpt^kArtéria Femoral^i2#^tm^
lpt^kDiálise Renal^i2#other#20#20100714#July 14, 2010#20100916#September 16, 201
0#20101019#October 19, 2010#a13v26n1.htm#Internet^ihttp://www.scielo.br/scielo.p
hp?script=sci_arttext&pid=S0102-86502011000100013##
00311000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704007900073002001300152#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#5#1#article#137#<p align="right"><font
 face="Verdana" size="2"><b>13 - ORIGINAL ARTICLE    ^cY#a13v26n1.htm##
00284000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704005200073002001300125#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#6#2#article#137#<br>   INVESTIGATIVE S
URGERY</b></font></p>     ^cY#a13v26n1.htm##
00268000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704003600073002001300109#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#7#3#article#137#<p align="right">&nbsp
;</p>     ^cY#a13v26n1.htm##
00510000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704027800073002001300351#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#8#4#article#137#<p><b><font face="Verd
ana" size="2"><a name="top"></a></font><font face="Verdana" size="4">Latero-late
ral    femoro-femoral arteriovenous fistula. A new surgical approach for hemodia
lysis    patients with no vascular access<SUP><a href="#end">1</a></SUP></font><
/b></p>     ^cY#a13v26n1.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#9#5#article#137#<p>&nbsp;</p>     ^cY#
a13v26n1.htm##
00481000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704024800074002001300322#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#10#6#article#137#<p><b><font face="Ver
dana" size="3">F&iacute;stula art&eacute;riovenosa f&ecirc;moro-femoral    l&aac
ute;tero-lateral. Uma nova abordagem para hemodi&aacute;lise de pacientes    sem
 op&ccedil;&atilde;o de acesso vascular</font></b></p>         ^cY#a13v26n1.htm#
#
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#11#7#article#137#<p>&nbsp;</p>     ^cY
#a13v26n1.htm##
00461000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704022800074002001300302#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#12#8#article#137#<p><font face="Verdan
a" size="2"><B>Jesualdo Cerri<SUP>I</SUP>, Eduardo Ramacciotti<SUP>II</SUP>,    
Marise Gomes<SUP>II</SUP>, Wagner Tedeschi Filho<SUP>III</SUP>, Carlos Eli Picci
nato<SUP>IV</SUP></B>    </font></p>       ^cY#a13v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002400074002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#13#9#article#137#<p>&nbsp;</p>       ^
cY#a13v26n1.htm##
00555000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704032100075002001300396#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#14#10#article#137#<p><font face="Verda
na" size="2"><SUP>I </SUP>PhD, Associate Professor, Division    of Vascular and 
Endovascular Surgery, Ribeirao Preto School of Medicine, Department    of Surger
y and Anatomy, University Hospital, FMRP-USP, Ribeirao Preto-SP, Brazil.    <I>C
onception and design. Responsible surgical procedure.    ^cY#a13v26n1.htm##
00411000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017700075002001300252#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#15#11#article#137#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>II </SUP>MD, PhD, Research Laboratories,    Vas
cular Surgery, University of Michigan, MI, USA. <I>Critical revision.    ^cY#a13
v26n1.htm##
00544000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031000075002001300385#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#16#12#article#137#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>III </SUP>MD, Master degree, Division    of Vas
cular and Endovascular Surgery, Ribeirao Preto School of Medicine, Department   
 of Surgery and Anatomy, University Hospital, FMRP-USP, Ribeirao Preto-SP, Brazi
l.    <I>Data acquisition and iconography.    ^cY#a13v26n1.htm##
00609000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704037500075002001300450#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#17#13#article#137#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>IV </SUP>MD, PhD, Chairman and    Head of the D
ivision of Vascular and Endovascular Surgery, Department of Surgery    and Anato
my, University Hospital, FMRP-USP, Ribeirao Preto-SP, Brazil. <I>Main    author.
 Supervised all phases of the study. Provided guidelines for the surgical    int
erventions.</I></font></p>     ^cY#a13v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#18#14#article#137#<p><font face="Verda
na" size="2"><a href="#end">Correspondence</a></font></p>     ^cY#a13v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#19#15#article#137#<p>&nbsp;</p>     ^c
Y#a13v26n1.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#20#16#article#137#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a13v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#21#17#article#137#<p><font face="Verda
na" size="2"><B>ABSTRACT </B></font></p>     ^cY#a13v26n1.htm##
01824000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704159000075002001301665#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#22#18#article#137#<p><font face="Verda
na" size="2"><B>Purpose</b>: A new surgical approach for vascular    access for 
hemodialysis using a latero-lateral arteriovenous fistula (AVF) in    the thigh 
between the femoral artery (FA) and superficial femoral vein (SFV)    transposed
 to the subcutaneous layer in patients with no other access options    is descri
bed. <B>Methods</B>: Ten patients (mean age: 37,9 years) for whom all    possibl
e sites for execution of any other procedure had been exhausted, underwent    la
tero-lateral AVF close to the adductor channel between the FA and the SFV.    Th
e FSV was released and sectioned 2 cm from its confluence with the deep femoral 
   vein and transposed in the subcutaneous tissue with extensions using saphenou
s    vein or prosthetic material (PTFE) when needed. Follow -up included patency
,    flow evaluation and complications. <B>Results</B>: Postoperative follow-up 
ranged    from 3 to 96 months, with a mean of 38 months. The AVFs presented a fl
ow of    more than 350 ml/min and the AVFs remained patent for a mean period of 
38 months.    There were three failures of the procedures at 3, 5 and 7 months d
uring postoperative    follow-up due to graft infection and thrombosis (a case),
 anaphylactic shock    and thrombosis (a case) and calf pain during dialysis (a 
case). Two patients    developed slight inferior limb edema. <B>Conclusion</B>: 
The new surgical approach    for access for hemodialysis represents a feasible p
rocedure, with acceptable    patency rates in exceptional cases where no other a
ccess option is available.    </font></p>     ^cY#a13v26n1.htm##
00405000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704017100075002001300246#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#23#19#article#137#<p><font face="Verda
na" size="2"><B>Key words</B>: Arteriovenous Fistula. Femoral    Vein. Femoral A
rtery. Renal Dialysis. </font></p> <hr size="1" noshade>           ^cY#a13v26n1.
htm##
00301000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006700075002001300142#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#24#20#article#137#<p><font face="Verda
na" size="2"><B>RESUMO </B></font></p>     ^cY#a13v26n1.htm##
01917000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704168300075002001301758#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#25#21#article#137#<p><font face="Verda
na" size="2"><B>Objetivo</b>: Nova abordagem para acesso vascular    para hemodi
&aacute;lise usando fistula art&eacute;rio-venosa (FAV) l&aacute;tero-lateral   
 na coxa entre a art&eacute;ria femoral (AF) e a veia femoral superficial (VFS) 
   transposta no subcut&acirc;neo em pacientes sem op&ccedil;&atilde;o de acesso
.    <B>M&eacute;todos</B>: Dez pacientes (idade m&eacute;dia 37,9 anos), cuja p
ossibilidade    de acesso havia sido exaurido, foram submetidos a FAV l&aacute;t
ero-lateral    na coxa entre a AF e a VFS.Esta veia foi liberada e seccionada 2 
cm de sua conflu&ecirc;ncia    com a veia femoral profunda e transposta no plano
 superficial com extens&atilde;o    usando a veia safena ou material prot&eacute
;tico (PTFE) quando necess&aacute;rio.O    seguimento inclu&iacute;u a perviedad
e , fluxo e complica&ccedil;&otilde;es.    <B>Resultados</B>: O seguimento p&oac
ute;s-operat&oacute;rio foi de 3 a 96 meses    (m&eacute;dia 38). A FAV apresent
ou fluxo m&iacute;nimo de 350 ml/min e permaneceu    p&eacute;rvia no per&iacute
;odo m&eacute;dio de 38 meses. Houve 3 fal&ecirc;ncias    aos 3, 5, e 7 meses p&
oacute;s-operat&oacute;rios por infec&ccedil;&atilde;o    de pr&oacute;tese e tr
ombose da FAV (um caso), choque anafil&aacute;tico e trombose    (um caso) e dor
 na panturrilha na hemodi&aacute;lise (um caso). Dois pacientes    desenvolveram
 discreto edema de membro inferior. <B>Conclus&atilde;o</B>: A    nova abordagem
 para acesso vascular para hemodi&aacute;lise representa um procedimento    fact
&iacute;vel, com aceit&aacute;vel perviedade em casos excepcionais onde    nenhu
m outro acesso &eacute; dispon&iacute;vel. </font></p>     ^cY#a13v26n1.htm##
00425000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704019100075002001300266#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#26#22#article#137#<p><font face="Verda
na" size="2"><B>Descritores</B>: F&iacute;stula Arteriovenosa.    Veia Femoral. 
Art&eacute;ria Femoral. Di&aacute;lise Renal.    </font></p> <hr size="1" noshad
e>     ^cY#a13v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#27#23#article#137#<p>&nbsp;</p>     ^c
Y#a13v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#28#24#article#137#<p>&nbsp; </p>     ^
cY#a13v26n1.htm##
00309000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007500075002001300150#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#29#25#article#137#<p><font face="Verda
na" size="3"><B>Introduction</B> </font></p>       ^cY#a13v26n1.htm##
01077000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704084300075002001300918#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#30#26#article#137#<p><font face="Verda
na" size="2"> Treatment quality with periodic hemodialysis    (HD) is widely dep
endent on a good vascular access. The most commonly used access    for HD, an ar
teriovenous fistula (AVF) was described in 1966 by Brescia and    Cimino<SUP>1</
SUP>. However, due to repeated punctures and new dissections,    thrombophebitis
 and occlusions are frequent complications leading to the vascular    access los
s. New means of vascular access are required while those patients    remain in l
ine waiting for kidney transplantation<SUP>2</SUP>. Moreover, the    alternative
 method involving the use of Continuous Ambulatory Peritoneal Dialysis    (CAPD)
<SUP>3</SUP> is not available for a large number of patients; this procedure    
requires thorough sterile management, with peritonitis as a major complication. 
   </font></p>     ^cY#a13v26n1.htm##
00565000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704033100075002001300406#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#31#27#article#137#<p><font face="Verda
na" size="2"> A vascular access using the superficial femoral    vein (SFV) has 
been previously reported<SUP>4-7</SUP> with contradictory results.    Some patie
nts developed severe chronic venous insufficiency, others display    steal syndr
ome and even amputations are reported<SUP>8</SUP>. </font></p>     ^cY#a13v26n1.
htm##
00867000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704063300075002001300708#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#32#28#article#137#<p><font face="Verda
na" size="2"> In a recent meta-analysis, Antoniou <I>et al.</I><SUP>9    </SUP>c
ompared the upper thigh prosthetic, the mid-thigh prosthetic and the    femoral 
vein transposition arteriovenous as lower-extremity vascular     access. They re
port femoral vein transposition having better patency rates than    femoral graf
ts, with a 12 months mean primary patency rates of 48%, 43% and    83%, respecti
vely. Access loss as a result of infection was more common in upper    thigh and
 mid-thigh grafts than femoral vein transposition arteriovenous access    (18.40
%, 18.33% vs. 1.61%; p&lt;0.05). </font></p>     ^cY#a13v26n1.htm##
00698000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704046400075002001300539#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#33#29#article#137#<p><font face="Verda
na" size="2"> We present our experience with a possible alternative    vascular 
access procedure namely the latero-lateral femoro-femoral arteriovenous    fistu
la with the superficialization of the superficial femoral vein (SFV). In    this
 new approach, the distal femoral artery (FA) is anastomosed to the SFV    avoid
ing popliteal vein (PV) ligation, effectively preserving the deep venous    flow
 from the lower limb. </font></p>       ^cY#a13v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#34#30#article#137#<p>&nbsp; </p>     ^
cY#a13v26n1.htm##
00304000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007000075002001300145#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#35#31#article#137#<p><font face="Verda
na" size="3"><B>Methods</B> </font></p>       ^cY#a13v26n1.htm##
00623000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704038900075002001300464#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#36#32#article#137#<p><font face="Verda
na" size="2"> A total of 10 patients underwent this vascular    access procedure
 at University Hospital, Ribeirao Preto-School of Medicine,    University of Sao
 Paulo. Seven were females and three males patients. The details    of the demog
raphic features of these patients are given in <a href="/img/revistas/acb/v26n1/
a13tab01.jpg">Table    1</a>.</font></p>     ^cY#a13v26n1.htm##
00491000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025700075002001300332#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#37#33#article#137#<p><font face="Verda
na" size="2"> The basic criterion for inclusion in the exception    group was th
e presence of permeable arterial and venous systems, absence of    chronic arter
ial obstruction, and chronic venous insufficiency (CVI). </font></p>     ^cY#a13
v26n1.htm##
00524000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704029000075002001300365#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#38#34#article#137#<p><font face="Verda
na" size="2"> Institutional review board (Research Ethics    Committee - Hospita
l of the Faculty of Medicine of Ribeirao Preto-University    of Sao Paulo) appro
val was obtained. All patients signed informed consent forms    prior to any pro
cedure. </font></p>       ^cY#a13v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#39#35#article#137#<p>&nbsp;</p>     ^c
Y#a13v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#40#36#article#137#<p>&nbsp;</p>     ^c
Y#a13v26n1.htm##
00400000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704016600075002001300241#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#41#37#article#137#<p align="center"><a
 href="/img/revistas/acb/v26n1/a13tab02.jpg"><img src="/img/revistas/acb/v26n1/a
13tab02.jpg" border="0" width="300" height="300"></a></p>     ^cY#a13v26n1.htm##
00375000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704014100075002001300216#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#42#38#article#137#<p align="center"><f
ont face="Verdana" size="2"><a href="/img/revistas/acb/v26n1/a13tab02.jpg">Cliqu
e    para ampliar</a></font></p>     ^cY#a13v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#43#39#article#137#<p>&nbsp;</p>     ^c
Y#a13v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#44#40#article#137#<p>&nbsp;</p>     ^c
Y#a13v26n1.htm##
00315000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008100075002001300156#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#45#41#article#137#<p><font face="Verda
na" size="2"><I>Surgical technique</I> </font></p>       ^cY#a13v26n1.htm##
01381000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704114700075002001301222#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#46#42#article#137#<p><font face="Verda
na" size="2"> The procedures were carried out with continuous    epidural anesth
esia. A latero-lateral AVF between femoral artery (FA) and the    SFV was perfor
med close to the adductor channel. The length of the arteriotomy    was &#177; 1
 cm. The FSV was released and sectioned 2 cm from its confluence    with the dee
p femoral vein and transposed to the superficial plane in the subcutaneous    ti
ssue. The continuity of the FSV was reestablished in 3 patients by interposing  
  a PTFE segment measuring 4 cm in length and 8 mm in diameter between the proxi
mal    and distal stumps of the sectioned vein. Separate stitches with polypropy
lene    6.0 sutures were used. In the remaining cases, the continuity of the vei
n was    reestablished using the greater saphenous vein in 3 patients. In 2 pati
ents,    the procedure involved resection of a segment of the bifid FSV, which w
as interposed    between the proximal and distal stumps of the sectioned vein, w
ith polypropylene    6.0 sutures using an automatic needle (<a href="#img01">Fig
ures 1</a>, <a href="#img02">2</a>    and <a href="#img03">3</a>). </font></p>  
   ^cY#a13v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#47#43#article#137#<p>&nbsp;</p>     ^c
Y#a13v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#48#44#article#137#<p>&nbsp;</p>     ^c
Y#a13v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#49#45#article#137#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a13img01.jpg"><a name="img01"></a></p>     ^cY#a
13v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#50#46#article#137#<p align="center">&n
bsp;</p>     ^cY#a13v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#51#47#article#137#<p align="center">&n
bsp;</p>     ^cY#a13v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#52#48#article#137#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a13img02.jpg"><a name="img02"></a></p>     ^cY#a
13v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#53#49#article#137#<p align="center">&n
bsp;</p>     ^cY#a13v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#54#50#article#137#<p align="center">&n
bsp;</p>     ^cY#a13v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#55#51#article#137#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a13img03.jpg"><a name="img03"></a></p>     ^cY#a
13v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#56#52#article#137#<p>&nbsp;</p>     ^c
Y#a13v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#57#53#article#137#<p>&nbsp;</p>     ^c
Y#a13v26n1.htm##
00304000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007000075002001300145#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#58#54#article#137#<p><font face="Verda
na" size="2"><i>Follow-up</i> </font></p>     ^cY#a13v26n1.htm##
00712000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704047800075002001300553#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#59#55#article#137#<p><font face="Verda
na" size="2"> Previous access failure causes were analyzed.    Surgical procedur
e duration, vessels diameter and length measurements, blood    loss and anastomo
sis site were also recorded. Post-operative follow - up included    AVF patency,
 venous flow (measured on HD) and complications such as congestive    heart fail
ure, steal syndrome, venous hypertension, occlusions, thrombosis,    wound heali
ng and infection were also evaluated. </font></p>     ^cY#a13v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#60#56#article#137#<p>&nbsp; </p>     ^
cY#a13v26n1.htm##
00302000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006800075002001300143#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#61#57#article#137#<p><font face="Verda
na" size="3"><b>Results</b> </font></p>     ^cY#a13v26n1.htm##
00959000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704072500075002001300800#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#62#58#article#137#<p><font face="Verda
na" size="2"> Thrombosis of the fistula, infection of the    prosthesis and Hick
man catheters, veins of small diameters, thickened arteries,    and peritonitis 
were the most common events responsible for the loss of vascular    access, with
 a mean of 10,1 events/patient. Mean time of dialysis during the    preoperative
 period was 66.1 months. The procedures were carried out with no    intra- opera
tive complications and lasted on average 2 h and 56 min. Anastomosis    sites we
re all involving distal FA and SFV. Blood loss was minimum, no patient    requir
ed blood transfusions. Mean arterial diameter was 0.71 cm. SFV mean diameter    
was 0.89 cm, with a mean length of 14.53 cm. </font></p>     ^cY#a13v26n1.htm##
01439000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704120500075002001301280#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#63#59#article#137#<p><font face="Verda
na" size="2"> All AVFs were patent at the end of the procedure.    Mean time fro
m the beginning of dialysis was 35.6 days. The AVFs presented a    flow of more 
than 350 ml/min. Postoperative follow-up ranged from 3 to 96 months,    with a m
ean of 38 months. Two complications from the surgical wound occurred    during t
he postoperative period, with partial necrosis of the skin and of subcutaneous  
  cellular tissue that healed with the application of daily dressings. There wer
e    three failures of vascular access at 3, 5 and 7 months during postoperative
    follow-up due to a case of infection of the PTFE prosthesis which had to be 
   removed, one case of AVF thrombosis resulting from anaphylactic shock with pr
olonged    hypotension, and one case of a patient presenting calf pain (with no 
signal    of ischemia) during the dialysis sections who requested interruption o
f the    fistula. Two patients developed slight inferior limb edema, which was c
orrected    with an elastic stocking. One patient presented cardiac insufficienc
y not related    to the fistula. No steal syndrome was observed. The AVFs remain
ed patent in    an overall time of 38 months.</font></p>     ^cY#a13v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#64#60#article#137#<p>&nbsp;</p>     ^c
Y#a13v26n1.htm##
00307000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007300075002001300148#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#65#61#article#137#<p><font face="Verda
na" size="3"><B>Discussion</B> </font></p>       ^cY#a13v26n1.htm##
00539000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704030500075002001300380#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#66#62#article#137#<p><font face="Verda
na" size="2"> The best results with AVF for HD are still achieved    with the cl
assic Bescia and Cimino AVF, a distal anastomosis of the radial artery    with t
he cephalic vein. The patency rates are around 80 to 87% in a follow-up    of 36
 months<SUP>10-12</SUP>. </font></p>     ^cY#a13v26n1.htm##
00402000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704016800075002001300243#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#67#63#article#137#<p><font face="Verda
na" size="2"> When upper limbs are no longer available for    vascular access, l
ower limbs (particularly thighs) are an option. </font></p>     ^cY#a13v26n1.htm
##
01254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704102000075002001301095#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#68#64#article#137#<p><font face="Verda
na" size="2"> SFV is an excellent vessel to use in HD<SUP>13</SUP>.    The diame
ter ranges from 6 to 8 mm for an adult, and the wall is thick. This    vein has 
been used extensively as a conduit for aortic reconstructions, venous    reconst
ructions, infra-inguinal revascularizations and as an arteriovenous fistula    f
or HD with good long term results<SUP>13</SUP>. Jackson and colleagues<SUP>6</SU
P>    reported that the superficial femoral vein is an ideal material for vascul
ar    access in the lower extremities. However, complications are frequent inclu
ding    thromboses, cardiac failure, symptomatic distal leg ischemia (steal synd
rome),    aneurysm, edema of the limb and infection<SUP>14,15</SUP>. Despite of 
having    reported low incidence of CVI, steal syndrome is a major concern as we
ll. Grandman    and collaborators<SUP>5,16</SUP> reported 8 cases of steal syndr
ome in a series    of 25 patients, including a case of amputation due to compart
mental syndrome.    </font></p>     ^cY#a13v26n1.htm##
00596000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036200075002001300437#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#69#65#article#137#<p><font face="Verda
na" size="2"> We constructed a different SFV access for two    reasons. Primaril
y, avoiding popliteal ligature would prevent CVI. Secondly,    a distal anastomo
sis with a small AV diameter would prevent steal syndrome,    as previously repo
rted by Holman<SUP>17</SUP>, Storey<SUP>18</SUP> and Ramacciotti<SUP>19</SUP>.  
  </font></p>     ^cY#a13v26n1.htm##
00733000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049900075002001300574#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#70#66#article#137#<p><font face="Verda
na" size="2"> In our series, no steal syndrome was observed.    Only two patient
s developed edema. Infection occurred in only one subject, in    the 7 month fol
low-up of a patient who had a PTFE composite graft. Infections    of PTFE are re
ported as 4 fold higher than native vessels<SUP>20</SUP>. Three    patients rece
ived PTFE extensions, and 7 had a venous interposition (either    GSF of duplica
ted SFV segment), justifying this low infection incidence. </font></p>     ^cY#a
13v26n1.htm##
00432000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704019800075002001300273#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#71#67#article#137#<p><font face="Verda
na" size="2"> The flow observed in the HD was 350 ml/min;    no patient presente
d decreased flow nor needed ancillary maneuvers to increase    dialysis flow. </
font></p>     ^cY#a13v26n1.htm##
00728000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704049400075002001300569#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#72#68#article#137#<p><font face="Verda
na" size="2"> Failures occurred in 3 patients in the follow-up.    However, in t
wo cases no relation with the technique was found; one patient    experienced an
aphylactic shock and another was submitted to a surgical interruption    of the 
vascular access due to personal reasons. Considering the mean duration    of pat
ency reported of 38 months, it exceeds the results obtained by other investigato
rs    using autogenous fistulae of the upper limbs. </font></p>       ^cY#a13v26
n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#73#69#article#137#<p>&nbsp; </p>     ^
cY#a13v26n1.htm##
00307000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007300075002001300148#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#74#70#article#137#<p><font face="Verda
na" size="3"><B>Conclusion</B> </font></p>       ^cY#a13v26n1.htm##
00601000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704036700075002001300442#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#75#71#article#137#<p><font face="Verda
na" size="2"> This new procedure, keeping the deep venous    flow of the inferio
r limb, is an alternative for patients who are no longer    candidates to conven
tional vascular access. Results of this procedure are satisfactory    with good 
flow rates, and can be used as alternative vascular access for exceptional    ca
ses. </font></p>       ^cY#a13v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#76#72#article#137#<p>&nbsp;</p>     ^c
Y#a13v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002400075002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#77#73#article#137#<p>&nbsp;</p>       
^cY#a13v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#78#74#article#137#<p>&nbsp;</p>     ^c
Y#a13v26n1.htm##
00307000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007300075002001300148#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#79#75#article#137#<p><font face="Verda
na" size="3"><B>References</B> </font></p>       ^cY#a13v26n1.htm##
00460000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704021200077002001300289#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#80#76#article#137#1#<p><fo
nt face="Verdana" size="2">1. Brescia MJ, Cimino JE, Appel K, Hurwich BJ.    Chr
onic hemodialysis using venipuncture and a surgically created arteriovenous    f
istula. N Engl J Med. 1966;275:1089-2.    ^cY#a13v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#81#77#article#137# </font></p>     ^cY
#a13v26n1.htm##
00526000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704027800077002001300355#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#82#78#article#137#2#<p><fo
nt face="Verdana" size="2">2. Budruddin M, Mohsin N, Amitabh J, Ehab M,    Pramo
d K, Abbas P, Khalil M, Al-Lawati S. Femoral vein tunneled catheters as    a las
t resort to vascular access: report of five -cases and review of literature.    
Ren Fail. 2009;31:320-2.    ^cY#a13v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#83#79#article#137# </font></p>     ^cY
#a13v26n1.htm##
00390000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704014200077002001300219#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#84#80#article#137#3#<p><fo
nt face="Verdana" size="2">3. Boen ST. The clinical importance of peritoneal    
dialysis. Ned Tijdschr Geneeskd. 1962;106:353-6.    ^cY#a13v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#85#81#article#137# </font></p>     ^cY
#a13v26n1.htm##
00562000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704031400077002001300391#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#86#82#article#137#4#<p><fo
nt face="Verdana" size="2">4. Bolton WD, Cull DL, Taylor SM, Carsten CG    3rd, 
Snyder BA, Sullivan TM, Youkey JR, Langan EM 3rd, Gray BH. The use of cryopreser
ved    femoral vein grafts for hemodialysis access in patients at high risk for 
infection:    a word of caution. J Vasc Surg. 2002;36:464-8.    ^cY#a13v26n1.htm
##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#87#83#article#137# </font></p>     ^cY
#a13v26n1.htm##
00476000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704022800077002001300305#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#88#84#article#137#5#<p><fo
nt face="Verdana" size="2">5. Gradman WS, Cohen W, Haji-Aghaii M. Arteriovenous 
   fistula construction in the thigh with transposed superficial femoral vein:  
  our initial experience. J Vasc Surg. 2001;33:968-75.    ^cY#a13v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#89#85#article#137# </font></p>     ^cY
#a13v26n1.htm##
00451000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704020300077002001300280#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#90#86#article#137#6#<p><fo
nt face="Verdana" size="2">6. Jackson MR. The superficial femoral-popliteal    v
ein transposition fistula: description of a new vascular access procedure.    J 
Am Coll Surg. 2000;191:581-4.    ^cY#a13v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#91#87#article#137# </font></p>     ^cY
#a13v26n1.htm##
00450000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704020200077002001300279#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#92#88#article#137#7#<p><fo
nt face="Verdana" size="2">7. Kapala A, Szczesny W, Stankiewicz W, Hryncewicz   
 W. Vascular access for chronic dialysis using the superficial femoral vein.    
J Vasc Access. 2003;4:150-3.    ^cY#a13v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#93#89#article#137# </font></p>     ^cY
#a13v26n1.htm##
00448000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704020000077002001300277#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#94#90#article#137#8#<p><fo
nt face="Verdana" size="2">8. Huber TS, Ozaki CK, Flynn TC, Ross EA, Seeger    J
M. Use of superficial femoral vein for hemodialysis arteriovenous access. J    V
asc Surg. 2000;31:1038-41.    ^cY#a13v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#95#91#article#137# </font></p>     ^cY
#a13v26n1.htm##
00504000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000200075704025600077002001300333#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#96#92#article#137#9#<p><fo
nt face="Verdana" size="2">9. Antoniou GA, Lazarides MK, Georgiadis GS,    Sfyro
eras GS, Nikolopoulos ES, Giannoukas AD. Lower-extremity arteriovenous    access
 for haemodialysis: a systematic review. Eur J Vasc Endovasc Surg. 2009;38:365-7
2.    ^cY#a13v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002400075002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#97#93#article#137#    </font></p>     
^cY#a13v26n1.htm##
00517000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071888000300075704026800078002001300346#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#98#94#article#137#10#<p><f
ont face="Verdana" size="2">10. Kinnaert P, Vereerstraeten P, Toussaint C,    Va
n Geertruyden J. Nine years experience with internal arteriovenous fistulas    f
or haemodialysis: a study of some factors influencing the results. Br J Surg.   
 1977;64:242-6.    ^cY#a13v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002100075002001300096#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#99#95#article#137# </font></p>     ^cY
#a13v26n1.htm##
00434000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704018400079002001300263#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#100#96#article#137#11#<p><
font face="Verdana" size="2">11. Reilly DT, Wood RF, Bell PR. Prospective    stu
dy of dialysis fistulas: problem patients and their treatment. Br J Surg.    198
2;69:549-53.    ^cY#a13v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#101#97#article#137# </font></p>     ^c
Y#a13v26n1.htm##
00487000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072888000300076704023700079002001300316#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#102#98#article#137#12#<p><
font face="Verdana" size="2">12. Zibari GB, Rohr MS, Landreneau MD, Bridges    R
M, DeVault GA, Petty FH, Costley KJ, Brown ST, McDonald J. Complications from   
 permanent hemodialysis vascular access. Surgery. 1988;104:681-6.    ^cY#a13v26n
1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002100076002001300097#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#103#99#article#137# </font></p>     ^c
Y#a13v26n1.htm##
00463000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021200080002001300292#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#104#100#article#137#13#<p>
<font face="Verdana" size="2">13. Moncef G. Arterio-arterial graft interposition
    and superficial femoral vein transposition: an unusual vascular access. Saud
i    J Kidney Dis Transpl. 2005;16:171-5.    ^cY#a13v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#105#101#article#137# </font></p>     ^
cY#a13v26n1.htm##
00415000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704016400080002001300244#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#106#102#article#137#14#<p>
<font face="Verdana" size="2">14. Fee HJ Jr., Golding AL. Lower extremity ischem
ia    after femoral arteriovenous bovine shunts. Ann Surg. 1976;183:42-5.    ^cY
#a13v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#107#103#article#137# </font></p>     ^
cY#a13v26n1.htm##
00454000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704020300080002001300283#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#108#104#article#137#15#<p>
<font face="Verdana" size="2">15. Fee HJ, Levisman J, Doud RB, Golding AL.    Hi
gh-output congestive failure from femoral arteriovenous shunts for vascular    a
ccess. Ann Surg. 1976;183:321-3.    ^cY#a13v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#109#105#article#137# </font></p>     ^
cY#a13v26n1.htm##
00511000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704026000080002001300340#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#110#106#article#137#16#<p>
<font face="Verdana" size="2">16. Gradman WS, Laub J, Cohen W. Femoral vein    t
ransposition for arteriovenous hemodialysis access: improved patient selection  
  and intraoperative measures reduce postoperative ischemia. J Vasc Surg. 2005;4
1:279-84.    ^cY#a13v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#111#107#article#137#    </font></p>   
  ^cY#a13v26n1.htm##
00447000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019600080002001300276#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#112#108#article#137#17#<p>
<font face="Verdana" size="2">17. Holman E, Taylor G. Problems in the dynamics  
  of blood flow. II. Pressure relations at site of an arteriovenous fistula. Ang
iology.    1952;3:415-30.    ^cY#a13v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#113#109#article#137# </font></p>     ^
cY#a13v26n1.htm##
00475000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022400080002001300304#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#114#110#article#137#18#<p>
<font face="Verdana" size="2">18. Storey BG, George CR, Stewart JH, Tiller    DJ
, May J, Sheil AG. Embolic and ischemic complications after anastomosis of    ra
dial artery to cephalic vein. Surgery. 1969;66:325-7.    ^cY#a13v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#115#111#article#137# </font></p>     ^
cY#a13v26n1.htm##
00510000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704025900080002001300339#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#116#112#article#137#19#<p>
<font face="Verdana" size="2">19. Ramacciotti E, Galego SJ, Gomes M, Goldenberg 
   S, De Oliveira Gomes P, Pinto Ortiz J. Fistula size and hemodynamics: an expe
rimental    model in canine femoral arteriovenous fistulas. J Vasc Access. 2007;
8:33-43.    ^cY#a13v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#117#113#article#137#    </font></p>   
  ^cY#a13v26n1.htm##
00446000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704019500080002001300275#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#p#118#114#article#137#20#<p>
<font face="Verdana" size="2">20. Minga TE, Flanagan KH, Allon M. Clinical    co
nsequences of infected arteriovenous grafts in hemodialysis patients. Am J    Ki
dney Dis. 2001;38:975-8.    ^cY#a13v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#119#115#article#137# </font></p>     ^
cY#a13v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#120#116#article#137#<p>&nbsp; </p>    
 ^cY#a13v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#121#117#article#137#<p>&nbsp;</p>     
^cY#a13v26n1.htm##
00265000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002900077002001300106#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#122#118#article#137#<p>&nbsp; </p>    
       ^cY#a13v26n1.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704015500077002001300232#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#123#119#article#137#<p><font face="Ver
dana" size="2"><B><a name="end"></a><a href="#top"><img src="/img/revistas/acb/v
26n1/seta.gif" border="0"></a>Correspondence</B>:    ^cY#a13v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003500077002001300112#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#124#120#article#137#<br>   Carlos Eli 
Piccinato    ^cY#a13v26n1.htm##
00301000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006500077002001300142#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#125#121#article#137#<br>   Divis&atild
e;o de Cirurgia Vascular e Endovascular    ^cY#a13v26n1.htm##
00277000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004100077002001300118#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#126#122#article#137#<br>   Depto. Ciru
rgia e Anatomia    ^cY#a13v26n1.htm##
00297000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006100077002001300138#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#127#123#article#137#<br>   Faculdade d
e Medicina de Ribeir&atilde;o Preto    ^cY#a13v26n1.htm##
00291000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005500077002001300132#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#128#124#article#137#<br>   Campus Univ
ersit&aacute;rio Monte Alegre    ^cY#a13v26n1.htm##
00294000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005800077002001300135#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#129#125#article#137#<br>   14048-900 R
ibeir&atilde;o Preto - SP Brasil    ^cY#a13v26n1.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003800077002001300115#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#130#126#article#137#<br>   Phone: (55 
16)3602-2593    ^cY#a13v26n1.htm##
00272000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003600077002001300113#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#131#127#article#137#<br>   Fax: (55 16
)3633-0836    ^cY#a13v26n1.htm##
00325000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704008900077002001300166#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#132#128#article#137#<br>   <a href="ma
ilto:cepiccin@fmrp.usp.br">cepiccin@fmrp.usp.br</a></font></p>     ^cY#a13v26n1.
htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#133#129#article#137#<p>&nbsp; </p>    
 ^cY#a13v26n1.htm##
00300000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006400077002001300141#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#134#130#article#137#<p><font face="Ver
dana" size="2">Received: July 14, 2010    ^cY#a13v26n1.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#135#131#article#137#<br>   </font><fon
t face="Verdana" size="2">Review: September 16, 2010    ^cY#a13v26n1.htm##
00327000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009100077002001300168#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#136#132#article#137#<br>   </font><fon
t face="Verdana" size="2">Accepted: October 19, 2010 </font></p>     ^cY#a13v26n
1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006700077002001300144#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#137#133#article#137#<p><font face="Ver
dana" size="2">Conflict of interest: none    ^cY#a13v26n1.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704008700077002001300164#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#138#134#article#137#<br>   </font><fon
t face="Verdana" size="2">Financial source: none </font></p>     ^cY#a13v26n1.ht
m##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#139#135#article#137#<p>&nbsp;</p>     
^cY#a13v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#140#136#article#137#<p>&nbsp;</p>     
^cY#a13v26n1.htm##
00546000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704031000077002001300387#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a13v26n1.htm#S#p#141#137#article#137#<p><font face="Ver
dana" size="2"><sup><a name="end"></a><a href="#top">1</a> </sup>Research    per
formed at Division of Vascular and Endovascular, Department of Surgery and    An
atomy, University Hospital, School of Medicine of Ribeirao Preto (FMRP), Sao    
Paulo University (USP), Brazil. </font></p>     ^cY#a13v26n1.htm##
00588000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100017000940100
01500111010001800126012009100144030001400235710000200249065000900251064000500260
031000400265014000700269865000900276002001300285#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a13v26n1.htm#S#c#142#1#article#20#1#^rND^sBrescia^nMJ#^rND^sCimino^nJE#
^rND^sAppel^nK#^rND^sHurwich^nBJ#Chronic hemodialysis using venipuncture and a s
urgically created arteriovenous fistula^len#N Engl J Med.#2#19660000#1966#275#10
89-2#20110200#a13v26n1.htm##
00723000000000337000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100016000950100
01700111010001400128010001600142010001500158010001600173010001900189012012000208
03000100032871000020033806500090034006400050034903100030035401400060035786500090
0363002001300372#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#c#143#2#
article#20#2#^rND^sBudruddin^nM#^rND^sMohsin^nN#^rND^sAmitabh^nJ#^rND^sEhab^nM#^
rND^sPramod^nK#^rND^sAbbas^nP#^rND^sKhalil^nM#^rND^sAl-Lawati^nS#Femoral vein tu
nneled catheters as a last resort to vascular access: report of five -cases and 
review of literature^len#Ren Fail.#2#20090000#2009#31#320-2#20110200#a13v26n1.ht
m##
00467000000000253000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100015000760120051000910300
02300142710000200165065000900167064000500176031000400181014000600185865000900191
002001300200#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#c#144#3#arti
cle#20#3#^rND^sBoen^nST#The clinical importance of peritoneal dialysis^len#Ned T
ijdschr Geneeskd.#2#19620000#1962#106#353-6#20110200#a13v26n1.htm##
00777000000000349000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100015000930100
01700108010002200125010001700147010001900164010001700183010002100200010001500221
01201310023603000130036771000020038006500090038206400050039103100030039601400060
0399865000900405002001300414#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.ht
m#S#c#145#4#article#20#4#^rND^sBolton^nWD#^rND^sCull^nDL#^rND^sTaylor^nSM#^rND^s
Carsten^nCG 3rd#^rND^sSnyder^nBA#^rND^sSullivan^nTM#^rND^sYoukey^nJR#^rND^sLanga
n^nEM 3rd#^rND^sGray^nBH#The use of cryopreserved femoral vein grafts for hemodi
alysis access in patients at high risk for infection: a word of caution^len#J Va
sc Surg.#2#20020000#2002#36#464-8#20110200#a13v26n1.htm##
00586000000000277000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100015000940100
02100109012011700130030001300247710000200260065000900262064000500271031000300276
014000700279865000900286002001300295#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13
v26n1.htm#S#c#146#5#article#20#5#^rND^sGradman^nWS#^rND^sCohen^nW#^rND^sHaji-Agh
aii^nM#Arteriovenous fistula construction in the thigh with transposed superfici
al femoral vein: our initial experience^len#J Vasc Surg.#2#20010000#2001#33#968-
75#20110200#a13v26n1.htm##
00525000000000253000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760120113000940300
01600207710000200223065000900225064000500234031000400239014000600243865000900249
002001300258#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#c#147#6#arti
cle#20#6#^rND^sJackson^nMR#The superficial femoral-popliteal vein transposition 
fistula: description of a new vascular access procedure^len#J Am Coll Surg.#2#20
000000#2000#191#581-4#20110200#a13v26n1.htm##
00578000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100018000920100
02100110010002000131012007600151030001500227710000200242065000900244064000500253
031000200258014000600260865000900266002001300275#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a13v26n1.htm#S#c#148#7#article#20#7#^rND^sKapala^nA#^rND^sSzczesny^nW#^
rND^sStankiewicz^nW#^rND^sHryncewicz^nW#Vascular access for chronic dialysis usi
ng the superficial femoral vein^len#J Vasc Access.#2#20030000#2003#4#150-3#20110
200#a13v26n1.htm##
00594000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100016000920100
01600108010001500124010001700139012007400156030001300230710000200243065000900245
064000500254031000300259014000800262865000900270002001300279#v26n1#V:\Scielo\ser
ial\acb\v26n1\markup\a13v26n1.htm#S#c#149#8#article#20#8#^rND^sHuber^nTS#^rND^sO
zaki^nCK#^rND^sFlynn^nTC#^rND^sRoss^nEA#^rND^sSeeger^nJM#Use of superficial femo
ral vein for hemodialysis arteriovenous access^len#J Vasc Surg.#2#20000000#2000#
31#1038-41#20110200#a13v26n1.htm##
00668000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100019000760100020000950100
02100115010002000136010002300156010002100179012008000200030002600280710000200306
065000900308064000500317031000300322014000700325865000900332002001300341#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#c#150#9#article#20#9#^rND^sAnton
iou^nGA#^rND^sLazarides^nMK#^rND^sGeorgiadis^nGS#^rND^sSfyroeras^nGS#^rND^sNikol
opoulos^nES#^rND^sGiannoukas^nAD#Lower-extremity arteriovenous access for haemod
ialysis: a systematic review^len#Eur J Vasc Endovasc Surg.#2#20090000#2009#38#36
5-72#20110200#a13v26n1.htm##
00642000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100024000960100
01900120010002500139012013000164030001100294710000200305065000900307064000500316
031000300321014000600324865000900330002001300339#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a13v26n1.htm#S#c#151#10#article#20#10#^rND^sKinnaert^nP#^rND^sVereerstr
aeten^nP#^rND^sToussaint^nC#^rND^sVan Geertruyden^nJ#Nine years experience with 
internal arteriovenous fistulas for haemodialysis: a study of some factors influ
encing the results^len#Br J Surg.#2#19770000#1977#64#242-6#20110200#a13v26n1.htm
##
00543000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100015000950100
01500110012008100125030001100206710000200217065000900219064000500228031000300233
014000700236865000900243002001300252#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13
v26n1.htm#S#c#152#11#article#20#11#^rND^sReilly^nDT#^rND^sWood^nRF#^rND^sBell^nP
R#Prospective study of dialysis fistulas: problem patients and their treatment^l
en#Br J Surg.#2#19820000#1982#69#549-53#20110200#a13v26n1.htm##
00704000000000349000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100015000950100
02100110010001800131010001800149010001600167010001800183010001600201010001800217
01200620023503000090029771000020030606500090030806400050031703100040032201400060
0326865000900332002001300341#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.ht
m#S#c#153#12#article#20#12#^rND^sZibari^nGB#^rND^sRohr^nMS#^rND^sLandreneau^nMD#
^rND^sBridges^nRM#^rND^sDeVault^nGA#^rND^sPetty^nFH#^rND^sCostley^nKJ#^rND^sBrow
n^nST#^rND^sMcDonald^nJ#Complications from permanent hemodialysis vascular acces
s^len#Surgery.#2#19880000#1988#104#681-6#20110200#a13v26n1.htm##
00535000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780120112000940300
02800206710000200234065000900236064000500245031000300250014000600253865000900259
002001300268#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#c#154#13#art
icle#20#13#^rND^sMoncef^nG#Arterio-arterial graft interposition and superficial 
femoral vein transposition: an unusual vascular access^len#Saudi J Kidney Dis Tr
anspl.#2#20050000#2005#16#171-5#20110200#a13v26n1.htm##
00508000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100018000960120
07100114030001000185710000200195065000900197064000500206031000400211014000500215
865000900220002001300229#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#
c#155#14#article#20#14#^rND^sFee^nHJ Jr.#^rND^sGolding^nAL#Lower extremity ische
mia after femoral arteriovenous bovine shunts^len#Ann Surg.#2#19760000#1976#183#
42-5#20110200#a13v26n1.htm##
00580000000000289000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100018000920100
01500110010001800125012008900143030001000232710000200242065000900244064000500253
031000400258014000600262865000900268002001300277#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a13v26n1.htm#S#c#156#15#article#20#15#^rND^sFee^nHJ#^rND^sLevisman^nJ#^
rND^sDoud^nRB#^rND^sGolding^nAL#High-output congestive failure from femoral arte
riovenous shunts for vascular access^len#Ann Surg.#2#19760000#1976#183#321-3#201
10200#a13v26n1.htm##
00619000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100018000780100014000960100
01500110012015500125030001300280710000200293065000900295064000500304031000300309
014000700312865000900319002001300328#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13
v26n1.htm#S#c#157#16#article#20#16#^rND^sGradman^nWS#^rND^sLaub^nJ#^rND^sCohen^n
W#Femoral vein transposition for arteriovenous hemodialysis access: improved pat
ient selection and intraoperative measures reduce postoperative ischemia^len#J V
asc Surg.#2#20050000#2005#41#279-84#20110200#a13v26n1.htm##
00537000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100016000940120
10300110030001100213710000200224065000900226064000500235031000200240014000700242
865000900249002001300258#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#
c#158#17#article#20#17#^rND^sHolman^nE#^rND^sTaylor^nG#Problems in the dynamics 
of blood flow. II. Pressure relations at site of an arteriovenous fistula^len#An
giology.#2#19520000#1952#3#415-30#20110200#a13v26n1.htm##
00637000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100017000780100017000950100
01800112010001700130010001300147010001600160012009100176030000900267710000200276
065000900278064000500287031000300292014000600295865000900301002001300310#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#c#159#18#article#20#18#^rND^sSto
rey^nBG#^rND^sGeorge^nCR#^rND^sStewart^nJH#^rND^sTiller^nDJ#^rND^sMay^nJ#^rND^sS
heil^nAG#Embolic and ischemic complications after anastomosis of radial artery t
o cephalic vein^len#Surgery.#2#19690000#1969#66#325-7#20110200#a13v26n1.htm##
00672000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100021000780100017000990100
01500116010002000131010002700151010002100178012009800199030001500297710000200312
065000900314064000500323031000200328014000600330865000900336002001300345#v26n1#V
:\Scielo\serial\acb\v26n1\markup\a13v26n1.htm#S#c#160#19#article#20#19#^rND^sRam
acciotti^nE#^rND^sGalego^nSJ#^rND^sGomes^nM#^rND^sGoldenberg^nS#^rND^sDe Oliveir
a Gomes^nP#^rND^sPinto Ortiz^nJ#Fistula size and hemodynamics: an experimental m
odel in canine femoral arteriovenous fistulas^len#J Vasc Access.#2#20070000#2007
#8#33-43#20110200#a13v26n1.htm##
00554000000000277000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100019000940100
01500113012008400128030001700212710000200229065000900231064000500240031000300245
014000600248865000900254002001300263#v26n1#V:\Scielo\serial\acb\v26n1\markup\a13
v26n1.htm#S#c#161#20#article#20#20#^rND^sMinga^nTE#^rND^sFlanagan^nKH#^rND^sAllo
n^nM#Clinical consequences of infected arteriovenous grafts in hemodialysis pati
ents^len#Am J Kidney Dis.#2#20010000#2001#38#975-8#20110200#a13v26n1.htm##
00270000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660910009000680920007000770020013000847030
00300097#v26n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#o#1#1#text#1#201
10120#130208#a14v26n1.htm#66##
01072000000000421000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030001600102
03100030011803200020012106500090012301400090013203500100014112300020015101200720
01530120083002250100040003080100033003480700140003810700108005211170006006290720
00200635002001300637#v26n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#h#2#
1#text#1#ra#en#br1.1#1#4.0#ND#14#ACB820#nd#Acta Cir. Bras.#26#1#20110200#^f77^l7
8#0102-8650#1#Peer review, science, young investigators feelings and frustration
s^len#Revisão por pares, ciência, sentimentos e frustrações de jovens investigad
ores^lpt#^rND^1A01^nPaulo Roberto Barbosa^sEvora#^rND^1A02^nAndrea Carla^sCelott
o#University of Sao Paulo^iA01^1Ribeirao Preto Faculty of Medicine^2Head of the 
Department of Surgery and Anatomy^cRibeirao Preto^sSP^pBrazil#USP^iA02^1Ribeirao
 Preto Faculty of Medicine^2Department of Surgery and Anatomy^cRibeirao Preto^sS
P^pBrazil#other#9#a14v26n1.htm##
01086000000000421000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030001600102
03100030011803200020012106500090012301400090013203500100014112300020015101200790
01530120090002320100040003220100033003620700140003950700108005351170006006430720
00200649002001300651#v26n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#f#3#
1#text#1#ra#en#br1.1#1#4.0#ND#14#ACB820#nd#Acta Cir. Bras.#26#1#20110200#^f77^l7
8#0102-8650#1#<b>Peer review, science, young investigators feelings and frustrat
ions</b>^len#<b>Revisão por pares, ciência, sentimentos e frustrações de jovens 
investigadores</b>^lpt#^rND^1A01^nPaulo Roberto Barbosa^sEvora#^rND^1A02^nAndrea
 Carla^sCelotto#University of Sao Paulo^iA01^1Ribeirao Preto Faculty of Medicine
^2Head of the Department of Surgery and Anatomy^cRibeirao Preto^sSP^pBrazil#USP^
iA02^1Ribeirao Preto Faculty of Medicine^2Department of Surgery and Anatomy^cRib
eirao Preto^sSP^pBrazil#other#9#a14v26n1.htm##
01191000000000433000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660640018000680710003000860400003000890010
00600092042000200098120000400100121000300104049000700107158000300114030001500117
03100030013203200020013506500090013701400090014603500100015512300020016501200720
01670120083002390100040003220100033003620700142003950700110005371170006006470720
00200653002001300655008008900668#v26n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n
1.htm#S#l#4#1#text#1#^mJan./Feb.^a2011#ra#en#br1.1#1#4.0#14#ACB820#nd#Acta cir. 
bras#26#1#20110200#^f77^l78#0102-8650#1#Peer review, science, young investigator
s feelings and frustrations^len#Revisão por pares, ciência, sentimentos e frustr
ações de jovens investigadores^lpt#^rND^1A01^nPaulo Roberto Barbosa^sEvora#^rND^
1A02^nAndrea Carla^sCelotto#^iA01^1University of Sao Paulo^2Ribeirao Preto Facul
ty of Medicine^3Head of the Department of Surgery and Anatomy^cRibeirao Preto^sS
P^pBrazil#^iA02^1USP^2Ribeirao Preto Faculty of Medicine^3Department of Surgery 
and Anatomy^cRibeirao Preto^sSP^pBrazil#other#9#a14v26n1.htm#Internet^ihttp://ww
w.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502011000100014##
00320000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704009200069002001300161#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#5#1#text#53#<p align="right"><font fac
e="Verdana" size="2"><b>14 - POINT OF VIEW</b></font></p>     ^cY#a14v26n1.htm##
00265000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704003700069002001300106#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#6#2#text#53#<p align="left">&nbsp;</p>
       ^cY#a14v26n1.htm##
00359000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704013100069002001300200#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#7#3#text#53#<p><font face="Verdana" si
ze="4"><B>Peer review, science, young investigators    feelings and frustrations
 </B></font></p>     ^cY#a14v26n1.htm##
00250000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704002200069002001300091#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#8#4#text#53#<p>&nbsp;</p>     ^cY#a14v
26n1.htm##
00397000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704016900069002001300238#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#9#5#text#53#<p><b><font face="Verdana"
 size="3">Revis&atilde;o por pares, ci&ecirc;ncia, sentimentos    e frustra&cced
il;&otilde;es de jovens investigadores </font></b></p>     ^cY#a14v26n1.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704002200070002001300092#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#10#6#text#53#<p>&nbsp;</p>     ^cY#a14
v26n1.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704002200070002001300092#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#11#7#text#53#<p>&nbsp;</p>     ^cY#a14
v26n1.htm##
00369000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704014000070002001300210#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#12#8#text#53#<p><font face="Verdana" s
ize="2"><B>Paulo Roberto Barbosa Evora<SUP>I</SUP>, Andrea    Carla Celotto<SUP>
II</SUP> </B> </font></p>      ^cY#a14v26n1.htm##
00444000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704021500070002001300285#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#13#9#text#53#<p><font face="Verdana" s
ize="2"><SUP>I</SUP>Full Professor, Head of the Department    of Surgery and Ana
tomy, Ribeirao Preto Faculty of Medicine, University of Sao    Paulo (USP), Ribe
irao Preto-SP, Brazil.    ^cY#a14v26n1.htm##
00443000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704021300071002001300284#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#14#10#text#53#<br>   </font><font face
="Verdana" size="2"><SUP>II</SUP>PhD, Postdoctoral, Department    of Surgery and
 Anatomy, Ribeirao Preto Faculty of Medicine, USP, Ribeirao Preto-SP,    Brazil.
 <B> </B></font></p>     ^cY#a14v26n1.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704010400071002001300175#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#15#11#text#53#<p><font face="Verdana" 
size="2"><a name="top"></a><a href="#end">Correspondence</a></font></p>     ^cY#
a14v26n1.htm##
00274000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004400071002001300115#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#16#12#text#53#<p>&nbsp;</p> <hr size="
1" noshade>     ^cY#a14v26n1.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#17#13#text#53#<p>&nbsp;</p>     ^cY#a1
4v26n1.htm##
00252000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002200071002001300093#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#18#14#text#53#<p>&nbsp;</p>     ^cY#a1
4v26n1.htm##
00304000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007400071002001300145#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#19#15#text#53#<p><font face="Verdana" 
size="2"><b>Brief history</b> </font></p>     ^cY#a14v26n1.htm##
02305000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704207500071002001302146#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#20#16#text#53#<p><font face="Verdana" 
size="2"> David Flaxbart Chemistry Librarian from University    of Texas, Austin
, commenting about the book <I>&quot;Editorial Peer Review:    Its Strength and 
Weaknesses,&quot;</I><SUP>1</SUP> wrote by Ann Weller<SUP>2</SUP>,    that peer 
review can be defined simply as the process by which journal editors    solicit 
evaluations of submitted articles from outside experts who remain anonymous    t
o the authors. The role of journals as gatekeepers to the scientific record    d
ates to the 17th century, when the Royal Society's council was instructed to    
review submissions to its <I>Philosophical Transactions</I>. But the modern    p
rocess of &quot;blind&quot; peer review is much more recent. Until the mid-20th 
   century many papers were approved solely by a journal's editors rather than  
  independent reviewers, and for some major journals this is still the case. The
    explosion of scientific output after World War II strained the review proces
s,    significantly extending the lag times between submission and publication. 
Peer    review has always had to strike a balance between speed and quality. Eac
h end    of this continuum has its champions. How the question plays out depends
 largely    on the &quot;culture&quot; of a particular scientific discipline. In
 fast-moving    fields like physics, today's breakthrough is tomorrow's old news
, and speed    is preferred over editorial thoroughness. This led physicists to 
create the    preprint system, whereby pre-publication copies of papers under re
view were    traded among scientists, essentially relegating their journals to a
rchival repositories    rather than front-line communication mechanisms. This pr
eprint culture was quickly    and enthusiastically converted to an &quot;e-print
&quot; system pioneered by    Paul Ginsparg at Los Alamos in the early 90s. Yet 
in other fields, such as chemistry,    preprints did not catch on and journals r
emain supreme, although rapid-publication    &quot;letters&quot; journals steppe
d in to speed up the process. </font></p>      ^cY#a14v26n1.htm##
00312000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704008200071002001300153#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#21#17#text#53#<p><font face="Verdana" 
size="2"><B> Peer review methods</B> </font></p>      ^cY#a14v26n1.htm##
01402000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704117200071002001301243#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#22#18#text#53#<p><font face="Verdana" 
size="2"> In open peer review, the identities of both    authors and reviewers a
re revealed, affording the authors the ability to identify    the reviewers' com
ments to a person. Even though this might be an equitable    strategy to prevent
 unfair rejections, this process has no safeguard against    unfair acceptance o
f papers - reviewers, and especially newcomers, may feel    pressured into accep
ting a mediocre paper from a more established lab in fear       of future repris
als. Single-blind peer review (SBPR), in which the reviewer    knows the identit
y of the author but not vice versa, is the currently accepted    practice. Becau
se SBPR can be vulnerable to sexism and nepotism<SUP>1</SUP>    its ethical foun
dations have come under criticism; the method is frequently    recognized to be 
biased against new ideas, women, young scientists, career changers,    and schol
ars from less prestigious universities and/or from developing countries<SUP>3</S
UP>.    Generally, two policies have been proposed to eliminate bias from the pe
er-review    process: open peer review and doubleblind peer review (DBPR)<SUP>4<
/SUP>. </font></p>      ^cY#a14v26n1.htm##
00325000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704009500071002001300166#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#23#19#text#53#<p><font face="Verdana" 
size="2"><B> Effects of editorial peer review</B> </font></p>      ^cY#a14v26n1.
htm##
02551000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704232100071002001302392#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#24#20#text#53#<p><font face="Verdana" 
size="2"> Editorial peer review is widely used to select    submissions to journ
als for publication and is presumed to improve their usefulness.    Sufficient r
esearch on peer review has been published to consider a synthesis    of its effe
cts. To examine the evidence of the effects of editorial peer-review    processe
s in biomedical journals, Jefferson <I>et al.</I><SUP>5 </SUP>conducted    elect
ronic and full-text searches of private and public databases to June 2000    and
 corresponded with the World Association of Medical Editors, European Associatio
n    of Science Editors, Council of Science Editors, and researchers in the fiel
d    to locate comparative studies assessing the effects of any stage of the pee
r-review    process that made some attempt to control for confounding. Nineteen 
of 135 identified    studies fulfilled our criteria. Because of the diversity of
 study questions,    methods, and outcomes, they did not pool results. The revie
w resulted in nine    studies considered the effects of concealing reviewer/auth
or identity. Four    studies suggested that concealing reviewer or author identi
ty affected review    quality (mostly positively); however, methodological limit
ations make their    findings ambiguous, and other studies' results were either 
negative or inconclusive.    One study suggested that a statistical checklist ca
n improve report quality,    but another failed to find an effect of publishing 
another checklist. One study    found no evidence that training referees improve
s performance and another showed    increased interrater reliability; both used 
open designs, making interpretation    difficult. Two studies of how journals co
mmunicate with reviewers did not demonstrate    any effect on review quality. On
e study failed to show reviewer bias, but the    findings may not be generalizab
le. One nonrandomized study compared the quality    of articles published in pee
r-reviewed vs other journals. Two studies showed    that editorial processes mak
e articles more readable and improve the quality    of reporting, but the findin
gs may have limited generalizability to other journals.    The authors concluded
 that editorial peer review, although widely used, is largely    untested and it
s effects are uncertain<SUP>6</SUP>. </font></p>     ^cY#a14v26n1.htm##
00847000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704061700071002001300688#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#25#21#text#53#<p><font face="Verdana" 
size="2"> Five years later the same author, trough a wide    methanalisys conclu
ded that little empirical evidence is available to support    the use of editori
al peer review as a mechanism to ensure quality of biomedical    research. Howev
er, the methodological problems in studying peer review are many    and complex.
 At present, the absence of evidence on efficacy and effectiveness    cannot be 
interpreted as evidence of their absence. A large, well-funded programme    of r
esearch on the effects of editorial peer review should be urgently launched<SUP>
5</SUP>.    </font></p>      ^cY#a14v26n1.htm##
00340000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704011000071002001300181#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#26#22#text#53#<p><font face="Verdana" 
size="2"><B> Peer review and young investigators feelings</B>    </font></p>    
  ^cY#a14v26n1.htm##
00953000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704072300071002001300794#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#27#23#text#53#<p><font face="Verdana" 
size="2"> Most trainees and young scientists experience    their first encounter
s with the peer review process in the role of an author.    Non-acceptance of ma
nuscripts is unfortunate, but occurs frequently, and is    occasionally perceive
d as a personal rejection. If trainees understand the tasks    and roles of auth
ors, editors, and reviewers, they may be able to appreciate    the feedback mech
anism of peer review. In addition, they can recognize that    the primary goal o
f the feedback is to assess the research and not the researcher.    As trainees 
have limited exposure as authors, editors often do not know the    trainees and 
their area of expertise<SUP>7-9</SUP>. </font></p>     ^cY#a14v26n1.htm##
01019000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704078900071002001300860#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#28#24#text#53#<p> <font face="Verdana"
 size="2">&quot;As far as we know this is the first study    demonstrating the&#
133;&quot; This kind of phrase became a kind of jargon, it    is dangerous becau
se it may suggest ignorance, scientific immaturity, or even    sound like preten
tious. Once again I had this reaction when reviewing a paper    on a quiet Sunda
y. But I was struck by doubt about young researchers. With this    romantic doub
t turned to Google and MEDLINE. A Google search showed a strong    correlation b
etween peer review, and young researcher grants. A MEDLINE search    showed no p
aper and I had the desire to write for the first time endeavored    to correlate
 the peer review system with the frustration of young researchers.    But I'm no
t getting any younger... </font></p>     ^cY#a14v26n1.htm##
00779000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704054900071002001300620#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#29#25#text#53#<p><font face="Verdana" 
size="2"> Many years ago, as a young researcher, I wrote    this kind of concept
 and one reviewer taught me a great lesson: &quot;it would    be a first study, 
but is it important or relevant?&quot; I am writing this comment    because I am
 sure that it is a great kind of scientific advice. I incorporated    it to my b
asic directions on research. It's a    pity I have not known this reviewer to sa
y thanks. This is a great peculiarity    of science and of the peer review syste
m for paper evaluations. </font></p>     ^cY#a14v26n1.htm##
01107000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704087700071002001300948#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#30#26#text#53#<p><font face="Verdana" 
size="2"> Approving a paper is a pleasurable activity,    but rejection implies 
some degree of emotional distress. However, when the revised    paper is publish
ed and indexed the reviewer get a little pride in his anonymous    contribution.
 This is one of the best feelings that a scientist can have. For    this reason 
is that the activity of peer review, often a hard, is gratifying,    but I neede
d to express my concern, once again, with the paper rejection frustrations.    W
ith all the criticism possible peer review is the best, most democratic and    h
onest evaluation system. The reviewers, in addition to their anonymous participa
tion    in publications, have a great opportunity to confront their opinions wit
h other    &quot;anonymous&quot; colleagues. Surely, this is one of the most rew
arding    ways of doing science. </font></p>     ^cY#a14v26n1.htm##
00610000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704038000071002001300451#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#31#27#text#53#<p><font face="Verdana" 
size="2"> This text is a tribute to every young researcher    and why not to eve
ry researcher and his sadness at the difficulties in publishing    a paper? It i
s a particular tribute to our students of graduation and post-graduation    many
 times that I share their frustrations when one paper, the result of hard    wor
k, is rejected. </font></p>     ^cY#a14v26n1.htm##
00253000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002300071002001300094#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#32#28#text#53#<p>&nbsp;</p>      ^cY#a
14v26n1.htm##
00325000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704009500071002001300166#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#33#29#text#53#<p> <font face="Verdana"
 size="2"><B><font size="3">References</font></B> </font></p>      ^cY#a14v26n1.
htm##
00479000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704023500073002001300308#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#p#34#30#text#53#1#<p><font f
ace="Verdana" size="2">1. Weller Ann C. Editorial peer review: its strength    a
nd weaknesses. (ASIST monograph series) Medford NJ: American Society for Informa
tion    Science and Technology, 2001. ISBN 1-57387-100-1.    ^cY#a14v26n1.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#35#31#text#53# </font></p>     ^cY#a14
v26n1.htm##
00573000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704032900073002001300402#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#p#36#32#text#53#2#<p><font f
ace="Verdana" size="2">2. Flaxbart D. Book Reviews Weller, Ann C. Editorial    p
eer review: its strength and weaknesses. Issues in Science and Technology Librar
ianship,    Summer. 2001. <a href="http://www.istl.org/01-summer/review.html" ta
rget="_blank">http://www.istl.org/01-summer/review.html</a></font></p>     ^cY#a
14v26n1.htm##
00370000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704012600073002001300199#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#p#37#33#text#53#3#<p><font f
ace="Verdana" size="2">3. Wenneras C, Wold A. Nepotism and sexism in    peer-rev
iew. Nature. 1997;387:341_3.    ^cY#a14v26n1.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#38#34#text#53# </font></p>     ^cY#a14
v26n1.htm##
00516000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704027200073002001300345#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#p#39#35#text#53#4#<p><font f
ace="Verdana" size="2">4. Abate T. What's the verdict on peer review?    Availab
le from <a href="http://www.columbia.edu/cu/21stC/issue-1.1/peer.htm" target="_b
lank">http://www.columbia.edu/cu/21stC/issue-1.1/peer.htm</a>.    1996. Accessed
 20 July 2005.    ^cY#a14v26n1.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#40#36#text#53# </font></p>     ^cY#a14
v26n1.htm##
00414000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704017000073002001300243#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#p#41#37#text#53#5#<p><font f
ace="Verdana" size="2">5. Jefferson T, Alderson P, Wager E, Davidoff    F. Effec
ts of editorial peer review: a systematic review. JAMA. 2002;287:2784-6.    ^cY#
a14v26n1.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002400071002001300095#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#42#38#text#53#    </font></p>     ^cY#
a14v26n1.htm##
00390000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704014600073002001300219#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#p#43#39#text#53#6#<p><font f
ace="Verdana" size="2">6. Mainguy G, Motamedi MR, Mietchen D. Peer review-the   
 newcomers' perspective. PLoS Biol. 2005;3:e326.    ^cY#a14v26n1.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#44#40#text#53# </font></p>     ^cY#a14
v26n1.htm##
00471000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704022700073002001300300#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#p#45#41#text#53#7#<p><font f
ace="Verdana" size="2">7. Jefferson T, Rudin M, Brodney Folse S, Davidoff    F. 
Editorial peer review for improving the quality of reports of biomedical    stud
ies. Cochrane Database Syst Rev. 2007;2:MR000016.    ^cY#a14v26n1.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#46#42#text#53# </font></p>     ^cY#a14
v26n1.htm##
00392000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704014800073002001300221#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#p#47#43#text#53#8#<p><font f
ace="Verdana" size="2">8. Pernetta AP. Mentors could support a student    review
er database (Comment). Nature. 2007;448(7150):129.    ^cY#a14v26n1.htm##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#48#44#text#53# </font></p>     ^cY#a14
v26n1.htm##
00483000000000157000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068888000200071704023900073002001300312#v26
n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#p#49#45#text#53#9#<p><font f
ace="Verdana" size="2">9. Aronsky D, Haux R, Leong TY, McCray A. The    student 
editorial board of methods of information in medicine-an opportunity    to educa
te tomorrow's peer reviewers. Methods Inf Med. 2007;46:623-4.    ^cY#a14v26n1.ht
m##
00251000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002100071002001300092#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#50#46#text#53# </font></p>     ^cY#a14
v26n1.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704002400071002001300095#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#51#47#text#53#<p>&nbsp; </p>      ^cY#
a14v26n1.htm##
00385000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704015500071002001300226#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#52#48#text#53#<p><font face="Verdana" 
size="2"><B><a name="end"></a><a href="#top"><img src="/img/revistas/acb/v26n1/s
eta.gif" border="0"></a>Correspondence</B>:    ^cY#a14v26n1.htm##
00267000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704003700071002001300108#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#53#49#text#53#<br>   Paulo Roberto B. 
Evora    ^cY#a14v26n1.htm##
00268000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704003800071002001300109#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#54#50#text#53#<br>   Rua Rui Barbosa, 
367/15    ^cY#a14v26n1.htm##
00288000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704005800071002001300129#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#55#51#text#53#<br>   14015-120 Ribeir&
atilde;o Preto _ SP Brasil    ^cY#a14v26n1.htm##
00272000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704004200071002001300113#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#56#52#text#53#<br>   Phone/Fax: (55 16
)3602-2497    ^cY#a14v26n1.htm##
00319000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704008900071002001300160#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a14v26n1.htm#S#p#57#53#text#53#<br>   <a href="mailto:p
rbevora@fmrp.usp.br">prbevora@fmrp.usp.br</a></font></p>     ^cY#a14v26n1.htm##
00541000000000253000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690160020000710180055000910250
02300146066001200169062005600181065000900237064000500246069001400251865000900265
002001300274#v26n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#c#58#1#text#
9#1#^rND^sWeller Ann^nC#Editorial peer review: its strength and weaknesses^len#A
SIST monograph series#Medford^eNJ#American Society for Information Science and T
echnology#20010000#2001#1-57387-100-1#20110200#a14v26n1.htm##
00516000000000217000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690160018000710180131000890650
00900220064000500229037004200234865000900276002001300285#v26n1#V:\Scielo\serial\
acb\v26n1\markup\a14v26n1.htm#S#c#59#2#text#9#2#^rND^sFlaxbart^nD#Book Reviews W
eller, Ann C. Editorial peer review: its strength and weaknesses. Issues in Scie
nce and Technology Librarianship^len#20010000#2001#http://www.istl.org/01-summer
/review.html#20110200#a14v26n1.htm##
00464000000000265000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100018000710100014000890120
03900103030000800142710000200150065000900152064000500161031000400166014000600170
865000900176002001300185#v26n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#
c#60#3#text#9#3#^rND^sWenneras^nC#^rND^sWold^nA#Nepotism and sexism in peer-revi
ew^len#Nature.#2#19970000#1997#387#341_3#20110200#a14v26n1.htm##
00478000000000241000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690160016000710180039000870370
05200126065000900178064000500187110000900192109001300201865000900214002001300223
#v26n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#c#61#4#text#9#4#^rND^sAb
ate^nT.#What's the verdict on peer review?^len#http://www.columbia.edu/cu/21stC/
issue-1.1/peer.htm#19960000#1996#20050720#20 July 2005#20110200#a14v26n1.htm##
00544000000000289000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100019000710100018000900100
01500108010001800123012005800141030000600199710000200205065000900207064000500216
031000400221014000700225865000900232002001300241#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a14v26n1.htm#S#c#62#5#text#9#5#^rND^sJefferson^nT#^rND^sAlderson^nP#^rN
D^sWager^nE#^rND^sDavidoff^nF#Effects of editorial peer review: a systematic rev
iew^len#JAMA.#2#20020000#2002#287#2784-6#20110200#a14v26n1.htm##
00502000000000277000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100017000710100019000880100
01800107012004300125030001100168710000200179065000900181064000500190031000200195
014000500197865000900202002001300211#v26n1#V:\Scielo\serial\acb\v26n1\markup\a14
v26n1.htm#S#c#63#6#text#9#6#^rND^sMainguy^nG#^rND^sMotamedi^nMR#^rND^sMietchen^n
D#Peer review-the newcomers' perspective^len#PLoS Biol.#2#20050000#2005#3#e326#2
0110200#a14v26n1.htm##
00598000000000289000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100019000710100015000900100
02300105010001800128012008500146030002800231710000200259065000900261064000500270
031000200275014000900277865000900286002001300295#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a14v26n1.htm#S#c#64#7#text#9#7#^rND^sJefferson^nT#^rND^sRudin^nM#^rND^s
Brodney Folse^nS#^rND^sDavidoff^nF#Editorial peer review for improving the quali
ty of reports of biomedical studies^len#Cochrane Database Syst Rev.#2#20070000#2
007#2#MR000016#20110200#a14v26n1.htm##
00479000000000265000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100019000710120064000900300
00800154710000200162065000900164064000500173031000400178032000500182014000400187
865000900191002001300200#v26n1#V:\Scielo\serial\acb\v26n1\markup\a14v26n1.htm#S#
c#65#8#text#9#8#^rND^sPernetta^nAP#Mentors could support a student reviewer data
base (Comment)^len#Nature.#2#20070000#2007#448#7150#129#20110200#a14v26n1.htm##
00610000000000289000450000400060000070200470000670500020005370600020005570000030
00577010002000607090005000627080002000671180002000690100017000710100014000880100
01600102010001600118012012200134030001700256710000200273065000900275064000500284
031000300289014000600292865000900298002001300307#v26n1#V:\Scielo\serial\acb\v26n
1\markup\a14v26n1.htm#S#c#66#9#text#9#9#^rND^sAronsky^nD#^rND^sHaux^nR#^rND^sLeo
ng^nTY#^rND^sMcCray^nA#The student editorial board of methods of information in 
medicine-an opportunity to educate tomorrow's peer reviewers^len#Methods Inf Med
.#2#20070000#2007#46#623-4#20110200#a14v26n1.htm##
00270000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660910009000680920007000770020013000847030
00300097#v26n1#V:\Scielo\serial\acb\v26n1\markup\a15v26n1.htm#S#o#1#1#text#1#201
10120#130210#a15v26n1.htm#30##
00537000000000337000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030001600102
03100030011803200020012106500090012301400090013203500100014112300020015101200330
0153002001300186#v26n1#V:\Scielo\serial\acb\v26n1\markup\a15v26n1.htm#S#h#2#1#te
xt#1#le#pt#br1.1#1#4.0#ND#15#ACB980#nd#Acta Cir. Bras.#26#1#20110200#^f79^l79#01
02-8650#2#Carta do editor aos leitores^lpt#a15v26n1.htm##
00544000000000337000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660710003000680400003000710010006000740420
00200080120000400082038000300086121000300089049000700092158000300099030001600102
03100030011803200020012106500090012301400090013203500100014112300020015101200400
0153002001300193#v26n1#V:\Scielo\serial\acb\v26n1\markup\a15v26n1.htm#S#f#3#1#te
xt#1#le#pt#br1.1#1#4.0#ND#15#ACB980#nd#Acta Cir. Bras.#26#1#20110200#^f79^l79#01
02-8650#2#<b>Carta do editor aos leitores</b>^lpt#a15v26n1.htm##
00652000000000349000450000400060000070200470000670500020005370600020005570000020
00577010002000597090005000617080002000660640018000680710003000860400003000890010
00600092042000200098120000400100121000300104049000700107158000300114030001500117
03100030013203200020013506500090013701400090014603500100015512300020016501200330
0167002001300200008008900213#v26n1#V:\Scielo\serial\acb\v26n1\markup\a15v26n1.ht
m#S#l#4#1#text#1#^mjan./fev.^a2011#le#pt#br1.1#1#4.0#15#ACB980#nd#Acta cir. bras
#26#1#20110200#^f79^l79#0102-8650#2#Carta do editor aos leitores^lpt#a15v26n1.ht
m#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-8650201
1000100015##
00332000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704010400069002001300173#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#5#1#text#26#<p align="right"><B><font 
face="Verdana" size="2">CARTA DO EDITOR AOS LEITORES</font></B>  </p>     ^cY#a1
5v26n1.htm##
00264000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704003600069002001300105#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#6#2#text#26#<p align="right">&nbsp;</p
>     ^cY#a15v26n1.htm##
00266000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704003800069002001300107#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#7#3#text#26#<p align="right">&nbsp; </
p>      ^cY#a15v26n1.htm##
00371000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704014300069002001300212#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#8#4#text#26#<p><font face="Verdana" si
ze="2"><I>ACTA CIR&Uacute;RGICA BRASILEIRA - APENAS    A IMPRESS&Atilde;O ELETR&
Ocirc;NICA </I> </font></p>      ^cY#a15v26n1.htm##
00531000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000500061708000300066704030300069002001300372#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#9#5#text#26#<p><font face="Verdana" si
ze="2"> Todos n&oacute;s que trabalhamos para publicar    uma revista cient&iacu
te;fica, que editamos e distribu&iacute;mos, esperamos    que os artigos sejam a
preciados, lidos linha a linha e citados. Tenham f&aacute;cil    visibilidade e 
acessibilidade. </font></p>      ^cY#a15v26n1.htm##
00550000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704032100070002001300391#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#10#6#text#26#<p><font face="Verdana" s
ize="2"> A edi&ccedil;&atilde;o gr&aacute;fica tem um    custo no que se refere 
a diagrama&ccedil;&atilde;o e formata&ccedil;&atilde;o    dos artigos, a arte fi
nal, o n&uacute;mero de p&aacute;ginas e a quantidade    dos fasc&iacute;culos. 
Depois, o custo da remessa postal. </font></p>      ^cY#a15v26n1.htm##
00376000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704014700070002001300217#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#11#7#text#26#<p><font face="Verdana" s
ize="2"> Na edi&ccedil;&atilde;o eletr&ocirc;nica apenas    a formata&ccedil;&at
ilde;o e arte final. </font></p>      ^cY#a15v26n1.htm##
00609000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704038000070002001300450#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#12#8#text#26#<p><font face="Verdana" s
ize="2"> A SciELO recebe os artigos formatados e os torna    acess&iacute;veis <
I>online</I> em formato HTML para leitura, e PDF para a impress&atilde;o    fiel
 do artigo original, inclusive com as fotos coloridas. A impress&atilde;o    em 
cores no papel tem um custo elevado. As fotos em preto e branco perdem muito    
em qualidade. </font></p>      ^cY#a15v26n1.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000500062708000300067704016200070002001300232#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#13#9#text#26#<p><font face="Verdana" s
ize="2"> O fasc&iacute;culo enviado ocupa espa&ccedil;o.    Fica a d&uacute;vida
: quantos mant&eacute;m a revista ? </font></p>      ^cY#a15v26n1.htm##
00370000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704014000071002001300211#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#14#10#text#26#<p><font face="Verdana" 
size="2"> A SciELO permite acesso r&aacute;pido a todos    os n&uacute;meros a p
artir de 1997. </font></p>      ^cY#a15v26n1.htm##
00650000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704042000071002001300491#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#15#11#text#26#<p><font face="Verdana" 
size="2"> Permite acesso r&aacute;pido na busca de autores    e de assuntos. Per
mite acesso a cole&ccedil;&atilde;o da biblioteca eletr&ocirc;nica    oferecendo
 a lista alfab&eacute;tica de 242 peri&oacute;dicos listados at&eacute;    novem
bro de 2010. Dados atualizados podem ser obtidos em <B><U><a href="http://www.sc
ielo.br" target="_blank">www.scielo.br</a></U></B>.    </font></p>      ^cY#a15v
26n1.htm##
00326000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704009600071002001300167#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#16#12#text#26#<p> <font face="Verdana"
 size="2"><B>Relat&oacute;rios de uso do site </B> </font></p>      ^cY#a15v26n1
.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704009300071002001300164#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#17#13#text#26#<p><font face="Verdana" 
size="2"> * <U>Acessos aos peri&oacute;dicos</U> </font></p>     ^cY#a15v26n1.ht
m##
00324000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704009400071002001300165#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#18#14#text#26#<p><font face="Verdana" 
size="2"> * <U>Acessos aos artigos por idioma</U> </font></p>     ^cY#a15v26n1.h
tm##
00323000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704009300071002001300164#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#19#15#text#26#<p><font face="Verdana" 
size="2"> * <U>Acessos aos fasc&iacute;culos</U> </font></p>     ^cY#a15v26n1.ht
m##
00314000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704008400071002001300155#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#20#16#text#26#<p><font face="Verdana" 
size="2"> * <U>Acessos aos artigos</U> </font></p>      ^cY#a15v26n1.htm##
00324000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704009400071002001300165#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#21#17#text#26#<p> <font face="Verdana"
 size="2"><B>Relat&oacute;rio de co-autoria </B> </font></p>      ^cY#a15v26n1.h
tm##
00305000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007500071002001300146#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#22#18#text#26#<p><font face="Verdana" 
size="2"> * <U>Coautoria </U> </font></p>      ^cY#a15v26n1.htm##
00351000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704012100071002001300192#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#23#19#text#26#<p> <font face="Verdana"
 size="2"><B>Relat&oacute;rios de cita&ccedil;&otilde;es    de revistas</B> </fo
nt></p>      ^cY#a15v26n1.htm##
00306000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704007600071002001300147#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#24#20#text#26#<p><font face="Verdana" 
size="2"> * <U>Dados fonte </U> </font></p>     ^cY#a15v26n1.htm##
00348000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704011800071002001300189#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#25#21#text#26#<p><font face="Verdana" 
size="2"> * <U>Fator de impacto em um per&iacute;odo de    dois anos </U> </font
></p>     ^cY#a15v26n1.htm##
00353000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704012300071002001300194#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#26#22#text#26#<p><font face="Verdana" 
size="2"> * <U>Fator de impacto em um per&iacute;odo de    tr&ecirc;s anos</U> <
/font></p>     ^cY#a15v26n1.htm##
00312000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704008200071002001300153#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#27#23#text#26#<p><font face="Verdana" 
size="2"> * <U>Vida m&eacute;dia </U> </font></p>     ^cY#a15v26n1.htm##
00327000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704009700071002001300168#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#28#24#text#26#<p><font face="Verdana" 
size="2"> * <U>Cita&ccedil;&otilde;es recebidas </U> </font></p>     ^cY#a15v26n
1.htm##
00329000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704009900071002001300170#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#29#25#text#26#<p><font face="Verdana" 
size="2"> * <U>Cita&ccedil;&otilde;es concedidas</U> </font></p>       ^cY#a15v2
6n1.htm##
00379000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000500063708000300068704014900071002001300220#v26n1#V:\Scielo
\serial\acb\v26n1\markup\a15v26n1.htm#S#p#30#26#text#26#<p> <font face="Verdana"
 size="2"><U>A partir de 2011 a ACTA ter&aacute; apenas    a edi&ccedil;&atilde;
o eletr&ocirc;nica.</U> </font></p>      ^cY#a15v26n1.htm##
00274000000000169000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690910009000710920007000800020013000877030
00400100#v26n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#o#1#1#article#1#
20110408#112138#a05v26n1.htm#188##
04850000000000829000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400090014103500100015001200680
01600120074002280100037003020100038003390100039003770100054004160100034004700100
03700504010004900541010003400590010003400624070006800658070007500726070008500801
07000740088607000480096007001050100807000700111307000750118308311130125808500080
23710850022023790850026024010850044024270850030024710850017025010831240025180850
00803758085002203766085003603788085004203824085003103866085001803897117000603915
07200030392105800060392411200090393011100140393911600090395311500190396211400090
3981113001703990002001304007#v26n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.ht
m#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#GRA#05#ACB720#nd#Acta Cir. Bras.#26#1
#20110200#^f19^l24#0102-8650#Angiogenic activity of Calendula officinalis flower
s L. in rats^len#Atividade angiogênica das flores da Calendula officinalis L. em
 ratos^lpt#^rND^1A01^nLeila Maria Leal^sParente#^rND^1A02^nMaria Auxiliadora^sAn
drade#^rND^1A03^nLuiz Augusto Batista^sBrito#^rND^1A04^nVeridiana Maria Brianezi
 Dignani de^sMoura#^rND^1A05^nMarina Pacheco^sMiguel#^rND^1A06^nRuy de Souza^sLi
no-Júnior#^rND^1A07^nLeonice Faustino Manrique^sTresvenzol#^rND^1A07^nJosé Reali
no de^sPaula#^rND^1A08^nNeusa Margarida^sPaulo#UFG^iA01^1Veterinary School^2Depa
rtment of Pathology^cGoias^pBrazil#UFG^iA02^1Veterinary School^2Preventive Medic
ine Department^cGoias^pBrazil#UFG^iA03^1Veterinary Medicine School^2Animal Patho
logy Department^cGoias^sGO^pBrazil#UFG^iA04^1Veterinary Medicine School^2Patholo
gy Department^cGoias^pBrazil#UFG^iA05^1Biomedicine Department^cGoias^pBrazil#UFG
^iA06^1Institute of Tropical Pathology and Public Health^2General Pathology Depa
rtment^cGoias^pBrazil#UFG^iA07^1Pharmacy School^2Natural Products Laboratory^cGo
ias^pBrazil#UFG^iA08^1Veterinary School^2Veterinary Medicine Department^cGoias^p
Brazil#^len^aPurpose: In this work, angiogenic activity of Calendula officinalis
 L. (Asteraceae) ethanolic extract and dichloromethane and hexanic fractions wer
e evaluated, considering medicinal properties, especially healing activity, are 
attributed to this plant. Methods: Models using 36 rats and 90 embryonated eggs 
were used to evaluate healing and angiogenic activities of extracts and fraction
s of the plant, through the induction of skin wounds and the chorioallantoic mem
brane, respectively. The effect of vascular proliferation was also tested from t
he study to verify the intensity of expression of vascular endothelial growth fa
ctor (VEGF) in cutaneous wounds in rats. Results: The angiogenic activity of the
 extract and the fractions was evidenced in both experimental models. It was ver
ified that this effect is not directly related to the expression of VEGF and it 
could be associated to other pro-angiogenic factors. Conclusion: The healing act
ivity referred to C. officinalis is related, among other factors, to its positiv
e effect on angiogenesis, characterized by the induction of neovascularization.#
^dnd^i1#^tm^len^kCalendula^i1#^tm^len^kWound Healing^i1#^tm^len^kNeovascularizat
ion, Physiologic^i1#^tm^len^kPlants, Medicinal^i1#^tm^len^kRats^i1#^lpt^aObjetiv
o: Neste trabalho a atividade sobre a angiogênese do extrato etanólico (EEC) e d
as frações diclorometano e hexânica das flores de Calendula officinalis L. (Aste
raceae) cultivada no Brasil foram avaliados, visto que propriedades medicinais t
êm sido atribuídas às flores da planta, destacando-se a atividade cicatrizante. 
Métodos: Modelos utilizando 36 ratos e 90 ovos embrionados foram usados para ava
liar as atividades cicatrizante e angiogênica dos extratos e frações da planta, 
por meio da indução de feridas cutâneas e da membrana corioalantóide, respectiva
mente. O efeito proliferativo vascular foi também testado a partir do estudo imu
noistoquímico, realizado para verificar a intensidade da expressão do fator de c
rescimento endotelial vascular (VEGF) na derme de ratos. Resultados: A atividade
 angiogênica do extrato e das frações foi evidenciada nos dois modelos experimen
tais empregados. Foi evidenciado que este efeito não estava diretamente relacion
ado à expressão do VEGF, podendo estar associado a outros fatores pró-angiogênic
os. Conclusão: A atividade cicatrizante referida a C. officinalis está relaciona
da ao seu efeito positivo sobre a angiogênese, e este foi caracterizado pela ind
ução de neovascularização.#^dnd^i2#^tm^lpt^kCalendula^i2#^tm^lpt^kCicatrização d
e Feridas^i2#^tm^lpt^kNeovascularização Fisiológica^i2#^tm^lpt^kPlantas Medicina
is^i2#^tm^lpt^kRatos^i2#other#16#CAPES#20100712#July 12, 2010#20100920#September
 20, 2010#20101021#October 21, 2010#a05v26n1.htm##
04962000000000829000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690710003000710400003000740010006000770420
00200083120000400085038000500089038000400094121000300098049000700101158000300108
03000160011103100030012703200020013006500090013201400090014103500100015001200820
01600120088002420100037003300100038003670100039004050100054004440100034004980100
03700532010004900569010003400618010003400652070006800686070007500754070008500829
07000740091407000480098807001050103607000700114107000750121108311550128608500080
24410850022024490850026024710850044024970850030025410850017025710831282025880850
00803870085002203878085003603900085004203936085003103978085001804009117000604027
07200030403305800060403611200090404211100140405111600090406511500190407411400090
4093113001704102002001304119#v26n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.ht
m#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#GRA#05#ACB720#nd#Acta Cir. Bras.#26#1
#20110200#^f19^l24#0102-8650#<b>Angiogenic activity of <i>Calendula officinalis<
/i> flowers L. in rats</b>^len#<b>Atividade angiogênica das flores da <i>Calendu
la officinalis</i> L. em ratos</b>^lpt#^rND^1A01^nLeila Maria Leal^sParente#^rND
^1A02^nMaria Auxiliadora^sAndrade#^rND^1A03^nLuiz Augusto Batista^sBrito#^rND^1A
04^nVeridiana Maria Brianezi Dignani de^sMoura#^rND^1A05^nMarina Pacheco^sMiguel
#^rND^1A06^nRuy de Souza^sLino-Júnior#^rND^1A07^nLeonice Faustino Manrique^sTres
venzol#^rND^1A07^nJosé Realino de^sPaula#^rND^1A08^nNeusa Margarida^sPaulo#UFG^i
A01^1Veterinary School^2Department of Pathology^cGoias^pBrazil#UFG^iA02^1Veterin
ary School^2Preventive Medicine Department^cGoias^pBrazil#UFG^iA03^1Veterinary M
edicine School^2Animal Pathology Department^cGoias^sGO^pBrazil#UFG^iA04^1Veterin
ary Medicine School^2Pathology Department^cGoias^pBrazil#UFG^iA05^1Biomedicine D
epartment^cGoias^pBrazil#UFG^iA06^1Institute of Tropical Pathology and Public He
alth^2General Pathology Department^cGoias^pBrazil#UFG^iA07^1Pharmacy School^2Nat
ural Products Laboratory^cGoias^pBrazil#UFG^iA08^1Veterinary School^2Veterinary 
Medicine Department^cGoias^pBrazil#^len^a<b>Purpose</b>: In this work, angiogeni
c activity of <i>Calendula officinalis</i> L. (Asteraceae) ethanolic extract and
 dichloromethane and hexanic fractions were evaluated, considering medicinal pro
perties, especially healing activity, are attributed to this plant. <b>Methods</
b>: Models using 36 rats and 90 embryonated eggs were used to evaluate healing a
nd angiogenic activities of extracts and fractions of the plant, through the ind
uction of skin wounds and the chorioallantoic membrane, respectively. The effect
 of vascular proliferation was also tested from the study to verify the intensit
y of expression of vascular endothelial growth factor (VEGF) in cutaneous wounds
 in rats. <b>Results</b>: The angiogenic activity of the extract and the fractio
ns was evidenced in both experimental models. It was verified that this effect i
s not directly related to the expression of VEGF and it could be associated to o
ther pro-angiogenic factors. <b>Conclusion</b>: The healing activity referred to
 <i>C. officinalis</i> is related, among other factors, to its positive effect o
n angiogenesis, characterized by the induction of neovascularization.#^dnd^i1#^t
m^len^kCalendula^i1#^tm^len^kWound Healing^i1#^tm^len^kNeovascularization, Physi
ologic^i1#^tm^len^kPlants, Medicinal^i1#^tm^len^kRats^i1#^lpt^a<b>Objetivo</b>: 
Neste trabalho a atividade sobre a angiogênese do extrato etanólico (EEC) e das 
frações diclorometano e hexânica das flores de <i>Calendula officinalis</i> L. (
Asteraceae) cultivada no Brasil foram avaliados, visto que propriedades medicina
is têm sido atribuídas às flores da planta, destacando-se a atividade cicatrizan
te. <b>Métodos</b>: Modelos utilizando 36 ratos e 90 ovos embrionados foram usad
os para avaliar as atividades cicatrizante e angiogênica dos extratos e frações 
da planta, por meio da indução de feridas cutâneas e da membrana corioalantóide,
 respectivamente. O efeito proliferativo vascular foi também testado a partir do
 estudo imunoistoquímico, realizado para verificar a intensidade da expressão do
 fator de crescimento endotelial vascular (VEGF) na derme de ratos. <b>Resultado
s</b>: A atividade angiogênica do extrato e das frações foi evidenciada nos dois
 modelos experimentais empregados. Foi evidenciado que este efeito não estava di
retamente relacionado à expressão do VEGF, podendo estar associado a outros fato
res pró-angiogênicos. <b>Conclusão</b>: A atividade cicatrizante referida a <i>C
. officinalis</i> está relacionada ao seu efeito positivo sobre a angiogênese, e
 este foi caracterizado pela indução de neovascularização.#^dnd^i2#^tm^lpt^kCale
ndula^i2#^tm^lpt^kCicatrização de Feridas^i2#^tm^lpt^kNeovascularização Fisiológ
ica^i2#^tm^lpt^kPlantas Medicinais^i2#^tm^lpt^kRatos^i2#other#16#CAPES#20100712#
July 12, 2010#20100920#September 20, 2010#20101021#October 21, 2010#a05v26n1.htm
##
04996000000000853000450000400060000070200470000670500020005370600020005570000020
00577010002000597090008000617080002000690640018000710710003000890400003000920010
00600095042000200101120000400103038000500107038000400112121000300116049000700119
15800030012603000150012903100030014403200020014706500090014901400090015803500100
01670120068001770120074002450100037003190100038003560100039003940100054004330100
03400487010003700521010004900558010003400607010003400641070007000675070007700745
07000870082207000760090907000500098507001070103507000720114207000770121408311130
12910850008024040850022024120850026024340850044024600850030025040850017025340831
24002551085000803791085002203799085003603821085004203857085003103899085001803930
11700060394807200030395405800060395711200090396311100140397211600090398611500190
3995114000904014113001704023002001304040008008904053#v26n1#V:\SciELO\serial\acb\
v26n1\markup\a05v26n1.htm#S#l#4#1#article#1#^mJan./Feb.^a2011#oa#en#br1.1#1#4.0#
ilus#gra#05#ACB720#nd#Acta cir. bras#26#1#20110200#^f19^l24#0102-8650#Angiogenic
 activity of Calendula officinalis flowers L. in rats^len#Atividade angiogênica 
das flores da Calendula officinalis L. em ratos^lpt#^rND^1A01^nLeila Maria Leal^
sParente#^rND^1A02^nMaria Auxiliadora^sAndrade#^rND^1A03^nLuiz Augusto Batista^s
Brito#^rND^1A04^nVeridiana Maria Brianezi Dignani de^sMoura#^rND^1A05^nMarina Pa
checo^sMiguel#^rND^1A06^nRuy de Souza^sLino-Júnior#^rND^1A07^nLeonice Faustino M
anrique^sTresvenzol#^rND^1A07^nJosé Realino de^sPaula#^rND^1A08^nNeusa Margarida
^sPaulo#^iA01^1UFG^2Veterinary School^3Department of Pathology^cGoias^pBrazil#^i
A02^1UFG^2Veterinary School^3Preventive Medicine Department^cGoias^pBrazil#^iA03
^1UFG^2Veterinary Medicine School^3Animal Pathology Department^cGoias^sGO^pBrazi
l#^iA04^1UFG^2Veterinary Medicine School^3Pathology Department^cGoias^pBrazil#^i
A05^1UFG^2Biomedicine Department^cGoias^pBrazil#^iA06^1UFG^2Institute of Tropica
l Pathology and Public Health^3General Pathology Department^cGoias^pBrazil#^iA07
^1UFG^2Pharmacy School^3Natural Products Laboratory^cGoias^pBrazil#^iA08^1UFG^2V
eterinary School^3Veterinary Medicine Department^cGoias^pBrazil#^len^aPurpose: I
n this work, angiogenic activity of Calendula officinalis L. (Asteraceae) ethano
lic extract and dichloromethane and hexanic fractions were evaluated, considerin
g medicinal properties, especially healing activity, are attributed to this plan
t. Methods: Models using 36 rats and 90 embryonated eggs were used to evaluate h
ealing and angiogenic activities of extracts and fractions of the plant, through
 the induction of skin wounds and the chorioallantoic membrane, respectively. Th
e effect of vascular proliferation was also tested from the study to verify the 
intensity of expression of vascular endothelial growth factor (VEGF) in cutaneou
s wounds in rats. Results: The angiogenic activity of the extract and the fracti
ons was evidenced in both experimental models. It was verified that this effect 
is not directly related to the expression of VEGF and it could be associated to 
other pro-angiogenic factors. Conclusion: The healing activity referred to C. of
ficinalis is related, among other factors, to its positive effect on angiogenesi
s, characterized by the induction of neovascularization.#^dnd^i1#^tm^len^kCalend
ula^i1#^tm^len^kWound Healing^i1#^tm^len^kNeovascularization, Physiologic^i1#^tm
^len^kPlants, Medicinal^i1#^tm^len^kRats^i1#^lpt^aObjetivo: Neste trabalho a ati
vidade sobre a angiogênese do extrato etanólico (EEC) e das frações diclorometan
o e hexânica das flores de Calendula officinalis L. (Asteraceae) cultivada no Br
asil foram avaliados, visto que propriedades medicinais têm sido atribuídas às f
lores da planta, destacando-se a atividade cicatrizante. Métodos: Modelos utiliz
ando 36 ratos e 90 ovos embrionados foram usados para avaliar as atividades cica
trizante e angiogênica dos extratos e frações da planta, por meio da indução de 
feridas cutâneas e da membrana corioalantóide, respectivamente. O efeito prolife
rativo vascular foi também testado a partir do estudo imunoistoquímico, realizad
o para verificar a intensidade da expressão do fator de crescimento endotelial v
ascular (VEGF) na derme de ratos. Resultados: A atividade angiogênica do extrato
 e das frações foi evidenciada nos dois modelos experimentais empregados. Foi ev
idenciado que este efeito não estava diretamente relacionado à expressão do VEGF
, podendo estar associado a outros fatores pró-angiogênicos. Conclusão: A ativid
ade cicatrizante referida a C. officinalis está relacionada ao seu efeito positi
vo sobre a angiogênese, e este foi caracterizado pela indução de neovascularizaç
ão.#^dnd^i2#^tm^lpt^kCalendula^i2#^tm^lpt^kCicatrização de Feridas^i2#^tm^lpt^kN
eovascularização Fisiológica^i2#^tm^lpt^kPlantas Medicinais^i2#^tm^lpt^kRatos^i2
#other#16#CAPES#20100712#July 12, 2010#20100920#September 20, 2010#20101021#Octo
ber 21, 2010#a05v26n1.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_a
rttext&pid=S0102-86502011000100005##
00310000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704007800073002001300151#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#5#1#article#168#<p align="right"><font
 face="Verdana" size="2"><b>5 - ORIGINAL ARTICLE    ^cY#a05v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704008800073002001300161#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#6#2#article#168#<br>   </b></font><b><
font face="Verdana" size="2">WOUND HEALING</font></b></p>     ^cY#a05v26n1.htm##
00268000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704003600073002001300109#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#7#3#article#168#<p align="right">&nbsp
;</p>     ^cY#a05v26n1.htm##
00451000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704021900073002001300292#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#8#4#article#168#<p><b><font face="Verd
ana" size="2"><a name="top"></a></font><font face="Verdana" size="4">Angiogenic 
   activity of <I>Calendula officinalis</I> flowers L. in rats<SUP><a href="#end
">1</a></SUP></font></b></p>     ^cY#a05v26n1.htm##
00254000000000145000450000400060000070200470000670500020005370600020005570000020
0057701000200059709000800061708000400069704002200073002001300095#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#9#5#article#168#<p>&nbsp;</p>     ^cY#
a05v26n1.htm##
00418000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704018500074002001300259#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#10#6#article#168#<p><b><font face="Ver
dana" size="3">Atividade angiog&ecirc;nica das flores da    <I>Calendula officin
alis</I> L. em ratos </font></b><font face="Verdana" size="2"></font></p>       
^cY#a05v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#11#7#article#168#<p>&nbsp;</p>     ^cY
#a05v26n1.htm##
00255000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704002200074002001300096#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#12#8#article#168#<p>&nbsp;</p>     ^cY
#a05v26n1.htm##
00699000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000200060709000800062708000400070704046600074002001300540#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#13#9#article#168#<p><font face="Verdan
a" size="2"><B>Leila Maria Leal Parente<SUP>I</SUP>, Maria    Auxiliadora Andrad
e<SUP>II</SUP>, Luiz Augusto Batista Brito<SUP>III</SUP>,    Veridiana Maria Bri
anezi Dignani de Moura<SUP>IV</SUP>, Marina Pacheco Miguel<SUP>V</SUP>,    Ruy d
e Souza Lino-J&uacute;nior<SUP>VI</SUP>, Leonice Faustino Manrique Tresvenzol<SU
P>VII</SUP>,    Jos&eacute; Realino de Paula<SUP>VII</SUP>, Neusa Margarida Paul
o<SUP>VIII</SUP></B>    </font></p>      ^cY#a05v26n1.htm##
00484000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704025000075002001300325#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#14#10#article#168#<p><font face="Verda
na" size="2"><SUP>I</SUP>PhD in Animal Science, Department    of Pathology, Vete
rinary School, UFG, Goias, Brazil. <I>Conception and design,    data acquisition
, statistical analysis and interpretation, manuscript writing.    ^cY#a05v26n1.h
tm##
00437000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704020300075002001300278#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#15#11#article#168#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>II</SUP>Associate Professor, Preventive    Medi
cine Department, Veterinary School, UFG, Goias, Brazil. <I>Involved in technical
    procedures.    ^cY#a05v26n1.htm##
00455000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022100075002001300296#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#16#12#article#168#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>III</SUP>PhD, Full Professor,    Animal Patholo
gy Department, Veterinary Medicine School, UFG. Goias-GO, Brazil.    <I>Manuscri
pt writing and critical revision.    ^cY#a05v26n1.htm##
00444000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704021000075002001300285#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#17#13#article#168#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>IV</SUP>Associate Professor, Pathology    Depar
tment, Veterinary Medicine School, UFG, Goias, Brazil.<I> Manuscript writing    
and critical revision.    ^cY#a05v26n1.htm##
00428000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704019400075002001300269#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#18#14#article#168#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>V</SUP>PhD, Assistant Professor,    Biomedicine
 Department, UFG, Campus Jatai, Goias, Brazil. <I>Involved in technical    proce
dures.    ^cY#a05v26n1.htm##
00508000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027400075002001300349#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#19#15#article#168#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>VI</SUP>PhD, Associate Professor,    General Pa
thology Department, Institute of Tropical Pathology and Public Health,    UFG, G
oias, Brazil.<I> Morphometric analysis, statistical analysis, technical    proce
dures.    ^cY#a05v26n1.htm##
00466000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704023200075002001300307#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#20#16#article#168#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>VII</SUP>Associate Professor,    Natural Produc
ts Laboratory, Pharmacy School, UFG, Goias, Brazil. <I>Data acquisition,    coll
ection and processing of study intormations.    ^cY#a05v26n1.htm##
00516000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704028200075002001300357#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#21#17#article#168#<br>   </I></font><f
ont face="Verdana" size="2"><SUP>VIII</SUP>Assistant Professor,    Veterinary Me
dicine Department of, Veterinary School, UFG, Goias, Brazil. <I>Conception    an
d design, intellectual and scientific content of the study, critical revision.</
I></font></p>     ^cY#a05v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#22#18#article#168#<p><font face="Verda
na" size="2"><a href="#end">Correspondence</a></font></p>     ^cY#a05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#23#19#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00278000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704004400075002001300119#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#24#20#article#168#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a05v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#25#21#article#168#<p><font face="Verda
na" size="2"><B>ABSTRACT </B></font></p>     ^cY#a05v26n1.htm##
01478000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704124400075002001301319#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#26#22#article#168#<p><font face="Verda
na" size="2"><B>Purpose</b>: In this work, angiogenic activity    of <I>Calendul
a officinalis</I> L. (Asteraceae) ethanolic extract and dichloromethane    and h
exanic fractions were evaluated, considering medicinal properties, especially   
 healing activity, are attributed to this plant. <B>Methods</B>: Models using   
 36 rats and 90 embryonated eggs were used to evaluate healing and angiogenic   
 activities of extracts and fractions of the plant, through the induction of    
skin wounds and the chorioallantoic membrane, respectively. The effect of vascul
ar    proliferation was also tested from the study to verify the intensity of ex
pression    of vascular endothelial growth factor (VEGF) in cutaneous wounds in 
rats. <B>Results</B>:    The angiogenic activity of the extract and the fraction
s was evidenced in both    experimental models. It was verified that this effect
 is not directly related    to the expression of VEGF and it could be associated
 to other pro-angiogenic    factors. <B>Conclusion</B>: The healing activity ref
erred to <I>C. officinalis</I>    is related, among other factors, to its positi
ve effect on angiogenesis, characterized    by the induction of neovascularizati
on. </font></p>     ^cY#a05v26n1.htm##
00415000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704018100075002001300256#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#27#23#article#168#<p><font face="Verda
na" size="2"><B>Key words</B>: Calendula. Wound Healing. Neovascularization,    
Physiologic. Plants, Medicinal. Rats. </font></p>  <hr size="1" noshade>     ^cY
#a05v26n1.htm##
00301000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006700075002001300142#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#28#24#article#168#<p><font face="Verda
na" size="2"><B>RESUMO </B></font></p>     ^cY#a05v26n1.htm##
01847000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704161300075002001301688#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#29#25#article#168#<p><font face="Verda
na" size="2"><B>Objetivo</b>: Neste trabalho a atividade sobre    a angiog&ecirc
;nese do extrato etan&oacute;lico (EEC) e das fra&ccedil;&otilde;es    diclorome
tano e hex&acirc;nica das flores de <I>Calendula officinalis</I> L.    (Asterace
ae) cultivada no Brasil foram avaliados, visto que propriedades medicinais    t&
ecirc;m sido atribu&iacute;das &agrave;s flores da planta, destacando-se a    at
ividade cicatrizante. <B>M&eacute;todos</B>: Modelos utilizando 36 ratos e    90
 ovos embrionados foram usados para avaliar as atividades cicatrizante e angiog&
ecirc;nica    dos extratos e fra&ccedil;&otilde;es da planta, por meio da indu&c
cedil;&atilde;o    de feridas cut&acirc;neas e da membrana corioalant&oacute;ide
, respectivamente.    O efeito proliferativo vascular foi tamb&eacute;m testado 
a partir do estudo    imunoistoqu&iacute;mico, realizado para verificar a intens
idade da express&atilde;o    do fator de crescimento endotelial vascular (VEGF) 
na derme de ratos. <B>Resultados</B>:    A atividade angiog&ecirc;nica do extrat
o e das fra&ccedil;&otilde;es foi evidenciada    nos dois modelos experimentais 
empregados. Foi evidenciado que este efeito n&atilde;o    estava diretamente rel
acionado &agrave; express&atilde;o do VEGF, podendo estar    associado a outros 
fatores pr&oacute;-angiog&ecirc;nicos. <B>Conclus&atilde;o</B>:    A atividade c
icatrizante referida a <I>C. officinalis</I> est&aacute; relacionada    ao seu e
feito positivo sobre a angiog&ecirc;nese, e este foi caracterizado pela    indu&
ccedil;&atilde;o de neovasculariza&ccedil;&atilde;o. </font></p>     ^cY#a05v26n
1.htm##
00463000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704022900075002001300304#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#30#26#article#168#<p><font face="Verda
na" size="2"><B>Descritores</B>: Calendula. Cicatriza&ccedil;&atilde;o    de Fer
idas. Neovasculariza&ccedil;&atilde;o Fisiol&oacute;gica. Plantas Medicinais.   
 Ratos.</font></p> <hr size="1" noshade>     ^cY#a05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#31#27#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#32#28#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007400075002001300149#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#33#29#article#168#<p><font face="Verda
na" size="3"><B>Introduction</B> </font></p>      ^cY#a05v26n1.htm##
00749000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704051500075002001300590#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#34#30#article#168#<p><font face="Verda
na" size="2"> Since the Antiquity, medicinal properties have    been attributed 
to the flower commonly known as calendula (<I>Calendula officinalis</I>    L.), 
from the Asteraceae family. It seems that its use has been more disseminated    
from the XIII century on, and it was initially utilized for healing wounds.    I
t was employed as unguent and ointment, as an antiseptic and an anti-inflammator
y,    during the North American Civil War and the World War<SUP>1-5</SUP>. </fon
t></p>     ^cY#a05v26n1.htm##
00591000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704035700075002001300432#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#35#31#article#168#<p><font face="Verda
na" size="2"> Few experimental models have been carried out    for the evaluatio
n of the anti-inflammatory activity of the <I>C. officinalis</I>.    One of thes
e models was conducted by means of the induction of ear edema by    croton oil a
nd another one by the use of carrageenan-induced paw edema<SUP>4-6</SUP>.    </f
ont></p>     ^cY#a05v26n1.htm##
00763000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052900075002001300604#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#36#32#article#168#<p><font face="Verda
na" size="2"> Patrick <I>et al.</I><SUP>7</SUP> carried out    a study with Euro
pean <I>C. officinalis</I> flowers by the use of the chorioallantoic    membrane
 (CAM) of chicken fertilized egg. They demonstrated the inductive role    of the
 plant on the microvascularization. The CAM has been often used in the    assess
ment os substances with pro-angiogenic activity, such as the vascular    endothe
lial growth factor (VEGF), and antiangiogenic, such as the endostatin<SUP>8-10</
SUP>.    </font></p>     ^cY#a05v26n1.htm##
01018000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704078400075002001300859#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#37#33#article#168#<p><font face="Verda
na" size="2"> The CAM is transparent, composed by a highly    vascular mesoderm,
 which is part of the three extra-embryonic membranes that    protect and nouris
h the embryo<SUP>11</SUP>. The use of CAM as an experimental    model is justifi
ed because it is simpler and cheaper than the use of mammals.    The FDA (<I>Uni
ted States Food and Drug Administration</I>) has aproved the    carrying out of 
pre-clinical evaluations with this experimental model in studies    of substance
s employed in the treatment of chronic cutaneous ulcers and burn    wounds<SUP>8
-12</SUP>. The quantitation of angiogenic response in the CAM can    be carried 
out by manual score, morphometry with the aid of softwares, or the    imaged poi
nts count<SUP>13</SUP>. </font></p>     ^cY#a05v26n1.htm##
00755000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704052100075002001300596#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#38#34#article#168#<p><font face="Verda
na" size="2"> In this study, we aimed to evaluate the angiogenic    activity of 
the ethanolic extract and its fractions produced from <I>C. officinalis</I>    f
lowers (CEE) cultivated in Brazil. For that, models of CAM of fertilized chicken
    eggs and of mice's cutaneous wounds were used. The immunohistochemical    te
chnique was used to evaluate the effect of the CEE in the angiogenesis and    in
 the expression of vascular endothelial growth factor (VEGF) on rats's    derm. 
</font></p>      ^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#39#35#article#168#<p>&nbsp; </p>     ^
cY#a05v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#40#36#article#168#<p><font face="Verda
na" size="3"><B>Methods</B> </font></p>      ^cY#a05v26n1.htm##
00352000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704011800075002001300193#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#41#37#article#168#<p><font face="Verda
na" size="2"><I>Preparation of the ethanolic extract and its    fracions</I> </f
ont></p>      ^cY#a05v26n1.htm##
00735000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704050100075002001300576#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#42#38#article#168#<p><font face="Verda
na" size="2"> Dry and pulverized <I>C. officinalis</I> flowers    from Parana St
ate (February, 2006) were obtained at the company Empresa Clorofila    (Goiania-
GO, Brazil). As for quality control, pharmacognostic evaluation of    this veget
al species was carried out at the Laboratory of Natual Products Research,    fro
m the Phamarcy Faculty, Federal University of Goias, according to the techniques
    described by the Brazilian Pharmacopeia IV<SUP>14</SUP>. </font></p>     ^cY
#a05v26n1.htm##
00552000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704031800075002001300393#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#43#39#article#168#<p><font face="Verda
na" size="2"> To obtain the ethanolic extract (CEE), 200g    of the pulverized f
lowers were extract with 100 mL of ethanol PA 96&#186; GL,    by maceration, for
 three days, at room temperature, with occasionally shaking,    and concentrated
 in a rotary evaporator at 40&#186;C. </font></p>     ^cY#a05v26n1.htm##
00909000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704067500075002001300750#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#44#40#article#168#<p><font face="Verda
na" size="2"> Hexanic and dichloromethane fractions were obtained    from 10g of
 the CEE, which was solubilized in a methanol/ H<SUB>2</SUB>O (7:1)    mixture a
nd firstly extracted three times with 50 mL of hexane and, later, extracted    t
hree times with 50mL of dichloromethane. The extracts were concentrated on    a 
rotary evaporator. Ethanolic extract and hexanic and dichloromethane fractions  
  solutions at 1%, solubilized in 70% ethanol, were prepared to evaluate the ang
iogenic    activity in the CAM. To evaluate the angiogenic activity in cutaneous
 wounds    on rat's derm, a CEE aqueous solution at 1% was daily prepared. </fon
t></p>     ^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#45#41#article#168#<p>&nbsp;</p>      ^
cY#a05v26n1.htm##
00316000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008200075002001300157#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#46#42#article#168#<p><font face="Verda
na" size="2"><I>Experimental animals</I> </font></p>      ^cY#a05v26n1.htm##
01065000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704083100075002001300906#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#47#43#article#168#<p><font face="Verda
na" size="2"> The experimental protocol with the animals used    in this study w
as approved by the Research Ethics Comitee of the Federal University    of Goias
, under the number 019/2007. Twelve female rats (<I>Rattus norvegicus    albinus
</I>), Wistar lineage, at 80 days of age, weight of 150-200g were used.    Anima
ls came from the Animal Colony of the Federal University of Goias (UFG),    Goia
nia-GO, Brazil. Animals were adapted at the Experimental Surgery of the    Veter
inary School, UFG, for 10 days, and kept in individual polyethylene cages    cov
ered with coarse sawdust, under controled environmental conditions (temperature 
   at 23&#177;2&#186;C, relative humidity of air at 50-70%, and 12-hour-light/da
rk    photoperiod). Water and ration were supplied <I>ad libitum</I>. </font></p
>      ^cY#a05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#48#44#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00331000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009700075002001300172#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#49#45#article#168#<p><font face="Verda
na" size="2"><I>Chorioallantoic membrane (CAM) model</I></font></p>      ^cY#a05
v26n1.htm##
00313000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704007900075002001300154#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#50#46#article#168#<p><font face="Verda
na" size="2"><U>Preparing the CAM</U> </font></p>      ^cY#a05v26n1.htm##
01022000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704078800075002001300863#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#51#47#article#168#<p><font face="Verda
na" size="2"> The CAM was prepared for the evaluation of the    angiogenic activ
ity according to methodology adapted from Kim <I>et al.</I><SUP>16    </SUP>Nine
ty 2-year-old embryonated eggs of Cobb chicken, obtained from 34-35    week-old 
female broiler breeders, were used. The eggs were placed in incubators    (Premi
um Ecol&oacute;gica IP-130), under invariable humidity (67.5%) and temperature  
  at 37&#186;C, and randomly divided into six groups with 15 eggs each to underg
o    the following treatments: SC<SUB>1</SUB> = solvent control (ethanol 70%); S
C<SUB>2</SUB>    = distilled water; PC = positive control at 1% (17 &szlig;-estr
adiol); CEE =    ethanolic extract 1%; DCF = dichloromethane fraction 1%; and HC
F = hexanic fraction    1%. </font></p>     ^cY#a05v26n1.htm##
00744000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704051000075002001300585#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#52#48#article#168#<p><font face="Verda
na" size="2"> Egg shell opening, albumen withdrawn and the    treatments were pe
rformed in a Chamber of Biological Safe type II. On the third    incubation day,
 2-3 mL of albumen were withdrawn, through a small opening in    the shell. Late
r, the opening was sealed with histological paraffin at melting    point. Incuba
tion continued until the tenth day, when the eggs were treated    with 0.1mL of 
the solution specific to each group, instilled on the CAM surface.    </font></p
>     ^cY#a05v26n1.htm##
00557000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704032300075002001300398#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#53#49#article#168#<p><font face="Verda
na" size="2">   The eggs were resealed and incubated for two more days. After th
e embryos euthanasia    by medullar section at the atlanto-occipital joint, the 
CAM fragments of each    egg were collected for morphometric analysis and quanti
tation of the number    of blood vessels. </font></p>      ^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#54#50#article#168#<p>&nbsp; </p>     ^
cY#a05v26n1.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008900075002001300164#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#55#51#article#168#<p><font face="Verda
na" size="2"><U>CAM morphometric evaluation</U> </font></p>      ^cY#a05v26n1.ht
m##
00464000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704023000075002001300305#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#56#52#article#168#<p><font face="Verda
na" size="2"> As for the morphometric analysis, a fragment    of fresh CAM of te
n eggs from each group was collected and expanded on a glass    slide, over whic
h a coverslip was superposed. </font></p>     ^cY#a05v26n1.htm##
00924000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704069000075002001300765#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#57#53#article#168#<p><font face="Verda
na" size="2"> The slides reading was carried oud with the    aid of an image dig
ital analysis system, that is, a digital videocamera (Sony    Cyber-Shot 3.2 MP,
 model DSC-P71) that transmits the captured imaged from the    microscope (Carl 
Zeiss<SUP>&#169;</SUP>, model Jenaval, with plan achromatic    objectives) to a 
computer (Pentium<SUP>&#174;</SUP>4, 3,20 GHz, 1GB RAM memory),    with digitizi
ng board and software Image J 1.3.1, NIH, United States. The percentage    of va
scular area per field, matching the red marked areas, was calculated in    a Win
dows environmet. Thirty random fields that presented blood vessels were    photo
graphed. </font></p>      ^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#58#54#article#168#<p>&nbsp; </p>     ^
cY#a05v26n1.htm##
00364000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704013000075002001300205#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#59#55#article#168#<p><font face="Verda
na" size="2"><U>Evaluation of the inflammatory cells and of    the CAM blood ves
sels</U> </font></p>      ^cY#a05v26n1.htm##
00831000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704059700075002001300672#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#60#56#article#168#<p><font face="Verda
na" size="2"> The membranes fixed in buffered formaline were    processed, inclu
ded in paraffin, and stained by the hematoxylin and eosin technique.    The imag
es were captured as described above. The inflammatory cells present    in the CA
M were evaluated in twenty randomly photographed fields. The results    were vis
ually classified according to the intensity found, and the data were    transfor
med into quantitative variables, by assigning the following scores:    absent (0
), discrete (1 to 25%), moderate (25 to 50%), and accentuated (over    50%). </f
ont></p>     ^cY#a05v26n1.htm##
00717000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048300075002001300558#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#61#57#article#168#<p><font face="Verda
na" size="2"> Blood vessels count of the CAM mesoderm was    carried out by the 
use of planimetry by point counting, with the aid of the    software GIMP 2.4.3.
 A square lattice composed by 25 points was suporposed to    the histological im
age, and only the vessels in the interssections within the    visual field were 
counted, according to the models suggested by Ribatti <I>et    al.</I><SUP>11 </
SUP>and Prado <I>et al.</I><SUP>16</SUP>. </font></p>      ^cY#a05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#62#58#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00323000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008900075002001300164#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#63#59#article#168#<p><font face="Verda
na" size="2"><I>Rat's cutaneous wound model</I> </font></p>      ^cY#a05v26n1.ht
m##
00474000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024000075002001300315#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#64#60#article#168#<p><font face="Verda
na" size="2"> The animals were randomly distributed into two    groups with six 
animals each and submitted to the treatments: SC _ solvent control    (distilled
 water) and CEE _ ethanolic extract 1%. </font></p>     ^cY#a05v26n1.htm##
00905000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704067100075002001300746#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#65#61#article#168#<p><font face="Verda
na" size="2"> To induce the wounds, a circular metal punch    (1cm diam) was use
d in the dorsocervical region of each animal. The anesthesia    consisted of the
 administration of ketamine (70 mg/Kg, IM) and xylazine (10mg/Kg,    IM). After 
the surgery, 100&#181;L of the test solution (CEE) and solvent wore    instilled
 on the wounds. This procedure was repeated daily at the same time.    On the 7t
h day of the postoperative period, the animals were submitted to euthanasia    i
n CO<SUB>2</SUB> chamber, in order to collect a skin fragment    from the surgic
al wound area. The fragments were preserved in 10% buffered formol.    </font></
p>     ^cY#a05v26n1.htm##
00910000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704067600075002001300751#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#66#62#article#168#<p><font face="Verda
na" size="2"> Tissue sections (5&#181;m) were expanded on    silane-coated histo
logical slides (3, <I>aminopropyl-triethoxysilane</I>, Sigma    Aldrich, USA), a
nd kept in a hothouse at 36&#186;C for a better tissue adhesion    to the slide.
 After that, the sections were deparaffinized and rehydrated. Then,    the antig
enic recovery was performed in a citrate solution (pH 6.0), in a water    bath a
t 95&#186;C, for 30 minutes, followed by endogenous peroxidase blocking.    The 
slides were incubated in bovine serum albumin (BSA) at 3%, for one hour,    at r
oom temperature in a wet chamber, in order to block unespecific marking.    </fo
nt></p>     ^cY#a05v26n1.htm##
01043000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704080900075002001300884#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#67#63#article#168#<p><font face="Verda
na" size="2"> After that, the slides were incubated in VEGF    primary antibody 
(147) (Santa Cruz Biotechnology, Antibody sc-507), 1:500 dilution,    in wet cha
mber, overnight, at 4&#186;C. Then the streptavidin-biotin-peroxidase    complex
 (kit LSAB _ Dako K0690) was instilled on the slides for 20 minutes each    reac
tion, in a wet chamber at room temperature. The reaction was revealed with    di
aminobenzidine (DAB) solution, for 1 minute. A PBS solution was used for washing
    between the steps. The sections were counterstained with Mayer's hematoxylin
,    for 30 seconds, and the slides were mounted with synthetic resin (Sigma Ald
rich,    USA) and histological coverslips. As for negative control, the skin sam
ples    were incubated with TRIS buffer, pH 7.4. </font></p>     ^cY#a05v26n1.ht
m##
00506000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704027200075002001300347#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#68#64#article#168#<p><font face="Verda
na" size="2"> Derm images were captured by the same procedures    used to captur
e CAM images. Planimetry by point counting was used to count blood    vessels an
d to evaluate the intensity of VEGF expression in endothelial cells.    </font><
/p>     ^cY#a05v26n1.htm##
00476000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704024200075002001300317#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#69#65#article#168#<p><font face="Verda
na" size="2"> The histological slides preparation, the photomicrographies    of 
the fresh CAM fragments, morphometric analysis, and planimetry by point counting
    were performed by the same observer. </font></p>      ^cY#a05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#70#66#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00316000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008200075002001300157#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#71#67#article#168#<p><font face="Verda
na" size="2"><I>Statistical analysis</I> </font></p>      ^cY#a05v26n1.htm##
00720000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704048600075002001300561#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#72#68#article#168#<p><font face="Verda
na" size="2"> The results were submitted to statistical treatment    by the use 
of GraphPad InStat software (Version 3.05 for Windows). From the    Kolmogorov-S
mirnov test for normality, the CAM data were evaluated by Kruskal-Wallis    test
 and then by Dunn post-test. The data analysis of immunoistochemistry of    the 
mice's skin fragments was performed by means of the Mann-Whitney test.    The si
gnificance level was p&lt;0.05<SUP>17</SUP>. </font></p>      ^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002300075002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#73#69#article#168#<p>&nbsp; </p>     ^
cY#a05v26n1.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704006900075002001300144#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#74#70#article#168#<p><font face="Verda
na" size="3"><B>Results</B> </font></p>      ^cY#a05v26n1.htm##
00320000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008600075002001300161#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#75#71#article#168#<p><font face="Verda
na" size="2"><I>Chorioallantoic membrane</I> </font></p>      ^cY#a05v26n1.htm##
00835000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704060100075002001300676#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#76#72#article#168#<p><font face="Verda
na" size="2"> In morphometric evaluation increase of the vascular    area and of
 percentage of red-marked areas was observed in CAM treated as positive    contr
ol 1% (17 &szlig;-estradiol), ethanolic extract 1%, dichloromethane fraction    
1% and hexanic fraction 1%, compared to solvent control (ethanol 70%). No differ
ences    were observed regarding the same parameter among the following groups: 
positive    control 1%, ethanolic extract 1%, dichloromethane fraction 1% and he
xanic fraction    1% (<a href="#img01">Figures 1</a> and <a href="#img02">2</a>)
.</font></p>     ^cY#a05v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#77#73#article#168#<p align="center">&n
bsp;</p>     ^cY#a05v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#78#74#article#168#<p align="center">&n
bsp;</p>     ^cY#a05v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#79#75#article#168#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a05img01.jpg"><a name="img01"></a></p>     ^cY#a
05v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#80#76#article#168#<p align="center">&n
bsp;</p>     ^cY#a05v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#81#77#article#168#<p align="center">&n
bsp;</p>     ^cY#a05v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#82#78#article#168#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a05img02.jpg"><a name="img02"></a></p>     ^cY#a
05v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#83#79#article#168#<p align="center">&n
bsp;</p>     ^cY#a05v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704003700075002001300112#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#84#80#article#168#<p align="center">&n
bsp;</p>     ^cY#a05v26n1.htm##
00572000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704033800075002001300413#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#85#81#article#168#<p align="left"><fon
t face="Verdana" size="2">The presence of inflammatory cells    in CAM stained w
ith hematoxylin and eosin was discrete in all evaluated groups,    with predomin
ance of heterofile polymorphonuclears, indicating that the effects    of the obs
erved treatments are not related to inflammatory activity.</font></p>     ^cY#a0
5v26n1.htm##
00877000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704064300075002001300718#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#86#82#article#168#<p><font face="Verda
na" size="2"><I> </I> The quantitation of blood vessels, carried    out by plani
metry in CAM stained with hematoxylin-eosin and treated with positive    control
 1% (17 &szlig;-estradiol), <I>C.officinalis</I> flowers ethanolic extract    1%
, dichloromethane fraction 1% and hexanic fraction 1%, indicated vessels increas
e    compared to solvent control (ethanol 70%). No significant differences were 
observed    regarding the same parameter among the following groups: positive co
ntrol 1%,    ethanolic extract 1%, dichloromethane fraction 1% and hexanic fract
ion 1% (<a href="#img03">Figure    3</a>). </font></p>     ^cY#a05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#87#83#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#88#84#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#89#85#article#168#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a05img03.jpg"><a name="img03"></a></p>     ^cY#a
05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#90#86#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#91#87#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00318000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704008400075002001300159#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#92#88#article#168#<p><font face="Verda
na" size="2"><I>Rat's cutaneous wounds</I> </font></p>      ^cY#a05v26n1.htm##
00700000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704046600075002001300541#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#93#89#article#168#<p><font face="Verda
na" size="2"> Digital planimetry by point counting performed    on mice derm tra
ted with ethanolic extract 1% revealed an increase in the number    of blood ves
sels compared to solvent control (<a href="#img04">Figures 4</a>    and <a href=
"#img05">5</a>). There was significant difference among the groups.    As for in
tensity of VEGF espression in endothelial cells, there was no significant    dif
ference among the groups. </font></p>     ^cY#a05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#94#90#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#95#91#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00333000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704009900075002001300174#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#96#92#article#168#<p align="center"><i
mg src="/img/revistas/acb/v26n1/a05img04.jpg"><a name="img04"></a></p>     ^cY#a
05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#97#93#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#98#94#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00256000000000145000450000400060000070200470000670500020005370600020005570000030
0057701000300060709000800063708000400071704002200075002001300097#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#99#95#article#168#<p>&nbsp;</p>     ^c
Y#a05v26n1.htm##
00334000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704009900076002001300175#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#100#96#article#168#<p align="center"><
img src="/img/revistas/acb/v26n1/a05img05.jpg"><a name="img05"></a></p>     ^cY#
a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002200076002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#101#97#article#168#<p>&nbsp;</p>     ^
cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704002200076002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#102#98#article#168#<p>&nbsp;</p>     ^
cY#a05v26n1.htm##
00289000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000300061709000800064708000400072704005400076002001300130#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#103#99#article#168#<p><font face="Verd
ana" size="2"> </font></p>     ^cY#a05v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#104#100#article#168#<p>&nbsp;</p>     
^cY#a05v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007200077002001300149#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#105#101#article#168#<p><font face="Ver
dana" size="3"><B>Discussion</B> </font></p>      ^cY#a05v26n1.htm##
00881000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704064500077002001300722#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#106#102#article#168#<p><font face="Ver
dana" size="2"> The increase of chorioallantoic membrane vascular    area of CEE
, DCF and HCF indicated a positive effect of these compounds on angiogenesis.   
 This activity was confirmed by the quantitation of menbrane blood vessel on    
the histological sections. The results demonstrated that ethanolic extract and  
  dichloromethane and hexanic fractions of <I>Calendula officinalis</I> flowers 
   present inducer effect on the angiogenesis process. The same results were des
cribed    by Patrick<I> et al.</I><SUP>7 </SUP>when they used an aqueous extract
 of <I>C.    officinalis</I> grown in England. </font></p>     ^cY#a05v26n1.htm#
#
01010000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704077400077002001300851#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#107#103#article#168#<p><font face="Ver
dana" size="2"> From the CEE fractioning, the obtaiment of dichloromethane,    h
exanic, ethyl acetate and methanol-water fraction was possible. However, in    t
his experiment, only the angiogenic effects of ethanolic extract and of the    d
ichloromethane and hexanic fraction were tested, because Patrick <I>et al.</I><S
UP>7    </SUP>had already proved the angiogenic activity of calendula aqueous ex
tract.    Therefore, the angiogenic activity was verified in less polar fraction
s (dichloromethane    and hexanic), considering Moom <I>et al.</I><SUP>18</SUP>,
 Hsu<SUP>19</SUP>    and Leung <I>et al.</I><SUP>20 </SUP>pointed out that compo
unds with such polarity    have saponins and flavonoids, which may present angio
genic activity. </font></p>     ^cY#a05v26n1.htm##
01225000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704098900077002001301066#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#108#104#article#168#<p><font face="Ver
dana" size="2"> Many compounds are present in the crude extract    of a plant. T
ogether or not, these extracts are responsible for certain biological    activit
y<SUP>21</SUP>. In this study, CEE, DCF and HCF angiogenic effect of<I>    C. of
ficinalis</I> on CAM was verified, suggesting that both extract and fractions   
 present compounds responsible for the observed vascular proliferative effects. 
   In the way, Volpato<SUP>22</SUP> determined, by chromatographic estudies, tha
t    dichloromethane and hexanic fractions of Brazilian <I>C. officinalis</I> fl
owers    are rich in triterpenes and steroids. Besides, Della-Loggia <I>et al.</
I><SUP>5    </SUP>related calendula antiinflammatory activity to the presence of
 treterpenes.    Thus the angiogenic activity verified in this work can be relat
ed mainly to    these two compound classes, triterpenes and steroids, that are p
robably present    in both extract and fractions of calendula flowers. </font></
p>     ^cY#a05v26n1.htm##
01008000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704077200077002001300849#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#109#105#article#168#<p><font face="Ver
dana" size="2"> When substances are administered on CAM surface,    unespecific 
inflammatory reaction may occur, inducing to a secondary vascular    proliferati
ve response<SUP>11</SUP>. In this work, CAM    treated with calendula extract or
 fraction presented discrete inflammatory infiltrate.    Also, ethanol and disti
lled water were used as solvent control in the experiment    in order to verify 
if the ethanol would present any irritation on CAM. Therefore,    it can be conc
luded that the increase of neovascularization observed in CAM    is due to the <
I>C. officinalis</I> direct activity on the membrane, and it    is not related t
o the inflammatory reaction, confirming the findings by Patrick    <I>et al.</I>
<SUP>7</SUP>. </font></p>     ^cY#a05v26n1.htm##
01405000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704116900077002001301246#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#110#106#article#168#<p><font face="Ver
dana" size="2"> The increase of the number of blood vessels    on rat's derm tre
ated with ethanolic extract and verified by positive immunohistochemical    for 
VEGF confirmed the intense activity on the neovacularization promoted by    CEE 
in CAM model. The immunohistochemical technique, as a viable way for angiogenesi
s    evaluation by positive marking for VEGF in this experimental model, indicat
ed    that the CEE angiogenic activity is not directly related to the increase o
f    expression of this groth factor. Carmeliet<SUP>23-24</SUP> observed that ot
her    proangiogenic factors, such as fibroblasts growth factors (FGF), or angio
genic    cytokines, such as interleukin-8 (ILL-8), tumor necrosis factor-<IMG SR
C="../PAGEMA~1/Simbolo1.JPG" WIDTH="6" HEIGHT="8"  ALIGN="BOTTOM"> (TNF-<IMG SRC
="../PAGEMA~1/Simbolo2.JPG" WIDTH="6" HEIGHT="8"  ALIGN="BOTTOM">) and transform
ation and growth factor-&szlig; (TGF-&szlig;), may    also be related to angioge
nesis mechanisms. This way, it is possible that other    factors are involved in
 vascular proliferation generated by calendula flowers    extract, verified in t
his work. </font></p>      ^cY#a05v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#111#107#article#168#<p>&nbsp; </p>    
 ^cY#a05v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007200077002001300149#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#112#108#article#168#<p><font face="Ver
dana" size="3"><B>Conclusion</B> </font></p>      ^cY#a05v26n1.htm##
00482000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704024600077002001300323#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#113#109#article#168#<p> <font face="Ve
rdana" size="2"><I>Calendula officinalis</I> grown in Brazil    showed accentuat
ed angiogenic activity in both models used: chorioallantoic    membrane of chick
en fertilized eggs and rat's cutaneous wounds. </font></p>      ^cY#a05v26n1.htm
##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#114#110#article#168#<p>&nbsp; </p>    
 ^cY#a05v26n1.htm##
00308000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007200077002001300149#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#115#111#article#168#<p><font face="Ver
dana" size="3"><B>References</B> </font></p>      ^cY#a05v26n1.htm##
00619000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704036900079002001300448#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#116#112#article#168#1#<p><
font face="Verdana" size="2">1. Re T A, Mooney D, Antignac E, Dufour, E, Bark   
 I, Srinivasan V, Nohynek G. Application of the threshold of toxicological conce
rn    approach for thesafety evaluation of calendula flower (<I>Calendula offici
nalis</I>)    petals and extracts used in cosmetic and personal care products. F
ood Chem Toxicol.    2009;47:1246-54.    ^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#117#113#article#168# </font></p>     ^
cY#a05v26n1.htm##
00565000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704031500079002001300394#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#118#114#article#168#2#<p><
font face="Verdana" size="2">   2. Pommier P, Gomez F, Sunyach MP, D'Hombres A, 
Carrie C, Montbarbon X. Phase    III randomized trial of <I>Calendula officinali
s</I> compared with trolamine    for the prevention of acute dermatitis during i
rradiation for breast cancer.    J Clin Oncol. 2004;22:1447_53.    ^cY#a05v26n1.
htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#119#115#article#168# </font></p>     ^
cY#a05v26n1.htm##
00553000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704030300079002001300382#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#120#116#article#168#3#<p><
font face="Verdana" size="2">3. Zitterl-Eglseer K, Sosa S, Jurenitsch J, Schuber
t-Zssilavecz    M, Della Loggia R,Tubaro A, Bertoldi M, Franz C. Anti-oedematous
 activities    of the main triterpendiol esters of marigold (<I>Calendula offici
nalis</I> L.).    J Ethnopharmacol. 1997;57:139_44.    ^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#121#117#article#168# </font></p>     ^
cY#a05v26n1.htm##
00413000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704016300079002001300242#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#122#118#article#168#4#<p><
font face="Verdana" size="2">4. Brown DJ, Dattner AM. Phytotherapeutic approache
s    to common dermatologic conditions. Arch Dermatol. 1998;134:1401_4.    ^cY#a
05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#123#119#article#168# </font></p>     ^
cY#a05v26n1.htm##
00489000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704023900079002001300318#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#124#120#article#168#5#<p><
font face="Verdana" size="2">5. Della-Loggia R, Tubaro A, Sosa S, Becker H,    I
saac O. The role of triterpenoids in the topical anti-inflammatory activity    o
f <I>Calendula officinalis</I> flowers. Planta Med. 1994;60:516-20.    ^cY#a05v2
6n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#125#121#article#168# </font></p>     ^
cY#a05v26n1.htm##
00504000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704025400079002001300333#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#126#122#article#168#6#<p><
font face="Verdana" size="2">6. Hamburguer M, Adler S, Baumann D, Forg A,    Wei
nreich B. Preparative purification of the major anti-inflammatory triterpenoid  
  ester from Marigold (<I>Calendula officinalis</I>). Fitoterapia. 2003;74:328-3
8.    ^cY#a05v26n1.htm##
00260000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002400077002001300101#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#127#123#article#168#    </font></p>   
  ^cY#a05v26n1.htm##
00474000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704022400079002001300303#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#128#124#article#168#7#<p><
font face="Verdana" size="2">7. Hazel SJ. A novel early chorioallantoic membrane
    assay demonstrates quantitative and qualitative changes caused by antiangiog
enic    substances. J Lab Clin Med. 2003;141:217-28.    ^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#129#125#article#168# </font></p>     ^
cY#a05v26n1.htm##
00462000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704021200079002001300291#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#130#126#article#168#8#<p><
font face="Verdana" size="2">8. RibattiI D, Vacca A, Roncali L, Dammacco F.    T
he chick embryo membrane as model for in vivo research on anti-angiogenesis.    
Curr Pharmacol Biotechnol. 2000;1:73-82.    ^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#131#127#article#168# </font></p>     ^
cY#a05v26n1.htm##
00363000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000200077704011300079002001300192#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#132#128#article#168#9#<p><
font face="Verdana" size="2">9. Farmacop&eacute;ia Brasileira IV. Atheneu:    S&
atilde;o Paulo; 2001.    ^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#133#129#article#168# </font></p>     ^
cY#a05v26n1.htm##
00471000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704022000080002001300300#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#134#130#article#168#10#<p>
<font face="Verdana" size="2">10. Kim MS, Lee YM, Moon EJ, Kim SE, Lee JJ,    Ki
m KW. Anti-angiogenic activity of torilin, a sesquiterpene compound from <I>Tori
lis    japonica</I>. Int J Cancer 2000;87:269_75.    ^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#135#131#article#168# </font></p>     ^
cY#a05v26n1.htm##
00498000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704024700080002001300327#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#136#132#article#168#11#<p>
<font face="Verdana" size="2">11. Prado FA, Anbinder AL, Jaime, APG, Lima AP,   
 Balducci I, Rocha RF. Defeitos &oacute;sseos em tibias de ratos: padroniza&cced
il;&atilde;o    do modelo experimental. Rev Odontol UNICID. 2006;18(1):7-13.    
^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#137#133#article#168# </font></p>     ^
cY#a05v26n1.htm##
00485000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704023400080002001300314#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#138#134#article#168#12#<p>
<font face="Verdana" size="2">12. Sampaio IBM. Estat&iacute;stica aplicada    &a
grave; experimenta&ccedil;&atilde;o animal Belo Horizonte: Funda&ccedil;&atilde;
o    de Ensino e Pesquisa em Medicina Veterin&aacute;ria; 1998.    ^cY#a05v26n1.
htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#139#135#article#168# </font></p>     ^
cY#a05v26n1.htm##
00465000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704021400080002001300294#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#140#136#article#168#13#<p>
<font face="Verdana" size="2">13. Moom EJ, Lee YM, Lee OH, Lee MJ, Lee SK,    Ch
ung MH. A novel angiogenic factor derived from Aloe vera gel: b-sitosterol,    a
 plant sterol. Angiogenesis. 1999;3:117-23.    ^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#141#137#article#168# </font></p>     ^
cY#a05v26n1.htm##
00366000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704011500080002001300195#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#142#138#article#168#14#<p>
<font face="Verdana" size="2">14. Hsu S. Green tea and the skin. J Am Acad    De
rmatol. 2005;52:1049-59.    ^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#143#139#article#168# </font></p>     ^
cY#a05v26n1.htm##
00395000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704014400080002001300224#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#144#140#article#168#15#<p>
<font face="Verdana" size="2">15. Carmeliet P. Mechanisms of angiogenesis and   
 arteriogenesis: Review. Nature Am. 2000;6(3):389-95.    ^cY#a05v26n1.htm##
00257000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002100077002001300098#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#145#141#article#168# </font></p>     ^
cY#a05v26n1.htm##
00385000000000157000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073888000300077704013400080002001300214#v26
n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#p#146#142#article#168#16#<p>
<font face="Verdana" size="2">16. Carmeliet P. Angiogenesis in health and diseas
e:    Review. Nature Med. 2003;9(6):653-60.    ^cY#a05v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#147#143#article#168# </font></p>      
^cY#a05v26n1.htm##
00259000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002300077002001300100#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#148#144#article#168#<p>&nbsp; </p>    
 ^cY#a05v26n1.htm##
00315000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007900077002001300156#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#149#145#article#168#<p><font face="Ver
dana" size="3"><B>Acknowledgements </B> </font></p>      ^cY#a05v26n1.htm##
00502000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704026600077002001300343#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#150#146#article#168#<p><font face="Ver
dana" size="2"> To the Company Perdigao S/A (Rio Verde-GO) for    rendering avai
lable the embryonated eggs. To the Animal Colony of Federal University    of Goi
as for giving the Wistar rats (<I>Rattus norvegicus albinus</I>). </font></p>   
    ^cY#a05v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#151#147#article#168#<p>&nbsp;</p>     
^cY#a05v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#152#148#article#168#<p>&nbsp;</p>     
^cY#a05v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#153#149#article#168#<p>&nbsp;</p>     
^cY#a05v26n1.htm##
00391000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704015500077002001300232#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#154#150#article#168#<p><font face="Ver
dana" size="2"><B><a name="end"></a><a href="#top"><img src="/img/revistas/acb/v
26n1/seta.gif" border="0"></a>Correspondence</B>:    ^cY#a05v26n1.htm##
00275000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003900077002001300116#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#155#151#article#168#<br>   Leila Maria
 Leal Parente    ^cY#a05v26n1.htm##
00271000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003500077002001300112#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#156#152#article#168#<br>   Campus II S
amambaia,    ^cY#a05v26n1.htm##
00267000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704003100077002001300108#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#157#153#article#168#<br>   Caixa Posta
l 131    ^cY#a05v26n1.htm##
00285000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704004900077002001300126#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#158#154#article#168#<br>   74001- 970 
Goi&acirc;nia-GO Brasil    ^cY#a05v26n1.htm##
00290000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704005400077002001300131#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#159#155#article#168#<br>   Phone/Fax: 
(55 62)8431-1906 / 3521-1566    ^cY#a05v26n1.htm##
00327000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009100077002001300168#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#160#156#article#168#<br>   <a href="ma
ilto:lathosvet@hotmail.com">lathosvet@hotmail.com</a></font></p>     ^cY#a05v26n
1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#161#157#article#168#<p>&nbsp;</p>     
^cY#a05v26n1.htm##
00300000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006400077002001300141#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#162#158#article#168#<p><font face="Ver
dana" size="2">Received: July 12, 2010    ^cY#a05v26n1.htm##
00314000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704007800077002001300155#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#163#159#article#168#<br>   </font><fon
t face="Verdana" size="2">Review: September 20, 2010    ^cY#a05v26n1.htm##
00326000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704009000077002001300167#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#164#160#article#168#<br>   </font><fon
t face="Verdana" size="2">Accepted: October 21, 2010</font></p>     ^cY#a05v26n1
.htm##
00303000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704006700077002001300144#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#165#161#article#168#<p><font face="Ver
dana" size="2">Conflict of interest: none    ^cY#a05v26n1.htm##
00324000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704008800077002001300165#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#166#162#article#168#<br>   </font><fon
t face="Verdana" size="2">Financial source: CAPES </font></p>     ^cY#a05v26n1.h
tm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#167#163#article#168#<p>&nbsp;</p>     
^cY#a05v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#168#164#article#168#<p>&nbsp;</p>     
^cY#a05v26n1.htm##
00489000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704025300077002001300330#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#169#165#article#168#<p><font face="Ver
dana" size="2"><sup><a name="end"></a><a href="#top">1</a></sup>    Research per
formed at Departments of Pathology, Preventive Medicine and Natural    Products 
Laboratory, Federal University of Goias (UFG), Brazil. </font></p>     ^cY#a05v2
6n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#170#166#article#168#<p>&nbsp;</p>     
^cY#a05v26n1.htm##
00258000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704002200077002001300099#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#171#167#article#168#<p>&nbsp;</p>     
^cY#a05v26n1.htm##
00555000000000145000450000400060000070200470000670500020005370600020005570000040
0057701000400061709000800065708000400073704031900077002001300396#v26n1#V:\SciELO
\serial\acb\v26n1\markup\a05v26n1.htm#S#p#172#168#article#168#<p><font face="Ver
dana" size="2">This article has received corrections asked by    the editor on A
pr/2011 in agreement with the ERRATUM published in Volume 26    Number 2. (<a hr
ef="http://www.scielo.br/pdf/acb/v26n2/v26n2a15.pdf" target="_blank">http://www.
scielo.br/pdf/acb/v26n2/v26n2a15.pdf</a>)</font></p>     ^cY#a05v26n1.htm##
00786000000000325000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100014000760100016000900100
01800106010001700124010001400141010002000155010001700175012020000192030001900392
71000020041106500090041306400050042203100030042701400080043086500090043800200130
0447#v26n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#c#173#1#article#16#1
#^rND^sRe^nT A#^rND^sMooney^nD#^rND^sAntignac^nE#^rND^sDufour,^nE#^rND^sBark^nI#
^rND^sSrinivasan^nV#^rND^sNohynek^nG#Application of the threshold of toxicologic
al concern approach for thesafety evaluation of calendula flower (Calendula offi
cinalis) petals and extracts used in cosmetic and personal care products^len#Foo
d Chem Toxicol.#2#20090000#2009#47#1246-54#20110200#a05v26n1.htm##
00714000000000313000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100017000760100015000930100
01800108010001900126010001600145010002000161012015600181030001400337710000200351
065000900353064000500362031000300367014000800370865000900378002001300387#v26n1#V
:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#c#174#2#article#16#2#^rND^sPommi
er^nP#^rND^sGomez^nF#^rND^sSunyach^nMP#^rND^sD'Hombres^nA#^rND^sCarrie^nC#^rND^s
Montbarbon^nX#Phase III randomized trial of Calendula officinalis compared with 
trolamine for the prevention of acute dermatitis during irradiation for breast c
ancer^len#J Clin Oncol.#2#20040000#2004#22#1447_53#20110200#a05v26n1.htm##
00742000000000337000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100025000760100014001010100
02000115010002900135010002200164010001600186010001800202010001500220012010300235
03000180033871000020035606500090035806400050036703100030037201400070037586500090
0382002001300391#v26n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#c#175#3#
article#16#3#^rND^sZitterl-Eglseer^nK#^rND^sSosa^nS#^rND^sJurenitsch^nJ#^rND^sSc
hubert-Zssilavecz^nM#^rND^sDella Loggia^nR#^rND^sTubaro^nA#^rND^sBertoldi^nM#^rN
D^sFranz^nC#Anti-oedematous activities of the main triterpendiol esters of marig
old (Calendula officinalis L.)^len#J Ethnopharmacol.#2#19970000#1997#57#139_44#2
0110200#a05v26n1.htm##
00506000000000265000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760100018000920120
06600110030001500176710000200191065000900193064000500202031000400207014000700211
865000900218002001300227#v26n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#
c#176#4#article#16#4#^rND^sBrown^nDJ#^rND^sDattner^nAM#Phytotherapeutic approach
es to common dermatologic conditions^len#Arch Dermatol.#2#19980000#1998#134#1401
_4#20110200#a05v26n1.htm##
00626000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100022000760100016000980100
01400114010001600128010001500144012010500159030001200264710000200276065000900278
064000500287031000300292014000700295865000900302002001300311#v26n1#V:\SciELO\ser
ial\acb\v26n1\markup\a05v26n1.htm#S#c#177#5#article#16#5#^rND^sDella-Loggia^nR#^
rND^sTubaro^nA#^rND^sSosa^nS#^rND^sBecker^nH#^rND^sIsaac^nO#The role of triterpe
noids in the topical anti-inflammatory activity of Calendula officinalis flowers
^len#Planta Med.#2#19940000#1994#60#516-20#20110200#a05v26n1.htm##
00641000000000301000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100020000760100015000960100
01700111010001400128010001900142012011700161030001300278710000200291065000900293
064000500302031000300307014000700310865000900317002001300326#v26n1#V:\SciELO\ser
ial\acb\v26n1\markup\a05v26n1.htm#S#c#178#6#article#16#6#^rND^sHamburguer^nM#^rN
D^sAdler^nS#^rND^sBaumann^nD#^rND^sForg^nA#^rND^sWeinreich^nB#Preparative purifi
cation of the major anti-inflammatory triterpenoid ester from Marigold (Calendul
a officinalis)^len#Fitoterapia.#2#20030000#2003#74#328-38#20110200#a05v26n1.htm#
#
00546000000000253000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100016000760120135000920300
01600227710000200243065000900245064000500254031000400259014000700263865000900270
002001300279#v26n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#c#179#7#arti
cle#16#7#^rND^sHazel^nSJ#A novel early chorioallantoic membrane assay demonstrat
es quantitative and qualitative changes caused by antiangiogenic substances^len#
J Lab Clin Med.#2#20030000#2003#141#217-28#20110200#a05v26n1.htm##
00588000000000289000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740100018000760100015000940100
01700109010001800126012008100144030002700225710000200252065000900254064000500263
031000200268014000600270865000900276002001300285#v26n1#V:\SciELO\serial\acb\v26n
1\markup\a05v26n1.htm#S#c#180#8#article#16#8#^rND^sRibattiI^nD#^rND^sVacca^nA#^r
ND^sRoncali^nL#^rND^sDammacco^nF#The chick embryo membrane as model for in vivo 
research on anti-angiogenesis^len#Curr Pharmacol Biotechnol.#2#20000000#2000#1#7
3-82#20110200#a05v26n1.htm##
00378000000000217000450000400060000070200470000670500020005370600020005570000040
00577010002000617090008000637080003000711180002000740180030000760620008001060660
01000114065000900124064000500133865000900138002001300147#v26n1#V:\SciELO\serial\
acb\v26n1\markup\a05v26n1.htm#S#c#181#9#article#16#9#Farmacopéia Brasileira IV^l
pt#Atheneu#São Paulo#20010000#2001#20110200#a05v26n1.htm##
00659000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100014000780100014000920100
01500106010001400121010001400135010001400149012008800163030001300251065000900264
06400050027303100030027801400070028186500090028800200130029703500100031080100130
0320#v26n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#c#182#10#article#16#
10#^rND^sKim^nMS#^rND^sLee^nYM#^rND^sMoon^nEJ#^rND^sKim^nSE#^rND^sLee^nJJ#^rND^s
Kim^nKW#Anti-angiogenic activity of torilin, a sesquiterpene compound from Toril
is japonica^len#Int J Cancer#20000000#2000#87#269_75#20110200#a05v26n1.htm#0020-
7136#Int J Cancer##
00650000000000325000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100016000780100019000940100
01800113010001500131010001800146010001600164012007600180030002000256710000200276
06500090027806400050028703100030029203200020029501400050029786500090030200200130
0311#v26n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#c#183#11#article#16#
11#^rND^sPrado^nFA#^rND^sAnbinder^nAL#^rND^sJaime,^nAPG#^rND^sLima^nAP#^rND^sBal
ducci^nI#^rND^sRocha^nRF#Defeitos ósseos em tibias de ratos: padronização do mod
elo experimental^lpt#Rev Odontol UNICID.#2#20060000#2006#18#1#7-13#20110200#a05v
26n1.htm##
00469000000000217000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750160019000780180064000970620
05400161065000900215064000500224865000900229002001300238#v26n1#V:\SciELO\serial\
acb\v26n1\markup\a05v26n1.htm#S#c#184#12#article#16#12#^rND^sSampaio^nIBM#Estatí
stica aplicada à experimentação animal Belo Horizonte^lpt#Fundação de Ensino e P
esquisa em Medicina Veterinária#19980000#1998#20110200#a05v26n1.htm##
00627000000000313000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100015000780100014000930100
01400107010001400121010001400135010001600149012008700165030001400252710000200266
065000900268064000500277031000200282014000700284865000900291002001300300#v26n1#V
:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#c#185#13#article#16#13#^rND^sMoo
m^nEJ#^rND^sLee^nYM#^rND^sLee^nOH#^rND^sLee^nMJ#^rND^sLee^nSK#^rND^sChung^nMH#A 
novel angiogenic factor derived from Aloe vera gel: b-sitosterol, a plant sterol
^len#Angiogenesis.#2#19990000#1999#3#117-23#20110200#a05v26n1.htm##
00441000000000253000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100013000780120027000910300
02000118710000200138065000900140064000500149031000300154014000800157865000900165
002001300174#v26n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#c#186#14#art
icle#16#14#^rND^sHsu^nS#Green tea and the skin^len#J Am Acad Dermatol.#2#2005000
0#2005#52#1049-59#20110200#a05v26n1.htm##
00481000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780120058000970300
01100155710000200166065000900168064000500177031000200182032000200184014000700186
865000900193002001300202#v26n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#
c#187#15#article#16#15#^rND^sCarmeliet^nP#Mechanisms of angiogenesis and arterio
genesis: Review^len#Nature Am.#2#20000000#2000#6#3#389-95#20110200#a05v26n1.htm#
#
00471000000000265000450000400060000070200470000670500020005370600020005570000040
00577010003000617090008000647080003000721180003000750100019000780120047000970300
01200144710000200156065000900158064000500167031000200172032000200174014000700176
865000900183002001300192#v26n1#V:\SciELO\serial\acb\v26n1\markup\a05v26n1.htm#S#
c#188#16#article#16#16#^rND^sCarmeliet^nP#Angiogenesis in health and disease: Re
view^len#Nature Med.#2#20030000#2003#9#6#653-60#20110200#a05v26n1.htm##
